PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cuppen, E; Nagata, S; Wieringa, B; Hendriks, W				Cuppen, E; Nagata, S; Wieringa, B; Hendriks, W			No evidence for involvement of mouse protein-tyrosine phosphatase-BAS-like Fas-associated phosphatase-1 in Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; CELL-DEATH; MOLECULAR-CLONING; GUANYLATE KINASES; ANTI-FAS; DOMAIN; BINDING; FAMILY; PSD-95/SAP90; SIMILARITIES	Recently, one of the PDZ domains in the cytosolic protein-tyrosine phosphatase Fas-associated phosphatase-1 (FAP-1)/protein-tyrosine phosphatase-BAS (PTP-BAS) was shown to interact with the carboxyl-terminal tS-L-V peptide of the human Fas receptor (Sato, T., Irie, S., Kitada, S., and Reed, J. C. (1995) Science 268, 411-415), suggesting a role for protein (de)phosphorylation in Fas signaling, To investigate whether this interaction is conserved in mouse, we performed yeast two-hybrid interaction experiments and transfection studies in mouse T cell lines, For the corresponding PDZ motif in the mouse homologue of FAP-1/PTP-BAS, protein-tyrosine phosphatase-BAS-like (PTP-BL), only an interaction with human but not with mouse Fas could be detected, Presence of the tS-L-V motif proper, which is unique for human Fas, rather than the structural context of its carboxyl terminus, apparently explains the initially observed binding, To test for functional conservation of any indirect involvement of PTP-BL in Fas-mediated signaling, we generated T lymphoma cell lines stably expressing mouse or human Fas receptor with and without PTP-BL, No inhibitory effect of PTP-BL was observed upon triggering apoptosis using mouse or human Fas-activating antibodies. Together with the markedly different tissue expression patterns for PTP-BL and Fas receptor, our findings suggest that protein-tyrosine phosphatase PTP-BL does not play a key role in the Fas-mediated death pathway.	UNIV NIJMEGEN,INST CELLULAR SIGNALING,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Radboud University Nijmegen; Osaka University			Hendriks, Wiljan/Q-4325-2019; Cuppen, Edwin/H-2389-2016; Cuppen, Edwin/F-5696-2011; Hendriks, Wiljan J.A.J./A-5214-2013; Nagata, Shigekazu/AAG-3203-2019; Wieringa, Berend/A-5346-2011	Hendriks, Wiljan/0000-0001-9481-8281; Cuppen, Edwin/0000-0002-0400-9542; Cuppen, Edwin/0000-0002-0400-9542; Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Nagata, Shigekazu/0000-0001-9758-8426; Wieringa, Berend/0000-0001-9192-8020				Atkinson EA, 1996, J BIOL CHEM, V271, P5968, DOI 10.1074/jbc.271.11.5968; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIDA D, 1995, FEBS LETT, V358, P233, DOI 10.1016/0014-5793(94)01432-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Janssen O, 1996, IMMUNOL LETT, V49, P63, DOI 10.1016/0165-2478(95)02482-4; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LEMMONMA, 1996, CELL, V85, P621; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Niethammer M, 1996, J NEUROSCI, V16, P2157; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Orlinick JR, 1996, J BIOL CHEM, V271, P8627, DOI 10.1074/jbc.271.15.8627; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1997, PROTEIN SCI, V6, P464; Sambrook J., 2002, MOL CLONING LAB MANU; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; Takayama H, 1996, J IMMUNOL, V157, P3943; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	43	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30215	30220		10.1074/jbc.272.48.30215	http://dx.doi.org/10.1074/jbc.272.48.30215			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374505	Green Published, hybrid			2022-12-25	WOS:A1997YH61300037
J	Fukata, M; Kuroda, S; Fujii, K; Nakamura, T; Shoji, I; Matsuura, Y; Okawa, K; Iwamatsu, A; Kikuchi, A; Kaibuchi, K				Fukata, M; Kuroda, S; Fujii, K; Nakamura, T; Shoji, I; Matsuura, Y; Okawa, K; Iwamatsu, A; Kikuchi, A; Kaibuchi, K			Regulation of cross-linking of actin filament by IQGAP1, a target for Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; RHO-FAMILY GTPASES; BINDING PROTEIN; PUTATIVE TARGET; ALPHA-ACTININ; F-ACTIN; KINASE; IDENTIFICATION; CALMODULIN; EFFECTOR	We have previously shown that IQGAP1, a recently identified target for Cdc42 and Rad small GTPases, showed a distribution similar to that of cortical actin cytoskeleton at the membrane ruffling area induced by insulin and Rac1(val12) (Kuroda, S., Fukata, M,, Kobayashi, K., Nakafuku, M., Nomura, N., Iwamatsu, A., and Kaibuchi, K. (1996) J. Biol. Chem. 271, 28363-23367). Here we identified an IQGAP1-interacting molecule with molecular mass of 43 kDa (p43) from bovine brain cytosol, using glutathione S-transferase (GST)-IQGAP1 affinity column chromatography. The amino acid sequencing of the protein revealed that p43 was identical to beta- and gamma-actin. IQGAP1 was cosedimentated with filamentous actin (F-actin). The amino-terminal domain (amino acids 1-216) of IQGAP1 was responsible for the interaction with F-actin. Falling ball viscometry assay revealed that IQGAP1 cross-linked the F-actin. This IQGAP1 activity was further enhanced by guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) GST-Cdc42 but not by GDP-GST-Cdc42. The gel filtration analysis of IQGAP1 revealed that IQGAP1 appeared as oligomers and that GTP gamma S-GST-Cdc42 but not GDP GST-Cdc42 enhanced the oligomerization of IQGAP1. These results strongly suggest that IQGAP1, acting downstream of Cdc42, can cross-link the actin filament through its oligomerization.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,HIROSHIMA 734,JAPAN; PRECURSORY RES EMBRYON SCI & TECHNOL,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN; NATL INST INFECT DIS,DIV VIROL 2,TOKYO 162,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Hiroshima University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID); Kirin Brewery Company Limited			Shoji, Ikuo/Y-7079-2019; Fukata, Masaki/AAZ-2476-2021; KURODA, SHINYA/G-4961-2014	Shoji, Ikuo/0000-0002-0730-4379; Fukata, Masaki/0000-0001-5200-9806; 				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; APSENSTROM P, 1996, CURR BIOL, V6, P70; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; Brill S, 1996, MOL CELL BIOL, V16, P4869; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MEYER RK, 1990, J CELL BIOL, V110, P2013, DOI 10.1083/jcb.110.6.2013; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SANTOS E, 1988, J BIOL CHEM, V263, P9853; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SUZUKI A, 1976, J BIOL CHEM, V251, P6860; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	159	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29579	29583		10.1074/jbc.272.47.29579	http://dx.doi.org/10.1074/jbc.272.47.29579			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368021	hybrid			2022-12-25	WOS:A1997YG64700031
J	Hoedemaeker, FJ; Signorelli, T; Johns, K; Kuntz, DA; Rose, DR				Hoedemaeker, FJ; Signorelli, T; Johns, K; Kuntz, DA; Rose, DR			A single chain Fv fragment of P-glycoprotein-specific monoclonal antibody C219 - Design, expression, and crystal structure at 2.4 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CELL-LINES; ESCHERICHIA-COLI; PROTEIN; IMMUNOGLOBULIN; ANTIGEN; CRYSTALLIZATION; RECOGNITION; DOMAIN; MODEL	A construct encoding a single chain variable fragment of the anti-P-glycoprotein monoclonal antibody C219 was made by combining the coding sequences for the heavy and light chain variable domains with a sequence encoding the flexible linker (GGGGS)(3), an OmpA signal sequence, a c-myc identification tag, and a five-histidine purification tag, The construct was expressed in Escherichia coli and purified from the periplasmic fraction using a nickel chelate column and ion exchange chromatography, Three-step Western blot analysis showed that the construct retains binding affinity for P-glycoprotein, Crystals of 1.0 x 0.2 x 0.2 mm were grown in 100 mM citrate, pH 4.5, 21% polyethylene glycol 6000 in the presence of low concentrations of subtilisin, resulting in proteolytic removal of the linker and purification tags, The structure was solved to a resolution of 2.4 Angstrom with an R factor of 20.6, an R-free of 28.5, and good stereochemistry, This result could lead to a clinically useful product based on antibody C219 for the diagnosis of P-glycoprotein-mediated multidrug resistance, The molecule will also be useful in biophysical studies of functional do mains of P-glycoprotein, as well as studies of the intact molecule.	UNIV TORONTO, ONTARIO CANC INST, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								Alvarez RD, 1997, HUM GENE THER, V8, P229, DOI 10.1089/hum.1997.8.2-229; Alyahyaee SAS, 1996, BIOCONJUGATE CHEM, V7, P451, DOI 10.1021/bc960030k; ANAND NN, 1991, J BIOL CHEM, V266, P21874; Annereau JP, 1997, FEBS LETT, V407, P303, DOI 10.1016/S0014-5793(97)00363-3; BARRAND MA, 1992, BRIT J CANCER, V65, P239, DOI 10.1038/bjc.1992.48; BEAULIEU E, 1995, BBA-BIOMEMBRANES, V1233, P27, DOI 10.1016/0005-2736(94)00239-L; Beck WT, 1996, CANCER RES, V56, P3010; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETTER M, 1995, J BIOL CHEM, V270, P14951, DOI 10.1074/jbc.270.25.14951; BRUNGER AT, 1989, XPLOR VERSION 3 1; CHAN HSL, 1995, HEMATOL ONCOL CLIN N, V9, P889, DOI 10.1016/S0889-8588(18)30077-7; CHAN HSL, 1995, HEMATOL ONCOL CLIN N, V9, P275, DOI 10.1016/S0889-8588(18)30096-0; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FINSTAD CL, 1991, J HISTOCHEM CYTOCHEM, V39, P1603, DOI 10.1177/39.12.1682363; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOEDEMAEKER PJ, 1997, IN PRESS PROTEINS ST; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; Kovari LC, 1995, STRUCTURE, V3, P1291, DOI 10.1016/S0969-2126(01)00266-0; KRISHAN A, 1991, CYTOMETRY, V12, P731, DOI 10.1002/cyto.990120807; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JJ, 1996, CANCER, V77, P1892, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1892::AID-CNCR20>3.0.CO;2-U; Lynch TJ, 1997, J CLIN ONCOL, V15, P723, DOI 10.1200/JCO.1997.15.2.723; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORRIS MD, 1995, GENE, V1565, P313; OSTERMEIER C, 1995, NAT STRUCT BIOL, V2, P842, DOI 10.1038/nsb1095-842; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reiter Y, 1996, NAT BIOTECHNOL, V14, P1239, DOI 10.1038/nbt1096-1239; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056; TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005; VASUDEVAN S, 1996, PROTEIN MOTIONS, P109; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; YOKOTA T, 1992, CANCER RES, V52, P3402; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	50	27	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29784	29789		10.1074/jbc.272.47.29784	http://dx.doi.org/10.1074/jbc.272.47.29784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368049	hybrid			2022-12-25	WOS:A1997YG64700059
J	Layton, JE; Iaria, J; Smith, DK; Treutlein, HR				Layton, JE; Iaria, J; Smith, DK; Treutlein, HR			Identification of a ligand-binding site on the granulocyte colony-stimulating factor receptor by molecular modeling and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; COMMON BETA-CHAIN; GROWTH-HORMONE RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; IL-5 RECEPTORS; GM-CSF; COMPLEX; RESIDUES; IMMUNOGLOBULIN	Granulocyte colony-stimulating factor (G-CSF) initiates its effects on cells of the neutrophil lineage by inducing formation of a homodimeric receptor complex. The structure of the G-CSF receptor has not yet been determined, therefore we used molecular modeling to identify regions of the receptor that were likely to be involved in ligand binding, The G-CSF receptor sequence was aligned with all the available sequences of the gp130 and growth hormone receptor families and a model of the cytokine receptor homologous domain was constructed, based on the growth hormone receptor structure. Alanine substitution mutagenesis was performed on loops and individual residues that mere predicted to bind ligand. Mutant receptors were expressed in factor-dependent Ba/F3 cells and assessed for proliferation response and ligand binding, Six residues were identified that significantly reduced receptor function, with Arg(288) in the F'-G' loop having the greatest effect. These residues formed a binding face on the receptor model resembling the growth hormone receptor site, which suggests that the model is reasonable. However, electrostatic analysis of the model provided further evidence that the mechanism of receptor dimerization is different from that of the growth hormone receptor.	ROYAL MELBOURNE HOSP,COOPERAT RES CTR CELLULAR GROWTH FACTORS,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital	Layton, JE (corresponding author), ROYAL MELBOURNE HOSP,MELBOURNE TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,POB 2008,PARKVILLE,VIC 3050,AUSTRALIA.		Treutlein, Herbert Rudolf/AAC-7648-2021	Treutlein, Herbert Rudolf/0000-0001-5553-5553; Smith, David/0000-0003-3608-0586				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; Groenen LC, 1997, BIOCHEMISTRY-US, V36, P3826, DOI 10.1021/bi9614141; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Kalai M, 1997, BLOOD, V89, P1319, DOI 10.1182/blood.V89.4.1319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; Layton JE, 1997, GROWTH FACTORS, V14, P117, DOI 10.3109/08977199709021515; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NICOLA NA, 1987, J CELL PHYSL S5, V133, P9; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; SMITH DK, 1994, FEBS LETT, V350, P275, DOI 10.1016/0014-5793(94)00785-3; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WAGN HM, 1992, J BIOL CHEM, V267, P979; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498	59	30	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29735	29741		10.1074/jbc.272.47.29735	http://dx.doi.org/10.1074/jbc.272.47.29735			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368043	hybrid			2022-12-25	WOS:A1997YG64700053
J	Nishino, T; Nishino, T				Nishino, T; Nishino, T			The conversion from the dehydrogenase type to the oxidase type of rat liver xanthine dehydrogenase by modification of cysteine residues with fluorodinitrobenzene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DROSOPHILA-MELANOGASTER; ALDEHYDE OXIDOREDUCTASE; O-2-DEPENDENT TYPES; MOLECULAR-CLONING; DEPENDENT TYPE; CDNA CLONING; ROSY LOCUS; PURIFICATION; ENZYME	When rat liver xanthine dehydrogenase was incubated with fluorodinitrobenzene (FDNB) at pH 8.5, the total enzyme activity decreased gradually to a Limited value of initial activity with modification of two lysine residues in a similar way to the modification of bovine milk xanthine oxidase with FDNB (Nishino, T., Tsushima, R., Hille, R. and Massey, V. (1982) J. Biol. Chem. 257, 7348-1353). After modification with FDNB, the two peptides containing dinitrophenyl-lysine were isolated from the molybdopterin domain after proteolytic digestion and were identified as Lys(754) and Lys(771) by sequencing the peptides. During the modification of these lysine residues, xanthine dehydrogenase was found to be converted to an oxidase form in the early stage of incubation. Incorporation of the H-3-dinitrophenyl group into enzyme cysteine residues was 0.96 mol per enzyme FAD for 68% conversion to the oxidase form. The modified enzyme was reconverted to the dehydrogenase form by incubation with dithiothreitol with concomitant release of H-3-dinitrophenyl compounds. After modification with H-3-FDNB followed by carboxymethylation under denaturating conditions, the enzyme was digested with proteases. Three H-3-dinitrophenyl-labeled peptides were isolated and sequenced. The modified residues were identified to be Cys(535), Cys(992) and Cys(1324). These residues are conserved among the all known mammalian enzymes, but Cys(992) and Cys(1324) are not conserved in the chicken enzyme. Cys(1324) Of the rat enzyme was found not to be involved in the conversion from the dehydrogenase to the oxidase by limited proteolysis experiments, but Cys(535) and Cys(992) which seemed to be modified alternatively with FDNB appear to be involved in the conversion.	YOKOHAMA CITY UNIV, SCH MED, DEPT BIOCHEM, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN	Yokohama City University	Nishino, T (corresponding author), NIPPON MED COLL, DEPT BIOCHEM & MOL BIOL, BUNKYO KU, 1-1-5 SENDAGI, TOKYO 113, JAPAN.							AMAYA Y, 1990, J BIOL CHEM, V265, P14170; Berglund L, 1996, J DAIRY SCI, V79, P198, DOI 10.3168/jds.S0022-0302(96)76351-8; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; Della Corte E, 1968, Biochem J, V108, P349; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1995, FASEB J, V9, P995, DOI 10.1096/fasebj.9.11.7649415; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUNT J, 1992, J BIOL CHEM, V267, P21479; ICHIDA K, 1993, GENE, V133, P279; IKEDA T, 1976, EXPT METHODS BIOCH 2, V1, P118; IKEGAMI T, 1986, ARCH BIOCHEM BIOPHYS, V247, P254, DOI 10.1016/0003-9861(86)90582-5; KAMINSKI ZW, 1982, BIOCHEM J, V207, P341, DOI 10.1042/bj2070341; KEITH TP, 1987, GENETICS, V116, P67; LEE CS, 1987, GENETICS, V116, P55; Li Calzi Marco, 1995, Journal of Biological Chemistry, V270, P31037; MASSEY V, 1989, J BIOL CHEM, V264, P10567; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAKAMURA M, 1982, J BIOCHEM-TOKYO, V92, P1279, DOI 10.1093/oxfordjournals.jbchem.a134046; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1994, J BIOCHEM, V116, P1; NISHINO T, 1982, J BIOL CHEM, V257, P7348; RAKITZIS ET, 1985, BIOCHEM J, V231, P492; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SAITO T, 1987, Yokohama Medical Bulletin, V38, P151; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; SHALTIEL S, 1967, BIOCHEM BIOPH RES CO, V29, P178, DOI 10.1016/0006-291X(67)90583-9; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P365, DOI 10.1016/0003-9861(76)90088-6; WAUD WR, 1976, ARCH BIOCHEM BIOPHYS, V172, P354, DOI 10.1016/0003-9861(76)90087-4; WEBER K, 1969, J BIOL CHEM, V244, P4406; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690	38	65	66	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29859	29864		10.1074/jbc.272.47.29859	http://dx.doi.org/10.1074/jbc.272.47.29859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368059	hybrid			2022-12-25	WOS:A1997YG64700069
J	Boneca, IG; Xu, NX; Gage, DA; deJonge, BLM; Tomasz, A				Boneca, IG; Xu, NX; Gage, DA; deJonge, BLM; Tomasz, A			Structural characterization of an abnormally cross-linked muropeptide dimer that is accumulated in the peptidoglycan of methicillin- and cefotaxime-resistant mutants of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAIN	Laboratory mutants of Staphylococcus aureus strain ATCC 8325 (275) selected for increased minimal inhibitory concentration (MIG) values to methicillin and cefotaxime showed increased rates of cell wall turnover and detergent-induced autolysis in virtual parallel with the increasing MIC for the antibiotic. Also in parallel with the increasing MICs for the particular antibiotic used in the selection was the gradual accumulation of an unusual muropeptide in the peptidoglycan of the mutants, muropeptide 12, which is a minor component of the cell wall of the parental strain. Analysis of muropeptide 12, its peptide derivative, and its lysostaphin degradation products by high pressure liquid chromatography, Edman degradation, and mass spectrometry suggests that muropeptide 12 is a dimer in which the two monomeric components are interlinked by two pentaglycyl crossbridges, thus generating a Ii-member macrocyclic ring structure, This unusual cross-linked structure may be the product of the abnormal activity of penicillin-binding protein 2 which has grossly reduced antibiotic binding capacity in the mutant staphylococci.	ROCKEFELLER UNIV,MICROBIOL LAB,NEW YORK,NY 10021; MICHIGAN STATE UNIV,DEPT BIOCHEM,NIH,MASS SPECTROMETRY FACIL,E LANSING,MI 48824	Rockefeller University; Michigan State University; National Institutes of Health (NIH) - USA			Boneca, Ivo G/H-1677-2014; DeJonge, Boudewijn/AAR-6717-2020	Boneca, Ivo G/0000-0001-8122-509X; 				ATHERTON D, 1989, TECHNIQUES PROTEIN C, V273; DEJONGE BLM, 1991, J BACTERIOL, V173, P1105, DOI 10.1128/jb.173.3.1105-1110.1991; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GARCIABUSTOS JF, 1987, ANTIMICROB AGENTS CH, V31, P178, DOI 10.1128/AAC.31.2.178; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; SCHINDLER CA, 1965, BIOCHIM BIOPHYS ACTA, V97, P242, DOI 10.1016/0304-4165(65)90088-7; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; Severin A, 1996, J BACTERIOL, V178, P168, DOI 10.1128/jb.178.1.168-174.1996; TONIN E, 1986, ANTIMICROB AGENTS CH, V30, P577, DOI 10.1128/AAC.30.4.577; Xu NX, 1997, ANAL BIOCHEM, V248, P7, DOI 10.1006/abio.1997.2073	12	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29053	29059		10.1074/jbc.272.46.29053	http://dx.doi.org/10.1074/jbc.272.46.29053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360979	hybrid			2022-12-25	WOS:A1997YF68400038
J	Diamond, DL; Randall, LL				Diamond, DL; Randall, LL			Kinetic partitioning - Poising SecB to favor association with a rapidly folding ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI SECB; CHAPERONE SECB; SELECTIVE BINDING; EXPORTED PROTEIN; LEADER PEPTIDE; TRANSLOCATION; RECOGNITION; INVITRO; INVIVO	Chaperones are a class of proteins that possess the remarkable ability to selectively bind polypeptides that are in a nonnative state, The selectivity of SecB, a molecular chaperone in Escherichia coli, for its Ligands can be explained in part by a kinetic partitioning between folding of the polypeptide and association with SecB. It has clearly been established that kinetic partitioning can be poised to favor association with SecB by changing the rate constant for folding of the ligand, We now demonstrate that binding to SecB can be given a kinetic advantage over the pathway for folding by modulating the properties of the chaperone. By poising SecB to expose a hydrophobic patch, we were able to detect a complex between SecB and maltose-binding protein under conditions in which rapid folding of the polypeptide otherwise precludes formation of a kinetically stable complex. The data presented here are interpreted within the framework of a kinetic partitioning between binding to SecB and folding of the polypeptide. We propose that exposure of a hydrophobic patch on SecB increases the surface area for binding and thereby increases the rate constant for association. In this way association of SecB with the polypeptide ligand has a kinetic advantage over the pathway for folding.			Diamond, DL (corresponding author), WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,POB 644660,PULLMAN,WA 99164, USA.				NIGMS NIH HHS [GM 29798] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029798, R37GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUN SY, 1993, J BIOL CHEM, V268, P20855; DenBlaauwen T, 1996, ARCH MICROBIOL, V165, P1, DOI 10.1007/s002030050289; DIAMOND DL, 1995, PROTEIN SCI, V4, P1118, DOI 10.1002/pro.5560040610; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; HARDY SJS, 1993, PHILOS T R SOC B, V339, P343, DOI 10.1098/rstb.1993.0033; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KHISTY VJ, 1995, J BIOL CHEM, V270, P25920, DOI 10.1074/jbc.270.43.25920; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; KUMAMOTO CA, 1993, J BACTERIOL, V175, P2184, DOI 10.1128/JB.175.8.2184-2188.1993; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LIU G, 1988, J BIOL CHEM, V263, P14790; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Smith VF, 1996, PROTEIN SCI, V5, P488; SMITH VF, 1997, PROTEIN SCI, V6, P1; TOPPING TB, 1994, PROTEIN SCI, V3, P730; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	30	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28994	28998		10.1074/jbc.272.46.28994	http://dx.doi.org/10.1074/jbc.272.46.28994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360972	hybrid			2022-12-25	WOS:A1997YF68400031
J	Geiss, GK; Radebaugh, CA; Paule, MR				Geiss, GK; Radebaugh, CA; Paule, MR			The fundamental ribosomal RNA transcription initiation factor-IB (TIF-IB, SL1, factor D) binds to the rRNA core promoter primarily by minor groove contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIES-SPECIFIC TRANSCRIPTION; PROTEIN-DNA CONTACTS; TATA-BOX COMPLEX; POLYMERASE-I; RDNA TRANSCRIPTION; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENE PROMOTER; DISTAMYCIN-A	Acanthamoeba castellanii transcription initiation factor-IB (TIF-IB) is the TATA-binding protein containing transcription factor that binds the rRNA promoter to form the committed complex. Minor groove-specific drugs inhibit TIF-IB binding, with higher concentrations needed to disrupt preformed complexes because of drug exclusion by bound TIF-IB. TIF-IB/DNA interactions were mapped by hydroxyl radical and uranyl nitrate footprinting. TIF-IB contacts four minor grooves in its binding site. TIF-IB and DNA wrap around each other in a right-handed superhelix of high pitch, so the upstream and downstream contacts are on opposite faces of the helix. Dimethyl sulfate protection assays revealed limited contact with a few guanines in the major groove. This detailed analysis suggests significant DNA conformation dependence of the interaction.	COLORADO STATE UNIV, DEPT BIOCHEM & MOL BIOL, FT COLLINS, CO 80523 USA	Colorado State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022580] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22580] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATEMAN E, 1986, CELL, V47, P445, DOI 10.1016/0092-8674(86)90601-X; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BATEMAN E, 1985, P NATL ACAD SCI USA, V82, P8004, DOI 10.1073/pnas.82.23.8004; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BRUZIK JP, 1987, BIOCHEMISTRY-US, V26, P950, DOI 10.1021/bi00377a040; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONS BMG, 1989, NUCLEIC ACIDS RES, V17, P5447, DOI 10.1093/nar/17.14.5447; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DEVILLIERS J, 1982, NUCLEIC ACIDS RES, V10, P7965, DOI 10.1093/nar/10.24.7965; DOELLING JH, 1995, PLANT J, V8, P683, DOI 10.1046/j.1365-313X.1995.08050683.x; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; FOX KR, 1985, NUCLEIC ACIDS RES, V13, P8695, DOI 10.1093/nar/13.24.8695; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; GONG XL, 1995, MOL CELL BIOL, V15, P4956; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; IIDA CT, 1985, P NATL ACAD SCI USA, V82, P1668, DOI 10.1073/pnas.82.6.1668; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBODEN MA, 1992, J BIOL CHEM, V267, P24601; JEPPESEN C, 1989, NUCLEIC ACIDS RES, V17, P4947, DOI 10.1093/nar/17.13.4947; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOWNIN P, 1985, NUCLEIC ACIDS RES, V13, P6237, DOI 10.1093/nar/13.17.6237; KOWNIN P, 1988, MOL CELL BIOL, V8, P747, DOI 10.1128/MCB.8.2.747; KOWNIN P, 1987, CELL, V50, P693, DOI 10.1016/0092-8674(87)90327-8; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; MANIATIS T, 1982, MOL CLONING LABORATO, P454; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NEIDLE S, 1987, BIOCHEM J, V243, P1; NIELSEN PE, 1988, FEBS LETT, V235, P122, DOI 10.1016/0014-5793(88)81245-6; NIELSEN PE, 1990, NUCLEIC ACIDS RES, V18, P3847, DOI 10.1093/nar/18.13.3847; NIELSEN PE, 1992, J AM CHEM SOC, V114, P4967, DOI 10.1021/ja00039a003; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Paule Marvin R., 1993, Gene Expression, V3, P1; PAULE MR, 1984, BIOCHEMISTRY-US, V23, P4167, DOI 10.1021/bi00313a025; PAULE MR, 1990, NATURE, V344, P819, DOI 10.1038/344819a0; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Pyott A, 1996, BRIT J OPHTHALMOL, V80, P849, DOI 10.1136/bjo.80.9.849; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RAEEBAUGH CA, 1997, J BIOL CHEM, V272, P3141; REEDER RH, 1992, TRANSCRIPTIONAL REGU, P315; SAFRANY G, 1989, MOL CELL BIOL, V9, P349, DOI 10.1128/MCB.9.1.349; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; Shaw PE, 1994, DNA PROTEIN INTERACT, P79, DOI [10.1385/0-89603-256-6:79, DOI 10.1385/0-89603-256-6:79]; Smith S. David, 1993, Gene Expression, V3, P229; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; TOWER J, 1989, MOL CELL BIOL, V9, P1513, DOI 10.1128/MCB.9.4.1513; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WOLFFE AP, 1994, J CELL SCI, V107, P2055; WONG JM, 1992, GENE, V117, P91, DOI 10.1016/0378-1119(92)90494-A; WOYNAROWSKI JM, 1989, BIOCHEMISTRY-US, V28, P3850, DOI 10.1021/bi00435a034; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2; ZWICK MG, 1991, NUCLEIC ACIDS RES, V19, P1681, DOI 10.1093/nar/19.7.1681	75	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29243	29254		10.1074/jbc.272.46.29243	http://dx.doi.org/10.1074/jbc.272.46.29243			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361004	hybrid			2022-12-25	WOS:A1997YF68400063
J	Orlinick, JR; Vaishnaw, A; Elkon, KB; Chao, MV				Orlinick, JR; Vaishnaw, A; Elkon, KB; Chao, MV			Requirement of cysteine-rich repeats of the Fas receptor for binding by the Fas ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; GROWTH-FACTOR RECEPTOR; LYMPHOPROLIFERATIVE SYNDROME; MEDIATED APOPTOSIS; GENE-MUTATIONS; CELL-DEATH; EXPRESSION; ACTIVATION; ANTIGEN; DOMAIN	The Fas receptor is a member of a family of cell death receptors, including tumor necrosis factor receptor I (TNFR I), death receptor 3 and 4 (DR3 and DR4), and cytopathic avian receptor 1 (CAR1), The Fas receptor is composed of several discrete domains, including three cysteine-rich domains (CRDs), a transmembrane do main, and an intracellular domain responsible for transmitting an apoptotic signal, While the mechanism of Fas-mediated cell death has become elucidated, the requirements for Fas ligand binding to the receptor have not been fully defined, Using a series of chimeric F-c-receptor fusion proteins between the human Fas receptor and TNFR I, each cysteine-rich domain of Fas was found to be required for interaction with the Fas ligand, Interestingly, TNFR I CRD1 could partially substitute for the Fas CRD1, The importance of this domain was underscored by the analysis of a Fas extracellular mutation (C66R), which resulted in a complete loss of ligand binding, This mutation was cloned from a human patient suffering from Canale-Smith syndrome, which is characterized by autoimmunity resembling that observed in the lpr and lpr(cg) mice, The localization of essential ligand binding domains in the Fas receptor correlated exactly with the ability of the Fas receptor fusion proteins to prevent cell death mediated by the Fas ligand.	CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,DEPT CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,DEPT MED,NEW YORK,NY 10021	Cornell University; Cornell University				Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline; NIAMS NIH HHS [P50AR-425888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHU J, 1994, J EXP MED, V178, P723; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; HSU KC, 1993, J BIOL CHEM, V268, P16430; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOBAYASHI S, 1993, BIOCHEM BIOPH RES CO, V191, P617, DOI 10.1006/bbrc.1993.1262; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ONEL KB, 1995, EUR J IMMUNOL, V25, P2940, DOI 10.1002/eji.1830251034; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Starling GC, 1997, J EXP MED, V185, P1487, DOI 10.1084/jem.185.8.1487; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; YAN H, 1991, J BIOL CHEM, V266, P12099	38	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28889	28894		10.1074/jbc.272.46.28889	http://dx.doi.org/10.1074/jbc.272.46.28889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360957	hybrid			2022-12-25	WOS:A1997YF68400016
J	Accili, EA; Kiehn, J; Wible, BA; Brown, AM				Accili, EA; Kiehn, J; Wible, BA; Brown, AM			Interactions among inactivating and noninactivating Kv beta subunits, and Kv alpha 1.2, produce potassium currents with intermediate inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; K+ CHANNELS; RAT-BRAIN; EXPRESSION; KV-BETA-1	Experiments were carried out to determine whether coinjection of Kv alpha 1.2 with inactivating and noninactivating Kv beta subunits would produce currents with intermediate kinetics and channel complexes containing a mixture of these subunits. Upon coexpression with a saturating amount of Kv beta 1.2 and increasing levels of a noninactivating deletion mutant of Kv beta 1.2, we show that macroscopic Kv alpha 1.2 currents have levels of fractional inactivation and inactivation time constants that are intermediate between those obtained with either the inactivating Kv beta 1.2 or the noninactivating Kv beta 1.2 mutant. We also find that coexpression of Kv alpha 1.2 with saturating amounts of Kv beta 1.2 and the deletion mutant produces a population of single channels with properties intermediate to either the inactivating or noninactivating parental phenotype. Our data can best be explained by the presence of an intermediate population of heterooligomeric channels consisting of Kv alpha 1.2 with different combinations of both types of subunits. Since Kv alpha 1.2 subunits coexist in cells with inactivating and noninactivating Kv beta subunits, our findings suggest that heterooligomeric assembly of these subunits occurs to increase the range of K+ current kinetics and expression levels.	RAMMELKAMP CTR RES,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44109; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44109	MetroHealth System; Case Western Reserve University; Case Western Reserve University					NHLBI NIH HHS [HL55404, HL-36930] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930, R01HL055404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accili E. A., 1997, Biophysical Journal, V72, pA349; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; KIEHN J, 1996, CIRCULATION, V94, P1151; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; RHODES KJ, 1995, J NEUROSCI, V15, P5360; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Wang ZG, 1996, J BIOL CHEM, V271, P28311, DOI 10.1074/jbc.271.45.28311; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	16	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28232	28236		10.1074/jbc.272.45.28232	http://dx.doi.org/10.1074/jbc.272.45.28232			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353274	hybrid			2022-12-25	WOS:A1997YF21900014
J	Haribabu, B; Richardson, RM; Fisher, I; Sozzani, S; Peiper, SC; Horuk, R; Ali, H; Snyderman, R				Haribabu, B; Richardson, RM; Fisher, I; Sozzani, S; Peiper, SC; Horuk, R; Ali, H; Snyderman, R			Regulation of human chemokine receptors CXCR4 - Role of phosphorylation in desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PLATELET-ACTIVATING-FACTOR; HIV-1 ENTRY; BETA-ARRESTIN; CHEMOATTRACTANT RECEPTORS; PEPTIDE CHEMOATTRACTANTS; INTERLEUKIN-8 RECEPTOR; TRANSDUCTION PATHWAYS; CROSS-DESENSITIZATION; SIGNAL-TRANSDUCTION	Members of the chemokine receptor family CCR5 and CXCR4 have recently been shown to be involved in the entry of human immunodeficiency virus (HIV) into tar; get cells. Here, we investigated the regulation of CXCR4 in rat basophilic leukemia cells (RBL-2H3) stably transfected with wild type (Wt CXCR4) or a cytoplasmic tail deletion mutant (Delta Cyto CXCR4) of CXCR4. The ligand, stromal cell derived factor-1 (SDF-1) stimulated higher G-protein activation, inositol phosphate generation, add a more sustained calcium elevation in cells expressing Delta Cyto CXCR4 relative to Wt CXCR4. SDF-1 and phorbol 12-myristate 13-acetate (PMA), but not a membrane permeable cAMP analog induced rapid phosphorylation as well as desensitization of Wt CXCR4. Phosphorylation of Delta Cyto CXCR4 was not detected under any of these conditions. Despite lack of receptor phosphorylation, calcium mobilization by SDF-1 in Delta Cyto CXCR4 cells was partially desensitized by prior treatment with SDF-1. Of interest, the rapid release of calcium was inhibited without affecting the sustained calcium elevation, indicating independent regulatory pathways for these processes. PMA completely inhibited phosphoinositide hydrolysis and calcium mobilization in Wt CXCR4 but only partially inhibited these responses ill Delta Cyto CXCR4, cAMP also partially inhibited these responses in both, Wt CXCR4, and Delta Cyto CXCR4. SDF-1, PMA, and cAMP caused phosphorylation of phospholipase C beta 3 in Wt add Delta Cyto CXCR4 cells. Both SDF-1 as well as PMA induced rapid internalization of Wt CXCR4. SDF-1 but not PMA induced internalization of Delta Cyto CXCR4 albeit at reduced levels relative: td Wt CXCR4. These results indicate that signaling and internalization of CXCR4 are regulated by receptor phosphorylation dependent and independent mechanisms. Desensitization of CXCR4 signaling, independent of receptor phosphorylation, appears to be a consequence of the phosphorylation of phospholipase C beta 3.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710; IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY; UNIV LOUISVILLE,JAMES GRAHAM BROWN CANC CTR,LOUISVILLE,KY 40292; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	Duke University; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Louisville	Haribabu, B (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3680,DURHAM,NC 27710, USA.		Sozzani, Silvano/C-1447-2009; Bodduluri, Haribabu/A-2584-2010	Sozzani, Silvano/0000-0002-3144-8743; Bodduluri, Haribabu/0000-0002-8261-3294	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038910, R01AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1993, J BIOL CHEM, V268, P24247; ALI H, 1994, J BIOL CHEM, V269, P24567; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; GOLDING H, 1995, J VIROL, V69, P6140, DOI 10.1128/JVI.69.10.6140-6148.1995; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu MY, 1996, NATURE, V382, P83, DOI 10.1038/382083a0; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; Prado GN, 1996, J BIOL CHEM, V271, P19186, DOI 10.1074/jbc.271.32.19186; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SOZZANI S, 1994, J IMMUNOL, V152, P3615; TAKANO T, 1994, J BIOL CHEM, V269, P22453; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	52	246	252	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28726	28731		10.1074/jbc.272.45.28726	http://dx.doi.org/10.1074/jbc.272.45.28726			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353342	hybrid			2022-12-25	WOS:A1997YF21900082
J	Krishnamurti, U; Rondeau, E; Sraer, JD; Michael, AF; Tsilibary, EC				Krishnamurti, U; Rondeau, E; Sraer, JD; Michael, AF; Tsilibary, EC			Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION; IV COLLAGEN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MESANGIAL CELLS; MESSENGER-RNA; INTEGRINS; EXPRESSION	The glomerular epithelial cells and the glomerular basement membrane are important constituents of the permselective barrier in the kidney. These are affected in diabetic nephropathy, one of the long-term complications in diabetic patients. Nonenzymatic glycosylation resulting in the accumulation of advanced glycosylation end products correlates with the development of longterm complications in diabetes, The interaction of cells with extracellular matrix proteins plays a critical role in a variety of biological processes. Recent studies show that cell-matrix interactions mediated by integrins can transduce biochemical signals to the cell interior and regulate cell behavior. In this paper we demonstrate that interactions of human glomerular epithelial cells with a nonenzymatically glycated matrix are altered with defective cell spreading, reduced phosphorylation of focal adhesion kinase and reduced activity df mitogen-activated protein kinase. These data suggest that matrix glycation interferes with normal cell-matrix interactions and intracellular signaling that can potentially result in differential gene expression contributing to the changes seen in diabetic nephropathy.	UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; HOP TENON, INSERM, U64, F-75970 PARIS, FRANCE; DEMOKRITOS NATL CTR SCI RES, INST BIOL, ATHENS 60228, GREECE	University of Minnesota System; University of Minnesota Twin Cities; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; National Centre of Scientific Research "Demokritos"	Krishnamurti, U (corresponding author), UNIV MINNESOTA, DEPT LAB MED & PATHOL, BOX 609 UMHC, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.		Krishnamurti, Uma/AAA-1733-2022; Krishnamurti, Uma/AAW-9867-2020		NIAID NIH HHS [AI-10704] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010704, R37AI010704] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRASS CK, 1988, DIABETES, V37, P1695, DOI 10.2337/diabetes.37.12.1695; Anderson Shane S., 1992, Journal of the American Society of Nephrology, V3, P625; ANDERSON SS, 1994, KIDNEY INT, V46, P1359, DOI 10.1038/ki.1994.405; AYO SH, 1991, AM J PHYSIOL, V260, pF185, DOI 10.1152/ajprenal.1991.260.2.F185; BISELL MJ, 1987, J CELL SCI S, V8, P327; BORDER WA, 1989, SEMIN NEPHROL, V9, P307; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; CHARONIS AS, 1992, DIABETES, V41, P49, DOI 10.2337/diab.41.2.S49; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen Y, 1996, KIDNEY INT, V49, P153, DOI 10.1038/ki.1996.20; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COSIO FG, 1992, AM J KIDNEY DIS, V20, P294, DOI 10.1016/S0272-6386(12)80705-0; COSIO FG, 1995, KIDNEY INT S51, V48, P12; DELARUE F, 1991, KIDNEY INT, V40, P906, DOI 10.1038/ki.1991.292; HAITOGLOU CS, 1992, J BIOL CHEM, V267, P12404; HASEGAWA G, 1995, J BIOL CHEM, V270, P3278, DOI 10.1074/jbc.270.7.3278; HUMPHRIES MJ, 1993, BIOESSAYS, V15, P391, DOI 10.1002/bies.950150605; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KORHONEN M, 1990, J CELL BIOL, V111, P1245, DOI 10.1083/jcb.111.3.1245; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Krishnamurti U, 1996, LAB INVEST, V74, P650; LEDBETTER S, 1990, DIABETES, V39, P196, DOI 10.2337/diabetes.39.2.196; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSTERBY R, 1980, DIABETOLOGIA, V18, P493; OVEREND WG, 1981, J CHEM SCI, P3487; RAHILLY MA, 1992, J PATHOL, V167, P327, DOI 10.1002/path.1711670311; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SETTY S, 1995, CELL ADHES COMMUN, V3, P187, DOI 10.3109/15419069509081286; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; WOLF P, 1983, ANAL BIOCHEM, V129, P145, DOI 10.1016/0003-2697(83)90062-3; Yasuda T., 1996, Journal of the American Society of Nephrology, V7, P1880	44	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27966	27970		10.1074/jbc.272.44.27966	http://dx.doi.org/10.1074/jbc.272.44.27966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346947	hybrid			2022-12-25	WOS:A1997YD47300073
J	Watanabe, H; Cheung, SC; Itano, N; Kimata, K; Yamada, Y				Watanabe, H; Cheung, SC; Itano, N; Kimata, K; Yamada, Y			Identification of hyaluronan-binding domains of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PIG LARYNGEAL CARTILAGE; LINK PROTEIN; EXTRACELLULAR-MATRIX; KERATAN SULFATE; BIOTINYLATED HYALURONAN; MOLECULAR-CLONING; BOVINE CARTILAGE; ACID; RECEPTOR	Aggrecan, a large cartilage proteoglycan, interacts with hyaluronan (HA), to form aggregates which function to resist compression in joints. The N-terminal region of aggrecan contains two structurally related globular domains, G(1) and G(2) separated by IGD domain. The G(1) domain consists of three subdomains, A, B, and B', structural features characteristic to many other HA-binding proteoglycans. Here, we studied the interaction of aggrecan domains with HA using recombinant proteins expressed in 293 cells, an embryonal kidney cell line. Deglycosylation of the recombinant aggrecan fragment reduced the HA binding activity. We found that both the B and B' subdomains were required for HA binding and that a single module of A, B, or B' was unable to bind HA. The A subdomain increased the HA binding activity of the B-B' region. The G(2) domain had no HA binding activity confirming previous reports. Studies of HA-binding properties using a BIAcore(TM) biosensor system revealed that the K-D of recombinant aggrecan fragment (AgW) consisting of G(1), IGD, and G(2) was 0.226 mu M, whereas the K-D of another HA-binding protein, native bovine link protein, is 0.089 mu M. In contrast, Ag-Mut11 which lacked subdomain A showed little HA binding activity. AgMut12 consisting of only B-B' had a 3.4-fold lower affinity and AgMut13 containing A-B-B' was 1.5-fold lower than AgW. These results suggest that carbohydrates are essential for high level aggrecan binding to HA and that the A subdomain of aggrecan functions in a cooperative manner with subdomains B and B'.	NIDR, CRANIOFACIAL DEV BIOL & REGENERAT BRANCH, NIH, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL, LAB HEMOSTASIS, ROCKVILLE, MD 20852 USA; AICHI MED UNIV, INST MOL SCI MED, NAGAKUTE, AICHI 48011, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA); Aichi Medical University								BARRY FP, 1994, MATRIX BIOL, V14, P323, DOI 10.1016/0945-053X(94)90198-8; BARRY FP, 1995, J BIOL CHEM, V270, P20516, DOI 10.1074/jbc.270.35.20516; BARRY FP, 1992, BIOCHEM J, V286, P761, DOI 10.1042/bj2860761; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; CHEN L, 1994, J BIOL CHEM, V269, P28282; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HOARE K, 1993, CONNECT TISSUE RES, V30, P117, DOI 10.3109/03008209309041327; HORITA DA, 1994, J BIOL CHEM, V269, P1699; HORVATH E, 1989, J NEUROSCI RES, V24, P398, DOI 10.1002/jnr.490240309; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson W, 1996, AM J PATHOL, V148, P1721; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LESK AM, 1982, J MOL BIOL, V160, P325, DOI 10.1016/0022-2836(82)90179-6; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NIEDUSZYNSKI IA, 1980, BIOCHEM J, V185, P107, DOI 10.1042/bj1850107; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SANDY JD, 1990, J BIOL CHEM, V265, P21108; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; SUGIURA N, 1993, J BIOL CHEM, V268, P15779; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YANG BH, 1995, ANAL BIOCHEM, V228, P299, DOI 10.1006/abio.1995.1354; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	46	106	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28057	28065		10.1074/jbc.272.44.28057	http://dx.doi.org/10.1074/jbc.272.44.28057			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346959	hybrid			2022-12-25	WOS:A1997YD47300085
J	Wan, HS; Dawson, MI; Hong, WK; Lotan, R				Wan, HS; Dawson, MI; Hong, WK; Lotan, R			Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: Dependence on AP-1 activation, but not on retinoid response element activation	ONCOGENE			English	Article						retinoids; AP-1; lung cancer; nuclear receptors; growth stimulation	ACID RECEPTOR-GAMMA; PROTEIN-KINASE-C; BRONCHIAL EPITHELIAL-CELLS; BREAST-CANCER CELLS; BETA-CAROTENE; ESTROGEN-RECEPTOR; MAMMARY-CARCINOMA; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; GENE-EXPRESSION	Many lung cancer cell lines are resistant to the growth inhibitory effects of retinoids, However, some small-cell lung cancer cell lines were inhibited by all trans-retinoic acid (ATRA) in serum-free medium, We compared the responses of seven non-small cell lung cancer (NSCLC) cell lines to ATRA in serum-free medium and in medium supplemented with delipidized serum, Whereas the growth of four cell lines was inhibited more in serum-free medium, the growth of the Calu-1 cell line was stimulated by ATRA in a dose-dependent fashion with a maximum at 10(-8) M. Delipidized serum (>2.5%) but not bovine serum albumin (0.15%) suppressed growth stimulation by ATRA, Transcripts of RA receptors RAR alpha and RAR gamma but not of RAR beta were detected in Calu-1 cells, Receptor expression, the formation of a complex among receptors and a RA-responsive element (RARE), and the transcriptional activation RARE were not suppressed by serum, Natural retinoids and synthetic receptor class-or subtype-selective retinoid agonists, which activated RARs and RXRs for gene transcription from a RARE, and a RAR antagonist (CD2366), which was unable to do so, stimulated the growth of Calu-1 cells in serum-free medium but not in serum-containing medium, Both ATRA and CD2366 enhanced the transcriptional activation of an Activator Protein-1 (AP-1)-luciferase reporter construct in serum-free medium but not in delipidized serum, Transcriptional activation of the RARE by ATRA occurred both in the presence or absence of delipidized serum, These results demonstrate that retinoid-induced growth stimulation of Calu-1 cells is associated with enhanced AP-1 transactivation but not with RARE transactivation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; SRI INT, RETINOID PROGRAM, MENLO PK, CA 94025 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; SRI International					NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; AMOS B, 1990, METHOD ENZYMOL, V190, P217; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AVIS I, 1995, CELL GROWTH DIFFER, V6, P485; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DAWSON MI, 1983, J MED CHEM, V26, P1653, DOI 10.1021/jm00365a021; DAWSON MI, 1995, CANCER RES, V55, P4446; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GITTER BD, 1991, CLIN IMMUNOL IMMUNOP, V61, P191, DOI 10.1016/S0090-1229(05)80023-6; Gottardis MM, 1996, CANCER RES, V56, P5566; Gudas Lorraine J., 1994, P443; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; Hodam JR, 1996, BBA-MOL CELL RES, V1311, P102, DOI 10.1016/0167-4889(95)00203-0; Hong WK, 1995, CLIN CANCER RES, V1, P677; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JIANG XL, 1992, INT J IMMUNOPHARMACO, V14, P195, DOI 10.1016/0192-0561(92)90031-F; KAGECHIKA H, 1989, J MED CHEM, V32, P1098, DOI 10.1021/jm00125a027; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kazmi SMI, 1996, CANCER RES, V56, P1056; KITABAYASHI I, 1994, IN VITRO CELL DEV-AN, V30A, P761; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; KURIE JM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P203, DOI 10.1016/0167-4889(93)90142-C; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOTAN R, 1995, RETINOIDS ONCOLOGY, P1031; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Oridate N, 1996, ONCOGENE, V12, P2019; PENG YM, 1987, J NATL CANCER I, V78, P95, DOI 10.1093/jnci/78.1.95; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SANCHEZ JH, 1987, TOXICOL IN VITRO, V1, P183, DOI 10.1016/0887-2333(87)90019-1; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAO ZM, 1995, ONCOGENE, V11, P493; SHARIF M, 1992, ONCOGENE, V7, P953; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Soprano DR, 1996, ONCOGENE, V12, P577; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; YANG PC, 1992, AM J RESP CELL MOL, V7, P161, DOI 10.1165/ajrcmb/7.2.161; ZHANG QY, 1992, J IMMUNOL, V149, P1402; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZOU CP, 1994, CANCER RES, V54, P5479; ZYLBERKATZ E, 1986, LEUKEMIA RES, V10, P1425, DOI 10.1016/0145-2126(86)90009-3	72	16	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2109	2118		10.1038/sj.onc.1201381	http://dx.doi.org/10.1038/sj.onc.1201381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366527				2022-12-25	WOS:A1997YC28400011
J	Zauberman, A; Oren, M; Zipori, D				Zauberman, A; Oren, M; Zipori, D			Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition	ONCOGENE			English	Article						activin A; hepatoma; p21(WAF1/Cip1); CDK4; Rb; p53	ERYTHROID-DIFFERENTIATION FACTOR; RAT SEMINIFEROUS EPITHELIUM; CYCLIN-DEPENDENT KINASES; TGF-BETA; RETINOBLASTOMA PROTEIN; MESODERM INDUCTION; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; IDENTIFICATION	Cytokines are growth inhibitory in a target cell specific manner. The signaling pathways that characterize each cell type play a crucial role in determining the responsiveness to cytokine triggering. Activin A has been shown to suppress the growth of primary hepatocytes, Similarly, the human HepG2 hepatoma cell line was growth arrested by activin A as judged by lack of cell proliferation and suppression of DNA synthesis. In HepG2 cells activin A further induced accumulation of retinoblastoma protein in the hypophosphorylated form known to prevent entrance into S phase. This finding implies the involvement of cyclin dependent kinases and CDK inhibitors. Examination of HepG2 cells following addition of activin A revealed reduced expression of CDK4 and conversely, an increase in the CKI p21(WAF1/Cip1). This accumulation of p21(WAF1/Cip1) protein was partly due to increased transcriptional activity. Functional inactivation of p53, using a miniprotein that oligomerizes with p53 and abrogates DNA binding, abolished the ability of activin A to induce transcriptional activation from the p21(WAF1/Cip1) promoter. Thus, activin A, like transforming growth factor beta, seems to suppress cell growth through the downstream target Rb. However, each of these cytokines seem to operate through a distinct pathway.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BHASIN S, 1989, ENDOCRINOLOGY, V124, P987, DOI 10.1210/endo-124-2-987; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chun SY, 1996, ENDOCRINOLOGY, V137, P1447, DOI 10.1210/en.137.4.1447; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V174, P1163, DOI 10.1016/0006-291X(91)91543-L; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KADOURI A, 1992, INT J CELL CLONING, V10, P299, DOI 10.1002/stem.5530100508; KAIPIA A, 1993, ENDOCRINOLOGY, V132, P477, DOI 10.1210/en.132.1.477; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu QY, 1996, CANCER RES, V56, P1155; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MINE T, 1989, ENDOCRINOLOGY, V125, P586, DOI 10.1210/endo-125-2-586; Miro F, 1996, ENDOCRINOLOGY, V137, P464, DOI 10.1210/en.137.2.464; MITAKA T, 1995, CELL STRUCT FUNCT, V20, P167, DOI 10.1247/csf.20.167; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J., 2002, MOL CLONING LAB MANU; SEHY DW, 1992, J CELL BIOCHEM, V50, P255, DOI 10.1002/jcb.240500306; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERNBERG D, 1995, GROWTH FACTORS, V12, P227; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547	60	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1705	1711		10.1038/sj.onc.1201348	http://dx.doi.org/10.1038/sj.onc.1201348			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349504				2022-12-25	WOS:A1997XY63100010
J	Haller, M; Hoffmann, U; Schanding, T; Goody, RS; Vogel, PD				Haller, M; Hoffmann, U; Schanding, T; Goody, RS; Vogel, PD			Nucleotide hydrolysis-dependent conformational changes in p21(ras) as studied using ESR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN-RESONANCE SPECTROSCOPY; H-RAS P21; BINDING-SITES; GTPASE REACTION; MECHANISM; F1-ATPASE; PROTEINS; SUPERFAMILY; ANALOG; ATP	We have employed ESR spectroscopy using guanine nucleotides that contain a spin label at the 2',3'-position of the ribose to investigate structural changes in the proto oncogene product p21(ras) that are dependent on nucleotide hydrolysis. The three nucleotide analogs used were 2',3'-(2,2,5,5-tetramethyl-3-pyrroline-1-oxyl-3-carboxylic acid ester (SL) GTP, SL-GDP, and the nonhydrolyzable analog SL-guanylylimidodiphosphate. SL-GTP was hydrolyzed by p21 with rates similar to those for GTP hydrolysis and appears to be an excellent substrate analog, The ESR spectra of SL-GTP and SL-GDP in complex with p21 differ significantly when acquired at 0 degrees C or 5 degrees C indicating different environments (conformations) of the protein-bound radicals depending on the phosphorylation state of the bound nucleotide, We calculated the rate constant for the conformational change as deduced from the changes in the corresponding ESR spectra upon incubation of the p21 SL-GTP complex at 25 degrees C and compared it to the rate constant of hydrolysis of SL-GTP at the same temperature. The rate constant deduced from the ESR method was similar to that determined by a high performance liquid chromatography technique, The data are in agreement with the idea that a conformational change during GTP hydrolysis by p21 occurs simultaneously with the actual hydrolysis step.	UNIV KAISERSLAUTERN,FACHBEREICH CHEM BIOCHEM,D-67663 KAISERSLAUTERN,GERMANY; MAX PLANCK INST MOL PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	University of Kaiserslautern; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Vogel, Pia/0000-0002-8135-4649				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGARD S, 1994, J BIOL CHEM, V269, P17815; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOFFMANN U, 1995, THESIS U DORTMUND DO; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; Losel RM, 1997, BIOCHEMISTRY-US, V36, P1188, DOI 10.1021/bi9614601; Losel RM, 1996, SPECTROCHIM ACTA A, V52, P73, DOI 10.1016/0584-8539(95)01549-3; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; MACARA IG, 1991, CELL SIGNAL, V3, P179, DOI 10.1016/0898-6568(91)90043-T; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NIXON AE, 1995, BIOCHEMISTRY-US, V34, P15592, DOI 10.1021/bi00047a026; PARK JH, 1989, BIOL MAGN RESON, V8, P547; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Satoh T, 1992, Semin Cancer Biol, V3, P169; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; STRECKENBACH B, 1980, BIOCHIM BIOPHYS ACTA, V601, P34, DOI 10.1016/0005-2736(80)90511-8; TROMMER WE, 1987, PYRIDINE NUCLEOTID A, V2, P613; TROMMER WE, 1992, BIOACTIVE SPIN LABEL, P405; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0	29	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30103	30107		10.1074/jbc.272.48.30103	http://dx.doi.org/10.1074/jbc.272.48.30103			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374488	hybrid			2022-12-25	WOS:A1997YH61300020
J	Mackey, D; Sugden, B				Mackey, D; Sugden, B			Studies on the mechanism of DNA linking by Epstein-Barr virus nuclear antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN-BINDING-PROTEIN; PLASMID MAINTENANCE; REPLICATION ORIGIN; LATENT INFECTION; EBNA-1; CELLS; SEQUENCE; DOMAIN; SITES; ORIP	Epstein-Barr virus nuclear antigen 1 (EBNA1) can both bind to and link DNA. Dimers of EBNA1 bind specific sites, two clusters of which, the FR and DS, comprise the necessary cis-acting elements of the Epstein-Barr viral origin of plasmid replication. EBNA1-dimers can link FR and DS, looping out the intervening DNA. EBNA1 can also intermolecularly link DNAs to which it binds. Residues of EBNA1 that can mediate linking have been mapped to at least three, non-overlapping domains. These domains, when fused to the dimerization and DNA-binding domain of GALA, can self-associate and thereby link DNAs bound site specifically by GAL4. Two disparate mechanisms could underlie self-association of linking domains: 1) linking domains could associate with other linking domains directly, or 2) linking domains could associate indirectly by binding to a common nucleic acid intermediate. We have found that EBNA1 can link DNA by each of these mechanisms, however, the linking domains associate directly with a greater apparent affinity than through a nonspecific nucleic acid intermediate.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NCI NIH HHS [CA22443, CA07175] Funding Source: Medline; NIGMS NIH HHS [T32-GM07215] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; INOUE N, 1991, VIROLOGY, V182, P84, DOI 10.1016/0042-6822(91)90651-Q; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; KIRCHMAIER AL, 1995, J VIROL, V69, P1280, DOI 10.1128/JVI.69.2.1280-1283.1995; Laine A, 1995, J BIOL CHEM, V270, P30914, DOI 10.1074/jbc.270.52.30914; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; POLVINOBODNAR M, 1992, VIROLOGY, V187, P591, DOI 10.1016/0042-6822(92)90461-W; Puglielli MT, 1997, J VIROL, V71, P120, DOI 10.1128/JVI.71.1.120-128.1997; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Sambrook J., 2002, MOL CLONING LAB MANU; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; STERNAS L, 1990, J VIROL, V64, P2407; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; SUGDEN B, 1988, MOL BIOL MED, V5, P84; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; YATES JL, 1988, CANCER CELL, V6, P197	36	24	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29873	29879		10.1074/jbc.272.47.29873	http://dx.doi.org/10.1074/jbc.272.47.29873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368061	hybrid			2022-12-25	WOS:A1997YG64700071
J	Simon, KO; Nutt, EM; Abraham, DG; Rodan, GA; Duong, LT				Simon, KO; Nutt, EM; Abraham, DG; Rodan, GA; Duong, LT			The alpha(v)beta(3) integrin regulates alpha(5)beta(1)-mediated cell migration toward fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-MONOCYTES; HUMAN-ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIB-IIIA; SMOOTH-MUSCLE CELLS; VITRONECTIN RECEPTOR; CYTOPLASMIC DOMAIN; ALPHA-V; ALPHA-V-BETA-3 INTEGRIN; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION	This study examines the interactions of alpha(v) beta(3) and alpha(5) beta(1) in the regulation of cell migration, Human embryonic kidney (HEK) 293 cells that express alpha(5) beta(1) endogenously were transfected with alpha(v) beta(3) and beta(3) mutants, and their attachment and migration to fibronectin (Fn) and vitronectin (Vn) were measured, An alpha(v) beta(3) blocking antibody and the alpha(v) beta(3) ligand cyclic G-Pen-GRGDSPC-A inhibited alpha(5) beta(1)-mediated migration toward Fn, but not attachment to Fn. This function was alpha(v) beta(3)-specific since alpha(v) beta(5) transfection and alpha(v) beta(5) blocking antibody did not produce this effect, Mutations introduced into the beta(3) integrin subunit to dissect this phenomenon revealed the following, Disruption of the ligand binding domain by the Glanzmann thrombasthenia mutation beta(3)-D119Y constitutively abolished migration toward both Vn and Fn, and attachment to Vn but not to Fn. Insertion of the Glanzmann mutation beta(3)-S752P into the cytoplasmic domain or its truncation (beta(3)-Delta 717) abolished binding to Vn but not to Fn, Inhibition of migration toward Fn was inhibited in these cells by alpha(v) beta(3), blocking antibody. alpha(v) beta(3)-mediated inhibition was, however, abolished by truncation of the transmembrane domain (beta(3)-Delta 693). These findings demonstrate alpha(v) beta(3) regulation of alpha(5) beta(1)-mediated cell migration and suggest that the beta(3) transmembrane domain is essential for this function.	MERCK RES LABS, DEPT BONE BIOL & OSTEOPOROSIS, West Point, PA 19486 USA; MERCK RES LABS, DEPT PHARMACOL, West Point, PA 19486 USA	Merck & Company; Merck & Company								Abraham DG, 1997, MOL PHARMACOL, V52, P227, DOI 10.1124/mol.52.2.227; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROWN EJ, 1988, J EXP MED, V167, P777, DOI 10.1084/jem.167.3.777; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONFORTI G, 1992, BLOOD, V80, P437; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DONATI MB, 1977, THROMB RES, V10, P173, DOI 10.1016/0049-3848(77)90092-5; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUJIMOTO T, 1995, BLOOD, V86, P2174, DOI 10.1182/blood.V86.6.2174.bloodjournal8662174; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hendey B, 1996, BLOOD, V87, P2038; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KIM JP, 1994, J BIOL CHEM, V269, P26926; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANTZ LM, 1995, BIOTECHNIQUES, V18, P56; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; REINHOLD MI, 1995, J CELL SCI, V108, P3419; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Simon K. O., 1994, INTEGRINS MOL BIOL R, P49; SMYTH SS, 1993, BLOOD, V81, P2827; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WRIGHT SD, 1984, J CELL BIOL, V99, P336, DOI 10.1083/jcb.99.1.336; WRIGHT SD, 1983, J EXP MED, V158, P1338, DOI 10.1084/jem.158.4.1338; WU CY, 1995, J CELL SCI, V108, P821; YLANNE J, 1995, J BIOL CHEM, V270, P9550	58	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29380	29389		10.1074/jbc.272.46.29380	http://dx.doi.org/10.1074/jbc.272.46.29380			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361020	hybrid			2022-12-25	WOS:A1997YF68400079
J	Wu, RC; Schonthal, AH				Wu, RC; Schonthal, AH			Activation of p53-p21(waf1) pathway in response to disruption of cell-matrix interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; ANCHORAGE-INDEPENDENT GROWTH; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; A EXPRESSION; P53; P21; INHIBITORS; GENES; TRANSCRIPTION	The proliferation of most cells is strictly dependent on cell-matrix interactions, a phenomenon called anchorage dependence, Because tumor cells often are independent of this regulation, it is important to characterize the molecular pathways that control cellular proliferation after detachment of cells from their matrix. In this report, we investigated a possible role of p53 and one of its target genes, p21(waf1/cip1), as components of anchorage-dependent cell growth control, We found that p53 protein is rapidly activated upon the disruption of cellular attachment. This led to p21 transcriptional activation via two p53 binding sites in its promoter. Elevated p21 protein levels blocked transcription and activity of the cell cycle-regulator cyclin A, and cells became arrested in G(1) of the cell cycle. Under the same conditions, fibroblasts from p53 knock out mice did not activate p21 and did not down-regulate cyclin A expression but rather induced another cell cycle inhibitor, p27, Thus, our results characterize a chain of events, starting from the activation of p53 and proceeding via p21 to cyclin A, that is activated in response to the loss of cellular adherence, This p53 regulated pathway may constitute one of a few redundant systems to ensure proper cell control in multicellular organisms.	UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; University of Southern California			Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRANA X, 1995, ONCOGENE, V11, P211; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Harlow E., 1988, ANTIBODIES LAB MANUA; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPPI K, 1994, ONCOGENE, V9, P3017; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kramer A, 1996, J BIOL CHEM, V271, P6579; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nikiforov MA, 1996, ONCOGENE, V13, P1709; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONTHAL A, 1993, ONCOGENE, V8, P433; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Zeng YX, 1996, ONCOGENE, V12, P1557; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	42	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29091	29098		10.1074/jbc.272.46.29091	http://dx.doi.org/10.1074/jbc.272.46.29091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360984	hybrid			2022-12-25	WOS:A1997YF68400043
J	Bhagwat, M; Hobbs, LJ; Nossal, NG				Bhagwat, M; Hobbs, LJ; Nossal, NG			The 5'-exonuclease activity of bacteriophage T4 RNase H is stimulated by the T4 gene 32 single-stranded DNA-binding protein, but its flap endonuclease is inhibited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; REPLICATION; EXONUCLEASE; CLEAVAGE; 3'-EXONUCLEASE; ENCODES; PRIMERS; FAMILY; FEN-1; A737V	Bacteriophage T4 RNase H is a 5'- to 3'-nuclease that has exonuclease activity on RNA DNA and DNA DNA duplexes and can remove the pentamer RNA primers made by the T4 primase-helicase (Hollingsworth, H, C., and Nossal, N. G. (1991) J. Biol. Chem. 266, 1888-1897; Hobbs, L. J., and Nossal, N. G. (1996) J. Bacteriol. 178, 6772-6777). Here we show that this exonuclease degrades du plex DNA nonprocessively, releasing a single oligonucleotide (nucleotides 1-4) with each interaction with the substrate, Degradation continues nonprocessively until the enzyme stops 8-11 nucleotides from the 3'-end of the substrate, T4 gene 32 single-stranded DNA-binding protein strongly stimulates the exonuclease activity of T4 RNase H, converting it into a processive nuclease that removes multiple short oligonucleotides with a combined length of 10-50 nucleotides each time it binds to the duplex substrate, 32 protein must bind on single-stranded DNA behind T4 RNase H for processive degradation, T4 RNase H also has a flap endonuclease activity that cuts preferentially on either side of the junction between single-and double-stranded DNA in flap and fork DNA structures, In contrast to the exonuclease, the endonuclease is inhibited completely by 32 protein binding to the single strand of the flap substrate, These results suggest an important role for T4 32 protein in controlling T4 RNase II degradation of RNA primers and adjacent DNA during each lagging strand cycle.	NIDDK,MOL & CELLULAR BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Nossal Nancy G., 1994, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; ROBINS P, 1994, J BIOL CHEM, V269, P28535; RUSSEL M, 1976, J BIOL CHEM, V251, P7263; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; Woodworth DL, 1996, GENETICS, V143, P1081; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967	28	22	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28523	28530		10.1074/jbc.272.45.28523	http://dx.doi.org/10.1074/jbc.272.45.28523			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353314	hybrid			2022-12-25	WOS:A1997YF21900054
J	Hampson, R; Humbert, O; Macpherson, P; Aquilina, G; Karran, P				Hampson, R; Humbert, O; Macpherson, P; Aquilina, G; Karran, P			Mismatch repair defects and O-6-methylguanine-DNA methyltransferase expression in acquired resistance to methylating agents in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR MISMATCHES; TUMOR-CELLS; DNA-REPAIR; MICROSATELLITE INSTABILITY; MUTATOR PHENOTYPE; COLON-CANCER; BINDING; DEFICIENCY; MUTATIONS; EXTRACTS	Fifteen variants with greater than or equal to 30-fold resistance to N-methyl-N-nitrosourea were isolated from the Burkitt's lymphoma Raji cell line. Eight had received a single treatment with a highly cytotoxic dose. The remainder, including the previously described RajiF12 cell line, arose following multiple exposures to initially moderate but escalating doses. Surprisingly, methylation resistance arose in three clones by reactivation of a previously silent O-6-methylguanine-DNA methyltransferase gene, Five clones, including RajiF12, displayed the microsatellite instability and increased spontaneous mutation rates at the hypoxanthine-guanine phosphoribosyltransferase locus, consistent with deficiencies in mismatch repair. Defects in either the hMutS alpha or hMutL alpha mismatch repair complexes were identified in extracts of these resistant clones by in vitro complementation using extracts from colorectal carcinoma cell lines. Defects in hMutL alpha were confirmed by Western blot analysis. Remarkably, five methylation-resistant clones in which mismatch repair defects were demonstrated by biochemical assays did not exhibit significant microsatellite instability.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; IST SUPER SANITA,I-00161 ROME,ITALY	Istituto Superiore di Sanita (ISS)			Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; AQUILINA G, 1995, CANCER RES, V55, P2569; Bobola MS, 1996, CLIN CANCER RES, V2, P735; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BROWN R, 1997, ONCOGENE, V15, P42; CAIRNSSMITH S, 1992, CANCER RES, V52, P5257; CATAPANO CV, 1987, CANCER RES, V47, P4884; Ceccotti S, 1996, CURR BIOL, V6, P1528, DOI 10.1016/S0960-9822(96)00758-0; CHU G, 1994, J BIOL CHEM, V269, P787; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; HESS P, 1994, SOMAT CELL MOLEC GEN, V20, P409, DOI 10.1007/BF02257458; Kane MF, 1997, CANCER RES, V57, P808; Karran P, 1996, CANCER SURV, V28, P69; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1993, J BIOL CHEM, V268, P15878; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LENGAUER C, 1997, P NATL ACAD SCI USA, V94, P2245; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORTEN JEN, 1992, CARCINOGENESIS, V13, P483, DOI 10.1093/carcin/13.3.483; NYCE J, 1989, CANCER RES, V49, P5829; ORegan NE, 1996, J BIOL CHEM, V271, P1789, DOI 10.1074/jbc.271.3.1789; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEGG AE, 1990, CANCER RES, V50, P6119; PIEPER RO, 1991, CANCER COMMUN, V3, P341; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Sambrook J., 2002, MOL CLONING LAB MANU; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; Tomlinson IPM, 1997, MUTAT RES-DNA REPAIR, V383, P177, DOI 10.1016/S0921-8777(96)00058-4; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; VONWRONSKI MA, 1994, CARCINOGENESIS, V15, P577, DOI 10.1093/carcin/15.4.577	49	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28596	28606		10.1074/jbc.272.45.28596	http://dx.doi.org/10.1074/jbc.272.45.28596			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353325	hybrid			2022-12-25	WOS:A1997YF21900065
J	Joyal, JL; Burks, DJ; Pons, S; Matter, WF; Vlahos, CJ; White, MF; Sacks, DB				Joyal, JL; Burks, DJ; Pons, S; Matter, WF; Vlahos, CJ; White, MF; Sacks, DB			Communication - Calmodulin activates phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; HEXOSE-TRANSPORT; SKELETAL-MUSCLE; INSULIN; IRS-1; CELLS; PHOSPHORYLATION	Calmodulin and phosphatidylinositol 3-kinase are vital components of a number of common intracellular events. Calmodulin, a ubiquitous Ca2+-dependent effector protein, regulates multiple processes in eukaryotic cells, including cytoskeletal organization, vesicular trafficking, and mitogenesis. Phosphatidylinositol 3-kinase participates in events downstream of the receptors for insulin and other growth factors. Here we demonstrate by coimmunoprecipitation and affinity chromatography that Ca2+/calmodulin associates with Src homology 2 domains in the 85-kDa regulatory subunit of phosphatidylinositol 3-kinase, thereby significantly enhancing phosphatidylinositol 3-kinase activity in vitro and in intact cells. Furthermore, CGS9343B, a calmodulin antagonist, inhibited basal and Ca2+-stimulated phosphorylation of phosphatidylinositol in intact cells. These data demonstrate a novel mechanism for modulating phosphatidylinositol 3-kinase and provide a direct link between components of two fundamental signaling pathways.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Eli Lilly			Pons, Sebastian/K-7794-2014	Pons, Sebastian/0000-0003-1027-0621; Sacks, David/0000-0003-3100-0735	NIDDK NIH HHS [DK47308, DK09062, DK43682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043682, R01DK047308, F32DK009062] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J BIOL CHEM, V269, P19005; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Cohen P, 1988, CALMODULIN; COMMUNI D, 1994, BIOCHEM J, V298, P669, DOI 10.1042/bj2980669; Davidkova G, 1996, NEUROSCIENCE, V75, P1003, DOI 10.1016/0306-4522(96)00230-8; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPPELLER R, 1994, BIOESSAYS, V16, P565; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; OKADA T, 1994, J BIOL CHEM, V269, P3568; RADDING W, 1994, J CELL PHYSIOL, V160, P17, DOI 10.1002/jcp.1041600104; RASMUSSEN CD, 1992, CELL MOTIL CYTOSKEL, V21, P45, DOI 10.1002/cm.970210106; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHASHKIN P, 1995, J BIOL CHEM, V270, P25613, DOI 10.1074/jbc.270.43.25613; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	29	139	140	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28183	28186		10.1074/jbc.272.45.28183	http://dx.doi.org/10.1074/jbc.272.45.28183			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353264	hybrid			2022-12-25	WOS:A1997YF21900004
J	Kurashima, K; Yu, FH; Cabado, AG; Szabo, EZ; Grinstein, S; Orlowski, J				Kurashima, K; Yu, FH; Cabado, AG; Szabo, EZ; Grinstein, S; Orlowski, J			Identification of sites required for down-regulation of Na+/H+ exchanger NHE3 activity by cAMP-dependent protein kinase - Phosphorylation-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL ELECTROLYTE TRANSPORT; INTRACELLULAR PH; H+ EXCHANGER; DIARRHEAL DISEASE; PROXIMAL TUBULES; NA/H EXCHANGER; CELLS; ISOFORM; SENSITIVITY; RECOGNITION	We recently identified a region within the cytoplasmic C-terminal tail of the Na+/H+ exchanger NHE3 isoform (residues 579 to 684) which is essential for inhibition of transport activity by cAMP-dependent protein kinase (PKA) (Cabado, A. G., Yu, F. H., Rapus, A., Gergely, L., Grinstein, S., and Orlowski, J. (1996) J. Biol. Chem. 271, 3590-3599). To further define determinants of PKA regulation, six serine residues located in potential recognition sequences for PKA within, or adjacent to, this region (positions 552, 605, 634, 661, 690, and 691) were altered either independently or in various combinations using site-directed mutagenesis. Wild type and mutant NHE3s tagged with the influenza virus hemagglutinin epitope were stably expressed in exchanger-deficient Chinese hamster ovary cells (AP-1) for functional studies. Of the individual mutations examined, only substitutions at Ser(605) or Ser(634) affected sensitivity to forskolin, an activator of adenylate cyclase, although partial inhibition of NHE3 activity by forskolin remained. By contrast, simultaneous mutation of both these serines completely abolished cAMP-mediated inhibition of NHE3 without greatly affecting basal transport activity. Two-dimensional analysis of tryptic digests of immunoprecipitated NHE3 labeled in vivo with [P-32]orthophosphate revealed several phosphopeptides under basal conditions. Phosphorylation was increased approximately 3-fold in one of these peptides following forskolin treatment, and this change was eliminated by mutation of residue Ser(605). Thus, phosphorylation of Ser(605) is essential for cAMP-mediated inhibition of NHE3. In addition, Ser(634) is also required for the effect of cAMP, even though this residue does not become phosphorylated upon activation of PKA.	MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA; HOSP SICK CHILDREN, RES INST, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Yu, Frank/0000-0001-9306-1731; Orlowski, John/0000-0001-7371-175X				Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BINDER HJ, 1990, AM J MED, V88, pS2, DOI 10.1016/0002-9343(90)90267-H; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; BROWN D, 1993, J CELL SCI, P49; Cabado AG, 1996, J BIOL CHEM, V271, P3590; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DONOWITZ M, 1987, PHYSL GASTROINTESTIN, P1351; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELD M, 1989, NEW ENGL J MED, V321, P879; FIELD M, 1989, NEW ENGL J MED, V321, P800; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marshansky V, 1996, BBA-BIOMEMBRANES, V1284, P171, DOI 10.1016/S0005-2736(96)00123-X; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SABOLIC I, 1990, AM J PHYSIOL, V258, pF1245, DOI 10.1152/ajprenal.1990.258.5.F1245; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	39	129	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28672	28679		10.1074/jbc.272.45.28672	http://dx.doi.org/10.1074/jbc.272.45.28672			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353335	hybrid			2022-12-25	WOS:A1997YF21900075
J	Quintana, DG; Hou, ZH; Thome, KC; Hendricks, M; Saha, P; Dutta, A				Quintana, DG; Hou, ZH; Thome, KC; Hendricks, M; Saha, P; Dutta, A			Identification of HsORC4, a member of the human origin of replication recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST ORIGIN; INITIATION; PROTEINS; ORC	A new member of human origin recognition complex (ORC) has been cloned and identified as the human homologue of Saccharomyces cerevisiae ORC4. HsORC4 is a 45-kDa protein encoded by a 2.2-kilobase mRNA whose amino acid sequence is 29% identical to ScORC4. HsORC4 has a putative nucleotide triphosphate binding motif that is not seen in ScORC4. HsORC4P also reveals an unsuspected homology to the ORC1-Cdc18 family of proteins, HsORC4 mRNA expression and protein levels remain constant through the cell cycle. HsORC4P is coimmunoprecipitated from cell extracts with another subunit of human ORC, HsORC2P, consistent with it being a part of the putative human origin recognition complex.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOL ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Dutta, Anindya/P-3203-2016; Quintana, David G/M-5628-2018	Quintana, David G./0000-0002-4909-6686; Dutta, Anindya/0000-0002-4319-0073; Saha, Partha/0000-0002-4514-6391	NCI NIH HHS [CA60499, R01 CA060499, R01 CA060499-04A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018	19	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28247	28251		10.1074/jbc.272.45.28247	http://dx.doi.org/10.1074/jbc.272.45.28247			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353276	hybrid			2022-12-25	WOS:A1997YF21900016
J	LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML				LeBrun, DP; Matthews, BP; Feldman, BJ; Cleary, ML			The chimeric oncoproteins E2A-PBX1 and E2A-HLF are concentrated within spherical nuclear domains	ONCOGENE			English	Article						leukemia; E2A-PBX1; E2A-HLF; transcription factors; translocations	ACUTE LYMPHOBLASTIC-LEUKEMIA; COOPERATIVE DNA-BINDING; PRE-B; TRANSCRIPTIONAL ACTIVATOR; HOMEODOMAIN PROTEIN; PBX1 HOMEODOMAIN; MESSENGER-RNA; HOX PROTEINS; E2A GENE; FUSION	Oncogenic mutation of nuclear transcription factors often is associated with altered patterns of subcellular localization that may be of functional importance, The leukemogenic transcription factor gene E2A-PBX1 is created through fusion of the genes E2A and PBX1 as a result of t(1;19) in acute lymphoblastic leukemia, We evaluated subcellular localization patterns of E2A-PBX1 protein in transfected cells using immunofluorescence. Full-length E2A-PBX1 was exclusively nuclear and was concentrated in spherical domains denoted chimeric-E2A oncoprotein domains (CODs), In contrast, nuclear fluorescence for wild-type E2A or PBX1 proteins was diffuse, Enhanced concentrations of RNA polymerase II within many CODs and the requirement for an E2A-encoded activation domain suggested transcriptional relevance, However, in situ co-detection of nascent transcripts labeled with bromouridine failed to confirm altered transcriptional activity in relation to CODs, CODs also failed to co-localize with other proteins known to occupy functional nuclear compartments, including the transcription factor PML, the spliceosome-associated protein SC-35 and the adenovirus replication factor DBP, or with foci of DNA replication, Co-transfection of Hoxb7, a homeodomain protein capable of enhancing DNA binding by PBX1, impaired COD formation, suggesting that CODs contain E2A-PBX1 protein not associated with DNA, We conclude that, as a 'gain of function' phenomenon requiring protein elements from both E2A and PBX1, COD formation may be relevant to the biology of E2A-PBX1 in leukemogenesis.	STANFORD UNIV,MED CTR,DEPT PATHOL,EXPT ONCOL LAB,STANFORD,CA 94305	Stanford University	LeBrun, DP (corresponding author), QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BERENDES P, 1995, LEUKEMIA, V9, P1321; BOROWITZ M, 1992, NEOPLASTIC HEMATOPAT, P1295; BRIDGE E, 1995, J VIROL, V69, P281, DOI 10.1128/JVI.69.1.281-290.1995; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARROLL AJ, 1984, BLOOD, V63, P721; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1992, CANCER SURV, V15, P89; CRIST WM, 1990, BLOOD, V76, P117; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FORNEROD M, 1995, ONCOGENE, V10, P1739; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, BLOOD, V83, P2970, DOI 10.1182/blood.V83.10.2970.2970; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; Inukai T., 1996, Blood, V88, p552A; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PUI CH, 1990, BLOOD, V76, P1449; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; REICH NC, 1983, VIROLOGY, V128, P480, DOI 10.1016/0042-6822(83)90274-X; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; REUTER R, 1984, EXP CELL RES, V154, P548, DOI 10.1016/0014-4827(84)90179-4; SPECTOR DL, 1983, BIOL CELL, V49, P1; SPECTOR DL, 1984, BIOL CELL, V51, P109, DOI 10.1111/j.1768-322X.1984.tb00289.x; SPECTOR DL, 1987, ONCOGENE, V1, P5; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; TISCHLER AS, 1992, J HISTOCHEM CYTOCHEM, V40, P1043, DOI 10.1177/40.7.1351491; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERHEIJEN R, 1986, J CELL SCI, V86, P173; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247	51	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2059	2067		10.1038/sj.onc.1201367	http://dx.doi.org/10.1038/sj.onc.1201367			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366523				2022-12-25	WOS:A1997YC28400007
J	Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M				Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M			Abnormal telomere dynamics of B-lymphoblastoid cell strains from Werner's syndrome patients transformed by Epstein-Barr virus	ONCOGENE			English	Article						Werner's syndrome; B-lymphoblastoid cells; telomere; telomerase; EBT	LINES; LYMPHOCYTES; ELONGATION	The characteristics of B-lymphoblastoid cell strains transformed by Epstein-Barr virus (EBV) from normal individuals and Werner's syndrome (WRN) patients were compared, We continuously passaged cell strains from 28 WRN patients and 20 normal individuals for about 2 years corresponding to over 160 population doubling levels (PDLs), First, the WRN mutation significantly suppressed the immortalization: all the 28 cell strains from WRN patients, as well as 15 out of 20 cell strains from normal individuals, died out before 160 PDLs mostly without developing a significant telomerase activity, The remaining five cell strains from normal individuals became moderately/strongly telomerase-positive and, three of them were apparently immortalized with an infinitively proliferating activity, Second, the monitoring of the telomere length of both normal and WRN cell strains during;the culture period suggests that the WRN gene mutation causes abnormal dynamics of the telomere: (1) a significant proportion of WRN cell strains showed drastic shortening or lengthening of telomere lengths during cell passages compared with normal cell strains, and (2) WRN cell strains terminated their life-span at a wide range of telomere length (between 3.5 and 18.5 Kbp), whereas normal cell strains terminated within a narrow telomere length range (between 5.5 and 9 Kbp), The chromosomal aberration characteristic of WRN cells, including translocation was confirmed in our experiment, We discussed the correlation between the chromosomal instability, abnormal telomere dynamics and inability of immortalization of the WRN B-lymphobloastoid cell strains.	AGENE,RES INST,KAMAKURA,KANAGAWA 247,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOSHIMA KU,TOKYO 170,JAPAN	Hiroshima University								Avilion AA, 1996, CANCER RES, V56, P645; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BRYAN TM, 1997, IN PRESS EUR J CAN; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P175; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOSDEN J, 1994, HUM MOL GENET, V3, P931, DOI 10.1093/hmg/3.6.931; Goto M, 1997, HUM GENET, V99, P191, DOI 10.1007/s004390050336; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; GOTO M, 1981, CLIN GENET, V19, P8; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIROSE M, 1997, IN PRESS J CANC RES; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; MILLER G, 1990, VIROLOGY, P1921; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Norrback KF, 1996, BLOOD, V88, P222; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1985, ADV EXP MED BIOL, V190, P541; SALK D, 1985, ADV EXP MED BIOL, P305; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; Schulz VP, 1996, HUM GENET, V97, P750; Strahl C, 1996, MOL CELL BIOL, V16, P53; Sugihara S, 1996, HUM GENET, V97, P1; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	115	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1911	1920		10.1038/sj.onc.1201377	http://dx.doi.org/10.1038/sj.onc.1201377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365237				2022-12-25	WOS:A1997YA87200005
J	SanchezAlcazar, JA; RuizCabello, J; HernandezMunoz, I; Pobre, PS; delaTorre, P; SilesRivas, E; Garcia, I; Kaplan, O; MunozYague, MT; SolisHerruzo, JA				SanchezAlcazar, JA; RuizCabello, J; HernandezMunoz, I; Pobre, PS; delaTorre, P; SilesRivas, E; Garcia, I; Kaplan, O; MunozYague, MT; SolisHerruzo, JA			Tumor necrosis factor-alpha increases ATP content in metabolically inhibited L929 cells preceding cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXICITY; MITOCHONDRIAL RESPIRATION; MOLECULAR MECHANISMS; CONSUMING PROCESSES; OXIDATIVE STRESS; MAMMALIAN-CELLS; APOPTOSIS; CYTOTOXICITY; INVOLVEMENT; GENERATION	The effects of tumor necrosis factor-alpha (TNF) on ATP levels were studied in metabolically inhibited L929 cells. Treatment of these cells with TNF in the presence of actinomycin D or cycloheximide induces cyclic changes in the intracellular ATP content preceding cell death. After 3 h of incubation, the intracellular ATP content increased by 48 +/- 6% (p < 0.001), but at 4 h, it decreased to the control level. Two hours later, it increased again by 23 +/- 5% over the control level (p < 0.001). Coinciding with cell death, ATP content decreased progressively until almost complete depletion. These changes in ATP content were associated with parallel alterations in the respiratory coupling and with increased generation of reactive oxygen species. The mechanism by which TNF/ actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP synthesis and related to the cytotoxic effect of TNF, since blockade of mitochondrial electron transport prevented the increase in cellular ATP, the formation of reactive oxygen species, and the apoptotic cell death caused by TNF. We suggest that the TNF/actinomycin Dor TNF/cycloheximide-induced changes in intracellular ATP levels may be involved in the cytotoxic effect of TNF in metabolically inhibited L929 cells.	HOSP UNIV 12 OCTUBRE,CTR INVEST,MADRID 28041,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,DEPT QUIM FIS 2,INST PLURIDISCIPLINAR,E-28040 MADRID,SPAIN; TEL AVIV MED CTR & SCH MED,DEPT SURG A,IL-64239 TEL AVIV,ISRAEL	Hospital Universitario 12 de Octubre; Complutense University of Madrid; Tel Aviv University; Sackler Faculty of Medicine			Sanchéz-Alcázar, José A. A/L-4925-2014; Ruiz-Cabello, Jesus/A-9570-2012; García-Ruiz, Inmaculada/G-8204-2015	Sanchéz-Alcázar, José A. A/0000-0001-9705-1469; Ruiz-Cabello, Jesus/0000-0001-8681-5056; García-Ruiz, Inmaculada/0000-0003-4185-8524; Siles Rivas, Eva/0000-0003-4192-7008				ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; Atkinson DE, 1977, CELLULAR ENERGY META, DOI DOI 10.1016/C2009-0-03136-5; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; BROWN GC, 1992, BIOCHEM J, V284, P1; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHOU CC, 1995, CANCER LETT, V96, P181, DOI 10.1016/0304-3835(95)03927-O; COLTTON T, 1979, ESTADICTICA MED, P103; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; EGUCHI Y, 1997, CANCER RES, V57, P835; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Grunfeld C, 1990, Adv Intern Med, V35, P45; Hampp R, 1985, METHOD ENZYMAT AN, VVII, P370; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KULL FC, 1981, CANCER RES, V41, P4885; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; MULLER M, 1986, EUR J BIOCHEM, V161, P701, DOI 10.1111/j.1432-1033.1986.tb10496.x; MURPHY MP, 1989, BIOCHIM BIOPHYS ACTA, V977, P123, DOI 10.1016/S0005-2728(89)80063-5; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; OLLER AR, 1989, J CELL SCI, V94, P43; REID TR, 1989, J BIOL CHEM, V264, P4583; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RUFF MR, 1986, LYMPHOKINES, V6, P549; SANCHEZALCAZAR JA, 1995, J BIOL CHEM, V270, P23944, DOI 10.1074/jbc.270.41.23944; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; STADLER J, 1992, ANN SURG, V216, P539, DOI 10.1097/00000658-199211000-00003; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	50	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30167	30177		10.1074/jbc.272.48.30167	http://dx.doi.org/10.1074/jbc.272.48.30167			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374498	hybrid, Green Published			2022-12-25	WOS:A1997YH61300030
J	Shapiro, RE; Specht, CD; Collins, BE; Woods, AS; Cotter, RJ; Schnaar, RL				Shapiro, RE; Specht, CD; Collins, BE; Woods, AS; Cotter, RJ; Schnaar, RL			Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BOTULINUM NEUROTOXIN; NUCLEOTIDE-SEQUENCE; AXONAL-TRANSPORT; B NEUROTOXIN; FRAGMENT-C; BINDING; GLYCOSPHINGOLIPIDS; RECEPTOR; ACIDS; CHROMATOGRAPHY	Tetanus toxin entry into vertebrate motorneurons may involve binding of neuronal surface gangliosides containing the ''1b'' substructure (a NeuAc alpha 2,8NeuAc group on an internal galactose residue), The domains of tetanus toxin involved in ganglioside binding are known to reside within the carboxyl-terminal half of the toxin's heavy chain (''C fragment''). We developed a navel photoaffinity reagent based upon the structure of the 1b ganglioside G(D1b) (I-125-azido-G(D1b)) to define the ganglioside-binding domains of tetanus toxin. Using this ligand, we observed radiolabeling of tetanus toxin C fragment which could be specifically inhibited by a ganglioside of the 1b series (G(T1b)) but not by a non-1b series ganglioside (G(M3)). When tetanus toxin C fragment was proteolyzed with clostripain, whether before or after reaction with I-125-azido-G(D1b), a radiolabelled band was observed by SDS-polyacrylamide gel electrophoresis autoradiography, which was selectively inhibited by G(T1b) Protein sequencing of proteolyzed tetanus toxin C fragment comigrating with that band revealed the carboxyl-terminal 34 amino acid residues of tetanus toxin. Matrix-assisted laser desorption/ionization mass spectrometry of a photoaffinity labeled synthetic polypeptide representing the 34-amino acid domain revealed modification at a single residue (His(1293)). We propose that this domain of tetanus toxin is sufficient for ganglioside binding.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484; Specht, Chelsea/0000-0001-7746-512X	NIGMS NIH HHS [R01 GM54882] Funding Source: Medline; NINDS NIH HHS [R01 NS37096, K08 NS01518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037096, K08NS001518] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSENBECKH B, 1989, INFECT IMMUN, V57, P3498, DOI 10.1128/IAI.57.11.3498-3505.1989; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BIZZINI B, 1977, J NEUROCHEM, V28, P529, DOI 10.1111/j.1471-4159.1977.tb10423.x; BUTTNERENNEVER JA, 1981, NEUROSCI LETT, V26, P233, DOI 10.1016/0304-3940(81)90138-5; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; EVINGER C, 1986, BRAIN RES, V380, P383, DOI 10.1016/0006-8993(86)90241-6; HABERMANN E, 1986, CURR TOP MICROBIOL, V129, P93; HALPERN JL, 1993, J BIOL CHEM, V268, P11188; HANNA PC, 1991, J BIOL CHEM, V266, P11037; HOLMGREN J, 1980, EUR J BIOCHEM, V106, P371, DOI 10.1111/j.1432-1033.1980.tb04583.x; KAMATA Y, 1993, BIOCHIM BIOPHYS ACTA, V1156, P213, DOI 10.1016/0304-4165(93)90138-X; KIMURA K, 1990, BIOCHEM BIOPH RES CO, V171, P1304, DOI 10.1016/0006-291X(90)90828-B; KITAMURA M, 1980, BIOCHIM BIOPHYS ACTA, V628, P328, DOI 10.1016/0304-4165(80)90382-7; KOZAKI S, 1989, INFECT IMMUN, V57, P2634, DOI 10.1128/IAI.57.9.2634-2639.1989; KOZAKI S, 1987, INFECT IMMUN, V55, P3051, DOI 10.1128/IAI.55.12.3051-3056.1987; KOZAKI S, 1984, FEMS MICROBIOL LETT, V211, P219; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MORRIS NP, 1980, J BIOL CHEM, V255, P6071; ROGERS TB, 1981, J BIOL CHEM, V256, P2402; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENGRUND CL, 1991, J NEUROCHEM, V57, P1024, DOI 10.1111/j.1471-4159.1991.tb08253.x; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; SCHWAB ME, 1976, BRAIN RES, V105, P213, DOI 10.1016/0006-8993(76)90422-4; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; VANHEYNINGEN S, 1980, PHARMACOL THERAPEUT, V11, P141, DOI 10.1016/0163-7258(80)90070-4; WELLER U, 1986, TOXICON, V24, P1055, DOI 10.1016/0041-0101(86)90132-7; WELLHONER HH, 1982, REV PHYSIOL BIOCH P, V93, P1, DOI 10.1007/BFb0032668; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992; WHELAN SM, 1992, EUR J BIOCHEM, V191, P657; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; [No title captured]	35	72	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30380	30386		10.1074/jbc.272.48.30380	http://dx.doi.org/10.1074/jbc.272.48.30380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374528	hybrid			2022-12-25	WOS:A1997YH61300060
J	Wade, DP; Puckey, LH; Knight, BL; Acquati, F; Mihalich, A; Taramelli, R				Wade, DP; Puckey, LH; Knight, BL; Acquati, F; Mihalich, A; Taramelli, R			Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATION; HORMONE RECEPTOR SUPERFAMILY; CORONARY HEART-DISEASE; APO(A) MESSENGER-RNA; TRANS-ACTING FACTOR; TRANSCRIPTION FACTOR; PEROXISOME PROLIFERATORS; HYPERSENSITIVE SITES; TRANSPOSABLE ELEMENT; SIZE HETEROGENEITY	Plasma concentrations of the atherogenic lipoprotein(a) (Lp(a)) are predominantly determined by inherited sequences within or closely linked to the apolipoprotein(a) gene locus, Much of the interindividual variability in Lp(a) levels is likely to originate at the level of apo(a) gene transcription, However, the liver-specific apo(a) basal promoter is extremely weak and does not exhibit common functional variations that affect plasma Lp(a) concentrations, In a search for additional apo(a) gene control elements, we have identified two fragments with enhancer activity within the 40-kilobase pair apo(a)-plasminogen intergenic region that coincide with DNase I-hypersensitive sites (DHII and DHIII) observed in liver chromatin of mice expressing a human apo(a) transgene. Neither enhancer exhibits tis sue specificity. DHIII activity was mapped to a BOG-base pair fragment containing nine DNase I-protected elements (footprints) that stimulates luciferase expression from the apo(a) promoter 10-15-fold in HepG2 cells, Binding of the ubiquitous transcription factor Spl plays a major role in the function of this enhancer, but no single site was indispensable for activity, DHIII com prises part of the regulatory region of an inactive long interspersed nucleotide element 1 retrotransposon, raising the possibility that retrotransposon insertion can influence the regulation of adjacent genes. DHII enhancer activity was localized to a 180-base pair fragment that stimulates transcription from the aps(a) promoter 4-8-fold in HepG2 cells. Mutations within an Spl site or either of two elements composed of direct repeats of the nuclear hormone receptor half-site AGGTCA in this sequence completely abolished enhancer function. Both nuclear hormone receptor elements were shown to bind peroxisome proliferator-activated receptors and other members of the nuclear receptor family, suggesting that this enhancer may mediate drug and hormone responsiveness.	HAMMERSMITH HOSP, MRC, LIPOPROT TEAM, CTR CLIN SCI, LONDON W12 0NN, ENGLAND; SAN RAFFAELE SCI INST, I-20132 MILAN, ITALY; UNIV CATANIA, DIPARTIMENTO BIOL ANIM, I-95124 CATANIA, ITALY	Imperial College London; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Catania				Mihalich, Alessandra/0000-0002-1835-8241				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOPP S, 1995, J LIPID RES, V36, P1721; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; Costa MW, 1996, BIOCHEMISTRY-US, V35, P8662, DOI 10.1021/bi952801y; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; DUBIK D, 1992, ONCOGENE, V7, P1587; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEDOR M J, 1992, Current Opinion in Cell Biology, V4, P436, DOI 10.1016/0955-0674(92)90009-2; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gaubatz J W, 1986, Methods Enzymol, V129, P167; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HASSTEDT SJ, 1986, GENET EPIDEMIOL, V3, P53, DOI 10.1002/gepi.1370030106; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOLMES SE, 1992, J BIOL CHEM, V267, P19765; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LAGNA G, 1990, NUCLEIC ACIDS RES, V18, P5811, DOI 10.1093/nar/18.19.5811; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAGNAGHI P, 1994, BIOCHEM BIOPH RES CO, V205, P930, DOI 10.1006/bbrc.1994.2754; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; Neele DM, 1996, CIRCULATION, V94, P214; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; RAMHARACK R, 1995, J LIPID RES, V36, P1294; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; STAVENHAGEN JB, 1988, CELL, V55, P247, DOI 10.1016/0092-8674(88)90047-5; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; SUN XM, 1995, HUM MOL GENET, V4, P2125, DOI 10.1093/hmg/4.11.2125; Suzuki K, 1997, J CLIN INVEST, V99, P1361, DOI 10.1172/JCI119295; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TING CN, 1992, GENE DEV, V6, P1457, DOI 10.1101/gad.6.8.1457; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WADE DP, 1994, J BIOL CHEM, V269, P19757; WADE DP, 1991, ATHEROSCLEROSIS, V91, P63, DOI 10.1016/0021-9150(91)90187-8; WADE DP, 1993, P NATL ACAD SCI USA, V90, P1369, DOI 10.1073/pnas.90.4.1369; WHITE AL, 1994, J BIOL CHEM, V269, P9060; WHITE AL, 1994, J BIOL CHEM, V269, P28716; Wild SH, 1997, ARTERIOSCL THROM VAS, V17, P239, DOI 10.1161/01.ATV.17.2.239; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58	80	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30387	30399		10.1074/jbc.272.48.30387	http://dx.doi.org/10.1074/jbc.272.48.30387			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374529	hybrid			2022-12-25	WOS:A1997YH61300061
J	Csukai, M; Chen, CH; DeMatteis, MA; MochlyRosen, D				Csukai, M; Chen, CH; DeMatteis, MA; MochlyRosen, D			The coatomer protein beta'-COP, a selective binding protein (RACK) for protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D; INTRACELLULAR RECEPTOR; COATED VESICLES; GOLGI; PHOSPHORYLATION; SUBUNIT; LOCALIZATION; ACTIVATION; CELLS	Distinct subcellular localization of activated protein kinase C (PKC) isozymes is mediated by their binding to isozyme-specific RACKs (receptors for activated C-kinase), Our laboratory has previously isolated one such protein, RACK1, and demonstrated that this protein displays specificity for PKC beta. We have recently shown that at least part of the PKC epsilon RACK-binding site on PKC epsilon lies within the unique V1 region of this isozyme (Johnson, J. A., Gray, M. O., Chen, C.-H., and Mochly-Rosen, D. (1996) J. Biol, Chem. 271, 24962-24966), Here, we have used the PKC epsilon V1 region to clone a PKC epsilon-selective RACK, which was identified as the COPI coatomer protein, beta'-COP. Similar to RACK1, beta'-COP contains seven repeats of the WD40 motif and fulfills the criteria previously established for RACKs. Activated PKC epsilon colocalizes with beta'-COP in cardiac myocytes and binds to Golgi membranes in a beta'-COP-dependent manner, A role for PKC in control of secretion has been previously suggested, but this is the first report of direct protein/protein interaction of PKC epsilon with a protein involved in vesicular trafficking.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,DEPT CELL BIOL & ONCOL,I-66030 SANTA MARIA IMBAR,CHIETI,ITALY	Stanford University; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			De Matteis, Maria Antonietta/AHE-5161-2022	De Matteis, Maria Antonietta/0000-0003-0053-3061; Csukai, Michael/0000-0003-0615-7802; Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buccione R, 1996, J BIOL CHEM, V271, P3523; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; CSUKAI M, 1997, PROTEIN TARGETING PR; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Eskildsen-Helmond Yvonne E. G., 1996, Journal of Molecular and Cellular Cardiology, V28, pA136; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FORBES MS, 1980, TISSUE CELL, V12, P467, DOI 10.1016/0040-8166(80)90037-3; GRAY MO, 1995, CIRCUALTION S1, V92, P137; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KATOH N, 1983, BIOCHEM J, V209, P189, DOI 10.1042/bj2090189; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIMAS CJ, 1980, BIOCHEM BIOPH RES CO, V96, P1378, DOI 10.1016/0006-291X(80)90103-5; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Singer WD, 1996, J BIOL CHEM, V271, P4504; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	34	209	224	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29200	29206		10.1074/jbc.272.46.29200	http://dx.doi.org/10.1074/jbc.272.46.29200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360998	hybrid			2022-12-25	WOS:A1997YF68400057
J	Hanisch, UK; Lyons, SA; Prinz, M; Nolte, C; Weber, JR; Kettenmann, H; Kirchhoff, F				Hanisch, UK; Lyons, SA; Prinz, M; Nolte, C; Weber, JR; Kettenmann, H; Kirchhoff, F			Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to janus kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GROWTH-FACTOR; IL-2 RECEPTOR; NITRIC-OXIDE; ALPHA-CHAIN; BETA-CHAIN; ACTIVATION; SUBUNITS; PROTEIN; JAK3; PHOSPHORYLATION	The cytokine, interleukin (IL)-15, and the T cell growth factor, IL-2, exhibit a similar spectrum of immune effects and share the IL-2 receptor (IL-2R) subunits IL-2R beta and IL-2R gamma for signaling in hematopoietic cells. Numerous neuroregulatory activities of IL-2 have been suggested, but its expression in the normal central nervous system (CNS) is apparently very low and regionally restricted. We show by RNA and protein detection that IL-15, its specific receptor molecule, IL-15R alpha, and the signal-transducing receptor subunits, IL-2R beta and IL-2R gamma, are constitutively present in various regions of the developing and adult mouse brain, We further demonstrate, also at the single-cell level, that IL-15 and the components for IL-15R alpha/IL-2R beta gamma receptors are expressed by microglia, Tyrosine phosphorylation data are presented showing that IL-15 signaling in microglia involves Janus kinase 1 activity, At doses of 0.1-10 ng/ml, IL-15 affected functional properties of these cells, such as the production of nitric oxide, and supported their growth in culture, suggestive of a role as an autocrine growth factor. Microglial IL-15 could thus play a pivotal role in the CNS and may participate in certain CNS and neuroendocrine functions previously ascribed to IL-2.	HUMBOLDT UNIV BERLIN,CHAR MED SCH,DEPT NEUROL,D-10098 BERLIN,GERMANY	Humboldt University of Berlin	Hanisch, UK (corresponding author), MAX DELBRUCK CTR MOL MED,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.		Kettenmann, Helmut/AAJ-5142-2021; Kirchhoff, Frank/B-9335-2008	Kirchhoff, Frank/0000-0002-2324-2761; Nolte, Christiane/0000-0001-5398-3440; Kettenmann, Helmut/0000-0001-8208-0291				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; deJong JLO, 1996, J IMMUNOL, V156, P1339; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Elkabes S, 1996, J NEUROSCI, V16, P2508; GIRI JG, 1995, J LEUKOCYTE BIOL, V57, P763, DOI 10.1002/jlb.57.5.763; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Han DS, 1996, ONCOGENE, V12, P1015; HANISCH UK, 1996, BRAIN RES REV, V21, P246; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; Kaplan D, 1996, IMMUNOL TODAY, V17, P303, DOI 10.1016/0167-5699(96)30017-0; KETTENMANN H, 1993, GLIA, V7, P93, DOI 10.1002/glia.440070115; Kirchhoff F, 1996, J NEUROCHEM, V66, P1383; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAPCHAK PA, 1991, NEUROSCIENCE, V44, P173, DOI 10.1016/0306-4522(91)90259-Q; Lee YB, 1996, NEUROREPORT, V7, P1062, DOI 10.1097/00001756-199604100-00022; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MINAMI Y, 1992, BIOCHIM BIOPHYS ACTA, V1114, P163, DOI 10.1016/0304-419X(92)90013-O; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Moller T, 1997, J NEUROSCI, V17, P615; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NICOLA NA, 1994, GUIDEBOOK CYTOKINES, P1; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PERRY VH, 1994, MACROPHAGES NERVOUS; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATOH T, 1992, J BIOL CHEM, V267, P25423; SAWADA M, 1995, J NEUROCHEM, V64, P1973; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; WALDMANN TA, 1993, TRENDS PHARMACOL SCI, V14, P159, DOI 10.1016/0165-6147(93)90201-T; WHITTINGTON R, 1993, DRUGS, V46, P446, DOI 10.2165/00003495-199346030-00009; WILKINSON PC, 1995, J EXP MED, V181, P1255, DOI 10.1084/jem.181.3.1255; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X	46	81	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28853	28860		10.1074/jbc.272.46.28853	http://dx.doi.org/10.1074/jbc.272.46.28853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360952	hybrid			2022-12-25	WOS:A1997YF68400011
J	Spiro, MJ; Bhoyroo, VD; Spiro, RG				Spiro, MJ; Bhoyroo, VD; Spiro, RG			Molecular cloning and expression of rat liver endo-alpha-mannosidase, an N-linked oligosaccharide processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHENYLALANINE-HYDROXYLASE; GLUCOSIDASE-II-DEFICIENT; NITRIC-OXIDE SYNTHASE; ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; GOLGI; ENDOMANNOSIDASE; PROTEIN; PATHWAY; INHIBITORS	A clone containing the open reading frame of endo-alpha-D-mannosidase, an enzyme involved in early N-linked oligosaccharide processing, has been isolated from a rat Liver lambda gt11 cDNA library. This was accomplished by a strategy that involved purification of the endomannosidase from rat liver Golgi by Ligand affinity chromatography (Hiraizumi, S., Spohr, U., and Spiro, R. G, (1991) J, Biol, Chem. 269, 4697-4700) and preparative electrophoresis, followed by sequence determinations of tryptic peptides. Using degenerate primers based on these sequences, the polymerase chain reaction with rat liver cDNA as a template yielded a 470-base pair product suitable for library screening as web as Northern blot hybridization. EcoRI digestion of the purified lambda DNA released a 5.4-kilobase fragment that was amplified in Bluescript II SK(-) vector. Sequence analysis indicated that the deduced open reading frame of the endomannosidase extended from nucleotides 89 to 1441, encoding a protein of 451 amino acids and corresponding to a molecular mass of 52 kDa. Data base searches revealed no homology with any other known protein. When a vector coding for this protein fused to an NH2-terminal peptide containing a polyhistidine region was introduced into Escherichia coli, high levels of the enzyme were expressed upon induction with isopropyl-beta-D-thiogalactoside. Purification of the endomannosidase to electrophoretic homogeneity from E. coli lysates was accomplished by Ni2+-chelate and Glc alpha 1-->3Man-O-(CH2)(8)CONH-Affi-Gel Ligand chromatographies. Polyclonal antibodies raised against this protein reacted with Golgi endomannosidase. By both immunoblotting and silver staining, the purified E. coli-expressed enzyme was approximately 8 kDa smaller than anticipated from the open reading frame; timed induction studies indicated that this was due to scission of the enzyme's COOH-terminal end by host cell proteases. All rat tissues examined demonstrated mRNA levels (4,9-kilobase message) for the endomannosidase that correlated well with their enzyme activity.	JOSLIN DIABET CTR, ELLIOT P JOSLIN RES LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; Dairaku K, 1997, GLYCOBIOLOGY, V7, P579, DOI 10.1093/glycob/7.4.579; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HIRAIZUMI S, 1994, J BIOL CHEM, V269, P4697; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEDLEY FD, 1987, J BIOL CHEM, V262, P2228; LIU JW, 1994, J BIOL CHEM, V269, P11691; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1992, J BIOL CHEM, V267, P8443; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Sambrook J., 2002, MOL CLONING LAB MANU; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Weng S, 1996, GLYCOBIOLOGY, V6, P861, DOI 10.1093/glycob/6.8.861	31	27	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29356	29363		10.1074/jbc.272.46.29356	http://dx.doi.org/10.1074/jbc.272.46.29356			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361017	hybrid			2022-12-25	WOS:A1997YF68400076
J	Tai, GH; Nieduszynski, IA; Fullwood, NJ; Huckerby, TN				Tai, GH; Nieduszynski, IA; Fullwood, NJ; Huckerby, TN			Human corneal keratan sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; II DIGESTION; CUPROMERONIC BLUE; LINKAGE-REGION; OLIGOSACCHARIDES; PROTEOGLYCAN; CHAIN; CHROMATOGRAPHY; DISACCHARIDE	The keratan sulfate-containing proteoglycans were isolated from fourteen pooled human corneas (thirteen from 61- to 86-year-olds, plus one from a 12-year-old). These proteoglycans were subjected to digestion with the enzyme keratanase II, and the released oligosaccharides, which included nonreducing termini and repeat region oligosaccharides but not linkage regions, were reduced with alkaline borohydride and identified on two separate ion-exchange columns. Both of the latter had been calibrated with samples, most of which had been derived from bovine corneal keratan sulfate (Tai, G.-H., Huckerby, T. N., and Nieduszynski, I. A. (1996) J. Biol, Chem. 271, 23535-23546) and all of which had been fully characterized by NMR spectroscopic analysis, The capping structures identified in human corneal keratan sulfates occurred in the relative proportions: NeuAc alpha(2-6)- >NeuAc alpha(2-3)- >GaINAc(S)beta(1-3)-. The other groups of capping structures which had been identified in bovine corneal keratan sulfate, i.e. NeuGc alpha(2-3)-, NeuGc alpha(2-6)-, GlcNAc(S)beta(1-3)- were absent, although the possibility of the presence of some Gal alpha(1-3)-structures could not be excluded. In addition, the human sample showed significantly higher levels of alpha(1-3) fucosylated repeat region structures than did the bovine sample, and it is not clear whether this reflects a species or age dependence as the bovine corneas were from young animals, whereas the human corneas were predominantly from an older group. The charge densities and keratan sulfate chain sizes of the human and bovine keratan sulfate-containing proteoglycans were seen to be similar.	UNIV LANCASTER,INST ENVIRONM & NAT SCI,DEPT SCI BIOL,LANCASTER LA1 4YQ,ENGLAND; UNIV LANCASTER,INST ENVIRONM & NAT SCI,SCH PHYS & CHEM,CTR POLYMER,LANCASTER LA1 4YA,ENGLAND	Lancaster University; Lancaster University				Fullwood, Nigel James/0000-0002-9405-8515	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMITAGE WJ, 1990, CURRENT OPHTHALMIC S, P193; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; BROWN GM, 1997, LAB GUIDE GLYCOCONJU, P161; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; FORBES EG, 1994, FEBS LETT, V351, P433, DOI 10.1016/0014-5793(94)00907-4; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; Funderburgh JL, 1996, INVEST OPHTH VIS SCI, V37, P2989; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; HOUNSELL EF, 1986, EUR J BIOCHEM, V157, P375, DOI 10.1111/j.1432-1033.1986.tb09679.x; KELLER R, 1981, H-S Z PHYSIOL CHEM, V362, P327, DOI 10.1515/bchm2.1981.362.1.327; MEEK KM, 1986, COLLAGEN REL RES, V6, P203; MEEK KM, 1993, BIOPHYS J, V64, P273, DOI 10.1016/S0006-3495(93)81364-X; MEYER K, 1953, J BIOL CHEM, V205, P611; MEYER K, 1970, CHEM MOL BIOL INTERC, P15; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; SCOTT JE, 1992, J ANAT, V180, P155; SCOTT JE, 1985, BIOSCIENCE REP, V5, P765, DOI 10.1007/BF01119875; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25	23	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28227	28231		10.1074/jbc.272.45.28227	http://dx.doi.org/10.1074/jbc.272.45.28227			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353273	hybrid			2022-12-25	WOS:A1997YF21900013
J	Wong, LH; Krauer, KG; Hatzinisiriou, I; Estcourt, MJ; Hersey, P; Tam, ND; Edmondson, S; Devenish, RJ; Ralph, SJ				Wong, LH; Krauer, KG; Hatzinisiriou, I; Estcourt, MJ; Hersey, P; Tam, ND; Edmondson, S; Devenish, RJ; Ralph, SJ			Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; STIMULATED-GENE FACTOR-3; TYROSINE PHOSPHORYLATION; ALPHA-INTERFERON; TRANSCRIPTION FACTOR; CELLULAR RESPONSIVENESS; ANTIVIRAL ACTIVITY; MAMMALIAN-CELLS; DOWN-REGULATION; ACTIVATION	The mechanism of IFN resistance was examined in three long-term cell lines, SK-MEL-28, SK-MEL-3, and MM96, exhibiting significant variation in responsiveness to the antiproliferative and antiviral effects of type to IFNs, The JAK-STAT components involved in IFN signal transduction were analyzed in detail, After exposure to IFN, activation of the IFN type I receptor-linked tyrosine kinases, JAk-1 and TYK-2, was detected at similar levels in both IFN-sensitive and IFN-resistant cell types, indicating that IFN resistance did not result from a deficiency in signaling at the level of receptor-associated kinase activation. However, analysis of ISGF3 transcription factor components, STAT1, STAT2, and p48-ISGF3 gamma, revealed that their expression and activation correlated with cellular IFN responsiveness. The analysis was extended to also include IFN-sensitive primary melanocytes, three additional IFN-resistant melanoma cell lines, and seven cell cultures recently established from melanoma patient biopsies, It was consistently observed that the most marked difference in ISGF3 was a lack of STAT1 in the resistant versus the sensitive cells, Transfection of the IFN-resistant MM96 cell line to express increased levels of STAT1 protein partially restored IFN responsiveness in an antiviral assay. We conclude that a defect in the level of STAT1 and possibly all three ISGF3 components in IFN-resistant human melanoma cells may be a general phenomenon responsible for reduced cellular responsiveness of melanomas to IFNs.	MONASH UNIV,DEPT BIOCHEM & MOL BIOL,CLAYTON,VIC 3168,AUSTRALIA; JOHN HUNTER HOSP,IMMUNOL & ONCOL UNIT,NEWCASTLE,NSW 2300,AUSTRALIA; ROYAL CHILDRENS HOSP,CTR HORMONE RES,PARKVILLE,VIC 3052,AUSTRALIA	Monash University; John Hunter Hospital; Royal Children's Hospital Melbourne			Estcourt, Marie/E-6884-2017; Ralph, Stephen J./AAE-4888-2019; Wong, Lee H/H-9757-2012	Estcourt, Marie/0000-0001-8403-6075; Ralph, Stephen J./0000-0002-4335-092X; Wong, Lee H/0000-0002-4005-7330				AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; [Anonymous], 1982, MOL CLONING LAB MANU; BILLARD C, 1986, BLOOD, V67, P821; COATES AS, 1977, J NATL CANCER I, V59, P1325, DOI 10.1093/jnci/59.4.1325; COLAMONICI OR, 1992, BLOOD, V80, P744; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRON M, 1993, J INTERFERON RES, V13, P377, DOI 10.1089/jir.1993.13.377; EILERS A, 1993, MOL CELL BIOL, V13, P3245, DOI 10.1128/MCB.13.6.3245; ESTROZ Z, 1993, INTERFERONS BASIC PR, P53; GAO PQ, 1993, J BIOL CHEM, V268, P12380; GOUGH NM, 1987, ANAL BIOCHEM, V173, P93; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HERTZOG PJ, 1990, BIOCHEM INT, V22, P1095; HEYMAN M, 1994, LEUKEMIA, V8, P425; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; JOKLIK W K, 1991, P343; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; KURZROCK R, 1991, BIOL THERAPY CANCER, P247; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MEYSKENS FL, 1984, J CLIN ONCOL, V2, P1223, DOI 10.1200/JCO.1984.2.11.1223; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PAYNE MJ, 1994, BIOCHEM MOL BIOL INT, V33, P283; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; PFEFFER LM, 1990, CANCER RES, V50, P2654; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RALPH SJ, 1995, J IMMUNOL, V154, P2248; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHILLER JH, 1986, J INTERFERON RES, V6, P615, DOI 10.1089/jir.1986.6.615; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAQUEZ I, 1994, CELL, V70, P313; Whitehead R, 1973, PIGMENT CELL, V1, P382; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WINES BD, 1993, BIOCHEM MOL BIOL INT, V31, P1111; XU B, 1994, BLOOD, V84, P1942	48	213	228	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28779	28785		10.1074/jbc.272.45.28779	http://dx.doi.org/10.1074/jbc.272.45.28779			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353349	hybrid			2022-12-25	WOS:A1997YF21900089
J	Dessauer, CW; Gilman, AG				Dessauer, CW; Gilman, AG			The catalytic mechanism of mammalian adenylyl cyclase - Equilibrium binding and kinetic analysis of P-site inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE RECEPTORS; MEDIATED INHIBITION; 2',5'-DIDEOXYADENOSINE; REQUIREMENTS; PURIFICATION; EXPRESSION; FORSKOLIN; DOMAINS; FORM	The mechanism of P-site inhibition of adenylyl cyclase has been probed by equilibrium binding measurements using 2'-[H-3]deoxyadenosine, a P-site inhibitor, and by kinetic analysis of both the forward and reverse reactions (i.e. cyclic BMP and ATP synthesis, respectively). There is one binding site for 2'-deoxyadenosine per C-1/C-2 heterodimer; the K-d is 40 +/- 3 mu M. finding is observed only in the presence of one of the products of the adenylyl cyclase reaction, pyrophosphate (PPi). A substrate analog, Ap(CH2)pp (alpha,beta-methylene adenosine 5'-triphosphate), and cyclic AMP compete for the P-site in the presence of PPi, but P-site analogs do not compete for substrate binding (in the absence of PPi). Kinetic analysis indicates that release of products from the enzyme is random. These facts permit formulation of a model for the adenylyl cyclase reaction, for which we provide substantial kinetic support. We propose that P-site analogs act as dead-end inhibitors of product release, stabilizing an enzyme-product (E-PPi) complex by binding at the active site. Although product release is random, cyclic AMP dissociates from the enzyme preferentially. Release of PPi is slow and partially rate-limiting.			Dessauer, CW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NIGMS NIH HHS [GM34497, GM16905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; FLORIO VA, 1983, THESIS U VIRGINIA; HAYAISHI O, 1971, J BIOL CHEM, V246, P5840; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; Johnson RA, 1997, J BIOL CHEM, V272, P8962; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; LEE E, 1994, METHOD ENZYMOL, V237, P146; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LONDOS C, 1977, J BIOL CHEM, V252, P5957; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; LONDOS C, 1979, PHYSL REGULATORY FUN, P271; Segel I.H., 1975, ENZYME KINETICS; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Takai K, 1974, Methods Enzymol, V38, P160; TAKAI K, 1971, J BIOL CHEM, V246, P5843; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WELTON AF, 1980, BIOCHIM BIOPHYS ACTA, V615, P252, DOI 10.1016/0005-2744(80)90028-5; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WOLFF J, 1978, ARCH BIOCHEM BIOPHYS, V191, P161, DOI 10.1016/0003-9861(78)90078-4; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WOLIN MS, 1981, THESIS YALE U; WONG SKF, 1994, J BIOL CHEM, V269, P18968; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	34	115	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27787	27795		10.1074/jbc.272.44.27787	http://dx.doi.org/10.1074/jbc.272.44.27787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346923	hybrid			2022-12-25	WOS:A1997YD47300049
J	Nacharaju, P; Roy, RP; White, SP; Nagel, RL; Acharya, AS				Nacharaju, P; Roy, RP; White, SP; Nagel, RL; Acharya, AS			Inhibition of sickle beta-chain (beta(s))-dependent polymerization by nonhuman alpha-chains - A superinhibitory mouse-horse chimeric alpha-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REFINED CRYSTAL-STRUCTURE; DEOXYHEMOGLOBIN-S; INTERMOLECULAR CONTACTS; HEMOGLOBIN FIBERS; MOLECULAR-BASIS; SEMISYNTHESIS	Horse alpha-chain inhibits sickle beta-chain-dependent polymerization; however, its inhibitory potential is not as high as that of mouse alpha-chain. Horse alpha-(1-30) and alpha-(31-141) segments make, respectively, minor and major con tributions to the inhibitory potential of horse alpha-chain. The sum of the inhibitory potential of the two segments does not account for the inhibitory potential of the full-length horse alpha-chain. Although the polymerization inhibitory potential of horse alpha-chain is lower than mouse alpha-chain, the inhibitory potential of horse alpha-(31-141) is comparable to that of mouse alpha-(31-141). When mouse alpha-(1-30) is stitched to horse alpha-(31-141), the product is a chimeric alpha-chain with an inhibitory potential greater than mouse alpha-chain. In contrast, the stitching of horse alpha-(1-30) with mouse alpha-(31-141) had no additional inhibitory potential. Molecular modeling studies of HbS containing the mouse-horse chimeric alpha-chain indicate altered sidechain interactions at the alpha(1) beta(1) interface when compared with HbS, In addition, the AB/GH corner perturbations facilitate a different stereochemistry for the interaction of the epsilon-amino group of Lys-16(alpha) with the beta-carboxyl group of Asp-116(alpha), resulting in a decrease in the accessibility of the side chain of Lys-16(alpha) to the solvent. Based on molecular modeling, we speculate that these perturbations by themselves, or in synergy with the altered conformational aspects of the alpha(1) beta(1) interactions, represent the molecular basis of the superinhibitory potential of the mouse-horse chimeric alpha-chains.	UNIV OKLAHOMA,DEPT BIOCHEM & MOL BIOL,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater	Nacharaju, P (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,DIV HEMATOL,BRONX,NY 10461, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038655] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55435-03, HL-38655] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1979, J BIOL CHEM, V254, P7765; BIHOREAU MT, 1990, P NATL ACAD SCI USA, V87, P145; CLEGG JB, 1966, J MOL BIOL, V19, P91, DOI 10.1016/S0022-2836(66)80052-9; CONSTANTINI F, 1986, SCIENCE, V233, P1192; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; ERHART MA, 1987, GENETICS, V115, P511; FABRY ME, 1992, P NATL ACAD SCI USA, V89, P12150, DOI 10.1073/pnas.89.24.12150; LADNER RC, 1976, J MOL BIOL, V103, P675, DOI 10.1016/0022-2836(76)90227-8; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; POPP RA, 1967, J MOL BIOL, V27, P916; RHODA MD, 1988, BIOCHIM BIOPHYS ACTA, V952, P208, DOI 10.1016/0167-4838(88)90117-3; ROY RP, 1993, J BIOL CHEM, V268, P16406; ROY RP, 1994, METHOD ENZYMOL, V231, P194; ROY RP, 1995, J PROTEIN CHEM, V14, P81, DOI 10.1007/BF01888365; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; YIP YK, 1977, P NATL ACAD SCI USA, V74, P64, DOI 10.1073/pnas.74.1.64	20	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27869	27876		10.1074/jbc.272.44.27869	http://dx.doi.org/10.1074/jbc.272.44.27869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346934	hybrid			2022-12-25	WOS:A1997YD47300060
J	Patterson, B; Ruppel, KM; Wu, Y; Spudich, JA				Patterson, B; Ruppel, KM; Wu, Y; Spudich, JA			Cold-sensitive mutants G680V and G691C of Dictyostelium myosin II confer dramatically different biochemical defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; MUSCLE-CONTRACTION; NUCLEOTIDE BINDING; CRYSTAL-STRUCTURE; HEAVY-CHAIN; DISCOIDEUM; COMPLEX; ACTIN; SUBFRAGMENT-1; MOVEMENT	Cold-sensitive myosin mutants represent powerful tools for dissecting discrete deficiencies in myosin function. Biochemical characterization of two such mutants, G680V and G691C, has allowed us to identify separate facets of myosin motor function perturbed by each alteration. Compared with wild type, the G680V myosin exhibits a substantially enhanced affinity for several nucleotides, decreased ATPase activity, and overoccupancy or creation of a novel strongly actin-binding state. The properties of the novel strong binding state are consistent with a partial arrest or pausing at the onset of the mechanical stroke. The G691C mutant, on the other hand, exhibits an elevated basal ATPase indicative of premature phosphate release. By releasing phosphate without a requirement for actin binding, the G691C can bypass the part of the cycle involving the mechanical stroke. The two mutants, despite having alterations in glycine residues separated by only 11 residues, have dramatically different consequences on the mechanochemical cycle.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University	Patterson, B (corresponding author), UNIV ARIZONA,DEPT MOL & CELL BIOL,LSS452,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055977, R01GM040509, R01GM033289] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40509, GM33289, GM55977] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CHAUSSEPIED P, 1988, BIOCHEMISTRY-US, V27, P1778, DOI 10.1021/bi00405a059; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; KUCZMARSKI ER, 1991, J CELL BIOL, V114, P1191, DOI 10.1083/jcb.114.6.1191; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; PATTERSON B, 1995, GENETICS, V140, P505; Patterson B, 1996, GENETICS, V143, P801; PHAN BC, 1993, BIOCHEMISTRY-US, V32, P7712, DOI 10.1021/bi00081a016; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, CURR OPIN STRUC BIOL, V3, P944, DOI 10.1016/0959-440X(93)90160-M; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SEIDEL JC, 1969, BIOCHIM BIOPHYS ACTA, V180, P216, DOI 10.1016/0005-2728(69)90215-1; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; UE K, 1987, BIOCHEMISTRY-US, V26, P1889, DOI 10.1021/bi00381a016; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V	23	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27612	27617		10.1074/jbc.272.44.27612	http://dx.doi.org/10.1074/jbc.272.44.27612			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346898	hybrid			2022-12-25	WOS:A1997YD47300024
J	Dickson, RC; Nagiec, EE; Skrzypek, M; Tillman, P; Wells, GB; Lester, RL				Dickson, RC; Nagiec, EE; Skrzypek, M; Tillman, P; Wells, GB; Lester, RL			Sphingolipids are potential heat stress signals in Saccharomyces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENT STRE; TRANSCRIPTIONAL ACTIVATOR; TREHALOSE SYNTHESIS; CEREVISIAE; YEAST; PROTEIN; GENE; CERAMIDE; THERMOTOLERANCE; IDENTIFICATION	The ability of organisms to quickly respond to stresses requires the activation of many intracellular signal transduction pathways. The sphingolipid intermediate ceramide is thought to be particularly important for activating and coordinating signaling pathways during mammalian stress responses. Here we present the first evidence that ceramide and other sphingolipid intermediates are signaling molecules in the Saccharomyces cerevisiae heat stress response. Our data show a 2-3 fold transient increase in the concentration of C-18-dihydrosphingosine and C18-phytosphingosine, more than a 100-fold transient increase in C-20-dihydrosphingosine and C-20-phytosphingosine, and a more stable 2-fold increase in ceramide containing C-18-phytosphingosine and a 5-fold increase in ceramide containing C-20-phytosphingosine following heat stress. Treatment of cells with dihydrosphingosine activates transcription of the TPS2 gene encoding a subunit of trehalose synthase and causes trehalose, a known thermoprotectant, to accumulate. Dihydrosphingosine induces expression of a STRE-LacZ reporter gene, showing that the global stress response element, STRE, found in many yeast promoter sequences can be activated by sphingolipid signals. The TPS2 promoter contains four STREs that may mediate dihydrosphingosine responsiveness. Using genetic and other approaches it should be possible to identify sphingolipid signaling pathways in S. cerevisiae and quantify the importance of each during heat stress.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky	Dickson, RC (corresponding author), UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536, USA.				NIGMS NIH HHS [GM41302] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CROWE JH, 1992, ANNU REV PHYSIOL, V54, P579, DOI 10.1146/annurev.ph.54.030192.003051; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; DEVIRGILIO C, 1994, EUR J BIOCHEM, V219, P179; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; GHEGREGZABHER M, 1976, J CHROMATOGR, V127, P133; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANSEN SA, 1975, J CHROMATOGR, V107, P224, DOI 10.1016/S0021-9673(00)82770-3; HANSON BA, 1980, J LIPID RES, V21, P309; HOTTIGER T, 1994, EUR J BIOCHEM, V219, P187, DOI 10.1111/j.1432-1033.1994.tb19929.x; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LESTER RL, 1993, ADV LIPID RES, V26, P253; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MERRILL AHJ, 1996, LIPID 2 MESSENGERS, V8, P205; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; OKUYAMA H, 1979, J BIOL CHEM, V254, P2281; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SUR IP, 1994, YEAST, V10, P199, DOI 10.1002/yea.320100207; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	33	211	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30196	30200		10.1074/jbc.272.48.30196	http://dx.doi.org/10.1074/jbc.272.48.30196			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374502	hybrid			2022-12-25	WOS:A1997YH61300034
J	Lindstedt, KA; Mahon, MG; Foisner, R; Hermann, M; Nimpf, J; Schneider, WJ				Lindstedt, KA; Mahon, MG; Foisner, R; Hermann, M; Nimpf, J; Schneider, WJ			Receptor-associated protein in an oviparous species is correlated with the expression of a receptor variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHICKEN OOCYTE RECEPTOR; HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND-BINDING; MULTIFUNCTIONAL RECEPTOR; SORTING RECEPTOR; FAMILY MEMBER; LAYING HEN; VITELLOGENIN	The biosynthesis of proteins containing cysteine-rich domains requires chaperones for their correct folding. For instance, the 39-kDa receptor-associated protein (RAP) aides in the cell-surface targeting of newly synthesized members of the mammalian low density lipoprotein receptor (LDLR) gene family, which contains tandemly arranged clusters of hexacysteine repeats. In the chicken, an LDLR relative with eight such repeats is expressed as two different splice variant forms in cell type-specific fashion (Bujo, H., Lindstedt, K. A., Hermann, M., Mola Dalmau, L., Nimpf, J., and Schneider, W. J. (1995) J. Biol. Chem. 270, 23546-23551). To learn more about evolutionary aspects of RAP, its role in escorting of these different receptor splice variants, and other potential functions, we have extended our studies on the avian LDLR family to RAP. cDNA cloning, determination of tissue expression at both the transcript and the protein level, stable expression in COS cells, and binding studies with chicken RAP revealed that mammalian RAPs have retained many features of the nonamniotic proteins. However, structural details, e.g. the well defined internal triplicate repeats in the chicken protein, have been somewhat diluted during evolution. Interestingly, chicken RAP was found to correlate positively with the expression levels in somatic cells of the larger splice variant of the eight-cysteine repeat receptor, but not with those of the smaller variant, expressed only in germ cells. This is compatible with the possibility that RAP may play a role in receptor biology that could be complementing its function in assisting folding. Chicken RAP in crude extracts of the stable expressor COS cells is able to bind to LDLR relatives in ligand blots without requirement for prior purification of the ligand. Thus, in conjunction with the avian model of massive lipid transport to germ cells, these cells provide a novel comparative system amenable to investigation of the biological functions of RAP.	UNIV & BIOCTR VIENNA, DEPT MOL GENET, A-1030 VIENNA, AUSTRIA; UNIV & BIOCTR VIENNA, DEPT BIOCHEM & CELL BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; University of Vienna			Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647; Nimpf, Johannes/0000-0002-9273-3492; Hermann, Marcela/0000-0003-2298-4269				BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU G, 1995, EMBO J, V14, P2389; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; ELKIN RG, 1995, J NUTR, V125, P1258; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; Hermann M, 1997, J LIPID RES, V38, P1308; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hiesberger T, 1996, J BIOL CHEM, V271, P28792, DOI 10.1074/jbc.271.46.28792; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Morwald S, 1997, ARTERIOSCL THROM VAS, V17, P996, DOI 10.1161/01.ATV.17.5.996; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P271, DOI 10.1016/0005-2760(90)90130-P; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	44	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30221	30227		10.1074/jbc.272.48.30221	http://dx.doi.org/10.1074/jbc.272.48.30221			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374506	hybrid			2022-12-25	WOS:A1997YH61300038
J	Scherzinger, E; Ziegelin, G; Barcena, M; Carazo, JM; Lurz, R; Lanka, E				Scherzinger, E; Ziegelin, G; Barcena, M; Carazo, JM; Lurz, R; Lanka, E			The RepA protein of plasmid RSF1010 is a replicative DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; XERODERMA-PIGMENTOSUM; OLIGOMERIC STRUCTURE; ELECTRON-MICROSCOPY; EXCISION-REPAIR; GENE-4 PROTEIN; T-ANTIGEN; BACTERIOPHAGE-T7; ORIGIN	The RepA protein of the mobilizable broad host range plasmid RSF1010 has a key function in its replication. RepA is one of the smallest known helicases. The protein forms a homohexamer of 29,896-Da subunits. A variety of methods were used to analyze the quaternary structure of RepA. Gel filtration and cross-linking experiments demonstrated the hexameric structure, which was confirmed by electron microscopy and image reconstruction. These results agree with recent data obtained from RepA crystals diffracting at 3.5-Angstrom resolution (Roleke, D., Hoier, H., Bartsch, C., Umbach, P., Scherzinger, E., Lurz, R., and Saenger, W. (1997) Acta Crystallogr. Sec. D 53, 213-216). The RepA helicase has 5' --> 3' polarity. As do most true replicative helicases, RepA prefers a tailed substrate with an unpaired 3'-tail mimicking a replication fork. Optimal unwinding activity was achieved at the remarkably low pH of 5.5. In the presence of Mg2+ (Mn2+) ions, the RepA activity is fueled by ATP, dATP, GTP, and dGTP and less efficiently by CTP and dCTP. UTP and dTTP are poor effectors. Nonhydrolyzable ATP analogues, ADP, and pyrophosphate inhibit the helicase activity, whereas inorganic phosphate does not. The presence of Escherichia coli single-stranded DNA-binding protein stimulates unwinding at physiological pH 2-3-fold, whereas the RSF1010 replicon-specific primase, RepB' protein, has no effect, either in the presence or in the absence of single-stranded DNA-binding protein.	MAX PLANCK INST MOL GENET, ABT LEHRACH, D-14195 BERLIN, GERMANY; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN	Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Barcena, Montserrat/B-5823-2012; Garcia, Jose Maria Carazo/E-9234-2016	Barcena, Montserrat/0000-0002-7719-4443; Garcia, Jose Maria Carazo/0000-0003-0788-8447				ARAI KI, 1951, PROG NUCL ACID RES M, V26, P9; Bollum F.J., 1974, ENZYMES, P145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DREISEIKELMANN B, 1987, NUCLEIC ACIDS RES, V15, P385, DOI 10.1093/nar/15.2.385; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GORMLEY EP, 1991, J BACTERIOL, V173, P6705, DOI 10.1128/jb.173.21.6705-6708.1991; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HARING V, 1985, P NATL ACAD SCI USA, V82, P6090, DOI 10.1073/pnas.82.18.6090; HARING V, 1989, PROMISCUOUS PLASMIDS, P95; HONDA Y, 1992, NUCLEIC ACIDS RES, V20, P1733, DOI 10.1093/nar/20.7.1733; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKA E, 1978, J BIOL CHEM, V253, P5847; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Richardson C. C., 1981, ENZYMES, P299; Roleke D, 1997, ACTA CRYSTALLOGR D, V53, P213, DOI 10.1107/S0907444996012565; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SanMartin MC, 1997, J MOL BIOL, V268, P15, DOI 10.1006/jmbi.1997.0952; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHEKMAN R, 1972, P NATL ACAD SCI USA, V69, P2691, DOI 10.1073/pnas.69.9.2691; SCHERZINGER E, 1991, NUCLEIC ACIDS RES, V19, P1203, DOI 10.1093/nar/19.6.1203; SCHERZINGER E, 1984, P NATL ACAD SCI-BIOL, V81, P654, DOI 10.1073/pnas.81.3.654; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TANAKA K, 1994, NUCLEIC ACIDS RES, V22, P767, DOI 10.1093/nar/22.5.767; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521	63	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30228	30236		10.1074/jbc.272.48.30228	http://dx.doi.org/10.1074/jbc.272.48.30228			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374507	hybrid			2022-12-25	WOS:A1997YH61300039
J	Takahashi, Y; Nakayama, K; Itoh, S; FujiiKuriyama, Y; Kamataki, T				Takahashi, Y; Nakayama, K; Itoh, S; FujiiKuriyama, Y; Kamataki, T			Inhibition of the transcription of CYP1A1 gene by the upstream stimulatory factor 1 in rabbits - Competitive binding of USF1 with AhR center dot Arnt complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; ARYL-HYDROCARBON RECEPTOR; NEGATIVE REGULATORY ELEMENT; DIOXIN-RESPONSIVE ENHANCER; HEAT-SHOCK PROTEIN; RNA POLYMERASE-II; DNA RECOGNITION; ONTOGENETIC EXPRESSION; CRYSTAL-STRUCTURE; HEPATOMA-CELLS	A xenobiotic-responsive element (XRE)-binding factor(s) other than the AhR.Arnt complex was found to inhibit the transcription of CYP1A1 gene in the liver from adult rabbits, known to be nonresponsive to CYP1A1 inducers, The constitutive factor(s) in liver nuclear extracts bound to the core sequence of XRE. The binding was eliminated by the presence of an excess amount of the AhR.Arnt complex synthesized in vitro. To identify the constitutive factor(s), a sequence similar to rabbit XRE was sought. It was found that the sequence of rabbit XRE overlapped with that of the upstream stimulatory factor 1 (USF1)-binding site in the mouse metallothionein I promoter, In fact, a super shift assay using a specific antibody against human USF1 indicated that USF1 was capable of binding to rabbit XRE. Additionally, the AhR.Arnt-mediated activation of XRE-TK/Luc reporter gene in RK13 cells was blocked by the transfection with a USF1 expression vector with the amounts of the expression vector transfected. These results indicate that the XRE of the rabbit CYP1A1 gene is recognized by the basic helix-loop-helix proteins to regulate the expression of CYP1A1 in both an agonistic (AhR.Arnt) and an antagonistic (USF1) manner.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,DIV DRUG METAB,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University				Itoh, Susumu/0000-0002-7967-0730				ALVARES AP, 1982, LIFE SCI, V30, P747, DOI 10.1016/0024-3205(82)90608-7; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; ATLAS SA, 1977, J BIOL CHEM, V252, P4712; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bhat R, 1996, INT J BIOCHEM CELL B, V28, P217; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BOUCHER PD, 1995, CARCINOGENESIS, V16, P383, DOI 10.1093/carcin/16.2.383; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; Corton JC, 1996, TOXICOL LETT, V85, P67, DOI 10.1016/0378-4274(96)03636-3; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; GONZALEZ FJ, 1993, PHARMACOGENETICS, V3, P51, DOI 10.1097/00008571-199302000-00006; GONZALEZ FJ, 1984, MOL PHARMACOL, V26, P117; GRADIN K, 1993, J BIOL CHEM, V268, P4061; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; KAGAWA N, 1987, J BIOCHEM-TOKYO, V101, P1471, DOI 10.1093/oxfordjournals.jbchem.a122017; KAHL GF, 1980, DEV PHARMACOL THERAP, V1, P137, DOI 10.1159/000455531; KITAMURA R, 1992, ARCH BIOCHEM BIOPHYS, V292, P136, DOI 10.1016/0003-9861(92)90061-Z; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MIMURA J, 1996, ABSTRACT JAPANESE BI, V68, P1302; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrock J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STERLING K, 1993, MOL PHARMACOL, V44, P560; STORM DK, 1992, ARCH BIOCHEM BIOPHYS, V294, P707; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	61	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30025	30031		10.1074/jbc.272.48.30025	http://dx.doi.org/10.1074/jbc.272.48.30025			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374477	hybrid			2022-12-25	WOS:A1997YH61300009
J	Monden, T; Wondisford, FE; Hollenberg, AN				Monden, T; Wondisford, FE; Hollenberg, AN			Isolation and characterization of a novel ligand-dependent thyroid hormone receptor-coactivating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; RESPONSE ELEMENT; TRANSACTIVATION DOMAIN; ESTROGEN-RECEPTOR; CO-REPRESSOR; A/B DOMAIN; IDENTIFICATION	The thyroid hormone receptor (TR) regulates the expression of target genes upon binding to triiodothyro nine (T-3) response elements, In the presence of T-3, the TR recruits coactivating proteins that both modulate and integrate the ligand response, We report here the cloning of a novel protein using the TR ligand-binding domain as bait in the yeast two-hybrid system. Analysis of a putative full length clone demonstrates a cDNA sequence that encodes a protein of 920 amino acids with a size of 120 kDa (p120), Alignment with known sequences shows homology to a previously identified protein of unknown function, termed skeletal muscle abundant protein, Interaction studies demonstrate that p120 interacts with the TR AF-2 domain in the presence of ligand through a 111-amino acid region. Northern analysis demonstrates widespread expression in human tissues. Cotransfection assays in CV-1 cells demonstrate that p120 enhances TR-mediated transactivation on multiple T-3 response elements in the presence of T-3. In addition, CREB-binding protein synergizes with p120 to enhance this effect. When linked to the GAL4 DNA-bind ing domain, p120 is an activator of transcription alone. Thus, p120 satisfies a number of important criteria as a nuclear receptor coactivator.	BETH ISRAEL MED CTR, DEPT MED, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, K08DK002354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02354, DK-49126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CARR FE, 1994, J BIOL CHEM, V269, P4175; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Collingwood TN, 1997, P NATL ACAD SCI USA, V94, P248, DOI 10.1073/pnas.94.1.248; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; Nielsen MS, 1996, BBA-GENE STRUCT EXPR, V1306, P14, DOI 10.1016/0167-4781(95)00239-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TOMURA H, 1995, P NATL ACAD SCI USA, V92, P5600, DOI 10.1073/pnas.92.12.5600; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	46	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29834	29841		10.1074/jbc.272.47.29834	http://dx.doi.org/10.1074/jbc.272.47.29834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368056	hybrid			2022-12-25	WOS:A1997YG64700066
J	Sugimoto, T; Stewart, S; Guan, KL				Sugimoto, T; Stewart, S; Guan, KL			The calcium/calmodulin-dependent protein phosphatase calcineurin is the major Elk-1 phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX-FORMATION; TRANSCRIPTIONAL ACTIVATION; CYCLOSPORINE-A; FACTOR P62TCF; KINASE; PHOSPHORYLATION; CELLS; SPECIFICITY; TRANSIENT; PROMOTER	The transcription factor Elk-1 is a component of ternary complex factor and regulates gene expression in response to a wide variety of extracellular stimuli. Phosphorylation of the C-terminal domain of Elk-1, especially at serine 383, is important for its transactivation activity. Recently mitogen-activated protein kinases, such as extracellular signal-regulated kinase, stress-activated protein kinase, and p38 mitogen-activated protein kinase have been demonstrated to be Elk-1 kinases. However, negative regulators of Elk-1, such as protein phosphatases, still remain to be identified. Here we report that COS cell. lysates were able to dephosphorylate an extracellular signal-regulated kinase-phosphorylated glutathione S-transferase-Elkc fusion protein, in eluding serine 383, The phosphatase activity was inhibited by cyclosporin A (a calcineurin inhibitor) but not by okadaic acid (a PPI and PP2A inhibitor). Purified calcineurin also could efficiently dephosphorylate glutathione S-transferase-Elkc in vitro. Pretreatment of COS cells with cyclosporin A significantly enhanced epidermal growth factor-induced serine 383 Elk-l phosphorylation whereas ionomycin inhibited the Elk-1 phosphorylation. These data provide both in vitro and in vivo evidence that calcineurin is the major Elk-l phosphatase and plays a critical role in Elk-l regulation. The identification of calcineurin as the major Elk-1 phosphatase may provide a mechanism for Elk-l regulation by Ca2+ signals as well as a possible biochemical basis for the neurotoxicity and nephrotoxicity of the immunosuppressant drug cyclosporin A.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,INST GERONTOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09676] Funding Source: Medline; NIGMS NIH HHS [GM 51586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAISER AR, 1989, CURRENT PROTOCOLS MO; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Hardie D. G., 1993, PROTEIN PHOSPHORYLAT; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; SEGAR R, 1995, FASEB J, V9, P726; SU QX, 1995, RENAL PHYSIOL BIOCH, V18, P128; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	36	111	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29415	29418		10.1074/jbc.272.47.29415	http://dx.doi.org/10.1074/jbc.272.47.29415			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367995	hybrid			2022-12-25	WOS:A1997YG64700005
J	Thompson, LJ; Bollen, M; Fields, AP				Thompson, LJ; Bollen, M; Fields, AP			Identification of protein phosphatase 1 as a mitotic lamin phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE-1; SACCHAROMYCES-CEREVISIAE; AFFINITY-CHROMATOGRAPHY; PHOSPHORYLATION SITES; OKADAIC ACID; TYPE-1; MITOSIS; ENCODES	At the onset of mitosis, the nuclear lamins are hyperphosphorylated leading to nuclear lamina disassembly, a process required for nuclear envelope breakdown and entry into mitosis, Multiple Iamin kinases have been identified, including protein kinase C, that mediate mitotic lamin phosphorylation and mitotic nuclear lamina disassembly. Conversely, lamin dephosphorylation is required for nuclear lamina reassembly at the completion of mitosis, However, the protein phosphatase(s) responsible for the removal of mitotic phosphates from the lamins is unknown, In this study, we use human lamin B phosphorylated at mitosis-specific sites as a substrate to identify and characterize a lamin phosphatase activity from mitotic human cells, Several lines of evidence demonstrate that the mitotic lamin phosphatase corresponds to type 1 protein phosphatase (PP1), First, mitotic lamin phosphatase activity is inhibited by high nanomolar concentrations of okadaic acid and the specific PPI peptide inhibitor, inhibitor-a, Second, mitotic Iamin phosphatase activity cofractionates with PP1 after ion exchange chromatography, Third, microcystin-agarose depletes mitotic extracts of both PP1 and Iamin phosphatase activity. Our results demonstrate that PP1 is the major mitotic lamin phosphatase responsible for removal of mitotic phosphates from lamin B, a process required for nuclear lamina reassembly.	UNIV TEXAS, MED BRANCH, SEALY CTR ONCOL & HEMATOL, GALVESTON, TX 77555 USA; KATHOLIEKE UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM	University of Texas System; University of Texas Medical Branch Galveston; KU Leuven								Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; JOHNSTON JA, 1994, CELL MOTIL CYTOSKEL, V29, P280, DOI 10.1002/cm.970290311; LUDLOW JW, 1995, SEMIN CANCER BIOL, V6, P195, DOI 10.1006/scbi.1995.0026; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; Moir RD, 1993, CURR OPIN CELL BIOL, V5, P408, DOI 10.1016/0955-0674(93)90004-A; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; Paulson JR, 1996, J CELL SCI, V109, P1437; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Tu JL, 1996, MOL CELL BIOL, V16, P4199	37	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29693	29697		10.1074/jbc.272.47.29693	http://dx.doi.org/10.1074/jbc.272.47.29693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368037	hybrid			2022-12-25	WOS:A1997YG64700047
J	Cherian, M; Smith, JB; Jiang, XY; Abraham, EC				Cherian, M; Smith, JB; Jiang, XY; Abraham, EC			Influence of protein-glutathione mixed disulfide on the chaperone-like function of alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; HUMAN LENS; MOLECULAR CHAPERONE; A-CRYSTALLIN; POSTTRANSLATIONAL MODIFICATIONS; TISSUES; CATARACTOGENESIS; EXPRESSION; OXIDATION	In an earlier report we showed that incubation of alpha-crystallin with oxidized glutathione results in significant loss of its chaperone-like activity. In the present study, we determined the effect of protein-glutathione mixed disulfides (PSSG), formed at Cys-131 in bovine alpha A-crystallin, and Cys-131 and Cys-142 in human alpha A-crystallin, on the function of alpha-crystallin as a molecular chaperone. After incubation of calf and young human alpha(L)-crystallin fractions with oxidized glutathione, levels of PSSG were determined by performic acid oxidation of the mixed disulfides followed by reversed-phase high pressure liquid chromatography separation of phenylisothiocyanate-derivatized glutathione sulfonic acid, Levels of PSSG increased from 0.01 to 0.14 nmol/nmol (20 kDa) in bovine alpha(L)-crystallin and from 0.022 to 0.25 nmol/nmol in human alpha(L)-crystallin. The presence of glutathione adducts at Cys-131 and Cys-142 mere confirmed by mass spectral analysis. The chaperone-like activity was determined by the heat denaturation assay using beta(L)-crystallin as the target protein, To examine the reversibility of the effect of mixed disulfides on chaperone activity, studies were done before and after reduction with the glutathione reductase system. Increased levels of PSSG resulted in lower chaperone activities, Treatment with the glutathione reductase system led to 80% reduction in PSSG levels with a concomitant recovery of the chaperone activity, These results suggest that cysteine(s) in the alpha A-crystallin subunit play an important role in the function of alpha-crystallin as a molecular chaperone.	MED COLL GEORGIA,DEPT BIOCHEM & MOL BIOL,AUGUSTA,GA 30912; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	University System of Georgia; Augusta University; University of Nebraska System; University of Nebraska Lincoln					NEI NIH HHS [EY07394, EY07609, EY11352] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007394, R01EY007609, R01EY011352] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; DICKERSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1157, P141, DOI 10.1016/0304-4165(93)90057-F; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FUJII N, 1994, BBA-PROTEIN STRUCT M, V1204, P157, DOI 10.1016/0167-4838(94)90003-5; GROENEN PJTA, 1993, FEBS LETT, V322, P69, DOI 10.1016/0014-5793(93)81113-E; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HORWITZ J, 1992, CURR EYE RES, V11, P817, DOI 10.3109/02713689209000754; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUMARI K, 1994, ANAL BIOCHEM, V220, P374, DOI 10.1006/abio.1994.1352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; Lund AL, 1996, EXP EYE RES, V63, P661, DOI 10.1006/exer.1996.0160; MIESBAUER LR, 1994, J BIOL CHEM, V269, P12494; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; ROA PV, 1995, BIOCHIM BIOPHYS ACTA, V1245, P439; SIPPEL THEODORE O., 1966, INVEST OPHTHALMOL, V5, P568; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; SWAMY MS, 1992, EXP EYE RES, V54, P337, DOI 10.1016/0014-4835(92)90046-U; TAKEMOTO L, 1992, CURR EYE RES, V11, P651, DOI 10.3109/02713689209000738; Takemoto LJ, 1996, BIOCHEM BIOPH RES CO, V223, P216, DOI 10.1006/bbrc.1996.0873; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311	36	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29099	29103		10.1074/jbc.272.46.29099	http://dx.doi.org/10.1074/jbc.272.46.29099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360985	hybrid			2022-12-25	WOS:A1997YF68400044
J	Nimchinsky, EA; Hof, PR; Janssen, WGM; Morrison, JH; Schmauss, C				Nimchinsky, EA; Hof, PR; Janssen, WGM; Morrison, JH; Schmauss, C			Expression of dopamine D-3 receptor dimers and tetramers in brain and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CYTOPLASMIC DOMAIN; MONKEY PREFRONTAL CORTEX; SF9 CELLS; PRIMATE NEOCORTEX; CEREBRAL-CORTEX; MACAQUE MONKEY; IN-VIVO; PHOSPHORYLATION; PALMITOYLATION; IDENTIFICATION	The expression and characteristics of the dopamine D-3 receptor protein were studied in brain and in stably transfected GH3 cells, Monoclonal antibodies were used for immunoprecipitation and immunoblot experiments. Immunoprecipitates obtained from primate and rodent brain tissues contain a low molecular weight D-3 protein and one or two larger protein species whose molecular mass are integral multiples of the low molecular weight protein and thus appear to have resulted from dimerization and tetramerization of a D-3 monomer, Whereas D-3 receptor multimers were found to be abundantly expressed in brain, the major D-3 immunoreactivity expressed in stable D-3-expressing rat GH3 cells was found to be a monomer, However, multimeric D-3 receptor species with electrophoretic mobilities similar to those expressed in brain were also seen in D-3-expressing GH3 cells when a truncated D-3-like protein (named D-3nf) was coexpressed in these cells, Furthermore, results from immunoprecipitation experiments with D-3- and D-3nf-specific antibodies show that the higher order D-3 proteins extracted from brain and D-3/D-3nf double transfectants also contain D-3nf immunoreactivity, and immunocytochemical studies show that the expression of D-3 and D-3nf immunoreactivities overlaps substantially in monkey and rat cortical neurons. Altogether, these data show oligomeric D-3 receptor protein expression in vivo and they suggest that at least some of these oligomers are heteroligomeric protein complexes containing D-3 and the truncated D-3nf protein.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, NEUROBIOL AGING LABS, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OPHTHALMOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR DEV & MOL BIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Nimchinsky, Esther/GXF-5277-2022; Morrison, John/F-9229-2012		NIMH NIH HHS [MH45212, MH51623] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALI H, 1994, J BIOL CHEM, V269, P24557; ARIANO MA, 1994, BRAIN RES, V649, P95, DOI 10.1016/0006-8993(94)91052-9; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501; GOLDMANRAKIC PS, 1992, J NEURAL TRANSM-GEN, P163; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERROELEN L, 1994, BRAIN RES, V648, P222, DOI 10.1016/0006-8993(94)91121-5; HOF PR, 1995, J COMP NEUROL, V352, P161, DOI 10.1002/cne.903520202; HOF PR, 1992, CEREB CORTEX, V2, P456, DOI 10.1093/cercor/2.6.456; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LARSON ER, 1995, SYNAPSE, V20, P325, DOI 10.1002/syn.890200406; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; LEWIS DA, 1986, HUM NEUROBIOL, V5, P181; LEWIS DA, 1988, BRAIN RES, V449, P225, DOI 10.1016/0006-8993(88)91040-2; LEWIS DA, 1987, J NEUROSCI, V7, P279; LIU K, 1994, J BIOL CHEM, V269, P29220; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MURRAY AM, 1992, EUR J PHARM-MOLEC PH, V227, P443, DOI 10.1016/0922-4106(92)90164-Q; MURRAY AM, 1994, P NATL ACAD SCI USA, V91, P11271, DOI 10.1073/pnas.91.23.11271; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; SCHMAUSS C, 1993, P NATL ACAD SCI USA, V90, P8942, DOI 10.1073/pnas.90.19.8942; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; SMILEY JF, 1993, CEREB CORTEX, V3, P223, DOI 10.1093/cercor/3.3.223; SMILEY JF, 1992, J COMP NEUROL, V321, P325, DOI 10.1002/cne.903210302; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	33	144	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29229	29237		10.1074/jbc.272.46.29229	http://dx.doi.org/10.1074/jbc.272.46.29229			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361002	hybrid			2022-12-25	WOS:A1997YF68400061
J	Oligino, L; Lung, FDT; Sastry, L; Bigelow, J; Cao, T; Curran, M; Burke, TR; Wang, SM; Krag, D; Roller, PP; King, CR				Oligino, L; Lung, FDT; Sastry, L; Bigelow, J; Cao, T; Curran, M; Burke, TR; Wang, SM; Krag, D; Roller, PP; King, CR			Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; MITOGENIC SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDE EXCHANGE; PHAGE DISPLAY LIBRARIES; TERMINAL SH2 DOMAIN; ADAPTER PROTEIN; EGF RECEPTOR; CRYSTAL-STRUCTURE; RAS PATHWAY; CELL-LINES	Critical intracellular signals in normal and malignant cells are transmitted by the adaptor protein Grb2 by means of its Src homology 2 (SH2) domain, which binds to phosphotyrosyl (pTyr) residues generated by the activation of tyrosine kinases, To understand this important control point and to design inhibitors, previous investigations have focused on the molecular mechanisms by which the Grb2 SH2 domain selectively binds pTyr containing peptides, In the current study, we demonstrate that the Grb2 SH2 domain can also bind in a pTyr independent manner, Using phage display, an 11-amino acid cyclic peptide, G1, has been identified that binds to the Grb2 SH2 domain but not the src SH2 domain, Synthetic G1 peptide blocks GrbP SH2 domain association (IC50 10-25 mu M) with a g-amino acid pTyr-containing peptide derived from the SHC protein (pTyr317), These data and amino acid substitution analysis indicate that G1 interacts in the phosphopeptide binding site, G1 peptide requires a YXN sequence similar to that found in natural pTyr-containing ligands, and phosphorylation of the tyrosine increases G1 inhibitory activity. G1 also requires an internal disulfide bond to maintain the active binding conformation, Since the G1 peptide does not contain pTyr, it defines a new type of SH2 domain binding motif that may advance the design of Grb2 antagonists.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; UNIV VERMONT, VERMONT CANC CTR, BURLINGTON, VT 05405 USA; NCI, MED CHEM LAB, DIV BASIC SCI, NIH, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, MED CTR, DEPT NEUROL, WASHINGTON, DC 20007 USA	Georgetown University; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Burke, Terrence R/N-2601-2014	Wang, Shaomeng/0000-0002-8782-6950; Burke, Terrence/0000-0001-9925-8586				Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DALY RJ, 1994, ONCOGENE, V9, P2723; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILMER T, 1994, J BIOL CHEM, V269, P31711; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; HANAZONO Y, 1995, JPN J CANCER RES, V86, P336, DOI 10.1111/j.1349-7006.1995.tb03061.x; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; HENSMANN M, 1994, PROTEIN SCI, V3, P1020, DOI 10.1002/pro.5560030704; JANES PW, 1994, ONCOGENE, V9, P3601; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Li M, 1996, NAT BIOTECHNOL, V14, P986, DOI 10.1038/nbt0896-986; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MARENGERE LEM, 1994, J CELL SCI, P97; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Metzler WJ, 1996, BIOCHEMISTRY-US, V35, P6201, DOI 10.1021/bi960157x; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIKOL V, 1995, J MOL BIOL, V254, P86, DOI 10.1006/jmbi.1995.0601; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Raffel GD, 1996, J BIOL CHEM, V271, P4640; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; ROBEY F, 1994, BROMOACETYLATED SYNT; Rojas M, 1997, BIOCHEM BIOPH RES CO, V234, P675, DOI 10.1006/bbrc.1997.6694; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Thornton KH, 1996, BIOCHEMISTRY-US, V35, P11852, DOI 10.1021/bi952615s; WAKSMAN G, 1994, CELL MOL BIOL, V40, P611; Wang YS, 1996, J BIOMOL NMR, V7, P89; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; XU RX, 1995, BIOCHEMISTRY-US, V34, P2107, DOI 10.1021/bi00007a003; YE B, 1995, J MED CHEM, V38, P4270, DOI 10.1021/jm00021a016; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	62	99	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29046	29052		10.1074/jbc.272.46.29046	http://dx.doi.org/10.1074/jbc.272.46.29046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360978	hybrid			2022-12-25	WOS:A1997YF68400037
J	Scherer, PE; Lewis, RY; Volonte, D; Engelman, JA; Galbiati, F; Couet, J; Kohtz, DS; vanDonselaar, E; Peters, P; Lisanti, MP				Scherer, PE; Lewis, RY; Volonte, D; Engelman, JA; Galbiati, F; Couet, J; Kohtz, DS; vanDonselaar, E; Peters, P; Lisanti, MP			Cell-type and tissue-specific expression of caveolin-2 - Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEMBRANE-PROTEIN; TRANSPORT VESICLES; TRANSFORMED-CELLS; PLASMA-MEMBRANE; COMPONENT; SEQUENCE; VIP21-CAVEOLIN; DIFFERENTIATION; IDENTIFICATION	Caveolae are microdomains of the plasma membrane that have been implicated in organizing and compartmentalizing signal transducing molecules, Caveolin, a 21-24-kDa integral membrane protein, is a principal structural component of caveolae membrane in vivo. Recently, we and other laboratories have identified a family of caveolin-related proteins; caveolin has been retermed caveolin-1. Here, we examine the cell type and tissue-specific expression of caveolin-2, For this purpose, we generated a novel mono-specific monoclonal antibody probe that recognizes only caveolin-2, but not caveolins-1 and -3, A survey of cell and tissue types demonstrates that the caveolin-2 protein is most abundantly expressed in endothelial cells, smooth muscle cells, skeletal myoblasts (L6, BC3H1, C2C12), fibroblasts, and 3T3-L1 cells differentiated to adipocytes. This pattern of caveolin-2 protein expression most closely resembles the cellular distribution of caveolin-1, In line with these observations, co-immunoprecipitation experiments with mono-specific antibodies directed against either caveolin-1 or caveolin-2 directly show that these molecules form a stable hetero-oligomeric complex, The in vivo relevance of this complex was further revealed by dual-labeling studies employing confocal laser scanning fluorescence microscopy. Our results indicate that caveolins 1 and 2 are strictly co localized within the plasma membrane and other internal cellular membranes, Ultrastructurally, this pattern of caveolin-2 localization corresponds to caveolae membranes as seen by immunoelectron microscopy, Despite this strict co-localization, it appears that regulation of caveolin-2 expression occurs independently of the expression of either caveolin-1 or caveolin-3 as observed using two different model cell systems, Although caveolin-1 expression is down-regulated in response to oncogenic transformation of NIH 3T3 cells, caveolin-2 protein levels remain unchanged, Also, caveolin-2 protein levels remain unchanged during the differentiation of C2C12 cells from myoblasts to myotubes, while caveolin-3 levels are dramatically induced by this process, These results suggest that expression levels of caveolins 1, 2, and 3 can be independently up-regulated or down-regulated in response to a variety of distinct cellular cues.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, BRONX, NY 10461 USA; LAVAL HOSP, RES CTR, Ste Foy, PQ, CANADA; CUNY MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA; UNIV UTRECHT, FAC MED, NL-3584 CX UTRECHT, NETHERLANDS	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Utrecht University			Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Couet, Jacques/0000-0001-5409-8689				BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRETSCHER MS, 1977, J ULTRA MOL STRUCT R, V61, P215, DOI 10.1016/S0022-5320(77)80088-9; COLE F, 1993, J BIOL CHEM, V268, P1580; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FORBES MS, 1979, J ULTRA MOL STRUCT R, V67, P325, DOI 10.1016/S0022-5320(79)80032-5; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Harlow E., 1988, ANTIBODIES LAB MANUA; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIMIONESCU N, 1983, HISTOLOGY CELL TISSU, P371; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tang ZL, 1997, J BIOL CHEM, V272, P2437, DOI 10.1074/jbc.272.4.2437; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	43	457	472	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29337	29346		10.1074/jbc.272.46.29337	http://dx.doi.org/10.1074/jbc.272.46.29337			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361015	hybrid			2022-12-25	WOS:A1997YF68400074
J	Yang, W; Chan, VC; Kirkpatrick, A; Ramshaw, JAM; Brodsky, B				Yang, W; Chan, VC; Kirkpatrick, A; Ramshaw, JAM; Brodsky, B			Gly-Pro-Arg confers stability similar to Gly-Pro-Hyp in the collagen triple-helix of host-guest peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING AMINO-ACIDS; THERMODYNAMIC SCALE; FORMING TENDENCIES; HYDROXYPROLINE; STABILIZATION; PARAMETERS; WATER	A set of host-guest peptides of the form Ac(Gly-Pro-Hyp)(3)-Gly-X-Y-(Gly-Pro-Hyp)(4)-Gly-Gly-NH2 has been designed to evaluate the propensity of different Gly-X-Y triplets for the triple-helix conformation (Shah, N, K,, Ramshaw, J. A. M., Kirkpatrick, A., Shah, C., and Brodsky, B, (1996) Biochemistry 35, 10262-10268), All Gly-X-Y guest triplets led to a decrease in melting temperature from the host (Gly-Pro-Hyp), peptide except for Gly-Pro-Arg, In this Gly-Pro-Hyp-rich environment, Gly-Pro-Arg was found to be as stabilizing as Gly-Pro-Hyp. Decreased stability of host-guest peptides containing Gly-Pro-Lys, Gly-Pro-homo-Arg, and Gly Arg-Hyp compared with Gly-Pro-Arg indicated a stabilization that is optimal for Arg and specific to the Y-position, Arg was found to have a similar stabilizing effect when residues other than Pro are in the X-position, Both Arg and Hyp stabilize the triple-helix preferentially in the Y-position in a stereospecific manner and occupy largely Y-positions in collagen, However, contiguous Gly-Pro-Hyp units are highly stable and promote triple helix folding, whereas incorporation of multiple Gly-Pro-Arg triplets was destabilizing and folded slowly due to charge repulsion, In collagen, Gly-Pro-Arg may contribute maximally to local triple-helix stability while also having the potential for electrostatic interactions in fibril formation and binding.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; CSIRO,DIV MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Ramshaw, John AM/A-9411-2011	Ramshaw, John A.M./0000-0002-2131-3685	NIAMS NIH HHS [AR 19626] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BANSAL M, 1978, INT J PEPT PROT RES, V11, P73; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BELLA J, 1995, STRUCTURE, V3, P393; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Cappello J., 1994, PLASTICS MICROBES, P35; CHAN VC, 1997, IN PRESS J BIOL CHEM, V272; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; GERMANN HP, 1988, BIOPOLYMERS, V27, P157, DOI 10.1002/bip.360270112; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; LINDEBERG EGG, 1976, INT J PEPT PROT RES, V8, P193; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; Ramachandran G.N., 1967, TREATISE COLLAGEN, P103; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; Shah NK, 1997, BIOCHEMISTRY-US, V36, P5878, DOI 10.1021/bi963146c; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	27	93	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28837	28840		10.1074/jbc.272.46.28837	http://dx.doi.org/10.1074/jbc.272.46.28837			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360948	hybrid			2022-12-25	WOS:A1997YF68400007
J	Zhang, XH; Xing, GX; Fraizer, GC; Saunders, GF				Zhang, XH; Xing, GX; Fraizer, GC; Saunders, GF			Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; FUNCTIONAL SYNERGY; MAMMALIAN-CELLS; WT1; EXPRESSION; DELETION; FAMILY; DNA; DIFFERENTIATION; LEUKEMIAS	The Wilms' tumor 1 gene (WT1) encodes a zinc-finger transcription factor which is expressed in a tissue-specific manner. Our studies indicate that in addition to the promoter, other regulatory elements are required for tissue-specific expression of this gene, A 258-base pair hematopoietic specific enhancer in intron 3 of the WT1 gene increased the transcriptional activity of the WT1 promoter by 8-10-fold in K562 and HL60 cells, Sequence analysis revealed both a GATA and a c-Myb motif in the enhancer fragment. Mutation of the GATA motif decreased the enhancer activity by 60% in K562 cells. Electrophoretic mobility shift assays showed that the GATA-1 protein in K562 nuclear extracts binds to this motif. Cotransfection of the enhancer containing reporter construct with a GATA-1 expression vector showed that GATA-1 transactivated this enhancer, increasing the CAT reporter activity 10-15-fold. Similar analysis of the c-Myb motif by cotransfection with the enhancer CAT reporter construct and a c-Myb expression vector showed that c-Myb transactivated the enhancer by B-fold. A DNase I-hypersensitive site has also been mapped in the 258-base pair enhancer region, These data suggest that GATA-1 and c-Myb are responsible for the activity of this enhancer in hematopoietic cells and may bind to the enhancer in vivo.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34936, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; FRAIZER GC, 1995, BLOOD, V86, P4704, DOI 10.1182/blood.V86.12.4704.bloodjournal86124704; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HUFF V, 1991, AM J HUM GENET, V48, P997; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KingUnderwood L, 1996, BLOOD, V87, P2171, DOI 10.1182/blood.V87.6.2171.bloodjournal8762171; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEVYWILSON B, 1988, MOL CELL BIOL, V8, P71, DOI 10.1128/MCB.8.1.71; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MANIATIS T, 1982, MOL CLONING LABORATO, P309; MATSUNAGA E, 1981, HUM GENET, V57, P231; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIWA H, 1992, LEUKEMIA, V6, P405; OKA T, 1991, ONCOGENE, V6, P2077; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; Patmasiriwat P, 1996, LEUKEMIA, V10, P1127; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PEVNY L, 1995, DEVELOPMENT, V121, P163; PHELAN SA, 1994, CELL GROWH DIFFER, V5, P667; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEKIYA M, 1994, BLOOD, V83, P1876; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944	36	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29272	29280		10.1074/jbc.272.46.29272	http://dx.doi.org/10.1074/jbc.272.46.29272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361007	hybrid			2022-12-25	WOS:A1997YF68400066
J	Chandra, S; Low, PS				Chandra, S; Low, PS			Measurement of Ca2+ fluxes during elicitation of the oxidative burst in aequorin-transformed tobacco cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE DISEASE RESISTANCE; DEPENDENT PROTEIN-KINASE; HYPHAL WALL COMPONENTS; CYTOSOLIC FREE CALCIUM; CULTURED PLANT-CELLS; ACTIVE OXYGEN; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PHYTOPHTHORA-INFESTANS; ERWINIA-AMYLOVORA	We have employed suspension cultured aequorin-transformed tobacco cells to examine the involvement of Ca2+ in signal transduction of the oxidative burst. Use of cultured cells for this purpose was validated by demonstrating that the cells responded to cold shock quantitatively and qualitatively similarly to the intact transgenic plants from which they were derived. Stimulation of the oxidative burst in the cell suspension was achieved by administration of oligogalacturonic acid, Mas-7 (a peptide known to activate G proteins and Ca2+ fluxes), hypo-osmotic stress, or harpin (a protein from the pathogenic bacterium Erwinia amylovora). The latter failed to promote any detectable increase ia cytoplasmic Ca2+ concentration, whereas each of the former three triggered a rapid rise in cytosolic Ca2+ followed by a return within seconds to basal Ca2+ levels. Peak Ca2+ concentrations induced by the former three elicitors were similar to 0.7, 1.4, and 1.3 mu M, respectively. Three lines of evidence suggest that the observed Ca2+ pulses are essential to transduction of the oxidative burst signals by their respective elicitors: (i) inhibition of the Ca2+ transients with Ca2+ chelators or Ca2+ channel blockers prevented expression of the oxidative burst, (ii) introduction of exogenous Ca2+ into the same cells initiated the burst even in the absence of other inducers of the response, and (iii) the observed Ca2+ transients often returned to near basal levels well before any H2O2 synthesis could be detected; suggesting that the Ca2+ influx is required to communicate the burst signal but not maintain the defense response. These data suggest that Ca2+ pulses serve frequently, but not invariably, to transduce an oxidative burst signal.	PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Low, Philip/0000-0001-9042-5528				ALLEN DG, 1976, SCIENCE, V195, P996; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; APOSTOL I, 1987, PLANT PHYSIOL, V84, P1276, DOI 10.1104/pp.84.4.1276; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BUSH DS, 1990, PLANT PHYSIOL, V93, P841, DOI 10.1104/pp.93.3.841; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; Chandra S, 1996, P NATL ACAD SCI USA, V93, P13393, DOI 10.1073/pnas.93.23.13393; Chandra S, 1996, PLANT PHYSIOL, V110, P979, DOI 10.1104/pp.110.3.979; CHANDRA S, 1995, P NATL ACAD SCI USA, V92, P4120, DOI 10.1073/pnas.92.10.4120; DEMARTY M, 1984, PLANT CELL ENVIRON, V7, P441, DOI 10.1111/j.1365-3040.1984.tb01434.x; Desikan R, 1996, FEBS LETT, V382, P213, DOI 10.1016/0014-5793(96)00177-9; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P359, DOI 10.1016/0048-4059(83)90020-6; Dwyer SC, 1996, BBA-GEN SUBJECTS, V1289, P231, DOI 10.1016/0304-4165(95)00156-5; FranklinTong VE, 1996, PLANT CELL, V8, P1305, DOI 10.1105/tpc.8.8.1305; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GILROY S, 1991, PLANT CELL, V3, P333, DOI 10.1105/tpc.3.4.333; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; HALEY A, 1995, P NATL ACAD SCI USA, V92, P4124, DOI 10.1073/pnas.92.10.4124; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Knight H, 1995, METHOD CELL BIOL, V49, P201, DOI 10.1016/S0091-679X(08)61455-7; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEGENDRE L, 1993, J BIOL CHEM, V268, P24559; LEGENDRE L, 1993, PLANT PHYSIOL, V102, P233, DOI 10.1104/pp.102.1.233; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LEVINE A, 1996, CURR BIOL, V6, P4237; Low PS, 1996, PHYSIOL PLANTARUM, V96, P533, DOI 10.1111/j.1399-3054.1996.tb00469.x; LOW PS, 1997, PLANT MICROBE INTERA; LOW PS, 1994, P 1994 KOR BOT SOC S, P75; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MESSIAEN J, 1993, J CELL SCI, V104, P365; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; OKUDA T, 1991, PLANT PHYSIOL, V97, P1265, DOI 10.1104/pp.97.3.1265; OLSON PD, 1993, PLANT J, V4, P887, DOI 10.1046/j.1365-313X.1993.04050887.x; PENG M, 1992, PHYTOPATHOLOGY, V82, P696, DOI 10.1094/Phyto-82-696; PICAL C, 1992, PLANT PHYSIOL, V100, P1296, DOI 10.1104/pp.100.3.1296; Pierson ES, 1996, DEV BIOL, V174, P160, DOI 10.1006/dbio.1996.0060; PREISIG CL, 1994, PHYTOCHEMISTRY, V36, P857, DOI 10.1016/S0031-9422(00)90451-5; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SCHROEDER JI, 1991, PLANT CELL, V3, P555, DOI 10.2307/3869184; SCHWACKE R, 1992, PLANTA, V187, P136, DOI 10.1007/BF00201635; Takahashi K, 1997, PLANT PHYSIOL, V113, P587, DOI 10.1104/pp.113.2.587; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Tucker EB, 1996, PLANT PHYSIOL, V111, P459, DOI 10.1104/pp.111.2.459; VERAESTRELLA R, 1992, PLANT PHYSIOL, V99, P1208, DOI 10.1104/pp.99.3.1208; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WU GS, 1995, PLANT CELL, V7, P1357, DOI 10.1105/tpc.7.9.1357; YAHRAUS T, 1995, PLANT PHYSIOL, V109, P1259, DOI 10.1104/pp.109.4.1259	63	119	133	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28274	28280		10.1074/jbc.272.45.28274	http://dx.doi.org/10.1074/jbc.272.45.28274			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353281	hybrid			2022-12-25	WOS:A1997YF21900021
J	Gong, LM; Kamitani, T; Fujise, K; Caskey, LS; Yeh, ETH				Gong, LM; Kamitani, T; Fujise, K; Caskey, LS; Yeh, ETH			Communication - Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DEGRADATION; PROTEASOME PATHWAY; HUMAN HOMOLOG; CLONING; IDENTIFICATION; GENE; CDNA	Sentrin is a ubiquitin-like molecule that has been shown to interact with the death domains of Fas and tumor necrosis factor receptor 1 (TNFR1), PML, Rad51, Rad52, and RanGAP1. We have reported previously that sentrin can be conjugated to other proteins in a manner analogous to protein ubiquitination (Kamitani, T., Nguyen, H. P., and Yeh, E. T. H. (1997) J. Biol. Chem. 272, 14001-14004). Furthermore, the conserved C-terminal Gly-Gly residues are required for sentrinization to occur. To identify enzymes which play a role in sentrinization, the yeast two-hybrid system was used to screen a human placenta cDNA library using sentrin as bait. A strong positive interacting clone was found to contain a cDNA insert encoding the ubiquitin-conjugating enzyme, Ubc9. The interaction between sentrin and Ubc9 required the ubiquitin domain and the C-terminal Gly-Gly residues of sentrin. This interaction appears to be specific because sentrin could only interact weakly with UbcH5B, but could not interact with HHR6B, UbcH6 nor E2-EPF. In vitro translated sentrin could be precipitated by a GST-Ubc9 fusion protein, but not by glutathione S-transferase. A beta-mercaptoethanol-sensitive Ubc9-sentrin conjugate could also be identified in the in vitro binding assay. Substitution of the conserved cysteine residue of Ubc9 by serine abolished the formation of the Ubc9-sentrin conjugate. Taken together, Ubc9 is a strong candidate to be the key conjugating enzyme in the sentrinization pathway.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST MOL MED PREVENT HUMAN DIS,RES CTR CARDIOVASC DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; CENCIARELLI C, 1995, J BIOL CHEM, V271, P8709; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPKIN K, 1997, J NIH RES, V9, P36; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang WD, 1996, MOL GEN GENET, V251, P153; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LIU Z, 1992, J BIOL CHEM, V267, P15829; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Okura T, 1996, J IMMUNOL, V157, P4277; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Wright DA, 1996, J BIOL CHEM, V271, P31037, DOI 10.1074/jbc.271.49.31037; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	32	164	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28198	28201		10.1074/jbc.272.45.28198	http://dx.doi.org/10.1074/jbc.272.45.28198			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353268	hybrid			2022-12-25	WOS:A1997YF21900008
J	Hidari, KIPJ; Weyrich, AS; Zimmerman, GA; McEver, RP				Hidari, KIPJ; Weyrich, AS; Zimmerman, GA; McEver, RP			Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; TUMOR-NECROSIS-FACTOR; MAP KINASE; CYTOPLASMIC DOMAIN; AMINO-TERMINUS; MYELOID CELLS; MONOCYTES; PLATELETS; PSGL-1; BINDING	During inflammation, P-selectin on activated platelets and endothelial cells initiates adhesion of leukocytes through interactions with P-selectin glycoprotein ligand-1 (PSGL-1). We investigated whether ligation of PSGL-1 also transmits signals into leukocytes, Neutrophils incubated with anti-PSGL-1 monoclonal antibodies, but not with Fab fragments of these antibodies, rapidly increased tyrosine phosphorylation of proteins with relative molecular masses of 105-120, 70-84, and 42-44 kDa. PSGL-1-dependent adhesion of neutrophils to P-selectin increased tyrosine phosphorylation of similarly sized proteins, Cytochalasin B did not prevent the tyrosine phosphorylation induced by ligation of PSGL-1, suggesting that an intact cytoskeleton is not required fdr signaling, Engagement of PSGL-1 activated the GTPase Pas through a mechanism that did not require tyrosine phosphorylation of PSGL-1 or association of the Shc-Grbs-Sos1 complex with PSGL-1. Engagement of PSGL-1 activated the 42-44-kDa extracellular signal-regulated kinase family of mitogen-activated protein (MAP) kinases through a pathway that required activation of the MAP kinase kinase, Ligation of PSGL-1 also stimulated secretion of interleukin-8. The tyrosine kinase inhibitor, genistein, blocked tyrosine phosphorylation and secretion of interleukin-8, whereas the MAP kinase kinase inhibitor PD98059 partially inhibited secretion of interleukin-8. Tyrosine phosphorylation stimulated through PSGL-1 on selectin-tethered leukocytes may propagate a signaling cascade that is integrated with signals generated by other mediators.	UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV UTAH, HLTH SCI CTR, NORA ECCLES HARRISON CARDIOVASC RES & TRAINING IN, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84112 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHLBI NIH HHS [HL 54804, HL 44525, HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL044525, P01HL054804, R01HL044525, R01HL034363, R37HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brenner B, 1997, BIOCHEM BIOPH RES CO, V231, P802, DOI 10.1006/bbrc.1997.6191; Brenner B, 1996, P NATL ACAD SCI USA, V93, P15376, DOI 10.1073/pnas.93.26.15376; CELI A, 1994, P NATL ACAD SCI USA, V91, P8767, DOI 10.1073/pnas.91.19.8767; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; COOPER D, 1994, J IMMUNOL, V153, P3199; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; ELSTAD MR, 1995, J IMMUNOL, V155, P2109; Evangelista V, 1996, BLOOD, V88, P4183, DOI 10.1182/blood.V88.11.4183.bloodjournal88114183; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haller H, 1997, J IMMUNOL, V158, P1061; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laszik Z, 1996, BLOOD, V88, P3010, DOI 10.1182/blood.V88.8.3010.bloodjournal8883010; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LORANT DE, 1995, J CLIN INVEST, V96, P171, DOI 10.1172/JCI118018; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Moore Kevin L., 1994, Journal of Tissue Culture Methods, V16, P255, DOI 10.1007/BF01540662; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NAGATA K, 1993, J IMMUNOL, V151, P3267; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; RUF A, 1995, BRIT J HAEMATOL, V90, P791, DOI 10.1111/j.1365-2141.1995.tb05197.x; RUF A, 1992, BLOOD, V80, P1238; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tu LL, 1996, J IMMUNOL, V157, P3995; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YEO EL, 1994, BLOOD, V83, P2498; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	71	193	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28750	28756		10.1074/jbc.272.45.28750	http://dx.doi.org/10.1074/jbc.272.45.28750			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353345	hybrid			2022-12-25	WOS:A1997YF21900085
J	Lam, YA; DeMartino, GN; Pickart, CM; Cohen, RE				Lam, YA; DeMartino, GN; Pickart, CM; Cohen, RE			Specificity of the ubiquitin isopeptidase in the PA700 regulatory complex of 26 S proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEUBIQUITINATING ENZYME; MULTIUBIQUITIN CHAIN; DEPENDENT PROTEOLYSIS; POLYUBIQUITIN CHAINS; PROTEIN-DEGRADATION; IDENTIFICATION; DIUBIQUITIN; GENE; INHIBITION; RESOLUTION	The specificity of the ubiquitin (Ub) isopeptidase in the PA700 regulatory complex of the bovine 26 S proteasome was investigated. Disassembly of poly-Ub by this enzyme is restricted to the distal-end Ub of the substrate, i.e. the Ub farthest from the site of protein attachment in poly-Ub-protein conjugates. The determinants recognized by the isopeptidase were probed by the use of mutant ubiquitins incorporated into Lys(48)-linked poly-Ub substrates. PA700 could not disassemble poly-Ub chains that contained a distal Ub(L8A,I44A). This suggested either that the enzyme interacts directly with Leu(8) or Ile(44) or that it recognizes a higher order structure that caps the distal end of a poly-Ub substrate and is destabilized by Ub(L8A,I44A). The previously determined di-Ub crystal structure (Cook, W. J., Jeffrey, L. C., Carson, M., Chen, Z., and Pickart, C. M. (1992) J. Biol. Chem. 267, 16467-16471) offered a candidate for such a ''cap.'' In solution, however, this structure was not observed by H-1 NMR spectroscopy. This and the finding that di-Ub with a single proximal Ub(L8A,I44A) is cleaved efficiently suggest that Leu(8) and Ile(44) in the distal-end Ub contact the isopeptidase directly. In addition to Lys(48)-linked chains, PA700 also could disassemble Lys(6)- and Lys-(11)-linked poly-Ub, but, surprisingly, not alpha-linked di-Ub. Results with these and other substrates suggest that specificity determinants for the PA700 isopeptidase include Leu(8), Ile(44), and Lys(48) on the distal Ub and, for poly-Ub, some features of the Ub-Ub linkage itself.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; JOHNS HOPKINS UNIV, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984, R56DK046181, R01DK046181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037666] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46181, DK46984] Funding Source: Medline; NIGMS NIH HHS [GM37666] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGELL N, 1988, P NATL ACAD SCI USA, V85, P3693, DOI 10.1073/pnas.85.11.3693; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DISTEFANO DL, 1987, BIOCHEMISTRY-US, V26, P7272, DOI 10.1021/bi00397a012; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; FALQUET L, 1995, FEBS LETT, V359, P73, DOI 10.1016/0014-5793(94)01451-6; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HADARI T, 1992, J BIOL CHEM, V267, P719; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P11; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; MA CP, 1994, J BIOL CHEM, V269, P3539; Melandri F, 1996, BIOCHEMISTRY-US, V35, P12893, DOI 10.1021/bi9612935; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P15076; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; Shaeffer JR, 1997, BLOOD, V90, P1300, DOI 10.1182/blood.V90.3.1300.1300_1300_1308; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WEBER PL, 1987, BIOCHEMISTRY-US, V26, P7282, DOI 10.1021/bi00397a013; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; XU W, 1997, THESIS U IOWA; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	60	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28438	28446		10.1074/jbc.272.45.28438	http://dx.doi.org/10.1074/jbc.272.45.28438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353303	hybrid			2022-12-25	WOS:A1997YF21900043
J	Walter, MJ; Look, DC; Tidwell, RM; Roswit, WT; Holtzman, MJ				Walter, MJ; Look, DC; Tidwell, RM; Roswit, WT; Holtzman, MJ			Targeted inhibition of interferon-gamma-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTORS; EPITHELIAL-CELLS; IFN-GAMMA; GENE; ACTIVATION; PROTEIN; ALPHA	A subset of epithelial immune-response genes (including intercellular adhesion molecule-1 (ICAM-1)) depends on an IFN-gamma signal transduction pathway with the Stat1 transcription factor as a critical intermediate, Excessive local activation of this pathway may lead to airway inflammation, so we sought to selectively downregulate the pathway using a dominant-negative strategy for inhibition of epithelial Stat1 in a primary culture airway epithelial cell model. Using a Stat1-deficient cell line, we demonstrated that transfection of wild-type Stat1 expression plasmid restored appropriate Stat1 expression and IFN-gamma-dependent phosphorylation as well as consequent lFN-gamma activation of cotransfected ICAM-1 promoter constructs and endogenous ICAM-1 gene expression. However, mutations of Stat1 at Tyr-701 (JAR kinase phosphorylation site), Glu-428/429 (putative DNA-binding site), His-713 (splice site resulting in Stat1 beta formation), or Ser-727 (MAP kinase phosphorylation site) all decreased Stat1 capacity to activate the ICAM-1 promoter, The Tyr-701 mutant (followed by the His-713 mutant) were most effective in disabling Stat1 function and in overcoming the activating effect of cotransfected wild-type Stat1 in this cell system thereby highlighting the effectiveness of blocking Stat1 homo-and hetero-dimerization. In experiments using primary culture human tracheobronchial epithelial cells (hTBECs) and each of the four Stat1 mutant plasmids, transfection with the Tyr-701 and His-713 mutants again most effectively inhibited IFN-gamma activation of an ICAM-1 gene promoter construct, Then by transfecting hTBECs with wild-type or mutant Stat1 tagged with a Flag reporter sequence, we used dual immunofluorescence to show that hTBECs expressing the Tyr-701 or His-713 mutants were prevented from expressing endogenous ICAM-1 in response to IFN-gamma treatment. The capacity of a specific Stat1 mutations to exert a potent dominant-negative effect on IFN-gamma signal transduction provides for further definition of Statl structure function and a means for natural or engineered expression of mutant Stat1 to selectively down-regulate activity of this pathway in a cell type-or tissue-specific manner during immune and/or inflammatory responses.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316, DOI 10.1165/ajrcmb.14.4.8600934; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KOGA T, 1997, AM J RESP CRIT CARE, V155, pA751; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LOOK DC, 1994, J BIOL CHEM, V269, P8952; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA S, 1994, AM J PHYSIOL-LUNG C, V267, pL422, DOI 10.1152/ajplung.1994.267.4.L422; NAKAJIMA S, 1995, J IMMUNOL, V155, P1117; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SAMPATH D, 1997, J ALLERGY CLIN IMMUN, V99, P475; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHANNON VR, 1993, AM REV RESPIR DIS, V147, P1024, DOI 10.1164/ajrccm/147.4.1024; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAGUCHI M, 1997, AM J RESP CRIT CARE, V155, pA360; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	72	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28582	28589		10.1074/jbc.272.45.28582	http://dx.doi.org/10.1074/jbc.272.45.28582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353323	hybrid			2022-12-25	WOS:A1997YF21900063
J	Yasui, H; Butscher, W; Cohen, M; Spriggs, N; Wersto, R; Kohn, EC; Liotta, L; Gardner, K				Yasui, H; Butscher, W; Cohen, M; Spriggs, N; Wersto, R; Kohn, EC; Liotta, L; Gardner, K			Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole - Calcium influx blockade represses HIV-1 transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; DNA-BINDING ACTIVITY; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; C-REL; MOLECULAR-BIOLOGY; GENE-EXPRESSION	Carboxyamidotriazole (CAI) is a calcium influx inhibitor that has both antiproliferative and antimetastatic activities, Pretreatment of human T-cells with micromolar concentrations of CAI causes a near complete inhibition of calcium-regulated mitogen-induced transcription from the human immunodeficiency virus (HIV) long terminal repeat (LTR). This inhibition is selective since other mitogen-activated gene regulatory elements, such as the 12-O-tetradecanoylphorbol-13-acetate response element, are not influenced by the drug, HIV LTR transcription inhibition is maximal at 1.0 mu M CAI, requires a pretreatment interval of at least 8 h for optimum inhibition, and shows no acute interference with the growth properties of the cells, Moreover, the inhibition is rapidly reversible upon removal of the drug from the medium, Studies to identify enhancer elements within the HIV LTR that are functionally sensitive to low-dose long-term pretreatment with CAI, indicate that the NF-kappa B-binding sites are among the major targets of drug action, In vitro DNA binding studies with nuclear extracts prepared from mitogen-induced T-cells stimulated in the presence of CAI indicate that the drug differentially influences the calcium-regulated downstream signal transduction pathways necessary for specific NF-KB DNA binding activity at the two KB sites within the HIV LTR, Studies with ionomycin and thapsigargin show that repression is specific for selected modes of inducible calcium entry and indicate that, in T-cells, a major mechanism of CAI action is to modulate calcium influx at a level that is proximal to the regulated release of calcium from intracellular stores, Measurement of calcium influx in CAI-treated cells reveals a dramatic and reversible inhibition of mitogen-induced calcium influx. These results indicate that CAI can be an important and effective pharmacological tool for analysis of the calcium-dependent modulation of HIV LTR transcription.	NCI,DEPT PATHOL,PATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANTONI BA, 1994, ADV VIRUS RES, V43, P53, DOI 10.1016/S0065-3527(08)60047-0; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BELL KD, 1993, P NATL ACAD SCI USA, V90, P1411, DOI 10.1073/pnas.90.4.1411; BENNETT V, 1981, P NATL ACAD SCI-BIOL, V78, P7550, DOI 10.1073/pnas.78.12.7550; BIELINSKA A, 1989, J VIROL, V63, P4097, DOI 10.1128/JVI.63.9.4097-4100.1989; BISWAS DK, 1993, P NATL ACAD SCI USA, V90, P11044, DOI 10.1073/pnas.90.23.11044; BISWAS DK, 1994, MOL MED, V1, P31; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GARDNER K, 1994, J BIOL CHEM, V269, P32963; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HASELTINE WA, 1988, SCI AM, V259, P52, DOI 10.1038/scientificamerican1088-52; HOLMES KA, 1993, J CHROMATOGR-BIOMED, V613, P317, DOI 10.1016/0378-4347(93)80148-W; HUSS R, 1995, RES IMMUNOL, V146, P101, DOI 10.1016/0923-2494(96)80243-4; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KARPAS A, 1992, P NATL ACAD SCI USA, V89, P8351, DOI 10.1073/pnas.89.17.8351; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MODIANO JF, 1988, J CELL PHYSIOL, V135, P451, DOI 10.1002/jcp.1041350312; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SEI Y, 1995, EXP CELL RES, V216, P222, DOI 10.1006/excr.1995.1028; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; Wang WH, 1997, IMMUNITY, V6, P165, DOI 10.1016/S1074-7613(00)80423-9; Weiss A, 1995, ANN NY ACAD SCI, V766, P149, DOI 10.1111/j.1749-6632.1995.tb26658.x; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; ZEICHNER SL, 1994, CLIN PERINATOL, V21, P39, DOI 10.1016/S0095-5108(18)30361-0	57	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28762	28770		10.1074/jbc.272.45.28762	http://dx.doi.org/10.1074/jbc.272.45.28762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353347	hybrid			2022-12-25	WOS:A1997YF21900087
J	Kuntz, MA; Shapiro, DJ				Kuntz, MA; Shapiro, DJ			Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; NUCLEAR RECEPTORS; PROTEINS; AFFINITY; GENE; SUBUNITS	In this work, we provide a rationale for the finding that the estrogen receptor (ER) binds to its DNA response element as a homodimer in vivo. Binding of the monomer estrogen receptor DNA binding domain (ER DBD) to a palindromic, consensus estrogen response element (ERE) is increased 5-6-fold when the ER DBD is dimerized either by a monoclonal antibody that recognizes an attached epitope tag or by expressing the ER DBD as a single molecule in which the two monomers are joined by a peptide linker, Most of the increase in binding is due to stabilization of the ER DBD ERE complex. We observed only an approximately 2.5-fold reduction in binding when a consensus ERE was replaced with widely spaced ERE half-sites, suggesting that the interaction between ER DBDs on the ERE is relatively weak, and that in full-length ER the DBDs can move independently of each other, To test binding to an imperfect palindrome, typical of the imperfect EREs found in almost all natural estrogen receptor responsive genes, we used the pS2 ERE. Even at high concentrations of ER DBD, specific binding of the ER DBD to the imperfect pS2 ERE was undetectable, Both of the dimerized ER DBDs exhibited efficient binding to the imperfect pS2 ERE, with an affinity at least 25-fold greater than monomer ER DBD, These data support the View that steroid receptor dimerization provides an important mechanism facilitating the recognition of naturally occurring, imperfect hormone response elements.	UNIV ILLINOIS,DEPT BIOCHEM,B4 RAL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16720] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Carlsson B, 1995, ANAL BIOCHEM, V232, P172, DOI 10.1006/abio.1995.0004; CHIANG CM, 1993, PEPTIDE RES, V6, P62; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; INCE BA, 1993, J BIOL CHEM, V268, P14026; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; KATO S, 1995, MOL CELL BIOL, V15, P5858; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; LUISI B, 1995, NATURE, V375, P359, DOI 10.1038/375359a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MURDOCH FE, 1995, BIOCHEMISTRY-US, V34, P9144, DOI 10.1021/bi00028a025; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; NARDULLI AM, 1993, MOL ENDOCRINOL, V7, P331, DOI 10.1210/me.7.3.331; Nardulli AM, 1996, MOL ENDOCRINOL, V10, P694, DOI 10.1210/me.10.6.694; PERCIPALLE P, 1995, EMBO J, V14, P3200, DOI 10.1002/j.1460-2075.1995.tb07322.x; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P109, DOI 10.1021/bi9521194; SASSE J, 1988, CURRENT PROTOCOLS MO, V2; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; WHITE R, 1991, J STEROID BIOCHEM, V40, P333, DOI 10.1016/0960-0760(91)90199-F	29	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27949	27956		10.1074/jbc.272.44.27949	http://dx.doi.org/10.1074/jbc.272.44.27949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346945	hybrid			2022-12-25	WOS:A1997YD47300071
J	Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS				Gao, SJ; Boshoff, C; Jayachandra, S; Weiss, RA; Chang, Y; Moore, PS			KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway	ONCOGENE			English	Article						Kaposi's sarcoma-associated herpesvirus; interferon; oncogenesis; p21; lymphoma	KAPOSIS-SARCOMA; DNA-SEQUENCES; REGULATED EXPRESSION; CELL-GROWTH; BETA-GENE; HERPESVIRUS; TRANSCRIPTION; ALPHA; PROTEINS; IRF-1	Kaposi's sarcoma-associated herpesvirus (KSHV) is a gammaherpesvirus linked to the development of Kaposi's sarcoma and a rare B cell lymphoma, primary effusion lymphoma, The KSHV gene ORF K9 encodes vIRF which is a protein with low but significant homology to members of the interferon (IFN) regulatory factor (IRF) family responsible for regulating intracellular interferon signal transduction (Moore PS, Boshoff C, Weiss RA and Chang Y. (1996), Science, 274, 1739-1744), vIRF inhibits IPN-beta signal transduction as measured using an IFN-responsive ISG54 reporter construct co-transfected with ORI; K9 into HeLa and 293 cells, vIRF also suppresses genes under IFN regulatory control as shown by inhibition of the IFN-beta inducibility of p21(WAF1/CIP1), however, no direct DNA-binding or protein-protein interactions characteristic for IRF repressor proteins were identified, Stable transfectant NIH3T3 clones expressing vIRF grew in soft agar and at low serum concentrations, lost contact inhibition and formed tumors after injection into nude mice indicating that vIRF has the properties of a viral oncogene, Since vIRF is primarily expressed in KSHV-infected B cells, not KS spindle cells, this study suggests that vIRF is a transforming oncogene active in B cell neoplasias that may provide a unique immune escape mechanism for infected cells, This data is consistent with tumor suppressor pathways serving a dual function as host cell antiviral pathways.	COLUMBIA UNIV,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Columbia University; Columbia University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Moore, Patrick S./F-3960-2011; Gao, Shou-Jiang/B-8641-2012; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA067391] Funding Source: NIH RePORTER; NCI NIH HHS [CA67391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLUYSSEN HAR, 1994, EUR J BIOCHEM, V220, P395, DOI 10.1111/j.1432-1033.1994.tb18636.x; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, INFECT AGENT DIS, V5, P215; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MOORE PS, 1997, IN PRESS J NCI; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Neil JC, 1997, TRENDS MICROBIOL, V5, P115, DOI 10.1016/S0966-842X(96)10083-4; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; OLSEN SJ, 1997, IN PRESS MOL IMMUNOL; RABKIN CS, 1995, CLIN CANCER RES, V1, P257; Rabkin CS, 1997, NEW ENGL J MED, V336, P988, DOI 10.1056/NEJM199704033361403; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	52	292	301	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1979	1985		10.1038/sj.onc.1201571	http://dx.doi.org/10.1038/sj.onc.1201571			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365244				2022-12-25	WOS:A1997YA87200012
J	Guesdon, F; Knight, CG; Rawlinson, LM; Saklatvala, J				Guesdon, F; Knight, CG; Rawlinson, LM; Saklatvala, J			Dual specificity of the interleukin 1- and tumor necrosis factor-activated beta casein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; PROTEIN-KINASE; C-JUN; INFLAMMATORY CYTOKINES; PHOSPHORYLATION; SUBSTRATE; PATHWAY; DOMAIN; IDENTIFICATION; TYROSINE	Tumor necrosis factor (TNF) and interleukin 1 (IL1) activate a protein kinase, TIP kinase, which phosphorylates beta casein in vitro. We have now identified its main phosphorylation site on beta casein, Ser(124) (K-m approximate to 28 mu M), and a minor phosphorylation site, Ser(142) (K-m approximate to 0.7 mM). The sequence motif that determined the phosphorylation of Ser(124) by the kinase was studied with synthetic peptides bearing deletions or substitutions of the neighboring residues. This allowed synthesis of improved substrates (K-m approximate to 6 mu M) and showed that efficient phosphorylation of Ser(124) was favored by the presence of large hydrophobic residues at positions +1, +9, +11, and +13 (counted relative to the position of the phosphoacceptor amino acid) and of a cysteine at position -2. Peptides in which Ser(124) was replaced by tyrosine were also phosphorylated by TIP kinase, showing it to have dual specificity. It is unable to phosphorylate the MAP kinases in vitro and is therefore not directly involved in their activation. Its biochemical characteristics indicate that TIP kinase is a novel dual specificity kinase, perhaps related to the mixed lineage kinases. It copurified with a phosphoprotein of about 95 kDa, which could correspond either to the autophosphorylated kinase or to an associated substrate.	HAMMERSMITH HOSP,KENNEDY INST RHEUMATOL,LONDON W6 8LH,ENGLAND; STRANGEWAYS RES LAB,DEPT CELL ADHES & SIGNALING,CAMBRIDGE CB1 4RN,ENGLAND; ROYAL HALLAMSHIRE HOSP,DIV MOL & GENET MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	Imperial College London; University of Oxford; University of Sheffield	Guesdon, F (corresponding author), ROYAL HALLAMSHIRE HOSP,DIV MOL & GENET MED,M FLOOR,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							Baker SJ, 1996, ONCOGENE, V12, P1; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BIRD TA, 1994, J BIOL CHEM, V269, P31836; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CARLES C, 1988, FEBS LETT, V229, P265, DOI 10.1016/0014-5793(88)81138-4; CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DINARELLO CA, 1991, BLOOD, V77, P1627; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GUESDON F, 1993, J BIOL CHEM, V268, P4236; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hirai S, 1996, ONCOGENE, V12, P641; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; LEATHERBARROW RJ, 1990, ANAL BIOCHEM, V184, P274, DOI 10.1016/0003-2697(90)90680-8; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MAHONEY WC, 1981, BIOCHEMISTRY-US, V20, P443, DOI 10.1021/bi00505a033; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ridley SH, 1997, J IMMUNOL, V158, P3165; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; WANG QM, 1994, J BIOL CHEM, V269, P14566; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30017	30024		10.1074/jbc.272.48.30017	http://dx.doi.org/10.1074/jbc.272.48.30017			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374476	hybrid			2022-12-25	WOS:A1997YH61300008
J	Li, F; Srinivasan, A; Wang, Y; Armstrong, RC; Tomaselli, KJ; Fritz, LC				Li, F; Srinivasan, A; Wang, Y; Armstrong, RC; Tomaselli, KJ; Fritz, LC			Cell-specific induction of apoptosis by microinjection of cytochrome c - Bcl-x(L) has activity independent of cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; DEATH; ENCODES; PRODUCT; MEDIATOR; PROTEIN; ENZYME; FAMILY; CPP32; BCL-2	Bcl-x(L), an antiapoptotic member of the Bcl-2 family, inhibits programmed cell death in a broad variety of cell types, Recent reports have demonstrated that cytochrome c is released from mitochondria during apoptosis and have suggested that this release may be a critical step in the activation of proapoptotic caspases and subsequent cell death, Furthermore, it has been demonstrated that Bcl-2 can prevent the release of cytochrome c from mitochondria in cells triggered to undergo apoptosis, This has led to the hypothesis that the antiapoptotic effects of Bcl-2 family members are due specifically to their ability to prevent cytochrome c release thus preventing subsequent cytochrome c-dependent caspase activation, In the present report, we use microinjection techniques to investigate the relationship between cytochrome c release, induction of apoptosis, and Bcl-x(L) activity in intact cells, We demonstrate that microinjection of cytochrome c into the cytosol of human kidney 293 cells results in a dose-dependent induction of apoptosis, In contrast, MCF7 breast carcinoma cells (stably transfected to express the Fas antigen CD95, and denoted MCF7F) that lack detectable levels of caspase 3 (CPP32), are totally resistant to microinjection of cytochrome c, However, transfection of MCF7F cells with an expression plasmid coding for pro-caspase 3, but not other pro-caspases, restores cytochrome c sensitivity, Although MCF7F cells are insensitive to cytochrome c microinjection, they rapidly undergo apoptosis in a caspase dependent manner in response to either tumor necrosis factor or anti-Fas plus cycloheximide, and these deaths are strongly inhibited by Bcl-x(L) expression, Furthermore, microinjection of cytochrome c does not overcome these antiapoptotic effects of Bcl-x(L). Our results support the concept that the release of cytochrome c into the cytoplasm can promote the apoptotic process in cells expressing pro-caspase 3 but that cytochrome c release is not sufficient to induce death in all cells, Importantly, the ability of Bcl-x(L) to inhibit cell death in the cytochrome c-insensitive MCF7F cells cannot be due solely to inhibition of cytochrome c release from mitochondria.	IDUN PHARMACEUT INC,LA JOLLA,CA 92037									Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BORDEN D, 1976, HDB BIOCHEMISTRY MOL, V3, P268; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; DEROBERTIS EDP, 1975, CELL BIOL, P200; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHU W, 1996, J EMBO, V15, P4130	37	330	335	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30299	30305		10.1074/jbc.272.48.30299	http://dx.doi.org/10.1074/jbc.272.48.30299			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374516	hybrid			2022-12-25	WOS:A1997YH61300048
J	Nonaka, T; Dohmae, N; Hashimoto, T; Takio, K				Nonaka, T; Dohmae, N; Hashimoto, T; Takio, K			Amino acid sequences of metalloendopeptidases specific for acyl-lysine bonds from Grifola frondosa and Pleurotus ostreatus fruiting bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED FUCOSE; GROWTH-FACTOR DOMAIN; PROTEIN; CLONING; PURIFICATION; COLLAGENASES; ALIGNMENT; ASTACINS; PEPTIDE; YEAST	The complete amino acid sequences of two lysine-specific zinc metalloendopeptidases (EC 3.4.24), Grifola frondosa metalloendopeptidase (GFMEP) and Pleurotus ostreatus metalloendopeptidase (POMEP), from the fruiting bodies of these two edible mushrooms have been established based on the sequence information of the peptides generated from the reduced and alkylated GFMEP and POMEP by proteolytic digestions using GFMEP, trypsin, and other proteinases as well as by several chemical cleavages. From the sequences, it was found that GFMEP and POMEP were polypeptides composed of 167 and 168 amino acid residues, from which their molecular weights were calculated to be 18,040.5 and 17,921.3 in accord with the observed (M+H)(+) values of 18,028 and 17,927, respectively, as determined by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Two disulfide bonds in GFMEP were found to link Cys(5) to Cys(75) and Cys(77) to Cys(97). An unusual post-translational modification of GFMEP was corroborated to be a partial attachment of a single mannose to Thr(42). Comparison of the sequences revealed that overall identity between the enzymes was 61.3%. Although a highly homologous sequence was not found in sequence data bases except for a consensus zinc-binding sequence, HEXXH, both metalloendopeptidases somewhat resembled a family of metalloproteinases categorized as deuterolysin. These proteases together with GFMEP and POMEP do not have conserved third and/or fourth liganding amino acid residues seen in metzincin or thermolysin superfamily proteins and belong to a novel zinc metalloendopeptidase superfamily.	RIKEN, INST PHYS & CHEM RES, DIV BIOMOL CHARACTERIZAT, WAKO, SAITAMA 35101, JAPAN; SAITAMA UNIV, FAC SCI, DEPT BIOCHEM, URAWA, SAITAMA 338, JAPAN	RIKEN; Saitama University			Dohmae, Naoshi/C-2040-2011; Nonaka, Takashi/L-8572-2017	Dohmae, Naoshi/0000-0002-5242-9410; Nonaka, Takashi/0000-0002-0830-9403				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cole R.D., 1967, METHOD ENZYMOL, V11, P315; DOHMAE N, 1995, BIOSCI BIOTECH BIOCH, V59, P2074, DOI 10.1271/bbb.59.2074; DOONAN S, 1975, BIOCHEM J, V149, P497, DOI 10.1042/bj1490497d; DOONAN S, 1975, EUR J BIOCHEM, V56, P421, DOI 10.1111/j.1432-1033.1975.tb02248.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS WG, 1978, BIOCHIM BIOPHYS ACTA, V522, P551, DOI 10.1016/0005-2744(78)90087-6; MATSUMOTO K, 1994, BBA-GENE STRUCT EXPR, V1218, P469, DOI 10.1016/0167-4781(94)90209-7; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; NONAKA T, 1995, J BIOCHEM-TOKYO, V118, P1014, DOI 10.1093/jb/118.5.1014; OMENN GS, 1970, J BIOL CHEM, V245, P1895; RAMESH MV, 1995, GENE, V165, P121, DOI 10.1016/0378-1119(95)00434-8; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; SPIRO RG, 1980, J BIOL CHEM, V255, P5347; STAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185; Stark G R, 1977, Methods Enzymol, V47, P129; STOCKER W, 1995, PROTEIN SCI, V4, P823; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; TATSUMI H, 1991, MOL GEN GENET, V228, P97, DOI 10.1007/BF00282453; TERASHITA T, 1985, AGR BIOL CHEM TOKYO, V49, P2293, DOI 10.1080/00021369.1985.10867077; TERASHITA T, 1985, T MYCOL SOC JPN, V26, P397; YUN SJ, 1991, J BIOL CHEM, V266, P693	35	50	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30032	30039		10.1074/jbc.272.48.30032	http://dx.doi.org/10.1074/jbc.272.48.30032			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374478	hybrid			2022-12-25	WOS:A1997YH61300010
J	Upston, JM; Neuzil, J; Witting, PK; Alleva, R; Stocker, R				Upston, JM; Neuzil, J; Witting, PK; Alleva, R; Stocker, R			Oxidation of free fatty acids in low density lipoprotein by 15-lipoxygenase stimulates nonenzymic, alpha-tocopherol-mediated peroxidation of cholesteryl esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; PERFORMANCE LIQUID-CHROMATOGRAPHY; LIPID-PROTEIN ADDUCTS; MAMMALIAN LIPOXYGENASES; SCREENING-TEST; MESSENGER-RNA; VITAMIN-E; HYDROPEROXIDES; OXYGENATION; LDL	15-Lipoxygenase has been implicated in the in vivo oxidation of low density lipoprotein (LDL) a process thought to be important in the origin and/or progression of human atherogenesis, We have suggested previously that oxidation of LDL's cholesteryl esters (CE) and phospholipids by soybean (SLO) or human recombinant 15-lipoxygenase (rhLO) can be ascribed largely to alpha-tocopherol (alpha-TOH)-mediated peroxidation (TMP). In this study we demonstrate that addition to LDL of unesterified linoleate (18:2), other free fatty acid (FFA) substrates, or phospholipase A(2) (PLA(2)) significantly enhanced the accumulation of CE hydro(pero)xides (CEO(O)H) induced by rhLO, whereas the corresponding CE and nonsubstrate FFA were without effect. The enhanced CE-O(O)H accumulation showed a dependence on the concentration of free 18:2 in LDL, In contrast, addition of 18:2 had little effect on LDL oxidation induced by aqueous peroxyl radicals or Cu2+ ions, Analyses of the regio- and stereoisomers of oxidized 18:2 in SLO-treated native LDL demonstrated that the small amounts of 18:2 associated with the lipoprotein were oxidized enzymically and within minutes, whereas cholesteryl linoleate (Ch18:2) was oxidized nonenzymically and continuously over hours, alpha-Tocopheroxyl radical (alpha-TO.) formed in LDL exposed to SLO was enhanced by addition of 18:2 or PLA(2). With rhLO and 18:2-supplemented LDL, oxidation of 18:2 was entirely enzymic, whereas that of Ch18:2 was largely, though not completely, nonenzymic, The small extent of enzymic Ch18:2 oxidation increased with increasing enzyme to LDL ratios. Ascorbate and the reduced form of coenzyme Q, ubiquinol-10, which are both capable of reducing alpha-TO. and thereby preventing TMP, inhibited nonenzymic Ch18:2 oxidation induced by rhLO. Trolox and ascorbyl palmitate, which also inhibit TMP, ameliorated both enzymic and nonenzymic oxidation of LDL's lipids, whereas probucol, a radical scavenger not capable of preventing TRIP, was ineffective, These results demonstrate that rhLO-induced oxidation of CE is largely nonenzymic and increases with LDL's content of FFA substrates, We propose that conditions which increase LDL's FFA content, such as the presence of lipases, increase 15-LO-induced LDL lipid peroxidation and that this process requires only an initial, transient enzymic activity.	HEART RES INST,BIOCHEM UNIT,CAMPERDOWN,NSW 2050,AUSTRALIA; UNIV ANCONA,SCH MED,INST BIOCHEM,I-60131 ANCONA,ITALY	University of Sydney; Heart Research Institute; Marche Polytechnic University			Stocker, Roland/AAV-4489-2021; Witting, Paul/ABD-2053-2020; Witting, Paul/L-9786-2019; Neuzil, Jiri/H-7204-2014	Witting, Paul/0000-0003-2237-7004; Neuzil, Jiri/0000-0002-2478-2460				BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELKNER J, 1991, FEBS LETT, V279, P110, DOI 10.1016/0014-5793(91)80263-3; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; DAVIES MJ, 1987, BIOCHEM J, V245, P167, DOI 10.1042/bj2450167; ESKOLA J, 1983, BIOCHIM BIOPHYS ACTA, V751, P305, DOI 10.1016/0005-2760(83)90288-6; EZAKI M, 1995, J LIPID RES, V36, P1996; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Gan QF, 1996, J BIOL CHEM, V271, P25412, DOI 10.1074/jbc.271.41.25412; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P300, DOI 10.1161/01.ATV.17.2.300; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ITABE H, 1994, J BIOL CHEM, V269, P15274; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; Kenar JA, 1996, CHEM RES TOXICOL, V9, P737, DOI 10.1021/tx9600098; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; Lass A, 1996, BIOCHEM J, V314, P577, DOI 10.1042/bj3140577; LUND E, 1992, J BIOL CHEM, V267, P12462; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; RAPAPORT SM, 1979, EUR J BIOCHEM, V96, P545; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; Upston JM, 1996, J LIPID RES, V37, P2650; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1997, BIOCHEMISTRY-US, V36, P1251, DOI 10.1021/bi962493j; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; YLAHERTTUALA S, 1994, ARTERIOSCLER THROMB, V14, P32, DOI 10.1161/01.ATV.14.1.32; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	43	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30067	30074		10.1074/jbc.272.48.30067	http://dx.doi.org/10.1074/jbc.272.48.30067			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374483	hybrid			2022-12-25	WOS:A1997YH61300015
J	Zheng, J; Chen, RH; CorblanGarcia, S; Cahill, SM; BarSagi, D; Cowburn, D				Zheng, J; Chen, RH; CorblanGarcia, S; Cahill, SM; BarSagi, D; Cowburn, D			The solution structure of the pleckstrin homology domain of human SOS1. A possible structural role for the sequential association of diffusion and pleckstrin homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; EXCHANGE FACTOR SON; INOSITOL PHOSPHATES; BINDING-SITE; PH DOMAIN; DYNAMIN; RAS; IDENTIFICATION; DBL; SEVENLESS	A large subset of pleckstrin homology (PH) domains are immediately to the C terminus of diffuse B cell lymphoma (Dbl) homology (DbH) domains. Dbl domains are generally considered to be GTPase-exchange factors; many are proto oncogenes. PH domains appear to function as membrane-recruitment factors, or have specific protein-protein interactions, Since dual domain (DbH/PH) constructs are known to have significant properties in other pathways, it is possible that a defined interdomain relationship is required for DbH/PH function. We determined the solution structure of the human SOS1 PH domain for a construct partially extended into the preceding DbH domain, There are specific structural contacts between the PH and the vestigial DbH domain. This appears to involve structural elements common to this subfamily of PH domains, and to DbH domains. The human SOS1 PH domain binds to inositol 1,4,5-triphosphate with a similar to 60 mu M affinity. Using chemical shift titration, the binding site is identified to be essentially identical to that observed crystallographically for the inositol 1,4,5-triphosphate complex with the PH domain of phospholipase C delta. This site may serve as an interdomain regulator of DbH or other domains' functions. While the overall fold of the human SOS1 PH domain is similar to other PH domains, the size and position of the intrastrand loops and the presence of an N-terminal cu-helix of the vestigial DbH domain suggest that the subfamily of PH domains associated with DbH domains may be a well defined structural group in which the PR domain is a membrane recruiter and modulator.	ROCKEFELLER UNIV,LAB PHYS BIOCHEM,NEW YORK,NY 10021; SUNY STONY BROOK,DEPT MOL GENET & MICROBIOL,STONY BROOK,NY 11794	Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Corbalan-Garcia, Senena/C-6477-2009; Cowburn, David/A-8448-2008	Corbalan-Garcia, Senena/0000-0003-1840-5578; Zheng, Jie/0000-0001-6524-6800; Bar-Sagi, Dafna/0000-0003-2597-8948; Cowburn, David/0000-0001-6770-7172	NIGMS NIH HHS [GM-47021] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Dalvit C, 1996, J MAGN RESON SER B, V112, P282, DOI 10.1006/jmrb.1996.0143; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	32	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30340	30344		10.1074/jbc.272.48.30340	http://dx.doi.org/10.1074/jbc.272.48.30340			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374522	hybrid			2022-12-25	WOS:A1997YH61300054
J	Zheng, WJ; Xu, HE; Johnston, SA				Zheng, WJ; Xu, HE; Johnston, SA			The cysteine-peptidase bleomycin hydrolase is a member of the galactose regulon in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY GENE GAL80; SACCHAROMYCES-CEREVISIAE; EXPRESSION; CLONING; PROTEIN; VECTORS; FAMILY; DNA; TRANSCRIPTION; SEQUENCE	Bleomycin hydrolase is a cysteine peptidase discovered through its ability to detoxify the anti-cancer glycopeptide, bleomycin, Although found in all tissues in mammals and in both eukaryotes and prokaryotes, the normal cellular function of this peptidase is not known. We had previously reported the purification of bleomycin hydrolase hom yeast based on its unexpected ability to bind DNA. Recently we collaborated in solving the crystal structure of this protein, revealing a hexameric ring organization. We now report that the molecular characterization of the gene encoding yeast bleomycin hydrolase is also surprising. The transcription of the gene is regulated by galactose. Furthermore, this regulation is conveyed by a binding site for the Gal4 regulatory protein in its promoter, prompting the designation of this gene as GAL6. Gal6p also appears to have a negative effect on the GAL system as a deletion of the gene leads to a 2-5-fold higher expression of the GAL1, GAL2, GAL7, and MEL1 genes. The GAL6 deletion does slat affect the expression of another inducible gene, HSP26. Neither the peptidase nor the nucleic acid binding activity of Gal6p as assayed is apparently required to convey this regulation, implying yet another function for this new member of the GAL regulon.	UNIV TEXAS,SW MED CTR,DEPT MED,GRAD PROGRAM BIOCHEM & MOL BIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,GRAD PROGRAM BIOCHEM & MOL BIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Xu, H. Eric/ABD-7487-2021	Xu, H. Eric/0000-0002-6829-8144	NATIONAL CANCER INSTITUTE [R01CA067982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040700] Funding Source: NIH RePORTER; NCI NIH HHS [CA67982] Funding Source: Medline; NIGMS NIH HHS [GM40700] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BAJWA W, 1988, MOL CELL BIOL, V8, P3439, DOI 10.1128/MCB.8.8.3439; BHAT PJ, 1990, GENETICS, V125, P281; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; CIGAN AM, 1987, GENE, V59, P1; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI M, 1987, MOL GEN GENET, V207, P273, DOI 10.1007/BF00331589; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KANE SA, 1994, PROG NUCLEIC ACID RE, V49, P313; Lazo J S, 1993, Cancer Chemother Biol Response Modif, V14, P37; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Melcher K., 1997, YEAST SUGAR METABOLI, P235; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NOGI Y, 1986, J BACTERIOL, V165, P101, DOI 10.1128/jb.165.1.101-106.1986; NOGI Y, 1984, NUCLEIC ACIDS RES, V12, P9287, DOI 10.1093/nar/12.24.9287; Pei ZD, 1996, BIOCHEMISTRY-US, V35, P10751, DOI 10.1021/bi9605447; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHIMADA H, 1985, GENE, V39, P1; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TORCHIA TE, 1986, GENETICS, V113, P229; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; XU HE, 1994, J BIOL CHEM, V269, P21177	33	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30350	30355		10.1074/jbc.272.48.30350	http://dx.doi.org/10.1074/jbc.272.48.30350			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374524	hybrid			2022-12-25	WOS:A1997YH61300056
J	Garces, C; RuizHidalgo, MJ; deMora, JF; Park, C; Miele, L; Goldstein, J; Bonvini, E; Porras, A; Laborda, J				Garces, C; RuizHidalgo, MJ; deMora, JF; Park, C; Miele, L; Goldstein, J; Bonvini, E; Porras, A; Laborda, J			Notch-1 controls the expression of fatty acid-activated transcription factors and is required for adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-DIFFERENTIATION; BINDING-PROTEIN-ALPHA; PEROXISOME PROLIFERATOR; ADIPOCYTE DIFFERENTIATION; DROSOPHILA-MELANOGASTER; RECEPTOR-GAMMA; 3T3-L1 CELLS; NEUROGENESIS; GENE; WINGLESS	Notch, a transmembrane receptor member of the homeotic epidermal growth factor-like family of proteins, participates in cell-to-cell signaling to control cell fate during development, Activated Notch-1 constructs lacking the extracellular region prevent differentiation of several mammalian cells in vitro, This effect, however, bypasses the normal mechanisms of cell-to-cell interactions in which Notch-1 participates, We investigated the role of Notch-1. in the hormone-induced adipocyte differentiation of 3T3-L1 fibroblasts, a paradigmatic model of adipogenesis that requires cell-to-cell contact, Unlike other differentiation models, Notch-1 expression and function were necessary conditions for adipogenesis, Impaired Notch-1 expression by antisense Notch-1 constructs prevented adipocyte differentiation. Strategies aimed at blocking putative Notch/ligand interactions also blocked adipogenesis, implicating Notch as a critical molecule in cell-to-cell signaling necessary for differentiation, Inhibition of Notch-1 expression or function decreased the expression of peroxisomal proliferator-activated receptors delta and gamma, transcription factors that control adipocyte differentiation and that are up-regulated at cell confluence, These results implicate Notch in the commitment of 3T3-L1 cells to undergo adipogenesis by controlling the expression of the principal regulators of this process.	CTR BIOL EVALUAT & RES, DIV MONOCLONAL ANTIBODIES, IMMUNOBIOL LAB, ROCKVILLE, MD 20852 USA; NCI, CELLULAR & MOL BIOL LAB, NIH, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Porras, Almudena/N-2121-2015; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021; Laborda, Jorge/L-5726-2014; Ruiz-Hidalgo, Maria J/L-1956-2014	Porras, Almudena/0000-0002-6495-3308; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095; Laborda, Jorge/0000-0002-9210-838X; Ruiz-Hidalgo, Maria J/0000-0003-2508-8398; Miele, Lucio/0000-0002-5853-7287; Garces, Carmen/0000-0002-1099-2061				AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Blair SS, 1996, SCIENCE, V271, P1822, DOI 10.1126/science.271.5257.1822; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Heitzler P, 1996, DEVELOPMENT, V122, P161; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lardelli M, 1995, INT J DEV BIOL, V39, P769; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MIELE L, 1990, J BIOL CHEM, V265, P6427; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; PAN MG, 1995, ONCOGENE, V11, P2005; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PORRAS A, 1992, J BIOL CHEM, V267, P21124; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SAFONOVA I, 1994, BIOCHEM BIOPH RES CO, V204, P498, DOI 10.1006/bbrc.1994.2487; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464	59	133	134	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29729	29734		10.1074/jbc.272.47.29729	http://dx.doi.org/10.1074/jbc.272.47.29729			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368042	hybrid			2022-12-25	WOS:A1997YG64700052
J	Kudo, N; Khochbin, S; Nishi, K; Kitano, K; Yanagida, M; Yoshida, M; Horinouchi, S				Kudo, N; Khochbin, S; Nishi, K; Kitano, K; Yanagida, M; Yoshida, M; Horinouchi, S			Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-FUNGAL ANTIBIOTICS; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; LEPTOMYCIN-B; CHROMOSOME CONDENSATION; DOSAGE COMPENSATION; GENE; TRANSCRIPTION; RESISTANCE; MUTATIONS	Crm1 of Schizosaccharomyces pombe, a nuclear protein essential for proliferation and chromosome region maintenance, is a possible target of leptomycin B, an antifungal and antitumor antibiotic with cell cycle-arresting activity, cDNA encoding a human homolog of Crm1 was cloned, Human CRM1 (hCRM1) consisted of 1071 amino acids, of which the sequence showed 52% homology with S. pombe Crm1. hCRM1 weakly complemented the cold sensitive mutation of S. pombe crm1-809, as did S. pombe crm1(+), Overproduction of hCRM1 under the control of a series of nmt1 promoters suppressed cell proliferation in wild-type S. pombe in an expression level-dependent manner, A similar inhibitory effect was also observed for crm1(+). Cells overproducing either hCRM1 or S. pombe Crm1 were distinctly larger than uninduced cells and contained compacted and fragmented nuclei, Furthermore, calcofluor stain ing demonstrated that most of these cells formed two septa per cell and accumulated a large amount of chitin or its related polysaccharides around the septa, Closely similar phenotypes between hCRM1- and S. pombe Crm1-induced cells indicate that the cloned cDNA encodes a functional homolog of S. pombe crm1(+). Northern blot analyses with RNAs isolated from synchronized mammalian cells showed that the expression of mammalian CRM1 was initiated in late G(1) and reached a peak at G(2)/M, although its protein level unchanged during the cell cycle, Transient expression of hCRM1 fused to the green fluorescent protein (GFP) in NIH3T3 cells showed that hCRM1 was localized preferentially in the nuclear envelope and was also detectable in the nucleoplasm and the cytoplasm, A crm1 mutation of S. pombe caused nuclear import of a GFP fusion protein containing a nuclear export signal but no change in the distribution of a GFP fusion protein containing a nuclear localization signal, All of these data suggest that CRM1 is a novel cell-cycle regulated gene that is essential for the nuclear export signal-dependent nuclear export of proteins.	UNIV TOKYO, GRAD SCH AGR & LIFE SCI, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN; FAC MED, INST ALBERT BONNIOT, INSERM, U309, LA TRONCHE, FRANCE; TAKEDA CHEM IND LTD, PHARMACEUT DISCOVERY RES DIV, TSUKUBA, IBARAKI 30042, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 60601, JAPAN	University of Tokyo; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Takeda Chemical Industries; Kyoto University			Yoshida, Minoru/C-8049-2014; Khochbin, Saadi/M-8090-2013; Kudo, Nobuaki/AAU-7196-2021	Yoshida, Minoru/0000-0002-4376-5674; Khochbin, Saadi/0000-0002-0455-0857; Kudo, Nobuaki/0000-0001-8134-1242				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Alfa C, 1993, EXPT FISSION YEAST L; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GANNON JV, 1991, NATURE, V349, P802; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gutz H., 1974, HDB GENETICS, V1, P395; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; Hatakeyama M, 1995, Prog Cell Cycle Res, V1, P9; Hensey C, 1995, Prog Cell Cycle Res, V1, P149; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KHOCHBIN S, 1989, CYTOMETRY, V10, P484, DOI 10.1002/cyto.990100418; KOMIYAMA K, 1985, J ANTIBIOT, V38, P224, DOI 10.7164/antibiotics.38.224; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Maniatis T., 1982, MOL CLONING; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHIMANUKI M, 1995, J CELL SCI, V108, P569; TANAKA K, 1993, MOL CELL BIOL, V13, P80, DOI 10.1128/MCB.13.1.80; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; USUI T, 1995, GENE, V161, P93, DOI 10.1016/0378-1119(95)00229-Y; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	39	184	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29742	29751		10.1074/jbc.272.47.29742	http://dx.doi.org/10.1074/jbc.272.47.29742			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368044	hybrid			2022-12-25	WOS:A1997YG64700054
J	Ochem, AE; Skopac, D; Costa, M; Rabilloud, T; Vuillard, L; Simoncsits, A; Giacca, M; Falaschi, A				Ochem, AE; Skopac, D; Costa, M; Rabilloud, T; Vuillard, L; Simoncsits, A; Giacca, M; Falaschi, A			Functional properties of the separate subunits of human DNA helicase II Ku autoantigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; V(D)J RECOMBINATION; BINDING PROPERTIES; P70; ANTIGEN; PURIFICATION; REQUIREMENT; MECHANISM; ENZYME; CELLS	The Ku antigen consists of two subunits of 70 and 83 kDa and is endowed with both duplex DNA end-binding capacity and helicase activity (human DNA helicase II). HeLa Ku can be isolated from in vitro cultured human cells uniquely as a heterodimer, and the subunits can be separated by electrophoresis only under denaturing conditions. To dissect the molecular functions of the two subunits of the heterodimer, we have cloned and expressed their cDNAs separately in Escherichia coli. The two activities of Ku (DNA binding and unwinding) were reconstituted by mixing and refolding both subunits in equimolar amounts (Tuteja, N., Tuteja, R, Ochem, A, Taneja, P., Huang, N-W., Simoncsits, A, Susic, S., Rahman, K., Marusic, L., Chen, J., Zang, J., Wang, S., Pongor, S., and Falaschi, k (1994) EMBO J. 13, 4991-5001). Renaturation of the separate subunits can be achieved in the presence of a synthetic solubilizing and stabilizing agent, dimethyl ethylammonium propane sulfonate (NDSB 195). The helicase activity of the Ku protein resides uniquely in the 70-kDa subunit, whereas the DNA end-binding activity can be reconstituted only through renaturation of the two subunits in the heterodimeric form and is practically absent in the separate subunits. The 83-kDa subunit, when refolded in the absence of the 70-kDa subunit, forms homodimers unable to unwind DNA and bind duplex ends. The three separate species (heterodimer, 70-kDa subunit, and 83-kDa subunit homodimer) all have ssDNA-dependent ATPase activity.	INT CTR GENET ENGN & BIOTECHNOL, MOL BIOL UNIT, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, PROT STRUCT & FUNCT GRP, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, MOL MED UNIT, I-34012 TRIESTE, ITALY; CTR ETUD NUCL GRENOBLE, DEPT BIOL MOL & STRUCT, F-38042 GRENOBLE 09, FRANCE; INST MAX VON LAUE PAUL LANGEVIN, F-38042 GRENOBLE 09, FRANCE; CNR, IST GENET BIOCHIM & EVOLUZIONIST, I-27100 PAVIA, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB); CEA; Institut Laue-Langevin (ILL); Consiglio Nazionale delle Ricerche (CNR)			Giacca, Mauro/J-9287-2016	Giacca, Mauro/0000-0003-2927-7225				CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; CSORDASTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3257; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HIGASHIURA M, 1992, EXP CELL RES, V201, P444, DOI 10.1016/0014-4827(92)90293-H; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TRIBIOLI C, 1987, NUCLEIC ACIDS RES, V15, P10211, DOI 10.1093/nar/15.24.10211; TUTEJA N, 1995, NUCLEIC ACIDS RES, V23, P2457, DOI 10.1093/nar/23.13.2457; TUTEJA N, 1992, NUCLEIC ACIDS RES, V20, P5329, DOI 10.1093/nar/20.20.5329; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VUILLARD L, 1994, FEBS LETT, V353, P294, DOI 10.1016/0014-5793(94)01060-9; VUILLARD L, 1995, BIOCHEM J, V305, P339; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	30	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29919	29926		10.1074/jbc.272.47.29919	http://dx.doi.org/10.1074/jbc.272.47.29919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368068	hybrid			2022-12-25	WOS:A1997YG64700078
J	Okumura, N; Gorkun, OV; Lord, ST				Okumura, N; Gorkun, OV; Lord, ST			Severely impaired polymerization of recombinant fibrinogen gamma-364 Asp->His, the substitution discovered in a heterozygous individual	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FIBRINOGEN; FIBRINOPEPTIDE-B; CLOT FORMATION; THROMBIN; RELEASE; CALCIUM; CHAIN; SITE; AGGREGATION	During blood coagulation, soluble fibrinogen is converted to fibrin monomers that polymerize to form an insoluble clot, Polymerization has been described as a two-step process: the formation of double-stranded protofibrils and the subsequent lateral aggregation of protofibrils into fibers, Previous studies have shown that gamma chain residues Tyr-363 and Asp-364 have a significant role in polymerization, most likely in protofibril formation, To better define the role of these residues, me synthesized three fibrinogens with single substitutions at these two positions: Tyr-363 --> Ala, Asp-364 --> Ala, and Asp-364 --> His, We found that the release of fibrinopeptides A and B was the same for these variants and normal recombinant fibrinogen, showing that all variants had normal fibrin formation, In contrast, we found that polymerization was significantly delayed for both Ala variants and was almost nonexistent for the His variant, Clottability for the Ala variants was only slightly reduced, and fibrin gels were formed. Surprisingly, clottability of the His variant was substantially reduced, and fibrin gels were not formed, Our data suggest that both protofibril formation and lateral aggregation were altered by these substitutions, indicating that the C-terminal domain of the gamma chain has a role in both polymerization steps.	UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048, R23HL031048] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31048] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BIRKEN S, 1975, THROMB RES, V7, P599, DOI 10.1016/0049-3848(75)90106-1; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CARR ME, 1986, BIOCHEM J, V239, P513, DOI 10.1042/bj2390513; CIERNIEWSKI CS, 1992, BIOCHEMISTRY-US, V31, P4248, DOI 10.1021/bi00132a014; COTE H, 1997, THROMB HAEMOSTASIS S, V78, P757; Ebert RF., 1994, INDEX VARIANT HUMAN; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; GORKUN OV, 1994, BIOCHEMISTRY-US, V33, P6986, DOI 10.1021/bi00188a031; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; LEWIS SD, 1985, J BIOL CHEM, V260, P192; LITVINOVICH SV, 1995, EUR J BIOCHEM, V229, P605, DOI 10.1111/j.1432-1033.1995.tb20504.x; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; NG AS, 1993, METHOD ENZYMOL, V222, P341; Nickoloff J A, 1996, Methods Mol Biol, V58, P455; OKADA M, 1983, THROMB RES, V29, P269, DOI 10.1016/0049-3848(83)90039-7; Okumura N, 1996, THROMB HAEMOSTASIS, V75, P887; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; RUF W, 1988, BIOCHIM BIOPHYS ACTA, V965, P169, DOI 10.1016/0304-4165(88)90053-0; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; TAKEBE M, 1995, THROMB HAEMOSTASIS, V73, P662; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; YAMAZUMI K, 1992, P NATL ACAD SCI USA, V89, P2893, DOI 10.1073/pnas.89.7.2893; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; YOSHIDA N, 1991, BLOOD, V77, P1958	32	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29596	29601		10.1074/jbc.272.47.29596	http://dx.doi.org/10.1074/jbc.272.47.29596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368024	hybrid			2022-12-25	WOS:A1997YG64700034
J	Sabourin, LA; Tamai, K; Narang, MA; Korneluk, RG				Sabourin, LA; Tamai, K; Narang, MA; Korneluk, RG			Overexpression of 3'-untranslated region of the myotonic dystrophy kinase cDNA inhibits myoblast differentiation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PROTEIN-KINASE; TRIPLET REPEAT; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; CTG REPEAT; EXPRESSION; GENE; EXPANSION; CELLS	The genetic defect underlying myotonic dystrophy (DM) has been identified as an unstable CTG trinucleotide repeat amplification in the 3'-untranslated region (3'-UTR) of the DM kinase gene (DMK). Individuals with the most severe congenital form display a marked delay in muscle terminal differentiation. To gain insight into the role of DMK during myogenesis, we have examined the effect of DMK overexpression on the terminal differentiation of the murine myoblast cell line C2C12, We demonstrate that a 4-10-fold constitutive overexpression of DMK mRNA in myoblasts caused a marked inhibition of terminal differentiation. Surprisingly, this activity was mapped to a 239-nucleotide region of the 3'-UTR of the DMK transcript. When the DMK 3'-UTR was placed downstream of a reporter gene, the same inhibition of myogenesis was observed, Following the induction of differentiation of myoblast clones overexpressing the DMK 3'-UTR, the levels of myogenin mRNA were reduced by approximately Li-fold, whereas the steady state levels of mef-2c transcripts were not affected. These data suggest that overexpression of the DMK 3'-UTR may interfere with the expression of muscle leading to a delay in terminal specific mRNAs differentiation.	UNIV OTTAWA,DEPT IMMUNOL & MICROBIOL,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DEPT PEDIAT,OTTAWA,ON K1H 8L1,CANADA; CHILDRENS HOSP EASTERN ONTARIO,DEPT GENET,OTTAWA,ON K1H 8L1,CANADA	University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; Belasco J.G., 2012, CONTROL MESSENGER RN; BLACK RA, 1985, P NATL ACAD SCI USA, V82, P124, DOI 10.1073/pnas.82.1.124; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Bush EW, 1996, J BIOL CHEM, V271, P548, DOI 10.1074/jbc.271.1.548; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Dunne PW, 1996, CELL MOTIL CYTOSKEL, V33, P52; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FARKASBARGETON E, 1988, J NEUROL SCI, V83, P145, DOI 10.1016/0022-510X(88)90064-0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HUNTER T, 1991, METHODS ENZYMOL, V200; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Reddy S, 1996, NAT GENET, V13, P325, DOI 10.1038/ng0796-325; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J., 2002, MOL CLONING LAB MANU; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P466, DOI 10.1001/archneur.1976.00500070008002; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; Soussi-Yanicostas N, 1991, Neuromuscul Disord, V1, P103, DOI 10.1016/0960-8966(91)90057-Y; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; Thornton CA, 1997, NAT GENET, V16, P407, DOI 10.1038/ng0897-407; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a	54	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29626	29635		10.1074/jbc.272.47.29626	http://dx.doi.org/10.1074/jbc.272.47.29626			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368029	hybrid			2022-12-25	WOS:A1997YG64700039
J	Hao, LN; Tiganis, T; Tonks, NK; Charbonneau, H				Hao, LN; Tiganis, T; Tonks, NK; Charbonneau, H			The noncatalytic C-terminal segment of the T cell protein tyrosine phosphatase regulates activity via an intramolecular mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION; ACTIVATION; SEQUENCE; PHOSPHOTYROSINE; TRANSCRIPTION; PURIFICATION; SPECIFICITY; MUTAGENESIS; QUANTITIES	Human T cell protein tyrosine phosphatase (TCPTP) is a nontransmembrane enzyme, the first of the protein tyrosine phosphatase family to be cloned, Alternative mRNA splicing results in variation in the sequence at the extreme C terminus of TCPTP and generates a 45-kDa form (TC45) that is targeted to the nucleus and a 48-kDa variant (TC48) associated with membranes of the endoplasmic reticulum, In this report, we assessed the role of the C-terminal, noncatalytic segment of TCPTP in regulating activity, concentrating primarily on the TC45 variant, We have demonstrated that limited tryptic proteolysis of TC45 releases first a 42-kDa fragment, then a 33-kDa catalytic domain, Using reduced carboxyamidomethylated and maleylated lysozyme as substrate (RCML), the catalytic domain displays 20-100-fold more activity than the full-length enzyme, Analysis of the time course of limited trypsinolysis revealed that proteolytic activation occurred following cleavage of a protease-sensitive region (residues 353-387) located at the C terminus of TC45, The activity of truncation mutants illustrated that removal of 20 C-terminal residues was sufficient to activate the enzyme fully, The 33-kDa catalytic domain, but not the full-length enzyme, was inhibited in a concentration-dependent manner by addition of the noncatalytic C-terminal segment of TC45, A monoclonal antibody to TCPTP, CF4, which recognizes an epitope located between residues 350 and 363, was capable of fully activating TC45. These data indicate that the noncatalytic segment of TC45 contains an autoregulatory site that modulates activity via a reversible intramolecular interaction with the catalytic domain, These studies suggest that the C-terminal noncatalytic segment of TC45, and possibly TC48, may not only direct the enzyme to different subcellular locations but may also modulate activity in response to the binding of regulatory proteins and/or posttranslational modification.	PURDUE UNIV,DEPT BIOCHEM 1153,W LAFAYETTE,IN 47907; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Cold Spring Harbor Laboratory			Tiganis, Tony/AAV-3495-2020	Tiganis, Tony/0000-0002-8065-9942	NCI NIH HHS [CA53840, CA59935] Funding Source: Medline; NIDDK NIH HHS [DK20542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053840, R01CA053840, R29CA059935, R01CA059935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kamatkar S, 1996, J BIOL CHEM, V271, P26755, DOI 10.1074/jbc.271.43.26755; Kemp B E, 1996, Adv Pharmacol, V36, P221, DOI 10.1016/S1054-3589(08)60584-0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Reddy RS, 1995, DNA CELL BIOL, V14, P1007, DOI 10.1089/dna.1995.14.1007; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022; ZHAO ZZ, 1992, ANAL BIOCHEM, V202, P361, DOI 10.1016/0003-2697(92)90119-R	32	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29322	29329		10.1074/jbc.272.46.29322	http://dx.doi.org/10.1074/jbc.272.46.29322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361013	hybrid			2022-12-25	WOS:A1997YF68400072
J	Mu, D; Wakasugi, M; Hsu, DS; Sancar, A				Mu, D; Wakasugi, M; Hsu, DS; Sancar, A			Characterization of reaction intermediates of human excision repair nuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; COMPLEMENTATION GROUP-C; RNA-POLYMERASE-II; DNA-REPAIR; XERODERMA-PIGMENTOSUM; TRANSCRIPTION FACTOR; FACTOR TFIIH; DAMAGED DNA; CIS-SYN; COMPLEX	Nucleotide excision repair in humans is a complex reaction involving 14 polypeptides in six repair factors for dual incisions on either sides of a DNA lesion, To identify the reaction intermediates that form by the human excision repair nuclease, we adopted three approaches: purification of functional DNA protein complexes, permanganate footprinting, and the employment as substrate of presumptive DNA reaction intermediates containing unwound sequences 5' to, 3' to, or encompassing the DNA lesion. The first detectable reaction intermediate was formed by substrate binding of XPA, RPA, XPC.HHR23B plus TFIIH (preincision complex 1, PIC1), In this complex the DNA was unwound on either side of the lesion by no more than 10 bases. Independent of the XPG nuclease function, the XPG protein stabilized this complex, forming a long lived preincision complex 2 (PIC2). The XPF.ERCC1 complex bound to PIC2, forming PIC3, which led to dual incisions and the release of the excised oligomer, With partially unwound DNAs, thymine cyclobutane dimer was excised at a fast rate independent of XPC.HHR23B, indicating that a major function of this protein is to stabilize the unwound DNA or to aid lesion unwinding in preincision complexes.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Wakasugi, Mitsuo/D-8417-2015; Mu, David/E-8933-2011	Wakasugi, Mitsuo/0000-0001-9593-0566; Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARSALOU LS, 1994, MUTAT RES, V315, P43, DOI 10.1016/0921-8777(94)90027-2; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLUGSTON CK, 1992, CANCER RES, V52, P6375; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FRIEDBERG EC, 1995, DNA REPAIR; Gunz D, 1996, J BIOL CHEM, V271, P25089, DOI 10.1074/jbc.271.41.25089; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hwang JR, 1996, J BIOL CHEM, V271, P15898, DOI 10.1074/jbc.271.27.15898; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; LI L, 1995, MOL CELL BIOL, V15, P1993; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Mu D, 1997, PROG NUCLEIC ACID RE, V56, P63, DOI 10.1016/S0079-6603(08)61002-8; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SMITH CA, 1993, J BIOL CHEM, V268, P11143; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TAYLOR JS, 1994, ACCOUNTS CHEM RES, V27, P76, DOI 10.1021/ar00039a003; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	52	135	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28971	28979		10.1074/jbc.272.46.28971	http://dx.doi.org/10.1074/jbc.272.46.28971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360969	Green Published, hybrid			2022-12-25	WOS:A1997YF68400028
J	Patterson, BC; Sang, QXA				Patterson, BC; Sang, QXA			Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B type IV collagenase (MMP-9)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMINOGEN; MATRIX METALLOPROTEINASES; ANGIOGENESIS INHIBITOR; CANCER METASTASIS; ACTIVATION; PROGELATINASE; SUPPRESSION; EXPRESSION; CARCINOMA	Angiostatin is one of the most potent inhibitors of angiogenesis. Reports have shown that metalloelastase, pancreas elastase, plasmin reductase, and plasmin convert plasminogen to angiostatin. However, the cleavage sites of plasminogen by those enzymes have not been determined. Here we demonstrate that two members of the human matrix metalloproteinase (MMP) family, matrilysin (MMP-7) and gelatinase B/type lV collagenase (MMP-9), hydrolyze human plasminogen to generate angiostatin fragments, The cleavage sites have been determined, The 58-kDa bands derived from plasminogen by MMP-7 and MMP-9 both have the N-terminal sequence KVYLSEXKTG, which corresponds to that of angiostatin. This N terminus is identical to that of the starting plasminogen itself and corresponds to residues 97-106 of prepro-plasminogen. The 42- and 38-kDa bands generated by MMP-7 both have the N-terminal sequence VVLLPNVETP, which corresponds to the amino acid sequence 467-476 of prepro-plasminogen, between kringle domain 4 and 5, MMP-9 cleaves plasminogen to generate a 42-kDa fragment with the N-terminal sequence PVVLLPNVE, 1 residue upstream of the MMP-7 cleavage site, These results indicate that MMP-7 and MMP-9 may regulate new blood vessel formation by cleaving plasminogen and generating angiostatin molecules.	FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University								ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; BUSIEK DF, 1992, J BIOL CHEM, V267, P9087; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, EUR J CANCER, V32A, P2534, DOI 10.1016/S0959-8049(96)00423-6; FORSGREN M, 1987, FEBS LETT, V213, P254, DOI 10.1016/0014-5793(87)81501-6; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; GROSKOPF WR, 1969, J BIOL CHEM, V244, P3590; Heppner KJ, 1996, AM J PATHOL, V149, P273; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SALAMONSEN LA, 1994, CELL BIOL INT, V18, P1139, DOI 10.1006/cbir.1994.1040; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; Sim BKL, 1997, CANCER RES, V57, P1329; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; WIMAN B, 1975, EUR J BIOCHEM, V50, P489, DOI 10.1111/j.1432-1033.1975.tb09887.x; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032	28	359	376	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28823	28825		10.1074/jbc.272.46.28823	http://dx.doi.org/10.1074/jbc.272.46.28823			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360944	hybrid			2022-12-25	WOS:A1997YF68400003
J	Wadsworth, SJ; Gebauer, G; vanRossum, GDV; Dhanasekaran, N				Wadsworth, SJ; Gebauer, G; vanRossum, GDV; Dhanasekaran, N			Ras-dependent signaling by the GTPase-deficient mutant of G alpha(12)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+/H+ EXCHANGER; PHOSPHOLIPASE-C; ACTIVATION; PATHWAY; CELLS; HYDROLYSIS; TRANSDUCTION; MECHANISMS	G alpha(12) and G alpha(13) regulate diverse responses through the small GTPases Ras, CDC42, Rac, and Rho, Whereas they activate similar responses in many different cell types, they also activate more specific and critical signaling pathways in other cell types, In COS cells, in which both G alpha(12) and G alpha(13) stimulate Na+/H+ exchange, they do so by activating different signaling pathways, Here we report that the differential recruitment of specific small GTPases by G alpha(12) and G alpha(13) defines the molecular basis for their functional differences. We have observed that the stimulation of Na+/H+ exchange by the GTPase-deficient mutant of G alpha(12) (G alpha(12)QL) requires a functional Ras and is independent of Rac/CDC42 and Jun kinase signaling module. By contrast, the stimulation of Na+/H+ exchange by G alpha(13)QL requires a functional Rac/CDC42 CDC42 and the Jun kinase signaling module, Our results also indicate that G alpha(12)QL-Ras stimulation of Na+/H+ exchange involves a D609-sensitive phospholipase and protein kinase C, These studies, for the first time, describe a novel G alpha(12)-specific signaling pathway involving Has, phosphatidylcholine hydrolysis, and protein kinase C in the regulation of Na+/H+ exchange.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARNERO A, 1994, ONCOGENE, V9, P1387; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; Li YS, 1996, MOL CELL BIOL, V16, P5947; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin X, 1996, J BIOL CHEM, V271, P22604, DOI 10.1074/jbc.271.37.22604; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITSUI H, 1997, J BIOL CHEM, V22, P4904; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081	30	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28829	28832		10.1074/jbc.272.46.28829	http://dx.doi.org/10.1074/jbc.272.46.28829			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360946	hybrid			2022-12-25	WOS:A1997YF68400005
J	Dvir, A; Tan, SY; Conaway, JW; Conaway, RC				Dvir, A; Tan, SY; Conaway, JW; Conaway, RC			Promoter escape by RNA polymerase II - Formation of an escape-competent transcriptional, intermediate is a prerequisite for exit of polymerase from the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; ABORTIVE INITIATION; TERMINAL-DOMAIN; FACTOR-EPSILON; FACTOR-DELTA; RAT-LIVER; ELONGATION; MECHANISM; SELECTION	Shortly after initiating promoter-specific transcription in vitro, mammalian RNA polymerase II becomes highly susceptible td arrest in a promoter-proximal region 9-13 base pairs downstream of the transcriptional start site (Dvir, A., Conaway, R. C., and Conaway, J. W. (1996) J. Biol, Chem, 271, 23352-23356), Arrest by polymerase in this region is suppressed by TFIIH in an ATP-dependent reaction (Dvir, A.; Conaway, R. C., and Conaway, J. W. (1997) Proc. Natl. Acad, Sci, U. S. A. 94, 9006-9010), In this report, we present evidence that, in addition to TFIIH and an ATP cofactor, efficient transcription by RNA polymerase II through this promoter-proximal region requires formation of an ''escape-competent'' transcriptional intermediate, Formation of this intermediate requires template DNA 40-50 base pairs downstream of the transcriptional start site. This requirement for downstream DNA is transient, since template DNA downstream of +40 is dispensable for assembly of the preinitiation complex, for initiation and synthesis of the first 10-12 phosphodiester bonds of nascent transcripts and for further extension of transcripts longer than similar to 14 nucleotides, Thus, promoter escape requires that the RNA polymerase, II transcription complex undergoes a critical structural transition, likely driven by interaction of one or more components of the transcriptional machinery with template DNA 40-50 base pairs downstream of the transcriptional start site.	OAKLAND UNIV,DEPT BIOL SCI,ROCHESTER,MI 48309; STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oakland University; Stanford University; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LUSE DS, 1987, J BIOL CHEM, V262, P14990; PETERSON MG, 1991, NATURE, V354, P369; REINES D, 1992, J BIOL CHEM, V267, P15516; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEIL PA, 1979, CELL, V18, P469	27	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28175	28178		10.1074/jbc.272.45.28175	http://dx.doi.org/10.1074/jbc.272.45.28175			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353262	hybrid			2022-12-25	WOS:A1997YF21900002
J	Koshelnick, Y; Ehart, M; Hufnagl, P; Heinrich, PC; Binder, BR				Koshelnick, Y; Ehart, M; Hufnagl, P; Heinrich, PC; Binder, BR			Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FOS GENE-EXPRESSION; PROTEIN-C INHIBITOR; PLASMINOGEN-ACTIVATOR; DIFFERENTIAL ACTIVATION; INTERLEUKIN-6 FAMILY; ENDOTHELIAL-CELLS; MEMBRANE DOMAINS; TYROSINE KINASE; GP130	The urokinase type plasminogen activator (uPA) binds to cells via a specific receptor attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. Despite the lack of a transmembrane domain, the urokinase receptor (uPAR) is capable of transducing extracellular signals affecting growth, migration, and adhesion. Several Tyr kinases of the are family as well as beta 1, beta 2, and beta 3 integrins were found to be associated with the uPAR. We found that in the human kidney epithelial line TCL-598, also components of the JAK1/STAT1 signal transduction pathway including gp130, are associated with uPAR as revealed by coimmunoprecipitation and are co-localized in caveolae. Upon clustering of uPA.uPAR complex by a monoclonal antibody, JAK1 associates with uPAR, which in turn leads to STAT1 phosphorylation, dimerization, specific binding to DNA, and gene activation. To prove the dependence of STAT1 activation on the uPAR, TCL-598 cells were treated with sense and antisense uPAR oligo-nucleotides. In antisense-treated cells in which uPAR expression was reduced to less then one third, activation of STAT1 by the clustering antibody was abolished while STAT1 activation by interferon-gamma was unaffected. Therefore, in this cell line, uPA uPAR also utilizes the JAK1/STAT1 pathway for signaling, and gp130 might be the transmembrane adapter for this signal transduction pathway.	UNIV VIENNA, DEPT VASC BIOL & THROMBOSIS RES, A-1090 VIENNA, AUSTRIA; RHEIN WESTFAL TH AACHEN, INST BIOCHEM, D-5100 AACHEN, GERMANY	University of Vienna; RWTH Aachen University								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; ANICHINI E, 1994, EXP CELL RES, V213, P438, DOI 10.1006/excr.1994.1221; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUCKNER A, 1992, CANCER RES, V52, P3043; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FALUS A, 1995, IMMUNOL LETT, V44, P221, DOI 10.1016/0165-2478(95)00218-T; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GEIGER M, 1991, J BIOL CHEM, V266, P11851; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HANSEN JG, 1988, J INVEST DERMATOL, V90, P790; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PERALDI SG, 1995, EUR J BIOCHEM, V234, P656; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Ruthner M., 1994, Fibrinolysis, V8, P97; Ruthner M., 1996, Fibrinolysis, V10, P17; RUTHNER M, 1995, THROMB HAEMOSTASIS, V73, P1132; SCHNAPER HW, 1995, J CELL PHYSIOL, V165, P107, DOI 10.1002/jcp.1041650114; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STAHL N, 1994, BRAZ J MED BIOL RES, V27, P297; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WANG N, 1995, AM J PHYSIOL-CELL PH, V268, pC1062, DOI 10.1152/ajpcell.1995.268.4.C1062; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016	47	143	151	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28563	28567		10.1074/jbc.272.45.28563	http://dx.doi.org/10.1074/jbc.272.45.28563			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353320	hybrid			2022-12-25	WOS:A1997YF21900060
J	Mao, CG; Wadleigh, M; Jenkins, GM; Hannun, YA; Obeid, LM				Mao, CG; Wadleigh, M; Jenkins, GM; Hannun, YA; Obeid, LM			Identification and characterization of Saccharomyces cerevisiae dihydrosphingosine-1-phosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE; QUANTITATION; ARREST; LIVER	We have identified the yeast sphingosine resistance gene (YSR2) of Saccharomyces cerevisiae as encoding a protein that specifically dephosphorylates dihydrosphingosine 1-phosphate (DHS-1-P), and we refer to this protein as dihydrosphingosine-1-phosphate phosphatase. Overexpression of YSR2 conferred sphingosine resistance to the dihydrosphingosine-1-P lyase-defective mutant (JS16) of S. cerevisiae, which is hypersensitive to sphingosine. The ysr2 Delta deletion mutant of S. cerevisiae accumulated DHS-1-P compared with its wild type strain upon labeling with n-erythro-[4,5-H-3]dihydrosphingosine, whereas overexpression of YSR2 increased dephosphorylation of DHS-1-P. An epitope-tagged fusion protein (YSR2-Flag) was partially purified and found to specifically dephosphorylate DHS-1-P to yield dihydrosphingosine. YSR2 failed to dephosphorylate ceramide l-phosphate or phosphatidic acid. Functionally, the mutant bearing the ysr2 Delta deletion decreased labeling of sphingolipids and increased labeling of glycerolipids dramatically following in vivo labeling with D-erythro-[H-3]dihydrosphingosine, but it slightly affected labeling of sphingolipids with inositol. Taken together, these results identify YSR2 as dihydrosphingosine-1-phosphate phosphatase. They also raise the intriguing possibility that phosphorylation followed by dephosphorylation is required for incorporation of exogenous long chain sphingoid bases into sphingolipids.	DUKE UNIV, MED CTR, DEPT MED, DIV GERIATR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, VET AFFAIRS GERIATR RES EDUC & CLIN CTR, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center				obeid, lina/0000-0002-0734-0847	NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; Badiani K, 1996, BBA-LIPID LIPID MET, V1304, P190, DOI 10.1016/S0005-2760(96)00119-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECEUSTER P, 1995, BIOCHEM J, V311, P139, DOI 10.1042/bj3110139; FISHBEIN JD, 1993, J BIOL CHEM, V268, P9255; Gietz RD, 1994, MOL GENETICS YEAST P; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; MANDALA SM, 1995, J ANTIBIOT, V48, P349, DOI 10.7164/antibiotics.48.349; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stukey J, 1997, PROTEIN SCI, V6, P469; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171	26	132	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28690	28694		10.1074/jbc.272.45.28690	http://dx.doi.org/10.1074/jbc.272.45.28690			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353337	hybrid			2022-12-25	WOS:A1997YF21900077
J	McMahon, GA; Garfinkel, S; Prudovsky, I; Hu, YG; Maciag, T				McMahon, GA; Garfinkel, S; Prudovsky, I; Hu, YG; Maciag, T			Communication - Intracellular precursor interleukin (IL)-1 alpha, but not mature IL-1 alpha, is able to regulate human endothelial cell migration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NUCLEAR-LOCALIZATION SEQUENCE; FACTOR RECEPTOR-1; FACTOR-I; C-SRC; ASSOCIATION; CORTACTIN; CLONING; PHOSPHORYLATION; IDENTIFICATION	The human umbilical vein endothelial cell (HUVEC) has a finite lifespan in vitro, and senescent HUVEC contain elevated levels of the negative growth regulator interleukin (IL)-1 alpha, IL-1 alpha is translated as a signal peptide sequence-less cytosolic 31-kDa precursor (IL-1 alpha p), which undergoes proteolytic activation to release the mature carboxyl terminus 17-kDa protein (IL-1 alpha m), Both the IL-1 alpha p and IL-1 alpha m proteins are biologically active as exogenous cytokines. Interestingly, only IL-1 alpha p contains a nuclear localization sequence between residues 79 and 85, To further study the role of intracellular IL-1 alpha in the regulation of human endothelial cell function, a spontaneous HUVEC transformant was stably transfected with IL-1 alpha p, IL-1 alpha m, and the IL-1 alpha p K82N mutant, which attenuates the nuclear traffic of IL-1 alpha p, Interestingly, the IL-1 alpha p transfectants were found to have a lower migratory potential than either IL-1 alpha m or IL-1 alpha p K82N transfectants, and the addition of the IL-1 receptor antagonist did not alter the migration of these cells. Immunofluorescence microscopy demonstrated that only the IL-1 alpha p transfectants exhibited prominent staining for beta-catenin-associated cell-to-cell contacts, as well as pronounced vimentin intermediate filaments and actin cytoskeleton staining, These data suggest that IL-1 alpha p, and not IL-1 alpha m, may function as an intracellular regulator of the migratory capacity of the human endothelial cell and that the nuclear localization sequence present within IL-1 alpha p may be involved in regulating this function.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOL MOL,ROCKVILLE,MD 20855	American Red Cross			Prudovsky, Igor/GVU-1521-2022		NIA NIH HHS [AG07450] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DUNLEVY JR, 1993, J CELL SCI, V105, P489; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GARFINKEL S, 1992, J BIOL CHEM, V267, P24375; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; GIRI JG, 1985, J IMMUNOL, V134, P343; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NAKAI S, 1988, BIOCHEM BIOPH RES CO, V154, P1189, DOI 10.1016/0006-291X(88)90266-5; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TERRANOVA VP, 1985, J CELL BIOL, V101, P2330, DOI 10.1083/jcb.101.6.2330; WANG E, 1985, J CELL BIOL, V100, P1466, DOI 10.1083/jcb.100.5.1466; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1994, J BIOL CHEM, V269, P20221	40	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28202	28205		10.1074/jbc.272.45.28202	http://dx.doi.org/10.1074/jbc.272.45.28202			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353269	hybrid			2022-12-25	WOS:A1997YF21900009
J	Okada, S; Pessin, JE				Okada, S; Pessin, JE			Communication - Insulin and epidermal growth factor stimulate a conformational change in Rap1 and dissociation of the CrkII-C3G complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR TYROSINE KINASES; PROTEIN-KINASE; SH3 DOMAIN; SOS-GRB2 COMPLEX; RAS-P21 GTPASE; RAS ACTIVATION; FACTOR C3G; C-CRK	Insulin and epidermal growth factor (EGF) stimulation of Chinese hamster ovary cells expressing the human insulin and EGF receptors resulted in a time dependent decrease in the ability of a Rap1 antibody (amino acid epitope 121-136) to immunoprecipitate Rap1 from whole cell detergent extracts. This was due to an apparent masking of Rap1 as heat denaturation of the whole cell detergent extracts (5 min at 100 degrees C) resulted in equal immunoprecipitation of Rap1 with this epitope specific antibody. The time-dependent change in Rap1 immunoreactivity was paralleled with an insulin-stimulated dissociation of the CrkII-C3G complex. Similarly, EGF treatment also resulted in a time-dependent dissociation of the CrkII-C3G complex that occurred concomitant with the masking of the 121-136 Rap1 epitope. Furthermore, pretreatment of the cells with the tyrosine kinase inhibitor, genistein, decreased both the basal and insulin-stimulated tyrosine phosphorylation of CrkII that directly correlated with the amount of CrkII that was immunoprecipitated with C3G. Together, these data suggest that insulin and EGF stimulation result in the dissociation of the CrkII-C3G complex, thereby inducing an apparent conformation change in Rap1.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NIDDK NIH HHS [DK25295, DK49781, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK049781, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Downward J, 1996, CANCER SURV, V27, P87; FELLER SM, 1995, ONCOGENE, V10, P1465; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HATA Y, 1990, J BIOL CHEM, V265, P7104; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	47	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28179	28182		10.1074/jbc.272.45.28179	http://dx.doi.org/10.1074/jbc.272.45.28179			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353263	hybrid			2022-12-25	WOS:A1997YF21900003
J	Schecter, AD; Rollins, BJ; Zhang, YJ; Charo, IF; Fallon, JT; Rossikhina, M; Giesen, PLA; Nemerson, Y; Taubman, MB				Schecter, AD; Rollins, BJ; Zhang, YJ; Charo, IF; Fallon, JT; Rossikhina, M; Giesen, PLA; Nemerson, Y; Taubman, MB			Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; FUNCTIONAL EXPRESSION; CHEMOTACTIC PROTEIN-1; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; IN-VITRO; ATHEROSCLEROTIC LESIONS	Monocyte chemoattractant protein-1 (MCP-1) is a C-C chemokine thought to play a major role in recruiting monocytes to the atherosclerotic plaque. Tissue factor (TF), the initiator of coagulation, is found in the atherosclerotic plaque, macrophages, and human aortic smooth muscle cells (SMC). The exposure of TF during plaque rupture likely induces acute thrombosis, leading to myocardial infarction and stroke. This report demonstrates that MCP-1 induces the accumulation of TF mRNA and protein in SMC and in THP-1 myelomonocytic leukemia cells. MCP-1 also induces TF activity on the surface of human SMC. The induction of TF by MCP-1 in SMC is inhibited by pertussis toxin, suggesting that the SMC MCP-1 receptor is coupled to a G(i)-protein. Chelation of intracellular calcium and inhibition of protein kinase C block the induction of TF by MCP-1, suggesting that in SMC it is mediated by activation of phospholipase C. SMC bind MCP-1 with a K-d similar to that previously reported for macrophages. However, mRNA encoding the macrophage MCP-1 receptors, CCR2A and B, is not present in SMC, indicating that they possess a distinct MCP-1 receptor. These data suggest that in addition to being a chemoattractant, MCP-I may have a procoagulant function and raise the possibility of an autocrine pathway in which MCP-1, secreted by SMC and macrophages, induces TF activity in these same cells.	CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,CARDIOVASC INST,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DIV THROMBOSIS RES,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PATHOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco				Fallon, John/0000-0002-7677-4868	NHLBI NIH HHS [HL09402, HL 54469, HL29019] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054469, F32HL009402, P01HL029019] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; ANNEX BH, 1995, CIRCULATION, V91, P619, DOI 10.1161/01.CIR.91.3.619; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BIZZARRI C, 1995, BLOOD, V86, P2388, DOI 10.1182/blood.V86.6.2388.bloodjournal8662388; Carson SD, 1996, BLOOD COAGUL FIBRIN, V7, P303, DOI 10.1097/00001721-199604000-00004; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DEMARCO R, 1992, CELL IMMUNOL, V140, P304, DOI 10.1016/0008-8749(92)90198-X; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DONOVANPELUSO M, 1994, J BIOL CHEM, V269, P1361; Dubois PM, 1996, J IMMUNOL, V156, P1356; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ERNST CA, 1994, J IMMUNOL, V152, P3541; FERNANDEZORTIZ A, 1994, J AM COLL CARDIOL, V23, P1562, DOI 10.1016/0735-1097(94)90657-2; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GRABOWSKI EF, 1993, BLOOD, V81, P3265; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; KIRCHHOFER D, 1993, BLOOD, V81, P2050; LE DT, 1994, THROMB HAEMOSTASIS, V72, P848; LEE MW, 1994, AM J PHYSIOL, V267, pC659, DOI 10.1152/ajpcell.1994.267.3.C659; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; Mulder AB, 1996, BLOOD, V88, P1306, DOI 10.1182/blood.V88.4.1306.bloodjournal8841306; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEMERSON Y, 1988, BLOOD, V71, P1; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARRY GCN, 1995, ARTERIOSCL THROM VAS, V15, P612, DOI 10.1161/01.ATV.15.5.612; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SOZZANI S, 1993, J IMMUNOL, V150, P1544; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; SPEIDEL CM, 1995, CIRCULATION, V92, P3323, DOI 10.1161/01.CIR.92.11.3323; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; TAKAHASHI M, 1995, CIRC RES, V76, P750, DOI 10.1161/01.RES.76.5.750; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; Wilcox J N, 1992, J Vasc Surg, V15, P913; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; ZELDIS SM, 1972, SCIENCE, V175, P766, DOI 10.1126/science.175.4023.766; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	64	178	198	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28568	28573		10.1074/jbc.272.45.28568	http://dx.doi.org/10.1074/jbc.272.45.28568			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353321	hybrid			2022-12-25	WOS:A1997YF21900061
J	Mandeville, R; Franco, E; SidracGhali, S; ParisNadon, L; Rocheleau, N; Mercier, G; Desy, M; Gaboury, L				Mandeville, R; Franco, E; SidracGhali, S; ParisNadon, L; Rocheleau, N; Mercier, G; Desy, M; Gaboury, L			Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats	FASEB JOURNAL			English	Article						carcinogenesis; solid tumor; mononuclear cell leukemia; tumor incidence	FREQUENCY ELECTROMAGNETIC-FIELDS; TUMOR PROMOTION; MAMMARY CARCINOGENESIS; EPIDEMIOLOGIC EVIDENCE; LIVER FOCI; EXPOSURE; CANCER; SURVIVAL; 50-HZ; MICE	Electric and magnetic fields (EMFs) associated with the production, transmission, and use of electricity are ubiquitous in industrialized societies. These fields are predominantly of low frequency (50/60 Hz) and are generally of low intensity. Review of the epidemiological evidence shows that the association between exposure to EMFs and cancer is weak and inconsistent, and generally fails to show a dose-response relationship. Moreover, in view of the methodological problems of these epidemiological studies, animal and laboratory studies are urgently needed to determine whether EMFs could be initiators and/or promoters of cancers. The objective of the present study was to determine whether chronic exposure to 60 Hz linear (single axis) sinusoidal, continuous-wave magnetic fields (MFs) of different intensities might increase the risk of leukemia and solid tumor development in rodents born and raised under these fields. Five groups of 50 female F344 rats were exposed for 20 h/day to 60 Hz MFs at intensities of <0.02 (sham controls), 2, 20, 200, and 2000 mu T. Full body exposure to the different fields was administered for 104 wk starting from the prenatal period (2 days before birth) and continuing during lactation and weaning until late adult Life. Body weight, survival, and clinical observations were evaluated in all groups of animals during in-life exposure. Necropsy was performed on all exposed and control animals that died, were found moribund, or were killed at termination of the study. To preserve and demonstrate the absence of any experimental bias, all clinical observations and pathological evaluations were conducted under ''blinded'' conditions. Fifty organs and tissues were evaluated in each animal, with special attention to the incidence of mononuclear cell leukemia, brain tumors, and mammary tumors. The findings from this chronic carcinogenicity study dem onstrate that, under our defined experimental conditions, exposure to 60 Hz linear (single axis) sinusoidal, continuous wave MFs did not affect animal survival, solid tumor, or mononuclear cell leukemia development in female F344 rats. No statistically significant, consistent, positive dose-related trends with the number of tumor-bearing animals per study group could be attributed to MF exposure.	MCGILL UNIV, DEPT ONCOL, DIV EPIDEMIOL, MONTREAL, PQ H3G 1Y6, CANADA; UNIV MONTREAL, DEPT PATHOL, MONTREAL, PQ H3C 3J7, CANADA	McGill University; Universite de Montreal	Mandeville, R (corresponding author), UNIV QUEBEC, INST ARMAND FRAPPIER, IMMUNOL RES CTR, 531 BOUL PRAIRES, LAVAL, PQ H7N 4Z3, CANADA.		Franco, Eduardo/C-6445-2014	Franco, Eduardo/0000-0002-4409-8084				ALDRICH TE, 1992, ELECTRO MAGNETOBIOL, V11, P127, DOI 10.3109/15368379209009822; ANDERSON LE, 1993, AM IND HYG ASSOC J, V54, P186, DOI 10.1202/0002-8894(1993)054<0186:BEOELE>2.0.CO;2; [Anonymous], PATHOLOGY F344 RAT; BATES MN, 1991, ENVIRON HEALTH PERSP, V95, P147, DOI 10.2307/3431121; BAUM A, 1995, CARCINOGENESIS, V16, P119, DOI 10.1093/carcin/16.1.119; BELLOSSI A, 1986, RADIAT ENVIRON BIOPH, V25, P75, DOI 10.1007/BF01209687; BENIASHVILI DS, 1991, CANCER LETT, V61, P75, DOI 10.1016/0304-3835(91)90079-W; Boorman G.A., 1985, HDB CARCINOGEN TESTI, P345; FAIRBAIRN DW, 1994, CELL MOL BIOL, V40, P561; Feldman D.B., 1988, NECROPSY GUIDE RODEN; FIORANI M, 1992, MUTAT RES, V282, P25, DOI 10.1016/0165-7992(92)90069-T; GART JJ, 1986, DESIGN ANAL LONG TER, V3; Haseman JK, 1996, MUTAT RES-FUND MOL M, V350, P131, DOI 10.1016/0027-5107(95)00098-4; HENDEE WR, 1994, HEALTH PHYS, V66, P127, DOI 10.1097/00004032-199402000-00001; HUFF J, 1982, ENVIRON HEALTH PERSP, V45, P185, DOI 10.2307/3429406; JUUTILAINEN J, 1986, HEREDITAS, V104, P145, DOI 10.1111/j.1601-5223.1986.tb00527.x; KAICER EK, 1997, IN PRESS MAGNETISM E; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUNE KT, 1990, EXTREMELY LOW FREQUE, P17; LOSCHER W, 1994, LIFE SCI, V54, P1531, DOI 10.1016/0024-3205(94)90024-8; LOSCHER W, 1993, CANCER LETT, V71, P75, DOI 10.1016/0304-3835(93)90100-N; LOSCHER W, 1994, ONCOLOGY-BASEL, V51, P288; LOSCHER W, 1996, ANN REV RES BIOL EFF, P7; MANDEVILLE R, 1993, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P419; MANDEVILLE R, 1991, AIR WASTE MANAGEMENT, V5, P1; MANDEVILLE R, 1992, AIR WASTE MANAGEMENT, V1, P1; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCORMICK DL, 1996, ANN REV RES BIOL EFF, P7; MEVISSEN M, 1993, BIOELECTROMAGNETICS, V14, P131, DOI 10.1002/bem.2250140206; NAFZIGER J, 1993, BIOELECTROCH BIOENER, V30, P133, DOI 10.1016/0302-4598(93)80071-2; Percy C., 1990, INT CLASSIFICATION D; PORTIER CJ, 1986, CANCER RES, V46, P4372; RANNUG A, 1993, BIOELECTROMAGNETICS, V14, P17, DOI 10.1002/bem.2250140105; RANNUG A, 1994, CARCINOGENESIS, V15, P153, DOI 10.1093/carcin/15.2.153; RANNUG A, 1993, ENVIRON RES, V62, P223, DOI 10.1006/enrs.1993.1107; RAO GN, 1990, TOXICOL PATHOL, V18, P61, DOI 10.1177/019262339001800109; SAGAN LA, 1992, JAMA-J AM MED ASSOC, V268, P625, DOI 10.1001/jama.268.5.625; SAVITZ DA, 1993, ENVIRON HEALTH PERSP, V101, P83, DOI 10.2307/3431664; STUCHLY MA, 1992, CANCER LETT, V65, P1, DOI 10.1016/0304-3835(92)90205-A; Tremblay L, 1996, BIOELECTROMAGNETICS, V17, P373, DOI 10.1002/(SICI)1521-186X(1996)17:5<373::AID-BEM4>3.0.CO;2-0; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; YASUI M, 1993, BIOELECTROMAGNETICS, V14, P535, DOI 10.1002/bem.2250140605	42	42	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1127	1136		10.1096/fasebj.11.13.9367347	http://dx.doi.org/10.1096/fasebj.11.13.9367347			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367347				2022-12-25	WOS:A1997YE98300010
J	Myllarniemi, M; Calderon, L; Lemstrom, K; Buchdunger, E; Hayry, P				Myllarniemi, M; Calderon, L; Lemstrom, K; Buchdunger, E; Hayry, P			Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation	FASEB JOURNAL			English	Article						PDGF receptor; ballooning injury; cell proliferation; SMC migration	SIGNAL-TRANSDUCTION; ARTERIAL INJURY; PORCINE ARTERIES; GENE-EXPRESSION; FACTOR-BETA; FACTOR-I; B GENE; PDGF; PROTEIN; INVIVO	Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have been linked to vascular smooth muscle cell (SMC) migration and proliferation leading to atherosclerosis, restenosis, and chronic allograft rejection. This study describes the effect of CGP 53716, a specific PDGFR tyrosine kinase inhibitor on SMC proliferation and migration in vitro and in neointimal formation in vivo. CGP 53716 inhibited dose dependently tyrosine phosphorylation of both the known PDGFRs: the PDGFR-alpha and PDGFR-beta. In primary rat SMC cultures, a dose-dependent inhibition of PDGF-AA and PDGF-BB induced migration, and tritiated thymidine incorporation of SMC was seen at nontoxic concentrations. After rat carotid artery ballooning injury in vivo, the migration of alpha-actin-positive cells on the luminal side of internal elastic lamina was decreased with 50 mg.kg(-1).day(-1) of CGP 53716 from 38 +/- 10 (control group) to 4 +/- 2 (P < 0.0001, Mann-Whitney U test, N = 18). CGP 53716 did not inhibit the number of replicating bromodeoxyuridine (BrdU)-incorporating cells in the intima, media, or adventitia during BrdU labeling at 0-96 postoperative h, though it inhibited significantly (P < 0.01) the replication of medial and intimal cells from 93 h onward. Intima/ media ratio was inhibited by 40% after 14 days in the CGP 53716-treated group (P = 0.028) after rat aortic denudation. The results indicate that inhibition of the PDGFR tyrosine kinase inhibits SMC migration and proliferation in vitro, SMC migration, and, to a lesser extent, proliferation after ballooning injury in vivo, confirming a causal role for activation of the PDGFR and the formation of neointimal lesions.	UNIV HELSINKI,CENT HOSP,HELSINKI,FINLAND; NOVARTIS PHARMACEUT DIV,BASEL,SWITZERLAND	University of Helsinki; Helsinki University Central Hospital; Novartis	Myllarniemi, M (corresponding author), UNIV HELSINKI,TRANSPLANTAT LAB,POB 21,FIN-00014 HELSINKI,FINLAND.		Lemström, Karl B/J-8885-2016	Lemström, Karl B/0000-0001-6920-4093; Myllarniemi, L Marjukka/0000-0001-9343-0867				Bendeck MP, 1996, CIRC RES, V78, P38, DOI 10.1161/01.RES.78.1.38; BILDER GE, 1992, CIRCULATION, V86, P169; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Casscells W, 1991, Prog Growth Factor Res, V3, P177, DOI 10.1016/0955-2235(91)90006-P; CERCEK B, 1991, AM J CARDIOL, V68, pC24; CLOWES AW, 1983, LAB INVEST, V49, P327; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; GORDON D, 1992, J HEART LUNG TRANSPL, V11, P57; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAUDENSCHILD CC, 1993, AM J MED, V94, pS40; HAYRY P, 1995, FASEB J, V9, P1336; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; Levitzki A, 1996, CURR OPIN CELL BIOL, V8, P239, DOI 10.1016/S0955-0674(96)80071-8; LIBBY P, 1992, CIRCULATION, V86, P47; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; POWELL JS, 1991, J AM COLL CARDIOL, V17, pB137; RECHTER MD, 1994, CIRC RES, V75, P410; ROSS R, 1991, TRENDS CARDIOVAS MED, V1, P277, DOI 10.1016/1050-1738(91)90043-E; ROSS R, 1995, ANN NY ACAD SCI, V748, P1; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Scott NA, 1996, CIRCULATION, V93, P2178, DOI 10.1161/01.CIR.93.12.2178; SHIMOKADO K, 1995, ANN NY ACAD SCI, V748, P171; THYBERG J, 1983, DIFFERENTIATION, V25, P156; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; Waltenberger J, 1996, ARTERIOSCL THROM VAS, V16, P1516, DOI 10.1161/01.ATV.16.12.1516; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28	39	104	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1119	1126		10.1096/fasebj.11.13.9367346	http://dx.doi.org/10.1096/fasebj.11.13.9367346			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367346				2022-12-25	WOS:A1997YE98300009
J	Walzog, B; Jeblonski, F; Zakrzewicz, A; Gaehtgens, P				Walzog, B; Jeblonski, F; Zakrzewicz, A; Gaehtgens, P			beta(2) integrins (CD11/CD18) promote apoptosis of human neutrophils	FASEB JOURNAL			English	Article						PMN; signal transduction; inflammation; DNA fragmentation assay; cell morphology; migration	PROTEIN-TYROSINE PHOSPHORYLATION; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; RESPIRATORY BURST; NONADHERENT NEUTROPHILS; MOLECULAR MECHANISMS; AGING NEUTROPHILS; CROSS-LINKING; ACTIVATION; RECEPTOR	Apoptosis of human polymorphonuclear neutrophils (PMN) is thought to be critical for the control of the inflammatory process, but the mechanisms underlying its regulation in physiological settings are still incompletely understood, This study was undertaken to test the hypothesis that the beta(2) integrin (CD11/CD18) family of leukocyte adhesion molecules contributes to the control of activated PMN by up-regulating apoptosis, Apoptosis of isolated human PMN was investigated by 1) analysis of DNA content, 2) detection of DNA degradation, 3) morphological studies, and 4) measurement of CD16 expression on the cell surface, We found that beta(2) integrins potentiated the tumor necrosis factor alpha (TNF-alpha) -induced apoptosis within 4 and 8 h after stimulation, The effect required aggregation of the beta(2) integrin Mac-1 (CD11b/CD18), which was induced by antibody cross-linking, and was independent of Fc receptors, An enhancement of apoptosis was also observed after migration of PMN through an endothelial cell monolayer, TNF-alpha-induced apoptosis as well as potentiation' by beta(2) integrins was prevented by inhibition of tyrosine kinases with herbimycin A or genistein, The present study provides a new model for the regulation of PMN apoptosis by a functional cross-talk between beta(2) integrins and TNF-alpha with a promoting role for the beta(2) integrins, This mechanism, which allows enhanced elimination of previously emigrated PMN, may be critical to abate local inflammatory processes in vivo.			Walzog, B (corresponding author), FREE UNIV BERLIN,DEPT PHYSIOL,ARNIMALLEE 22,D-14195 BERLIN,GERMANY.							ARNAOUT MA, 1990, BLOOD, V75, P1037; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAGGIOLINI M, 1993, FASEB J, V7, P1004, DOI 10.1096/fasebj.7.11.8396540; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Chitnis D, 1996, J LEUKOCYTE BIOL, V59, P835, DOI 10.1002/jlb.59.6.835; COX G, 1992, AM J RESP CELL MOL, V7, P507, DOI 10.1165/ajrcmb/7.5.507; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Dusi S, 1996, J IMMUNOL, V157, P4615; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HALL SE, 1994, J IMMUNOL, V153, P3218; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Liles WC, 1995, J LEUKOCYTE BIOL, V58, P690, DOI 10.1002/jlb.58.6.690; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; OHATA H, 1994, FEBS LETT, V355, P267; PAYNE CM, 1994, MICROSC RES TECHNIQ, V28, P327, DOI 10.1002/jemt.1070280408; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TSUCHIDA H, 1995, J IMMUNOL, V154, P2403; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Walzog B, 1996, J LEUKOCYTE BIOL, V59, P747, DOI 10.1002/jlb.59.5.747; WALZOG B, 1994, J LEUKOCYTE BIOL, V56, P625, DOI 10.1002/jlb.56.5.625; Watson RWG, 1997, J IMMUNOL, V158, P945; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1997, J IMMUNOL, V158, P1902; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	42	81	83	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1177	1186		10.1096/fasebj.11.13.9367353	http://dx.doi.org/10.1096/fasebj.11.13.9367353			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367353				2022-12-25	WOS:A1997YE98300016
J	Aritomi, M; Kunishima, N; Inohara, N; Ishibashi, Y; Ohta, S; Morikawa, K				Aritomi, M; Kunishima, N; Inohara, N; Ishibashi, Y; Ohta, S; Morikawa, K			Crystal structure of rat Bcl-x(L) - Implications for the function of the Bcl-2 protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; X PROTEIN; IN-VIVO; APOPTOSIS; DEAMIDATION; ASPARAGINYL; INHIBITION; GENE; BAX; SURVIVAL	Bcl-x(L) is a member of the Bcl-2 protein family, which regulates apoptosis. Preparation of recombinant rat Bcl-x(L) yielded two forms, one deamidated at -Asn-Gly-sequences to produce isoaspartates and the other not deamidated. The crystal structures of the two forms show that they both adopt an essentially identical backbone structure which resembles the fold of human Bcl-x(L): three layers of two alpha-helices each, capped at one end by two short helices. Both forms have a long disordered region, which contains the potential deamidation sites. The molecular structure exhibits a low level of interhelical interactions, the presence of three cavities, and a notable hydrophobic cleft surrounded by walls rich in basic residues. These unique structural features may be favorable for its accommodation into membranes or for possible rearrangement to modulate homo-/heterodimerization. Homology modeling of Bcl-2 and Bax, based on the Bcl-x(L), structure, suggests that Bax has the strongest potential for membrane insertion. Furthermore, we found a possible interface for interaction with non-Bcl-2 family member proteins, such as CED-4 homologues.	BIOMOL ENGN RES INST, SUITA, OSAKA 565, JAPAN; NIPPON MED COLL, INST GERONTOL, DEPT BIOCHEM & CELL BIOL, NAKAHARA KU, KAWASAKI, KANAGAWA 211, JAPAN	Nippon Medical School			Kunishima, Naoki/N-7464-2015	Aritomi, Masaharu/0000-0003-3002-8779; Kunishima, Naoki/0000-0001-9826-9902				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GEIGER T, 1987, J BIOL CHEM, V262, P785; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6171, DOI 10.1021/bi00075a009; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; LURA R, 1988, BIOCHEMISTRY-US, V27, P7671, DOI 10.1021/bi00420a015; MEINWALD YC, 1986, INT J PEPT PROT RES, V28, P79; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizuguchi M, 1996, BRAIN RES, V712, P281, DOI 10.1016/0006-8993(95)01453-5; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; MURSHUDOV GN, 1996, P CCP4 STUD WEEK SER, P85; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTWINOSKI Z, 1992, OSCILLATION DATA PRO; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V13, P21; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Sohma O, 1996, J NEUROSCI RES, V43, P175, DOI 10.1002/(SICI)1097-4547(19960115)43:2<175::AID-JNR5>3.0.CO;2-D; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TAKEMOTO L, 1991, CURR EYE RES, V10, P865, DOI 10.3109/02713689109013882; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	56	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27886	27892		10.1074/jbc.272.44.27886	http://dx.doi.org/10.1074/jbc.272.44.27886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346936	hybrid			2022-12-25	WOS:A1997YD47300062
J	Ford, JM; Hanawalt, PC				Ford, JM; Hanawalt, PC			Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LI-FRAUMENI SYNDROME; XERODERMA-PIGMENTOSUM REVERTANT; DECREASED DNA-REPAIR; C-TERMINAL DOMAIN; MUTANT P53; TRANSCRIBED STRAND; CELL-LINE; PYRIMIDINE DIMERS; ULTRAVIOLET-LIGHT; TUMOR-SUPPRESSOR	We have shown previously that Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in the removal of UV-induced cyclobutane pyrimidine dimers from genomic DNA, but still proficient in the transcription-coupled repair pathway (Ford, J. M., and Hanawalt, P. C. (1995) Proc, Natl, Acad. Sci, U. S. A. 92, 8876-8880), We have now utilized monoclonal antibodies specific for cyclobutane pyrimidine dimers or 6-4 photoproducts, respectively, to measure their repair in UV-irradiated human fibroblasts, Cells homozygous for p53 mutations were deficient in the repair of both photoproducts, whereas cells heterozygous for mutant p53 exhibited normal repair of 6-4 photoproducts, but decreased initial rates of removal of cyclobutane pyrimidine dimers, compared with normal cells, The specificity of the effect of wild-type p53 on nucleotide excision repair was demonstrated in a p53 homozygous mutant cell line containing a tetracycline-regulated wild-type p53 gene, Wild-type p53 expression and activity were suppressed in the presence of tetracycline, whereas withdrawal of tetracycline resulted in the induction of p53 expression, cell cycle checkpoint activation, and DNA damage-induced apoptosis, The regulated expression of wild-type p53 resulted in the recovery of normal levels of repair of both cyclobutane pyrimidine dimers and 6-4 photoproducts in genomic DNA, but did not alter the transcription-coupled repair of cyclobutane pyrimidine dimers, Therefore, the wild-type p53 gene product is an important determinant of nucleotide excision repair activity in human cells.			Ford, JM (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Ford, James/0000-0002-2513-7025	NATIONAL CANCER INSTITUTE [K08CA064330, R35CA044349] Funding Source: NIH RePORTER; NCI NIH HHS [K08-CA64330, CA44349] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; CLEAVER JE, 1994, SOMAT CELL MOLEC GEN, V20, P327, DOI 10.1007/BF02254721; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; FRITSCHE M, 1993, ONCOGENE, V8, P307; HANN BC, 1995, NAT GENET, V9, P221, DOI 10.1038/ng0395-221; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; Liu PK, 1996, ONCOGENE, V12, P2267; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; PAN ZQ, 1995, J BIOL CHEM, V270, P2208; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SMITH CA, 1981, DNA REPAIR LABORAT B, V1, P289; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TEITZ T, 1987, P NATL ACAD SCI USA, V84, P8801, DOI 10.1073/pnas.84.24.8801; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	42	315	321	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28073	28080		10.1074/jbc.272.44.28073	http://dx.doi.org/10.1074/jbc.272.44.28073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346961	hybrid			2022-12-25	WOS:A1997YD47300087
J	Jump, DB; Badin, MV; Thelen, A				Jump, DB; Badin, MV; Thelen, A			The CCAAT box binding factor, NF-Y, is required for thyroid hormone regulation of rat liver S14 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; RESPONSE ELEMENTS; PRIMARY HEPATOCYTES; SYNERGISTIC ACTION; SEQUENCE IDENTITY; RECEPTOR-BETA; YEAST HAP2; CLASS-II; PROMOTER; PROTEIN	Triiodothyronine (T-3) activates rat liver S14 gene transcription through T-3 receptors (TR beta) binding distal thyroid hormone response elements located between -2.8 and -2.5 kilobase pairs upstream from the transcription start site. Previous studies suggested that proximal promoter elements located between -220 to -80 base pairs upstream from the 5' end of the S14 gene were involve din hormone activation of the S14 gene. This report identifies an inverted CCAAT box (or Y box) at (-104)ATTGG(-100) as a core cis-regulatory element. Gel shift studies using rat liver nuclear proteins show that at least three CCAAT-binding factors interact with this region as follows: NF-Y and c/EBP-related proteins formed major complexes, whereas NF-1/CTF forms a minor complex in gel shift assay. Mutation of the Y box indicated that loss of NF-Y binding, but not c/EBP or NF-1, correlated closely with a decline in basal activity and a loss of T-3-mediated transactivation. Substitution of the S14 Y box in reporter genes with elements binding only NF-Y elevated basal activity and T-3-mediated transactivation, whereas substitution with elements binding c/EBP-related proteins or SP1 displayed low basal activity and T-3-mediated transactivation. These studies indicate that NF-Y and TR beta functionally interact to confer T-3 control to the S14 gene.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	Jump, DB (corresponding author), MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824, USA.				NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BRENT GA, 1989, J BIOL CHEM, V264, P178; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DESVERGNE B, 1991, J BIOL CHEM, V266, P1088; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUMP DB, 1990, J BIOL CHEM, V265, P3474; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1985, ENDOCRINOLOGY, V117, P2259, DOI 10.1210/endo-117-6-2259; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1986, ENDOCRINOLOGY, V118, P1892, DOI 10.1210/endo-118-5-1892; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KAMIE Y, 1996, CELL, V85, P403; LEPAR GJ, 1989, MOL ENDOCRINOL, V3, P1207, DOI 10.1210/mend-3-8-1207; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V182, P631, DOI 10.1016/0006-291X(92)91779-P; MACDOUGALD OA, 1992, BIOCHEM BIOPH RES CO, V188, P470, DOI 10.1016/0006-291X(92)92408-P; MACDOUGALD OA, 1990, BIOCHEM J, V280, P761; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; ONATE SA, 1995, SCIENCE, V270, P1354; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; PARK EA, 1995, BIOCHEM J, V309, P913, DOI 10.1042/bj3090913; Park EA, 1997, BIOCHEM J, V322, P343, DOI 10.1042/bj3220343; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SUDO Y, 1994, ENDOCRINOLOGY, V134, P2532, DOI 10.1210/en.134.6.2532; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	59	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27778	27786		10.1074/jbc.272.44.27778	http://dx.doi.org/10.1074/jbc.272.44.27778			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346922	hybrid			2022-12-25	WOS:A1997YD47300048
J	Kovoor, A; Nappey, V; Kieffer, BL; Chavkin, C				Kovoor, A; Nappey, V; Kieffer, BL; Chavkin, C			mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+-CHANNEL; AGONIST-INDUCED DESENSITIZATION; GAMMA-SUBUNITS; RAT-BRAIN; EXPRESSION CLONING; POTASSIUM CHANNEL; PROTEIN-KINASE; I-KACH; MORPHINE; BINDING	The Xenopus oocyte expression system was used to test the hypothesis that homologous opioid receptor desensitization results from receptor phosphorylation by G protein-coupled receptor kinases. Activation of delta (DOR), mu (MOR) opioid, or beta(2)-adrenergic receptors increased K+ conductance in oocytes coexpressing the G protein-gated inwardly rectifying K+ channel subunits GIRK1 and GIRK4, and the intrinsic rate of desensitization was small. Coexpression of beta-adrenergic receptor kinase 2 (beta-ARK2) and beta-arrestin 2 (beta-arr2) synergistically produced a rapid desensitization of both DOR and beta 2-adrenergic receptor signaling with a t(1/2) < 4 min. beta-ARK2 and beta-arr2 more slowly desensitized MOR responses; a similar synergistic effect on MOR required 2-3 h of agonist treatment. DOR mutants lacking serine and threonine residues at the end of the cytoplasmic tail coupled effectively to GIRK channels but were insensitive to beta-ARK2 and beta-arr2. However, a DOR mutant having serine residues mutated to alanine in the third cytoplasmic loop was indistinguishable in coupling and desensitization from the wild type DOR. These studies establish that opioid receptors can be regulated by beta-ARK2 and beta-arr2 and that a portion of the COOH terminus of DOR enhances sensitivity to this modulation.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV STRASBOURG 1, ECOLE SUPER BIOTECHNOL, F-67085 STRASBOURG, FRANCE	University of Washington; University of Washington Seattle; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672, DA04123] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004123, R37DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Befort K, 1996, MOL PHARMACOL, V49, P216; BLANCHARD G, 1988, OPIATE RECEPTORS, P426; BRADY LS, 1989, BRAIN RES, V477, P382, DOI 10.1016/0006-8993(89)91432-7; BRODSKY M, 1995, BRAIN RES BULL, V38, P135, DOI 10.1016/0361-9230(95)00079-T; CHILDERS SR, 1977, EUR J PHARMACOL, V46, P289, DOI 10.1016/0014-2999(77)90346-6; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; GRUDT TJ, 1995, REV NEUROSCIENCE, V6, P279; HAGA K, 1994, J BIOL CHEM, V269, P12594; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HOLLT V, 1975, LIFE SCI, V16, P1823, DOI 10.1016/0024-3205(75)90284-2; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; ISHII K, 1994, J BIOL CHEM, V269, P1125; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; NOMURA K, 1994, J PHARMACOL EXP THER, V270, P466; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; Sim LJ, 1996, J NEUROSCI, V16, P2684; STERNE MR, 1995, VITAM HORM, V51, P193; TAO PL, 1993, EUR J PHARM-MOLEC PH, V246, P233, DOI 10.1016/0922-4106(93)90036-9; TAO PL, 1987, J PHARMACOL EXP THER, V240, P809; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRUJILLO KA, 1991, NEW BIOL, V3, P915; Wang ZJ, 1996, FEBS LETT, V387, P53, DOI 10.1016/0014-5793(96)00467-X; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	47	115	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27605	27611		10.1074/jbc.272.44.27605	http://dx.doi.org/10.1074/jbc.272.44.27605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346897	hybrid			2022-12-25	WOS:A1997YD47300023
J	Mangiarotti, G; Chiaberge, S; Bulfone, S				Mangiarotti, G; Chiaberge, S; Bulfone, S			rRNA maturation as a ''quality'' control step in ribosomal subunit assembly in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; PRECURSOR; YEAST; CELLS	In Dictyostelium discoideum, newly assembled ribosomal subunits enter polyribosomes while they still contain immature rRNA. rRNA maturation requires the engagement of the subunits in protein synthesis and leads to stabilization of their structure. Maturation of pre-17 S rRNA occurs only after the newly formed 40 S ribosomal particle has entered an 80 S ribosome and participated at least in the formation of one peptide bond or in one translocation event; maturation of pre-26 S rRNA requires the presence on the 80 S particle of a peptidyl-tRNA containing at least 6 amino acids. Newly assembled particles that cannot fulfill these requirements for structural reasons are disassembled into free immature rRNA and ribosomal proteins.			Mangiarotti, G (corresponding author), OSPED S LUIGI,DEPT CLIN & BIOL SCI,ORBASSANO,TORINO,ITALY.							ADESNIK M, 1969, J MOL BIOL, V46, P281, DOI 10.1016/0022-2836(69)90422-7; APIRION D, 1993, BIOESSAYS, V15, P113, DOI 10.1002/bies.950150207; BLEYMAN M, 1969, J BACTERIOL, V97, P27, DOI 10.1128/JB.97.1.27-31.1969; CECCARELLI A, 1978, FEBS LETT, V93, P348, DOI 10.1016/0014-5793(78)81137-5; DAHLBERG AE, 1971, J MOL BIOL, V55, P61, DOI 10.1016/0022-2836(71)90281-6; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3286; EICHLER BC, 1984, PROG NUCL ACIDS RES, V49, P197; FIRTEL RA, 1974, GENETICS, V78, P355; GREINGER RM, 1980, CELL, V20, P619; HAYES D, 1973, CR ACAD SCI III-VIE, V227, P881; HAYES F, 1971, BIOCHIMIE, V53, P369, DOI 10.1016/S0300-9084(71)80104-9; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HUGES JM, 1991, EMBO J, V10, P4231; KAEMPFER R, 1970, NATURE, V228, P534, DOI 10.1038/228534a0; KOSSMAN CR, 1971, NATURE-NEW BIOL, V234, P102, DOI 10.1038/newbio234102a0; LIAU MC, 1968, BIOCHIM BIOPHYS ACTA, V169, P196, DOI 10.1016/0005-2787(68)90020-8; LINDAHL L, 1973, NATURE-NEW BIOL, V243, P170, DOI 10.1038/newbio243170a0; Maden B.E.H., 1971, PROGR BIOPHYS MOL BI, V22, P127; MADEN BEH, 1972, NATURE-NEW BIOL, V237, P5, DOI 10.1038/newbio237005a0; MANGIAROTTI G, 1975, NATURE, V253, P569, DOI 10.1038/253569a0; MANGIAROTTI G, 1982, DEV BIOL, V89, P82, DOI 10.1016/0012-1606(82)90296-2; MANGIAROTTI G, 1985, P NATL ACAD SCI USA, V82, P5786, DOI 10.1073/pnas.82.17.5786; MANGIAROTTI G, 1967, J MOL BIOL, V29, P395, DOI 10.1016/0022-2836(67)90107-6; MANGIAROTTI G, 1974, NATURE, V247, P147, DOI 10.1038/247147a0; MANGIAROTTI G, 1979, EXP CELL RES, V119, P428, DOI 10.1016/0014-4827(79)90378-1; MANGIAROTTI G, 1980, MOL CELL BIOL, V1, P35; MANGIAROTTI G, 1984, NATURE, V301, P616; MANGIAROTTI G, 1977, J BIOL CHEM, V272, P19682; NIKOLAEV N, 1973, J BIOL CHEM, V248, P7967; NIKOLAEV N, 1973, P NATL ACAD SCI USA, V70, P3361, DOI 10.1073/pnas.70.12.3361; NOMURA M, 1970, NATURE, V228, P744, DOI 10.1038/228744a0; OZAKI T, 1984, NUCLEIC ACIDS RES, V12, P4171, DOI 10.1093/nar/12.10.4171; RAMAGOPAL S, 1980, EUR J BIOCHEM, V105, P245, DOI 10.1111/j.1432-1033.1980.tb04495.x; SCHLESSINGER D, 1967, P NATL ACAD SCI USA, V58, P1782, DOI 10.1073/pnas.58.4.1782; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; TURCO E, 1974, BIOCHEMISTRY-US, V13, P4752, DOI 10.1021/bi00720a011; UDEM SA, 1973, J BIOL CHEM, V248, P1412; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; VELDMAN GM, 1980, NUCLEIC ACIDS RES, V8, P2907, DOI 10.1093/nar/8.13.2907; WEINBERG RA, 1970, J MOL BIOL, V47, P169, DOI 10.1016/0022-2836(70)90337-2	40	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27818	27822		10.1074/jbc.272.44.27818	http://dx.doi.org/10.1074/jbc.272.44.27818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346927	hybrid			2022-12-25	WOS:A1997YD47300053
J	McCormack, FX; Pattanajitvilai, S; Stewart, J; Possmayer, F; Inchley, K; Voelker, DR				McCormack, FX; Pattanajitvilai, S; Stewart, J; Possmayer, F; Inchley, K; Voelker, DR			The Cys(6) intermolecular disulfide bond and the collagen-like region of rat SP-A play critical roles in interactions with alveolar type II cells and surfactant lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; PULMONARY SURFACTANT; PHOSPHOLIPID SECRETION; HIGH-AFFINITY; LUNG; APOPROTEIN; RECEPTOR; DOMAINS; GENE; PHOSPHATIDYLCHOLINE	Rat pulmonary surfactant protein A is an oligomer of 18 polypeptide chains which are associated by triple helix formation in the collagen-like domain and interchain disulfide bridges at the NH2 terminus. The roles of the intermolecular bond at Cys(6) and the collagen-like domain (Gly(8)-Pro(80)) in the interactions of SP-A with phospholipids and alveolar type II cells were investigated using mutant forms of the protein. Wild type SP-A (SP-A(hyp)), SP-A with the substitution Cys(6) --> Ser to prevent disulfide formation (SP-A(hyp,C6S)), and SP-A with the collagen-domain deleted (SP-A(Delta G8-P80)) were synthesized sized in insect cells using recombinant baculoviruses. The SP-As were glycosylated and secreted from the invertebrate cells and the binding affinities of the wild type and mutant proteins for the mannose-Sepharose matrix used for purification were nearly identical. The SP-A(hyp) and SP-A(Delta G8-P80) were at least nonameric in solution based on gel exclusion chromatography, and demonstrated extensive sulfhydryl-dependent oligomerization under nonreducing conditions. The SP-A(hyp,C6S) was also oligomeric in solution and formed disulfide-dependent dimers, indicating the presence of at least one additional interchain disulfide bond. The SP-A(Delta G8-P80) but not the SP-A(hyp,C6S) aggregated lipid vesicles at 20 degrees C and augmented the surface tension lowering effect of extracts of natural surfactant. The SP-A(Delta G8-P80) competed poorly with native SP-A for receptor occupancy on isolated alveolar type II cells and was a potent but nonspecific (concanavalin A-like) inhibitor of surfactant secretion. In contrast, the SP-A(hyp,C6S) partially competed for receptor occupancy and weakly inhibited surfactant secretion in a specific manner, Neither the SP-A(Delta G8-P80) nor the SP-A(hyp,C6S) supported the association of phospholipid liposomes with type II cells. We conclude that: 1) the Cys(6) interchain disulfide bond of SP-A is required for aggregation of liposomes and for potent inhibition of surfactant secretion, 2) The collagen-like region is required for competition with I-125-SP-A for receptor occupancy and specific inhibition of surfactant secretion in the presence of competing sugars. 3) Both the NH2-terminal disulfide and the collagen-like region are required to enhance the association of phospholipid vesicles with type II cells.	NATL JEWISH MED & RES CTR,LORD & TAYLOR LAB LUNG BIOCHEM,ANNA PERAHIA ADATTO CLIN LABS,DENVER,CO 80206; NATL JEWISH MED & RES CTR,DEPT MED,DENVER,CO 80206; UNIV WESTERN ONTARIO,DEPT OBSTET & GYNECOL,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,DEPT BIOCHEM,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,MRC,GRP FETAL & NEONATAL HLTH & DEV,LONDON,ON N6A 5A5,CANADA; UNIV CINCINNATI,DEPT MED,DIV PULM & CRIT CARE MED,CINCINNATI,OH 45267	National Jewish Health; National Jewish Health; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Cincinnati			McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL-29891, HL-45286] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045286, R37HL029891, R01HL029891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1978, AM REV RESPIR DIS, V118, P705, DOI 10.1164/arrd.1978.118.4.705; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; ENHORNING G, 1977, J APPL PHYSIOL, V43, P198, DOI 10.1152/jappl.1977.43.2.198; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GAYNOR C, 1994, J IMMUNOL, V155, P5343; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL442; HANIU M, 1994, ARCH BIOCHEM BIOPHYS, V310, P433, DOI 10.1006/abbi.1994.1189; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KING RJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P294, DOI 10.1016/0005-2760(89)90114-8; KING RJ, 1972, AM J PHYSIOL, V223, P707, DOI 10.1152/ajplegacy.1972.223.3.707; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KUROKI Y, 1991, BIOCHEM INT, V24, P225; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMACK FX, 1990, BIOCHIM BIOPHYS ACTA, V1087, P190, DOI 10.1016/0167-4781(90)90204-F; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V969, P176, DOI 10.1016/0167-4889(88)90073-0; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; ROSS GF, 1991, BIOCHEMISTRY-US, V30, P858, DOI 10.1021/bi00217a040; ROSS GF, 1986, J BIOL CHEM, V261, P14283; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1987, BIOCHEM BIOPH RES CO, V144, P367, DOI 10.1016/S0006-291X(87)80519-3; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VOELKER DR, 1989, LUNG CELL BIOL, P487; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; YUKITAKE K, 1995, PEDIATR RES, V37, P21, DOI 10.1203/00006450-199501000-00005	52	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27971	27979		10.1074/jbc.272.44.27971	http://dx.doi.org/10.1074/jbc.272.44.27971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346948	hybrid			2022-12-25	WOS:A1997YD47300074
J	Rossetti, L; Massillon, D; Barzilai, N; Vuguin, P; Chen, W; Hawkins, M; Wu, J; Wang, JL				Rossetti, L; Massillon, D; Barzilai, N; Vuguin, P; Chen, W; Hawkins, M; Wu, J; Wang, JL			Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; OBESE GENE; CONSCIOUS RATS; BODY-WEIGHT; FOOD-INTAKE; OB/OB MICE; OB PROTEIN; GLUCOSE; EXPRESSION; MOUSE	Long term administration of leptin decreases caloric intake and fat mass and improves glucose tolerance. Here we examine whether leptin acutely regulates peripheral and hepatic insulin action. Recombinant mouse leptin (0.3 mg/kg.h, Leptin +) or vehicle (Leptin -) were administered for 6 h to 4-month-old rats (n = 20), and insulin (3 milliunits/kg.min) clamp studies were performed. During physiologic hyperinsulinemia (plasma insulin similar to 65 microunits/ml), the rates of whole body glucose uptake, glycolysis, and glycogen synthesis and the rates of 2-deoxyglucose uptake in individual tissues were similar in Leptin - and Leptin +. Post-absorptive hepatic glucose production (HGP) was similar in the two groups. However, leptin enhanced insulin's inhibition of HGP (4.1 +/- 0.7 and 6.2 +/- 0.7 mg/kg.min; p < 0.05). The decreased HGP in the Leptin + group was due to a marked suppression of hepatic glycogenolysis (0.7 +/- 0.1 versus 4.1 +/- 0.6 mg/kg.min, in Leptin + versus Leptin -, respectively; p < 0.001), whereas the % contribution of gluconeogenesis to HGP was markedly increased (82 +/- 3% versus 36 +/- 4% in Leptin + and Leptin -, respectively; p < 0.001). At the end of the 6-h leptin infusion, the hepatic abundance of glucokinase mRNA was decreased, whereas that of phosphoenolpyruvate carboxykinase mRNA was increased compared with Leptin -. We conclude that an acute increase in plasma leptin 1) enhances insulin's ability to inhibit HGP, 2) does not affect peripheral insulin action, and 3) induces a redistribution of intrahepatic glucose fluxes and changes in the gene expression of hepatic enzymes that closely resemble those of fasting.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,1300 MORRIS PK AVE,BRONX,NY 10461, USA.			vuguin, patricia/0000-0002-4982-0400	NIDDK NIH HHS [DK 45024, DK 48321] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045024, R37DK048321, R01DK045024, R01DK048321] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; BARZILAI N, 1995, BIOCHEM J, V310, P819, DOI 10.1042/bj3100819; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Considine RV, 1996, DIABETES, V45, P992, DOI 10.2337/diabetes.45.7.992; CONSIDINE RV, 1996, NEW ENGL J MED, V334, P324; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FRONTONI S, 1992, HYPERTENSION, V20, P192, DOI 10.1161/01.HYP.20.2.192; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jacob RJ, 1997, DIABETES, V46, P150, DOI 10.2337/diabetes.46.1.150; Kieffer TJ, 1996, BIOCHEM BIOPH RES CO, V224, P522, DOI 10.1006/bbrc.1996.1059; KISSEBAH AH, 1991, INT J OBESITY, V15, P109; Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RENTSCH J, 1995, BIOCHEM BIOPH RES CO, V214, P131, DOI 10.1006/bbrc.1995.2266; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Sidossis LS, 1996, J CLIN INVEST, V98, P2244, DOI 10.1172/JCI119034; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	38	255	260	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27758	27763		10.1074/jbc.272.44.27758	http://dx.doi.org/10.1074/jbc.272.44.27758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346919	hybrid			2022-12-25	WOS:A1997YD47300045
J	Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL				Sivak, LE; Tai, KF; Smith, RS; Dillon, PA; Brodeur, GM; Carroll, WL			Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines	ONCOGENE			English	Article						N-myc promoter; neuroblastoma; autoregulation	HUMAN C-MYC; GENE AMPLIFICATION; MAMMALIAN-CELLS; NEURO-BLASTOMA; NEGATIVE AUTOREGULATION; DIFFERENTIAL EXPRESSION; REGULATORY ELEMENTS; BURKITT-LYMPHOMA; TRANSGENIC MICE; CYCLIN D1	Amplification of the N-myc gene is a significant adverse prognostic factor in neuroblastoma, a common childhood tumor, In non-transformed cells, myc expression is controlled through an autoregulatory circuit, through which elevated Myc protein levels lead to down-regulation of myc transcription, The precise mechanism of myc gene autoregulation is unknown, Loss of c-myc autoregulation has been documented in transformed cells from a number of different lineages, but N-myc autoregulation has not yet been investigated, In neuroblastoma, the increased N-Myc protein produced by amplified tumors mould be expected to silence N-myc transcription if the autoregulatory loop were intact, To determine whether N-myc autoregulation is operative in human neuroblastoma, and to localize cis-acting elements which mediate N-myc autosuppression, we transfected a series of N-myc 5' promoter constructs into a panel of human neuroblastoma cell lines carrying one or multiple copies of N-myc, The transfected promoter was equally amplified lines, Significant promoter activity in the presence of abundant Myc protein in amplified neuroblastoma Lines indicates that autoregulation is disabled in this subset of tumors, To investigate,whether single-copy lines produce insufficient N-Myc protein to trigger autosuppression yet retain an intact autoregulatory circuit, we transfected neuroblastoma lines with 5' promoter constructs in the presence of a c- or N-myc expression vector, Overexpression of c- or N-Myc resulted in diminution of activity of both the transfected promoter and the endogenous N-myc gene in single-copy, but not amplified lines, Using a series of 5' promoter-deletion minigenes, we localized a cis-acting element required for autoregulation close to the transcription start sites, While the precise mechanism of autosuppression remains unknown, we demonstrated that Myc is incapable of silencing the adenovirus major late promoter (AdMLP) in neuroblastoma cells, indicating that Myc suppression of its own promoter and the AdMLP involve distinct components, These studies provide the first systematic investigation of autoregulation in neuroblastoma, and indicate that single-copy neuroblastoma lines produce insufficient N-Myc protein to activate downstream effector(s) of autosuppression; the autoregulatory circuit is otherwise intact, Amplified lines, in contrast, have lost autoregulation.	UNIV UTAH, SCH MED, ECCLES INST HUMAN GENET, HUNTSMAN CANC INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT 84112 USA; JOHNS HOPKINS UNIV, DIV PEDIAT SURG, BALTIMORE, MD USA; CHILDRENS HOSP PHILADELPHIA, DIV PEDIAT HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NCI NIH HHS [5T32CA09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1986, NATURE, V321, P702; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERTLING W, 1987, J BIOCHEM BIOPH METH, V14, P223, DOI 10.1016/0165-022X(87)90011-X; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUCKLE RS, 1996, ONCOGENE, V10; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CROUCH DH, 1990, ONCOGENE, V5, P683; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Goldman SC, 1996, AM J PATHOL, V148, P1381; GRADY EF, 1987, CANCER RES, V47, P2931; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HILLER S, 1991, ONCOGENE, V6, P969; JAKOBVITS A, 1985, NATURE, V318, P1188; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MA A, 1991, MOL CELL BIOL, V11, P440, DOI 10.1128/MCB.11.1.440; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NEPVEU A, 1987, ONCOGENE, V1, P243; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SLAVC I, 1990, CANCER RES, V50, P1459; SOLOMON DLC, 1995, ONCOGENE, V11, P1893; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TLSTY TD, 1992, SCIENCE, V255, P1425, DOI 10.1126/science.1542791; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; VOGAN K, 1993, CANCER RES, V53, P5269; WADA RK, 1992, ONCOGENE, V7, P711; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG YS, 1992, ONCOGENE, V7, P1241; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	65	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1937	1946		10.1038/sj.onc.1201363	http://dx.doi.org/10.1038/sj.onc.1201363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365240				2022-12-25	WOS:A1997YA87200008
J	Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K				Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K			Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells	ONCOGENE			English	Article						hepatitis B virus; X gene transfection; X protein; p53 tumor suppressor gene; p53 protein; nuclear localization	HUMAN HEPATOCELLULAR-CARCINOMA; LONG TERMINAL REPEAT; WILD-TYPE; DNA-BINDING; TRANSACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVITY; CELLULAR PROTEINS; EXPRESSION SYSTEM; TRANS-ACTIVATION; VIRAL ENHANCERS	It has been suggested that hepatitis B virus (HBV) X gene activates X gene expression by disrupting the function of p53 tumor suppressor gene (Takada et al., 1996). To find out their connection, effect of X protein expression on the nuclear localization of p53 protein in human hepatoma cells was examined by the immunofluorescent double-staining technique. The location of transiently-expressed p53 protein was examined in X gene-transfected cells, where X protein was detected in the cytoplasm. The nuclear location of transiently-expressed p53 protein was changed to the cytoplasm by X protein co-expression. Endogenous p53 protein was also observed in the cytoplasm by X protein expression. The transcriptional activation domain of X protein and the carboxy-terminal region of p53 protein were found mutually responsible for the cytoplasmic retention of p53 in X gene-transfected cells. Therefore, the cytoplasmic retention of p53 protein may be closely correlated to the function of X protein expressed in transfected cells.	JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT MOL & CELLULAR ONCOL,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)								ARII M, 1992, ONCOGENE, V7, P397; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAKTOR O, 1990, ONCOGENE, V5, P867; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBAYASHI M, 1984, GENE, V30, P227; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAKAI E, 1992, ONCOGENE, V7, P927; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; TAKADA S, 1994, VIRAL HEPATITIS LIVE, P753; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1895	1901		10.1038/sj.onc.1201369	http://dx.doi.org/10.1038/sj.onc.1201369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365235				2022-12-25	WOS:A1997YA87200003
J	Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS				Kroll, M; Conconi, M; Desterro, MJP; Marin, A; Thomas, D; Friguet, B; Hay, RT; Virelizier, JL; ArenzanaSeisdedos, F; Rodriguez, MS			The carboxy-terminus of I kappa B alpha determines susceptibility to degradation by the catalytic core of the proteasome	ONCOGENE			English	Article						I kappa B alpha; carboxy-terminus; NF-kappa B; 20S proteasome	CASEIN KINASE-II; SIGNAL-INDUCED DEGRADATION; CONSTITUTIVE PHOSPHORYLATION; INDUCIBLE DEGRADATION; TRANSCRIPTION FACTORS; PROTEIN-DEGRADATION; INDUCED APOPTOSIS; PRECURSOR P105; DNA-BINDING; ACTIVATION	The Rel/NF-kappa B family of transcription factors controls the expression of a wide variety of genes that are implicated in immune and inflammatory responses and cellular proliferation. Disregulation of NF-kappa B is associated with cellular transformation and the maintenance of a high anti-apoptotic threshold in transformed cells. NF-kappa B activity is in turn regulated by its sequestration in the cytoplasm by the inhibitor I kappa B. I kappa B alpha, the most abundant and well-characterized member of the I kappa B multiprotein family, is rapidly degraded in response to multiple physiologic stimuli. In the present study we show that not only the amino-terminus, but also the carboxy-terminus of I kappa B alpha contain transferable signals that must be simultaneously present in an unrelated protein to render it susceptible to activation-induced, proteasome-mediated degradation. We show here that I kappa B alpha amino-terminal modifications occur independently of the carboxy-terminus. Moreover, we present evidence indicating a critical role far the carboxy-terminal region in facilitating proteolysis by the catalytic core of the proteasome. When incubated with 20S proteasome extracted from rat liver, I kappa B alpha was quickly degraded while a deletion mutant lacking the carboxy-terminus was resistant to proteolysis. Likewise, chimeric proteins of beta-galactosidase with the I kappa B alpha carboxy-terminus were degraded in vitro independently of the presence of the I kappa B alpha amino-terminus, whereas chimeric proteins lacking the I kappa B alpha carboxy-terminus were stable. Our results identify the carboxy-terminus of I kappa B alpha as a domain critical for degradation through interaction with an as yet unidentified component of the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald/S-3233-2019; Arenzana-Seisdedos, Fernando/E-5835-2016; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233; Friguet, Bertrand/0000-0001-8085-1961				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Aoki T, 1996, ONCOGENE, V12, P1159; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lin RT, 1996, MOL CELL BIOL, V16, P1401; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROGERS SW, 1986, BIOMED BIOCHIM ACTA, V45, P1611; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	66	32	33	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1841	1850		10.1038/sj.onc.1201560	http://dx.doi.org/10.1038/sj.onc.1201560			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362451				2022-12-25	WOS:A1997XZ72500011
J	Chen, G; Shu, JY; Stacey, DW				Chen, G; Shu, JY; Stacey, DW			Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide	ONCOGENE			English	Article						oncogene; apoptosis; SAPK; cell cycle; etoposide	SIGNAL-TRANSDUCTION PATHWAYS; CYCLIN-DEPENDENT KINASES; PROGRAMMED CELL-DEATH; PROTEIN-KINASES; C-MYC; INTERCALATING AGENTS; ANTICANCER AGENTS; GAMMA-RADIATION; JNK ACTIVATION; CANCER-THERAPY	The exact mechanisms for the selective toxicity of chemotherapeutic drugs against tumor cells are not fully understood, We designed a series of experiments to test the possibility that the positive proliferative signal initiated by oncogenes might change the sensitivity for apoptosis induction by the anticancer drug etoposide (VP16), an inhibitor of topoisomerase IT (Topo II), Treatment with VP16 induced significantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells, Apopototic changes involved nuclear DNA fragmentation, morphological alterations and decreased viability, Furthermore it was shown that stress-activated protein kinase (SAPK) was activated much more strongly in all three transformed lines compared to untransformed cells by VP16 treatment, while slight activation of extracellular signal-regulated kinase (ERK1) was observed in all four cell lines, In addition, the transformed cells displayed arrest in mid-S-phase following the treatment, whereas NIH3T3 cells were primarily arrested in late S and G(2)/M phase. Finally, the cyclin-dependent kinase inhibitor p21 WAF1 was induced in all four cell lines, although induction of p53 was not detected in any of these cell lines. Taken together our results demonstrated that oncogenic transformation can sensitize the cells to apoptosis induction, stress kinase activation and cell cycle arrest in response to VP16 treatment, These results may have important implications for understanding the selective toxicity of anti-cancer drugs in tumor cells.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM52271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELANI CP, 1994, CANCER CHEMOTH PHARM, V34, pS118, DOI 10.1007/BF00684875; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chresta CM, 1996, CANCER RES, V56, P1834; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7274; GLISSON B, 1986, CANCER RES, V46, P1939; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOCK RB, 1994, CANCER RES, V54, P4933; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shu JY, 1996, ONCOGENE, V13, P2421; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	56	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1643	1651		10.1038/sj.onc.1201347	http://dx.doi.org/10.1038/sj.onc.1201347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349497				2022-12-25	WOS:A1997XY63100003
J	Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW				Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW			Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas	ONCOGENE			English	Article						Barrett's esophagus; fragile sites; FRA3B; gene deletion; human chromosome 3	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCUS; COMMON FRAGILE SITES; LUNG-CANCER; SHORT ARM; 3P14.2; GENE; DNA; BREAKAGE; LINES	The FHIT gene, which spans the common fragile site FRA3B, has been shown to produce aberrant transcripts in a variety of tumor types, Homozygous deletions within the FHIT locus have been detected only in tumor-derived cell lines and LOH has been described in numerous primary tumors, Based on these findings and its location on 3p, FHIT has been proposed as a tumor suppressor gene, To further study the relationship of FRA3B to the findings regarding the FHIT gene and to determine the extent of FHIT mRNA alterations in early stages of tumor development, the status of the FHIT gene was evaluated in the premalignant condition of Barrett's esophagus and associated esophageal adenocarcinomas, FHIT expression was investigated by RT-PCR in normal esophageal, Barrett's metaplasia and adenocarcinoma tissues from 15 patients, Alterations of FHIT transcripts were observed in 12/14 (86%) of Barrett's metaplasia and in 14/15 (93%) of the adenocarcinomas from the same patients, Characterization of the altered transcripts revealed FHIT mRNA lacking one or more exons, with deletion of exons 5-7 being most frequent, Analysis of genomic DNA from 20 patients showed homozygous deletions involving exon 5 of FHIT in 4/20 (20%) esophageal adenocarcinomas, and 7/20 (35%) tumors demonstrated hemizygous loss, Genomic deletions also involved the BE758-6 locus, indicating that a large region is deleted. Fluorescence ill situ hybridization (FISH) analysis demonstrated that this region of deletion is localized within FRA3B, Our results extend the range of tumor types in which altered FHIT transcripts have been demonstrated and show that these alterations can be seen in the premalignant stage of esophageal tumor development, These results indicate that the fragility and recombination-prone nature of FRA3B is related to tumor-specific chromosomal instability affecting the FHIT gene in esophageal adenocarcinoma development.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SURG,THORAC SURG SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 71606, CA 43222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIERICK HA, 1995, GENOMICS, V28, P462, DOI 10.1006/geno.1995.1175; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Druck T, 1997, CANCER RES, V57, P504; Gantz I, 1996, CYTOGENET CELL GENET, V74, P286, DOI 10.1159/000134436; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; JONES MH, 1992, ONCOGENE, V7, P1631; Kastury K, 1996, CANCER RES, V56, P978; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; Shridhar R, 1996, CANCER RES, V56, P4347; SOZZI G, 1996, CELL, V85, P7; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	42	105	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1653	1659						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349498				2022-12-25	WOS:A1997XY63100004
J	Chaturvedi, MM; Kumar, A; Darnay, BG; Chainy, GBN; Agarwal, S; Aggarwal, BB				Chaturvedi, MM; Kumar, A; Darnay, BG; Chainy, GBN; Agarwal, S; Aggarwal, BB			Sanguinarine (pseudochelerythrine) is a potent inhibitor of NP-kappa B activation, I kappa B alpha phosphorylation, and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BENZOPHENANTHRIDINE ALKALOIDS; ADENOSINE-TRIPHOSPHATASE; BASE COMPOSITION; PROTEINS; BINDING; DNA; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; CHELERYTHRINE	The nuclear factor NF-kappa B is a pleiotropic transcription factor whose activation results in inflammation, viral replication, and growth modulation. Due to its role in pathogenesis, NF-kappa KB is considered a key target for drug development. In the present report we show that sanguinarine (a benzophenanthridine alkaloid), a known anti-inflammatory agent, is a potent inhibitor of NF-kappa B activation. Treatment of human myeloid ML-1a cells with tumor necrosis factor rapidly activated NF-kappa B this activation was completely suppressed by sanguinarine in a dose- and time-dependent manner. Sanguinarine did not inhibit the binding of NF-kappa B protein to the DNA but rather inhibited the pathway leading to NF-kappa B activation. The reversal of inhibitory effects of sanguinarine by reducing agents suggests a critical sulfhydryl group is involved in NF-kappa B activation. Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and degradation of I kappa B alpha, an inhibitory subunit of NF-kappa B, and inhibited translocation of p65 subunit to the nucleus. As sanguinarine also inhibited NF-kappa B activation induced by interleukin-1, phorbol ester, and okadaic acid but not that activated by hydrogen peroxide or ceramide, the pathway leading to NF-kappa B activation is likely different for different inducers, Overall, our results demonstrate that sanguinarine is a potent suppressor of NF-kappa B activation and it acts at a step prior to I kappa B alpha phosphorylation.	UNIV TEXAS,MD ANDERSON CANC CTR,CYTOKINE RES SECT,DEPT MOL ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,SCH DENT MED,DEPT MICROBIOL BIOCHEM,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Aggarwal, Bharat B/G-3388-2013; Chainy, Gagan B.N./G-7020-2012	Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848; Chainy, Gagan/0000-0002-6418-0480				AGARWAL S, 1991, ORAL MICROBIOL IMMUN, V6, P51, DOI 10.1111/j.1399-302X.1991.tb00451.x; AKERA T, 1977, SCIENCE, V198, P569, DOI 10.1126/science.144320; ARNASON JT, 1992, PHOTOCHEM PHOTOBIOL, V55, P35, DOI 10.1111/j.1751-1097.1992.tb04206.x; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; FADEEVA MD, 1988, TSITOLOGIYA, V30, P685; FADEEVA MD, 1987, TSITOLOGIYA+, V29, P576; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FIRATLI E, 1994, J CLIN PERIODONTOL, V21, P680, DOI 10.1111/j.1600-051X.1994.tb00786.x; GODOWSKI K C, 1989, Journal of Clinical Dentistry, V1, P96; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kumar Arvind, 1992, Biomedical and Environmental Sciences, V5, P251; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; Lombardini JB, 1996, BIOCHEM PHARMACOL, V51, P151, DOI 10.1016/0006-2952(95)02166-3; LUHOVA L, 1995, J ENZYM INHIB, V9, P295, DOI 10.3109/14756369509036558; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; MAITI M, 1987, J BIOMOL STRUCT DYN, V5, P159, DOI 10.1080/07391102.1987.10506383; MITSCHER LA, 1978, LLOYDIA, V41, P145; NANDI R, 1985, BIOCHEM PHARMACOL, V34, P321, DOI 10.1016/0006-2952(85)90038-3; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; PARSONS LG, 1987, J CLIN PERIODONTOL, V14, P381, DOI 10.1111/j.1600-051X.1987.tb01540.x; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; SARAN A, 1995, INDIAN J BIOCHEM BIO, V32, P74; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; SHAMMA M, 1986, NAT PROD REP, V3, P345, DOI 10.1039/np9860300345; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SOUTHARD GL, 1984, J AM DENT ASSOC, V108, P338, DOI 10.14219/jada.archive.1984.0022; STRAUB KD, 1975, BIOCHEM BIOPH RES CO, V62, P913, DOI 10.1016/0006-291X(75)90410-6; ULRICHOVA J, 1983, PLANTA MED, V48, P174, DOI 10.1055/s-2007-969916; Vavreckova Ctirada, 1994, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V138, P7; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047	45	251	265	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30129	30134		10.1074/jbc.272.48.30129	http://dx.doi.org/10.1074/jbc.272.48.30129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374492	hybrid			2022-12-25	WOS:A1997YH61300024
J	Dong, LQ; Ma, Q; Whitlock, JP				Dong, LQ; Ma, Q; Whitlock, JP			Down-regulation of major histocompatibility complex Q1(b) gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENE; MESSENGER-RNA; AROMATIC-HYDROCARBONS; DIFFERENTIAL DISPLAY; CHROMATIN STRUCTURE; AH-RECEPTOR; MOUSE; CELLS; MECHANISM; TRANSCRIPTION	We analyzed mouse hepatoma cells using differential display to discover new genes that respond to the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We identified a class I major histocompatibility complex (MHC) gene, which we designated as MHC Q1(b), whose expression decreases in the presence of TCDD. TCDD-induced down-regulation of MHC Q1(b) requires both the aromatic hydrocarbon receptor and the aromatic hydrocarbon receptor nuclear translocator, transcription factors that up-regulate other genes in response to TCDD. Down-regulation of MHC Q1(b) by TCDD appears to involve both transcriptional and posttranscriptional regulatory events; the post-transcriptional destabilization of MHC Q1(b) mRNA is probably a secondary response to TCDD. Our findings reveal new mechanistic aspects of gene regulation by TCDD, In addition, our observations suggest a mechanism that might account for some of TCDD's immunotoxic effects.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA 53887] Funding Source: Medline; NIEHS NIH HHS [NRSA ES 05679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CHEN YT, 1985, J EXP MED, V162, P1134, DOI 10.1084/jem.162.4.1134; CHEROUTRE H, 1991, J IMMUNOL, V146, P3263; CONNEY AH, 1982, CANCER RES, V42, P4875; DEVILIN JJ, 1985, EMBO J, V4, P369; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; DURAN LW, 1989, J IMMUNOL, V142, P288; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; FLAVELL RA, 1986, SCIENCE, V233, P437, DOI 10.1126/science.3726537; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; HOOD L, 1983, ANNU REV IMMUNOL, V1, P529, DOI 10.1146/annurev.iy.01.040183.002525; KALIYAPERUMAL A, 1995, J IMMUNOL, V155, P2379; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRESS M, 1983, CELL, V34, P189, DOI 10.1016/0092-8674(83)90149-6; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; Lee DC, 1996, TOXICOL APPL PHARM, V137, P90, DOI 10.1006/taap.1996.0060; LI H, 1994, J BIOL CHEM, V269, P28098; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; MELLOR AL, 1984, CELL, V36, P139, DOI 10.1016/0092-8674(84)90082-5; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; Murphy C, 1996, J BIOL CHEM, V271, P30992, DOI 10.1074/jbc.271.48.30992; OBATA Y, 1988, P NATL ACAD SCI USA, V85, P3541, DOI 10.1073/pnas.85.10.3541; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; REYESENGEL A, 1993, J REPROD IMMUNOL, V23, P73, DOI 10.1016/0165-0378(93)90028-G; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; THIGPEN JE, 1975, INFECT IMMUN, V12, P1319, DOI 10.1128/IAI.12.6.1319-1324.1975; WANECK GL, 1987, J EXP MED, V165, P1358, DOI 10.1084/jem.165.5.1358; WATTS S, 1989, EMBO J, V8, P1749, DOI 10.1002/j.1460-2075.1989.tb03568.x; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157	40	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29614	29619		10.1074/jbc.272.47.29614	http://dx.doi.org/10.1074/jbc.272.47.29614			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368027	hybrid			2022-12-25	WOS:A1997YG64700037
J	Ikonen, T; Palvimo, JJ; Janne, OA				Ikonen, T; Palvimo, JJ; Janne, OA			Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; HUMAN ESTROGEN-RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; ACTIVATION FUNCTION AF-2; BULBAR MUSCULAR-ATROPHY; NONRECEPTOR FACTORS; HORMONE RECEPTORS; RESPONSE ELEMENT; TRANS-ACTIVATION; PROMOTER-CONTEXT	Identical N-terminal deletions in the wild-type rat androgen receptor (rAR) and a constitutively active rAR (AR Delta 641-902) devoid of the ligand-binding domain (LED) resulted in dissimilar consequences in transcriptional activation: deletion of residues 149-295 abolished wild-type AR activity, but did not influence that of AR Delta 641-902. The activity of the N-terminal transactivation domain is thus controlled by the hormone-occupied LED, suggesting that the N- and C-terminal regions of rAR communicate. Consistent with this idea, a strong androgen-dependent interaction between the N-terminal region and LED was demonstrated in a mammalian two-hybrid system using GAL4 and VP16 fusion proteins. This interaction can be direct or indirect. Several nuclear receptor coactivators (CEP, F-SRC-1, SRC-1, and RIP140) that interact with other steroid receptors were tested as potential mediators of the Nand C-terminal interaction of rAR using the mammalian two-hybrid system. CBP or F-SRC-1 not only enhanced AR-mediated transactivation, but also facilitated the androgen-dependent interaction between the N- and C-terminal domains, implying that part of the coactivator-dependent transcriptional activation occurs via this mechanism. In contrast, SRC-1, a coactivator for the progesterone receptor, inhibited both AR-mediated transactivation and interaction between the Pd and C termini. Recruitment of coregulators may involve AR domains other than the LED, as F-SRC-1 and CBP enhanced, but SRC-1 repressed, the transcriptional activity of AR Delta 641-902. Collectively, interplay between the N-terminal region and LED of rAR results in the formation of a transactivation complex that includes coregulators and that is mandatory for optimal activation of androgen-induced promoters.	UNIV HELSINKI, INST BIOMED, DEPT PHYSIOL, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, DEPT CLIN CHEM, FIN-00014 HELSINKI, FINLAND	University of Helsinki; University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LHorset F, 1996, MOL CELL BIOL, V16, P6029; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Palvimo JJ, 1996, BIOCHEM J, V316, P993, DOI 10.1042/bj3160993; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WILSON CM, 1994, P NATL ACAD SCI USA, V91, P1234, DOI 10.1073/pnas.91.4.1234; XIE YB, 1992, J BIOL CHEM, V267, P4939; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yen PM, 1997, MOL ENDOCRINOL, V11, P162, DOI 10.1210/me.11.2.162; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	67	309	312	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29821	29828		10.1074/jbc.272.47.29821	http://dx.doi.org/10.1074/jbc.272.47.29821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368054	hybrid			2022-12-25	WOS:A1997YG64700064
J	Sahlman, L; Wong, W; Powlowski, J				Sahlman, L; Wong, W; Powlowski, J			A mercuric ion uptake role for the integral inner membrane protein, MerC, involved in bacterial mercuric ion resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOBACILLUS-FERROOXIDANS MERC; T7 RNA-POLYMERASE; ESCHERICHIA-COLI; TRANSPOSON TN501; BINDING-PROTEIN; INORGANIC MERCURY; STRUCTURAL GENES; OPERON; EXPRESSION; SEQUENCE	Bacterial detoxification of mercuric ion depends on the presence of one or more integral membrane proteins (MerT and/or MerC) whose postulated function is in transport of Hg2+ from a periplasmic Hg2+-binding protein (MerP) to cytoplasmic mercuric reductase, In this study, MerC from the Tn21-encoded mer operon was overexpressed and studied in vesicles and in purified form to clarify the role played by this protein in mercuric ion resistance. MerC-containing vesicles were found to take up mercuric ion independently of MerP. Since uptake correlated with the level of MerC expression was unaffected by osmotic pressure, and was only partially decreased in the presence of 0.05% Triton X-100, the observed uptake appears to represent mainly binding to MerC. Binding was inhibited by thiol-specific reagents, consistent with an essential role for cysteine residues, The essential thiol groups were inaccessible to hydrophilic thiol reagents, whereas hydrophobic reagents completely abolished Hg2+ binding, These observations are consistent with the predicted topology of the protein, wherein all 4 cysteine residues are either in the cytoplasm or the bilayer, A role for MerC in Hg2+ transport is thus also likely, Based on these results, a modified model for bacterial Hg2+ transport is proposed.	CONCORDIA UNIV, DEPT CHEM & BIOCHEM, MONTREAL, PQ H3G 1M8, CANADA	Concordia University - Canada	Sahlman, L (corresponding author), UMEA UNIV, DEPT BIOCHEM, S-90187 UMEA, SWEDEN.							AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BARRINEAU P, 1984, Journal of Molecular and Applied Genetics, V2, P601; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; BROWN NL, 1985, TRENDS BIOCHEM SCI, V10, P400, DOI 10.1016/0968-0004(85)90069-6; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FOSTER TJ, 1979, J BACTERIOL, V140, P167, DOI 10.1128/JB.140.1.167-181.1979; FOX BS, 1983, BIOCHEMISTRY-US, V22, P4082, DOI 10.1021/bi00286a014; Girault L, 1996, EUR BIOPHYS J BIOPHY, V24, P413, DOI 10.1007/BF00576713; GUTKNECHT J, 1981, J MEMBRANE BIOL, V61, P61, DOI 10.1007/BF01870753; HAMLETT NV, 1992, J BACTERIOL, V174, P6377, DOI 10.1128/JB.174.20.6377-6385.1992; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hobman JL, 1996, MOL GEN GENET, V250, P129, DOI 10.1007/s004380050059; Inoue C, 1996, BIOSCI BIOTECH BIOCH, V60, P1289, DOI 10.1271/bbb.60.1289; INOUE C, 1990, GENE, V96, P115, DOI 10.1016/0378-1119(90)90349-V; JACKSON WJ, 1982, J BACTERIOL, V149, P479, DOI 10.1128/JB.149.2.479-487.1982; JACKSON WJ, 1982, J BACTERIOL, V151, P962, DOI 10.1128/JB.151.2.962-970.1982; Jones PC, 1996, MOL MEMBR BIOL, V13, P53, DOI 10.3109/09687689609160575; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KIM YJ, 1994, CELL, V78, P845; KUSANO T, 1990, J BACTERIOL, V172, P2688, DOI 10.1128/jb.172.5.2688-2692.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND PA, 1986, J GEN MICROBIOL, V132, P465; LUND PA, 1987, GENE, V52, P207, DOI 10.1016/0378-1119(87)90047-3; MISRA TK, 1985, GENE, V34, P253, DOI 10.1016/0378-1119(85)90134-9; MISRA TK, 1984, P NATL ACAD SCI-BIOL, V81, P5975, DOI 10.1073/pnas.81.19.5975; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; MUKHOPADHYAY D, 1991, J BIOL CHEM, V266, P18538; NAIR SK, 1991, J BIOL CHEM, V266, P17320; NAKAHARA H, 1979, J BACTERIOL, V140, P161, DOI 10.1128/JB.140.1.161-166.1979; NIBHRIAN N, 1986, GENE, V42, P323; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAHLMAN L, 1992, EUR J BIOCHEM, V205, P375, DOI 10.1111/j.1432-1033.1992.tb16790.x; SAHLMAN L, 1993, BIOCHEM BIOPH RES CO, V196, P583, DOI 10.1006/bbrc.1993.2289; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SELIFONOVA OV, 1994, APPL ENVIRON MICROB, V60, P3503, DOI 10.1128/AEM.60.10.3503-3507.1994; SHUMAN HA, 1993, J BIOENERG BIOMEMBR, V25, P613; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.mi.40.100186.003135; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1	48	37	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29518	29526		10.1074/jbc.272.47.29518	http://dx.doi.org/10.1074/jbc.272.47.29518			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368013	hybrid			2022-12-25	WOS:A1997YG64700023
J	Berditchevski, F; Chang, S; Bodorova, J; Hemler, ME				Berditchevski, F; Chang, S; Bodorova, J; Hemler, ME			Generation of monoclonal antibodies to integrin-associated proteins - Evidence that alpha(3)beta(1) complexes with EMMPRIN/basigin/OX47/M6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; CELL-ADHESION; IMMUNOGLOBULIN SUPERFAMILY; T-CELLS; HISTOCOMPATIBILITY ANTIGENS; UROKINASE RECEPTOR; BETA-1 INTEGRINS; CD9 ANTIGEN; SURFACE; DOMAIN	The alpha(3) beta(1) integrin forms complexes with other cell-surface proteins, including transmembrane-4 superfamily (TM4SF) proteins (e.g. CD9, CD53, CD63, CD81, and CD82). To identify additional cell-surface proteins associated with alpha(3) beta(1) integrin, a monoclonal antibody selection protocol was developed, Mice were immunized with integrin alpha(3) beta(1)-containing complexes isolated from HT1080 fibrosarcoma cells, and then 712 hybridoma clones were produced, and 95 secreted antibodies that recognized the HT1080 cell surface, Among these, 12 antibodies directly recognizing integrin alpha(3) or beta(1) subunits were eliminated, Of the remaining 83, 16 co-immunoprecipitated proteins that resembled integrins under non-stringent detergent conditions. These 16 included 15 monoclonal antibodies recognizing EMMPRIN/basigin/OX-47/M6, a 45-55-kDa transmembrane protein with two immunoglobulin domains. The EMMPRIN protein associated with alpha(3) beta(1) and alpha(6) beta(1), but not alpha(2) beta(1) or alpha(5) beta(1), as shown by reciprocal immunoprecipitation experiments, Also, association with alpha(3) beta(1) was confirmed by cell-surface cross-linking and immunofluorescence co-localization experiments, Importantly, EMMPRIN-alpha(3) beta(1) complexes appear not to contain TM4SF proteins, suggesting that they are distinct from TM4SF protein-alpha(3) beta(1) complexes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA42368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTRUDA F, 1989, GENE, V85, P445, DOI 10.1016/0378-1119(89)90438-1; ANDERSON GP, 1991, BRIT J HAEMATOL, V79, P75, DOI 10.1111/j.1365-2141.1991.tb08010.x; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BISWAS C, 1995, CANCER RES, V55, P434; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Chintala SK, 1996, CANCER LETT, V103, P201, DOI 10.1016/0304-3835(96)04215-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Guo HM, 1997, J BIOL CHEM, V272, P24; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HEMLER ME, 1983, J IMMUNOL, V131, P334; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Igakura T, 1996, BIOCHEM BIOPH RES CO, V224, P33, DOI 10.1006/bbrc.1996.0980; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; LARJAVA H, 1993, J CELL PHYSIOL, V157, P190, DOI 10.1002/jcp.1041570125; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Mannion BA, 1996, J IMMUNOL, V157, P2039; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NEHME CL, 1993, J CELL BIOL, V120, P687, DOI 10.1083/jcb.120.3.687; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PASQUALINI R, 1993, J CELL SCI, V105, P101; PASQUALINI R, 1994, J CELL BIOL, V125, P477; PATARROYO M, 1994, IMMUNOBIOLOGY, V191, P474, DOI 10.1016/S0171-2985(11)80453-5; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHLOSSHAUER B, 1995, EUR J CELL BIOL, V68, P159; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SEULBERGER H, 1990, EMBO J, V9, P2151, DOI 10.1002/j.1460-2075.1990.tb07384.x; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TARONE G, 1988, EUR J BIOCHEM, V172, P713, DOI 10.1111/j.1432-1033.1988.tb13947.x; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	59	229	244	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29174	29180		10.1074/jbc.272.46.29174	http://dx.doi.org/10.1074/jbc.272.46.29174			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360995	hybrid			2022-12-25	WOS:A1997YF68400054
J	Chang, W; Gelman, MS; Prives, JM				Chang, W; Gelman, MS; Prives, JM			Calnexin-dependent enhancement of nicotinic acetylcholine receptor assembly and surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; MUSCLE-CELLS; CHAPERONE CALNEXIN; IN-VITRO; DEGRADATION; PROTEIN; SUBUNIT; PROTEASOME; ALPHA	The muscle-type nicotinic acetylcholine receptor (AChR)(2) is a pentameric membrane ion channel assembled in the endoplasmic reticulum from four homologous subunits by mechanisms that are insufficiently understood, Nascent AChR subunits were recently found to form complexes with the endoplasmic reticulum-resident molecular chaperone calnexin, To determine the contribution of this interaction to AChR assembly and surface expression, we have now used transient transfection of mouse AChR subunits and calnexin into nonmuscle cells. Co-transfection of calnexin along with AChR subunits into COS and HEK 293 cells was found to enhance AChR subunit folding and assembly, and to decrease degradation rates of newly synthesized AChR alpha-subunits, resulting in elevated surface expression of assembled AChR. Moreover, inhibition of the interaction between endogenous calnexin and AChR by castanospermine resulted in decreased AChR subunit folding, assembly, and surface expression in muscle and HEK 293 cells. Together, these findings provide evidence that calnexin directly contributes to AChR biogenesis by promoting subunit folding and assembly.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER; NINDS NIH HHS [NS25945] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CHANG W, 1995, THESIS STATE U NEW Y; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; Gelman MS, 1996, J BIOL CHEM, V271, P10709, DOI 10.1074/jbc.271.18.10709; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1984, CELL, V36, P573, DOI 10.1016/0092-8674(84)90335-0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSS AF, 1987, J BIOL CHEM, V262, P14640; Sambrook J., 2002, MOL CLONING LAB MANU; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WADA I, 1991, J BIOL CHEM, V266, P19599; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	47	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28925	28932		10.1074/jbc.272.46.28925	http://dx.doi.org/10.1074/jbc.272.46.28925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360963	hybrid			2022-12-25	WOS:A1997YF68400022
J	Folberg, A; Kovacs, EN; Featherstone, MS				Folberg, A; Kovacs, EN; Featherstone, MS			Characterization and retinoic acid responsiveness of the murine Hoxd4 transcription unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HOMEOBOX GENE; HOMEOTIC TRANSFORMATIONS; NERVOUS-SYSTEM; MESSENGER-RNAS; HOX-4.2 GENE; MUTANT MICE; EXPRESSION; INITIATION; PROMOTERS; ELEMENT	We have characterized the transcription unit of a murine Hox gene in the fourth paralogous group, Hoxd4, We have identified two HoxdB transcription start sites by S1 analysis, The upstream promoter (P2) is 5.2 kilobase pairs upstream from the coding region, while the downstream promoter (P1) is 1.1 kilobase pairs distant, Both promoters bear a cluster of start sites, Multiple transcripts were identified by Northern blot, originating from both promoters and multiple polyadenylation signals. Expression of P1 transcripts in the neural tube shows an anterior border at the rhombomere 6/7 boundary, corresponding to previous reports (Gaunt, S. J., Krumlauf, R,, and Duboule, D. (1989) Development 107, 131-141; Morrison, A., Moroni, M, C,, Ariza-McNaughton, L,, Krumlauf, R,, and Mavilio, F, (1996) Development 122, 1895-1907), A more posterior boundary in the central nervous system was observed for P2 transcripts, We observed strong expression up to somite 6 and weak expression in somite 5, correlating with the phenotype of Hoxd4 null mutant mice (Horan, G, S. B,, Nagy Kovacs, E,, Behringer, R, R,, and Featherstone, RI, S, (1995) Dev. Biol. 169, 359-372), In response to retinoic acid, expression from P1 in the hindbrain was anteriorized after 4 or 24 h of treatment, P2 transcripts seemed to be less responsive and/or to have an indirect response to retinoic acid, The long 5'-untranslated region found in all Hoxd4 transcripts suggests that translation does not occur by a classical ribosome scanning mechanism.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,DIV EXPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University			Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				AUSUBELL FM, 1989, CURRENT PROTOCOLS MO, V1; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Boulet AM, 1996, DEV BIOL, V177, P232, DOI 10.1006/dbio.1996.0159; BURGLIN TR, 1987, NATURE, V330; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; CONLON RA, 1992, DEVELOPMENT, V116, P357; COULY GF, 1993, DEVELOPMENT, V117, P409; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORAN GSB, 1994, P NATL ACAD SCI USA, V91, P12644, DOI 10.1073/pnas.91.26.12644; HORAN GSB, 1995, DEV BIOL, V169, P359, DOI 10.1006/dbio.1995.1150; IZPISUABELMONTE JC, 1990, DEVELOPMENT, V110, P733; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRUMLAUF R, 1987, DEVELOPMENT, V99, P603; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; MORONI MC, 1993, MECH DEVELOP, V44, P139, DOI 10.1016/0925-4773(93)90063-4; Morrison A, 1996, DEVELOPMENT, V122, P1895; NEDELLEC P, 1994, J VIROL, V68, P4525; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; POPPERL H, 1993, MOL CELL BIOL, V13, P257; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUDDLE FH, 1994, ANNU REV GENET, V28, P423, DOI 10.1146/annurev.ge.28.120194.002231; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P847; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; Zeltser L, 1996, DEVELOPMENT, V122, P2475	44	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29151	29157		10.1074/jbc.272.46.29151	http://dx.doi.org/10.1074/jbc.272.46.29151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360992	hybrid			2022-12-25	WOS:A1997YF68400051
J	Mathias, RS; Zhang, SHJ; Wilson, E; Gardner, P; Ives, HE				Mathias, RS; Zhang, SHJ; Wilson, E; Gardner, P; Ives, HE			Non-capacitative calcium entry in Chinese hamster ovary cells expressing the platelet-derived growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; JURKAT T-CELLS; RAT MAST-CELLS; MESANGIAL CELLS; PLASMA-MEMBRANE; ANGIOTENSIN-II	Platelet-derived growth factor !PDGF) is believed to produce intracellular calcium (Ca-i(2+)) transients by inositol trisphosphate (InsP(3))-mediated release of intracellular Ca2+ stores followed by ''capacitative'' Ca2+ entry due to emptying of these stores, me examined the roles for the phospholipase C gamma-InsP(3) pathway and the emptying of InsP(3)-dependent intracellular Ca2+ stores In PDGF-mediated Ca2+ entry, Intracellular Ca2+ release and Ca2+ entry were measured with fluorometric methods in Chinese hamster ovary cells expressing wild type or mutant PDGF receptors, Activation of the wild type PDGF receptor caused both intracellular ''Ca2+ release,'' measured in nominally 0 Ca2+ extracellular medium, and ''Ca2+ entry,'' measured upon addition of 2 mM Ca2+ medium, Both phases were absent in Chinese hamster ovary cells expressing a PDGF receptor mutant (Y977F,Y989F) that fails to bind phospholipase C gamma. Blockade of the InsP(3) receptor, by microinjection of single cells with low molecular weight heparin (5-50 mg/ml), blocked only Ca-i(2+) release (following PDGF or flash photolysis of caged InsP(3)) and had no effect on PDGF-induced Ca2+ entry, In whole cell patch-clamp experiments, intracellular heparin also failed to block PDGF-evoked ion currents. Release of InsP(3)-dependent intracellular Ca2+ stores, by flash photolysis of caged InsP(3), was apparently not sufficient to maximally activate Ca2+ entry. Intracellular InsP(3) caused significantly less Ca2+ entry than PDGF alone, These data suggest that InsP(3) alone is not sufficient to maximally activate Ca2+ entry by the capacitative pathway and that products of phosphatidylinositol 4,5-bisphosphate breakdown other than InsP, probably play a role in PDGF-mediated Ca2+ entry.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	Mathias, RS (corresponding author), UNIV CALIF SAN FRANCISCO,MED CTR,DEPT PEDIAT,CHILDRENS RENAL CTR,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NHLBI NIH HHS [HL-41210, HL07740] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041210, T32HL007740] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BARANSKA J, 1995, CELL CALCIUM, V17, P207, DOI 10.1016/0143-4160(95)90035-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BLATTER LA, 1992, AM J PHYSIOL, V263, pH576, DOI 10.1152/ajpheart.1992.263.2.H576; BYRON KL, 1992, J BIOL CHEM, V267, P108; CHOW SC, 1993, BIOCHEM J, V293, P395, DOI 10.1042/bj2930395; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DAWRA RK, 1993, J BIOL CHEM, V268, P20237; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; Gargus J J, 1993, EXS, V66, P289; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; Graessmann A, 1980, Methods Enzymol, V65, P816; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMADA E, 1993, J GEN PHYSIOL, V102, P667, DOI 10.1085/jgp.102.4.667; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUANG CL, 1987, J BIOL CHEM, V262, P14134; HUANG CL, 1991, J BIOL CHEM, V266, P4045; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LACY P, 1992, PFLUG ARCH EUR J PHY, V420, P127, DOI 10.1007/BF00374980; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; Lobo E. P., 1996, Molecular Biology of the Cell, V7, p368A; Ma HP, 1996, J CLIN INVEST, V97, P2332, DOI 10.1172/JCI118676; MATSUNAGA H, 1994, AM J PHYSIOL, V267, pC456, DOI 10.1152/ajpcell.1994.267.2.C456; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SHIRAKAWA H, 1995, CELL CALCIUM, V17, P1, DOI 10.1016/0143-4160(95)90097-7; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; SZOLLOSI J, 1991, CELL CALCIUM, V12, P477, DOI 10.1016/0143-4160(91)90030-I; THORN P, 1993, J BIOL CHEM, V268, P23219; Tinton SA, 1996, EUR J BIOCHEM, V238, P576, DOI 10.1111/j.1432-1033.1996.0576z.x; Ubl JJ, 1997, PFLUG ARCH EUR J PHY, V433, P312; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; XUAN YT, 1994, AM J PHYSIOL, V266, pC1550; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29076	29082		10.1074/jbc.272.46.29076	http://dx.doi.org/10.1074/jbc.272.46.29076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360982	hybrid			2022-12-25	WOS:A1997YF68400041
J	StClair, EG; Anderson, SJ; Oltvai, ZN				StClair, EG; Anderson, SJ; Oltvai, ZN			Bcl-2 counters apoptosis by Bax heterodimerization-dependent and -independent mechanisms in the T cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS MULTIPLE FORMS; CAENORHABDITIS-ELEGANS; NEGATIVE SELECTION; TRANSGENIC MICE; DEFICIENT MICE; IN-VIVO; DEATH; PROTEIN; EXPRESSION; RECEPTOR	The effect of the cell death inhibitor Bcl-2 in relation to its capacity to dimerize with apoptosis promoter Bax or its homologs at their physiological expression levels was explored in the T-cell lineage. Transgenic mice expressing a BH1 mutant Bcl-2 (Bcl-2 mI-3), which fails to heterodimerize with proapoptotic members of the Bcl-2 family, such as Bax, were generated. Bcl-2 mI-3 protected immature CD4(+)8(+) thymocytes from spontaneous, glucocorticoid and anti-CD3-induced apoptosis and altered T cell maturation, resulting in increased percentages of CD3(hi) and CD4(-)8(+) thymocytes. In contrast, apoptosis of peripheral T-cells was unaffected by transgene expression. This correlated with their high Bax expression level and insensitivity to the caspase inhibitor, zVAD-fmk, a functional hallmark of Bax-like activity. Thus, within the T-cell lineage Bcl-2 can inhibit apo ptosis independent of its association with Bax or its homologs; yet, above a threshold level of their physiologic proapoptotic activity, the capacity of Bcl-2 to heterodimerize with Bax or its homologs appears essential for it to counter cell death.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University					NATIONAL CANCER INSTITUTE [R29CA072535, K08CA071890] Funding Source: NIH RePORTER; NCI NIH HHS [CA71890-01, CA72535-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Blomgren H, 1970, Cell Immunol, V1, P545, DOI 10.1016/0008-8749(70)90041-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clayton LK, 1997, EMBO J, V16, P2282, DOI 10.1093/emboj/16.9.2282; COHEN JJ, 1984, J IMMUNOL, V132, P38; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GERDES K, 1990, New Biologist, V2, P946; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li T, 1996, CELL GROWTH DIFFER, V7, P107; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHI YF, 1991, J IMMUNOL, V146, P3340; SHORTMAN K, 1991, J EXP MED, V173, P323, DOI 10.1084/jem.173.2.323; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TucekSzabo CL, 1996, J IMMUNOL, V156, P192; VASILAKOS JP, 1995, J IMMUNOL, V155, P3433; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEIS DJ, 1993, J IMMUNOL, V151, P2546; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	65	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29347	29355						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361016				2022-12-25	WOS:A1997YF68400075
J	Han, JH; Cote, HCF; Tollefsen, DM				Han, JH; Cote, HCF; Tollefsen, DM			Inhibition of meizothrombin and meizothrombin(desF1) by heparin cofactor .2.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHROMBIN ACTIVATION PRODUCTS; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; FACTOR-XA; CATALYZED ACTIVATION; BOVINE PROTHROMBIN; DERMATAN SULFATE; BINDING EXOSITE; GLYCOSAMINOGLYCANS; INTERMEDIATE	Meizothrombin and meizothrombin(desF1) are intermediates formed during the conversion of prothrombin to thrombin by factor Xa, factor Va, phospholipids, and Ca2+ (prothrombinase). These intermediates are active toward synthetic peptide substrates but have limited ability to interact with platelets or macromolecular substrates such as fibrinogen, Meizothrombin and meizothrombin(desF1) activate protein C, however, and may exert primarily an anticoagulant effect. In this study, we investigated the inhibition of meizothrombin and meizothrombin(desF1) by two glycosaminoglycan-dependent protease inhibitors, heparin cofactor II (HCII) and antithrombin (AT), Purified recombinant meizothrombin and meizothrombin(desF1) were inhibited by HCII in the presence of dermatan sulfate with maximal second-order rate constants of 8 x 10(6) M-1.min(-1) and 1.8 x 10(7) M-1.min(-1), respectively, but were inhibited less than one-tenth as fast by AT in the presence of heparin, Similarly, the products of the prothrombinase reaction were inhibited in situ more effectively by HCII than by AT, When HCII and dermatan sulfate were present continuously during the prothrombinase reaction, meizothrombin was trapped as a sodium dodecyl sulfate-stable complex with HCII and no amidolytic activity could be detected with a thrombin substrate, Our findings indicate that HCII is an effective inhibitor of meizothrombin and meizothrombin(desF1) and, therefore, might regulate the anticoagulant activity of these proteases.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,DIV HEMATOL,ST LOUIS,MO 63110; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA	Washington University (WUSTL); Washington University (WUSTL); University of British Columbia			Cote, Helene/K-7896-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055520] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-55520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON TR, 1986, SCAND J HAEMATOL, V36, P96; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BERTINA RM, 1987, THROMB HAEMOSTASIS, V57, P196; BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; COUGHLIN SR, 1994, SEMIN HEMATOL, V31, P270; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7782; FERNANDEZ F, 1986, BRIT J HAEMATOL, V64, P309, DOI 10.1111/j.1365-2141.1986.tb04124.x; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Hackeng TM, 1996, BIOCHEM J, V319, P399, DOI 10.1042/bj3190399; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORITA T, 1981, METHOD ENZYMOL, V80, P303; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NESHEIM ME, 1988, J BIOL CHEM, V263, P1037; OLSON ST, 1991, J BIOL CHEM, V266, P6353; PIETERS J, 1987, THROMB RES, V45, P573, DOI 10.1016/0049-3848(87)90320-3; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; ROSING J, 1986, J BIOL CHEM, V261, P4224; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TOLLEFSEN DM, 1995, METABOLIC MOL BASES, P3313; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WU QY, 1992, J BIOL CHEM, V267, P7083	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28660	28665		10.1074/jbc.272.45.28660	http://dx.doi.org/10.1074/jbc.272.45.28660			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353333	hybrid			2022-12-25	WOS:A1997YF21900073
J	Itin, C; Rancano, C; Nakajima, Y; Pfeffer, SR				Itin, C; Rancano, C; Nakajima, Y; Pfeffer, SR			A novel assay reveals a role for soluble N-ethylmaleimide-sensitive fusion attachment protein in mannose 6-phosphate receptor transport from endosomes to the trans Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; MEMBRANE-FUSION; ALPHA-SNAP; ENDOPLASMIC-RETICULUM; TYROSINE SULFATION; NSF; YEAST; CELLS; REQUIRES; COMPLEX	Soluble N-ethylmaleimide sensitive fusion protein (NSF) attachment protein (alpha-SNAP) is a soluble protein that enables the NSF ATPase to associate with membranes and facilitate membrane trafficking events, Although NSF and alpha-SNAP have been shown to be required for many membrane transport processes, their role in the transport of mannose 6-phosphate receptors from endosomes to the trans Golgi network was not established. We present here a novel in vitro assay that monitors the transport of cation-dependent mannose 6-phosphate receptors between endosomes and the trans Golgi network, The assay relies on the trans Golgi network localization of tyrosine sulfotransferase and monitors transport of mannose 6-phosphate receptors engineered to contain a consensus sequence for modification by this enzyme. Using this new assay we show that alpha-SNAP strongly stimulates transport in reactions containing limiting amounts of cytosol. Together with alpha-SNAP, NSF can increase the extent of transport. These data show that alpha-SNAP, a soluble component of the SNAP receptor machinery, facilitates transport from endosomes to the trans Golgi network.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIDDK NIH HHS [DK37332] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037332, R01DK037332, R37DK037332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAEUERLE PA, 1986, J CELL BIOL, V129, P577; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; EHRHARDT DW, 1995, J BACTERIOL, V177, P6237, DOI 10.1128/jb.177.21.6237-6245.1995; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER B, 1994, J BIOL CHEM, V269, P8115; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	52	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27737	27744		10.1074/jbc.272.44.27737	http://dx.doi.org/10.1074/jbc.272.44.27737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346916	hybrid			2022-12-25	WOS:A1997YD47300042
J	Liang, PQ; Wu, JM; Garami, M; Gardner, DG				Liang, PQ; Wu, JM; Garami, M; Gardner, DG			Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADHESION MOLECULE-1 EXPRESSION; AORTIC ENDOTHELIAL-CELLS; ADRENERGIC STIMULATION; INDUCED HYPERTROPHY; RIBONUCLEIC-ACID; ANGIOTENSIN-II; C-JUN; ATRIAL; PATHWAYS	Using a device that applies cyclical strain (1 Hz) to ventricular cardiocytes cultured on collagen-coated silicone elastomer surfaces, we have demonstrated strain-dependent increases in brain natriuretic peptide (BNP) secretion, BNP mRNA levels, and expression of a transiently transfected -1595 human BNP-luciferase reporter. When actinomycin D (10 mu M) was introduced concomitantly with the strain stimulus, the strain-induced increase in BNP mRNA was eliminated, and the decay of transcripts was identical in the control and strained cells, indicating the lack of independent effects on transcript stability. Strain-dependent -1595 human BNP-luciferase activity was completely inhibited by chelerythrine, a-aminopurine, genistein, and W-7 and only partially or not at all by KN-62, wortmannin, and H-89. The effects of these individual agents paralleled their effects on mitogen-activated protein kinase (MAPK) activity, but not c-Jun N-terminal kinase (JNK) activity, in the cells. Overexpression of wild-type MAPK and, to a lesser extent, JNK increased strain-dependent BNP promoter activity, whereas dominant-negative mutants of MAPK kinase, JNK kinase, or Ras completely blocked strain-dependent reporter activity. These findings provide the first demonstration that mechanical strain can increase myocardial gene expression through a transcriptional mechanism and suggest important roles for MAPK and JNK in mediating this effect.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, HSW 1141, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; BENES AJ, 1985, J CELL SCI, V75, P35; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Cheng JJ, 1996, HYPERTENSION, V28, P386, DOI 10.1161/01.HYP.28.3.386; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAGNINO L, 1991, MOL ENDOCRINOL, V5, P1292, DOI 10.1210/mend-5-9-1292; DAGNINO L, 1992, HYPERTENSION, V20, P690, DOI 10.1161/01.HYP.20.5.690; DENE H, 1987, MOL ENDOCRINOL, V1, P614, DOI 10.1210/mend-1-9-614; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GARDNER DG, 1992, AM J PHYSIOL, V263, pE239, DOI 10.1152/ajpendo.1992.263.2.E239; GARDNER DG, 1988, J CLIN INVEST, V82, P1275, DOI 10.1172/JCI113726; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HANFORD DS, 1994, J BIOL CHEM, V269, P26227; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; KOMURO I, 1990, J BIOL CHEM, V265, P3595; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kuppuswamy D, 1997, J BIOL CHEM, V272, P4500, DOI 10.1074/jbc.272.7.4500; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; MORITA T, 1993, J CLIN INVEST, V92, P1706, DOI 10.1172/JCI116757; MUKOYAMA M, 1990, NEW ENGL J MED, V323, P757; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SAITO Y, 1989, J CLIN INVEST, V83, P298, DOI 10.1172/JCI113872; SEI CA, 1991, J BIOL CHEM, V266, P15910; SUDOH T, 1989, BIOCHEM BIOPH RES CO, V159, P1427, DOI 10.1016/0006-291X(89)92269-9; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; VONHARSDORF R, 1989, CIRC RES, V65, P494, DOI 10.1161/01.RES.65.2.494; WEI YF, 1987, J CLIN INVEST, V79, P1325, DOI 10.1172/JCI112957; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WU JP, 1988, AM J PHYSIOL, V255, pE388, DOI 10.1152/ajpendo.1988.255.3.E388; WU JP, 1991, MOL ENDOCRINOL, V5, P1311, DOI 10.1210/mend-5-9-1311; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054	50	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28050	28056		10.1074/jbc.272.44.28050	http://dx.doi.org/10.1074/jbc.272.44.28050			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346958	hybrid			2022-12-25	WOS:A1997YD47300084
J	Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG				Zhang, LR; Kharbanda, S; Chen, D; Bullocks, J; Miller, DL; Ding, IYF; Hanfelt, J; McLeskey, SW; Kern, FG			MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice	ONCOGENE			English	Article						estrogen independence; antiestrogen resistance; angiogenesis; metastasis; fibroblast growth factors	FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; ESTROGEN-DEPLETED CONDITIONS; HUMAN MAMMARY-GLAND; CANCER-CELLS; FACTOR-I; EPITHELIAL-CELLS; FACTOR RECEPTORS; FACTOR FAMILY; CONSTITUTIVE ACTIVATION	FGF-1 is expressed in a high proportion of breast tumors, While overexpression of FGF-4 in the MCF-7 breast carcinoma cell line confers the ability to form spontaneously metastasizing tumors in ovariectomized nude mice without estrogen supplementation and in mice that receive tamoxifen pellets, the response of a cell to individual FGFs can be controlled at multiple levels, and the significance of FGF-1 expression in human breast tumors is uncertain, To study the role of FGF-1, MCF-7 human breast cancer carcinoma cells, previously transfected with bacterial beta-galactosidase, were retransfected with FGF-1 expression vectors, FGF-1 transfectants formed large, vascularized tumors in ovariectomized nude mice without estrogen supplementation as web as in mice that received tamoxifen pellets, Lymphatic and pulmonary micrometastases were detected as deposits of X-gal-stained cells as early as 17 days after cell inoculation whereas no metastases were detected in estrogen-supplemented mice bearing similar-sized control tumors, When compared with controls, both clonal and polyclonal populations of FGF-1 overexpressing cells exhibited increased anchorage-independent growth and decreased population doubling times in estrogen-depleted or 4-hydroxytamoxifen containing medium, These results suggest that FGF signaling may be important in the transition of breast cancer cells from hormone-dependent to hormone-independent and from nonmetastatic to metastatic.	GEORGETOWN UNIV, MED CTR, SCH NURSING, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University; Georgetown University; Georgetown University					NCI NIH HHS [P50CA53185, R01-CA50376, R29-CA6614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLAM SB, 1988, ONCOGENE, V3, P129; BRIOZZO P, 1991, EXP CELL RES, V194, P252, DOI 10.1016/0014-4827(91)90362-X; BROWN KJ, 1995, J CELL BIOCHEM, V58, P6, DOI 10.1002/jcb.240580103; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DALY RJ, 1991, CELL GROWTH DIFFER, V2, P457; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DING IY, 1992, P ANN M AM ASS CANC, V33, pA1610; ENGEL LW, 1978, CANCER RES, V38, P4327; Fenig E, 1997, CLIN CANCER RES, V3, P135; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GLOVER JF, 1988, CANCER RES, V48, P3693; GOMM JJ, 1991, CANCER RES, V51, P4685; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KE YQ, 1993, J CELL SCI, V106, P135; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEHTOLA L, 1992, INT J CANCER, V50, P598, DOI 10.1002/ijc.2910500419; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MCLESKEY SW, 1993, CANCER RES, V53, P2168; McLeskey SW, 1996, BRIT J CANCER, V73, P1053, DOI 10.1038/bjc.1996.204; MCLESKEY SW, 1994, CANCER RES, V54, P523; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X; SOMMERS CL, 1990, CANCER RES, V50, P67; SPIRITO P, 1991, CIRCULATION, V84, P322, DOI 10.1161/01.CIR.84.1.322; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRYDOM DJ, 1986, BIOCHEMISTRY-US, V25, P945, DOI 10.1021/bi00353a001; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOI M, 1994, JPN J CANCER RES, V85, P1045, DOI 10.1111/j.1349-7006.1994.tb02904.x; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	88	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2093	2108		10.1038/sj.onc.1201386	http://dx.doi.org/10.1038/sj.onc.1201386			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366526				2022-12-25	WOS:A1997YC28400010
J	Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C				Carpentier, A; Balitrand, N; RochetteEgly, C; Shroot, B; Degos, L; Chomienne, C			Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers	ONCOGENE			English	Article						neuroblastoma; retinoic acid; retinoid receptor agonist; retinoic acid receptor	INDUCED GRANULOCYTIC DIFFERENTIATION; NEURO-BLASTOMA CELLS; BINDING PROTEIN-II; RAR-ALPHA; ACID RECEPTORS; 13-CIS-RETINOIC ACID; CHILDRENS-CANCER; RXR HETERODIMERS; WILD-TYPE; PHASE-I	Retinoic acid (RA) plays a major role in embryogenesis of the nervous system and has been reported to induce differentiation in neuroblastoma cell lines. To identify RA signaling pathways involved in such differentiation processes, two RA-sensitive neuroblastoma cell lines (LA-N-5 and SH-SY5Y) were extensively studied. Northern blot experiments determined that of the three RAR mRNAs, only RAR alpha was significantly expressed, with respectively weak or undetectable levels of RAR gamma and RAR beta. RXRs (alpha and beta) receptors were weakly expressed, Western blotting analysis confirmed the constitutive expression of RAR alpha and absence of RAR beta and weak levels of RXR alpha. Treatment with all-trans-RA up-regulated RAR alpha and induced a drastic increase of RAR beta (both at the RNA and protein level). To further characterize the function of RAR alpha, RAR beta and RXR alpha in NB cells, nuclear extracts from LA-N-5 cells were analysed by EMSA studies. Three specific retarded complexes were observed which were significantly decreased or shifted in the presence of monoclonal antibodies to RAR alpha, RAR beta and RXR alpha. RA treatment dramatically induced a DR5-binding RXR alpha-RAR beta heterodimer. Treatment with combinations of RAR alpha or RAR beta agonists with a RXR alpha agonist or with a RAR alpha agonist alone, induced neurite-outgrowth supporting the probability that both RXR alpha-RAR alpha or RXR alpha-RAR beta heterodimers are involved in RA-mediated differentiation of NB cells. The availability of novel synthetic RA-specific receptor ligands should provide the possibility of tissue specific therapeutic regimes.	UNIV PARIS 07, HOP ST LOUIS,CNRS,EP 107,INST HEMATOL, LAB BIOL CELLULAIRE HEMATOPOIET, F-75475 PARIS 10, FRANCE; IGBMC, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; CIRD, GALDERMA, F-06902 SOPHIA ANTIPOLIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Galderma R&D SNC				CHOMIENNE, Christine/0000-0001-5513-5752; Carpentier, Antoine/0000-0003-2926-0060				BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Calabresse C, 1995, LEUKEMIA, V9, P2049; CARNEY DN, 1988, SEMIN ONCOL, V15, P199; CASTLE VP, 1992, J CLIN INVEST, V90, P1857, DOI 10.1172/JCI116062; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DE LUCA LM, 1991, FASEB J, V5, P2924; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FINKLESTEIN JZ, 1992, MED PEDIATR ONCOL, V20, P307, DOI 10.1002/mpo.2950200407; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HIGUCHI T, 1991, CANCER RES, V51, P3958; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEROY P, 1991, P NATL ACAD SCI USA, V87, P4804; Li C, 1994, Prog Clin Biol Res, V385, P221; LOVAT PE, 1993, NEUROSCI LETT, V162, P109, DOI 10.1016/0304-3940(93)90572-3; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Manohar CF, 1996, TUMOR BIOL, V17, P34, DOI 10.1159/000217965; MARSHALL GM, 1995, ONCOGENE, V11, P485; MARSHALL GM, 1994, ANTICANCER RES, V14, P437; NERVI C, 1990, CELL GROWTH DIFFER, V1, P535; PLUM LA, 1995, ARCH BIOCHEM BIOPHYS, V319, P457, DOI 10.1006/abbi.1995.1317; REDFERN CPF, 1994, BIOCHEM J, V304, P147, DOI 10.1042/bj3040147; REES JL, 1989, BIOCHEM J, V259, P917, DOI 10.1042/bj2590917; Reynolds CP, 1994, ADV NEUROBLASTOMA RE, V4, P237; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; ROSOLEN A, 1992, EUR CYTOKINE NETW, V2, P81; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1982, J NATL CANCER I, V68, P589; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; TANEJA R, 1995, P NATL ACAD SCI USA, V92, P7854, DOI 10.1073/pnas.92.17.7854; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615	51	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1805	1813		10.1038/sj.onc.1201335	http://dx.doi.org/10.1038/sj.onc.1201335			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362447				2022-12-25	WOS:A1997XZ72500007
J	Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T				Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T			Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping of human Efs	ONCOGENE			English	Article						Efs; Src homology; FAK; tyrosine phosphorylation; chromosomal mapping	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BINDING; SRC; GRB2; CRK; HYBRIDIZATION; EXPRESSION; P130(CAS); PEPTIDES	Efs was originally found by expression cloning of a mouse embryo cDNA library through its Fyn-SH3 binding capacity (Ishino et al., Oncogene 11, 2331-2338, 1995), Efs has characteristic regions important in intracellular signal transduction; these are an SH3 domain, a cluster of putative ligands for SH2 domains and proline-rich sequences with SH3-binding consensus, In this paper, we report cDNA cloning of human Efs and a variant of it from a hippocampal cDNA library, The human Efs gene was mapped to chromosome 14q11.2-q12 by fluorescence in situ hybridization. We identified two forms of human Efs, designated hEfs1 and hEfs2, hEfs1 represents the human counterpart of original mouse embryo Efs (mEfs1), hEfs2, the newly identified form, is identical to hEfs1, except for its lack of the SH3 domain, hEfs1 and mEfs1 are 80% identical in their amino acid sequences and 100% identical within the SH3 domain. Reverse transcription polymerase chain reaction analysis of adult mouse tissue RNA indicated expression of Efs2 and of Efs1 in various tissues, Evidence suggesting the presence of the Efs2 protein in human tissue was obtained by immunoprecipitation followed by immunoblotting with two different anti-Efs antibodies. Possible functions of Efs2 are discussed.	SAPPORO MED UNIV, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KAMIGYO KU, KYOTO 602, JAPAN	Sapporo Medical University; Kyoto Prefectural University of Medicine								AKASHI M, 1994, BLOOD, V83, P3182; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Ishino M, 1995, ONCOGENE, V11, P2331; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1741	1745		10.1038/sj.onc.1201346	http://dx.doi.org/10.1038/sj.onc.1201346			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349509				2022-12-25	WOS:A1997XY63100015
J	McWhirter, JR; Wang, JYJ				McWhirter, JR; Wang, JYJ			Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein	ONCOGENE			English	Article						actin filaments; ALL CML; Dbl-homology; tyrosine kinase	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW STROMA; TYROSINE KINASE; C-ABL; PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC PROGENITORS; COILED-COIL; BINDING; PROTEIN	In Philadelphia chromosome (Phl)-positive human leukemia, the c-Abl tyrosine kinase is activated by fusion to sequences encoded by the breakpoint cluster region (bcr) gene, Two major types of Bcr-Abl fusion proteins have been found in human leukemia, Fusion of the N-terminal 426 amino acids of Bcr generates p190(Bcr-Abl) which is mostly found in acute lymphocytic leukemia (ALL), whereas fusion of the N-terminal 902 or 927 amino acids of Bcr generates p210(Bcr-Abl) mostly found with chronic myelogenous leukemia (CML). Previous studies have demonstrated that both the Bcr and the Abl functional domains contribute to the oncogenic activity of Bcr-Abl proteins, Present in both p190 and p210 is the N-terminal coiled-coil of Bcr (aa 1-63), which is shown here to be functionally replaceable with the leucine zipper of the yeast transcription factor GCN4, The ZIP-Bcr-Abl protein transforms Rat-1/myc cells, is autophosphorylated on tyrosine and localized predominantly to actin filaments, Thus, formation of homo-oligomers through either Bcr or GCN4 coiled-coil can activate the tyrosine kinase and F-actin binding functions of Abl, We also found that a Bcr-Abl fusion containing only Bcr amino acids (1-191) can efficiently transform Rat-1/myc cells. Fusion of additional Bcr sequences (aa 192-923) did not affect the transformation of Rat-1/myc cells but progressively reduced the disruptive effect on the actin cytoskeleton, In particular, the Dbl homology domain present in p210(Bcr-Abl) but not in p190(Bcr-Abl) contributes to the stabilization of actin fibers, The modulatory effect of Bcr sequences on actin structure may underlie the apparent pathogenic variations between the different Bcr-Abl fusion proteins.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOL GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [CA43054, R37 CA043054, R01 CA043054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA R, 1995, J CLIN INVEST, V96, P931, DOI 10.1172/JCI118141; BHATIA R, 1994, J CLIN INVEST, V94, P384, DOI 10.1172/JCI117333; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DOWDING C, 1991, BLOOD, V78, P499; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOJI T, 1995, J BIOL CHEM, V279, P27880; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1995, MOL CELL BIOL, V15, P835; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Melo JV, 1996, LEUKEMIA, V10, P751; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; vanRhee F, 1996, BLOOD, V87, P5213, DOI 10.1182/blood.V87.12.5213.bloodjournal87125213; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VERFAILLIE CM, 1992, BLOOD, V79, P2821; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; WilsonRawls J, 1996, CANCER RES, V56, P3426	48	41	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1625	1634		10.1038/sj.onc.1201342	http://dx.doi.org/10.1038/sj.onc.1201342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349495				2022-12-25	WOS:A1997XY63100001
J	Ahmad, S; Alsayed, YM; Druker, BJ; Platanias, LC				Ahmad, S; Alsayed, YM; Druker, BJ; Platanias, LC			The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ALPHA-BETA RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; SUPPRESSOR ACTIVITY; KINASE; CELLS; GENE; ACTIVATION	Interferon (IFN) alpha induces rapid and transient tyrosine phosphorylation of the Src homology 2/Src homology 3 (SH2/SH3)-containing CrkL adaptor protein in a time-and dose-dependent manner. Such phosphorylation is most likely regulated by the Type I interferon receptor (IFNR)-associated Tyk-2 kinase, as suggested by the detection of Type I IFN-dependent tyrosine kinase activity in anti-CrkL immunoprecipitates and the IFN alpha-dependent association of CrkL with Tyk-2 in intact cells. Two other Type I IFNs, IFN beta and IFN omega, also induce tyrosine phosphorylation of CrkL, suggesting that the protein is involved in the signaling pathways of several different Type I IFNs. In the IFN alpha-sensitive U-266 and Daudi cell lines, CrkL interacts via its N terminus SH3 domain with the guanine exchange factor C3G that regulates activation of Rap-1, a small G-protein that exhibits tumor suppressor activity, Thus, tyrosine phosphorylation of CrkL links the functional Type I IFNR complex to the C3G-Rap-1 signaling cascade that mediates growth inhibitory responses.	UNIV ILLINOIS, HEMATOL ONCOL SECT, MBRB, CHICAGO, IL 60607 USA; W SIDE VET ADM MED CTR, CHICAGO, IL 60607 USA; OREGON HLTH SCI UNIV, DIV HEMATOL & MED ONCOL, PORTLAND, OR 97201 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Oregon Health & Science University				Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA73381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; Boussiotis VA, 1996, BLOOD, V88, P1847; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Cook JR, 1996, J BIOL CHEM, V271, P13448, DOI 10.1074/jbc.271.23.13448; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EVINGER M, 1981, J BIOL CHEM, V256, P2113; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLS GL, 1994, BLOOD, V84, P2912; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ODA T, 1994, J BIOL CHEM, V269, P22925; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; Pestka S, 1997, Semin Oncol, V24, pS9; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SOH JM, 1994, J BIOL CHEM, V269, P18102; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Uddin S, 1997, J IMMUNOL, V158, P2390; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	49	85	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29991	29994		10.1074/jbc.272.48.29991	http://dx.doi.org/10.1074/jbc.272.48.29991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374471	hybrid			2022-12-25	WOS:A1997YH61300003
J	DiGennaro, P; Sello, G; Bianchi, D; DAmico, P				DiGennaro, P; Sello, G; Bianchi, D; DAmico, P			Specificity of substrate recognition by Pseudomonas fluorescens N3 dioxygenase - The role of the oxidation potential and molecular geometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDRODIOL DEHYDROGENASE; SUBSTITUTED NAPHTHALENES; BIOCONVERSION	Pseudomonas fluorescens N3 is able to grow on naphthalene as the sole carbon and energy source, The mutant TTC1, blocked at the dihydrodiol dehydrogenase level, which can transform the hydrocarbon into the corresponding dihydrodiol, has been used to produce bioconversion products, To rationalize the different grades of conversion obtained with different substrates, a study was performed using non-naphthalene derivatives, including benzenes, conjugated benzenes, and polycyclic aromatic hydrocarbons, The corresponding diols obtained by bioconversion have been isolated and characterized, ia theoretical model that considers both energy and geometry factors has been proposed to rationalize the experimental data, Good agreement has been found between the calculated values and the experimental results.	UNIV MILAN,DIPARTIMENTO CHIM ORGAN & IND,I-20133 MILAN,ITALY; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICRORGANISMI,I-20133 MILAN,ITALY; IST GUIDO DONEGANI SPA,I-28100 NOVARA,ITALY	University of Milan; University of Milan			Sello, Guido/O-5833-2016	Sello, Guido/0000-0003-2538-9107				BESTETTI G, 1994, APPL MICROBIOL BIOT, V40, P791, DOI 10.1007/BF00173976; Bestetti G, 1995, APPL MICROBIOL BIOT, V44, P306, DOI 10.1007/BF00169921; Bosetti A, 1996, J CHEM TECHNOL BIOT, V66, P375, DOI 10.1002/(SICI)1097-4660(199608)66:4<375::AID-JCTB509>3.0.CO;2-A; *CHEM DES LTD, 1995, CHEMX VERS JUL95; CIDARIA D, 1994, APPL MICROBIOL BIOT, V41, P689, DOI 10.1007/BF00167286; Dagley S., 1986, BACTERIA, V10, P527; DIGENNARO P, 1995, THESIS U STUDI MILAN; ENSLEY BD, 1982, J BACTERIOL, V149, P948, DOI 10.1128/JB.149.3.948-954.1982; GEARY PJ, 1980, METHOD ENZYMOL, V188, P52; GIBSON DT, 1982, OXYGENASES OXYGEN ME, P51; Harayama S., 1989, Genetics of bacterial diversity., P151; KUNTZ ID, 1994, ACCOUNTS CHEM RES, V27, P117, DOI 10.1021/ar00041a001; Maniatis T., 1982, MOL CLONING; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Nugiel DA, 1996, J MED CHEM, V39, P2156, DOI 10.1021/jm960083n; PROVENCHER L, 1994, J ORG CHEM, V59, P2729, DOI 10.1021/jo00089a015; Silverman BD, 1996, J MED CHEM, V39, P2129, DOI 10.1021/jm950589q; SNYDER JP, 1993, 3D QSAR DRUG DESIGN, P336; STEWART JJP, 1990, 527 MOPAC IND U QUAN; Swaminathan P, 1996, J MED CHEM, V39, P2141, DOI 10.1021/jm950579p; TAKIZAWA N, 1994, J BACTERIOL, V176, P2444, DOI 10.1128/JB.176.8.2444-2449.1994	21	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30254	30260		10.1074/jbc.272.48.30254	http://dx.doi.org/10.1074/jbc.272.48.30254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374510	hybrid			2022-12-25	WOS:A1997YH61300042
J	Kasahara, K; Watanabe, Y; Yamamoto, T; Sanai, Y				Kasahara, K; Watanabe, Y; Yamamoto, T; Sanai, Y			Association of Src family tyrosine kinase Lyn with ganglioside G(D3) in rat brain - Possible regulation of Lyn by glycosphingolipid in caveolae-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CENTRAL-NERVOUS-SYSTEM; GPI-ANCHORED PROTEINS; ALPHA-2,8-SIALYLTRANSFERASE GD3 SYNTHASE; DETERGENT-RESISTANT COMPLEXES; ENRICHED MEMBRANE SUBDOMAINS; MONOCLONAL-ANTIBODY AA4; DEVELOPMENTAL-CHANGES; IMMUNOHISTOCHEMICAL LOCALIZATION; NEUROBLASTOMA-CELLS	Association of gangliosides with specific proteins in the central nervous system was examined by co-immunoprecipitation with anti-ganglioside antibody, Protein kinase activity was detected in precipitates with monoclonal antibody to ganglioside G(D3) (R24) from membranal fraction of rat brain, Using in vitro kinase assay, several phosphorylated proteins of 40, 53, 56, and 80 kDa were isolated by gel electrophoresis. Of these proteins, the proteins of 53 and 56 kDa (p55/56) were identified as two isoforms of Src family tyrosine kinase Lyn, based on co-migration during gel electrophoresis, comparative peptide mapping, and sequential immunoprecipitation with anti-lyn antibody, The identification was confirmed using a cDNA expression system in Chinese hamster ovary (CHO) cells, which express solely ganglioside G(M3), the enzymatic substrate of G(D3) synthase, In cotransfection with G(D3) synthase and Lyn expression plasmids, R24 immunoprecipitated Lyn and anti-lyn antibody immunoprecipitated G(D3). R24 treatment of rat primary cerebellar cultures induced Lyn activation and rapid tyrosine phosphorylation of several substrates including mitogen-activated protein kinases, Furthermore, sucrose density gradient analysis showed that Lyn of cerebellum and CHO transfectants were detected in a low density light-scattering band, i,e, the caveolae membrane fraction, R24 immunoprecipitated caveolin from Triton X-100 extract of CHO transfectants, These observations suggest that G(D3) may regulate Lyn in a caveolae-like domain on brain cell membranes.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	Kasahara, K (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM CELL RES,INST MED SCI,BUNKYO KU,3-18-22 HONKOMAGONE,TOKYO 113,JAPAN.			Kasahara, Kohji/0000-0001-7010-8365				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHATTERJEE D, 1992, BRAIN RES, V583, P31, DOI 10.1016/S0006-8993(10)80007-1; Chen S, 1996, NEUROSCIENCE, V71, P89, DOI 10.1016/0306-4522(95)00386-X; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; Draberova L, 1996, IMMUNOLOGY, V87, P141; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; FUKUDA M, 1995, ONCOGENE, V11, P239; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRAUS F, 1984, BRAIN RES, V324, P190, DOI 10.1016/0006-8993(84)90642-5; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HIDARI KIPJ, 1994, EUR J BIOCHEM, V221, P603, DOI 10.1111/j.1432-1033.1994.tb18772.x; HIDARI KIPJ, 1994, FEBS LETT, V353, P25, DOI 10.1016/0014-5793(94)01005-6; KASAHARA K, 1994, ANAL BIOCHEM, V218, P224, DOI 10.1006/abio.1994.1164; Kawashima I, 1996, BRAIN RES, V732, P75, DOI 10.1016/0006-8993(96)00493-3; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOTANI M, 1995, BRAIN RES, V700, P40, DOI 10.1016/0006-8993(95)00923-E; KOTANI M, 1994, GLYCOBIOLOGY, V4, P855, DOI 10.1093/glycob/4.6.855; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MANESS PF, 1992, DEV NEUROSCI-BASEL, V14, P257, DOI 10.1159/000111670; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MORI A, 1991, BIOCHEMISTRY-US, V30, P9341, DOI 10.1021/bi00102a029; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Nara K, 1996, EUR J BIOCHEM, V238, P647, DOI 10.1111/j.1432-1033.1996.0647w.x; NORIHISA Y, 1994, J IMMUNOL, V152, P485; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; OLIVE S, 1995, J NEUROCHEM, V65, P2307; OLIVER C, 1992, J CELL BIOL, V116, P635, DOI 10.1083/jcb.116.3.635; Ortaldo JR, 1996, J LEUKOCYTE BIOL, V60, P533, DOI 10.1002/jlb.60.4.533; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; PURPURA DP, 1978, NATURE, V276, P520, DOI 10.1038/276520a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SANAI Y, 1990, J BIOCHEM-TOKYO, V107, P740, DOI 10.1093/oxfordjournals.jbchem.a123118; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; THANGNIPON W, 1992, NEUROCHEM RES, V17, P45, DOI 10.1007/BF00966864; THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Watanabe Y, 1996, J BIOCHEM-TOKYO, V120, P1020; WELTE K, 1987, J IMMUNOL, V139, P1763; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; YAMAKAWA T, 1978, TRENDS BIOCHEM SCI, V3, P128, DOI 10.1016/S0968-0004(78)80031-0; YAMAMOTO T, 1993, IMMUNOL REV, V132, P187, DOI 10.1111/j.1600-065X.1993.tb00843.x; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x; YUZAKI M, 1992, J NEUROSCI, V12, P4253	79	168	171	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29947	29953		10.1074/jbc.272.47.29947	http://dx.doi.org/10.1074/jbc.272.47.29947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368072	hybrid			2022-12-25	WOS:A1997YG64700082
J	Thomas, SL; Chmelar, RS; Lu, CW; Halvorsen, SW; Nathanson, NM				Thomas, SL; Chmelar, RS; Lu, CW; Halvorsen, SW; Nathanson, NM			Tissue-specific regulation of G-protein-coupled inwardly rectifying K+ channel expression by muscarinic receptor activation in Ovo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC CHICK HEART; GTP-BINDING PROTEINS; ACETYLCHOLINE-RECEPTOR; POTASSIUM CHANNELS; CHOLINERGIC RECEPTORS; OPIOID RECEPTORS; XENOPUS OOCYTES; ATRIAL CELLS; RAT-BRAIN; AGONIST	We investigated the effects of muscarinic acetylcholine receptor stimulation on the expression levels of the G-protein-coupled inwardly rectifying K+ channel (GIRK) subunits using solution hybridization and immunoblot analyses, We report here that treatment of chick embryos in ovo with muscarinic agonist causes decreases in mRNA levels encoding GIRK1 and GIRK4 in atria but does not alter GIRK1 expression in ventricles, In addition, GIRKI protein levels also demonstrate a decrease in atria upon muscarinic acetylcholine receptor stimulation, Numerous receptors couple to the activation of the GIRK family of inwardly rectifying K+ channels; thus, these decreases represent a novel mechanism for regulating physiological responses to chronic agonist exposure.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195; SUNY BUFFALO,DEPT BIOCHEM PHARMACOL,BUFFALO,NY 14260	University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; Gadbut AP, 1996, J BIOL CHEM, V271, P6398, DOI 10.1074/jbc.271.11.6398; GADBUT AP, 1995, LIFE SCI, V56, P1022, DOI 10.1016/0024-3205(95)93756-5; GALPER JB, 1982, J BIOL CHEM, V257, P344; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5030; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HARDEN TK, 1985, J BIOL CHEM, V260, P3060; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; HENRY DJ, 1995, NEUROSCI LETT, V186, P91, DOI 10.1016/0304-3940(95)11289-9; HUNTER DD, 1984, P NATL ACAD SCI-BIOL, V81, P3582, DOI 10.1073/pnas.81.11.3582; KARSCHIN C, 1994, FEBS LETT, V348, P139, DOI 10.1016/0014-5793(94)00590-7; KLEIN WL, 1979, BIOCHEM BIOPH RES CO, V90, P506, DOI 10.1016/0006-291X(79)91264-6; KOPP R, 1990, BIOCHEM J, V269, P73, DOI 10.1042/bj2690073; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LINDEN J, 1987, FASEB J, V1, P119, DOI 10.1096/fasebj.1.2.2440752; Lu C. W., 1995, Society for Neuroscience Abstracts, V21, P1325; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P4876, DOI 10.1021/bi00389a040; MARTIN JM, 1987, J PHARMACOL EXP THER, V240, P683; MCKNIGHT GS, 1988, METHOD ENZYMOL, V159, P299; PAPPANO AJ, 1974, J PHARMACOL EXP THER, V191, P468; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; Spauschus A, 1996, J NEUROSCI, V16, P930; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40	31	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29958	29962		10.1074/jbc.272.47.29958	http://dx.doi.org/10.1074/jbc.272.47.29958			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368074	hybrid			2022-12-25	WOS:A1997YG64700084
J	Colognato, H; MacCarrick, M; ORear, JJ; Yurchenco, PD				Colognato, H; MacCarrick, M; ORear, JJ; Yurchenco, PD			The laminin alpha 2-chain short arm mediates cell adhesion through both the alpha 1 beta 1 and alpha 2 beta 1 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; HEPARIN-BINDING; BASEMENT-MEMBRANES; NEURITE OUTGROWTH; DIFFERENTIAL EXPRESSION; SCHWANN-CELLS; CHAIN GENE; MEROSIN; ISOFORMS; RECEPTOR	Laminin-2, a heterotrimer composed of alpha 2, beta 1, and gamma 1 subunits, is the primary laminin isoform found in muscle and peripheral nerve and is essential for the development and stability of basement membranes in these tissues, Expression of a domain VI-truncated laminin alpha 2-chain results in muscle degeneration and peripheral nerve dysmyelination in the dy(2J) dystrophic mouse, We have expressed amino-terminal domains VI through IVb of the laminin alpha 2-chain, as well as its laminin-1 alpha 1-chain counterpart, to identify candidate cell-interactive functions of this critical region, Using integrin-specific antibodies, recognition sites for the alpha 1 beta 1 and alpha 2 beta 1 integrins were identified in the short arms of both laminin alpha 1- and alpha 2-chain isoforms, Comparisons with a beta-alpha chimeric short arm protein possessing beta 1-chain domain VI further localized these activities to alpha-chain domain VI, In addition, we found that the laminin alpha 2-chain short arm supported neurite outgrowth independent of other laminin-2 subunits, A heparin/heparan sulfate binding activity was also localized to this region of the laminin alpha 2 subunit, These data provide the first evidence that domain VI of the laminin aa-chain mediates interactions with cell surface receptors and suggest that these integrin and heparin binding sites, alone or in concert, may play an important role in muscle and peripheral nerve function.	ROBERT W JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854					Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425, R01-DK48045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048045, R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allamand V, 1997, HUM MOL GENET, V6, P747, DOI 10.1093/hmg/6.5.747; ANDREW SM, 1992, BRIT J DERMATOL, V127, P359, DOI 10.1111/j.1365-2133.1992.tb00454.x; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BROWN JC, 1994, J CELL SCI, V107, P329; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DUBAND JL, 1987, DEVELOPMENT, V101, P461; DUBAND JL, 1992, DEVELOPMENT, V116, P585; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGVALL E, 1992, EXP CELL RES, V198, P115, DOI 10.1016/0014-4827(92)90156-3; Engvall E, 1996, J CELL BIOCHEM, V61, P493; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GEE SH, 1993, J BIOL CHEM, V268, P14972; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HSIAO LL, 1991, J CLIN INVEST, V87, P811, DOI 10.1172/JCI115084; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MECHTERSHEIMER G, 1994, LAB INVEST, V70, P740; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; Nissinen M, 1996, AM J HUM GENET, V58, P1177; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PERKINS CS, 1981, DEV BRAIN RES, V1, P213, DOI 10.1016/0165-3806(81)90109-7; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; SCHULER F, 1995, J CELL SCI, V108, P3795; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yao CC, 1996, J CELL SCI, V109, P3139; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	62	87	90	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29330	29336		10.1074/jbc.272.46.29330	http://dx.doi.org/10.1074/jbc.272.46.29330			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361014	hybrid			2022-12-25	WOS:A1997YF68400073
J	Vogan, KJ; Gros, P				Vogan, KJ; Gros, P			The C-terminal subdomain makes an important contribution to the DNA binding activity of the Pax-3 paired domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; CRYSTAL-STRUCTURE; HOMEODOMAIN; RECOGNITION; MUTATION; PROTEIN; GENE; IDENTIFICATION; SEQUENCE; FAMILY	The recognition of DNA targets by Pax-3 is achieved through the coordinate use of two distinct helix-turn-helix-based DNA-binding modules: a paired domain, composed of two structurally independent subdomains joined by a short linker, and a paired-type homeodomain, In mouse, the activity of the Pax-3 paired domain is modulated by an alternative splicing event in the paired domain linker region that generates isoforms (Q(+) and Q(-)) with distinct C-terminal subdomain-mediated DNA-binding properties, In this study, we have used derivatives of a classical high affinity paired domain binding site (CD19-2/A) to derive an improved consensus recognition sequence for the Pax-3 C-terminal subdomain, This new consensus differs at six out of eight positions from the C-terminal subdomain recognition motif present in the parent CD19-2/A sequence, and includes a 5'-TT-3' dinucleotide at base pairs 15 and 16 that promotes high affinity binding by both Pax-3 isoforms, However, with a less favorable guanine at position 15, only the Q(-) isoform retains high affinity binding to this sequence, suggesting that this alternative splicing event might serve to stabilize binding to suboptimal recognition sequences. Finally, mutagenic analysis of the linker demonstrates that both the sequence and the spacing in this region contribute to the enhanced DNA-binding properties of the Pax-3/Q(-) isoform. Altogether, our studies establish a clear role for the Pax-3 C-terminal subdomain in DNA recognition and, thus, provide insights into an important mechanism by which Pax proteins achieve distinct target specificities.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University				Vogan, Kyle/0000-0001-9565-9665				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Bertuccioli C, 1996, DEVELOPMENT, V122, P2673; BOBER E, 1994, DEVELOPMENT, V120, P603; CALZONE FJ, 1988, GENE DEV, V2, P1074, DOI 10.1101/gad.2.9.1074; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fujioka M, 1996, DEVELOPMENT, V122, P2697; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Jun S, 1996, DEVELOPMENT, V122, P2639; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Phelps DE, 1996, J BIOL CHEM, V271, P7978, DOI 10.1074/jbc.271.14.7978; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	38	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28289	28295		10.1074/jbc.272.45.28289	http://dx.doi.org/10.1074/jbc.272.45.28289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353283	hybrid			2022-12-25	WOS:A1997YF21900023
J	Funderburgh, JL; Corpuz, LM; Roth, MR; Funderburgh, ML; Tasheva, ES; Conrad, GW				Funderburgh, JL; Corpuz, LM; Roth, MR; Funderburgh, ML; Tasheva, ES; Conrad, GW			Mimecan, the 25-kDa corneal keratan sulfate proteoglycan, is a product of the gene producing osteoglycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOINDUCTIVE FACTOR; BOVINE BONE; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PROTEIN; UNIQUE; PURIFICATION; ISOFORMS; SEQUENCE; LUMICAN	Bovine cornea contains three unique keratan sulfate proteoglycans (KSPGs), of which two (lumican and keratocan) have been characterized using molecular cloning, The gene for the third protein (KSPG25) has not been identified, This study examined the relationship between the KSPG25 protein and the gene for osteoglycin, a 12-kDa bone glycoprotein, The N-terminal amino acid sequence of KSPG25 occurs in osteoglycin cDNA cloned from bovine cornea, The osteoglycin amino acid sequence makes up the C-terminal 47% of the deduced sequence of the KSPG25 protein, Antibodies to osteoglycin reacted with intact corneal KSPG, with KSPG25 protein, and with a 36-kDa protein, distinct from lumican and keratocan, KSPG25-related proteins, not modified with keratan sulfate, were also detected in several connective tissues, Northern blot analysis showed mRNA transcripts of 2.4, 2.5, and 2.6 kilobases in numerous tissues with the 2.4-kilobase transcript enriched in ocular tissues, Ribonuclease protection analysis detected several protected KSPG25 mRNA fragments, suggesting alternate splicing of KSPG25 transcripts, We conclude that the full-length translation product of the gene producing osteoglycin is a corneal keratan sulfate proteoglycan, also present in many non-corneal tissues without keratan sulfate chains, The multiple size protein products of this gene appear to result from ia situ proteolytic processing and/or alternative splicing of mRNA, The name mimecan is proposed for this gene and its products.			Funderburgh, JL (corresponding author), KANSAS STATE UNIV,DIV BIOL,ACKERT HALL,MANHATTAN,KS 66506, USA.				NATIONAL EYE INSTITUTE [R01EY009368, R01EY000952] Funding Source: NIH RePORTER; NEI NIH HHS [EY09368, EY00952] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BENTZ H, 1991, MATRIX, V11, P269, DOI 10.1016/S0934-8832(11)80234-9; BENTZ H, 1990, J BIOL CHEM, V265, P5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD GW, 1982, J BIOL CHEM, V257, P464; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DASCH JR, 1993, CONNECT TISSUE RES, V30, P11, DOI 10.3109/03008209309032927; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1983, CURR EYE RES, V2, P769; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Hascall V C, 1982, Prog Clin Biol Res, V110 Pt B, P3; Hassell J. R., 1997, Investigative Ophthalmology and Visual Science, V38, pS681; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; JOST CJ, 1991, J BIOL CHEM, V266, P13336; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; PIATIGORSKY J, 1994, EXS, V71, P241; Sax CM, 1996, J BIOL CHEM, V271, P33568, DOI 10.1074/jbc.271.52.33568; Suzuki M., 1939, J BIOCHEM, V30, P185, DOI [10.1093/oxfordjournals.jbchem.a125896, DOI 10.1093/OXFORDJOURNALS.JBCHEM.A125896]; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304	27	152	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28089	28095		10.1074/jbc.272.44.28089	http://dx.doi.org/10.1074/jbc.272.44.28089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346963	hybrid			2022-12-25	WOS:A1997YD47300089
J	Iivanainen, A; Kortesmaa, J; Sahlberg, C; Morita, T; Bergmann, U; Thesleff, I; Tryggvason, K				Iivanainen, A; Kortesmaa, J; Sahlberg, C; Morita, T; Bergmann, U; Thesleff, I; Tryggvason, K			Primary structure, developmental expression, and immunolocalization of the murine laminin alpha 4 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; HEPARAN-SULFATE PROTEOGLYCAN; HOMOZYGOUS NONSENSE MUTATION; A-CHAIN; MULTIDOMAIN PROTEIN; GENE LAMC2; CHROMOSOMAL ASSIGNMENT; NEUROMUSCULAR-JUNCTION; TISSUE DISTRIBUTION; MUSCULAR-DYSTROPHY	The complete primary structure of the mouse laminin alpha 4 chain was derived from cDNA clones. The translation product contains a 24-residue signal peptide preceding the mature alpha 4 chain of 1,792 residues. Northern analysis on whole mouse embryos revealed that the expression was weak at day 7, but it later increased and peaked at day 15. In adult tissues the strongest expression was observed in lung and cardiac and skeletal muscles. Weak expression was also seen in other adult tissues such as brain, spleen, liver, kidney, and testis. By in situ hybridization of fetal and newborn tissues, expression of the laminin alpha 4 chain was mainly localized to mesenchymal cells. Strong expression was seen in the villi and submucosa of the developing intestine, the mesenchymal stroma surrounding the branching lung epithelia, and the external root sheath of vibrissae follicles, as well as in cardiac and skeletal muscle fibers. In the developing kidney, intense but transient expression was associated with the differentiation of epithelial kidney tubules from the nephrogenic mesenchyme. Immunohistologic staining with affinity-purified IgG localized the laminin alpha 4 chain primarily to lung septa, heart, and skeletal muscle, capillaries, and perineurium.	KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, DIV MATRIX BIOL, S-17177 STOCKHOLM, SWEDEN; UNIV OULU, BIOCTR, SF-90570 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, SF-90570 OULU, FINLAND; UNIV HELSINKI, FAC VET MED, DEPT ANAT & EMBRYOL, FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, INST BIOTECHNOL, FIN-00014 HELSINKI, FINLAND	Karolinska Institutet; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; University of Helsinki								ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; BREITSCHOPF H, 1992, ACTA NEUROPATHOL, V84, P581; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; EHRIG K, 1989, P NATL ACAD SCI USA, V85, P3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GILBERT SF, 1991, DEV BIOL, P582; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1985, J CELL BIOCHEM, V27, P317, DOI 10.1002/jcb.240270402; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; MCGRATH JA, 1995, GENOMICS, V29, P282, DOI 10.1006/geno.1995.1246; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Nielsen H, 1996, PROTEINS, V24, P165, DOI 10.1002/(SICI)1097-0134(199602)24:2<165::AID-PROT4>3.0.CO;2-I; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; NOAKES PG, 1995, NAT GENET, V10, P400, DOI 10.1038/ng0895-400; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; PULKKINEN L, 1994, GENOMICS, V24, P357, DOI 10.1006/geno.1994.1627; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SUGIYAMA S, 1995, EUR J BIOCHEM, V228, P120, DOI 10.1111/j.1432-1033.1995.0120o.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; UTANI A, 1995, LAB INVEST, V72, P300; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; [No title captured]	59	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27862	27868		10.1074/jbc.272.44.27862	http://dx.doi.org/10.1074/jbc.272.44.27862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346933	hybrid			2022-12-25	WOS:A1997YD47300059
J	Kurachi, H; Wada, Y; Tsukamoto, N; Maeda, M; Kubota, H; Hattori, M; Iwai, K; Minato, N				Kurachi, H; Wada, Y; Tsukamoto, N; Maeda, M; Kubota, H; Hattori, M; Iwai, K; Minato, N			Human SPA-1 gene product selectively expressed in lymphoid tissues is a specific GTPase-activating protein for Rap1 and Rap2 - Segregate expression profiles from a rap1GAP gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; BINDING PROTEIN; SH3 DOMAIN; RAS; GRB2; VAV; TRANSFORMATION; IDENTIFICATION	Mouse Spa-1 gene with a region homologous to the human rap1GAP gene is transcriptionally induced in the lymphocytes by mitogenic stimulation, Herein we have cloned a cDNA for its human counterpart. SPA-1 cDNA encodes a 130-kDa protein (p130(SPA-1)) consisting of proline-rich regions and rap1GAP-related domain followed by a coiled coil stretch. Baculovirally expressed p130(SPA-1) exhibited GTPase-activating protein (GAP) activity for Rap1 and Rap2, but not for Ras, Rho, Cdc42, Pac, and Ran, with comparable specific activity to the rap1GAP gene product (p85/95(rap1GAP)). In the cells, p130(SPA-1) was mostly localized at the perinuclear membranous region co-localizing with Rap1 and Rap2, Expression of SPA-1 and rap1GAP genes tended to be segregate in various tissues, lymphoid tissues expressing abundant SPA-1 transcript without rap1GAP, while those such as brain, kidney, and pancreas exhibiting rap1GAP mRNA with little SPA-1, Promyelocytic HL-60 cells, which expressed p130(SPA-1) With little p85/95(rap1GAP) in uninduced state, showed progressive decline in p130(SPA-1) and conversely drastic increase in p85/95(rap1GAP) as they ceased from proliferation and differentiated into macrophages by 12-O-tetradecanoylphorbol-13-acetate. These results suggested that products of SPA-1 and rap1GAP genes, albeit comparable GAP activity for Rap1 and Rap2, functioned in the distinct contexts depending on cell types and/or states.	KYOTO UNIV,GRAD SCH MED,DEPT IMMUNOL & CELL BIOL,SAKYO KU,KYOTO 606,JAPAN; CHUGAI RES INST MOL MED,IBARAKI,OSAKA 30014,JAPAN	Kyoto University			IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HATTORI M, 1995, MOL CELL BIOL, V15, P552, DOI 10.1128/MCB.15.1.552; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; *TECTS, 1993, CELL, V75, P1305; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; Wada Y, 1997, GENOMICS, V39, P66, DOI 10.1006/geno.1996.4464; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS J, 1994, CYTOGENET CELL GENET, V66, P18, DOI 10.1159/000133655; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	104	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28081	28088		10.1074/jbc.272.44.28081	http://dx.doi.org/10.1074/jbc.272.44.28081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346962	hybrid			2022-12-25	WOS:A1997YD47300088
J	Szardenings, M; Tornroth, S; Mutulis, F; Muceniece, R; Keinanen, K; Kuusinen, A; Wikberg, JES				Szardenings, M; Tornroth, S; Mutulis, F; Muceniece, R; Keinanen, K; Kuusinen, A; Wikberg, JES			Phage display selection on whole cells yields a peptide specific for melanocortin receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INSECT CELLS; COMBINATORIAL LIBRARIES; RADIOLIGAND BINDING; FILAMENTOUS PHAGE; EXPRESSION SYSTEM; LIGAND-BINDING; AFFINITY; IDENTIFICATION; ANTAGONISTS	A phage display system for the selection of peptides binding to heterologously expressed human melanocortin receptor 1 on the surface of insect cells has been established. It could be shown that phage particles displaying the natural ligand alpha-melanocyte-stimulating hormone bind selectively to cells expressing this receptor and that these phages exhibit biological activity on mouse B16F1 melanoma cells. Insect cells were superior to other cell lines tested and have been used to select binders from a small library, in which critical determinants (Phe(7)-Arg(8)-Trp(9)) were kept, whereas the flanking regions where allowed to variate freely. One peptide displaying little similarity with native hormone was found that binds to the receptor also in its free form with an affinity of 7 nM. It showed a remarkable selectivity for this receptor, because it binds to the other melanocortin receptor subtypes with a maximum affinity of 21 mu M. This is the first time phage display has been used successfully with G-protein-coupled receptors lacking an extracellular binding domain.	LATVIAN INST ORGAN SYNTH,DEPT MED CHEM,LV-1006 RIGA,LATVIA; LATVIAN INST ORGAN SYNTH,PHARMACOL LAB,LV-1006 RIGA,LATVIA; VTT BIOTECHNOL & FOOD RES,FIN-02044 ESPOO,FINLAND	Latvian Institute of Organic Synthesis; Latvian Institute of Organic Synthesis; VTT Technical Research Center Finland	Szardenings, M (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT PHARMACEUT PHARMACOL,BOX 591,S-75124 UPPSALA,SWEDEN.		Keinanen, Kari/E-9122-2010; Törnroth-Horsefield, Susanna/B-2702-2010	Tornroth-Horsefield, Susanna/0000-0002-9435-8243; Szardenings, Michael/0000-0003-1553-9765				ADAN RAH, 1994, EUR J PHARM-MOLEC PH, V269, P331, DOI 10.1016/0922-4106(94)90041-8; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; CHUNG CT, 1993, METHOD ENZYMOL, V218, P621; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cortese Riccardo, 1995, Current Opinion in Biotechnology, V6, P73, DOI 10.1016/0958-1669(95)80012-3; DOOLEY CT, 1995, PEPTIDE RES, V8, P124; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; DOORBAR J, 1994, J MOL BIOL, V244, P361, DOI 10.1006/jmbi.1994.1736; DOYLE MV, 1995, COMBINATORIAL LIB SY, P159; EBERLE AN, 1988, MELANOTROPINS CHEM P, P210; EISINGER DP, 1996, BIOTECHNIQUES, V22, P250; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAM H, 1993, J IMMUNOL METHODS, V161, P169, DOI 10.1016/0022-1759(93)90292-F; HaskellLuevano C, 1996, J MED CHEM, V39, P432, DOI 10.1021/jm950407s; Hidajat R, 1997, BIOTECHNIQUES, V22, P32, DOI 10.2144/97221bm04; Hirschmann R, 1996, J MED CHEM, V39, P2441, DOI 10.1021/jm960281e; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HRUBY VJ, 1995, J MED CHEM, V38, P3454, DOI 10.1021/jm00018a005; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JACOBSSON K, 1995, BIOTECHNIQUES, V18, P878; JACOBSSON K, 1997, MICROBIOL RES, V152, P1; Kay B. K, 1996, PHAGE DISPLAY PEPTID; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; KUUSINEN A, 1995, EUR J BIOCHEM, V233, P720, DOI 10.1111/j.1432-1033.1995.720_3.x; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUNEC J, 1992, MELANOMA RES, V2, P5, DOI 10.1097/00008390-199205000-00002; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1991, PROTEIN ENG, V4, P955, DOI 10.1093/protein/4.8.955; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; ODONOHUE TL, 1982, PEPTIDES, V3, P353, DOI 10.1016/0196-9781(82)90098-5; ONEIL KT, 1994, METHOD ENZYMOL, V245, P370; PARMLEY SF, 1989, ADV EXP MED BIOL, V251, P215; PRUSIS P, 1995, BIOCHEM BIOPH RES CO, V210, P205, DOI 10.1006/bbrc.1995.1647; QUILLAN JM, 1995, P NATL ACAD SCI USA, V92, P2894, DOI 10.1073/pnas.92.7.2894; ROBERTS BL, 1992, GENE, V121, P9, DOI 10.1016/0378-1119(92)90156-J; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; SAHM UG, 1994, PEPTIDES, V15, P1297, DOI 10.1016/0196-9781(94)90157-0; Schioth HB, 1996, BIOCHEM BIOPH RES CO, V221, P807, DOI 10.1006/bbrc.1996.0678; Schioth HB, 1996, PHARMACOL TOXICOL, V79, P161, DOI 10.1111/j.1600-0773.1996.tb00261.x; SCHIOTH HB, 1995, EUR J PHARM-MOLEC PH, V288, P311, DOI 10.1016/0922-4106(95)90043-8; Schioth HB, 1996, LIFE SCI, V59, P797, DOI 10.1016/0024-3205(96)00370-0; Schioth HB, 1996, EUR J PHARMACOL, V314, P381, DOI 10.1016/S0014-2999(96)00566-3; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SZARDENINGS M, 1990, GENE, V94, P1, DOI 10.1016/0378-1119(90)90460-9; TESAR M, 1995, IMMUNOTECHNOLOGY, V1, P53, DOI 10.1016/1380-2933(95)00005-4; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKHAM TJ, 1992, BIOTECHNOL PROGR, V8, P391, DOI 10.1021/bp00017a003; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362; ZUCKERMANN RN, 1994, J MED CHEM, V37, P2678, DOI 10.1021/jm00043a007	65	72	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27943	27948		10.1074/jbc.272.44.27943	http://dx.doi.org/10.1074/jbc.272.44.27943			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346944	hybrid			2022-12-25	WOS:A1997YD47300070
J	Wang, L; Fast, DG; Attie, AD				Wang, L; Fast, DG; Attie, AD			The enzymatic and non-enzymatic roles of protein-disulfide isomerase in apolipoprotein B secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; HUMAN PROLYL 4-HYDROXYLASE; RETINOL-BINDING PROTEIN; ACTIVE-SITE CYSTEINE; RAT HEPATOMA-CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; HEPG2 CELLS; FATTY-ACIDS	Secretion of apolipoprotein B (apoB) from mammalian cells requires the presence of functional microsomal triglyceride transfer protein (MTP). We previously reported that co-expressing the human intestinal form of apoB, B48, with both subunits of human MTP in oleate-treated Sf21 cells led to a dramatic induction of B48 secretion. Deletion mutagenesis studies showed that the cysteine-enriched amino terminus of apoB was necessary for the MTP responsiveness (Gretch, D. G., Sturley, S. L., Wang, L., Dunning, A., Grunwald, K. A. A., Wetterau, J. R., Yao, Z., Talmud, P., and Attie, A. D. (1996) J. Biol. Chem. 271, 8682-8691). We therefore hypothesized that the small subunit of MTP, protein-disulfide isomerase (PDI), plays a role in apoB secretion by facilitating correct disulfide bond formation. To determine whether the enzymatic activities of PDI are important for MTP-stimulated apoB secretion, the wild type PDI subunit was replaced with an active site mutant, mPDI (Cys(36)--> Ser/Cys(380) --> Ser), lacking both disulfide shuffling and redox activities. MTP containing mPDI was fully functional in promoting apoB and triglyceride secretion. Therefore, the shufflase and redox activities of PDI are not necessary for the function of MTP. Since PDI exists in large molar excess over the other subunit of MTP, the role of free PDI (independent of the MTP complex) was investigated. PDI or mPDI was co-expressed with B48 and B17, a fragment encompassing the amino-terminal 17% of apoB. Mutant PDI significantly and specifically reduced the accumulation of the B17 and E48 both intracellularly and in the culture medium. The reduction was partially eliminated by the protease inhibitor N-acetyl-leucyl-leucyl-norleucinal, consistent with rapid co-or post-translational degradation of apoB in the presence of mPDI. Treating the cells with oleate reversed the effect of mPDI on B48 secretion in a dose-dependent manner, but had no effect on B17. In conclusion: 1) the role of PDI in the MTP complex involves functions other than its known enzymatic activities; 2) one or both of the enzymatic activities of free PDI is/are important for the MTP-independent steps of apoB secretion; 3) oleate can affect apoB secretion at high physiological concentrations and compensate for the insufficiency of PDI activities.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT COMPARAT BIOSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL37251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BONIFACINO JS, 1994, MODERN CELL BIOL CEL, V15, P137; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIVERS PT, 1995, EMBO J, V15, P2559; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DAVIS RA, 1982, J BIOL CHEM, V257, P908; Dirlam KA, 1996, PROTEIN EXPRES PURIF, V8, P489, DOI 10.1016/S1046-5928(96)90129-1; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; GRETCH DG, 1991, P NATL ACAD SCI USA, V88, P8530, DOI 10.1073/pnas.88.19.8530; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; KAJI EH, 1993, J BIOL CHEM, V268, P22188; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LABOISSIERE MCA, 1995, PROTEIN EXPRES PURIF, V6, P700, DOI 10.1006/prep.1995.1092; Lamberg A, 1996, BIOCHEM J, V315, P533, DOI 10.1042/bj3150533; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; MELHUS H, 1992, J BIOL CHEM, V267, P12036; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PATSCH W, 1983, J CLIN INVEST, V72, P371, DOI 10.1172/JCI110977; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALAM WH, 1988, BIOCHEM J, V251, P809, DOI 10.1042/bj2510809; SAUNDERS AJ, 1993, PROTEIN SCI, V2, P1183, DOI 10.1002/pro.5560020713; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Shelness GS, 1996, J LIPID RES, V37, P408; SINGH R, 1990, J AM CHEM SOC, V112, P1190, DOI 10.1021/ja00159a046; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1984, J BIOL CHEM, V259, P863; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	69	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27644	27651		10.1074/jbc.272.44.27644	http://dx.doi.org/10.1074/jbc.272.44.27644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346903	hybrid			2022-12-25	WOS:A1997YD47300029
J	Suzuki, J; Kaziro, Y; Koide, H				Suzuki, J; Kaziro, Y; Koide, H			An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-I	ONCOGENE			English	Article						R-Ras; apoptosis; PI3K; MAPK; IGF-I; Ras	GROWTH-FACTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; PROTO-ONCOGENES; H-RAS; APOPTOSIS; EXPRESSION; RECEPTOR; IDENTIFICATION	R-Ras belongs to a family of low molecular weight GTP-binding proteins and exhibits 55% amino acid identity to H-Ras. It has been demonstrated that H-Ras inhibits cell death caused by interleukin-3 (IL-3) withdrawal in BaF3 cells (Kinoshita rt al. (1995b); Terada et al. (1995)). In the present study, we examined whether R-Ras also rescues BaF3 cells from the factor-deprived cell death, To do this, several BaF3 transfectants were established, in which expression of wild-type as well as mutant R-Ras was regulated by an inducible promoter. Using these transfectants, we found that expression of an activated R-Ras mutant, R-Ras (Q87L), suppressed the death of IL-3-deprived BaF3 cells. On the other hand, expression of the wild-type and the dominant-negative mutant of R-Ras showed no inhibitory effect on cell death, indicating that R-Ras.GTP abrogated cell death caused by deprivation of IL-3, Furthermore, it was found that IGF-I in serum was required for the anti-apoptotic activity of R-Ras, Suppression of cell death by R-Ras(Q87L) was inhibited by wortmannin, LY294002 (phosphatidylinositol 3-kinase (PI3K) inhibitors), or PD98059 (inhibitor for MEK, a specific activator of mitogen-activated protein kinase (MAPK)), In addition, we have shown that, in HEK293 cells, R-Ras and IGF-I could activate MAPK synergistically. Also, PI3K activity was co-immunoprecipitated with an activated mutant of R-Ras. These results suggest that R-Ras in collaboration with IGF-I suppressed apoptotic cell death of BaF3 caused by IL-3 deprivation, presumably by modulating the activitites of MAPK and PI3K.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN	Tokyo Institute of Technology			Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONSCIENCE JF, 1986, EMBO J, V5, P317, DOI 10.1002/j.1460-2075.1986.tb04215.x; Cormier F, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104811; COX AD, 1994, ONCOGENE, V9, P3281; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Minshall C, 1996, J IMMUNOL, V156, P939; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; REY I, 1994, ONCOGENE, V9, P685; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	45	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1689	1697		10.1038/sj.onc.1201333	http://dx.doi.org/10.1038/sj.onc.1201333			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349502				2022-12-25	WOS:A1997XY63100008
J	Hoivik, D; Willett, K; Wilson, C; Safe, S				Hoivik, D; Willett, K; Wilson, C; Safe, S			Estrogen does not inhibit 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; CYTOCHROME P450IA1; GENE-EXPRESSION; MESSENGER-RNA; TRANSIENT EXPRESSION; ISOLATED HEPATOCYTES; DOWN-REGULATION; RECEPTOR; INDUCTION; CYP1A1	The estrogen receptor and aryl hydrocarbon receptor (AhR) are coexpressed in several Ah and estrogen-responsive human breast cancer cell lines. However, a recent study reported that 17 beta-estradiol (E2) inhibited Ah responsiveness in mouse Hepa 1c1c7 hepatoma cells (Kharat, I., and Saatcioglu, F. (1996) J. Biol. Chem. 271, 10533-10537), and therefore, estrogen receptor-AhR cross-talk was reinvestigated in MCF-7 and mouse Hepa 1c1c7 cells, Treatment of 1MCF-7 or Hepa 1c1c7 cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) resulted in induction of CYP1A1-dependent activity and mRNA levels, Treatment of both cell lines with E2 had no effect on basal or TCDD-inducible CYP1A1-dependent activity or mRNA levels, In MCF-7 and Hepa 1c1c7 cells transiently transfected with an Ah-responsive plasmid containing the 5'-regulatory region of the human CYP1A1 gene fused to the chloramphenicol acetyltransferase reporter gene 10 nM TCDD significantly induced chloramphenicol acetyltransferase activity; in cells cotreated with TCDD plus E2 the induced response was not affected by the hormone, Nuclear extracts from cells treated with dimethyl sulfoxide, E2, TCDD, and TCDD plus E2 were incubated with the [P-32]dioxin-responsive element and analyzed by gel electrophoretic mobility shift assays, A retarded band associated with formation of a [P-32]dioxin-responsive element-AhR complex was observed in nuclear extracts from cells treated with TCDD or TCDD plus E2 (cotreated), Collectively these studies suggest that E2 does not modulate AhR-mediated CYP1A1 gene expression in MCF-7 or Hepa 1c1c7 cells.	TEXAS A&M UNIV,DEPT PHYSIOL & PHARMACOL,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station					NIEHS NIH HHS [ESO3843, ESO5734] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005734, R01ES003843] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARKER CW, 1992, J BIOL CHEM, V267, P8050; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BEIGEL L, 1990, J STEROID BIOCH MOL, V37, P725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUAN R, 1995, TOXICOLOGIST, V15, P1253; FUKUDA Y, 1994, BIOCHEM PHARMACOL, V47, P1187, DOI 10.1016/0006-2952(94)90391-3; GIERTHY JF, 1993, CANCER RES, V53, P3149; HARPER N, 1994, MOL CELL ENDOCRINOL, V104, P47, DOI 10.1016/0303-7207(94)90050-7; HARRIS M, 1990, TOXICOL APPL PHARM, V105, P243, DOI 10.1016/0041-008X(90)90186-X; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOHNE M, 1990, FEBS LETT, V273, P219, DOI 10.1016/0014-5793(90)81089-7; ISRAEL DI, 1985, J BIOL CHEM, V260, P5648; KAWAJIRI K, 1991, JPN J CANCER RES, V82, P1325, DOI 10.1111/j.1349-7006.1991.tb01800.x; KELLERMANN G, 1973, NEW ENGL J MED, V289, P934, DOI 10.1056/NEJM197311012891802; KENNEDY SW, 1994, ANAL BIOCHEM, V222, P217, DOI 10.1006/abio.1994.1476; Kharat I, 1996, J BIOL CHEM, V271, P10533, DOI 10.1074/jbc.271.18.10533; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; PORTER W, 1995, TOXICOLOGIST, V15, P1261; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; SAFE SH, 1995, PHARMACOL THERAPEUT, V67, P247, DOI 10.1016/0163-7258(95)00017-B; SAMBROOK J, 1989, MOL CLONING LAB MANU, P187; SCHOLLER A, 1994, MOL PHARMACOL, V45, P944; SIVARAMAN L, 1994, CANCER RES, V54, P3692; SUNDSTROM S, 1989, BIOCHEM PHARMACOL, V38, P2215, DOI 10.1016/0006-2952(89)90079-8; TEIFELD RM, 1989, DNA-J MOLEC CELL BIO, V8, P329, DOI 10.1089/dna.1.1989.8.329; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; THOMSEN JS, 1995, TOXICOLOGIST, V15, P1270; TUKEY RH, 1982, CELL, V31, P275, DOI 10.1016/0092-8674(82)90427-5; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; VOGEL C, 1994, ARCH TOXICOL, V68, P303, DOI 10.1007/s002040050073; Wang WL, 1996, BRIT J CANCER, V73, P316, DOI 10.1038/bjc.1996.55; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; ZACHAREWSKI T, 1989, ARCH BIOCHEM BIOPHYS, V272, P344, DOI 10.1016/0003-9861(89)90228-2; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707	35	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30270	30274		10.1074/jbc.272.48.30270	http://dx.doi.org/10.1074/jbc.272.48.30270			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374512	hybrid			2022-12-25	WOS:A1997YH61300044
J	LeMaster, DM; Springer, PA; Unkefer, CJ				LeMaster, DM; Springer, PA; Unkefer, CJ			The role of the buried aspartate of Escherichia coli thioredoxin in the activation of the mixed disulfide intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE CYSTEINE; BOND FORMATION; CRYSTAL-STRUCTURE; ISOMERASE; RESIDUES; CATALYSIS; DSBA; RESOLUTION; REACTIVITY; IONIZATION	The structurally homologous protein disulfide isomerases and thioredoxins exhibit a 10(5) variation of redox equilibria. It is demonstrated that the kinetic distinction among these protein family members lies primarily in the rate of breakdown of the mixed disulfide intermediate, The conserved buried acid group serves as a proton transfer catalyst for the buried active site cysteine in the formation and breakdown of the mixed disulfide, The reduction rats of Escherichia coli thioredoxin by dithiothreitol is directly proportional to the fraction of Asp-26 in the protonated farm over the pH range of 6-9. The kinetic role of Asp-26 is further probed via differential solvent kinetic isotope effect measurements versus a D26N variant, The differential solvent isotope effect of 0.6 is consistent with a direct proton donation to the thiolate leaving group (Cys-35) via an enforced general acid catalysis by trapping mechanism, Such a donation necessitates a structural rearrangement as these two buried side chains are separated by 6 Angstrom in both the oxidized and reduced forms of the protein.			LeMaster, DM (corresponding author), LOS ALAMOS NATL LAB,CHEM SCI & TECHNOL GRP 4,POB 1663,LOS ALAMOS,NM 87545, USA.							CREIGHTON TE, 1975, J MOL BIOL, V96, P767, DOI 10.1016/0022-2836(75)90151-5; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; DYSON HJ, 1991, BIOCHEMISTRY-US, V30, P4262, DOI 10.1021/bi00231a023; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GILBERT HF, 1977, J AM CHEM SOC, V99, P7931, DOI 10.1021/ja00466a029; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Kortemme T, 1996, BIOCHEMISTRY-US, V35, P14503, DOI 10.1021/bi9617724; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LEMASTER DM, 1988, BIOCHEMISTRY-US, V27, P142, DOI 10.1021/bi00401a022; LeMaster DM, 1996, J AM CHEM SOC, V118, P9255, DOI 10.1021/ja960877r; LeMaster DM, 1996, BIOCHEMISTRY-US, V35, P14876, DOI 10.1021/bi961607o; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MILLS R, 1976, CHEM SOC REV, V5, P215, DOI 10.1039/cs9760500215; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHEPPELE SE, 1972, CHEM REV, V72, P511, DOI 10.1021/cr60279a004; SCHOWEN KB, 1982, METHDOS ENZYMOL, V87, P275; Schowen R. L., 1972, PROGR PHYS ORG CHEM, V9, P275; SINGH R, 1990, J AM CHEM SOC, V112, P6304, DOI 10.1021/ja00173a018; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Takahashi N, 1996, BIOCHEMISTRY-US, V35, P8342, DOI 10.1021/bi960465v; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	33	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29998	30001		10.1074/jbc.272.48.29998	http://dx.doi.org/10.1074/jbc.272.48.29998			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374473	hybrid			2022-12-25	WOS:A1997YH61300005
J	Bell, LC; Guengerich, FP				Bell, LC; Guengerich, FP			Oxidation kinetics of ethanol by human cytochrome P450 2E1 - Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b(5) on steady-state kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; FLAVIN-CONTAINING MONOOXYGENASES; N-NITROSODIMETHYLAMINE; METHANE MONOOXYGENASE; INDUCIBLE CYTOCHROME-P-450; ALIPHATIC HYDROXYLATION; CATALYTIC PROPERTIES; MULTIPLE PRODUCTS; ELECTRON-TRANSFER; DEUTERIUM	A number of cytochrome P450 (P450) 2E1 substrates are known to show kinetic deuterium isotope effects of similar to 5 on K-m (K-D = K-D(m)/K-H(m)), but not on k(cat), in rat liver microsomes (e.g. N-nitrosodimethylamine, ethanol, and CH2Cl2). We observed K-D(m) values of 3-5 for recombinant human P450 2E1-catalyzed ethanol oxidation. Replacing NADPH and O-2 with the oxygen surrogate cumene hydroperoxide yielded similar results. Ferric P450 2E1 reduction was fast (k > 1000 min(-1)) even in the absence of substrate. These results indicate that the basis for the increase in K-m is in the latter portion of the catalytic cycle, The intrinsic isotope effect ((D)k) for ethanol oxidation was determined (competitively) to be 3.8, indicating that C-H bond cleavage is isotopically sensitive. Presteady-state studies showed a burst of product formation (k = 410 min(-1)), with the burst amplitude corresponding to the P450 concentration, Deuteration of ethanol resulted in an isotope effect of 3.2 on the rate of the burst. We conclude that product release is rate-limiting in the oxidation of ethanol to acetaldehyde by P450 2E1. The steady-state kinetics can be described by a paradigm in which the k(cat) approximates the rate of product release, and K-m is an expression in which the denominator is dominated by the rate of C-H bond breaking.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [T32 ES0728, P30 ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMET Y, 1994, BIOCHEM BIOPH RES CO, V203, P1168, DOI 10.1006/bbrc.1994.2305; ANDERSEN ME, 1994, TOXICOL APPL PHARM, V128, P158, DOI 10.1006/taap.1994.1193; BEATY NB, 1981, J BIOL CHEM, V256, P4611; BRADY JF, 1988, MOL PHARMACOL, V33, P148; BRODIE BB, 1958, ANNU REV BIOCHEM, V27, P427, DOI 10.1146/annurev.bi.27.070158.002235; BROWN HC, 1967, J AM CHEM SOC, V89, P1522, DOI 10.1021/ja00982a043; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; DAGANI D, 1976, J NATL CANCER I, V57, P955, DOI 10.1093/jnci/57.4.955; EKSTROM G, 1987, BIOCHEMISTRY-US, V26, P7348, DOI 10.1021/bi00397a023; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GILLETTE JR, 1994, BIOCHEMISTRY-US, V33, P2927, DOI 10.1021/bi00176a024; GROVES JT, 1976, J AM CHEM SOC, V98, P859, DOI 10.1021/ja00419a049; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Guengerich FP, 1996, J BIOL CHEM, V271, P27321, DOI 10.1074/jbc.271.44.27321; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1995, BIOCHIMIE, V77, P573, DOI 10.1016/0300-9084(96)88173-9; GUENGERICH FP, 1985, CRC CR REV TOXICOL, V14, P259, DOI 10.3109/10408448509037460; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1988, J BIOL CHEM, V263, P8176; Guengerich FP, 1989, PRINCIPLES METHODS T, P777; HARADA N, 1984, J BIOL CHEM, V259, P3005; JOHNSON WW, 1997, IN PRESS BIOCHEMISTR; JONES JP, 1986, J AM CHEM SOC, V108, P7074, DOI 10.1021/ja00282a037; KEEFER LK, 1973, J NATL CANCER I, V51, P299, DOI 10.1093/jnci/51.1.299; KNAPP DR, 1979, HDB ANAL DERIVATIZAT, P485; KORZEKWA KR, 1989, BIOCHEMISTRY-US, V28, P9012, DOI 10.1021/bi00449a009; KOSHY KT, 1975, J CHROMATOGR SCI, V13, P97, DOI 10.1093/chromsci/13.2.97; Kostrubsky VE, 1997, ANN CLIN LAB SCI, V27, P57; KUBY SA, 1991, STUDY ENZYMES, V1, P272; Kunitoh S, 1996, ALCOHOL CLIN EXP RES, V20, pA22, DOI 10.1111/j.1530-0277.1996.tb01721.x; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEVIN W, 1986, ARCH BIOCHEM BIOPHYS, V248, P158, DOI 10.1016/0003-9861(86)90412-1; LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353; MICO BA, 1985, CANCER RES, V45, P6280; MIWA GT, 1984, J BIOL CHEM, V259, P3000; MIWA GT, 1987, BIOESSAYS, V7, P215, DOI 10.1002/bies.950070506; NELSON SD, 1987, MAMMALIAN CYTOCHROME, V2, P19; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; NORTHROP DB, 1977, P 4 ANN H STEENBOCK, P122; PALMER G, 1992, J BIOL CHEM, V267, P665; PATTEN CJ, 1995, ARCH BIOCHEM BIOPHYS, V317, P504, DOI 10.1006/abbi.1995.1194; PATTEN CJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P629, DOI 10.1016/0003-9861(86)90373-5; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T; RATAJ MJ, 1991, J BIOL CHEM, V266, P18684; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHRINER RL, 1965, SYSTEMATIC IDENTIFIC, P253; SNYDER R, 1993, TOXICOL APPL PHARM, V122, P172, DOI 10.1006/taap.1993.1185; Sund H., 1963, ENZYMES, V7, P25; SWAIN CG, 1958, J AM CHEM SOC, V80, P5885, DOI 10.1021/ja01554a077; SWANN PF, 1983, CARCINOGENESIS, V4, P821, DOI 10.1093/carcin/4.7.821; TERELIUS Y, 1991, BIOCHEM BIOPH RES CO, V179, P689, DOI 10.1016/0006-291X(91)91427-E; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; WADE D, 1987, CANCER RES, V47, P3373; WHITE RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P493, DOI 10.1016/0003-9861(84)90015-8; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; Yamazaki H, 1996, BIOCHEM PHARMACOL, V52, P301, DOI 10.1016/0006-2952(96)00208-0; Yamazaki H, 1996, J BIOL CHEM, V271, P27438, DOI 10.1074/jbc.271.44.27438; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; YANG CS, 1991, CHEM RES TOXICOL, V4, P408, DOI 10.1021/tx00022a002; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	68	97	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29643	29651		10.1074/jbc.272.47.29643	http://dx.doi.org/10.1074/jbc.272.47.29643			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368031	hybrid			2022-12-25	WOS:A1997YG64700041
J	Haak, D; Gable, K; Beeler, T; Dunn, T				Haak, D; Gable, K; Beeler, T; Dunn, T			Hydroxylation of Saccharomyces cerevisiae ceramides requires Sur2p and Scs7p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SPHINGOLIPIDS; ENDOPLASMIC-RETICULUM; YEAST; GENE; BIOSYNTHESIS; PROTEINS; DESATURASE; MUTANT; RVS161; IDENTIFICATION	The Saccharomyces cerevisiae SCS7 and SUR2 genes are members of a gene family that encodes enzymes that desaturate or hydroxylate lipids, Sur2p is required for the hydroxylation of C-4 of the sphingoid moiety of ceramide, and Scs7p is required for the hydroxylation of the very long chain fatty acid, Neither SCS7 nor SUR2 are essential for growth, and lack of the Scs7p- or Sur2p-dependent hydroxylation does not prevent the synthesis of mannosyldiinositolphosphorylceramide, the mature sphingolipid found in yeast, Deletion of either gene suppresses the Ca2+-sensitive phenotype of csg2 Delta mutants, which arises from overaccumulation of inositolphosphorylceramide due to a defect in sphingolipid mannosylation. Characterization of scs7 and sur2 mutants is expected to provide insight into the function of ceramide hydroxylation.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051891] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51891] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; BERTELLO LE, 1995, BIOCHEM J, V310, P255, DOI 10.1042/bj3100255; Cliften P, 1996, MICROBIOL-SGM, V142, P477, DOI 10.1099/13500872-142-3-477; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DUNN TM, 1997, IN PRESS YEAST; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HUNG CY, 1995, BIOCHEM J, V307, P107, DOI 10.1042/bj3070107; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KARLSSON KA, 1971, J LIPID RES, V12, P466; KARLSSON KA, 1968, BIOCHIM BIOPHYS ACTA, V152, P798, DOI 10.1016/0005-2760(68)90130-6; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LESTER RL, 1993, ADV LIPID RES, V26, P253; LI L, 1966, J BIOL CHEM, V271, P16927; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MORRIS LJ, 1963, J CHROMATOGR, V12, P321, DOI 10.1016/S0021-9673(01)83692-X; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PUOTI A, 1991, J CELL BIOL, V113, P515, DOI 10.1083/jcb.113.3.515; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1986, METHODS YEAST GENETI; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; WELLS GB, 1983, J BIOL CHEM, V258, P200; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; ZHAO C, 1994, J BIOL CHEM, V269, P21480	33	210	223	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29704	29710		10.1074/jbc.272.47.29704	http://dx.doi.org/10.1074/jbc.272.47.29704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368039	hybrid, Green Submitted			2022-12-25	WOS:A1997YG64700049
J	Zezula, J; Sexl, V; Hutter, C; Karel, A; Schutz, W; Freissmuth, M				Zezula, J; Sexl, V; Hutter, C; Karel, A; Schutz, W; Freissmuth, M			The cyclin-dependent kinase inhibitor p21(cip1) mediates the growth inhibitory effect of phorbol esters in human venous endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-SYNTHESIS; PROTEIN; EXPRESSION; P21; ACTIVATION; PATHWAY; PROLIFERATION; ANGIOGENESIS; P27(KIP1); INDUCTION	Long-term application of the phorbol ester phorbol 12,18-dibutyrate (PDBu) inhibits the proliferation of human venous endothelial cells, The cyclin-dependent kinase inhibitor p21(cip1) is a potential candidate mediating the PDBu-induced delayed entry of the cells into S-phase (by similar to 10 h when compared with cells stimulated with basic fibroblast growth factor (bFGF)), Levels of p21(cip1) (protein and mRNA) rapidly rise (within similar to 2 h) in endothelial cells treated with the active isomer beta-PDBu, but not with alpha-PDBu; this effect is blocked by the mitogen-activated protein kinase kinase-l (Mek1) inhibitor PD098059 and by the protein kinase C (PRC) antagonists GF109203X and rottlerin (selective for PKC-delta), but not Go 6976 (selective for Ca2+-dependent PRC isoforms), Rapamycin blocks the PDBu-induced accumulation of p21(cip1) (but not of the cognate mRNA), indicating an action of PKC on p21(cip1) mRNA translation, If endothelial cells are recruited into the cell cycle by bFGF, p21(cip1) mRNA and protein levels rise initially (within 2 h) and decline subsequently such that p21(cip1) drops to a minimum prior to the initiation of DNA synthesis (i.e. after similar to 12 h). In bFGF-stimulated cells, changes in p21(cip1) mRNA and protein are strictly linked, In contrast, the levels of p21(cip1) mRNA decline substantially (>10 h) before the protein decreases in PDBu-stimulated cells, Thus, PKC (presumably PKC-delta) regulates the amounts of p21(cip1) in endothelial cells at the level of mRNA accumulation and translation, leading to a rapid and robust induction; following persistent PKC activation, p21(cip1) remains elevated despite reduced mRNA levels, indicating an enhanced stability of the protein, The bFGF-mediated increase in p21(cip1) is blocked by the Mek1 inhibitor, but not by GF109203X; hence, in endothelial cells, induction of p21(cip1) by PKC- and growth factor-dependent signaling is achieved by distinct pathways that converge and require activation of the mitogen-activated protein kinase cascade, The beta-PDBu-induced delayed S-phase entry and drop in p21(cip1) are reversed if GF109203X is added 4 h after beta-PDBu to prevent persistent PKC activation, These observations indicate a cause and effect relation between sustained p21(cip1) elevations and the delay in S-phase entry induced by beta-PDBu.	UNIV VIENNA,INST PHARMACOL,A-1090 VIENNA,AUSTRIA	University of Vienna			Sexl, Veronika/B-8657-2016	Sexl, Veronika/0000-0001-9363-0412; Freissmuth, Michael/0000-0001-9398-1765				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEFLORA S, 1991, MUTAT RES, V250, P87, DOI 10.1016/0027-5107(91)90165-K; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Frey MR, 1997, J BIOL CHEM, V272, P9424; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HALEVY O, 1995, SCIENCE, V267, P963; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; JEOUNG DI, 1995, BIOCHEM BIOPH RES CO, V214, P361, DOI 10.1006/bbrc.1995.2296; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI Y, 1994, ONCOGENE, V9, P2261; LIU M, 1996, GENE DEV, V10, P42; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mancusi G, 1996, BIOCHEM J, V315, P281, DOI 10.1042/bj3150281; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOODIE SA, 1991, BRIT J PHARMACOL, V102, P101, DOI 10.1111/j.1476-5381.1991.tb12139.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHOU W, 1993, J BIOL CHEM, V268, P23041; ZHOU W, 1994, BIOCHEM BIOPH RES CO, V199, P191, DOI 10.1006/bbrc.1994.1213	46	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29967	29974		10.1074/jbc.272.47.29967	http://dx.doi.org/10.1074/jbc.272.47.29967			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368076	hybrid			2022-12-25	WOS:A1997YG64700086
J	Hunt, JE; Friend, DS; Gurish, MF; Feyfant, E; Sali, A; Huang, CF; Ghildyal, N; Stechschulte, S; Austen, KF; Stevens, RL				Hunt, JE; Friend, DS; Gurish, MF; Feyfant, E; Sali, A; Huang, CF; Ghildyal, N; Stechschulte, S; Austen, KF; Stevens, RL			Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTES-T; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; NEUTRAL PROTEASES; MOLECULAR-CLONING; GLOBIN GENE; MICE; DIFFERENTIATION; IDENTIFICATION; SEQUENCE	Mouse mast cell protease (mMCP) 1, mMCP-2, mMCP-4, and mMCP-5 are members of a family of related serine proteases whose genes reside within an similar to 850 kilobase (kb) complex on chromosome 14 that does not readily undergo crossover events, While mapping the mMCP-1 gene, we isolated a novel gene that encodes a homologous serine protease designated mMCP-9. The mMCP-9 and mMCP-1 genes are only similar to 7 kb apart on the chromosome and are oriented back to back, The proximity of the mMCP-1 and mMCP-9 genes now suggests that the low recombination frequency of the complex is due to the closeness of some of its genes, The mMCP-9 transcript and protein were observed in the jejunal submucosa of Trichinella spiralis-infected BALB/c mice, However, in normal BALB/c mice, mMCP-9 transcript and protein were found only in those mast cells that reside in the uterus, Thus, the expression of mMCP-9 differs from that of all other chymases. The observation that BALB/c mouse bone marrow-derived mast cells developed with interleukin (IL) 10 and c-kif ligand contain mMCP-9 transcript, whereas those developed with IL-3 do not, indicates that the expression of this particular chymase is regulated by the cytokine microenvironment, Comparative protein structure modeling revealed that mMCP-9 is the only known granule protease with three positively charged regions on its surface. This property may allow mMCP-9 to form multimeric complexes with serglycin proteoglycans and other negatively charged proteins inside the granule, Although mMCP-9 exhibits a >50% overall amino acid sequence identity with its homologous chymases, it has a unique substrate-binding cleft, This finding suggests that each member of the chromosome 14 family of serine proteases evolved to degrade a distinct group of proteins.	BRIGHAM & WOMENS HOSP, DIV RHEUMATOL ALLERGY & IMMUNOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Rockefeller University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R01AI023483, R37AI022531, T32AI007306] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07306, AI-23483, AI-22531] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BECKSTEAD JH, 1981, BLOOD, V57, P1088; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BOENISH T, 1989, IMMUNOLOGICAL STAINI, P11; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DEYOUNG MB, 1987, ARCH BIOCHEM BIOPHYS, V254, P222, DOI 10.1016/0003-9861(87)90098-1; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; HEUSEL JW, 1993, BLOOD, V81, P1614; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; JENNE D, 1988, P NATL ACAD SCI USA, V85, P4814, DOI 10.1073/pnas.85.13.4814; JENNE D, 1988, J IMMUNOL, V140, P318; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liao YB, 1997, J BIOL CHEM, V272, P2969, DOI 10.1074/jbc.272.5.2969; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MELOUN B, 1966, BIOCHIM BIOPHYS ACTA, V130, P543, DOI 10.1016/0304-4165(66)90258-3; MIKES O, 1966, BIOCHEM BIOPH RES CO, V24, P346, DOI 10.1016/0006-291X(66)90162-8; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; RAZIN E, 1984, J IMMUNOL, V132, P1479; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1993, J BIOL CHEM, V268, P9023; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STECHSCHULTE DJ, 1987, J CELL PHYSIOL, V132, P565, DOI 10.1002/jcp.1041320321; STEVENS RL, 1996, FASEB J, V10, pA1307; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010; Xia ZN, 1996, J BIOL CHEM, V271, P8747, DOI 10.1074/jbc.271.15.8747; YOKOI H, 1994, BIOL REPROD, V50, P1034, DOI 10.1095/biolreprod50.5.1034; ZON LI, 1991, J BIOL CHEM, V266, P22948	60	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29158	29166		10.1074/jbc.272.46.29158	http://dx.doi.org/10.1074/jbc.272.46.29158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360993	hybrid			2022-12-25	WOS:A1997YF68400052
J	IacobuzioDonahue, CA; Shuja, S; Cai, JG; Peng, P; Murnane, MJ				IacobuzioDonahue, CA; Shuja, S; Cai, JG; Peng, P; Murnane, MJ			Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG-CANCER; HUMAN BREAST; CELLS; CARCINOMAS; OLIGOSACCHARIDES; DEGLYCOSYLATION; GLYCOPROTEINS; ASSOCIATION; FIBROBLASTS; ACTIVATION	Western blots, enzyme assays, protein glycosylation studies, and immunohistochemical staining were used to characterize cathepsin B expression at successive stages of colorectal tumor progression, In normal colon mucosa and premalignant adenomas, cathepsin B expression was predominantly due to mature two-chain protein detected on Western blots as the nonglycosylated 27-kDa form, with overexpression of this protein occurring in only 4 of 18 adenomas, Overexpression increased significantly in Dukes A and B carcinomas (26 of 37 cases), with cathepsin B protein generally detectable in carcinomas as a combination of both 27-kDa nonglycosylated and 28-kDa glycosylated mature two-chain forms, Glycosylated cathepsin B protein in carcinoma extracts was sensitive to PNGase F but resistant to Endo H, indicating a pattern consistent with complex rather than high mannose type glycosylation, When sorted by advancing tumor stage, peak expression of cathepsin B protein occurred in carcinomas involved in local invasion compared with adenomas or metastatic cancers, At all stages, cathepsin B activity correlated significantly with the levels of heavy chain mature cathepsin B protein (r = 0.6682, p < 0.0001) irrespective of glycosylation, Immunohistochemical staining of cathepsin B protein revealed fine diffuse cytoplasmic staining in both adenomas and carcinomas compared with coarse granular cytoplasmic staining (typical of lysosomes) seen in matched normal mucosa, Our results demonstrate several sequential, apparently independent changes in cathepsin B expression during colorectal tumor progression including early changes in subcellular localization, up-regulation of cathepsin B protein and activity in invasive cancers, and altered protein glycosylation detected in malignant tumors at all stages.	BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; MALLORY INST PATHOL,BOSTON,MA 02118	Boston University; Boston University					NCI NIH HHS [CA67719, CA51865] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA067719] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAMPO E, 1994, AM J PATHOL, V145, P301; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CASTIGLIONI T, 1994, HUM PATHOL, V25, P857, DOI 10.1016/0046-8177(94)90003-5; CHU FK, 1981, ANAL BIOCHEM, V116, P152, DOI 10.1016/0003-2697(81)90338-9; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Farinati F, 1996, CARCINOGENESIS, V17, P2581, DOI 10.1093/carcin/17.12.2581; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FERNANDES B, 1991, CANCER RES, V51, P718; GORDON JI, 1985, J BIOL CHEM, V260, P4824; HALBAN PA, 1994, BIOCHEM J, V299, P1; HANEWINKEL H, 1987, J BIOL CHEM, V262, P12351; HASILIK A, 1982, EUR J BIOCHEM, V125, P317, DOI 10.1111/j.1432-1033.1982.tb06685.x; KEPPLER D, 1988, CANCER RES, V48, P6855; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KREPELA E, 1995, INT J CANCER, V61, P44, DOI 10.1002/ijc.2910610109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO G, 1994, INT J ONCOL, V5, P509; Leto G., 1994, In Vivo (Attiki), V8, P231; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR RR, 1979, J BIOL CHEM, V254, P4423; MACH L, 1993, BIOCHEM J, V293, P437, DOI 10.1042/bj2930437; MACH L, 1992, BIOCHEM J, V282, P577, DOI 10.1042/bj2820577; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MATSUOKA Y, 1992, NEOPLASMA, V39, P107; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MURNANE MJ, 1991, CANCER RES, V51, P1137; Murnane MJ, 1997, IN VIVO, V11, P209; MURNANE MJ, 1994, PROTEASES INVOLVED C, P11; OHTA T, 1994, BRIT J CANCER, V69, P152, DOI 10.1038/bjc.1994.25; PAGANO M, 1989, CANCER LETT, V45, P13, DOI 10.1016/0304-3835(89)90030-X; ROZHIN J, 1994, CANCER RES, V54, P6517; ROZHIN J, 1990, CANCER RES, V50, P6278; SHEAHAN K, 1989, CANCER RES, V49, P3809; SHUJA S, 1991, INT J CANCER, V49, P341, DOI 10.1002/ijc.2910490305; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; SLOANE BF, 1994, J CELL SCI, V107, P373; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; SPEISS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917; SUKOH N, 1994, CANCER, V74, P46, DOI 10.1002/1097-0142(19940701)74:1<46::AID-CNCR2820740109>3.0.CO;2-G; TAKAHASHI T, 1984, J BIOL CHEM, V259, P6059; TANIGUCHI T, 1985, J BIOCHEM-TOKYO, V97, P973, DOI 10.1093/oxfordjournals.jbchem.a135141; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TSUSHIMA H, 1991, MELANOMA RES, V1, P341; TURNBULL RB, 1967, ANN SURG, V166, P420; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	49	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29190	29199		10.1074/jbc.272.46.29190	http://dx.doi.org/10.1074/jbc.272.46.29190			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360997	hybrid			2022-12-25	WOS:A1997YF68400056
J	Nolan, DP; Jackson, DG; Windle, HJ; Pays, A; Geuskens, M; Micheli, A; Voorheis, HP; Pays, E				Nolan, DP; Jackson, DG; Windle, HJ; Pays, A; Geuskens, M; Micheli, A; Voorheis, HP; Pays, E			Characterization of a novel, stage-specific, invariant surface protein in Trypanosoma brucei containing an internal, serine-rich, repetitive motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; MICROTUBULE-ASSOCIATED PROTEIN; AFRICAN TRYPANOSOMES; PLASMODIUM-FALCIPARUM; CELL-SURFACE; CULTURE FORMS; GENE; ANTIGEN; IDENTIFICATION; GLYCOPROTEIN	A new surface membrane protein, invariant surface glycoprotein termed ISG(100), was identified in Trypanosoma brucei, using catalyzed surface, radioiodination of intact cells, This integral membrane glycoprotein was purified by a combination of detergent extraction, lectin-affinity, and ion exchange chromatography followed by preparative SDS-polyacrylamide gel electrophoresis. The protein was expressed only in bloodstream forms of the parasite, was heavily N-glycosylated, and was present in different clonal variants of the same serodeme as well as in different serodemes. The gene for this protein was isolated by screening a cDNA expression library with antibodies against the purified protein followed by screening of a genomic library. The nucleotide sequence of the gene (4050 base pairs) predicted a highly reiterative polypeptide containing three distinct domains, a unique N-terminal domain of about 10 kDa containing three potential N-glycosylation sites, which was followed by a large internal domain consisting entirely of 72 consecutive copies of a serine-rich, 17-amino acid motif (similar to 113 kDa) and terminated with an apparent transmembrane spanning region of about 3.3 kDa, The internal repeat region of this gene (3672 base pairs) represents the largest reiterative coding sequence to be fully characterized in any species of trypanosome. There was no significant homology with other known proteins, and overall the predicted protein was extremely hydrophobic, Unlike the genes for other surface proteins, the gene encoding ISG(100) was present as a single copy. Although present in the flagellar pocket, ISG(100) was predominantly associated with components of the pathways for endo/exocytosis, such as intracellular vesicles located in the proximity of the pocket as web a large, electron-lucent perinuclear digestive vacuole.	JOHN RADCLIFFE HOSP, INST MOL MED, OXFORD OX3 9DU, ENGLAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND; UNIV MONS, CHIM BIOL LAB, B-7000 MONS, BELGIUM	University of Oxford; Trinity College Dublin; University of Mons	Nolan, DP (corresponding author), UNIV BRUSSELS, DEPT MOL BIOL, 67 RUE CHEVAUX, B-1640 RHODE ST GENESE, BELGIUM.			Nolan, Derek/0000-0002-3742-4304; , david/0000-0002-4133-9364				ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; ANDERS RF, 1986, PARASITE IMMUNOL, V8, P529, DOI 10.1111/j.1365-3024.1986.tb00867.x; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; Bastin P, 1996, MOL BIOCHEM PARASIT, V76, P43, DOI 10.1016/0166-6851(95)02537-5; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BRICKMAN MJ, 1994, J CELL SCI, V107, P3191; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BRUN R, 1979, ACTA TROP, V36, P289; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; COPPENS I, 1991, BIOCHEM BIOPH RES CO, V178, P185, DOI 10.1016/0006-291X(91)91797-G; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COWMAN AF, 1985, CELL, V40, P775, DOI 10.1016/0092-8674(85)90337-X; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FLAVERLORO JM, 1986, NUCLEIC ACIDS RES, V14, P8265; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HEMPHILL A, 1992, J CELL BIOL, V117, P95, DOI 10.1083/jcb.117.1.95; HOBBS RN, 1989, J IMMUNOL METHODS, V117, P257, DOI 10.1016/0022-1759(89)90148-8; IMBODEN M, 1995, PARASITOLOGY, V110, P249, DOI 10.1017/S0031182000080835; JACKSON DG, 1990, BIOCHEM SOC T, V18, P1032, DOI 10.1042/bst0181032; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LEE MGS, 1994, J BIOL CHEM, V269, P8408; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; MCLAUGHLIN J, 1982, J IMMUNOL, V128, P2656; MULLER N, 1992, PARASITOLOGY, V104, P111, DOI 10.1017/S0031182000060856; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1980, NUCLEIC ACIDS RES, V8, P5965, DOI 10.1093/nar/8.24.5965; PAYS E, 1988, ANNU REV GENET, V22, P107, DOI 10.1146/annurev.ge.22.120188.000543; POLLEVICK GD, 1991, MOL BIOCHEM PARASIT, V47, P247, DOI 10.1016/0166-6851(91)90185-9; RODITI I, 1990, PARASITOL TODAY, V6, P79, DOI 10.1016/0169-4758(90)90216-Q; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHELL D, 1990, FEBS LETT, V271, P67, DOI 10.1016/0014-5793(90)80373-Q; SCHNEIDER A, 1988, SCIENCE, V241, P459, DOI 10.1126/science.3393912; SCHOFIELD L, 1991, PARASITOL TODAY, V7, P99, DOI 10.1016/0169-4758(91)90166-L; STAHL HD, 1985, P NATL ACAD SCI USA, V82, P543, DOI 10.1073/pnas.82.2.543; VOORHEIS HP, 1979, BIOCHEM J, V180, P11, DOI 10.1042/bj1800011; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; ZIEGELBAUER K, 1995, MOL BIOCHEM PARASIT, V69, P53, DOI 10.1016/0166-6851(94)00194-R; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	55	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29212	29221		10.1074/jbc.272.46.29212	http://dx.doi.org/10.1074/jbc.272.46.29212			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361000	hybrid			2022-12-25	WOS:A1997YF68400059
J	Tachibana, K; Urano, T; Fujita, H; Ohashi, Y; Kamiguchi, K; Iwata, S; Hirai, H; Morimoto, C				Tachibana, K; Urano, T; Fujita, H; Ohashi, Y; Kamiguchi, K; Iwata, S; Hirai, H; Morimoto, C			Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase - A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC FAMILY KINASES; CELL-ADHESION; EXTRACELLULAR-MATRIX; V-SRC; SIGNAL TRANSDUCTION; T-CELLS; PROTEIN; PP125(FAK); P130(CAS); BINDING	Integrin-ligand binding induces the tyrosine phosphorylation of various proteins including focal adhesion kinase (pp125(FAK)) and Crk-associated substrate (Gas). FAK is activated and autophosphorylated by the ligation of integrins, although the substrate of FAK has not been revealed. We show here that p130(Cas) and Cas-L are FAX substrates. FAK directly phosphorylates Cas proteins primarily at the YDYVHL sequence that is conserved among all Cas proteins. Furthermore, the phosphorylated YDYVHL sequence is a binding site for Src family protein-tyrosine kinases, and the recruited Src family kinase phosphorylates the other tyrosine residues within Gas. The Cas-L YDYVHL sequence is phosphorylated upon integrin-ligand binding, and this integrin-mediated tyrosine phosphorylation is inhibited by the cotransfection of the FAX COOH-terminal domain that does not contain a kinase domain, These findings strongly suggest that FAK initiates integrin-mediated tyrosine phosphorylation of Cas proteins; then, Src family tyrosine kinases, which are recruited to phosphorylated Cas and FAK, further phosphorylate Cas proteins.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MED SCI,DEPT CLIN IMMUNOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,AIDS RES CTR,MINATO KU,TOKYO 108,JAPAN	Tufts University; University of Tokyo; University of Tokyo; University of Tokyo	Tachibana, K (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT CANC IMMUNOL & AIDS,44 BINNEY ST,BOSTON,MA 02115, USA.		Iwata, Satoshi/A-8819-2011	Urano, Takeshi/0000-0003-3383-3554	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033713] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-29530] Funding Source: Medline; NIAMS NIH HHS [AR-33713] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALALB MB, 1995, MOL CELL BIOL, V15, P954; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishino M, 1995, ONCOGENE, V11, P2331; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TAPLEY P, 1989, ONCOGENE, V4, P325; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, J CELL SCI, V107, P1583; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	50	138	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29083	29090		10.1074/jbc.272.46.29083	http://dx.doi.org/10.1074/jbc.272.46.29083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360983	hybrid			2022-12-25	WOS:A1997YF68400042
J	JahngenHodge, J; Obin, MS; Gong, X; Shang, F; Nowell, TR; Gong, JX; Abasi, H; Blumberg, J; Taylor, A				JahngenHodge, J; Obin, MS; Gong, X; Shang, F; Nowell, TR; Gong, JX; Abasi, H; Blumberg, J; Taylor, A			Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-III; LENS EPITHELIAL-CELLS; PROTEIN S-THIOLATION; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEOLYSIS; POLYUBIQUITIN GENE; ACTIVATING ENZYME; HYDROGEN-PEROXIDE; CARRIER PROTEINS; INDUCED CATARACT	Upon oxidative stress cells show an increase in the oxidized glutathione (GSSG) to reduced glutathione (GSH) ratio with a concomitant decrease in activity of the ubiquitinylation pathway, Because most of the enzymes involved in the attachment of ubiquitin to substrate proteins contain active site sulfhydryls that might be covalently modified (thiolated) upon enhancement of GSSG levels (glutathiolation), it appeared plausible that glutathiolation might alter ubiquitinylation rates upon cellular oxidative stress. This hypothesis was explored using intact retina and retinal pigment epithelial (RPE) cell models, Exposure of intact bovine retina and RPE cells to H2O2 (0.1-1.7 mu mol/mg) resulted in a dose-dependent increase in the GSSG:GSH ratio and coincident dose-dependent reductions in the levels of endogenous ubiquitin-activating enzyme (E1)-ubiquitin thiol esters and endogenous protein-ubiquitin conjugates and in the ability to form de novo retinal protein(125)I-labeled ubiquitin conjugates. Oxidant-induced decrements in ubiquitin conjugates were associated with 60-80% reductions in El and ubiquitin-conjugating enzyme (E2) activities as measured by formation of ubiquitin thiol esters, When GSH levels in RPE cells recovered to preoxidation levels following H2O2 removal, endogenous El activity and protein-ubiquitin conjugates were restored, Evidence that S thiolation of El and E2 enzymes is the biochemical link between cellular redox state and E1/E2 activities includes: (i) 5-fold increases in levels of immunoprecipitable, dithiothreitollabile S-35-E1 adducts in metabolically labeled, H2O2-treated, RPE cells; (ii) diminished formation of El-and E2-I-125-labeled ubiquitin thiol esters, oligomerization of E2(25K), and coincident reductions in protein-I-125-labeled ubiquitin conjugates in supernatants from nonstressed retinas upon addition of levels of GSSG equivalent to levels measured in oxidatively stressed retinas; and (iii) partial restoration of El and E2 activities and levels of protein-I-125-labeled ubiquitin conjugates in supernatants from H2O2-treated retinas when GSSG:GSH ratios were restored to preoxidation levels by the addition of physiological levels of GSH. These data suggest that the cellular redox status modulates protein ubiquitinylation via reversible S thiolation of El and E2 enzymes, presumably by glutathione.	TUFTS UNIV, USDA, JMHNRCA, LAB NUTR & VIS RES, BOSTON, MA 02111 USA; TUFTS UNIV, USDA, JMHNRCA, ANTIOXIDANT RES LAB, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; United States Department of Agriculture (USDA)					NATIONAL EYE INSTITUTE [R29EY011735] Funding Source: NIH RePORTER; NEI NIH HHS [EY11735-01] Funding Source: Medline; PHS HHS [8566] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; BRIGELIUS R, 1982, BIOCHEM PHARMACOL, V31, P1637, DOI 10.1016/0006-2952(82)90393-8; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; COLLISON MW, 1987, BIOCHIM BIOPHYS ACTA, V928, P121, DOI 10.1016/0167-4889(87)90112-1; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HAYASHI T, 1993, BRAIN RES, V620, P171, DOI 10.1016/0006-8993(93)90288-X; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760; JANERO DR, 1995, BIOCHEM J, V306, P421, DOI 10.1042/bj3060421; KOWLURU R, 1994, CURR EYE RES, V13, P891, DOI 10.3109/02713689409015092; KUCK JFR, 1990, EXP EYE RES, V50, P659, DOI 10.1016/0014-4835(90)90110-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; Liu H, 1996, J BIOL CHEM, V271, P4805; LOU MF, 1995, CURR EYE RES, V14, P951, DOI 10.3109/02713689508995135; MEDRANO CJ, 1995, EXP EYE RES, V61, P273, DOI 10.1016/S0014-4835(05)80122-8; MILLER RM, 1990, ARCH BIOCHEM BIOPHYS, V276, P355, DOI 10.1016/0003-9861(90)90732-E; Mune M, 1995, AGE, V18, P43, DOI 10.1007/BF02432518; MURPHY ME, 1992, EUR J BIOCHEM, V210, P139, DOI 10.1111/j.1432-1033.1992.tb17401.x; NAASH M, 1991, J NEUROSCI RES, V30, P433, DOI 10.1002/jnr.490300220; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1988, J BIOL CHEM, V263, P12028; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176; SIES H, 1987, ADV ENZYME REGUL, V26, P175, DOI 10.1016/0065-2571(87)90013-6; SIEZEN RJ, 1989, EXP EYE RES, V48, P225, DOI 10.1016/S0014-4835(89)80072-7; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; Strack PR, 1996, BIOCHEMISTRY-US, V35, P7142, DOI 10.1021/bi9518048; Taylor A, 1997, Adv Pharmacol, V38, P515; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VESSEY DA, 1992, J INVEST DERMATOL, V99, P859, DOI 10.1111/1523-1747.ep12614831; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; WHITLEY TJ, 1995, BT TELECOMM, V5, P218; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012	60	234	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28218	28226		10.1074/jbc.272.45.28218	http://dx.doi.org/10.1074/jbc.272.45.28218			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353272	hybrid			2022-12-25	WOS:A1997YF21900012
J	Rybakova, IN; Ervasti, JM				Rybakova, IN; Ervasti, JM			Dystrophin-glycoprotein complex is monomeric and stabilizes actin filaments in vitro through a lateral association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ALPHA-ACTININ; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHY; BINDING DOMAIN; MUSCLE ACTIN; PROTEIN; DEPOLYMERIZATION; SARCOGLYCAN; EXPRESSION	The native molecular weight of the dystrophin-glycoprotein complex and its effect on actin depolymerization and polymerization were examined, First, we determined that the native molecular weight of purified dystrophin-glycoprotein complex is only large enough (M-r 1,200,000) to contain one copy of each protein in the complex, including dystrophira. Using different approaches, we also demonstrated that dystrophin-glycoprotein complex significantly protected a fraction of actin filaments from disassembly, while individual recombinant actin binding fragments of dystrophin or calpain-digested dystrophin-glycoprotein complex had no effect on F-actin depolymerization. The protective effect of dystrophin-glycoprotein complex on F-actin depolymerization saturated at a dystrophin:actin molar ratio of 0.04, corresponding to 1 dystrophin/25 actin monomers, which is highly consistent with the 1:24 stoichiometry of dystrophin-glycoprotein complex binding to F actin previously measured at equilibrium, However, dystrophin-glycoprotein complex did not bind G-actin or alter the kinetics or extent of actin polymerization, This excluded the possibility that dystrophin-glycoprotein complex inhibited actin depolymerization by capping the ends of actin filaments, It therefore appears that actin binding domains separated on the dystrophin molecule from each other by almost 1,200 amino acids act in concert to protect F-actin from depolymerization, Our data suggest that dystrophin stabilizes F-actin in vitro by binding alongside an actin filament and bridging actin monomers in a manner analogous to the actin side binding protein tropomyosin, It is noteworthy that we did not find any effect of skeletal muscle tropomyosin on dystrophin-glycoprotein complex binding to F-actin, This indicates that dystrophin-glycoprotein complex and tropomyosin may simultaneously bind the same actin filament and identifies another feature that distinguishes dystrophin from the other proteins in the actin-cross-linking superfamily.	UNIV WISCONSIN, DEPT PHYSIOL, SCH MED, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison			Ervasti, James/AAZ-4786-2020		NIAMS NIH HHS [AR42423, AR01985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985, R01AR042423] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CANO ML, 1992, J CELL BIOL, V116, P1123, DOI 10.1083/jcb.116.5.1123; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; COLUMBO R, 1993, J MOL BIOL, V230, P1151; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DAVIS J, 1983, J BIOL CHEM, V258, P7757; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ervasti JM, 1997, SOC GEN PHY, V52, P31; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FABBRIZIO E, 1995, BIOCHEM BIOPH RES CO, V213, P295, DOI 10.1006/bbrc.1995.2129; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HORI S, 1995, BIOCHEM BIOPH RES CO, V209, P1062, DOI 10.1006/bbrc.1995.1605; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; Kahana E, 1997, CELL MOTIL CYTOSKEL, V36, P246; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; Law D. J., 1996, Molecular Biology of the Cell, V7, p382A; LEBART MC, 1995, J MUSCLE RES CELL M, V16, P543, DOI 10.1007/BF00126438; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; MARUYAMA K, 1978, J BIOCHEM-TOKYO, V84, P1017, DOI 10.1093/oxfordjournals.jbchem.a132184; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHTAKI T, 1985, EUR J BIOCHEM, V153, P609, DOI 10.1111/j.1432-1033.1985.tb09344.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PONS F, 1990, P NATL ACAD SCI USA, V87, P7851, DOI 10.1073/pnas.87.20.7851; PUSZKIN S, 1978, BIOCHIM BIOPHYS ACTA, V513, P205, DOI 10.1016/0005-2736(78)90174-8; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Root DD, 1997, P NATL ACAD SCI USA, V94, P5685, DOI 10.1073/pnas.94.11.5685; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; SATO M, 1987, NATURE, V325, P828, DOI 10.1038/325828a0; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SENTER L, 1993, BIOCHEM BIOPH RES CO, V192, P899, DOI 10.1006/bbrc.1993.1500; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TIDBALL JG, 1991, AM J PATHOL, V138, P17; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WINDER SJ, 1995, J CELL SCI, V108, P63; WINDER SJ, 1995, FEBS LETT, V369, P27, DOI 10.1016/0014-5793(95)00398-S; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; ZIGMOND SH, 1992, J CELL BIOL, V119, P559, DOI 10.1083/jcb.119.3.559	62	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28771	28778		10.1074/jbc.272.45.28771	http://dx.doi.org/10.1074/jbc.272.45.28771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353348	hybrid			2022-12-25	WOS:A1997YF21900088
J	Sakuma, H; Ikeda, A; Oka, S; Kozutsumi, Y; Zanetta, JP; Kawasaki, T				Sakuma, H; Ikeda, A; Oka, S; Kozutsumi, Y; Zanetta, JP; Kawasaki, T			Molecular cloning and functional expression of a cDNA encoding a new member of mixed lineage protein kinase from human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; SH3 DOMAIN; C-JUN; CIRCULAR-DICHROISM; TERMINAL DOMAIN; CYCLIC-GMP; PHOSPHORYLATION; ACTIVATION; PATHWAY; FAMILY	We have cloned a novel protein kinase from human cerebellum and named it LZK (leucine zipper-bearing kinase). The LZK cDNA encoded a 966-amino acid polypeptide that contains a kinase catalytic domain and double leucine/isoleucine zippers separated by a short spacer region. The amino acid sequence of the kinase catalytic domain was a hybrid between those in serine/ threonine and tyrosine protein kinases, indicating that LZK belongs to the subfamily of the mixed lineage kinase (MLK) family. The kinase catalytic domain of LZK was most similar to DLK (Holtzman, L. B., Merritt, S.E., and Fan, G. (1994) J. Biol Chem. 269, 3080-30817), MUK (Hirai, S., Izawa, M., Osada, S., Spyrou, G., and Ohno, S. (1996) Oncogene 12, 641-650), and ZPK (Reddy, U. R., and Presure, D. (1994) Biochem. Biophys. Res. Commun. 202, 613-620), which belong to the same subfamily of the MLK family. However, besides the kinase catalytic domain and double leucine/isoleucine zippers, there was no significant homology with known proteins. The recombinant LZK autophosphorylated in the presence of ATP and divalent cations, and exhibited serine/threonine kinase catalytic activity. Northern blot analysis revealed that LZK is expressed most strongly in the pancreas, with a pattern that differs from other MLKs. Expression of LZK in COS7 cells induced phosphorylation of c-Jun and activation of JNK-1, indicating the association of LZK in the c-Jun amino-terminal kinase/ stress-activated protein kinase pathway. The expressed LZK was detected primarily in the membrane fraction, suggesting that LZK interacts with other cellular components in vivo.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAKYO KU, KYOTO 606, JAPAN; UNIV SCI & TECH LILLE FLANDRES ARTOIS, CHIM BIOL LAB, F-59655 VILLENEUVE DASCQ, FRANCE	Kyoto University; Universite de Lille - ISITE; Universite de Lille								ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V249, P1266; DERJARD B, 1994, CELL, V76, P1025; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DOROW DS, 1994, J PROTEIN CHEM, V13, P458; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Frederickson R M, 1992, Semin Cell Biol, V3, P107; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Hirai S, 1996, ONCOGENE, V12, P641; Holtzman LB, 1994, J BIOL CHEM, V269, P30808; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; ING YL, 1994, ONCOGENE, V9, P1745; KATOH M, 1995, ONCOGENE, V10, P1447; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LINBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YAN MH, 1994, NATURE, V372, P798; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	47	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28622	28629		10.1074/jbc.272.45.28622	http://dx.doi.org/10.1074/jbc.272.45.28622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353328	hybrid			2022-12-25	WOS:A1997YF21900068
J	Takaki, Y; Muta, T; Iwanaga, S				Takaki, Y; Muta, T; Iwanaga, S			A peptidyl-prolyl cis/trans-isomerase (cyclophilin G) in regulated secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; TACHYPLEUS-TRIDENTATUS HEMOCYTES; CIS-TRANS ISOMERASE; A-BINDING-PROTEIN; HORSESHOE-CRAB; FACTOR-C; LIMULUS-POLYPHEMUS; CYCLOSPORIN-A; HOMOLOG NINAA; S-CYCLOPHILIN	A 27-kDa protein (p27) in horseshoe crab hemocyte that cross-reacts with antiserum against a beta-glucan-sensitive protease zymogen was purified to homogeneity, and its cDNA was cloned, The 1.7-kilobase pair cDNA contains an open reading frame of 660 base pairs, encoding a 23 amino acid signal sequence followed by a mature protein of 197 residues. The sequence of p27 exhibits strong similarity to that of cyclophilin B, a peptidyl-prolyl cis/trans-isomerase. p27 exhibits isomerase activity with a k(cat)/K-m of 0.18 mu m(-1) s(-1) for a peptide substrate; this activity is inhibited by cyclosporin A but is not affected by FK506. Although the p27 precursor possesses an amino-terminal secretory hydrophobic signal sequence, unlike other cyclophilin B molecules, it lacks a conserved carboxyl-terminal endoplasmic reticulum retention signal and it contains a central 8-amino acid insertion, Although p27 is secreted into the culture media of transiently expressed COS cells, it is not detected in horseshoe crab hemolymph plasma brit rather is localized to the hemocyte large granules, the regulated secretory granules that are exocytosed upon stimulation. These results indicate that p27 is a new peptidyl-prolyl cis/trans-isomerase in the regulated secretory granules, and is thus designated cyclophilin G. This first report of a cyclophilin homologue in the secretory granule of the horseshoe crab hemocyte suggests that such chaperon-like proteins may constitute a key quality control system for stored proteins in exocytotic granules.	KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT BIOL MOL,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1991, J BIOL CHEM, V266, P10739; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Guggenheim EA, 1926, PHILOS MAG, V2, P538; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; HEITMAN J, 1993, METHODS COMPANION ME, V5, P178; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; IWAI N, 1990, KIDNEY INT, V37, P1460, DOI 10.1038/ki.1990.136; Kawabata Shun-ichiro, 1996, P255; KOSER PL, 1990, NUCLEIC ACIDS RES, V18, P1643, DOI 10.1093/nar/18.6.1643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; Lui J., 1991, CELL, V66, P807; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOKUNAGA F, 1991, J BIOCHEM, V109, P150, DOI 10.1093/oxfordjournals.jbchem.a123337; TOKUNAGA F, 1987, EUR J BIOCHEM, V167, P405, DOI 10.1111/j.1432-1033.1987.tb13352.x	45	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28615	28621		10.1074/jbc.272.45.28615	http://dx.doi.org/10.1074/jbc.272.45.28615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353327	hybrid			2022-12-25	WOS:A1997YF21900067
J	Cutler, NS; Heitman, J; Cardenas, ME				Cutler, NS; Heitman, J; Cardenas, ME			STT4 is an essential phosphatidylinositol 4-kinase that is a target of wortmannin in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C GENE; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; VACUOLAR PROTEIN; MAMMALIAN-CELLS; RAT ADIPOCYTES; YEAST; INHIBITOR; 5-KINASE; ACTIVATION	Wortmannin is a natural product that inhibits signal transduction. One target of wortmannin in mammalian cells is the 110-kDa catalytic subunit of phosphatidylinositol S-kinase (PI 3-kinase). We show that wortmannin is toxic to the yeast Saccharomyces cerevisiae and present genetic and biochemical evidence that a phosphatidylinositol 4-kinase (PI 4-kinase), STT4, is a target of wortmannin in yeast. In a strain background in which stt4 mutants are rescued by osmotic support with sorbitol, the toxic effects of wortmannin are similarly prevented by sorbitol. In contrast, in a different strain background, STT4 is essential under all conditions and wortmannin toxicity is not mitigated by sorbitol. Overexpression of STT4 confers wortmannin resistance, but overexpression of PIK1, a related PI 4-kinase, does not. In vitro, the PI 4-kinase activity of STT4, but not of PIK1, was potently inhibited by wortmannin. Overexpression of the phosphatidylinositol 4-phosphate 5-kinase homolog MSS4 conferred wortmannin resistance, as did deletion of phospholipase C-1. These observations support a model for a phosphatidylinositol metabolic cascade involving STT4, MSS4, and phospholipase C-1 and provide evidence that an essential product of this pathway is the lipid phosphatidylinositol 4,5-bisphosphate.	DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Heitman, Joseph/ABC-6006-2021		NHLBI NIH HHS [P01-HL50985-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL050985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; PAYNE WE, 1993, MOL CELL BIOL, V13, P4351, DOI 10.1128/MCB.13.7.4351; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; STACK JH, 1994, J BIOL CHEM, V269, P31552; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WONG K, 1994, J BIOL CHEM, V269, P28878; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YANO H, 1993, J BIOL CHEM, V268, P25846; YOKOO T, 1993, P NATL ACAD SCI USA, V90, P1804, DOI 10.1073/pnas.90.5.1804; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	47	66	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27671	27677		10.1074/jbc.272.44.27671	http://dx.doi.org/10.1074/jbc.272.44.27671			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346907	hybrid			2022-12-25	WOS:A1997YD47300033
J	Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK				Arap, W; Knudsen, E; Sewell, DA; Sidransky, D; Wang, JYJ; Huang, HJS; Cavenee, WK			Functional analysis of wild-type and malignant glioma derived CDKN2A beta alleles: Evidence for an RB-independent growth suppressive pathway	ONCOGENE			English	Article						CDKN2A; p16(INK4a); p16 beta; RB; tumor suppressor gene; malignant glioma	GENE; MUTATIONS; P16; DELETIONS; TRANSCRIPT; CANCER; LOCUS	The tumor suppressor gene CDKN2A (p16/MTS1/ 1NK4A), which encodes the cyclin-dependent kinase inhibitor p16(INK4a), is a target of 9p21 deletions during the malignant progression of human gliomas, This gene also encodes a second protein product (human p16 beta, murine p19(ARF)), which originates from an unrelated exon of CDKN2A (exon 1 beta) spliced onto exon 2 in an alternate reading frame, Cell cycle arrest by p16 beta is caused by an as yet unidentified pathway, In order to test the candidacy of p16 beta as a glioma suppressor, we replaced p16(INK4a), p15(INK4b) and p16 beta wild-type as well as a series of seven glioma-derived p16 beta alleles (R87H, A112V, R120H, A121V, G125R, A128A and A128V), into glioma cell lines that had either CDKN2A(-)/RB+ (U-87MG and U-251MG) or CDKN2A(+)/RB- (LN-319) endogenous backgrounds and demonstrated that p16 beta can act as a functional glioma cell growth suppressor, Moreover, p16 beta, but not p16(INK4a) or p15(INK4b) inhibited the growth of RE-negative LN-319 cells, indicating that p16 beta likely exerts its effects through an RB-independent pathway, In vitro and in vivo assays of pRB phosphorylation were consistent with this interpretation, Since none of the glioma-derived p16 beta mutations inactivated their growth suppressive activities, it appears that mutations in CDKN2A exon 2 (which is shared in the coding sequences of p16(INK4a) and p16 beta) likely exclusively target p16(INK4a).	UNIV CALIF SAN DIEGO,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; JOHNS HOPKINS UNIV,DEPT OTOLARYNGOL HEAD & NECK SURG,HEAD & NECK CANC RES DIV,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT ONCOL,BALTIMORE,MD 21205	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Stanford University; Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [R01 CA058320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ARAP W, 1995, CANCER RES, V55, P1351; DURO D, 1995, ONCOGENE, V11, P21; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; JAMES CD, 1993, CANCER RES, V53, P3674; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kyritsis AP, 1996, ONCOGENE, V12, P63; Liggett WH, 1996, CANCER RES, V56, P4119; Louis David N., 1997, P2013; LUCAS J, 1997, GENE DEV, V11, P1479; MAO L, 1995, CANCER RES, V55, P2995; MOULTON T, 1995, AM J PATHOL, V146, P613; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewell D. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P80; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; STONE S, 1995, CANCER RES, V55, P2988; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9	28	34	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2013	2020		10.1038/sj.onc.1201389	http://dx.doi.org/10.1038/sj.onc.1201389			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366518				2022-12-25	WOS:A1997YC28400002
J	McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T				McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T			p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status	ONCOGENE			English	Article						non-melanoma skin; transplantation; p53 gene; human papillomavirus	RENAL-TRANSPLANTATION; DNA; GENE; RECIPIENTS; ASSOCIATION; INSERTIONS; CARCINOMA; DELETIONS; CELLS; RISK	Mutations in p53 were detected in 11/23 (48%) of non melanoma skin cancers in renal allograft recipients and in 5/8 (63%) of sporadic tumours from immune competent patients, 9/12 (75%) of mutations in transplant patients and all 5 mutations in non transplant tumours were consistent with damage caused by ultraviolet (u,v,) irradiation, DNA sequences, predominantly of the epidermodysplasia verruciformis (EV) subgroup, were detected in 9/23 (39%) of transplant tumours and in 2/8 (25%) of eight non-transplant tumours, There was no relationship between HPV status and p53 mutation, HPV DNA being present in 5/16 (31%) of tumours with p53 mutation and 6/15 (40%) of tumours lacking p53 mutation, These data are consistent with an important role for sunlight in the development of post-transplant skin cancer, and with limited functional data suggesting that E6 proteins of the cutaneous and EV-related papillomaviruses do not target p53 for ubiquitin-mediated degradation.	INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,DEPT PHOTOBIOL,LONDON SE1 7EH,ENGLAND; UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,NL-1105 AZ AMSTERDAM,NETHERLANDS; KATHOLIEKE UNIV LEUVEN HOSP,DEPT DERMATOL,LEIDEN,NETHERLANDS; LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1,ENGLAND	University of London; Institute of Cancer Research - UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Amsterdam; Academic Medical Center Amsterdam; University of London; London School of Hygiene & Tropical Medicine								BAVINCK JNB, 1993, BRIT J DERMATOL, V129, P242, DOI 10.1111/j.1365-2133.1993.tb11841.x; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BLUM HF, 1948, J NATL CANCER I, V9, P247; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHENG KC, 1992, J BIOL CHEM, V267, P166; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DOLL R, 1970, BRIT MED J, V4, P420, DOI 10.1136/bmj.4.5732.420; Greenblatt MS, 1996, CANCER RES, V56, P2130; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; IARC, 1995, IARC MONOGRAPHS EVAL, V64; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; JEGO N, 1993, ONCOGENE, V8, P209; KELLY GE, 1987, BRIT J DERMATOL, V117, P429, DOI 10.1111/j.1365-2133.1987.tb04922.x; KIYONO T, 1989, VIROLOGY, V173, P551, DOI 10.1016/0042-6822(89)90567-9; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; Lewandowsky F, 1922, ARCH DERMATOL SYPH-G, V141, P193, DOI 10.1007/BF01938833; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MCGREGOR JM, 1995, LANCET, V346, P964, DOI 10.1016/S0140-6736(95)91584-2; McGregor JM, 1996, CANCER SURV, V26, P219; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1737	1740		10.1038/sj.onc.1201339	http://dx.doi.org/10.1038/sj.onc.1201339			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349508	Green Published			2022-12-25	WOS:A1997XY63100014
J	Uchida, T; Ishimori, K; Morishima, I				Uchida, T; Ishimori, K; Morishima, I			The effects of heme pocket hydrophobicity on the ligand binding dynamics in myoglobin as studied with leucine 29 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; NUCLEAR MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; ACID SIDE-CHAINS; CARBON-MONOXIDE; DISTAL HISTIDINE; MOLECULAR-DYNAMICS; OPTICAL-SPECTRA; PROTEIN; ORIENTATION	To examine the effects of heme pocket hydrophobicity on the ligand binding in myoglobin, some artificial mutants of human myoglobin have been prepared, in which less hydrophobic amino acid residue (Ala, Gly, Ser) is located at the Leu(29) (10th residue of the B helix) position, CO rebinding rates for the mutants were markedly decelerated, while the H-1, and N-15 NMR spectra of the mutants show that the structural changes around the heme iron for these mutants are rather small. The kinetic and structural properties of the mutants indicate that the ligand binding rate depends on the hydrophobicity inside the heme cavity for these mutants in addition to the volume of the side chain at the 29-position, On the basis of the IR stretching frequency of liganded CO, invasion of water molecules into the heme pocket in the mutants is suggested, which would be induced by the decrease in the hydrophobicity due to the amino acid substitution. A slight red shift of the position of the Soret peak for the serine mutant L29S also supports the reduced hydrophobicity inside the heme cavity, We can concluded that, together with the kinetic properties of the mutants, the hydrophobicity of the heme pocket is one of the key factors in regulating the ligand binding to the heme iron.	KYOTO UNIV,GRAD SCH ENGN,DEPT MOL ENGN,KYOTO 60601,JAPAN	Kyoto University			Ishimori, Koichiro/S-1247-2016; Uchida, Takeshi/A-6455-2017; Ishimori, Koichiro/AAQ-4434-2021	Ishimori, Koichiro/0000-0002-5868-0462; Uchida, Takeshi/0000-0001-9270-8329; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1992, J BIOL CHEM, V267, P12614; ADACHI S, 1989, J BIOL CHEM, V264, P18896; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P193; AVILES G, 1992, J CHEM SOC CHEM COMM, P31, DOI 10.1039/c39920000031; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; DALVIT C, 1987, J MOL BIOL, V194, P313, DOI 10.1016/0022-2836(87)90378-0; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Eaton W A, 1981, Methods Enzymol, V76, P175; EATON WA, 1978, J AM CHEM SOC, V100, P4991, DOI 10.1021/ja00484a013; EGEBERG KD, 1990, J BIOL CHEM, V265, P11788; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GOFF H, 1977, J AM CHEM SOC, V99, P6599, DOI 10.1021/ja00462a022; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; IIZUKA T, 1974, BIOCHIM BIOPHYS ACTA, V371, P126, DOI 10.1016/0005-2795(74)90161-5; JACKSON TA, 1994, CHEM PHYS, V180, P131, DOI 10.1016/0301-0104(93)E0414-Q; JUNG C, 1995, EUR J BIOCHEM, V233, P600, DOI 10.1111/j.1432-1033.1995.600_2.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LAIRD BB, 1989, J CHEM PHYS, V90, P3274, DOI 10.1063/1.455881; LAMAR GN, 1977, BIOCHEM BIOPH RES CO, V77, P104, DOI 10.1016/S0006-291X(77)80170-8; LAMBRIGHT DG, 1993, BIOCHEMISTRY-US, V32, P10116, DOI 10.1021/bi00089a030; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; LAMBRIGHT DG, 1989, J MOL BIOL, V207, P289, DOI 10.1016/0022-2836(89)90456-7; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; LINDSTORM TR, 1972, BIOCHEMISTRY-US, V9, P1677; MCCOY S, 1970, BIOCHEMISTRY-US, V9, P2387, DOI 10.1021/bi00814a001; MOORE JN, 1988, P NATL ACAD SCI USA, V85, P5062, DOI 10.1073/pnas.85.14.5062; MORISHIMA I, 1977, J CHEM SOC CHEM COMM, P616, DOI 10.1039/c39770000616; MORISHIMA I, 1977, BIOCHEM BIOPH RES CO, V78, P739, DOI 10.1016/0006-291X(77)90241-8; MORISHIMA I, 1978, J AM CHEM SOC, V100, P3568, DOI 10.1021/ja00479a046; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAMAPRASAD S, 1984, J AM CHEM SOC, V106, P5330, DOI 10.1021/ja00330a049; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SCHULMAN BA, 1994, PROTEIN SCI, V3, P2226, DOI 10.1002/pro.5560031208; SLICHTER CP, 1980, PHYS REV B, V22, P4097, DOI 10.1103/PhysRevB.22.4097; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; THOMAS KA, 1982, P NATL ACAD SCI-BIOL, V79, P4843, DOI 10.1073/pnas.79.16.4843; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; YAMAMOTO Y, 1993, BIOCHIM BIOPHYS ACTA, V1163, P287, DOI 10.1016/0167-4838(93)90164-M; YAMAMOTO Y, 1990, FEBS LETT, V264, P113; YOSHIKAWA S, 1985, J BIOL CHEM, V260, P3518	60	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30108	30114		10.1074/jbc.272.48.30108	http://dx.doi.org/10.1074/jbc.272.48.30108			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374489	hybrid			2022-12-25	WOS:A1997YH61300021
J	Kennedy, MW; Garside, LH; Goodrick, LE; McDermott, L; Brass, A; Price, NC; Kelly, SM; Cooper, A; Bradley, JE				Kennedy, MW; Garside, LH; Goodrick, LE; McDermott, L; Brass, A; Price, NC; Kelly, SM; Cooper, A; Bradley, JE			The Ov20 protein of the parasitic nematode Onchocerca volvulus - A structurally novel class of small helix-rich retinol-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREDICTING COILED COILS; FATTY-ACID; SECONDARY STRUCTURE; 3-DIMENSIONAL STRUCTURE; NEURAL NETWORKS; RAT-LIVER; ANTIGEN; POLYPROTEIN; ACCURACY; SITES	Ov20 is a major antigen of the parasitic nematode Onchocerca volvulus, the causative agent of river blindness in humans, and the protein is secreted into the tissue occupied by the parasite, DNA encoding Ov20 was isolated, and the protein was expressed in Escherichia coli, Fluorescence-based ligand binding assays show that the protein contains a high affinity binding site for retinol, fluorescent fatty acids (11-((5-dimethylamino-naphthalene-1-sulfonyl)amino)undecanoic acid, dansyl-DL-alpha-aminocaprylic acid, and parinaric acid) and, by competition, oleic and arachidonic acids, but not cholesterol, The fluorescence emission of dansylated fatty acids is significantly blue-shifted upon binding in comparison to similarly sized beta-sheet-rich mammalian retinol-and fatty acid-binding proteins, Secondary structure prediction algorithms indicate that a alpha-helix predominates in Ov20, possibly in a coiled coil motif, with no evidence of beta structures, and this was confirmed by circular dichroism, The protein is highly stable in solution, requiring temperatures in excess of 90 degrees C or high denaturant concentrations for unfolding, Ov20 there fore represents a novel class of small retinol-binding protein, which appears to be confined to nematodes, The retinol binding activity of Ov20 could possibly contribute to the eye defects associated with onchocerciasis and, because there is no counterpart in mammals? rep resents a strategic target for chemotherapy.	UNIV GLASGOW,DEPT CHEM,GLASGOW G12 8QQ,LANARK,SCOTLAND; UNIV SALFORD,DEPT BIOL SCI,SALFORD M5 4WT,LANCS,ENGLAND; UNIV MANCHESTER,DEPT BIOCHEM & MOL BIOL,MANCHESTER M13 9PT,LANCS,ENGLAND; UNIV STIRLING,DEPT BIOL & MOL SCI,STIRLING FK9 4LA,SCOTLAND	University of Glasgow; University of Salford; University of Manchester; University of Stirling	Kennedy, MW (corresponding author), UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV INFECT & IMMUN,JOSEPH BLACK BLDG,GLASGOW G12 8QQ,LANARK,SCOTLAND.		Cooper, Alan/F-7813-2011; Kelly, Sharon/K-4611-2013	Cooper, Alan/0000-0001-6709-7343; Brass, Andrew/0000-0002-0389-7058; Kelly, Sharon/0000-0002-3516-1387; Bradley, Janette/0000-0003-3973-7977; McDermott, Lindsay C./0000-0003-4723-6056	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRADLEY JE, 1995, J INFECT DIS, V172, P831, DOI 10.1093/infdis/172.3.831; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; BUELT MK, 1992, BIOCHEMISTRY-US, V31, P3493, DOI 10.1021/bi00128a025; CARMAN JA, 1992, J EXP MED, V175, P111, DOI 10.1084/jem.175.1.111; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Cooper A, 1994, Methods Mol Biol, V22, P109; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; FRAPIN D, 1993, J PROTEIN CHEM, V12, P443, DOI 10.1007/BF01025044; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GERRARD JM, 1985, PROSTAGLANDINS LEUKO; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; KENNEDY MW, 1995, J BIOL CHEM, V270, P19277, DOI 10.1074/jbc.270.33.19277; KENNEDY MW, 1995, MOL BIOCHEM PARASIT, V71, P41, DOI 10.1016/0166-6851(95)00028-Y; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; LAL PG, 1996, PARASITOLOGY, V112, P211; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; Mei BS, 1997, J BIOL CHEM, V272, P9933, DOI 10.1074/jbc.272.15.9933; MOSER D, 1991, J BIOL CHEM, V266, P8447; MURPHY RC, 1990, METHODS ENZYMOL, V187; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nozaki Y, 1972, Methods Enzymol, V26, P43; Olson JK, 1997, J VIROL, V71, P110, DOI 10.1128/JVI.71.1.110-119.1997; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RODGER FC, 1962, B WORLD HEALTH ORGAN, V27, P429; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SANI BP, 1985, BIOCHEM J, V232, P577, DOI 10.1042/bj2320577; SANI BP, 1988, BIOCHEM J, V249, P929, DOI 10.1042/bj2490929; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Szilak L, 1997, NAT STRUCT BIOL, V4, P112, DOI 10.1038/nsb0297-112; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TREE TIM, 1995, MOL BIOCHEM PARASIT, V69, P185, DOI 10.1016/0166-6851(94)00204-Z; WHITE MF, 1993, BIOCHEM J, V295, P743, DOI 10.1042/bj2950743; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419	49	91	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29442	29448		10.1074/jbc.272.47.29442	http://dx.doi.org/10.1074/jbc.272.47.29442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368002	hybrid			2022-12-25	WOS:A1997YG64700012
J	Paresce, DM; Chung, HY; Maxfield, FR				Paresce, DM; Chung, HY; Maxfield, FR			Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACYL-COENZYME-A; MOUSE PERITONEAL-MACROPHAGES; PRECURSOR PROTEIN; SCAVENGER RECEPTOR; SENILE PLAQUES; CHOLESTEROL ESTERIFICATION; ATHEROGENIC LIPOPROTEINS; CULTURED FIBROBLASTS; NEUROLOGICAL DISEASE	Microglia are immune system cells associated with senile plaques containing beta-amyloid (A beta) in Alzheimer's disease, Although microglia are an integral part of senile plaques, their role in the development of Alzheimer's disease is not known, Because microglia are phagocytic cells, it has been suggested that microglia may function as plaque-attacking scavenger cells, Microglia bind and internalize microaggregates of A beta that resemble those present in dense Alzheimer's disease plaques. In this study, we compared the degradation by microglia of A beta microaggregates with the degradation of two other proteins, acetylated low density lipoprotein and alpha(2)-macroglobulin. We found that the majority of the in internalized A beta in microaggregates was undegraded 72 h after uptake, whereas 70-80% of internalized acetylated low density lipoprotein or alpha(2)-macroglobulin was degraded and released from cells in trichloroacetic acid-soluble form after 4 h, In the continued presence of fluorescent A beta microaggregates for 4 days, microglia took up huge amounts of A beta and became engorged with undigested material, These data suggest that microglia can slowly degrade limited amounts of A beta plaque material, but the degradation mechanisms can be overwhelmed by larger amounts of A beta.	CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Cornell University; Columbia University			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866	NINDS NIH HHS [NS34761] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034761] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Christie RH, 1996, AM J PATHOL, V148, P399; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; Elkabes S, 1996, J NEUROSCI, V16, P2508; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GHOSH RN, 1995, J CELL BIOL, V128, P549, DOI 10.1083/jcb.128.4.549; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Giulian D, 1996, J NEUROSCI, V16, P6021; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Greenberg BD, 1996, NEUROBIOL AGING, V17, P153, DOI 10.1016/0197-4580(96)00001-2; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KNAUER MF, 1992, P NATL ACAD SCI USA, V89, P7437, DOI 10.1073/pnas.89.16.7437; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; Marx J, 1996, SCIENCE, V274, P1838, DOI 10.1126/science.274.5294.1838; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MAXFIELD FR, 1981, BIOCHEMISTRY-US, V20, P5353, DOI 10.1021/bi00521a041; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MITCHINSON MJ, 1987, LANCET, V2, P146; MUNRO JM, 1988, LAB INVEST, V58, P249; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Oh YK, 1996, J CELL BIOL, V132, P585, DOI 10.1083/jcb.132.4.585; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PERLMUTTER LS, 1983, NEUROSCI LETT, V52, P223; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SALZMAN NH, 1988, J CELL BIOL, V106, P1083, DOI 10.1083/jcb.106.4.1083; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SHAFFER LM, 1995, NEUROBIOL AGING, V16, P737, DOI 10.1016/0197-4580(95)00055-J; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; STEINBERG D, 1991, CIRCULATION, V84, P1420, DOI 10.1161/01.CIR.84.3.1420; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1994, J BIOL CHEM, V269, P22547; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WILLINGHAM MC, 1980, J HISTOCHEM CYTOCHEM, V28, P818, DOI 10.1177/28.8.6160180; WISNIEWSKI HM, 1990, AM J MED GENET, P287, DOI 10.1002/ajmg.1320370757; XU XX, 1991, J BIOL CHEM, V266, P17040; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIU WQ, 1996, J BIOL CHEM, V271, P8443	78	217	226	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29390	29397		10.1074/jbc.272.46.29390	http://dx.doi.org/10.1074/jbc.272.46.29390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361021	hybrid			2022-12-25	WOS:A1997YF68400080
J	Pinson, B; Napias, C; Chevallier, J; VandenBroek, PJA; Brethes, D				Pinson, B; Napias, C; Chevallier, J; VandenBroek, PJA; Brethes, D			Characterization of the Saccharomyces cerevisiae cytosine transporter using energizable plasma membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-MOTIVE FORCE; CYTOCHROME-C OXIDASE; CHAIN AMINO-ACIDS; STREPTOCOCCUS-CREMORIS; TRANSLOCATING ATPASE; PERMEASE; RECONSTITUTION; PROTEIN; BINDING; SYSTEM	The purine-cytosine permease is a carrier localized in the plasma membrane of the yeast Saccharomyces cerevisiae. The energetics of cytosine transport catalyzed by this permease has been studied in an artificial system obtained by fusion between proteoliposomes containing beef heart cytochrome c oxidase and plasma membrane-enriched fractions of a S. cerevisiae strain overexpressing the permease, Upon addition of an energy donor, a proton-motive force (inside alkaline and negative) is created in this system and promotes cytosine accumulation, By using different phospholipids, it is shown that cytosine uptake is dependent on the phospholipids surrounding the carrier, It was demonstrated that the purine-cytosine permease is able to catalyze a secondary active transport of cytosine, By using nigericin and valinomycin. the Delta pH component of the proton-motive force is shown to be the only force driving nucleobase accumulation, Moreover, transport measurements done at two pH values have shown that alkalinization of intravesicular pH leads to a significant increase in cytosine uptake rate. Finally, no specific role of K+ ions on cytosine transport could be demonstrated in this system.	CNRS,INST BIOCHIM GENET CELLULAIRE,UPR 9026,F-33077 BORDEAUX,FRANCE; LEIDEN UNIV,DEPT MOL CELL BIOL,SYLVIUS LAB,NL-2333 AL LEIDEN,NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Leiden University; Leiden University - Excl LUMC				Pinson, Benoit/0000-0003-2936-9058				Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BRETHES D, 1992, EUR J BIOCHEM, V210, P785, DOI 10.1111/j.1432-1033.1992.tb17481.x; BRETHES D, 1992, EUR J BIOCHEM, V204, P699, DOI 10.1111/j.1432-1033.1992.tb16684.x; CHEVALLIER MR, 1975, J BACTERIOL, V122, P629, DOI 10.1128/JB.122.2.629-641.1975; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DEVRIJ W, 1986, EUR J BIOCHEM, V156, P431; DRIESSEN AJM, 1987, J BIOL CHEM, V262, P12438; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1987, J BACTERIOL, V169, P5193, DOI 10.1128/jb.169.11.5193-5200.1987; DRIESSEN AJM, 1985, P NATL ACAD SCI USA, V82, P7555, DOI 10.1073/pnas.82.22.7555; FOLCH J, 1957, J BIOL CHEM, V226, P497; Geros H, 1996, YEAST, V12, P1263; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUERIN M, 1982, EUR J BIOCHEM, V124, P457; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOPKINS P, 1988, FEMS MICROBIOL LETT, V49, P173; HOPKINS P, 1992, YEAST, V8, P1053, DOI 10.1002/yea.320081208; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; LOLKEMA JS, 1982, BIOCHIM BIOPHYS ACTA, V681, P85, DOI 10.1016/0005-2728(82)90281-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; ONGJOCO R, 1987, J BACTERIOL, V169, P2926, DOI 10.1128/jb.169.7.2926-2931.1987; OPEKAROVA M, 1993, EUR J BIOCHEM, V211, P683, DOI 10.1111/j.1432-1033.1993.tb17596.x; POLAK A, 1973, EUR J BIOCHEM, V32, P276, DOI 10.1111/j.1432-1033.1973.tb02608.x; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; REICHERT U, 1977, FEBS LETT, V83, P325, DOI 10.1016/0014-5793(77)81033-8; SCHMIDT R, 1984, P NATL ACAD SCI-BIOL, V81, P6276, DOI 10.1073/pnas.81.20.6276; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; vandenBroek PJA, 1997, BIOCHEM J, V321, P487, DOI 10.1042/bj3210487; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; VANLEEUWEN CCM, 1991, J BIOL CHEM, V266, P12146; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; YU CA, 1975, J BIOL CHEM, V250, P1383	37	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28918	28924		10.1074/jbc.272.46.28918	http://dx.doi.org/10.1074/jbc.272.46.28918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360962	hybrid			2022-12-25	WOS:A1997YF68400021
J	Acs, P; Wang, QMJ; Bogi, K; Marquez, AM; Lorenzo, PS; Biro, T; Szallasi, Z; Mushinski, JF; Blumberg, PM				Acs, P; Wang, QMJ; Bogi, K; Marquez, AM; Lorenzo, PS; Biro, T; Szallasi, Z; Mushinski, JF; Blumberg, PM			Both the catalytic and regulatory domains of protein kinase C chimeras modulate the proliferative properties of NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; SIGNAL-TRANSDUCTION; PHORBOL ESTER; TYROSINE PHOSPHORYLATION; RAT FIBROBLASTS; PKC-DELTA; BETA-II; ALPHA; EPSILON; EXPRESSION	Protein kinase C (PKC) isozymes exhibit important differences in terms of their regulation and biological functions, Not only may some PKC isoforms be active and others not for a given response, but the actions of different isoforms may even be antagonistic, In NIH 3T3 cells, for example, PKC delta arrests cell growth whereas PKC epsilon stimulates it, To probe the contribution of the regulatory and the catalytic domains of PKC isozymes to isozyme-specific responses, we prepared chimeras between the regulatory and the catalytic domains of PKC alpha, -delta, and -epsilon. These chimeras, which preserve the overall structure of the native PKC enzymes, were stably expressed in mouse fibroblasts. A major objective was to characterize the growth properties of the cells that overexpress the various PKC constructs. Our data demonstrate that both the regulatory and the catalytic domains play roles in cell proliferation, The regulatory domain of PKC epsilon enhanced cell growth in the absence or presence of phorbol 12-myristate 13-acetate (PMA), and, in the presence of PMA, all chimeras with the PKC epsilon regulatory domain also gave rise to colonies in soft agar; the role of the catalytic domain of PKC epsilon was evident in the PMA-treated cells that overexpressed the PKC chimera containing the delta regulatory and the epsilon catalytic domains (PKC delta/epsilon). The important contribution of the PKC epsilon catalytic domain to the growth of PKC delta/epsilon-expressing cells was also evident in terms of a significantly increased saturation density in the presence of PMA, their formation of foci upon PMA treatment, and the induction of anchorage-independent growth. Aside from the growth-promoting effect of PKC epsilon, we have shown that most chimeras with PKC alpha and -delta regulatory domains inhibit cell growth. These results underscore the complex contributions of the regulatory and catalytic domains to the overall behavior of PKC.	NCI, MOL MECH TUMOR PROMOT SECT, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, NIH, BETHESDA, MD 20892 USA; NCI, GENET LAB, NIH, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT PHARMACOL, BETHESDA, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA			Wang, Qiming Jane/B-6064-2012	Wang, Qiming Jane/0000-0002-9502-4851; Szallasi, Zoltan/0000-0001-5395-7509				Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CACACE AM, 1993, ONCOGENE, V8, P2095; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; FlorinChristensen J, 1996, BIOCHEM J, V315, P513, DOI 10.1042/bj3150513; Herbert JM, 1996, J BIOL CHEM, V271, P25928; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KILEY S, 1997, 88 ANN M AM ASS CANC; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; LUO JH, 1993, J BIOL CHEM, V268, P23580; Manni A, 1996, CELL GROWTH DIFFER, V7, P1187; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; ONO Y, 1988, J BIOL CHEM, V263, P6927; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; RIEDEL H, 1993, MOL CELL BIOL, V13, P4728, DOI 10.1128/MCB.13.8.4728; Singer WD, 1996, J BIOL CHEM, V271, P4504; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	42	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28793	28799		10.1074/jbc.272.45.28793	http://dx.doi.org/10.1074/jbc.272.45.28793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353351	hybrid			2022-12-25	WOS:A1997YF21900091
J	Lu, M; Seufert, J; Habener, JF				Lu, M; Seufert, J; Habener, JF			Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT enhancer-binding protein beta - Inhibitory interactions with basic helix-loop-helix transcription factor E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH GLUCOSE-CONCENTRATIONS; REGULATED NUCLEAR-PROTEIN; HOMEOBOX FACTOR STF-1; HIT CELLS; SOMATOSTATIN GENE; CHRONIC EXPOSURE; MESSENGER-RNA; C/EBP-BETA; FACTOR EXPRESSION; LEUCINE ZIPPER	Chronic exposure of beta-cells to supraphysiologic glucose concentrations results in decreased insulin gene transcription, Here we identify the basic leucine zipper transcription factor, CCAAT/enhancer-binding protein beta (C/EBP beta), as a repressor of insulin gene transcription in conditions of supraphysiological glucose levels. C/EBP beta is expressed in primary rat islets, Moreover, after exposure to high glucose concentrations the beta-cell lines HIT-TIS and INS-1 express increased levels of C/EBP beta. The rat insulin I gene promoter contains a consensus binding motif for C/EBP beta (CEB box) that binds C/EBP beta. In non-beta-cells C/EBP beta stimulates the activity of the rat insulin I gene promoter through the CEB box. Paradoxically, in beta-cells C/EBP beta inhibits transcription, directed by the promoter of the rat insulin I gene by direct protein-protein interaction with a heptad leucine repeat sequence within activation domain 2 of the basic helix-loop-helix transcription factor E47. This interaction leads to the inhibition of both dimerization and DNA binding of E47 to the E-elements of the insulin promoter, thereby reducing functionally the transactivation potential of E47 on insulin gene transcription. We suggest that the induction of C/EBP beta in pancreatic beta-cells by chronically elevated glucose levels may contribute to the impaired insulin secretion in severe type II diabetes mellitus.	HARVARD UNIV, MOL ENDOCRINOL LAB,MASSACHUSETTS GEN HOSP,SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030834] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30834] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1992, CHEM IMMUNOL, V51, P299; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAILLAR JC, 1992, MED USES STAT; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIDDINGS SJ, 1985, DIABETOLOGIA, V28, P343; GOODISON S, 1992, BIOCHEM J, V285, P563, DOI 10.1042/bj2850563; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; ItkinAnsari P, 1996, ENDOCRINOLOGY, V137, P3540, DOI 10.1210/en.137.8.3540; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Olson LK, 1996, DIABETES, V45, P896; Osada S, 1996, J BIOL CHEM, V271, P3891; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK EA, 1993, J BIOL CHEM, V268, P613; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PHILIPPE J, 1994, ENDOCR REV, V2, P21; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; WEBSTER NJG, 1994, DIABETES, V43, P305, DOI 10.2337/diabetes.43.2.305; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	66	105	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28349	28359		10.1074/jbc.272.45.28349	http://dx.doi.org/10.1074/jbc.272.45.28349			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353292	hybrid			2022-12-25	WOS:A1997YF21900032
J	Bloom, LB; Chen, XL; Fygenson, DK; Turner, F; ODonnell, M; Goodman, MF				Bloom, LB; Chen, XL; Fygenson, DK; Turner, F; ODonnell, M; Goodman, MF			Fidelity of Escherichia coli DNA polymerase III holoenzyme - The effects of beta,gamma complex processivity proteins and epsilon proofreading exonuclease on nucleotide misincorporation efficiencies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; SPONTANEOUS MUTATION; ACCESSORY PROTEINS; BIOCHEMICAL BASIS; WILD-TYPE; TRANSIENT MISALIGNMENT; REVERSE-TRANSCRIPTASE; INSERTION FIDELITY; KINETIC-ANALYSIS; REPLICATION	The fidelity of Escherichia coli DNA polymerase III (pol III), is measured and the effects of beta, gamma processivity and epsilon proofreading subunits are evaluated using a gel kinetic assay, Pol III holoenzyme synthesizes DNA with extremely high fidelity, misincorporating dTMP, dAMP, and dGMP opposite a template G target with efficiencies f(inc) = 5.6 x 10(-6), 4.2 x 10(-7) and 7 x 10(-7), respectively. Elevated dGMP.G and dTMP.G misincorporation efficiencies of 3.2 x 10(-5) and 5.8 x 10(-4), attributed to a ''dNTP-stabilized'' DNA misalignment mechanism, occur when C and A, respectively, are located one base downstream from the template target G. At least 92% of mis-inserted nucleotides are excised by pol III holoenzyme in the absence of a next correct ''rescue'' nucleotide, As rescue dNTP concentrations are increased, pol III holoenzyme suffers a maximum 8-fold reduction in fidelity as proofreading of mispaired primer termini are reduced in competition with incorporation of a next correct nucleotide, Compared with pol III holoenzyme, the alpha holoenzyme, which cannot proofread, has 47-, 32-, and 13-fold higher misincorporation rates for dGMP.G, dTMP.G, and dAMP.G mispairs. Both the beta, gamma complex and the downstream nucleotide have little effect on the fidelity of catalytic alpha subunit, An analysis of the gel kinetic fidelity assay when multiple polymerase-DNA encounters occur is presented in the ''Appendix'' (see Fygenson, D. K., and Goodman, M. F. (1997) J. Biol. Chem, 272, 27931-27935 (accompanying paper)).	UNIV SO CALIF,DEPT BIOL SCI,HEDCO MOL BIOL LABS,LOS ANGELES,CA 90089; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; HEARST RES FDN,DEPT MICROBIOL,NEW YORK,NY	University of Southern California; Cornell University; Howard Hughes Medical Institute			Bloom, Linda B/F-3684-2014; Fygenson, Deborah K/U-3105-2017	Fygenson, Deborah K/0000-0002-5681-3938	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422, R01GM042554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSMAN MJ, 1974, J MOL BIOL, V88, P409, DOI 10.1016/0022-2836(74)90491-4; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAI H, 1993, J BIOL CHEM, V268, P23567; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DONG ZM, 1993, J BIOL CHEM, V268, P11758; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Efrati E, 1997, J BIOL CHEM, V272, P2559; FAY PJ, 1981, J BIOL CHEM, V256, P976; FERSHT A, 1985, ENZYME STRUCTURE MEC, P112; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; FERSHT AR, 1983, J MOL BIOL, V165, P669, DOI 10.1016/S0022-2836(83)80273-3; FERSHT AR, 1979, P NATL ACAD SCI USA, V76, P4946, DOI 10.1073/pnas.76.10.4946; FERSHT AR, 1983, J MOL BIOL, V165, P633, DOI 10.1016/S0022-2836(83)80271-X; FREESE E., 1959, PROC NATL ACAD SCI, V45, P622, DOI 10.1073/pnas.45.4.622; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GALAS DJ, 1978, J MOL BIOL, V88, P653; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; Nossal Nancy G., 1994, P43; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PATEL DJ, 1984, FED PROC, V43, P2663; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, J BIOL CHEM, V262, P16212; TRAUTNER TA, 1962, P NATL ACAD SCI USA, V48, P449, DOI 10.1073/pnas.48.3.449; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WATANABE SM, 1982, P NATL ACAD SCI-BIOL, V79, P6429, DOI 10.1073/pnas.79.21.6429; WATANABE SM, 1978, J VIROL, V25, P73, DOI 10.1128/JVI.25.1.73-77.1978; XIAO H, 1993, J BIOL CHEM, V268, P11773; YU H, 1992, J BIOL CHEM, V267, P10888	60	110	110	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27919	27930		10.1074/jbc.272.44.27919	http://dx.doi.org/10.1074/jbc.272.44.27919			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346941	hybrid			2022-12-25	WOS:A1997YD47300067
J	Johnson, GD; Bond, JS				Johnson, GD; Bond, JS			Activation mechanism of meprins, members of the astacin metalloendopeptidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZYMOGEN ACTIVATION; BETA-SUBUNIT; MEMBRANE; PROCOLLAGENASE; KIDNEY; COLLAGENASES; EXPRESSION; PROTEINASE; SEQUENCE; TRYPSIN	Meprins are mammalian zinc metalloendopeptidases with protease domains structurally related to astacin, the prototype of the ''astacin family'' of metalloproteases. Mature, active astacins are produced by proteolytic removal of an activation peptide to generate a new NH2-terminal residue. Structural studies indicate that the NH2-terminal ammonium group inserts into a water-filled cavity adjacent to the active site to form a salt bridge with a Glu residue that is conserved in all astacins. A similar interaction is known to play a crucial role in the activation of trypsin, resulting in the hypothesis that this salt bridge is required for the activation of astacin-like proteases. In this study, we have used the mouse meprin alpha subunit as a model to test this hypothesis of zymogen activation of the astacins. Mutants were generated to vary the NH2-terminal residue of the mature meprin alpha subunit (Asn(78)) and its putative salt bridge partner (Glu(178)). In addition, mutants-creating NH2-terminal extensions and truncations were expressed in human embryonic kidney 293 cells. The recombinant proteins were activated by limited protease digestion and assayed for enzymatic activity and thermal stability. Point mutations of Asn(78) resulted in enzymes with activity comparable to the wild-type enzyme, indicating that the structure of this side chain is not essential for activity. NH2-terminal extension mutants of meprin alpha retained partial activity, with greater decreases against peptide relative to protein substrates. A mutant with a deletion of Asn(78) to disrupt salt bridge formation with Glu(178) had full activity, indicating that the putative salt bridge with Glu(178) is not essential for enzyme activity. However, all changes in meprin alpha subunit NH2-terminal structure were found to decrease the thermal stability of the enzyme. These observations and additional data indicate that the zymogen activation mechanism of meprin and other astacins differs from that of the trypsin family of enzymes, and has some features in common with matrixins. It is proposed that prosequence removal of astacins allows the formation of hydrogen bonds involving the two NH2-terminal residues that are critical for enzyme structure.	PENN STATE UNIV,COLL MED,DEPT BIOCHEM & MOL BIOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NIDDK NIH HHS [DK19691, DK09238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R56DK019691, R01DK019691, F32DK009238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; Benbow U, 1996, J BIOL CHEM, V271, P10715, DOI 10.1074/jbc.271.18.10715; Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BRUNGER AT, 1987, BIOCHEMISTRY-US, V26, P5153; Chestukhin A, 1996, J BIOL CHEM, V271, P30272, DOI 10.1074/jbc.271.47.30272; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANT GA, 1987, J BIOL CHEM, V262, P5886; Hedstrom L, 1996, BIOCHEMISTRY-US, V35, P4515, DOI 10.1021/bi951928k; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; STOCKER W, 1995, PROTEIN SCI, V4, P823; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WANG JY, 1995, PROTEIN SCI, V4, P1758, DOI 10.1002/pro.5560040911; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; YAMAGUCHI T, 1991, EUR J BIOCHEM, V200, P563, DOI 10.1111/j.1432-1033.1991.tb16219.x	38	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28126	28132		10.1074/jbc.272.44.28126	http://dx.doi.org/10.1074/jbc.272.44.28126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346968	hybrid			2022-12-25	WOS:A1997YD47300094
J	Li, JP; HagnerMcWhirter, A; Kjellen, L; Palgi, J; Jalkanen, M; Lindahl, U				Li, JP; HagnerMcWhirter, A; Kjellen, L; Palgi, J; Jalkanen, M; Lindahl, U			Biosynthesis of heparin/heparan sulfate - DNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; ESCHERICHIA-COLI K5; HEPARAN-SULFATE; CAPSULAR POLYSACCHARIDE; AZOTOBACTER-VINELANDII; MOLECULAR-CLONING; ACID; PURIFICATION; EPIMERASE; BINDING	Glucuronyl C5-epimerases catalyze the conversion of D-glucuronic acid (GlcUA) to L-iduronic acid (IdceA) units during the biosynthesis of glycosaminoglycans. An epimerase implicated in the generation of heparin/heparan sulfate was previously purified to homogeneity from bovine liver (Campbell, P., Hannesson, H. H., Sandback, D., Roden, L., Lindahl, U., and Li, J.-p, (1994) J. Biol. Chem. 269, 2695-26958). The present report describes the molecular cloning and functional expression of the lung enzyme, The cloned enzyme contains 444 amino acid residues and has a molecular mass of 49,905 Da, N-terminal sequence analysis of the isolated liver enzyme showed this species to be a truncated form lacking a 73-residue N-terminal domain of the deduced amino acid sequence. The coding cDNA insert was cloned into a baculovirus expression vector and expressed in Sf9 insect cells, Cells infected with recombinant epimerase showed a 20-30-fold increase in enzyme activity, measured as release of (H2O)-H-3 from a polysaccharide substrate containing C5-H-3-labeled hexuronic acid units. Furthermore, incubation of the expressed protein with the appropriate (GlcUA-GlcNSO(3))(n) substrate resulted in conversion of similar to 20% of the GlcUA units into IdceA residues, Northern analysis implicated two epimerase transcripts in both bovine lung and liver tissues, a dominant similar to 9-kilobase (kb) mRNA and a minor similar to 5-kb species, Mouse mastocytoma cells showed only the similar to 5-kb transcript. A comparison of the cloned epimerase with the enzymes catalyzing an analogous reaction in alginate biosynthesis revealed no apparent amino acid sequence similarity.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN; UNIV TURKU,CTR BIOTECHNOL,FIN-20520 TURKU,FINLAND; ABO AKAD UNIV,FIN-20520 TURKU,FINLAND	Swedish University of Agricultural Sciences; University of Turku; Abo Akademi University	Li, JP (corresponding author), UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,POB 575,S-75123 UPPSALA,SWEDEN.		Kjellen, Lena/F-1362-2011					BACKSTROM G, 1979, J BIOL CHEM, V254, P2975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; HANNESSON HH, 1995, BIOCHEM J, V313, P589; HARLOW E, 1989, ANTIBODIES LAB MANUA, P78; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HAUG A, 1969, BIOCHIM BIOPHYS ACTA, V192, P557, DOI 10.1016/0304-4165(69)90414-0; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON KG, 1985, J BIOL CHEM, V260, P2154; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; MALMSTROM A, 1982, BIOCHEM J, V201, P1; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; PODUSLO JF, 1981, ANAL BIOCHEM, V114, P131, DOI 10.1016/0003-2697(81)90463-2; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SILBERT JE, 1963, J BIOL CHEM, V238, P3542; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	33	83	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28158	28163		10.1074/jbc.272.44.28158	http://dx.doi.org/10.1074/jbc.272.44.28158			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346972	hybrid			2022-12-25	WOS:A1997YD47300098
J	Muthukkumar, S; Han, SS; Muthukkumar, S; Rangnekar, VM; Bondada, S				Muthukkumar, S; Han, SS; Muthukkumar, S; Rangnekar, VM; Bondada, S			Role of Egr-1 gene expression in B cell receptor-induced apoptosis in an immature B cell lymphoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; GROWTH-INHIBITION; LYMPHOCYTES-B; PROTEIN; PROMOTER; TRANSCRIPTION; ACTIVATION; SURVIVAL; ELEMENT; STAGE	Ligation of B cell receptor (BCR) on BKS-2, an immature B cell lymphoma by anti-IgM antibodies (Ab) caused apoptosis. Here we report that signaling through B cell receptor in wild type BKS-2 cells down-regulated the expression of Egr-1, a zinc finger-containing transcription factor. A reduction in the level of Egr-1 mRNA could be demonstrated as early as 30 min after the ligation of BCR on BKS-2 cells. Immunocytochemical and Western blot analysis revealed that the expression of EGR-1 protein was also inhibited by anti-IgM treatment. Antisense oligonucleotides to Egr-1 caused growth inhibition and apoptosis in BKS-2 cells, suggesting that expression of Egr-1 is important for the survival of these B lymphoma cells. In contrast to wild type BKS-2 cells, the mutant 1.B5 cell line, which is refractory to B cell receptor-mediated growth-inhibitory signals, showed an increased expression of Egr-1 upon treatment with anti-IgM. These results implicate a role for Egr-1 in blocking B cell receptor-mediated apoptosis in immature B cells.	UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,SANDERS BROWN RES CTR AGING,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky				Han, Seong-Su/0000-0001-9824-6751	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 21490] Funding Source: Medline; NIA NIH HHS [AG 05731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Carman JA, 1996, J IMMUNOL, V156, P4562; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DAY ML, 1993, CANCER RES, V53, P5597; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLD MR, 1994, ADV IMMUNOL, V55, P221; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1995, ONCOGENE, V10, P467; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; LAMAIRE P, 1989, P NATL ACAD SCI USA, V85, P4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEPTIN M, 1985, EUR J IMMUNOL, V15, P131, DOI 10.1002/eji.1830150206; LIM RW, 1987, ONCOGENE, V1, P263; MADEN SL, 1991, SCIENCE, V253, P1550; Maltzman JS, 1996, J EXP MED, V183, P1747, DOI 10.1084/jem.183.4.1747; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; McMahon SB, 1996, J LEUKOCYTE BIOL, V60, P159, DOI 10.1002/jlb.60.2.159; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MONROE JG, 1993, ADV MOL CELL IMMUN B, V1, P1; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; MUTHUKKUMAR S, 1994, INT IMMUNOL, V7, P305; NAMAZEE DA, 1989, NATURE, V337, P562; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RACHAL MJ, 1989, NUCLEIC ACIDS RES, V17, P5135, DOI 10.1093/nar/17.13.5135; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; Reid S, 1996, J IMMUNOL METHODS, V192, P43, DOI 10.1016/0022-1759(96)00004-X; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SEIFERT VL, 1989, MOL CELL BIOL, V9, P2083; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SIDEROVSKI DP, 1990, DNA CELL BIOL, V9, P579, DOI 10.1089/dna.1990.9.579; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; UDHAYAKUMAR V, 1991, J IMMUNOL, V146, P4120; UDHAYAKUMAR V, 1989, CLIN IMMUNOL IMMUNOP, V51, P240, DOI 10.1016/0090-1229(89)90023-8; WANG ZY, 1992, BIOCHEM BIOPH RES CO, V188, P433, DOI 10.1016/0006-291X(92)92403-K; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	53	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27987	27993		10.1074/jbc.272.44.27987	http://dx.doi.org/10.1074/jbc.272.44.27987			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346950	Green Published, hybrid			2022-12-25	WOS:A1997YD47300076
J	Park, MS; Valdez, J; Gurley, L; Kim, CY				Park, MS; Valdez, J; Gurley, L; Kim, CY			Characterization of a putative helix-loop-helix motif in nucleotide excision repair endonuclease, XPG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-G; NONPOLYPOSIS COLON-CANCER; COMPLEMENTATION GROUP-G; XERODERMA-PIGMENTOSUM; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOMAL LOCALIZATION; MAMMALIAN-CELLS; YEAST RAD2	Complementation group G of xeroderma pigmentosum (XPG) is one of the most rare and pathophysiologically heterogeneous forms of this inherited disease. XPG patients exhibit varying phenotypes, from having a very mild defect in DNA repair to being severely affected, and a few cases are also associated with the neurological degeneracy and growth retardation of Cockayne's syndrome. The XPG gene encodes a 134-kDa nuclear protein that is essential for the incision steps of nucleotide excision repair. XPG protein contains a putative helix-loop-helix (HLH) motif in the region that is most conserved among the members of structure-specific endonuclease family. To establish the functional significance of the HLH motif, we used several approaches, including theoretical modeling, functional complementation assay, structure-specific endonuclease assay, and DNA binding assay. A secondary structure of the motif was predicted by energy minimization and the Monte Carlo simulation and empirically proven using the circular dichroism to contain a high content of alpha-helix. When an XPG mutant lacking the HLH was overexpressed in UV135 cells, which have defects in the hamster homolog of XPG, the mutant gene failed to confer to the hamster cells the resistance to UV light. A recombinant XPG protein lacking the HLH motif was purified from insect cells and tested for a structure-specific endonuclease activity. The mutant protein failed to cleave the flap strand. A recombinant peptide containing the HLH (amino acids 758-871) was expressed in and purified from bacteria, tested for DNA binding activity, and found to bind to a DNA substrate with the flap structure. These results suggest that the HLH motif is required for the catalytic and DNA binding activities of XPG.			Park, MS (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,M888,LOS ALAMOS,NM 87545, USA.		Park, Min Sung/HCH-2207-2022	Kim, Chang-Yub/0000-0001-9353-5909	NATIONAL CANCER INSTITUTE [R29CA071630] Funding Source: NIH RePORTER; NCI NIH HHS [CA71630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; DELEAGE G, 1989, PREDICTION PROTEIN S, P587; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLETCHER R, 1984, PRACTICAL METHODS OP, V1; FRIEDBERG EC, 1995, DNA REPAIR; GRAM FL, 1973, VIROLOGY, V52, P456; GUPTA G, PEPTIDES DESIGN SYNT, P324; GUPTA G, 1990, 5 C CENT GARD, V99, P143; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARADA YN, 1995, GENOMICS, V28, P59, DOI 10.1006/geno.1995.1106; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; JACQUIER A, 1992, YEAST, V8, P121, DOI 10.1002/yea.320080207; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MACINNES MA, 1993, MOL CELL BIOL, V13, P6393, DOI 10.1128/MCB.13.10.6393; MADURA K, 1986, J BACTERIOL, V166, P914, DOI 10.1128/jb.166.3.914-923.1986; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; MUDGETT JS, 1990, GENOMICS, V8, P623, DOI 10.1016/0888-7543(90)90248-S; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MUSER TC, 1996, CELL, V85, P1101; NORRIS PG, 1987, BRIT J DERMATOL, V116, P861, DOI 10.1111/j.1365-2133.1987.tb04906.x; NOUSPIKEL T, 1994, HUM MOL GENET, V3, P963, DOI 10.1093/hmg/3.6.963; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SHIOMI T, 1994, MUTAT RES, V314, P167, DOI 10.1016/0921-8777(94)90080-9; SIPPL MJ, 1984, J PHYS CHEM-US, V88, P6231, DOI 10.1021/j150669a035; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; WOOD RD, 1995, PHILOS T ROY SOC B, V347, P69, DOI 10.1098/rstb.1995.0011	52	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27823	27829		10.1074/jbc.272.44.27823	http://dx.doi.org/10.1074/jbc.272.44.27823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346928	hybrid			2022-12-25	WOS:A1997YD47300054
J	Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M				Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M			Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus	ONCOGENE			English	Article						translocation; 11q23; MLL; AF6; leukemogenesis	11Q23 CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; DROSOPHILA-TRITHORAX; ALL-1 GENE; CLONING; ABNORMALITIES; EXPRESSION; REARRANGEMENT; HOMOLOG	In infantile leukemias and therapy-related leukemias, the MLL gene is frequently found to be disrupted and fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL as a result of 11q23 translocations, We previously showed that the N-terminal portion common to various chimeric MLL products, as well as to MLL-LTG9 and MLL-LTG19, localizes in the nuclei, and therefore suggested that it might play an important role in leukemogenesis, In the present study, MLL-AF6 chimeric products found in the t(6;11) (q27;q23) translocation were analysed since AF6, a Ras-binding protein, exhibits a different subcellular localization from that of LTG9/AF9 and LTG19/ENL, Immunofluorescence staining data and cell fractionation analyses demonstrated that MLL-AF6 chimeric products localize in the nuclei despite the fact that AF6 itself localizes in the cytoplasm, confirming the importance of the nuclear localization of chimeric MLL products, The region in the N-terminal portion of MLL responsible for this nuclear localization was examined and found to be a region containing AT-hook motifs.	AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 260,JAPAN; NAGOYA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,NAGOYA,AICHI 464,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Chiba University; Nagoya City University; Nara Institute of Science & Technology								AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1996, ONCOGENE, V13, P1945; Kakuda H, 1996, BRIT J HAEMATOL, V95, P306, DOI 10.1046/j.1365-2141.1996.d01-1909.x; KANEKO Y, 1986, BLOOD, V67, P484; KURIYAMA M, 1996, J BIOL CHEM, V271, P606; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	35	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1681	1687		10.1038/sj.onc.1201332	http://dx.doi.org/10.1038/sj.onc.1201332			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349501				2022-12-25	WOS:A1997XY63100007
J	Chinery, R; Brockman, JA; Dransfield, DT; Coffey, RJ				Chinery, R; Brockman, JA; Dransfield, DT; Coffey, RJ			Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta - A critical role for protein kinase A-mediated phosphorylation of Ser(299)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; LEUCINE ZIPPER; SIGNAL TRANSDUCTION; C/EBP FAMILY; EXPRESSION; NF-IL6; CANCER; MEMBER; CELLS; ACID	Alterations in intracellular oxidative status activate several signal transduction pathways resulting in distinct patterns of gene expression. Treatment of colorectal cancer cells with antioxidants can lead to apoptosis by induction of p21 through a mechanism involving CCAAT/enhancer-binding protein beta (C/EBP beta). Herein, we demonstrate that the antioxidant pyrrolidinedithio-carbamate activates cAMP-dependent protein kinase (PKA) in a colorectal cancer cell line DKO-1. Activation of PKA phosphorylates Ser(299) within C/EBP beta, which is essential for protein translocation to the nucleus. Pharmacological inhibition of PKA and mutation of Ser(299) to alanine blocks C/EBP beta nuclear translocation and induction of p21. Our results indicate that a cAMP-dependent phosphorylation of C/EBP beta at Ser(299) is critical for nuclear translocation of this protein and its subsequent transactivation of genes in response to antioxidant treatment.	VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; VET AFFAIRS MED CTR,NASHVILLE,TN 37232; MED COLL GEORGIA,INST MOL MED & GENET,AUGUSTA,GA 30912	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University System of Georgia; Augusta University	Chinery, R (corresponding author), VANDERBILT UNIV,MED CTR,DEPT MED,CC2201 MED CTR N,NASHVILLE,TN 37232, USA.				NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER; NCI NIH HHS [CA46413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSSEY HJR, 1982, CANCER, V50, P1434, DOI 10.1002/1097-0142(19821001)50:7<1434::AID-CNCR2820500733>3.0.CO;2-F; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COFFEY RJ, 1987, CANCER RES, V47, P4590; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANIELSON P, 1988, DNA CELL BIOL, V12, P261; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gorospe M, 1996, MOL CELL DIFFER, V4, P47; GREENWALD P, 1995, CANCER EPIDEM BIOMAR, V4, P691; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONEY CW, 1992, J BIOL CHEM, V267, P19296; MASUDA H, 1993, JPN CIRC J, V57, P1007, DOI 10.1253/jcj.57.1007; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORSON BC, 1983, CANCER SURV, V2, P451; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	29	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30356	30361		10.1074/jbc.272.48.30356	http://dx.doi.org/10.1074/jbc.272.48.30356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374525	hybrid			2022-12-25	WOS:A1997YH61300057
J	Sorensen, T; Vilsen, B; Andersen, JP				Sorensen, T; Vilsen, B; Andersen, JP			Mutation Lys(758)->Ile of the sarcoplasmic reticulum Ca2+-ATPase enhances dephosphorylation of E2P and inhibits the E-2 to E1Ca2 transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; PERTURBED REACTION CYCLES; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; KINETIC CHARACTERIZATION; ATP HYDROLYSIS; CA2+ TRANSPORT; ALPHA-SUBUNIT; CA-2+-ATPASE; MECHANISM	The highly conserved lysine residue Lys(758) in the fifth stalk segment of the sarcoplasmic reticulum Ca2+-ATPase was substituted with either isoleucine or arginine by site-directed mutagenesis. The substitution with arginine was without significant effects on Ca2+-ATPase function, whereas multiple changes of functional characteristics were observed with the Lys(758) --> Ile mutant. These included insensitivity of ATPase activity to the calcium ionophore A23187, an alkaline shift of the pH dependence of ATPase activity, reduced maximum molecular turnover rate and steady-state phosphorylation level, reduced apparent affinities for Ca2+ and inorganic phosphate, as well as increased sensitivity to inhibition by vanadate. Analysis of the partial reaction steps of the enzyme cycle traced these changes to two steps. The rate of dephosphorylation of the ADP-insensitive phosphoenzyme intermediate (E2P) was increased, irrespective of variations of pH, K+, Ca2+, and dimethyl sulfoxide concentration. In addition, the rate of conversion of the dephosphoenzyme with low Ca2+ affinity (E-2) to the Ca2+-bound form activated for phosphorylation (E1Ca2) was reduced in the mutant, and the ATP-induced rate enhancement of this step required higher ATP concentrations in the mutant compared with the wild type.	AARHUS UNIV,DEPT PHYSIOL,DK-8000 AARHUS C,DENMARK	Aarhus University			Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499; Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1985, BIOCHIM BIOPHYS ACTA, V815, P9, DOI 10.1016/0005-2736(85)90467-5; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BISHOP JE, 1988, J BIOL CHEM, V263, P1886; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 1996, BIOCHEM J, V318, P689, DOI 10.1042/bj3180689; FORGE V, 1993, J BIOL CHEM, V268, P10953; HARA H, 1986, J BIOL CHEM, V261, P6584; HENAO F, 1991, EUR J BIOCHEM, V202, P559, DOI 10.1111/j.1432-1033.1991.tb16408.x; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1983, BIOPHYS J, V44, P271, DOI 10.1016/S0006-3495(83)84299-4; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V705, P38, DOI 10.1016/0167-4838(82)90333-8; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LUND S, 1988, J BIOL CHEM, V263, P1654; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6947; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STARLING AP, 1994, BIOCHEMISTRY-US, V33, P3023, DOI 10.1021/bi00176a035; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TAKISAWA H, 1978, J BIOCHEM-TOKYO, V83, P1275, DOI 10.1093/oxfordjournals.jbchem.a132034; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P10613, DOI 10.1021/bi00499a006; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Yonekura K, 1997, BIOPHYS J, V72, P997, DOI 10.1016/S0006-3495(97)78752-6; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	54	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30244	30253		10.1074/jbc.272.48.30244	http://dx.doi.org/10.1074/jbc.272.48.30244			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374509	hybrid			2022-12-25	WOS:A1997YH61300041
J	Cain, D; Hutson, SM; Wallin, R				Cain, D; Hutson, SM; Wallin, R			Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; PROTEIN DISULFIDE-ISOMERASE; DEPENDENT CARBOXYLASE; EPOXIDE REDUCTASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; GLUTATHIONE TRANSFERASE; SOLUBILIZATION; IDENTIFICATION; PROTHROMBIN; METABOLISM	gamma-Carboxylation of vitamin K-dependent proteins requires a functional vitamin K cycle to produce the active vitamin Ii cofactor for the gamma-carboxylase which posttranslationally modifies precursors of these proteins to contain gamma-carboxyglutamic acid residues, The warfarin-sensitive enzyme vitamin K epoxide reductase CVI(OR) of the cycle reduces vitamin K 2,3-epoxide to the active vitamin K hydroquinone cofactor, Because of the importance of warfarin as an anticoagulant in prophylactic medicine and as a poison in rodent pest control, numerous attempts have been made to understand the molec molecular mechanism underlying warfarin-sensitive vitamin K 2,3-epoxide reduction. In search for protein components that could be involved in this reaction we designed an in vitro gamma-carboxylation test system where the warfarin-sensitive VKOR produces the cofactor for the gamma-carboxylase. Dissection of this system by chromatographic techniques has identified a member(s) of the glutathione S-transferase gene family as one component of the VKOR enzyme complex in the endoplasmic reticulum membrane, The affinity-purified glutathione S-transferase(s) was sensitive to warfarin but lost its warfarin sensitivity and glutathione S-transferase activity upon association with lipids in the presence of Mn2+ or Ca2+. In the gamma-carboxylation test system, loss of warfarin-sensitive glutathione S-transferase activity coincided with formation of the VKOR enzyme complex, It is proposed that formation of VKOR in the endoplasmic reticulum membrane resembles formation of the Lipoxygenase enzyme complex where the glutathione S-transferase-related FLAP protein binds cytosolic lipoxygenase to form a membrane enzyme complex.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center								ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; ANDERSON C, 1994, BIOCHIM BIOPHYS ACTA, V1240, P298; ANDERSSON C, 1995, BBA-PROTEIN STRUCT M, V1247, P277, DOI 10.1016/0167-4838(94)00239-D; BELL R G, 1970, Archives of Biochemistry and Biophysics, V141, P473, DOI 10.1016/0003-9861(70)90164-5; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FASCO MJ, 1983, BIOCHEMISTRY-US, V22, P5655, DOI 10.1021/bi00293a031; FASCO MJ, 1983, J BIOL CHEM, V258, P4372; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRIEDBERG T, 1994, BIOCHEM J, V303, P967, DOI 10.1042/bj3030967; FRIEDBERG T, 1979, J BIOL CHEM, V254, P2028; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GUENTHNER TM, METHOD ENZYMOL, V77, P344; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HAYES JD, 1995, CRIT REV BIOCHEM MOL, V30, P446; HILDEBRANDT EF, 1984, ARCH BIOCHEM BIOPHYS, V228, P480, DOI 10.1016/0003-9861(84)90014-6; Jackson WB, 1988, CURRENT ADV VITAMIN, P381; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; LENAZ G, 1977, MOL BIOL MEMBRANES, P137; LIND C, 1981, ARCH BIOCHEM BIOPHYS, V207, P217, DOI 10.1016/0003-9861(81)90027-8; MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; MORGENSTERN R, 1985, J BIOL CHEM, V260, P3976; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; SADOWSKI JA, 1976, J BIOL CHEM, V251, P2770; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; STANTON C, 1991, BIOCHEM J, V277, P59, DOI 10.1042/bj2770059; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; Suttie J. W., 1978, Handbook of lipid research. Volume 2. The fat-soluble vitamins, P211; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; THIJSSEN HHW, 1994, BIOCHEM J, V297, P277, DOI 10.1042/bj2970277; Tishler M, 1940, J AM CHEM SOC, V62, P2866, DOI 10.1021/ja01867a066; VERKLEIJ AJ, 1984, BIOCHIM BIOPHYS ACTA, V779, P43, DOI 10.1016/0304-4157(84)90003-0; WALLIN R, 1978, BIOCHEM J, V169, P95, DOI 10.1042/bj1690095; WALLIN R, 1988, J BIOL CHEM, V263, P9994; WALLIN R, 1985, J CLIN INVEST, V76, P1879, DOI 10.1172/JCI112182; WALLIN R, 1984, P NATL ACAD SCI-BIOL, V81, P4095, DOI 10.1073/pnas.81.13.4095; Wallin R, 1997, METHOD ENZYMOL, V282, P395; WALLIN R, BIOCHEM J, V241, P389	44	93	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29068	29075		10.1074/jbc.272.46.29068	http://dx.doi.org/10.1074/jbc.272.46.29068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360981	hybrid			2022-12-25	WOS:A1997YF68400040
J	Costello, LC; Liu, YY; Franklin, RB; Kennedy, MC				Costello, LC; Liu, YY; Franklin, RB; Kennedy, MC			Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTOSTERONE; SECRETION; OXIDATION; BINDING	Prostate epithelial cells possess a uniquely limiting mitochondrial (m-) aconitase activity that minimizes their ability to oxidize citrate, These cells also possess uniquely high cellular and mitochondrial zinc levels, Correlations among zinc, citrate, and m-aconitase in prostate indicated that zinc might be an inhibitor of prostate m-aconitase activity and citrate oxidation, The present studies reveal that zinc at near physiological levels inhibited m-aconitase activity of mitochondrial sonicate preparations obtained from rat ventral prostate epithelial cells, Corresponding studies conducted with mitochondrial sonicates of rat kidney cells revealed that zinc also inhibited the kidney m-aconitase activity, However the inhibitory effect of zinc was more sensitive with the prostate m-aconitase activity. Zinc inhibition fit the competitive inhibitor model, The inhibitory effect of zinc occurred only with citrate as substrate and was specific for the citrate --> cis-aconitate reaction. Other cations (Ca2+, Mn2+, Cd2+) did not result in the inhibitory effects obtained with zinc, The presence of endogenous zinc inhibited the m-aconitase activity of the prostate mitochondrial preparations, Kidney preparations that contain lower endogenous zinc levels exhibited no endogenous inhibition of m-aconitase activity, Studies with pig prostate and seminal vesicle mitochondrial preparations also revealed that zinc was a competitive inhibitor against citrate of m-aconitase activity, The effects of zinc on purified beef heart m-aconitase verified the competitive inhibitor action of zinc, In contrast, zinc had no inhibitory effect on purified cytosolic aconitase, These studies reveal for the first time that zinc is a specific inhibitor of m-aconitase of mammalian cells, In prostate epithelial cells, in situ mitochondrial zinc levels inhibit m-aconitase activity, which provides a mechanism by which citrate oxidation is limited.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin	Costello, LC (corresponding author), UNIV MARYLAND,SCH DENT,CELLULAR & MOL BIOL SECT,666 W BALTIMORE ST,BALTIMORE,MD 21201, USA.				NATIONAL CANCER INSTITUTE [R01CA071207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051831] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71207] Funding Source: Medline; NIDDK NIH HHS [DK-28015] Funding Source: Medline; NIGMS NIH HHS [GM-51831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Costello LC, 1997, UROLOGY, V50, P3, DOI 10.1016/S0090-4295(97)00124-6; COSTELLO LC, 1995, MOL CELL ENDOCRINOL, V112, P45, DOI 10.1016/0303-7207(95)03582-R; Costello LC, 1996, UROLOGY, V48, P654, DOI 10.1016/S0090-4295(96)00217-8; COSTELLO LC, 1991, PROSTATE, V19, P181, DOI 10.1002/pros.2990190302; COSTELLO LC, 1991, PROSTATE, V18, P25, DOI 10.1002/pros.2990180104; COSTESCU A, 1981, REV ROUM PHYS, V26, P281; Franklin R. B., 1997, PROSTATE BASIC CLIN, P115; Frishman D, 1996, EUR J BIOCHEM, V239, P197, DOI 10.1111/j.1432-1033.1996.0197u.x; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Lauble H, 1996, P NATL ACAD SCI USA, V93, P13699, DOI 10.1073/pnas.93.24.13699; Liu Y, 1996, METABOLISM, V45, P442, DOI 10.1016/S0026-0495(96)90217-6; LIU Y, 1996, PROSTATE, V30, P26; LUTZ RA, 1986, ENZYME, V36, P197, DOI 10.1159/000469292; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Sillen L, 1964, STABILITY CONSTANTS; WESTERGAARD N, 1995, P NATL ACAD SCI USA, V92, P3367, DOI 10.1073/pnas.92.8.3367	18	182	218	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28875	28881		10.1074/jbc.272.46.28875	http://dx.doi.org/10.1074/jbc.272.46.28875			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360955	hybrid			2022-12-25	WOS:A1997YF68400014
J	Gurevich, VV; PalsRylaarsdam, R; Benovic, JL; Hosey, MM; Onorato, JJ				Gurevich, VV; PalsRylaarsdam, R; Benovic, JL; Hosey, MM; Onorato, JJ			Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTORS; BINDING; PHOSPHORYLATION; RHODOPSIN	The rapid decrease of a response to a persistent stimulus, often termed desensitization, is a widespread biological phenomenon, Signal transduction by numerous G protein-coupled receptors appears to be terminated by a strikingly uniform two-step mechanism, most extensively characterized for the beta(2)-adrenergic receptor (beta(2)AR), m2 muscarinic cholinergic receptor (m2 mAChR), and rhodopsin, The model predicts that activated receptor is initially phosphorylated and then tightly binds an arrestin protein that effectively blocks further G protein interaction, Here we report that complexes of beta(2)AR-arrestin and m2 mAChR-arrestin have a higher affinity for agonists (but not antagonists) than do receptors not complexed with arrestin. The percentage of phosphorylated beta(2)AR in this high affinity state in the presence of full agonists varied with different arrestins and was enhanced by selective mutations in arrestins, The percentage of high affinity sites also was proportional to the intrinsic activity of an agonist, and the coefficient of proportionality varies for different arrestin proteins. Certain mutant arrestins can form these high affinity complexes with unphosphorylated receptors, Mutations that enhance formation of the agonist-receptor-arrestin complexes should provide useful tools for manipulating both the efficiency of signaling and rate and specificity of receptor internalization.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706	Northwestern University; Jefferson University; University of Wisconsin System; University of Wisconsin Madison	Gurevich, VV (corresponding author), SUN HLTH RES INST,10515 W SANTA FE DR,SUN CITY,AZ 85372, USA.		Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NEI NIH HHS [EY11500] Funding Source: Medline; NHLBI NIH HHS [HL50201] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL050201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GOODMAN OB, 1997, J BIOL CHEM, V272, P15016; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; LEFKOWITZ RJ, 1982, FED PROC, V41, P2664; LIMBIRD LE, 1978, P NATL ACAD SCI USA, V75, P228, DOI 10.1073/pnas.75.1.228; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1170; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0	18	149	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28849	28852		10.1074/jbc.272.46.28849	http://dx.doi.org/10.1074/jbc.272.46.28849			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360951	hybrid			2022-12-25	WOS:A1997YF68400010
J	Yu, YK; Zhang, L; Yin, XX; Sun, H; Uhl, GR; Wang, JB				Yu, YK; Zhang, L; Yin, XX; Sun, H; Uhl, GR; Wang, JB			mu opioid receptor phosphorylation, desensitization, and ligand efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; OPIATE RECEPTOR; FUNCTIONAL DESENSITIZATION; DIFFERENTIAL REGULATION; POTASSIUM CHANNEL; CYCLIC-AMP; AGONIST; CELLS; METHADONE	mu opioid receptors are subject to phosphorylation and desensitization through actions of at least two distinct biochemical pathways: agonist-dependent mu receptor phosphorylation and desensitization induced by a biochemically distinct second pathway dependent on protein kinase C activation (1), To better understand the nature of the agonist-induced mu receptor phosphorylation events, we have investigated the effects of a variety of opiate ligands of varying potencies and intrinsic activities on mu receptor phosphorylation and desensitization, Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, and [D-Ala2, MePhe4, Glyol5]enkephalin (DAMGO) led to strong receptor phosphorylation, while methadone, l-alpha-acetyl-methadone (LAAM), morphine, meperidine, DADL, beta-endorphin((1-31)), enkephalins, and dynorphin A((1-17)) produced intermediate effects, The partial agonist buprenorphine minimally enhanced receptor phosphorylation while antagonists failed to alter phosphorylation, Buprenorphine and full antagonists each antagonized the enhanced mu receptor phosphorylation induced by morphine or DAMGO, The rank order of opiate ligand efficacies in producing mu receptor-mediated functional desensitization generally paralleled their rank order of efficacies in producing receptor phosphorylation, Interestingly, the desensitization and phosphorylation mediated by methadone and LAAM were disproportionate to their efficacies in two distinct test systems, This generally good fit between the efficacies of opiates in mu receptor activation, phosphorylation, and desensitization supports the idea that activated receptor/agonist/G-protein complexes and/or receptor conformational changes induced by agonists are required for agonist-induced mu receptor phosphorylation, Data for methadone and LAAM suggest possible contribution from their enhanced desensitizing abilities to their therapeutic efficacies.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; NIAAA,LAB MOL & CELLULAR NEUROBIOL,BETHESDA,MD 20892; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224; NIDA,MOL NEUROBIOL BRANCH,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)			Zhang, Li/W-2104-2019					ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BROWN BL, 1972, ADV CYCL NUCL RES<D>, V2, P25; CARTER BD, 1992, J NEUROCHEM, V58, P1611, DOI 10.1111/j.1471-4159.1992.tb10032.x; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CLAUDE PA, 1996, P NATL ACAD SCI USA, V83, P5715; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; Fiorillo CD, 1996, J NEUROSCI, V16, P1479; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IZENWASSER S, 1993, J PHARMACOL EXP THER, V267, P145; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KREEK MJ, 1994, ANN MED INTERNE, V145, P9; KREEK MJ, 1991, DRUG ADDICTION AIDS, P153; LAW PY, 1983, MOL PHARMACOL, V24, P413; LING W, 1994, J PSYCHOACTIVE DRUGS, V26, P119, DOI 10.1080/02791072.1994.10472259; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; ONOGI T, 1995, FEBS LETT, V357, P93, DOI 10.1016/0014-5793(94)01341-W; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Wang ZJ, 1996, FEBS LETT, V387, P53, DOI 10.1016/0014-5793(96)00467-X; YU VC, 1990, J NEUROCHEM, V55, P1390, DOI 10.1111/j.1471-4159.1990.tb03151.x; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	28	190	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28869	28874		10.1074/jbc.272.46.28869	http://dx.doi.org/10.1074/jbc.272.46.28869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360954	hybrid			2022-12-25	WOS:A1997YF68400013
J	Anafi, M; Kiefer, F; Gish, GD; Mbamalu, G; Iscove, NN; Pawson, T				Anafi, M; Kiefer, F; Gish, GD; Mbamalu, G; Iscove, NN; Pawson, T			SH2/SH3 adaptor proteins can link tyrosine kinases to a Ste20-related protein kinase, HPK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; CELL-DEATH; SH3-LIGAND INTERACTIONS; GENERAL-MODEL; CRK ADAPTER; BINDING; STRESS; PATHWAY; ACTIVATION; APOPTOSIS	Ste20-related protein kinases have been implicated as regulating a range of cellular responses, including stress-activated protein kinase pathways and the control of cytoskeletal architecture. An important issue involves the identities of the upstream signals and regulators that might control the biological functions of mammalian Ste20-related protein kinases. HPK1 is a protein-serine/threonine kinase that possesses a Ste20-like kinase domain, and in transfected cells activates a protein kinase pathway leading to the stress-activated protein kinase SAPK/JNK. Here we have investigated candidate upstream regulators that might interact with HPK1. HPK1 possesses an N-terminal catalytic domain and an extended C-terminal tail with four proline-rich motifs. The SH3 domains of Grb2 bound in vitro to specific proline-rich motifs in the HPK1 tail and functioned synergistically to direct the stable binding of Grb2 to HPK1 in transfected Cos1 cells. Epidermal growth factor (EGF) stimulation did not affect the binding of Grb2 to HPK1 but induced recruitment of the Grb2-HPK1 complex to the autophosphorylated EGF receptor and to the Shc docking protein. Several activated receptor and cytoplasmic tyrosine kinases, including the EGF receptor, stimulated the tyrosine phosphorylation of the HPK1 serine/threonine kinase. These results suggest that HPK1, a mammalian Ste20-related protein-serine/threonine kinase, can potentially associate with protein-tyrosine kinases through interactions mediated by SH2/SH3 adaptors such as Grb2. Such interaction may provide a possible mechanism for cross-talk between distinct biochemical pathways following the activation of tyrosine kinases.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, ONTARIO CANC INST, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto			Pawson, Tony J/E-4578-2013; Gish, Gerald D/C-7228-2017	Kiefer, Friedemann/0000-0002-3002-8237				Anafi M, 1996, J BIOL CHEM, V271, P21365, DOI 10.1074/jbc.271.35.21365; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIN N, 1993, NATURE, V863, P85; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Smit L, 1996, ONCOGENE, V13, P381; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	57	71	73	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27804	27811		10.1074/jbc.272.44.27804	http://dx.doi.org/10.1074/jbc.272.44.27804			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346925	hybrid			2022-12-25	WOS:A1997YD47300051
J	Duckworth, BC; Cantley, LC				Duckworth, BC; Cantley, LC			Conditional inhibition of the mitogen-activated protein Kinase cascade by wortmannin - Dependence of signal strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; MAMMALIAN-CELLS; RAS; PDGF; PHOSPHORYLATION; INSULIN; RAF-1	Phosphoinositide (PI) 3-kinase and the mitogen-activated protein (MAP) kinase cascades are activated by many of the same ligands, Several groups have reported involvement of PI 3-kinase in the activation of Erk1 and Erk2, whereas many other groups have shown that activation of Erk1 and Erk2 is not sensitive to inhibitors of PI 3-kinase such as wortmannin, Here we show that wortmannin inhibition of the MAP kinase pathway is cell type-and ligand-specific. Wortmannin blocks platelet derived growth factor (PDGF) dependent activation of Raf-l and the MAP kinase cascade in Chinese hamster ovary cells, which have few PDGF receptors, but has no significant effect on Erk activation in Swiss 3T3 cells, which have high levels of PDGF receptors. However, wortmannin blocks activation of Erk proteins if Swiss 3T3 cells are stimulated with lower, physiological levels of PDGF, These results suggest that PI 3-kinase is in an efficient pathway for activation of MAP kinase, but that MAP kinase can be stimulated by a redundant pathway when a large number of receptors are activated. We present evidence that a protein kinase C family member downstream of phospholipase C gamma is involved in the redundant pathway.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DUCKWORTH BC, 1996, LIPID 2 MESSENGERS H, V8, P125; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; HUANG JS, 1982, J BIOL CHEM, V257, P8130; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura K, 1996, AM J PHYSIOL-GASTR L, V271, pG640, DOI 10.1152/ajpgi.1996.271.4.G640; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SINGH JP, 1982, J CELL BIOL, V95, P667, DOI 10.1083/jcb.95.2.667; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807	45	178	182	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27665	27670		10.1074/jbc.272.44.27665	http://dx.doi.org/10.1074/jbc.272.44.27665			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346906	hybrid			2022-12-25	WOS:A1997YD47300032
J	Hashimoto, R; Ono, M; Fujiwara, H; Higashihashi, N; Yoshida, M; EnjohKimura, T; Sakano, K				Hashimoto, R; Ono, M; Fujiwara, H; Higashihashi, N; Yoshida, M; EnjohKimura, T; Sakano, K			Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ADULT-RAT SERUM; EXPRESSION; MUTANTS; PURIFICATION; RECEPTORS; DELETION; IGFBP-3; MAC25; CELLS	We have examined regions of rat IGF-binding protein-3 (IGFBP-3) important for complex formations using two kinds of deletion mutants, three kinds of chimera molecules between rat IGFBP-3 and rat IGFBP-2, and a synthetic peptide (41 residues, Glu(52)-Ala(92)) derived from rat IGFBP-3. Solid-phase binding assays using 96-well microtiter plates were designed to quantitate the relative binding affinities. It was found that not only the IGFBP-3 derivatives with the amino-terminal, cysteine-rich domain (N domain) but also the synthetic peptide maintained affinity for IGF-II. Ternary complex formation was observed with full-length IGFBP-3 and chimera IGFBP, the carboxyl-terminal cysteine-rich domain (C domain) of which was derived from IGFBP-3, unlike the mutants lacking the C domain and the chimera IGFBPs, the C domain of which was derived from IGFBP-2. These results were confirmed by affinity crosslinking experiments. Furthermore, the IGFBP-3 derivatives that possessed the C domain of IGFBP-3 bound to the acid-labile subunit, even in the absence of IGFs. Finally, we observed sites in IGF-II important for the ternary complex formation using various IGF-II mutants. These IGF-II mutants, which contained a substitution of Tyr(27) for Leu, had extremely reduced activity. These results strongly suggest that: 1) the N domain, containing at least Glu(52)-Ala(92), of rat IGFBP-3 is important for binding to IGF-II; 2) the C domain of IGFBP-3 is essential for binding to the acid-labile subunit both in the presence and absence of IGF-II; and 3) Tyr(27) of TGF-II is important for the ternary complex formation.			Hashimoto, R (corresponding author), DAIICHI PHARMACEUT CO LTD,BASIC TECHNOL RES LAB,EDOGAWA KU,16-13 KITAKASAI 1 CHOME,TOKYO 134,JAPAN.							BACH LA, 1993, J BIOL CHEM, V268, P9246; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAXTER RC, 1994, ENDOCRINOLOGY, V134, P848, DOI 10.1210/en.134.2.848; BINOUX M, 1991, MODERN CONCEPTS INSU, P329; BROWN AL, 1989, J BIOL CHEM, V264, P5148; CASCIERI MA, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P285; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DODSON EJ, 1979, CAN J BIOCHEM CELL B, V57, P469, DOI 10.1139/o79-060; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; HASHIMOTO R, 1995, J BIOL CHEM, V270, P18013, DOI 10.1074/jbc.270.30.18013; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LEE CY, 1995, ENDOCRINOLOGY, V136, P4982, DOI 10.1210/en.136.11.4982; LUTHI C, 1992, EUR J BIOCHEM, V205, P483, DOI 10.1111/j.1432-1033.1992.tb16804.x; MARUMOTO Y, 1992, BIOSCI BIOTECH BIOCH, V56, P13, DOI 10.1271/bbb.56.13; MARUMOTO Y, 1987, J GEN VIROL, V68, P2599, DOI 10.1099/0022-1317-68-10-2599; NAKAGAWA SH, 1991, J BIOL CHEM, V266, P11502; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID C, 1991, BIOCHEM BIOPH RES CO, V179, P579, DOI 10.1016/0006-291X(91)91410-E; SHIMASAKI S, 1989, BIOCHEM BIOPH RES CO, V165, P907, DOI 10.1016/S0006-291X(89)80052-X; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SHIMONAKA M, 1989, BIOCHEM BIOPH RES CO, V165, P189, DOI 10.1016/0006-291X(89)91053-X; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; ZAPF J, 1988, BIOCHEM BIOPH RES CO, V156, P1187, DOI 10.1016/S0006-291X(88)80758-7; ZAPF J, 1990, J BIOL CHEM, V265, P14892	35	44	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27936	27942		10.1074/jbc.272.44.27936	http://dx.doi.org/10.1074/jbc.272.44.27936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346943	hybrid			2022-12-25	WOS:A1997YD47300069
J	Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C				Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C			Abnormal erythropoietin (Epo) gene expression in the murine erythroleukemia IW32 cells results from a rearrangement between the G-protein beta 2 subunit gene and the Epo gene	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; G-protein beta 2 subunit	TRANSGENIC MICE; STAT5 ACTIVATION; LEUKEMIA-VIRUS; PYRUVATE-KINASE; RECEPTOR; IDENTIFICATION; SITE; DIFFERENTIATION; TUMORIGENICITY; TRANSCRIPTION	Abnormal production of erythropoietin (Epo) has been described in several human and murine erythroleukemia, The murine IW32 cell line is derived from an F-MuLV-induced erythroleukemia. An autocrine Epo production due to the rearrangement of one Epo allele has been previously described (Beru ed al., 1989), However, the exact mechanism leading to the transcriptional activation of the abnormal Epo gene was unknown, In this study, we show that this deregulated expression results from a deletion within chromosome 5, The Epo gene in the abnormal allele is under the control of the G-protein beta 2 subunit gene promoter and the expressed mRNA results from the fusion of the non coding exon 1 of the G-protein beta 2 subunit gene to a truncated Epo exon I gene, This resulting abnormal cDNA allows the expression of a normal Epo protein.	INST NATL TRANSFUS SANGUINE,F-75015 PARIS,FRANCE; HOP HENRI MONDOR,INSERM U91,F-94000 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chretien, S (corresponding author), UNIV PARIS 05,HOP COCHIN,IGGM,INSERM U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		maouche, leila/E-3887-2017; Chretien, Stany/M-5166-2018					BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERU N, 1989, DNA-J MOLEC CELL BIO, V8, P253, DOI 10.1089/dna.1.1989.8.253; CHIREUX MA, 1995, J NEUROSCI RES, V40, P427, DOI 10.1002/jnr.490400402; CHOPPIN J, 1984, BLOOD, V64, P341; CHOPPIN J, 1985, EXP HEMATOL, V13, P610; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DREYFUS F, 1990, LEUKEMIA, V4, P590; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HANKINS WD, 1986, BLOOD, V68, P263; HERMINE O, 1991, BLOOD, V78, P2253; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Howard JC, 1996, ONCOGENE, V12, P1405; Kozak CA, 1996, MAMM GENOME, V6, pS97; LACOMBE C, 1988, BLOOD, V72, P1440; LACOMBE C, 1987, MOL CELLULAR ASPECTS, P61; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAXWELL PH, 1993, KIDNEY INT, V44, P1149, DOI 10.1038/ki.1993.362; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MITJAVILA MT, 1991, J CLIN INVEST, V77, P461; MOREAUGACHELIN F, 1988, NATURE, V331, P227; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; SELS FT, 1992, ONCOGENE, V7, P643; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; StageMarroquin B, 1996, EXP HEMATOL, V24, P1322; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; VILLEVAL JL, 1992, LEUKEMIA, V6, P107; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	40	2	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1995	1999		10.1038/sj.onc.1201364	http://dx.doi.org/10.1038/sj.onc.1201364			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365246				2022-12-25	WOS:A1997YA87200014
J	PaasinenSohns, A; Holtta, E				PaasinenSohns, A; Holtta, E			Cells transformed by ODC, c-Ha-ras and v-src exhibit MAP kinase Erk-independent constitutive phosphorylation of Sos, Raf and c-Jun activation domain, and reduced PDGF receptor expression	ONCOGENE			English	Article						transformation; ODC; Ras; Src; MAP kinase; c-Jun phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; NIH 3T3 CELLS; ORNITHINE DECARBOXYLASE ACTIVITY; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE KINASE; ONCOGENIC TRANSFORMATION; PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTIONAL ACTIVITY	While it is known that the constitutive activity of a variety of signal transduction molecules leads to cell transformation, a key unresolved question is whether these wirings converge to a common intermediate(s) that dictates transformation, In this study, we investigated whether NIH3T3 and Rat-1 cells transformed by human ornithine decarboxylase (ODC), c-Ha-ras(Val12) and temperature-sensitive v-src oncogene display common alteration(s) in the components that relay PDGF-mediated signals in normal fibroblasts. The ras- and ODC-transformed cells did not show constitutively elevated tyrosine phosphorylation of the phospholipase Cy-l (PLC gamma-1), RasGTPase-activating protein (GAP), phosphotyrosine phosphatase Syp, She proteins, and phosphatidylinositol 3-kinase (PI3-K) or activation of the MAP kinase (Erk1 and Erk2), p70 S6 kinase or the Janus protein tyrosine kinase (JAK) and signal transducer and activator of transcription (STAT) protein-1 pathways. Instead, the Ras nucleotide exchange factor Sos-1 and Raf-l kinase exhibited constitutive phosphorylations, as deduced from their electrophoretic mobility shifts in polyacrylamide gels, Hence a kinase distinct from Erk1 and Erk2, previously known to feedback phosphorylate Sos-1 and Raf-l, is responsible for the phosphorylation of these molecules in the transformants. We also demonstrate that the ras- and ODC-transformed cells exhibit loss of both the PDGF alpha- and beta-receptors, while the v-Src-transformants show a predominant reduction in the beta-receptors. Moreover, all the transformed cell lines were found to display a constitutive increase in phosphorylation of c-Jun on serines 63 and 73, which appears to be governed by an as yet unknown kinase.	UNIV HELSINKI,HAARTMAN INST,DEPT PATHOL,FIN-00014 HELSINKI,FINLAND	University of Helsinki								Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; AUVINEN M, 1997, IN PRESS CANC RES, V57; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BARONDELAGE S, 1994, J BIOL CHEM, V15, P18686; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BAZENET CE, 1993, ONCOGENE, V9, P517; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; Greulich H, 1996, ONCOGENE, V12, P1689; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; HOLTTA E, 1994, BIOCHEM SOC T, V22, P853; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEHTOLA L, 1991, CELL REGUL, V2, P651, DOI 10.1091/mbc.2.8.651; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEGG AE, 1988, CANCER RES, V48, P759; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAKE JB, 1991, J BIOL CHEM, V266, P5348; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VAZRIL C, 1995, MOL CELL BIOL, V15, P1244; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	89	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1953	1966		10.1038/sj.onc.1201366	http://dx.doi.org/10.1038/sj.onc.1201366			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365242				2022-12-25	WOS:A1997YA87200010
J	Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A				Visconti, R; Cerutti, J; Battista, S; Fedele, M; Trapasso, F; Zeki, K; Miano, MP; deNigris, F; Casalino, L; Curcio, F; Santoro, M; Fusco, A			Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NF kappa B p65 protein expression	ONCOGENE			English	Article						NF kappa B; p65-p50; thyroid; carcinomas; antisense; oncogenes	C-MYC; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION ACTIVATOR; INHIBITS PROLIFERATION; MESSENGER-RNA; DNA-BINDING; REL FAMILY; SUBUNIT; DIFFERENTIATION; TRANSFORMATION	We have investigated the role of the NF kappa B complex in the process of thyroid carcinogenesis by analysing thyroid carcinoma cell lines, A significant increase in p65 NF kappa B mRNA and protein expression, compared to normal thyroid cultures or tissue, was found in all of the cancer cell lines, Conversely, only a modest increase in the p50 NF kappa B mRNA and protein was found in most, but not all carcinoma cell lines, The block of p65 protein synthesis with specific antisense oligonucleotides greatly reduced the ability of two undifferentiated carcinoma cell lines to form colonies in agar and reduced their growth rate, On the other hand, no effect was observed in the same cell lines when treated with p50 specific antisense oligonucleotides. These inhibitory effects seem to be mediated by the suppression of c-myc gene expression, since treatment with antisense oligonucleotides for p65 gene interfered negatively with c-myc gene expression, Our results indicate that activation of the NF kappa B complex by overexpression of p65 plays a critical role in the process of thyroid cell transformation.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT INTERNAL MED 1,YAHATONISHI KU,KITAKYUSHU,FUKUOKA 807,JAPAN; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV UDINE,DIPARTIMENTO PATOL & MED SPERIMENTALE & CLIN,I-33100 UDINE,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; University of Occupational & Environmental Health - Japan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Udine			Cerutti, Janete/D-3513-2014; Casalino, Laura/C-1506-2015; Miano, Maria Giuseppina/E-9056-2011; Miano, Maria Giuseppina/AAX-8437-2020; Battista, Sabrina/AAY-2981-2020; Visconti, Roberta/C-5299-2009; Giuseppina, Miano Maria/B-9169-2015; Fedele, Monica/C-1417-2015; Curcio, Francesco/K-4669-2014	Casalino, Laura/0000-0002-2557-0443; Miano, Maria Giuseppina/0000-0003-1396-9673; Miano, Maria Giuseppina/0000-0003-1396-9673; Battista, Sabrina/0000-0001-5899-9759; Fedele, Monica/0000-0002-9171-1312; de nigris, filomena/0000-0002-2322-1557; Cerutti, Janete/0000-0003-0156-8274; Fusco, Alfredo/0000-0003-3332-5197; Visconti, Roberta/0000-0001-7613-3801; CURCIO, Francesco/0000-0002-9070-4807				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P409; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; Cerutti J, 1996, CLIN CANCER RES, V2, P119; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARLOW E, 1989, IMMUNOBLOTTING LAB M; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IACOVELLI L, 1993, J BIOL CHEM, V268, P20402; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127	44	154	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1987	1994		10.1038/sj.onc.1201373	http://dx.doi.org/10.1038/sj.onc.1201373			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365245				2022-12-25	WOS:A1997YA87200013
J	Tang, JP; Feng, GS; Li, W				Tang, JP; Feng, GS; Li, W			Induced direct binding of the adapter protein Nck to the GTPase-activating protein-associated protein p62 by epidermal growth factor	ONCOGENE			English	Article						src-homology domains; adapters; receptor tyrosine kinases; signal transduction	RECEPTOR TYROSINE KINASES; ALDRICH SYNDROME PROTEIN; SRC HOMOLOGY-3 DOMAINS; SH3 DOMAINS; ACTIN POLYMERIZATION; MOLECULAR-CLONING; PHOSPHORYLATION; RAS; GAP; CELLS	The SH3-SH3-SH3-SH2 adapter protein Nck links receptor tyrosine kinases, such as EGF and PDGF receptors, to downstream signaling pathways, among which p21(cdc42/rac)-activated kinase cascade, Sos-activated Ras signaling and the human Wiskott-Aldrich Syndrome protein (WASp)-mediated actin cytoskeleton changes, have been implicated. In EGF stimulated cells, Nck coimmunoprecipitates with a number of phosphotyrosine proteins including the EGF receptor (Li et al., 1992 Mol. Cell. Biol. 12: 5824-2833). To identify the phosphotyrosine protein(s) that directly interacts with Nck and to distinguish it from indirectly associated proteins, preexisting phosphoytrosine protein complexes in the cell lysate were dissociated by heat and SDS prior to the test for binding to Nck. We found that Nck does not directly bind to EGF receptor, instead it binds via its SH2 domain to a 62 kDa phosphotyrosine protein. We present evidence demonstrating that the Nck-bound p62 is related to the previously identified GTPase-activating protein (GAP)-associated phosphotyrosine protein p62. (1) The Nck-bound and the GAP-bound p62 proteins comigrate with each other in SDS-PAGE. (2) SH2 domains from Nck and GAP compete for binding to p62 in vitro. (3) Purified GST-Nck-SH2 binds directly to the GAP-associated p62, Under these conditions, SH2 domains from PLC gamma, PI-3 kinase, SHC, and Grb2 did not bind p62. (4) Tryptic phosphopeptide maps of the Nck- and the GAP-associated p62 proteins are identical. However, Nck and GAP do not co-immunoprecipitate with each other and apparently bind to different pools of p62. This study suggests that the GAS-associated p62 acts as an SH2 domain docking protein and mediates the interaction between Nck and EGF receptor in response to EGF stimulation.	UNIV CHICAGO,BEN MAY INST CANC RES,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	University of Chicago; University of Chicago; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA65567-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1995, METHOD ENZYMOL, V255, P179; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1991, J BIOL CHEM, V266, P6808; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NEET K, 1995, MOL CELL BIOL, V15, P4908; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	47	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1823	1832		10.1038/sj.onc.1201351	http://dx.doi.org/10.1038/sj.onc.1201351			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362449				2022-12-25	WOS:A1997XZ72500009
J	Berchtold, S; Moriggl, R; Gouilleux, F; Silvennoinen, O; Beisenherz, C; Pfitzner, E; Wissler, M; Stocklin, E; Groner, B				Berchtold, S; Moriggl, R; Gouilleux, F; Silvennoinen, O; Beisenherz, C; Pfitzner, E; Wissler, M; Stocklin, E; Groner, B			Cytokine receptor-independent, constitutively active variants of STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; MAMMARY TISSUE; NUCLEAR FACTOR	STAT (signal transducers and activators of transcription) proteins are dual function proteins, which participate in cytokine-mediated signal transduction events at the cell. surface and transcriptional regulation in the nucleus, We have exploited insights into the activation mechanism of STAT factors to derive constitutively active variants, Chimeric genes encoding fusion proteins of STATE and the kinase domain of JAK2 have been derived, The functional properties of the fusion proteins have been investigated in transiently transfected COS cells or in HeLa cells stably transfected with STAT5-JAK2 gene constructs regulated by a tetracycline-sensitive promoter, The STAT5-JAK2 proteins exhibit tyrosine kinase activity and are phosphorylated on tyrosine, The molecules are activated through an intramolecular or a cross-phosphorylation reaction and exhibit constitutive, STAT5-specific DNA binding activity, The transactivation potentials of three constitutively activated STAT5-JAK2 variants comprising different transactivation domains (TADs) derived from STATE, STAT6, and VP16 were compared. The chimeric molecule containing the STAT5 TAD had no or only a very low, the molecule with the STAT6 TAD a medium, and the molecule with the VP16 TAD a very high transactivation potential, Transcription from STATE-responsive gene promoter regions of the beta-casein, oncostatin RI, and the cytokine-inducible Src homology 2 domain-containing protein genes was observed, These chimeric STAT molecules allow the study of the function of STATE independent of cytokine receptors and the activation of other signal transduction pathways.	TUMOR BIOL CTR,INST EXPT CANC RES,D-79106 FREIBURG,GERMANY; HOP COCHIN,INST COCHIN GENET MOL,INSERM,U363,F-75014 PARIS,FRANCE; UNIV TAMPERE,INST MED TECHNOL,FIN-33101 TAMPERE,FINLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Tampere University			Moriggl, Richard/H-8118-2019; Pfitzner, Edith/AAU-7927-2021	Moriggl, Richard/0000-0003-0918-9463; Pfitzner, Edith/0000-0002-3484-9649; Gouilleux, Fabrice/0000-0001-6047-1718				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Heim MH, 1996, EUR J CLIN INVEST, V26, P1, DOI 10.1046/j.1365-2362.1996.103248.x; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MINAMI Y, 1994, J IMMUNOL, V152, P5680; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stoecklin Elisabeth, 1996, Nature (London), V383, P726; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1996, CURR BIOL, V6, P668, DOI 10.1016/S0960-9822(09)00445-X; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30237	30243		10.1074/jbc.272.48.30237	http://dx.doi.org/10.1074/jbc.272.48.30237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374508	Green Published, hybrid			2022-12-25	WOS:A1997YH61300040
J	Durante, W; Liao, L; Peyton, KJ; Schafer, AI				Durante, W; Liao, L; Peyton, KJ; Schafer, AI			Lysophosphatidylcholine regulates cationic amino acid transport and metabolism in vascular smooth muscle cells - Role in polyamine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; ORNITHINE DECARBOXYLASE ACTIVITY; NECROSIS-FACTOR-ALPHA; HYDROXY-L-ARGININE; GENE-EXPRESSION; GROWTH-FACTOR; ENDOTHELIAL-CELLS; CULTURED HUMAN; MOUSE KIDNEY	Lysophosphatidylcholine (lyso-PC) is a major component of atherogenic lipids that stimulate vascular smooth muscle cell (SMC) proliferation. Because cationic amino acids are metabolized to growth-stimulatory polyamines, we examined whether lyso-PC regulates this transcellular transport and metabolism of cationic amino acids by vascular SMC. Treatment of SMC with lyso-PC initially (0-2 h) decreased cationic amino acid uptake, whereas longer exposures (6-24 h) progressively increased transport. Kinetic studies indicated that lyso-PC-induced inhibition was associated with a decrease in affinity for cationic amino acids, but the stimulation was mediated by an increase in transport capacity. Lyso-PC strongly induced the expression of cationic amino acid transporter-2 mRNA while modestly elevating the level of cationic amino acid transporter-1 mRNA. In addition, lyso-PC stimulated intracellular cationic amino acid metabolism by inducing ornithine decarboxylase activity and mRNA expression and also by inducing arginase activity in vascular SMC. In contrast, lyso-PC inhibited the catabolism of L-arginine to nitric oxide by blocking inducible nitric oxide synthase expression. Lyso-PC increased markedly the capacity of SMC to generate putrescine, a polyamine, from extracellular L-ornithine and L-arginine. The lyso-PC-mediated increase in the production of putrescine was reversed by N-G-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor. The formation of putrescine from L-arginine was also prevented by arginase inhibitor NC-hydroxy-L-arginine, These results demonstrate that lyso-PC stimulates polyamine synthesis in vascular SMC by inducing the expression of the genes that regulate both the transport and metabolism of cationic amino acids. The actions of lyso-PC in stimulating cationic amino acid uptake and directing their metabolism to growth-stimulatory polyamines while simultaneously inhibiting the synthesis of antiproliferative NO, may contribute to lyso-PC-induced SMC proliferation and atherosclerotic lesion formation.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHARMACOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), VET ADM MED CTR,BLDG 109,RM 128,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36045] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BARBUL A, 1986, JPEN-PARENTER ENTER, V10, P227, DOI 10.1177/0148607186010002227; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BERGER FG, 1984, J BIOL CHEM, V259, P7941; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; Durante W, 1996, CIRC RES, V78, P1075, DOI 10.1161/01.RES.78.6.1075; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1993, AM J PHYSIOL, V264, pH617, DOI 10.1152/ajpheart.1993.264.2.H617; Durante W, 1996, P ASSOC AM PHYSICIAN, V108, P356; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; DURANTE W, 1995, BIOCHEM J, V308, P231, DOI 10.1042/bj3080231; ENDEAN ED, 1991, J SURG RES, V50, P634, DOI 10.1016/0022-4804(91)90054-P; GARG UC, 1990, J CLIN INVEST, V83, P1018; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; GILMOUR SK, 1985, J BIOL CHEM, V260, P6439; GONZALEZ GG, 1991, CANCER RES, V51, P2932; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; LOCHER R, 1992, BIOCHEM BIOPH RES CO, V183, P156, DOI 10.1016/0006-291X(92)91622-W; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSL, V56, P626; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MAJESKY MW, 1987, CIRC RES, V61, P296, DOI 10.1161/01.RES.61.2.296; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MELLION BT, 1981, BLOOD, V57, P946; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIDA K, 1990, ATHEROSCLEROSIS, V83, P119, DOI 10.1016/0021-9150(90)90157-E; PEGG AE, 1988, CANCER RES, V48, P759; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P3906; RUSSELL AS, 1980, J IMMUNOL METHODS, V32, P375, DOI 10.1016/0022-1759(80)90029-0; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SAKAI M, 1994, J BIOL CHEM, V269, P31430; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stiko A, 1996, ARTERIOSCL THROM VAS, V16, P194, DOI 10.1161/01.ATV.16.2.194; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; Ulrich K. H., 1981, PHARMACOL REV, V33, P17; VADAS P, 1986, LAB INVEST, V55, P391; WEN L, 1989, J BIOL CHEM, V264, P9016; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WU GY, 1995, AM J PHYSIOL-HEART C, V269, pH1312, DOI 10.1152/ajpheart.1995.269.4.H1312; WU VS, 1984, BIOCHIM BIOPHYS ACTA, V804, P89, DOI 10.1016/0167-4889(84)90102-2; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	57	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30154	30159		10.1074/jbc.272.48.30154	http://dx.doi.org/10.1074/jbc.272.48.30154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374496	hybrid			2022-12-25	WOS:A1997YH61300028
J	McCallum, CD; Su, BX; Neuenschwander, PF; Morrissey, JH; Johnson, AE				McCallum, CD; Su, BX; Neuenschwander, PF; Morrissey, JH; Johnson, AE			Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain - A fluorescence resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR VIIA; FACTOR-X; CONFORMATIONAL SENSITIVITY; PHOSPHOLIPID SURFACE; EXTRACELLULAR DOMAIN; ORIENTATION FACTOR; HYDROPHOBIC STACK; CRYSTAL-STRUCTURE; BINDING; ASSOCIATION	Coagulation factor VIIa (fVIIa), a soluble serine protease, exhibits full proteolytic activity only when bound to its cofactor, tissue factor (TF). Both proteins interact with membranes; TF is an integral membrane protein, while fVIIa binds reversibly to phospholipid surfaces via its Gla domain. In this study, we examine the extent to which the location of the fVIIa active site in the fVIIa . TF complex is determined by the fVIIa Gla domain. A fluorescein dye was covalently attached to the active site of fVIIa lacking the Gla domain (Gla domainless fVIIa, GD-fVIIa) via a tripeptide tether to yield fluorescein- D-Phe-Pro-Arg-GD-fVIIa (Fl-FPR-GD-fVIIa). The location of the active site of GD-fVIIa relative to the membrane surface was determined using fluorescence resonance energy transfer between the fluorescein dye in the active site of GD-fVIIa and octadecylrhodamine (OR) at the surface of phospholipid vesicles. As expected, no energy transfer was observed between Fl-FPR-GD-fVIIa and OR in vesicles composed of phosphatidylcholine/phosphatidylserine (PC/PS, 4:1) because the Gla domain is required for the binding of fVIIa to phospholipid. However, when Fl-FPR-GD-fVIIa was titrated with PC or PC/PS vesicles into which purified TF had been reconstituted, energy transfer was observed. Based on the dependence of fluorescence resonance energy transfer on OR density, the average distance of closest approach between fluorescein in the active site of Fl-FPR-GD-fVIIa . TF and OR at the vesicle surface was determined to be 78 Angstrom (kappa(2) = 2/3). Since this value is nearly the same as that obtained with intact Fl-FPR-fVIIa bound to TF, the presence or absence of the fVIIa Gla domain has only a small effect on the location of the active site in the fVIIa . TF complex. The extracellular domain of tissue factor therefore must be fairly rigid and fixed relative to the surface to position and maintain the fVIIa active site far above the membrane even in the absence of the fVIIa Gla domain.	TEXAS A&M UNIV,HLTH SCI CTR,COLL MED,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation			Morrissey, James H/H-4933-2011; Johnson, Arthur E/G-3457-2012; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047014, R01HL032934] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 47014, R01 HL 32934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; FURIE B, 1988, CELL, V53, P508; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HOCHBERG Y, 1987, MULTIPLE COMP PROCED, P80; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; McCallum CD, 1996, J BIOL CHEM, V271, P28168, DOI 10.1074/jbc.271.45.28168; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; Persson E, 1996, HAEMOSTASIS, V26, P31; PETERSEN LC, 1994, FEBS LETT, V347, P73, DOI 10.1016/0014-5793(94)00513-3; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	33	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30160	30166		10.1074/jbc.272.48.30160	http://dx.doi.org/10.1074/jbc.272.48.30160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374497	hybrid			2022-12-25	WOS:A1997YH61300029
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Identification of an amino acid residue that lies between the exofacial vestibule and exofacial substrate-binding site of the Glut1 sugar permeation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE GLUCOSE TRANSPORTER; CHANNEL-LINING RESIDUES; ESCHERICHIA-COLI; XENOPUS-OOCYTES; TRANSLOCATION PATHWAY; SCANNING MUTAGENESIS; LACTOSE PERMEASE; LIGAND-BINDING; ALPHA-SUBUNIT; MEMBRANE	A valine-to-isoleucine mutation at amino acid residue 197 of Glut2 or the equivalent residue 165 of Glut1 has been shown to impair glucose transport activity. This mutation was originally discovered in the Glut2 gene of a patient with type 2 diabetes. We investigated the mechanism of the effect of this mutation on transport activity via the analysis of Glut1 mutants expressed in Xenopus oocytes combined with cysteine substitution mutagenesis and the use of cysteine-reactive chemical probes, Aliphatic side chain substitutions at position 165 that were bulkier than the native valine residue inhibited glucose transport activity, whereas substitutions of less bulky side chains had little effect on transport, suggesting a role for steric hindrance. A cysteine residue was introduced at position 165 of a functional, cysteine-less Glut1 construct, and this mutant was then tested for inhibition of transport activity by a membrane-impermeant sulfhydryl-specific reagent (p-chloromercuribenzenesulfonate). p-Chloromercuribenzenesulfonate inhibited activity of the Cys(165) mutant when it was added to the external buffer but not when it was injected directly into oocytes, indicating that this residue is accessible from the external solvent but not from the cytoplasm. Competition experiments indicated that Cys(165) lies near the exofacial substrate-binding site or directly in the sugar permeation pathway, These data provide evidence that the side chain of Val(165), which resides in the middle of transmembrane helix 5, juts into the aqueous permeation pathway of Glut1, probably between the exofacial substrate-binding site and the outer vestibule of the pathway.			Mueckler, M (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CAIRNS MT, 1987, BIOCHIM BIOPHYS ACTA, V905, P295, DOI 10.1016/0005-2736(87)90458-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; DAVIES A, 1990, BIOCHEM J, V266, P799; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P780; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P3950, DOI 10.1021/bi952601m; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Kaback HR, 1997, P NATL ACAD SCI USA, V94, P5539, DOI 10.1073/pnas.94.11.5539; KELLER K, 1989, J BIOL CHEM, V264, P18884; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P17765; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUECKLER M, 1989, RED BLOOD CELL MEMBR, P31; NISHIMURA H, 1993, J BIOL CHEM, V268, P8514; TANIZAWA Y, 1994, DIABETOLOGIA, V37, P420, DOI 10.1007/BF00408481; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6; WELLNER M, 1992, FEBS LETT, V309, P293, DOI 10.1016/0014-5793(92)80792-F; WIDDAS WF, 1988, BIOCHIM BIOPHYS ACTA, V947, P385, DOI 10.1016/0304-4157(88)90001-9; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30141	30146		10.1074/jbc.272.48.30141	http://dx.doi.org/10.1074/jbc.272.48.30141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374494	hybrid			2022-12-25	WOS:A1997YH61300026
J	Standaert, ML; Galloway, L; Karnam, P; Bandyopadhyay, G; Moscat, J; Farese, RV				Standaert, ML; Galloway, L; Karnam, P; Bandyopadhyay, G; Moscat, J; Farese, RV			Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes - Potential role in glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BC3H-1 MYOCYTES; ADIPOSE-CELLS; ACTIVATION; TRANSLOCATION; INHIBITORS; INCREASES; 3,4,5-TRISPHOSPHATE; DIACYLGLYCEROL; METABOLISM; MUSCLE	Insulin provoked rapid increases in enzyme activity of immunoprecipitable protein kinase C-zeta (PKC-zeta) in rat adipocytes. Concomitantly, insulin provoked increases in P-32 labeling of PKC-zeta both in intact adipocytes and during in vitro assay of immunoprecipitated PKC-zeta; the latter probably reflected autophosphorylation, as it was inhibited by the PKC-zeta pseudosubstrate. Insulin-induced activation of immunoprecipitable PKC-zeta was inhibited by LY294002 and wortmannin; this suggested dependence upon phosphatidylinositol (PI) 3-kinase. Accordingly, activation of PI 3-kinase by a pYXXM-containing peptide in vitro resulted in a wortmannin-inhibitable increase in immunoprecipitable PKC-zeta enzyme activity, Also, PI-3,4-(PO4)(2), PI-3,4,5-(PO4)(3), and PI-4,5-(PO4)(2) directly stimulated enzyme activity and autophosphoralytion in control PKC-zeta immunoprecipitates to levels observed in insulin-treated PKC-zeta immunoprecipitates. In studies of glucose transport, inhibition of immunoprecipitated PKC-zeta enzyme activity in vitro by both the PKC-zeta pseudosubstrate and RO 31-8220 correlated well with inhibition of insulin stimulated glucose transport in intact adipocytes. Also, in adipocytes transiently expressing hemagglutinin antigen-tagged GLUT4, co-transfection of wild-type or constitutive PKC-zeta stimulated hemagglutinin antigen-GLUT4 translocation, whereas dominant-negative PKC-zeta partially inhibited it. Our findings suggest that insulin activates PKC-zeta through PI 3-kinase, and PKC-zeta may act as a downstream effector of PI 3-kinase and contribute to the activation of GLUT4 translocation.	JA HALEY VET HOSP,RES SERV VAR 151,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM MOL BIOL,TAMPA,FL 33612; UNIV AUTONOMA MADRID,CTR BIO MOL SERVERO OCHOA,MADRID 280049,SPAIN	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Autonomous University of Madrid			Moscat, Jorge/A-7011-2009; Farese, Robert/B-3605-2015		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038079] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD TP, 1993, BIOCHEM J, V295, P155, DOI 10.1042/bj2950155; AVIGNON A, 1995, BIOCHEM J, V308, P181, DOI 10.1042/bj3080181; BANDYOPADHYAY B, 1997, J BIOL CHEM, V272, P2551; BANDYOPADHYAY G, 1997, IN PRESS ENDOCRINOLO; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FARESE RV, 1982, J BIOL CHEM, V257, P4042; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; FARESE RV, 1984, J BIOL CHEM, V259, P7094; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P296; KELLY KL, 1993, J BIOL CHEM, V268, P4391; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PENNINGTON SR, 1985, J BIOL CHEM, V260, P1039; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	23	402	409	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30075	30082		10.1074/jbc.272.48.30075	http://dx.doi.org/10.1074/jbc.272.48.30075			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374484	hybrid			2022-12-25	WOS:A1997YH61300016
J	Yamada, M; Ohnishi, H; Sano, S; Nakatani, A; Ikeuchi, T; Hatanaka, H				Yamada, M; Ohnishi, H; Sano, S; Nakatani, A; Ikeuchi, T; Hatanaka, H			Insulin receptor substrate (IRS)-1 and IRS-2 are tyrosine-phosphorylated and associated with phosphatidylinositol 3-kinase in response to brain-derived neurotrophic factor in cultured cerebral cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; SH2 DOMAINS; CHOLINERGIC NEURONS; SIGNAL-TRANSDUCTION; CATALYTIC DOMAINS; INTERFERON-GAMMA; BASAL FOREBRAIN; POSTNATAL RATS; BETA-RECEPTOR	Brain-derived neurotrophic factor (BDNF), a member of the neurotrophins, promotes differentiation and survival of various types of neurons in the central nervous system. BDNF binds to and activates the tyrosine kinase receptor, TrkB, initiating intracellular signaling and exerting its effects. Phosphatidylinositol 3-kinase (PI3-K), which has been implicated in promotion of neuronal survival by neurotrophic factors, is a component in the signaling pathway of BDNF. We examined how BDNF activates PI3-K in cultured cerebral cortical neurons. We found that insulin receptor substrate (IRS)-1 and -2 are involved in the BDNF signaling pathway that activates PI3-K, IRS-I and -2 were tyrosine-phosphorylated and bound to PI3-K in response to BDNF, This BDNF-stimulated signaling via IRS-I and -2 was inhibited by K-252a, an inhibitor of Trk tyrosine kinase, In addition, signaling via IRS-1 and -2 was markedly sustained as well as the BDNF-induced tyrosine phosphorylation of TrkB. On the other hand, we observed no association of PI3-K with TrkB in response to BDNF, These results indicate that the activation of TrkB by BDNF induces the activation of PI3-K via IRS-1 and -2 rather than by a direct interaction of TrkB with PI3-K in cultured cortical neurons.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN		Yamada, M (corresponding author), OSAKA UNIV, INST PROT RES, DIV PROT BIOSYNTH, 3-2 YAMADAOKA, SUITA, OSAKA 565, JAPAN.		Sancheti, Harsh/H-3538-2012					Abiru Y, 1996, DEV BRAIN RES, V91, P260, DOI 10.1016/0165-3806(95)00190-5; Akaneya Y, 1996, J NEUROPHYSIOL, V76, P4198, DOI 10.1152/jn.1996.76.6.4198; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; COCHET C, 1991, J BIOL CHEM, V266, P637; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENOKIDO Y, 1992, BRAIN RES, V599, P261, DOI 10.1016/0006-8993(92)90400-4; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Nonomura T, 1996, DEV BRAIN RES, V97, P42, DOI 10.1016/S0165-3806(96)00130-7; NONOMURA T, 1995, BRAIN RES, V683, P129, DOI 10.1016/0006-8993(95)00357-V; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RUIZLARREA F, 1993, BIOCHEM J, V290, P609, DOI 10.1042/bj2900609; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shimoke K, 1997, DEV BRAIN RES, V101, P197, DOI 10.1016/S0165-3806(97)00065-5; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEININGER TL, 1993, BRAIN RES, V612, P330, DOI 10.1016/0006-8993(93)91681-H; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Takei N, 1996, MOL BRAIN RES, V37, P283; Takei N, 1997, J NEUROCHEM, V68, P370; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; XU B, 1995, J BIOL CHEM, V270, P29825; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; YAMADA M, 1994, BRAIN RES, V661, P137, DOI 10.1016/0006-8993(94)91190-8; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	64	122	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30334	30339		10.1074/jbc.272.48.30334	http://dx.doi.org/10.1074/jbc.272.48.30334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374521	hybrid			2022-12-25	WOS:A1997YH61300053
J	Juhl, H; Downing, SG; Wellstein, A; Czubayko, F				Juhl, H; Downing, SG; Wellstein, A; Czubayko, F			HER-2/neu is rate-limiting for ovarian cancer growth - Conditional depletion of HER-2/neu by ribozyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; FACTOR PLEIOTROPHIN; GENE-EXPRESSION; BREAST-CANCER; NEU ONCOGENE; TUMOR-GROWTH; ERBB-2; CELLS; ANTIBODIES; RECEPTORS	Amplification and overexpression of the HER-2/neu proto-oncogene frequently coincide with an aggressive clinical course of certain human adenocarcinomas. To assess whether HER-2/neu plays a rate-limiting role in ovarian cancer, we used human SK-OV-3 ovarian cancer cells as a model, We applied a conditional mRNA depletion strategy of HER-2/neu with anti-HER-2/neu-targeted hammerhead ribozymes expressed under the con control of a tetracycline-regulated promoter system, In these ovarian cancer cells, we reduced HER-2/neu mRNA, protein expression, and tumor growth in nude mice by transfection with HER-a!neu-targeted ribozymes and generated cell lines expressing different levels of HER2/neu. Expression of the most effective ribozyme (Rz3) quenched HER-2/neu mRNA levels by >90%. Concomitantly, fluorescence-activated cell sorting analysis revealed that expression of the HER-2/neu encoded surface glycoprotein was almost completely abrogated, In nude mice, tumor growth was dramatically inhibited in the HER-2/neu-depleted Rz3-expressing SK-OV-3 cells, Furthermore, already established tumors started to regress when Rz3 expression was activated midstream by withdrawal of the tetracycline treatment, This study supports the thesis that HER-S/neu can be rate-limiting for the malignant phenotype of ovarian cancer in a gene dose dependent manner.	GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; CHRISTIAN ALBRECHTS UNIV KIEL KLINIKUM,DEPT SURG,D-24105 KIEL,GERMANY	Georgetown University; University of Kiel; Schleswig Holstein University Hospital				Wellstein, Anton/0000-0002-0570-4950				BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Chen SY, 1997, NATURE, V385, P78, DOI 10.1038/385078a0; CHRISTOFFERSEN RE, 1995, J MED CHEM, V38, P2023, DOI 10.1021/jm00012a001; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FANG WJ, 1992, J BIOL CHEM, V267, P25889; FENG M, 1995, CANCER RES, V55, P2024; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; Jarvis TC, 1996, RNA, V2, P419; JONES J, 1994, GYNECOL ONCOL, V55, P421, DOI 10.1006/gyno.1994.1316; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1994, REGULATORY MECH BREA, P161; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338	22	54	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29482	29486		10.1074/jbc.272.47.29482	http://dx.doi.org/10.1074/jbc.272.47.29482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368008	hybrid			2022-12-25	WOS:A1997YG64700018
J	Mellgren, RL				Mellgren, RL			Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; DEGRADATION; TRANSCRIPTION; PROTEOLYSIS; LACTACYSTIN; GROWTH; CYCLE	Cell-permeant peptidyl aldehydes and diazomethylketones are frequently utilized as inhibitors of regulatory intracellular proteases, In the present study the specificities of several peptidyl inhibitors for purified human mu-calpain and 20 S proteasome were investigated, Acetyl-LLnL aldehyde, acetyl-LLM aldehyde, carbobenzyloxy-LLnV aldehyde (ZLLnVal), and carbobenzyloxy-LLY-diazomethyl ketone produced half-maximum inhibition of the caseinolytic activity of mu-calpain at concentrations of 1-5 x 10(-7) nr. In contrast, only ZLLnVal was a reasonably potent inhibitor of the caseinolytic activity of 20 S proteasome, producing 50% inhibition at 10(-5) M, The other inhibitors were at least 10-fold less potent, producing substantial inhibition only at near saturating concentrations in the assay buffer, Further studies with ZLLnVal demonstrated that its inhibition of the proteasome was independent of casein concentration over a 25-fold range, Proteolysis of calpastatin or lysozyme by the proteasome was half-maximally inhibited by 4 and 22 mu M ZLLnVal, respectively, Thus, while other studies have shown that ZLLnVal is a potent inhibitor of the hydrophobic peptidase activity of the proteasome, it appears to be a much weaker inhibitor of its proteinase activity, The ability of the cell permeant peptidyl inhibitors to inhibit growth of the yeast Saccharomyces cerevisiae was studied because this organism expresses proteasome but not calpains, Concentrations of ZLLnVal as high as 200 mu M had no detectable effect on growth rates of overnight cultures, However, yeast cell lysates prepared from these cultures contained 2 mu M ZLLnVal, an amount which should have been sufficient to fully inhibit hydrophobic peptidase activity of yeast proteasome. Degradation of ubiquitinylated proteins in yeast extracts by endogenous proteasome was likewise sensitive only to high concentrations of ZLLnVal, The higher sensitivity of the proteinase activity of calpains to inhibition by the cell permeant inhibitors suggests that calpain-like activities may be targets of these inhibitors in animal cells.			Mellgren, RL (corresponding author), MED COLL OHIO,DEPT THERAPEUT & PHARMACOL,TOLEDO,OH 43614, USA.				NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bush KT, 1997, J BIOL CHEM, V272, P9086; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HADARI T, 1992, J BIOL CHEM, V267, P719; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; Walker G, 1997, J BIOL CHEM, V272, P16679, DOI 10.1074/jbc.272.26.16679; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	35	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29899	29903		10.1074/jbc.272.47.29899	http://dx.doi.org/10.1074/jbc.272.47.29899			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368065	hybrid			2022-12-25	WOS:A1997YG64700075
J	Morris, JC; MensaWilmot, K				Morris, JC; MensaWilmot, K			Role of 2,6-dideoxy-2,6-diaminoglucose in activation of a eukaryotic phospholipase C by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16S RIBOSOMAL-RNA; TRYPANOSOMA-BRUCEI; A-SITE; RESISTANCE; MECHANISMS	Recent emergence of microbial resistance to aminoglycoside antibiotics, and the documented cytotoxicity associated with their use, calls for sustained efforts at understanding the effects of the compounds on eukaryotic cells, Using a glycosyl phosphatidylinositol (GPI)phospholipase C (GPI-PLC) from the protozoan parasite Trypanosoma brucei, we demonstrate that a eukaryotic PLC can be activated 6-fold by aminoglycosides. Neomycin B protected GPI-PLC from a reduction in activity at pH 6.5, and increased the turnover number (k(cat)) of the enzyme, In structure-activity studies with the neomycin group, 2-deoxy-streptamine was mildly stimulatory; the concentration required to activate GPI-PLC a-fold (SC200) was 310 mu M. Neamine was 150-fold more active (SC200 = 2 mu M) than a deoxy-streptamine, indicating that a 2,6-dideoxy-2,6-diaminoglucose substituent at the 4-position of 2-deoxystreptamine plays an important role in activation of GPI-PLC. Ribostamycin and neomycin B also had SC200's of 2 mu M, implying that the ribose group in ribostamycin is not involved in activation of GPI-PLC, These conclusions were affirmed in studies with Bacillus thuringiensis phosphatidylinositol-specific phospholipase C, A 2,6-dideoxy-2,6-diaminoglucose substitution at the 4-OH of a deoxystreptamine activates the enzyme 17-fold, while a second 2,6-dideoxy-2,6-diaminoglucose moiety on the ribose ring of ribostamycin provides an additional 3.5-fold stimulation. Possible implications of these observations for the effects of aminoglycosides on eukaryote cells are discussed.	UNIV GEORGIA,DEPT CELLULAR BIOL,ATHENS,GA 30602	University System of Georgia; University of Georgia				Morris, James/0000-0003-2515-5714	NIAID NIH HHS [1-T32-AIO-78322, AI33383] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCHANAN JH, 1987, EUR J CELL BIOL, V43, P141; Butikofer P, 1996, J BIOL CHEM, V271, P15533, DOI 10.1074/jbc.271.26.15533; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GOMEZLUS R, 1995, J CHEMOTHERAPY, V7, P97, DOI 10.1179/joc.1995.7.2.97; Kettner M, 1995, INFECTION, V23, P380, DOI 10.1007/BF01713571; Landini P, 1996, BIOCHEMISTRY-US, V35, P15288, DOI 10.1021/bi9610818; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MILLER GH, 1995, J CHEMOTHERAPY, V7, P31; MINGEOTLECLERCQ MP, 1995, J TOXICOL ENV HEALTH, V44, P263, DOI 10.1080/15287399509531960; Miyaguchi H, 1996, NUCLEIC ACIDS RES, V24, P3700, DOI 10.1093/nar/24.19.3700; Morris JC, 1996, J BIOL CHEM, V271, P15468, DOI 10.1074/jbc.271.26.15468; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; SAGAWA N, 1983, BIOCHIM BIOPHYS ACTA, V752, P153, DOI 10.1016/0005-2760(83)90243-6; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; VANBAMBEKE F, 1995, EUR J PHARM-MOLEC PH, V289, P321, DOI 10.1016/0922-4106(95)90110-8; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; Wang Y, 1997, BIOCHEMISTRY-US, V36, P768, DOI 10.1021/bi962095g	18	6	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29554	29559		10.1074/jbc.272.47.29554	http://dx.doi.org/10.1074/jbc.272.47.29554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368017	hybrid			2022-12-25	WOS:A1997YG64700027
J	Brown, AM; Lemke, G				Brown, AM; Lemke, G			Multiple regulatory elements control transcription of the peripheral myelin protein zero gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SCHWANN-CELLS; BOX-BINDING PROTEINS; NERVOUS-SYSTEM; DNA-BINDING; IN-VIVO; NF-Y; NEGATIVE REGULATION; DEJERINE-SOTTAS; TRANSGENIC MICE; MAJOR MYELIN	The gene encoding protein zero (P-0), the most abundant protein of peripheral nervous system myelin, is expressed uniquely in Schwann cells. Previous studies have demonstrated that much of the cell type specificity of this expression is due to transcriptional control elements in the 1.1-kilobase pair 5'-regulatory region of the gene. We have now analyzed this region and have identified a set of functional elements in the 500 base pairs proximal to the transcription start site. DNA sequence conservation within the 5' regions of the human, mouse, and rat P-0 genes correlates closely with the results of promoter deletion analysis of the 1.1-kilobase pair region assayed in Schwann cell cultures and reveals a potent proximal region from position -350 to +45. Sites of protein/DNA interaction within the proximal 500 base pairs of the promoter were identified by footprinting assays. Functional transcriptional elements were identified within the protected regions in the proximal promoter by mutation and transient transfection analysis in P-0-expressing cell lines, The core (or basal) P-0 promoter is identified as two regulatory elements, a G/C-rich element that binds nuclear factor Sp1 and a CAAT box that binds NF-Y. These core elements are essential for the transcription observed from the transfected promoter in cultured Schwann cells.			Brown, AM (corresponding author), SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NINDS NIH HHS [NS23896] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023896] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BROCKES JP, 1980, J BIOL CHEM, V255, P8374; BROWN AM, 1993, J BIOL CHEM, V268, P26328; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; HAYASAKA K, 1993, NAT GENET, V5, P266, DOI 10.1038/ng1193-266; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LEMKE G, 1988, DEVELOPMENT, V102, P499; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; LEMKE G, 1986, TRENDS NEUROSCI, V9, P266, DOI 10.1016/0166-2236(86)90076-7; Lemke G., 1992, INTRO MOL NEUROBIOLO, P281; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MARTINI R, 1995, NAT GENET, V11, P281, DOI 10.1038/ng1195-281; MESSING A, 1994, J NEUROSCI, V14, P3533; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; Morell, 1984, MYELIN; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; POLITIS MJ, 1982, J NEUROSCI, V2, P1252; PORTER S, 1986, J NEUROSCI, V6, P3070; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; STAHL N, 1990, MOL BRAIN RES, V8, P209, DOI 10.1016/0169-328X(90)90018-9; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Warner LE, 1996, NEURON, V17, P451, DOI 10.1016/S0896-6273(00)80177-4; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978	50	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28939	28947		10.1074/jbc.272.46.28939	http://dx.doi.org/10.1074/jbc.272.46.28939			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360965	hybrid			2022-12-25	WOS:A1997YF68400024
J	Miyashita, T; OkamuraOho, Y; Mito, Y; Nagafuchi, S; Yamada, M				Miyashita, T; OkamuraOho, Y; Mito, Y; Nagafuchi, S; Yamada, M			Dentatorubral pallidoluysian atrophy (DRPLA) protein is cleaved by caspase-3 during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICE-LIKE; ICE/CED-3 PROTEASE; CELL-LINE; IN-VITRO; DEATH; MICE; IDENTIFICATION; SUBSTRATE; DISEASE; BCL-2	Dentatorubral pallidoluysian atrophy (DRPLA) is an autosomal dominant neurodegenerative disorder. It is associated with an abnormal CAG repeat expansion resulting in formation of a protein with an elongated poly glutamine stretch, However, neither the physiological roles of the DRPLA gene product nor molecular mechanisms of its pathogenesis have yet been elucidated. Here we report that the DRPLA protein is cleaved at a site near the N terminus during apoptosis induced by VP-16, staurosporine, or glucocorticoid. Moreover, the in vitro translated DRPLA protein is cleaved by recombinant caspase-3, a member of the cysteine protease family, which is thought to be a main executioner of apoptosis, Using mutant DRPLA proteins, the cleavage site was identified as (106)DSLDG(110). The cleavage, however, was not modulated by the length of the polyglutamine stretch, These findings suggest that the DRPLA protein is one of the physiological substrates of caspase-3, and its cleavage may result in structural and biochemical alterations associated with apoptosis.	NATL CHILDRENS MED RES CTR,DEPT GENET,TOKYO 154,JAPAN; TOHO UNIV,FAC SCI,DEPT BIOMOL SCI,FUNABASHI,CHIBA 274,JAPAN	National Center for Child Health & Development - Japan; Toho University								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CAILLIAU CP, 1995, J NEUROSCI, V15, P3775; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, BIOCHEM BIOPH RES CO, V233, P781, DOI 10.1006/bbrc.1997.6559; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAZAWA I, 1995, NAT GENET, V10, P99, DOI 10.1038/ng0595-99; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	34	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29238	29242		10.1074/jbc.272.46.29238	http://dx.doi.org/10.1074/jbc.272.46.29238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361003	hybrid			2022-12-25	WOS:A1997YF68400062
J	Yu, M; Yang, XY; Schmidt, T; Chinenov, Y; Wang, R; Martin, ME				Yu, M; Yang, XY; Schmidt, T; Chinenov, Y; Wang, R; Martin, ME			GA-binding protein-dependent transcription initiator elements - Effect of helical spacing between polyomavirus enhancer a factor 3(PEA3)/Ets-binding sites on initiator activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SUBUNIT-IV GENE; DIHYDROFOLATE-REDUCTASE PROMOTER; MURINE TISSUE INHIBITOR; ETS DOMAIN; COOPERATIVE BINDING; COLLAGENASE GENE; MAMMALIAN-CELLS; TATA BOX; DNA	Many eukaryotic RNA polymerase II promoters contain initiator elements which direct accurate transcription in a TATA-independent manner, The PEA3/Ets-binding site (PEA3/EBS) is a common enhancer element in eukaryotic genes and is also found near the transcriptional start sites of many TATA-less promoters. We demonstrate that two PEA3/EBSs driving expression of the luciferase reporter gene, function as a minimal transcriptional initiator element, Maximal levels of transcription was achieved when two PEA3/EBSs, in either orientation, were located on the same face of the DNA helix, and the sites could be separated by up to three helical turns, In vitro transcription start sites directed by PEA3/EBS elements were clustered on either side of the upstream PEA3/EBS and were abolished by immunodepletion of GA-binding protein (GABP) from FM3A cell nuclear extracts. In vivo, co-transfection of GABP alpha and GABP beta expression vectors enhanced reporter gene expression driven from PEA3/EBS initiator elements, Like other initiator elements, the PEA3/EBS elements were activated synergistically by upstream Spl-binding sites. Thus, our results establish GABP as both a transcriptional activator factor and as an initiator factor.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027200, R55HD027200] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27200] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASU A, 1993, J BIOL CHEM, V268, P4188; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CLEVERS HC, 1988, P NATL ACAD SCI USA, V85, P8156, DOI 10.1073/pnas.85.21.8156; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FLORES O, 1992, J BIOL CHEM, V267, P2786; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARVEY C, 1991, MOL ENDOCRINOL, V5, P836, DOI 10.1210/mend-5-6-836; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG Y, 1993, J BIOL CHEM, V268, P6535; Kadonaga JT, 1990, CURR OPIN CELL BIOL, V2, P496, DOI 10.1016/0955-0674(90)90133-Y; KANG ME, 1993, J BIOL CHEM, V268, P25033; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; LEDNICKY J, 1992, J VIROL, V66, P6379, DOI 10.1128/JVI.66.11.6379-6390.1992; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PETERSON MG, 1992, NATURE, V358, P620, DOI 10.1038/358620a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4396; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Sucharov C, 1995, GENE EXPRESSION, V5, P93; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOOZE J, 1981, MOL BIOL TUMOUR VIRU; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; XU LC, 1991, NUCLEIC ACIDS RES, V19, P6699, DOI 10.1093/nar/19.24.6699; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	64	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29060	29067		10.1074/jbc.272.46.29060	http://dx.doi.org/10.1074/jbc.272.46.29060			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360980	hybrid			2022-12-25	WOS:A1997YF68400039
J	Choi, YH; Lee, SJ; Nguyen, P; Jang, JS; Lee, J; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB				Choi, YH; Lee, SJ; Nguyen, P; Jang, JS; Lee, J; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB			Regulation of cyclin D1 by calpain protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA FAMILY PROTEINS; ACTIVATED NEUTRAL PROTEASE; PROGRAMMED CELL-DEATH; INHIBITOR P27; G1 PHASE; DEGRADATION; PATHWAY; G(1); PROGRESSION; TRANSITION	Cyclin D1, a critical positive regulator of G(1) progression, has been implicated in the pathogenesis of certain cancers. Regulation of cyclin D1 occurs at the transcriptional and posttranscriptional level. Here we present evidence that cyclin D1 levels are regulated at the posttranscriptional level by the Ca2+-activated protease calpain. Serum starvation of NIH 3T3 cells resulted in rapid loss of cyclin D1 protein that was completely reversible by calpain inhibitors. Actinomycin D and lovastatin induced rapid loss of cyclin D1 in prostate and breast cancer cells that was reversible by calpain inhibitors and not by phenylmethylsulfonyl fluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26 S proteasome. Treatment of intact NIH 3T3, prostate, and breast cancer cells with a calpain inhibitor dramatically increased the half-life of cyclin D1 protein, Addition of purified calpain to PC-3-M lysates resulted in Ca2+-dependent cyclin D1 degradation. Transient expression of the calpain inhibitor calpastatin increased cyclin D1 protein in serum-starved NIR 3T3 cells. Cyclins A, E, and El have been reported to be regulated by proteasome-associated proteolysis. The data presented here implicate calpain in cyclin D1 posttranslational regulation.	NCI, MED BRANCH, DIV CLIN SCI, NIH, BETHESDA, MD 20892 USA; NCI, DIV BASIC SCI, EXPT IMMUNOL BRANCH, NIH, BETHESDA, MD 20892 USA; NATL KYOTO HOSP, KYOTO 612, JAPAN; NAGOYA UNIV, NAGOYA, AICHI 46401, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University			Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491				ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bates S, 1996, ONCOGENE, V13, P1103; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Geng Y, 1996, ONCOGENE, V12, P1173; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KEYOMARSI K, 1991, CANCER RES, V51, P3602; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	61	148	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28479	28484		10.1074/jbc.272.45.28479	http://dx.doi.org/10.1074/jbc.272.45.28479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353308	hybrid			2022-12-25	WOS:A1997YF21900048
J	Li, XQ; Zhang, GH; Ngo, N; Zhao, XN; Kain, SR; Huang, CC				Li, XQ; Zhang, GH; Ngo, N; Zhao, XN; Kain, SR; Huang, CC			Deletions of the Aequorea victoria green fluorescent protein define the minimal domain required for fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CODON USAGE; CHROMOPHORE; MUTATIONS	The Green Fluorescent Protein (GFP) from the jellyfish Aequorea victoria is a widely used marker for gene expression and protein localization studies. Dissection of the structure of the protein would be expected to shed light on its potential applications to other fields such as the detection of protease activity. Using deletion analysis, we have defined the minimal domain in GFP required for fluorescence to amino acids 7-229. This domain starts at the middle of the first small cy helix at the N terminus of GFP and ends immediately following the last beta sheet. Studies of the amino acids at both termini of the minimal domain revealed that positions 6 and 7 at the N terminus are Glu-specific. Change of the Glu residues to other amino acids results in reduction of GFP fluorescence. Position 229 at the C terminus of GFP, however, is nonspecific: the De can be replaced with other amino acids with no measurable loss of fluorescence. A total of only 15 terminal amino acids can be deleted from GFP without disrupting fluorescence, consistent with findings of a previous study of GFP crystal structure (Ormo, M., Cubitt, A. B., Kallio, K., Gross, L. A., Tsien, R. Y., Remington, S. J. (1996) Science 273, 1392-1395 and Yang, F., Moss, L. G., and Phillips, G. N., Jr. (1996) Not. Biotechnol. 14, 1246-1251) that a tightly packed structure exists in the protein. We also generated internal deletions within the loop regions of GFP according to its crystal structure and found that all such deletions eliminated GFP fluorescence.			Li, XQ (corresponding author), CLONTECH LABS INC,1020 E MEADOW CIRCLE,PALO ALTO,CA 94303, USA.							CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592; YING DX, 1996, ANAL BIOCHEM, V235, P195	17	99	111	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28545	28549		10.1074/jbc.272.45.28545	http://dx.doi.org/10.1074/jbc.272.45.28545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353317	hybrid			2022-12-25	WOS:A1997YF21900057
J	Yao, SYM; Ng, AML; Muzyka, WR; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD				Yao, SYM; Ng, AML; Muzyka, WR; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD			Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; GUINEA-PIG; PYRIMIDINE NUCLEOSIDES; INHIBITOR SPECIFICITY; XENOPUS-LAEVIS; ERYTHROCYTES; BINDING; IDENTIFICATION; EXPRESSION; SYSTEM	Equilibrative nucleoside transport processes in mammalian cells are either nitrobenzylthioinosine (NBMPR)-sensitive (es) or NBMPR-insensitive (ei), Previously, we isolated a cDNA from human placenta encoding the 456-residue glycoprotein hENT1, When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site, We now report the molecular cloning and functional expression of es and ei homologs of hENT1 from rat tissues; rENT1 (457 residues) was 78% identical to hENT1 in amino acid sequence, and rENT2 (456 residues) was 49-50% identical to rENT1/hENT1 and corresponded to a full-length form of the delayed-early proliferative response gene product HNP36, a protein of unknown function previously cloned in truncated form, rENT1 was inhibited by NBMPR (IC50 = 4.6 nM at 10 mu M uridine), whereas rENT2 was NBMPR-insensitive (IC50 > 1 mu M). Both proteins mediated saturable uridine influx (K-m = 0.15 and 0.30 mM, respectively), were broadly selective for purine and pyrimidine nucleosides, including adenosine, and were relatively insensitive to inhibition by dipyridamole and dilazep (IC50 > 1 mu M). These observations demonstrate that es and ei nucleoside transport activities are mediated by separate, but homologous, proteins and establish a function for the HNP36 gene product.	UNIV ALBERTA,DEPT PHYSIOL,MEMBRANE TRANSPORT RES GRP,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT ONCOL,EDMONTON,AB T6G 2H7,CANADA; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Alberta; University of Alberta; University of Alberta; University of Leeds					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARROS LF, 1995, PFLUG ARCH EUR J PHY, V429, P394, DOI 10.1007/BF00374155; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; BELT JA, 1985, BIOCHEM J, V232, P681, DOI 10.1042/bj2320681; Boleti H, 1997, NEUROPHARMACOLOGY, V36, P1167, DOI 10.1016/S0028-3908(97)00136-6; CASS CE, 1974, BIOCHIM BIOPHYS ACTA, V345, P1, DOI 10.1016/0005-2736(74)90239-9; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CLUMECK N, 1993, J ANTIMICROB CHEMOTH, V32, P133, DOI 10.1093/jac/32.suppl_A.133; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; CRAWFORD CR, 1990, BIOCHIM BIOPHYS ACTA, V1024, P289, DOI 10.1016/0005-2736(90)90357-T; DAGNINO L, 1990, CANCER RES, V50, P6549; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; GATI WP, 1986, BIOCHEM J, V236, P665, DOI 10.1042/bj2360665; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; HAMMOND JR, 1992, BIOCHEM J, V287, P431, DOI 10.1042/bj2870431; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Jacobson K.A., 1990, PURINES CELLULAR SIG; JARVIS SM, 1980, BIOCHIM BIOPHYS ACTA, V597, P183, DOI 10.1016/0005-2736(80)90162-5; JARVIS SM, 1986, J MEMBRANE BIOL, V93, P1, DOI 10.1007/BF01871013; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; JARVIS SM, 1980, BIOCHEM J, V190, P377, DOI 10.1042/bj1900377; KWONG FYP, 1988, BIOCHEM J, V255, P243; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; LEE CW, 1988, NEUROCHEM INT, V12, P483, DOI 10.1016/0197-0186(88)90032-0; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; SHI MM, 1984, BIOCHEM BIOPH RES CO, V118, P584; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; WU JSR, 1983, J BIOL CHEM, V258, P3745; WU JSR, 1984, BIOCHEM J, V220, P499, DOI 10.1042/bj2200499; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388	40	187	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28423	28430		10.1074/jbc.272.45.28423	http://dx.doi.org/10.1074/jbc.272.45.28423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353301	hybrid			2022-12-25	WOS:A1997YF21900041
J	Muruganandam, A; Herx, LM; Monette, R; Durkin, JP; Stanimirovic, DB				Muruganandam, A; Herx, LM; Monette, R; Durkin, JP; Stanimirovic, DB			Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier	FASEB JOURNAL			English	Article						SV40 large T antigen; proliferation; immortalization; human; brain endothelial cells	GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; SV40 T-ANTIGEN; SV40-INDUCED IMMORTALIZATION; NEOPLASTIC TRANSFORMATION; EPITHELIAL-CELLS; INVIVO MODELS; INVITRO; ASSAY; IMPLANTATION; FIBROBLASTS	The objective of this study was to generate an immortal cell line representative of specialized human brain microvascular endothelia forming the blood-brain barrier (BBB) in vivo, Human capillary and microvascular endothelial cells (HCEC) were transfected with the plasmid pSV3-neo coding for the SV40 large T antigen and the neomycin gene, The neomycin-resistant transfected cells overcame proliferative senescence, and after a 6-8 wk period of crisis produced immortalization-competent cell colonies, Single-cell clones of near-diploid genotype were isolated from these colonies, propagated, and characterized, Immortalized HCEC (SV-HCEC) exhibited accelerated proliferation rates, but remained serum and anchorage dependent and retained the characteristic cobblestone morphology at confluence, SV-HCEC displayed a stable nuclear expression of SV40 large T antigen, lacked the invasiveness of transformed cells, and maintained major phenotypic properties of early passage control cells including expression of factor VIII-related antigen, uptake of acetylated low-density lipoprotein, binding of fluorescently labeled lectins, expression of transferrin receptor and transferrin receptor-mediated endocytosis, and high activities of the BBB-specific enzymes alkaline phosphatase and gamma-glutamyl transpeptidase, The diffusion of radiolabeled sucrose across SV-HCEC monolayers was fivefold lower than that observed with human lung microvascular endothelial cells, Furthermore, media conditioned by fetal human astrocytes increased the transendothelial electrical resistance of SV-HCEC monolayers by 2.5-fold, Therefore, this newly established human cell line expressing the specialized phenotype of BBB endothelium may serve as a readily available in vitro model for studying the properties of the human BBB.			Muruganandam, A (corresponding author), NATL RES COUNCIL CANADA, INST BIOL SCI, CELLULAR NEUROBIOL GRP, MONTREAL RD CAMPUS, BLDG M-54, OTTAWA, ON K1A 0R6, CANADA.							ABBOTT NJ, 1992, J CELL SCI, V103, P23; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; AMBERGER A, 1993, MOL CHEM NEUROPATHOL, V20, P33, DOI 10.1007/BF03160068; Angelis E.D., 1996, ADV DRUG DELIVERY RE, V18, P193; ARTHUR FE, 1987, DEV BRAIN RES, V36, P155, DOI 10.1016/0165-3806(87)90075-7; BECK DW, 1986, BRAIN RES, V381, P131, DOI 10.1016/0006-8993(86)90700-6; BOREK C, 1980, NATURE, V283, P776, DOI 10.1038/283776a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KA, 1993, J IMMUNOL METHODS, V163, P13, DOI 10.1016/0022-1759(93)90234-X; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Conzen SD, 1995, ONCOGENE, V11, P2295; DEHOUCK MP, 1992, J NEUROCHEM, V58, P1790, DOI 10.1111/j.1471-4159.1992.tb10055.x; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DOROVINIZIS K, 1991, LAB INVEST, V64, P425; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FICKLING SA, 1992, EXP CELL RES, V201, P517, DOI 10.1016/0014-4827(92)90303-P; Frey Andreas, 1993, P339; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; GIORDANO M, 1994, METH NEUROSCI, V21, P308; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; Hurst RD, 1996, J CELL PHYSIOL, V167, P81, DOI 10.1002/(SICI)1097-4652(199604)167:1<81::AID-JCP9>3.3.CO;2-F; Joo F, 1996, PROG NEUROBIOL, V48, P255, DOI 10.1016/0301-0082(95)00046-1; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; KIRINAKA H, 1995, BIOSCI BIOTECH BIOCH, V59, P912, DOI 10.1271/bbb.59.912; LAL B, 1994, P NATL ACAD SCI USA, V91, P9695, DOI 10.1073/pnas.91.21.9695; LATTERA J, 1990, J CELL PHYSL, V144, P204; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MISCHECK U, 1989, CELL TISSUE RES, V256, P221; Nagy Zoltan, 1996, Keio Journal of Medicine, V45, P200; PARDRIDGE WM, 1990, J PHARMACOL EXP THER, V253, P884; PRICE TNC, 1994, ONCOGENE, V9, P2897; Quinonero J, 1997, GENE THER, V4, P111, DOI 10.1038/sj.gt.3300360; REDDEL RR, 1995, INT J CANCER, V61, P199; ROUX F, 1993, ADV EXP MED BIOL, V331, P201; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SMITH JR, 1992, AM J CLIN NUTR, V55, P1215; SPATZ M, 1994, AM J PHYSIOL, V266, pC654, DOI 10.1152/ajpcell.1994.266.3.C654; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Stins MF, 1997, IN VITRO CELL DEV-AN, V33, P243; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TRAUTMAN OD, 1993, FRONTIERS CEREBRAL V, P205; TRAUTMANN OD, 1991, IN VITRO CELL DEV-AN, V27, P771; WHUR P, 1980, BRIT J CANCER, V42, P305, DOI 10.1038/bjc.1980.231; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; WORTON RG, 1979, CULTURE ANIMAL CELLS, P165	49	111	119	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1187	1197		10.1096/fasebj.11.13.9367354	http://dx.doi.org/10.1096/fasebj.11.13.9367354			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367354				2022-12-25	WOS:A1997YE98300017
J	Carr, JF; Hinshaw, JE				Carr, JF; Hinshaw, JE			Dynamin assembles into spirals under physiological salt conditions upon the addition of GDP and gamma-phosphate analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; GTP-BINDING PROTEINS; MECHANOCHEMICAL ENZYME; NERVE-TERMINALS; SH3 DOMAINS; MICROTUBULES; ENDOCYTOSIS; DROSOPHILA; MECHANISM; MUTANT	Dynamin is a 100-kDa GTPase that is believed to be involved in the constriction of clathrin-coated pits and the fission of clathrin-coated vesicles during receptor-mediated endocytosis and during membrane retrieval in nerve termini. It has been shown that purified dynamin incubated under low salt conditions forms rings and spirals that, in dimension and appearance, resemble the dense material occasionally observed at the necks of coated pits. In this report we show that purified dynamin forms spirals under physiological salt conditions when incubated with GDP and gamma-phosphate analogues (beryllium and aluminum fluoride) or when dialyzed into guanosine 5'-3-O-(thio)triphosphate. Moreover, spirals still form when dynamin is proteolyzed to either a predominant similar to 90-kDa species, lacking the C terminus, or to two smaller fragments, a similar to 55-kDa species originating from the N-terminal half of the protein and a similar to 30-kDa species lacking both the N and C termini. This work indicates that the addition of GDP and gamma-phosphate analogues arrests dynamin in a GTP or transition state that markedly stabilizes the spiral conformation under physiological ionic strength conditions and thereby suggests that dynamin in the absence of a receptor is capable of assembly into spirals at the necks of coated pits prior to vesicle fission.			Carr, JF (corresponding author), NIDDK,LAB CELL BIOCHEM & BIOL,NIH,BETHESDA,MD 20892, USA.							Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; CARLIER MF, 1988, BIOCHEMISTRY-US, V27, P3555, DOI 10.1021/bi00410a005; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HINSHAW JE, 1996, MOL BIOL CELL, V7, P83; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; NAKATA T, 1993, J CELL SCI, V105, P1; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TSURUHARA T, 1983, CELL TISSUE RES, V259, P199; TUMA PL, 1994, J BIOL CHEM, V269, P30842; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310	41	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28030	28035		10.1074/jbc.272.44.28030	http://dx.doi.org/10.1074/jbc.272.44.28030			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346955	hybrid			2022-12-25	WOS:A1997YD47300081
J	FernandezBusquets, X; Burger, MM				FernandezBusquets, X; Burger, MM			The main protein of the aggregation factor responsible for species-specific cell adhesion in the marine sponge Microciona prolifera is highly polymorphic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; IMMUNE-SYSTEM; TRANSPLANTATION IMMUNITY; INVERTEBRATE IMMUNITY; PERIPLANETA-AMERICANA; RECOGNITION MOLECULES; SELF-INCOMPATIBILITY; NATURAL-POPULATIONS; GEODIA-CYDONIUM; NICOTIANA-ALATA	Species-specific cell recognition in sponges, the oldest living metazoans, is based on a proteoglycan-like aggregation factor. We have screened individual sponge cDNA libraries, identifying multiple related forms for the aggregation factor core protein (MAFp3). Northern blots show the presence in several human tissues of transcripts strongly binding a MAFp3-specific probe. The open reading frame for MAFp3 is not interrupted in the 5' direction, revealing variable protein sequences that contain numerous introns equally spaced. We have studied tissue histocompatibility within a sponge population, finding 100% correlation between rejection behavior and the individual-specific restriction fragment length polymorphism pattern using aggregation factor-related probes. PCR amplifications with specific primers showed that at least some of the MAFp3 forms are allelic and distribute in the population used. A pronounced polymorphism is also observed when analyzing purified aggregation factor in polyacrylamide gels. Protease digestion of the polymorphic glycosaminoglycan-containing bands indicates that glycans are also responsible for the variability. The data presented reveal a high polymorphism of aggregation factor components, which matches the elevated sponge alloincompatibility, suggesting an involvement of the cell adhesion system in sponge allogeneic reactions.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Marine Biological Laboratory - Woods Hole	FernandezBusquets, X (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Fernàndez-Busquets, Xavier/K-1323-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631				AHO S, 1993, P NATL ACAD SCI USA, V90, P7288, DOI 10.1073/pnas.90.15.7288; AYALA FJ, 1978, SCI AM, V239, P56, DOI 10.1038/scientificamerican0978-56; BERGQUIST PR, 1978, SPONGES, P202; BERTHEUSSEN K, 1979, EXP CELL RES, V120, P373, DOI 10.1016/0014-4827(79)90397-5; BIGGER CH, 1980, BIOL BULL, V159, P117, DOI 10.2307/1541013; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BODMER WF, 1972, NATURE, V237, P139, DOI 10.1038/237139a0; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; CHENG TC, 1970, J INVERTEBR PATHOL, V15, P177, DOI 10.1016/0022-2011(70)90232-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFARO KA, 1977, SCIENCE, V197, P1389, DOI 10.1126/science.331476; COOPER EL, 1992, SCAND J IMMUNOL, V35, P247, DOI 10.1111/j.1365-3083.1992.tb02857.x; COOPER EL, 1969, J EXP ZOOL, V171, P69, DOI 10.1002/jez.1401710110; COOPER EL, 1990, BIOSCIENCE, V40, P720, DOI 10.2307/1311503; COOPER EL, 1969, SCIENCE, V166, P1414, DOI 10.1126/science.166.3911.1414; CURTIS ASG, 1982, TRANSPLANTATION, V33, P127, DOI 10.1097/00007890-198202000-00005; CURTIS ASG, 1971, J EMBRYOL EXP MORPH, V26, P295; DANSKA JS, 1990, INT IMMUNOL, V2, P796, DOI 10.1093/intimm/2.9.795; DESUTTER D, 1979, DEV COMP IMMUNOL, V3, P389, DOI 10.1016/S0145-305X(79)80036-1; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; EDELMAN GM, 1987, IMMUNOL REV, V100, P11, DOI 10.1111/j.1600-065X.1987.tb00526.x; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; FernandezBusquets X, 1996, J BIOL CHEM, V271, P23558, DOI 10.1074/jbc.271.38.23558; FLAJNIK MF, 1994, CIBA F SYMP, V186, P224; FUKE MT, 1985, BIOL BULL-US, V169, P631, DOI 10.2307/1541305; GEORGE JF, 1987, TRANSPLANTATION, V43, P514, DOI 10.1097/00007890-198704000-00012; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HILDEMAN.WH, 1972, TRANSPLANTATION, V14, P624, DOI 10.1097/00007890-197211000-00015; HILDEMANN WH, 1980, TRANSPLANTATION, V30, P297, DOI 10.1097/00007890-198010000-00012; HILDEMANN WH, 1979, SCIENCE, V204, P420, DOI 10.1126/science.441730; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; HOWCROFT TK, 1987, TRANSPLANTATION, V44, P129, DOI 10.1097/00007890-198707000-00026; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; HUMPHREYS T, 1994, IMMUNOL TODAY, V15, P316, DOI 10.1016/0167-5699(94)90079-5; HUMPHREYS T, 1994, ANN NY ACAD SCI, V712, P342, DOI 10.1111/j.1749-6632.1994.tb33590.x; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KELLY KL, 1992, J EXP ZOOL, V262, P202, DOI 10.1002/jez.1402620210; KLEIN J, 1989, SCAND J IMMUNOL, V29, P499, DOI 10.1111/j.1365-3083.1989.tb01152.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBOCK R, 1980, P NATL ACAD SCI-BIOL, V77, P6667, DOI 10.1073/pnas.77.11.6667; MARCHALONIS JJ, 1994, ANN NY ACAD SCI, V712, P1; MARCHALONIS JJ, 1990, BIOSCIENCE, V40, P758, DOI 10.2307/1311509; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MOSCONA AA, 1968, DEV BIOL, V18, P250, DOI 10.1016/0012-1606(68)90035-3; MUCHMORE AV, 1987, J IMMUNOL, V138, P2547; MUKAI H, 1975, P JPN ACAD, V51, P44, DOI 10.2183/pjab1945.51.44; MULLER WEG, 1981, EUR J BIOCHEM, V116, P573, DOI 10.1111/j.1432-1033.1981.tb05374.x; MULLER WEG, 1978, DIFFERENTIATION, V10, P45, DOI 10.1111/j.1432-0436.1978.tb00944.x; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; NEIGEL JE, 1985, EVOLUTION, V39, P724, DOI 10.1111/j.1558-5646.1985.tb00415.x; Oka H., 1957, Proceedings of the Japan Academy, V33, P657; OTTILIE S, 1992, ONCOGENE, V7, P1625; OXLEY D, 1995, GLYCOBIOLOGY, V5, P517, DOI 10.1093/glycob/5.5.517; Pancer Z, 1996, CELL ADHES COMMUN, V4, P327, DOI 10.3109/15419069609010776; PFEIFER K, 1993, J CELL SCI, V106, P545; PIMLOTT NJG, 1986, J IMMUNOL, V137, P2455; RATCLIFFE NA, 1985, INT REV CYTOL, V97, P183, DOI 10.1016/S0074-7696(08)62351-7; REINISCH CL, 1989, IMMUNOL TODAY, V10, P278, DOI 10.1016/0167-5699(89)90142-4; RINKEVICH B, 1993, BIOL BULL, V184, P79, DOI 10.2307/1542381; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROTHENBERG BE, 1978, DEV COMP IMMUNOL, V2, P23, DOI 10.1016/S0145-305X(78)80022-6; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SAJDERA S, 1969, J BIOL CHEM, V244, P77; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Schaecke Heike, 1994, Journal of Molecular Recognition, V7, P273, DOI 10.1002/jmr.300070406; SCHLUTER SF, 1994, ANN NY ACAD SCI, V712, P74, DOI 10.1111/j.1749-6632.1994.tb33563.x; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; SEEGER MA, 1988, CELL, V55, P589, DOI 10.1016/0092-8674(88)90217-6; SMITH LC, 1992, IMMUNOL TODAY, V13, P356, DOI 10.1016/0167-5699(92)90172-4; SOLECAVA AM, 1991, BIOL J LINN SOC, V44, P65, DOI 10.1111/j.1095-8312.1991.tb00607.x; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; THEODOR JL, 1970, NATURE, V227, P690, DOI 10.1038/227690a0; Van de Vyver G., 1975, Transactions Congr int Un Game Biol, V10, P123; van de Vyver G., 1970, Annls Embryol. Morphogen., V3, P251; Varner JA, 1996, J BIOL CHEM, V271, P16119; Weissman I L, 1988, Int Rev Immunol, V3, P397, DOI 10.3109/08830188809051207; WEISSMAN IL, 1990, IMMUNOL REV, V113, P227, DOI 10.1111/j.1600-065X.1990.tb00043.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1988, IMMUNOGENETICS, V27, P265, DOI 10.1007/BF00376121; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; WOODWARD JR, 1992, GLYCOBIOLOGY, V2, P241, DOI 10.1093/glycob/2.3.241; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; Yin CQ, 1996, BIOL BULL, V191, P159, DOI 10.2307/1542919	94	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27839	27847		10.1074/jbc.272.44.27839	http://dx.doi.org/10.1074/jbc.272.44.27839			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346930	hybrid			2022-12-25	WOS:A1997YD47300056
J	Mu, J; Skurat, AV; Roach, PJ				Mu, J; Skurat, AV; Roach, PJ			Glycogenin-2, a novel self-glucosylating protein involved in liver glycogen biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHORYLATION SITES; MOLECULAR-CLONING; RAT-HEART; SYNTHASE; BIOGENESIS; INITIATION; IDENTIFICATION; REQUIREMENT; MECHANISM	Glycogenin is a self-glucosylating protein involved in the initiation phase of glycogen biosynthesis. A single mammalian gene had been reported to account for glycogen biogenesis in Liver and muscle, the two major repositories of glycogen, We describe the characterization of novel forms of glycogenin, designated glycogenin-2 (GN-2), encoded by a second gene that is expressed preferentially in certain tissues, including liver, heart, and pancreas. Cloning of cDNAs encoding glycogenin-a indicated the existence of multiple species, including three liver forms (GN-2 alpha, GN-2 beta, and GN-2 gamma) generated in part by alternative splicing. Overall, GN-2 has 40-45% identity to muscle glycogenin but is 72% identical over a 200-residue segment thought to contain the catalytic domain. GN-2 expressed in Escherichia coli or COS cells is active in self-glucosylation assays, and self-glucosylated GN-2 can be elongated by skeletal muscle glycogen synthase. Antibodies raised against GN-2 produced in E. coli recognized proteins of M-r similar to 66,000 present in extracts of rat liver and in cultured H4IIEC3 hepatoma cells. In H4IIEC3 cells, most of the GN-2 was present as a free protein but some was covalently associated with glycogen fractions and was only released by treatment with alpha-amylase, H4IIEC3 cells also expressed the muscle form of glycogenin (glycogenin-1), which was attached to a chromatographically separable glycogen fraction.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis				Mu, James/0000-0001-8081-2401	NIDDK NIH HHS [DK27221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK027221, R56DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1995, FEBS LETT, V359, P110, DOI 10.1016/0014-5793(95)00018-5; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; BLUMENFELD ML, 1986, EUR J BIOCHEM, V156, P163, DOI 10.1111/j.1432-1033.1986.tb09562.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDER PC, 1988, BIOCHEM INT, V17, P711; CAMICI M, 1982, J BIOL CHEM, V257, P9898; CAMPBELL DG, 1989, EUR J BIOCHEM, V185, P119, DOI 10.1111/j.1432-1033.1989.tb15090.x; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CHENG C, 1995, MOL CELL BIOL, V15, P6632; ERCAN N, 1994, J BIOL CHEM, V269, P22328; GANNON MC, 1996, TRENDS GLYCOSCI GLYC, V8, P163; KRISMAN CR, 1975, EUR J BIOCHEM, V52, P117, DOI 10.1111/j.1432-1033.1975.tb03979.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1983, J BIOL CHEM, V258, P710; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MANZELLA S, 1995, ARCH BIOCHEM BIOPHYS, V320, P361, DOI 10.1016/0003-9861(95)90020-9; Mu J, 1996, J BIOL CHEM, V271, P26554, DOI 10.1074/jbc.271.43.26554; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; PITCHER J, 1987, EUR J BIOCHEM, V169, P497, DOI 10.1111/j.1432-1033.1987.tb13637.x; Preiss J., 1981, BIOL CARBOHYDRATES, V1, P199; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; Skurat AV, 1997, EUR J BIOCHEM, V245, P147, DOI 10.1111/j.1432-1033.1997.t01-1-00147.x; SKURAT AV, 1995, DIABETES MELLITUS FU, P213; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; STETTEN MR, 1961, J AM CHEM SOC, V83, P2912, DOI 10.1021/ja01474a029; THON VJ, 1993, J BIOL CHEM, V268, P7509; Tolmasky DS, 1996, CELL MOL BIOL, V42, P589; VISKUPIC E, 1992, J BIOL CHEM, V267, P25759; WANG YH, 1986, BIOCHIM BIOPHYS ACTA, V888, P225, DOI 10.1016/0167-4889(86)90025-X; YANG BZ, 1992, J BIOL CHEM, V267, P9294	37	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27589	27597		10.1074/jbc.272.44.27589	http://dx.doi.org/10.1074/jbc.272.44.27589			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346895	hybrid			2022-12-25	WOS:A1997YD47300021
J	Yang, Y; Yang, Y; Kovalski, K; Smith, HC				Yang, Y; Yang, Y; Kovalski, K; Smith, HC			Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CATALYTIC SUBUNIT; IN-VITRO; CYTIDINE DEAMINASE; PROTEIN; ENZYME; BINDING; COMPLEX; SITE; MUTAGENESIS	APOBEC-1-catalyzed apolipoprotein B (apoB) mRNA editing requires auxiliary factors, but the number and functions of these factors are unknown, We have partially purified the editing activity from extracts of a McArdle cell line overexpressing His(6)-hemagglutinin-tagged, rat APOBEC-1 using metal-chelating affinity chromatography, The 1,200-fold purification achieved by this approach was partially dependent on exogenously added RNA containing a mooring sequence for editosome assembly, Affinity-purified editing activity could be separated by 300 mM NaCl extraction into two fractions, a salt-resistant fraction (editing fraction 1; EF1) and a salt-soluble fraction (EF2). Neither EF1 nor EF2 alone could edit apoB RNA, but when added together they reconstituted full editing activity, Previously identified candidate auxiliary factors including the p66/p44 apoB RNA binding proteins and the presumptive editosome assembly factor p240 were all present in the affinity-purified editing complex, Moreover, virtually all of p66, p240, and APOBEC-1 were present in EF1, whereas p44 was quantitatively recovered in EF2, This is the first demonstration that p66 and p44 can bind to apoB RNA independently of one another. In addition, 100- and 55-kDa apoB RNA cross-linking proteins have been identified in the APOBEC-1 affinity-purified material. RNA competition studies demonstrated that p100, p66, and p55 bound selectively to apoB RNA, whereas p44 had general RNA cross-linking characteristics. The data underscore the multiplicity of auxiliary factors potentially involved in apoB RNA editing and suggest an editosome far more complicated than may have been previously appreciated.	UNIV ROCHESTER, DEPT BIOCHEM & BIOPHYS, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT PATHOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Smith, Harold/0000-0001-6257-6791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43739] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; FUNAHASHI T, 1995, J LIPID RES, V36, P414; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; NAGAI K, 1994, RNA PROTEIN INTERACT; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	30	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27700	27706		10.1074/jbc.272.44.27700	http://dx.doi.org/10.1074/jbc.272.44.27700			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346911	hybrid			2022-12-25	WOS:A1997YD47300037
J	Krook, A; Whitehead, JP; Dobson, SP; Griffiths, MR; Ouwens, M; Baker, C; Hayward, AC; Sen, SK; Maassen, JA; Siddle, K; Tavare, JM; ORahilly, S				Krook, A; Whitehead, JP; Dobson, SP; Griffiths, MR; Ouwens, M; Baker, C; Hayward, AC; Sen, SK; Maassen, JA; Siddle, K; Tavare, JM; ORahilly, S			Two naturally occurring insulin receptor tyrosine kinase domain mutants provide evidence that phosphoinositide 3-kinase activation alone is not sufficient for the mediation of insulin's metabolic and mitogenic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-UPTAKE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; P21(RAS)-GTP FORMATION; SIGNAL-TRANSDUCTION; GLUT4 TRANSLOCATION; SUBSTRATE-1; RESISTANCE; GENE	We have recently reported (1) that two naturally occurring mutants of the insulin receptor tyrosine kinase domain, Arg-1174 --> Gln and Pro-1178 --> Leu (Gln-1174 and Leu1178, respectively), both found in patients with inherited severe insulin resistance, markedly impaired receptor tyrosine autophosphorylation, with both mutant receptors; being unable to mediate the stimulation of glycogen synthesis or mitogenesis by insulin when expressed hh Chinese hamster ovary cells, However, these mutations did not fully prevent IRS-1 phosphorylation in response to insulin in these cells, suggesting that IRS-1 alone may not be sufficient to mediate insulin's metabolic and mitogenic effects, In the present study, we have demonstrated that these mutations also impair the ability of the insulin receptor to activate the transcription factor Elk-1 and promote GLUT4 translocation to the plasma membrane, Although at law concentrations of insulin, the mutant receptors were impaired in their ability to stimulate the tyrosine phosphorylation of IRS-1, at higher insulin concentrations we confirmed that the cells expressing the mutant receptors showed significantly increased tyrosine phosphorylation of IRS-1 compared with parental nontransfected cells, In addition, at comparable insulin concentrations, the association of the p85 alpha subunit of phosphoinositide 3-kinase (PI3-kinase) with IRS-1 and the enzymatic activity of IRS-1-associated PI3-kinase were significantly enhanced in cells expressing the mutant receptors, in contrast, no significant stimulation of the tyrosine phosphorylation of Shc, GTP loading of Ras, or mitogen-activated protein kinase phosphorylation was seen in cell lines expressing these mutant receptors. Thus, no activation of any measurable mitogenic or metabolic response was detectable, despite significant insulin-induced phosphorylation of IRS-1 and its association with PI3-kinase in cells stably expressing the mutant insulin receptors, These findings suggest that PI3-kinase activation alone may be insufficient to mediate a wide range of the metabolic and mitogenic effects of insulin, Additionally, the data provide support for the notion that insulin activation of Ras is more closely linked with Shc, and not IRS-1, phosphorylation.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QR,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; UNIV BRISTOL,DEPT BIOCHEM,BRISTOL,AVON,ENGLAND; LEIDEN UNIV,SYLVIUS LABS,DEPT MED BIOCHEM,NL-2300 RA LEIDEN,NETHERLANDS	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Bristol; Leiden University; Leiden University - Excl LUMC			Ouwens, Margriet/H-2442-2013; Whitehead, Jonathan/F-5022-2014; Krook, Anna/K-1192-2015; O'Rahilly, Stephen/ABF-6509-2020	Ouwens, Margriet/0000-0001-6709-2702; Krook, Anna/0000-0002-0891-0258; O'Rahilly, Stephen/0000-0003-2199-4449; Whitehead, Jonathan/0000-0003-3978-3148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Dobson SP, 1996, FEBS LETT, V393, P179, DOI 10.1016/0014-5793(96)00879-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen BF, 1996, BIOCHEM J, V315, P271; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Krook A, 1996, BAILLIERE CLIN ENDOC, V10, P97, DOI 10.1016/S0950-351X(96)80330-2; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG B, 1991, J BIOL CHEM, V266, P990	34	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30208	30214		10.1074/jbc.272.48.30208	http://dx.doi.org/10.1074/jbc.272.48.30208			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374504	hybrid			2022-12-25	WOS:A1997YH61300036
J	Nunomura, W; Takakuwa, Y; Tokimitsu, R; Krauss, SW; Kawashima, M; Mohandas, N				Nunomura, W; Takakuwa, Y; Tokimitsu, R; Krauss, SW; Kawashima, M; Mohandas, N			Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin - Implications for modulation of CD44-ankyrin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SKELETAL PROTEIN-4.1; ERYTHROCYTE ANION-EXCHANGER; SPECTRIN-ACTIN BINDING; PLASMA-MEMBRANE; ANKYRIN-BINDING; TRANSMEMBRANE GLYCOPROTEIN; OPTICAL BIOSENSOR; RESONANT MIRROR; GLYCOPHORIN-C; CELLS	Erythrocyte membrane skeletal protein 4.1 isoforms have been identified in a variety of non-erythroid cells. However, interactions between protein 4.1 and its binding partners in non-erythroid cell membranes are poorly understood. In the erythrocyte membrane, protein 4.1 binds to the cytoplasmic domain of band 3 and, through this interaction, modulates ankyrin binding to band 3. The sequences LRRRY or IRRRY in band 3 mediate the interaction between band 3 and protein 4.1. The cytoplasmic domain of CD44, a transmembrane glycoprotein found in erythroid as well. as non-erythroid cells, has internal sequences SRRRC and QKKKL. We wanted to determine if protein 4.1 binds to CD44 in a fashion analogous to its binding to band 3 and through this interaction modulates ankyrin binding to CD44, We report here that protein 4.1 binds to the cytoplasmic domain of CD44 with a dissociation constant on the order of 10(-7) M and that Ca2+ and calmodulin reduce the affinity of this interaction Furthermore, although independent binding of both protein 4.1 and ankyrin to CD44 could be documented, binding of protein 4.1 prevented subsequent ankyrin binding These studies have enabled us to identify a potentially important functional role for protein 4.1 in modulating ankyrin binding to CD44.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720; TOKYO WOMENS MED COLL,DEPT BIOCHEM,SHINJUKU KU,TOKYO 162,JAPAN; TOKYO WOMENS MED COLL,DEPT DERMATOL,SHINJUKU KU,TOKYO 162,JAPAN	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tokyo Women's Medical University; Tokyo Women's Medical University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, P01DK032094, R01DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579] Funding Source: Medline; NIDDK NIH HHS [DK26263, DK32094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DISCHER D, 1993, J BIOL CHEM, V268, P7186; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P887; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Luna EJ, 1991, CURR OPIN CELL BIOL, V3, P120, DOI 10.1016/0955-0674(91)90174-W; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MORROW JS, 1998, IN PRESS HDB PHYSL; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Schischmanoff PO, 1997, J BIOL CHEM, V272, P10254, DOI 10.1074/jbc.272.15.10254; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; Shimizu T, 1996, HISTOL HISTOPATHOL, V11, P495; Shimizu T, 1996, BIOL CELL, V86, P19, DOI 10.1016/0248-4900(96)89520-7; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; TAMMI R, 1994, ARCH DERMATOL RES, V286, P21, DOI 10.1007/BF00375839; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010	54	108	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30322	30328		10.1074/jbc.272.48.30322	http://dx.doi.org/10.1074/jbc.272.48.30322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374519	hybrid			2022-12-25	WOS:A1997YH61300051
J	Bisaillon, M; Lemay, G				Bisaillon, M; Lemay, G			Characterization of the reovirus lambda 1 protein RNA 5'-triphosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CAPPING ENZYME; 5'-TERMINAL STRUCTURE; GUANYLYLTRANSFERASE; CONTAINS; SEQUENCE; CORE; SEGMENT; CELLS; ACIDS	Characterization of the phosphohydrolytic activities of recombinant reovirus lambda 1 protein demonstrates that, in addition to the previously reported nucleoside triphosphate phosphohydrolase and helicase activities, the protein also possesses RNA 5'-triphosphatase activity, This activity was absolutely dependent on the presence of a divalent cation, Mg2+ or Mn2+, and specifically removes the 5'-gamma-phosphate at the end of triphosphate-terminated RNAs, Kinetic competition analysis showed that nucleoside triphosphate phosphohydrolase and RNA 5'-triphosphatase reactions are carried out at a common active site, These results strongly support the idea that, in addition to its role as an RNA helicase during transcription of the viral genome, lambda 1 also participates during formation of the cap structure at the 5' end of newly synthesized reovirus mRNAs, The lambda 1 protein represents only the third RNA triphosphatase whose primary structure is known and the first described in a double stranded RNA virus.	UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				BANERJEE AK, 1971, NATURE-NEW BIOL, V230, P169, DOI 10.1038/newbio230169a0; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; Bisaillon M, 1997, J BIOL CHEM, V272, P18298, DOI 10.1074/jbc.272.29.18298; BORSA J, 1970, J VIROL, V6, P295, DOI 10.1128/JVI.6.3.295-302.1970; CASHDOLLAR LW, 1994, RES VIROLOGY, V145, P277, DOI 10.1016/S0923-2516(07)80032-X; CLEVELAND DR, 1986, J VIROL, V60, P307, DOI 10.1128/JVI.60.1.307-311.1986; FAUST M, 1975, NUCLEIC ACIDS RES, V197, P1329; FURUICHI Y, 1977, NUCLEIC ACIDS RES, V4, P3341, DOI 10.1093/nar/4.10.3341; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; ITOH N, 1984, J BIOL CHEM, V259, P3923; KAPULER AM, 1970, NATURE, V225, P1209, DOI 10.1038/2251209a0; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; LEMAY G, 1994, J GEN VIROL, V75, P3261, DOI 10.1099/0022-1317-75-11-3261; MUTHUKRISHNAN S, 1975, NATURE, V255, P33, DOI 10.1038/255033a0; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Nibert Max L., 1996, P691; Noble S, 1997, J VIROL, V71, P2182, DOI 10.1128/JVI.71.3.2182-2191.1997; SELIGER LS, 1987, J BIOL CHEM, V262, P16289; SHUMAN S, 1990, J BIOL CHEM, V265, P11967; SHUMAN S, 1989, J BIOL CHEM, V264, P9690; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; XU PT, 1993, VIROLOGY, V197, P726, DOI 10.1006/viro.1993.1648; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996	30	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29954	29957		10.1074/jbc.272.47.29954	http://dx.doi.org/10.1074/jbc.272.47.29954			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368073	hybrid			2022-12-25	WOS:A1997YG64700083
J	Cryns, VL; Byun, Y; Rana, A; Mellor, H; Lustig, KD; Ghanem, L; Parker, PJ; Kirschner, MW; Yuan, JY				Cryns, VL; Byun, Y; Rana, A; Mellor, H; Lustig, KD; Ghanem, L; Parker, PJ; Kirschner, MW; Yuan, JY			Specific proteolysis of the kinase protein kinase C-related kinase 2 by caspase-3 during apoptosis - Identification by a novel, small pool expression cloning strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; ACTIVATION; CLEAVAGE; CELLS; ICE; PKN	The caspase family of proteases plays a critical role in the execution of apoptosis, However, efforts to decipher the molecular mechanisms by which caspases induce cell death have been greatly hindered by the lack of systematic and broadly applicable strategies to identify their substrates. Here we describe a novel expression cloning strategy to rapidly isolate cDNAs encoding caspase substrates that are cleaved during apoptosis, Small cDNA pools (approximately 100 clones each) are transcribed/translated in vitro in the presence of [S-35]methionine; these labeled protein pools are then incubated with cytosolic extracts from control and apoptotic cells, cDNA pools encoding proteins that are specifically cleaved by the apoptotic extract and whose cleavage is prevented by the caspase inhibitor acetyl-Tyr-Val-Ala-Asp chloromethylketone are subdivided and retested until a single cDNA is isolated, Using this approach, we isolated a partial cDNA encoding protein kinase C-related kinase 2 (PRK2), a serine-threonine kinase, and demonstrate that full-length human PRK2 is proteolyzed by caspase-3 at Asp(117) and Asp(700) in vitro, In addition, PRK2 is cleaved rapidly during Fas-and staurosporine-induced apoptosis in vitro by caspase-3 or a closely related caspase, Both of the major apoptotic cleavage sites of PRK2 in vivo lie within its regulatory domain, suggesting that its activity may be deregulated by proteolysis.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET UNIT,CHARLESTOWN,MA 02129; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Cancer Research UK			Ghanem, Louis/R-3733-2016; Parker, Peter j/D-5192-2013	Ghanem, Louis/0000-0002-7723-5241; parker, peter/0000-0002-6218-2933; Mellor, Harry/0000-0003-3894-0623	NCI NIH HHS [K08-CA01752-04] Funding Source: Medline; NIA NIH HHS [AG12859-01] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859, R01AG012859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Lustig KD, 1996, DEVELOPMENT, V122, P4001; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Yu WP, 1997, J BIOL CHEM, V272, P10030	26	85	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29449	29453		10.1074/jbc.272.47.29449	http://dx.doi.org/10.1074/jbc.272.47.29449			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368003	hybrid			2022-12-25	WOS:A1997YG64700013
J	Dickson, RC; Nagiec, EE; Wells, GB; Nagiec, MM; Lester, RL				Dickson, RC; Nagiec, EE; Wells, GB; Nagiec, MM; Lester, RL			Synthesis of mannose-(inositol-P)(2)-ceramide, the major sphingolipid in Saccharomyces cerevisiae, requires the IPT1 (YDR072c) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITOL-CONTAINING SPHINGOLIPIDS; YEAST HISTOPLASMA-CAPSULATUM; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPID BIOSYNTHESIS; STRAINS; RESISTANCE; MEMBRANE; CLONING; ENCODES; LCB1	Knowledge of the Saccharomyces cerevisiae genes and proteins necessary for sphingolipid biosynthesis is far from complete, Such information should expedite studies of pathway regulation and sphingolipid functions, Using the Aur1 protein sequence, recently identified as necessary for synthesis of the sphingolipid inositol-P-ceramide (IPC), we show that a homolog (open reading frame YDR072c), termed Ipt1 (inositolphosphotransferase 1) is necessary for synthesis of mannose-(inositol-P)(2)-ceramide (M(IP)(2)C), the most abundant and complex sphingolipid in S. cerevisiae, This conclusion is based upon analysis of an ipt1-deletion strain, which fails to accumulate M(IP)(2)C and instead accumulates increased amounts of the precursor mannose inositol-P-ceramide. The mutant also fails to incorporate radioactive precursors into M(IP)(2)C, and membranes prepared from it do not incorporate [H-3-inositol]phosphatidylinositol into M(IP)(2)C, indicating a lack of M(IP)(2)C synthase activity (putatively phosphatidylinositol:mannose-inositol-P-ceramide phosphoinositol transferase), M(IP)(2)C synthase activity is inhibited in the micromolar range by aureobasidin A, but drug sensitivity is over 1000-fold lower than reported for IPC synthase activity. An ipt1-deletion mutant has no severe phenotypic effects but is slightly more resistant to growth inhibition by calcium ions, Identification of the IPT1 gene should be helpful in determining the function of the M(IP)(2)C sphingolipid and in determining the catalytic mechanism of TPC and M(IP)(2)C synthases.	UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	University of Kentucky	Dickson, RC (corresponding author), UNIV KENTUCKY, MED CTR, DEPT BIOCHEM, LEXINGTON, KY 40536 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR K, 1984, BIOCHEMISTRY-US, V23, P5589, DOI 10.1021/bi00318a032; BARR K, 1984, BIOCHEMISTRY-US, V23, P5581, DOI 10.1021/bi00318a031; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; FEWSTER ME, 1969, J CHROMATOGR, V43, P120, DOI 10.1016/S0021-9673(00)99173-8; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HANSON BA, 1980, J LIPID RES, V21, P309; HashidaOkado T, 1996, MOL GEN GENET, V251, P236; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; HEIDLER SA, 1995, ANTIMICROB AGENTS CH, V39, P2765, DOI 10.1128/AAC.39.12.2765; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KERRIDGE D, 1986, ADV MICROB PHYSIOL, V27, P1, DOI 10.1016/S0065-2911(08)60303-3; Leber A, 1997, FEBS LETT, V411, P211, DOI 10.1016/S0014-5793(97)00692-3; LESTER RL, 1993, ADV LIPID RES, V26, P253; LESTER RL, 1993, J BIOL CHEM, V268, P845; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; SIKORSKI RS, 1989, GENETICS, V122, P19; SKIPSKI VP, 1969, METHOD ENZYMOL, V14, P545; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; VINCENT VL, 1995, MICROBIOL-UK, V141, P1829, DOI 10.1099/13500872-141-8-1829; Wells GB, 1996, J BACTERIOL, V178, P6223, DOI 10.1128/jb.178.21.6223-6226.1996; ZHAO C, 1994, J BIOL CHEM, V269, P21480	36	142	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29620	29625		10.1074/jbc.272.47.29620	http://dx.doi.org/10.1074/jbc.272.47.29620			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368028	hybrid			2022-12-25	WOS:A1997YG64700038
J	Kotake, K; Ozaki, N; Mizuta, M; Sekiya, S; Inagaki, N; Seino, S				Kotake, K; Ozaki, N; Mizuta, M; Sekiya, S; Inagaki, N; Seino, S			Noc2, a putative zinc finger protein involved in exocytosis in endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; CA2+-DEPENDENT EXOCYTOSIS; SYNAPTIC VESICLES; CHROMAFFIN CELLS; ALPHA-ACTININ; RABPHILIN-3A; SECRETION; RAB3A; DOC2; SYNAPTOTAGMINS	We have cloned a cDNA encoding a novel protein of 302 amino acids (designated Noc2, no C2 domain) that has 40.7% amino acid identity with and 77.9% similarity to the N-terminal region of rabphilin-3A, a target molecule of Rab3A However, unlike rabphilin-3A, Noc2 lacks two C2 domains that are thought to interact with Ca2+ and phospholipids. Noc2 is expressed predominantly in endocrine tissues and hormone-secreting cell lines and at very low levels in brain. Immunoblot analysis of subcellular fractions of the insulin-secreting cell line MING and immunocytochemistry reveal that Noc2 is a 38-kDa protein present in the cytoplasm. Overexpression of Noc2 in PC12 cells cotransfected with growth hormone enhances high K+-induced growth hormone secretion. Screening a mouse embryonic cDNA Library with the yeast two-hybrid system shows that Noc2 interacts with the LIM domain-containing protein zyxin, a component of the cytoskeleton, and this interaction is further confirmed by the coimmunoprecipitation experiment. Accordingly, Noc2 is probably involved in regulated exocytosis in endocrine cells by interacting with the cytoskeleton.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL MED,CHUO KU,CHIBA 260,JAPAN; MIYAZAKI MED COLL,DEPT INTERNAL MED 3,KIYOTAKE,MIYAZAKI 88916,JAPAN; CHIBA UNIV,SCH MED,DEPT OBSTET & GYNECOL,CHUO KU,CHIBA 260,JAPAN	Chiba University; University of Miyazaki; Chiba University				Inagaki, Nobuya/0000-0001-8261-2593				Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; Calakos N, 1996, PHYSIOL REV, V76, P1; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; HOLTZ RE, 1994, J BIOL CHEM, V269, P10229; INAGAKI N, 1994, J BIOCHEM-TOKYO, V116, P239, DOI 10.1093/oxfordjournals.jbchem.a124512; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MIZUTA M, 1997, IN PRESS DIABETES; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WENDLAND B, 1994, MOL ENDOCRINOL, V8, P1070, DOI 10.1210/me.8.8.1070; WICK PF, 1993, J BIOL CHEM, V268, P10983	27	70	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29407	29410		10.1074/jbc.272.47.29407	http://dx.doi.org/10.1074/jbc.272.47.29407			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367993	hybrid			2022-12-25	WOS:A1997YG64700003
J	Nakano, T; Ishimoto, Y; Kishino, J; Umeda, A; Inoue, K; Nagata, K; Ohashi, K; Mizuno, K; Arita, H				Nakano, T; Ishimoto, Y; Kishino, J; Umeda, A; Inoue, K; Nagata, K; Ohashi, K; Mizuno, K; Arita, H			Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; K-DEPENDENT PROTEINS; GAS6; AXL; EXPRESSION; LIGAND; BRAIN; SKY; PROTOONCOGENE; EXPOSURE	Gas6, a product of a growth arrest-specific gene 6, potentiates proliferation of vascular smooth muscle cells and prevents cell death of vascular smooth muscle cells. It has been also demonstrated that Gas6 is a ligand of receptor tyrosine kinases Axl, Sky, and Mer. Gas6 contains gamma-carboxyglutamic acid residues, which are found in some blood coagulation factors and mediate the interaction of the coagulation factors with negatively charged phospholipid. In this study, we clarified that Gas6 specifically bound to phosphatidylserine and the binding was dependent on Ca2+ and gamma-carboxyglutamic acid residues. Furthermore, we found that U937 cells, which express Gas6 receptor on their surfaces, adhered to phosphatidylserine-coated enzyme-linked immunosorbent assay (ELISA) plate only in the presence of Gas6 and Ca2+. U937 cells also bound to ELISA plate coated with phosphatidylinositol, but the binding was independent of Gas6 and Ca2+. On the other hand, U937 cells did not adhere to phosphatidylcholine-or phosphatidylethanolamine-coated ELISA plate even in the presence of Gas6 and Ca2+. These findings suggest that Gas6 may play a role in recognition of cells exposing phosphatidylserine on their surfaces by phagocytic cells, which is supposed to be one of the mechanisms for clearing dying tells.	TOKYO METROPOLITAN INST MED SCI,DEPT INFLAMMAT RES,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Kyushu University	Nakano, T (corresponding author), SHIONOGI & CO LTD,DISCOVERY RES LAB 2,FUKUSHIMA KU,5-12-4 SAGISU,OSAKA 553,JAPAN.		Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DAHLBACK B, 1990, J BIOL CHEM, V265, P8127; FADOK VA, 1992, J IMMUNOL, V148, P2207; FUJIMOTO J, 1994, ONCOGENE, V9, P693; FUKUSAWA M, 1996, EXP CELL RES, V222, P246; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; LAI C, 1994, ONCOGENE, V9, P2567; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; Nakano T, 1996, FEBS LETT, V387, P75, DOI 10.1016/0014-5793(96)00394-8; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; RESCIGNO J, 1991, ONCOGENE, V6, P1909; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	29	196	199	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29411	29414		10.1074/jbc.272.47.29411	http://dx.doi.org/10.1074/jbc.272.47.29411			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367994	hybrid			2022-12-25	WOS:A1997YG64700004
J	Niccoli, P; Fayadat, L; Panneels, V; Lanet, J; Franc, JL				Niccoli, P; Fayadat, L; Panneels, V; Lanet, J; Franc, JL			Human thyroperoxidase in its alternatively spliced form (TPO2) is enzymatically inactive and exhibits changes in intracellular processing and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROID PEROXIDASE; CONGENITAL GOITER; SECRETORY PATHWAY; GENE; IDENTIFICATION; DISEASE; CELLS; IODINATION; MYELOPEROXIDASE; HYPOTHYROIDISM	Thyroid peroxidase (TPO1) is a membrane-bound heme-containing glycoprotein that catalyzes the synthesis of thyroid hormones. We generated stable cell lines expressing TPO1 and the alternatively spliced isoform TPO2. Pulse-chase studies showed that TPO2 half-life was dramatically decreased as compared with TPO1, The sensitivity of TPO2 to endo-beta-N-acetylglucosaminidase H indicated that the protein is processed through the endoplasmic reticulum and bears high mannose-type structures. Cell surface biotinylation experiments showed that the two isoforms also differ in their intracellular trafficking, TPO2 was totally retained in the cell, whereas 15% of TPO1 reached the cell surface. The inability of TPO2 to come out of the intracellular compartments was related to structural changes in the molecule. Evidence of these changes was obtained through the lack of recognition of TPO2 by half of the 13 TPO monoclonal antibodies tested in immunoprecipitation experiments. Our data suggest that because of an improper folding, TPO2 is trapped in the endoplasmic reticulum and rapidly degraded. The failure of incorporation of [C-14]aminolevulinic acid in the cultured cells showed that TPO2 did not bind to heme, whereas TPO1 did, This result was confirmed through a guaiacol assay showing that TPO2 is enzymatically inactive.	FAC MED MARSEILLE,INSERM,U38,F-13385 MARSEILLE 05,FRANCE; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,B-1070 BRUSSELS,BELGIUM	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				ABRAMOWICZ MJ, 1992, J CLIN INVEST, V90, P1200, DOI 10.1172/JCI115981; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BANGA JP, FEBS LETT, V266, P133; BIKKER H, 1995, HUM MUTAT, V6, P9, DOI 10.1002/humu.1380060104; Bikker H, 1996, J CLIN ENDOCR METAB, V81, P2076, DOI 10.1210/jc.81.6.2076; Bikker H, 1997, J CLIN ENDOCR METAB, V82, P649, DOI 10.1210/jc.82.2.649; Bradbury FA, 1997, J BIOL CHEM, V272, P5921, DOI 10.1074/jbc.272.9.5921; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; Dermer SJ, 1996, ENDOCRINOLOGY, V137, P5502, DOI 10.1210/en.137.12.5502; EKHOLM R, 1984, ENDOCRINOLOGY, V115, P1558, DOI 10.1210/endo-115-4-1558; ELISEI R, 1990, J CLIN ENDOCR METAB, V72, P700; ELKOLM R, 1981, MOL CELL ENDOCRINOL, V24, P141; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; FINKE R, 1996, J ENDOCRINOL INVEST, V19, P20; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; FOTI D, 1990, ENDOCRINOLOGY, V126, P2983, DOI 10.1210/endo-126-6-2983; GIRAUD A, 1992, J ENDOCRINOL, V132, P317, DOI 10.1677/joe.0.1320317; GRUFFAT D, 1991, J ENDOCRINOL, V128, P51, DOI 10.1677/joe.0.1280051; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KULIAWAT R, 1995, J BIOL CHEM, V270, P2478, DOI 10.1074/jbc.270.6.2478; KULIAWAT R, 1994, J BIOL CHEM, V269, P4922; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; MEHTA A, 1997, CELL BIOL, V94, P1822; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; Ohtaki S, 1996, ENDOCR J, V43, P1, DOI 10.1507/endocrj.43.1; Rapoport B., 1994, ENDOCRINE REVS, V3, P96; RICHARDSON DR, 1996, BLOOD, V87, P3447; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; Sambrook J., 2002, MOL CLONING LAB MANU; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; TAUROG A, 1990, ARCH BIOCHEM BIOPHYS, V278, P333, DOI 10.1016/0003-9861(90)90268-4; Taurog A., 1991, WERNER INGBARS THYRO, P51; TONACCHERA M, 1995, EUR J ENDOCRINOL, V132, P53, DOI 10.1530/eje.0.1320053; Zimmer KP, 1997, HISTOCHEM CELL BIOL, V107, P115, DOI 10.1007/s004180050095; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	42	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29487	29492		10.1074/jbc.272.47.29487	http://dx.doi.org/10.1074/jbc.272.47.29487			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368009	hybrid			2022-12-25	WOS:A1997YG64700019
J	Tsujimura, M; Dohmae, N; Odaka, M; Chijimatsu, M; Takio, K; Yohda, M; Hoshino, M; Nagashima, S; Endo, I				Tsujimura, M; Dohmae, N; Odaka, M; Chijimatsu, M; Takio, K; Yohda, M; Hoshino, M; Nagashima, S; Endo, I			Structure of the photoreactive iron center of the nitrile hydratase from Rhodococcus sp. N-771 - Evidence of a novel post-translational modification in the cysteine ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFENIC ACID; TRANSCRIPTIONAL REGULATOR; BREVIBACTERIUM SP; ESCHERICHIA-COLI; ALPHA-SUBUNIT; SULFUR CENTER; PROTEIN; OXIDATION; OXIDE; PURIFICATION	Nitrile hydratase (NHase) from Rhodococcus sp, N-771 is a photoreactive enzyme that is inactivated by nitrosylation of the non-heme iron center and activated by photodissociation of nitric oxide (NO), To obtain structural information on the iron center, we isolated peptide complexes containing the iron center by proteolysis. When the tryptic digest of the alpha subunit isolated from the inactive form was analyzed by reversed-phase high performance liquid chromatography, the absorbance characteristic of the nitrosylated iron center was observed in the peptide fragment, Asn(105)-Val-Ile-Val-Cys-Ser-Leu-Cys-Ser-Cys-Thr-Ala-Trp-Pro-Ile-Pro-Pro-Thr-Trp-Tyr-Lys(128). The peptide contained 0.79 mol of iron/mol of molecule as well as endogenous NO. Subsequently, by digesting the peptide with thermolysin, carboxypeptidase Y, and leucine aminopeptidase hi, we found that the minimum peptide segment required for the nitrosylated iron center is the 11 amino acid residues from alpha lle(107) to alpha Trp(117), Furthermore, by using mass spectrometry, protein sequence, and amino acid composition analyses, we have shown that the 112th Cys residue of the cu subunit is post-translationally oxidized to a cysteine-sulfinic acid (Cys-SO2H) in the NHase, These results indicate that the NHase from Rhodococcus sp, N-771 has a novel non-heme iron enzyme containing a cysteine-sulfinic acid in the iron center, Possible ligand residues of the iron center are discussed.	SAITAMA UNIV,GRAD SCH SCI & ENGN,URAWA,SAITAMA 338,JAPAN; RIKEN,INST PHYS & CHEM RES,DIV BIOMOL CHARACTERIZAT,WAKO,SAITAMA 35101,JAPAN; RIKEN,INST PHYS & CHEM RES,BIOCHEM SYST LAB,WAKO,SAITAMA 35101,JAPAN; RIKEN,CHEM DYNAM LAB,WAKO,SAITAMA 35101,JAPAN	Saitama University; RIKEN; RIKEN; RIKEN			Odaka, Masafumi/C-2378-2013; Yohda, Masafumi/A-5149-2013; Dohmae, Naoshi/C-2040-2011	Yohda, Masafumi/0000-0001-8307-9671; Dohmae, Naoshi/0000-0002-5242-9410				ABATE C, 1990, SCIENCE, V249; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BEISSEL T, 1993, INORG CHEM, V32, P124, DOI 10.1021/ic00054a002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan BA, 1996, BIOCHEMISTRY-US, V35, P10068, DOI 10.1021/bi960163t; Brennan BA, 1996, J AM CHEM SOC, V118, P9194, DOI 10.1021/ja961920d; BRIAND D, 1994, MICROBIOS, V78, P205; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; Doan PE, 1996, J AM CHEM SOC, V118, P7014, DOI 10.1021/ja960611k; HAYASHI T, 1993, ANAL BIOCHEM, V209, P163, DOI 10.1006/abio.1993.1097; Huang WJ, 1997, STRUCTURE, V5, P691, DOI 10.1016/S0969-2126(97)00223-2; IKEHATA O, 1989, EUR J BIOCHEM, V181, P563, DOI 10.1111/j.1432-1033.1989.tb14761.x; JIN HY, 1993, J AM CHEM SOC, V115, P5290, DOI 10.1021/ja00065a048; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOMAROV A, 1993, BIOCHEM BIOPH RES CO, V195, P1191, DOI 10.1006/bbrc.1993.2170; Kowalak JA, 1996, PROTEIN SCI, V5, P1625, DOI 10.1002/pro.5560050816; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; NAGAMUNE T, 1990, PHOTOCHEM PHOTOBIOL, V51, P87, DOI 10.1111/j.1751-1097.1990.tb01687.x; NAGAMUNE T, 1990, BIOCHEM BIOPH RES CO, V168, P437, DOI 10.1016/0006-291X(90)92340-6; NAGAMUNE T, 1991, J MOL BIOL, V220, P221, DOI 10.1016/0022-2836(91)90006-R; NAKAJIMA Y, 1987, CHEM LETT, V9, P1767; NELSON MJ, 1991, J AM CHEM SOC, V113, P7072, DOI 10.1021/ja00018a074; NOGUCHI T, 1995, FEBS LETT, V358, P9, DOI 10.1016/0014-5793(94)01374-A; Noguchi T, 1996, BIOCHEMISTRY-US, V35, P16777, DOI 10.1021/bi961562r; Odaka M, 1996, BIOCHEM BIOPH RES CO, V221, P146, DOI 10.1006/bbrc.1996.0560; Odaka M, 1997, J AM CHEM SOC, V119, P3785, DOI 10.1021/ja962179c; RADI R, 1991, J BIOL CHEM, V266, P4244; SAKURAI H, 1988, INORG CHEM, V27, P3877; Scarrow RC, 1996, BIOCHEMISTRY-US, V35, P10078, DOI 10.1021/bi960164l; SHONER SC, 1995, INORG CHEM, V34, P4517, DOI 10.1021/ic00122a001; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Tsujimura M, 1996, J BIOCHEM-TOKYO, V119, P407; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	39	88	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29454	29459		10.1074/jbc.272.47.29454	http://dx.doi.org/10.1074/jbc.272.47.29454			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368004	hybrid			2022-12-25	WOS:A1997YG64700014
J	Apostol, I; Levine, J; Lippincott, J; Leach, J; Hess, E; Glascock, CB; Weickert, MJ; Blackmore, R				Apostol, I; Levine, J; Lippincott, J; Leach, J; Hess, E; Glascock, CB; Weickert, MJ; Blackmore, R			Incorporation of norvaline at leucine positions in recombinant human hemoglobin expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; AMINO-ACIDS; PROTEIN; NORLEUCINE; METHIONINE; REPLACEMENT; SUBSTITUTIONS; RESIDUES	We report here a novel finding that norvaline can be incorporated in place of leucine in recombinant human hemoglobin expressed in Escherichia coli, The presence of the norvaline was confirmed by several analytical methods such as amino acid analysis, peptide mapping, electrospray mass spectrometry, and Edman protein sequencing, It appears that substitution is distributed across both the beta- and di-alpha-globins in purified recombinant hemoglobin, The level of misincorporation correlated with the ratio of the free norvaline/leucine pool available in the cell culture, This suggests that the incorporation of norvaline for leucine occurs through misaminoacylation of tRNA(Leu), similar to the misincorporation of norleucine for methionine found in many recombinant proteins expressed in E. coli.			Apostol, I (corresponding author), SOMATOGEN INC,2545 CENT AVE,BOULDER,CO 80301, USA.							APOSTOL I, 1995, PROTEIN SCI, V4, P2616, DOI 10.1002/pro.5560041219; BARKER DG, 1979, J MOL BIOL, V133, P217, DOI 10.1016/0022-2836(79)90531-X; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; BOGOSIAN G, 1989, J BIOL CHEM, V264, P531; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; DAVIS MT, 1995, ANAL BIOCHEM, V224, P235, DOI 10.1006/abio.1995.1035; FIORINO A, 1989, J CHROMATOGR, V476, P83, DOI 10.1016/S0021-9673(01)93858-0; FLEMING J, 1992, 228212 HEWL PACK; GILLES AM, 1988, J BIOL CHEM, V263, P8204; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; KISUMI M, 1976, J BIOCHEM-TOKYO, V79, P1021, DOI 10.1093/oxfordjournals.jbchem.a131142; KISUMI M, 1977, J ANTIBIOT, V30, P111, DOI 10.7164/antibiotics.30.111; Lippincott J, 1997, ANAL BIOCHEM, V252, P314, DOI 10.1006/abio.1997.2334; LOOKER D, 1994, METHOD ENZYMOL, V231, P364; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; LU HS, 1988, BIOCHEM BIOPH RES CO, V156, P807, DOI 10.1016/S0006-291X(88)80916-1; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MIYAZAWA T, 1989, Patent No. 4879223; NANDI P, 1953, NATURE, V172, P841; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; PICUR B, 1994, ARCH BIOCHEM BIOPHYS, V315, P533, DOI 10.1006/abbi.1994.1534; PLOMER JJ, 1996, Patent No. 15151; RANDHAWA ZI, 1994, BIOCHEMISTRY-US, V33, P4352, DOI 10.1021/bi00180a032; SEMMES OJ, 1985, PEPTIDES, V6, P491, DOI 10.1016/0196-9781(85)90115-9; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; Strydom D. J., 1993, TECHNIQUES PROTEIN C, VIV, P299; TERASAWA M, 1991, APPL MICROBIOL BIOT, V35, P348, DOI 10.1007/BF00172724; TSAI LB, 1988, BIOCHEM BIOPH RES CO, V156, P733, DOI 10.1016/S0006-291X(88)80904-5; VIOLAND BN, 1989, TECHNIQUES PROTEIN C, P315; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23	32	67	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28980	28988		10.1074/jbc.272.46.28980	http://dx.doi.org/10.1074/jbc.272.46.28980			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360970	hybrid			2022-12-25	WOS:A1997YF68400029
J	Bour, S; Geleziunas, R; Wainberg, MA				Bour, S; Geleziunas, R; Wainberg, MA			Inhibition of CD4 translation mediated by human immunodeficiency virus type 1 envelope protein in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATED RNA SEQUENCES; INDEPENDENT DOWN-REGULATION; CYTOPLASMIC DOMAIN; MESSENGER-RNA; VPU PROTEIN; SURFACE CD4; ENDOPLASMIC-RETICULUM; DEPENDENT KINASE; HIV-1 INFECTION; BINDING-SITE	The human immunodeficiency virus type 1 (HIV-1) employs a number of complex strategies to interfere with the synthesis, stability, and subcellular localization of its specific cellular receptor CD4, To define better the mechanisms of inhibition of CD4 expression, we used a rabbit reticulocyte lysate in vitro system, in which cDNAs derived from HIV-1-infected cells were used to generate mRNA for the Tat, Vpu, and gp160 envelope proteins that were translated together with CD4-encoding mRNA, In the presence of microsomal membranes, we observed that cotranslation of Env mRNA resulted in a dose-dependent inhibition of CD4 translation, This effect was enhanced further when an mRNA-encoding Vpu in addition to Env mRNA was utilized, However, the activity of Vpu was mostly posttranslational, since translation of Vpu alone, but not Env, was able to destabilize CD4 molecules presynthesized into microsomes, The Env-mediated inhibitory effect was specifically targeted at CD4 and did not affect the synthesis or stability of the CD8 molecule, Interestingly, mutated CD4 species, with a 26-fold lower affinity for HIV-1 Env than wild-type, were less sensitive to cotranslational inhibition, Our report identifies the envelope as the HIV-1 protein responsible for down-regulation of CD4 translation, We further propose a mechanism whereby direct interactions between gp160 and nascent CD4 molecules can cause interference with and premature termination of CD4 protein elongation.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST,AIDS CTR,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University				Bour, Stephan/0000-0002-0211-0110				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ANDERSON SJ, 1994, J VIROL, V68, P3092, DOI 10.1128/JVI.68.5.3092-3101.1994; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BENSON RE, 1993, J EXP MED, V177, P1561, DOI 10.1084/jem.177.6.1561; BOUR S, 1995, J VIROL, V69, P1510, DOI 10.1128/JVI.69.3.1510-1520.1995; BOUR S, 1991, J VIROL, V65, P6387, DOI 10.1128/JVI.65.12.6387-6396.1991; BOUR S, 1995, MICROBIOL REV, V59, P65; BRADFORD AJ, 1988, SCIENCE, V240, P1335; BUTERA ST, 1991, J VIROL, V65, P4645, DOI 10.1128/JVI.65.9.4645-4653.1991; CACOULLOS N, 1991, VIROLOGY, V184, P747, DOI 10.1016/0042-6822(91)90445-H; CHEN MY, 1993, J VIROL, V67, P3877, DOI 10.1128/JVI.67.7.3877-3884.1993; CLARKE PA, 1990, EUR J BIOCHEM, V193, P635, DOI 10.1111/j.1432-1033.1990.tb19381.x; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DAVIES MV, 1991, J BIOL CHEM, V266, P14714; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; ELLERBROK H, 1992, J VIROL, V66, P5114, DOI 10.1128/JVI.66.8.5114-5118.1992; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GARCIA JV, 1992, J CELL BIOCH E S, V16, P21; GELEZIUNAS R, 1991, AIDS, V5, P29, DOI 10.1097/00002030-199101000-00004; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HOXIE JA, 1986, SCIENCE, V234, P1123, DOI 10.1126/science.3095925; JABBAR MA, 1990, J VIROL, V64, P6297, DOI 10.1128/JVI.64.12.6297-6304.1990; KATZE MG, 1990, ENZYME, V44, P332, DOI 10.1159/000468769; KAWAMURA I, 1989, J VIROL, V63, P3748, DOI 10.1128/JVI.63.9.3748-3754.1989; KOGA Y, 1990, J IMMUNOL, V144, P94; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; PETIT AJC, 1987, J CLIN INVEST, V79, P1883, DOI 10.1172/JCI113032; RICHARDSON NE, 1988, P NATL ACAD SCI USA, V85, P6102, DOI 10.1073/pnas.85.16.6102; SALMON P, 1988, J EXP MED, V168, P1953, DOI 10.1084/jem.168.6.1953; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRIDSON A, 1994, J BIOL CHEM, V269, P3917; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; SCHWARTZ S, 1990, J VIROL, V64, P5448, DOI 10.1128/JVI.64.11.5448-5456.1990; SCHWARTZ S, 1992, MOL CELL BIOL, V12, P207, DOI 10.1128/MCB.12.1.207; SERPENTE N, 1993, INT IMMUNOL, V5, P939, DOI 10.1093/intimm/5.8.939; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; STEVENSON M, 1988, CELL, V53, P483, DOI 10.1016/0092-8674(88)90168-7; STEVENSON M, 1987, J VIROL, V61, P3741, DOI 10.1128/JVI.61.12.3741-3748.1987; SU MJ, 1990, VIROLOGY, V179, P679, DOI 10.1016/0042-6822(90)90135-E; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VINCENT MJ, 1993, J VIROL, V67, P5538, DOI 10.1128/JVI.67.9.5538-5549.1993; WILLEY RL, 1992, J VIROL, V66, P226, DOI 10.1128/JVI.66.1.226-234.1992; WILLEY RL, 1994, J VIROL, V68, P1207, DOI 10.1128/JVI.68.2.1207-1212.1994; WILLEY RL, 1992, J VIROL, V66, P7193, DOI 10.1128/JVI.66.12.7193-7200.1992; YUILLE MAR, 1988, J ACQ IMMUN DEF SYND, V1, P131	56	2	2	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29005	29014		10.1074/jbc.272.46.29005	http://dx.doi.org/10.1074/jbc.272.46.29005			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360974	hybrid			2022-12-25	WOS:A1997YF68400033
J	Dreher, I; Jakobs, TC; Kohrle, J				Dreher, I; Jakobs, TC; Kohrle, J			Cloning and characterization of the human selenoprotein P promoter - Response of selenoprotein P expression to cytokines in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; RAT PLASMA; GLUTATHIONE-PEROXIDASE; TRANSCRIPTION FACTOR; SELENIUM DEFICIENCY; LIPID-PEROXIDATION; GROWTH-FACTORS; SERUM; PURIFICATION; GENES	We isolated an 18-kilobase (kb) genomic selenoprotein P clone from a human placenta library and cloned, sequenced, and characterized the 5'-flanking region of the human selenoprotein P gene. Sequence analysis revealed an intron between base pairs (bp) -13 and -14 upstream of the ATG codon and another one between bp 534 and 535 of the coding region. The major transcription start site of selenoprotein P in human HepG2 hepatocarcinoma cells was mapped to bp -70 by 5'-rapid amplification of cDNA ends and by primer extension, 1.8 kb of the 5'-flanking sequence were fused to a luciferase reporter gene, They exhibited functional promoter activity in HepG2 hepatocarcinoma and Caco2 colon carcinoma cells in transient transfection experiments, Treatment of transfected HepG2 cells with the cytokines interleukin 1 beta, tumor necrosis factor alpha, and interferon gamma repressed promoter activity, Nuclear extracts of interferon gamma-treated cells bound to a signal transducer and activator of transcription response element of the promoter in gel retardation experiments, By transfection of promoter-deletion constructs, a TATA box and a putative SP1 site were identified to be necessary for selenoprotein P transcription, These data indicate that the human selenoprotein P gene contains a strong promoter that is cytokine responsive, Furthermore, selenoprotein P, secreted by the liver, might react as a negative acute phase protein.	UNIV WURZBURG,MED POLIKLIN,KLIN FORSCHERGRP,D-97070 WURZBURG,GERMANY	University of Wurzburg			Köhrle, Josef/AAH-6438-2020	Köhrle, Josef/0000-0002-9187-9078; Jakobs, Tatjana/0000-0002-8104-9206				ADAMS MD, 1995, NATURE, V377, P3; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1980, J CLIN INVEST, V65, P1024, DOI 10.1172/JCI109754; BURK RF, 1995, HEPATOLOGY, V21, P561; Dreher I, 1997, J TRACE ELEM MED BIO, V11, P83, DOI 10.1016/S0946-672X(97)80031-4; EBERLE B, 1993, J TRACE ELEM ELECT H, V7, P217; EDWARDS JBD, 1991, NUCLEIC ACIDS RES, V11, P1475; EMI M, 1988, GENE, V62, P229, DOI 10.1016/0378-1119(88)90561-6; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRANDISON L, 1994, MOL CELL ENDOCRINOL, V106, P9; GROSS M, 1995, BIOCHEM J, V306, P851, DOI 10.1042/bj3060851; HERRMAN JL, 1977, BIOCHIM BIOPHYS ACTA, V500, P61, DOI 10.1016/0304-4165(77)90046-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Jakobs TC, 1997, EUR J BIOCHEM, V247, P288, DOI 10.1111/j.1432-1033.1997.00288.x; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; LUPO A, 1995, BIOCHEM BIOPH RES CO, V216, P69, DOI 10.1006/bbrc.1995.2593; Martin GW, 1996, RNA, V2, P171; MOTCHNIK PA, 1989, BIOCHIM BIOPHYS ACTA, V993, P27, DOI 10.1016/0304-4165(89)90138-4; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V709, P160, DOI 10.1016/0167-4838(82)90456-3; PERSSONMOSCHOS M, 1995, ANALYST, V120, P833, DOI 10.1039/an9952000833; READ R, 1990, J BIOL CHEM, V265, P17899; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steinert P, 1997, BIOFACTORS, V6, P311, DOI 10.1002/biof.5520060302; Sunde R. A., 1994, Selenium in biology and human health., P45; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON DS, 1993, J INORG BIOCHEM, V51, P707, DOI 10.1016/0162-0134(93)85003-Q; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; YANG JG, 1987, J BIOL CHEM, V262, P13372; YANG JG, 1989, J NUTR, V119, P1010, DOI 10.1093/jn/119.7.1010; Yasui Y, 1996, GENE, V175, P269, DOI 10.1016/0378-1119(96)00127-8; ZHAO Y, 1995, J BIOL CHEM, V270, P16449, DOI 10.1074/jbc.270.27.16449	39	93	95	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29364	29371		10.1074/jbc.272.46.29364	http://dx.doi.org/10.1074/jbc.272.46.29364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361018	hybrid			2022-12-25	WOS:A1997YF68400077
J	Chen, JG; Sachpatzidis, A; Rudnick, G				Chen, JG; Sachpatzidis, A; Rudnick, G			The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER TRANSPORTERS; CYSTEINE-SUBSTITUTION; AMINO-ACID; CHANNEL; RECEPTOR; MUTANTS; EXPRESSION; REUPTAKE; SEGMENT	Twenty residues in the third transmembrane domain of the serotonin transporter (SERT) were mutated, one at a time, to cysteine, Almost all of these mutants were fully active for serotonin (5-HT) transport and insensitive to inactivation by the positively charged cysteine reagent [2-(trimethylammonium)ethyl]methanethiosulfonate (MTSET), Two active mutants, I172C and I179C, were sensitive to rapid inactivation by MTSET but were relatively insensitive to the negatively charged reagent (2-sulfonatoethyl)methanethiosulfonate (MTSES). Inactivation of I172C was blocked by 5-HT and cocaine, but I179C was not similarly protected, Replacement of Tyr-175 with cysteine resulted in a mutant with low transport activity, and, at the neighboring Tyr-176, cysteine replacement completely blocked transport, The Y175C and Y176C mutants were expressed on the cell surface at levels 84% and 69%, respectively, that of wild type (C109A) SERT, Mutants Y175C and Y176C had lower cocaine affinity than C109A, as measured by displacement of the high affinity cocaine analog 2 beta-carbomethoxy-3 beta-(4-[I-125]iodophenyl)tropane (beta-CIT). For Y176C, 5-HT affinity also was decreased, MTSET inactivated beta-CIT binding to I172C and Y176C, but only slightly inhibited binding to I179C and C109A, The MTSET sensitivity of cysteine replacements at positions 172, 176, and 179 was not observed when these positions were replaced with alanine, serine, or methionine, The results suggest that Ile-172, Tyr-176 and Ile-l79 are on one face of an alpha-helical transmembrane element, and that Ile-172 and Tyr-176 are in proximity to the binding site for 5-HT and cocaine.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University				Sachpatzidis, Aristidis/0000-0002-5237-0842				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Barker EL, 1996, MOL PHARMACOL, V50, P957; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1993, SOC GEN PHY, V48, P283; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Borowsky B, 1995, INT REV NEUROBIOL, V38, P139, DOI 10.1016/S0074-7742(08)60526-7; BOYER WF, 1992, INT CLIN PSYCHOPHARM, V6, P5, DOI 10.1097/00004850-199206005-00001; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; GOTTARDI C, 1995, AM J PHYSIOL, V37, pE285; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NELSON N, 1994, J EXP BIOL, V196, P213; NELSON PJ, 1979, J BIOL CHEM, V254, P84; RUDNICK G, 1991, MOL PHARMACOL, V40, P421; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1994, J EXP BIOL, V196, P229; WALL SC, 1995, MOL PHARMACOL, V47, P544; WANG JB, 1995, J NEUROCHEM, V64, P1416; XU M, 1993, J BIOL CHEM, V268, P21505	31	156	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28321	28327		10.1074/jbc.272.45.28321	http://dx.doi.org/10.1074/jbc.272.45.28321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353288	hybrid			2022-12-25	WOS:A1997YF21900028
J	Qin, WS; Pappan, K; Wang, XM				Qin, WS; Pappan, K; Wang, XM			Molecular heterogeneity of phospholipase D (PLD) - Cloning of PLD gamma and regulation of plant PLD gamma, -beta, and -alpha by polyphosphoinositides and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; C2 DOMAIN; FAMILY; PURIFICATION; IDENTIFICATION; PROTEINS; BINDING; EXPRESSION; ACYLATION; GELSOLIN	Phospholipase D (PLD) has emerged as an important enzyme involved in signal transduction, Vesicle trafficking, and membrane metabolism. This report describes the cloning and expression of a new Arabidopsis PLD cDNA, designated PLD gamma, and the regulation of PLD gamma, -beta, and -alpha by phosphatidylinositol 4,5-bisphosphate (PIP2) and Ca2+, The PLD gamma cDNA is 3.3 kilobases in length and codes for an 855-amino acid protein of 95,462 Da with a pi of 6.9. PLD gamma shares a 66% amino acid sequence identity with PLD beta, but only a 41% identity with PLD alpha. A potential N-terminal myristoylation site is found in PLD gamma, but not in PLD alpha and -beta. Catalytically active PLD gamma was expressed in Escherichia coli, and its activity requires polyphosphoinositides. Both PLD gamma and -beta are most active at mu M Ca2+ concentrations, whereas the optimal PLD alpha activity requires mM Ca2+ concentrations. Binding studies showed that the PLDs bound PIP2 in the order of PLD beta > PLD gamma > PLD alpha. This binding ability correlates with the degree of conservation of a basic PIP2-binding motif located near the putative catalytic site. The binding of [H-3]PIP, was saturable and could be competitively decreased by addition of unlabeled PIP2. Neomycin inhibited the activities of PLD gamma and -beta, but not PLD alpha. These results demonstrate that PLD is ancoded by a heterogeneous gene family and that direct polyphosphoinositide binding is required for the activities of PLD gamma and -beta, but not PLD alpha. The different structural and biochemical properties suggest that PLD alpha, -beta, and -gamma are regulated differently and may mediate unique cellular functions.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506	Kansas State University			Wang, Xuemin/M-2853-2013; Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798; wang, xuemin/0000-0002-6251-6745				BRIEVIARIO D, 1995, PLANT MOL BIOL, V27, P953; CAMILLI PD, 1996, SCIENCE, V271, P1533; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Dyer JH, 1995, PLANT PHYSIOL, V109, P1497; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; MARCU MG, 1994, MOL CELL BIOCHEM, V141, P153, DOI 10.1007/BF00926179; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MICHAYLOVA V, 1971, ANAL CHIM ACTA, V53, P194, DOI 10.1016/S0003-2670(01)80088-X; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Pappan K, 1997, J BIOL CHEM, V272, P7055, DOI 10.1074/jbc.272.11.7055; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; Ponting CP, 1996, PROTEIN SCI, V5, P914; Ponting CP, 1996, PROTEIN SCI, V5, P162; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; UEKI J, 1995, PLANT CELL PHYSIOL, V36, P903, DOI 10.1093/oxfordjournals.pcp.a078837; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG XM, 1994, J BIOL CHEM, V269, P20312; WANG XM, 1993, ARCH BIOCHEM BIOPHYS, V306, P486, DOI 10.1006/abbi.1993.1541; YU FX, 1992, J BIOL CHEM, V267, P14616; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	33	146	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28267	28273		10.1074/jbc.272.45.28267	http://dx.doi.org/10.1074/jbc.272.45.28267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353280	hybrid			2022-12-25	WOS:A1997YF21900020
J	Zhao, SM; Lee, EYC				Zhao, SM; Lee, EYC			A protein phosphatase-1-binding motif identified by the panning of a random peptide display library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 CATALYTIC SUBUNIT; PHOSPHORYLASE-PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; REGULATORY SUBUNIT; MOLECULAR-CLONING; ESCHERICHIA-COLI; SEQUENCE; ENCODES; MUSCLE; PURIFICATION	An unusually large number of regulatory or targeting proteins that bind to the catalytic subunit of protein phosphatase-1 have been recently reported. This can be explained by their possession of a common protein motif that interacts with a binding site on protein phosphatase-1. The existence of such a motif was established by the panning of a random peptide library in which peptide sequences are displayed on the Escherichia coli bacterial flagellin protein for bacteria that bound to protein phosphatase-1. There were 79 isolates containing 46 unique sequences with the conserved motif VXF or VXW, where X was most frequently His or Arg. In addition, this sequence was commonly preceded by 2-5 basic residues and followed by 1 acidic residue. This study demonstrates that binding to protein phosphatase-1 can be conferred to a protein by the presentation of a peptide motif on a surface loop. This binding motif is found in a number of protein phosphatase-1-binding proteins.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOL BIOL, MIAMI, FL 33101 USA	University of Miami					NIDDK NIH HHS [DK18512] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BRANDT H, 1975, J BIOL CHEM, V250, P8038; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHUN YS, 1994, P NATL ACAD SCI USA, V91, P3319, DOI 10.1073/pnas.91.8.3319; Cori GT, 1943, J BIOL CHEM, V151, P31; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; FENG ZH, 1991, J BIOL CHEM, V266, P23796; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; Hausken ZE, 1996, BIOCHEM SOC T, V24, P986, DOI 10.1042/bst0240986; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4820; KILLILEA SD, 1978, BIOCHEM BIOPH RES CO, V81, P1040, DOI 10.1016/0006-291X(78)91455-9; KONDOH H, 1974, BIOCHIM BIOPHYS ACTA, V336, P117, DOI 10.1016/0005-2795(74)90390-0; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LEE EYC, 1995, ZOOL STUD, V34, P149; LU Z, 1995, BIOTECHNOLOGY, V13, P266; MACKINTOSH RW, 1990, FEBS LETT, V276, P156, DOI 10.1016/0014-5793(90)80531-M; MERLEVEDE W, 1984, CURR TOP CELL REGUL, V23, P177; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; ZHANG AJ, 1992, J BIOL CHEM, V267, P1784; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301	43	121	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28368	28372		10.1074/jbc.272.45.28368	http://dx.doi.org/10.1074/jbc.272.45.28368			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353294	hybrid			2022-12-25	WOS:A1997YF21900034
J	Lombardi, AM; Moller, D; Loizeau, M; Girard, J; Leturque, A				Lombardi, AM; Moller, D; Loizeau, M; Girard, J; Leturque, A			Phenotype of transgenic mice overexpressing GLUT4 and hexokinase II in muscle	FASEB JOURNAL			English	Article						insulin stimulated level; skeletal muscle; insulin tolerance; hyperglycemia; hypoinsulinemia; glucose utilization index; gluteal muscle	RATE-LIMITING STEPS; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; INSULIN ACTION; ADIPOSE-TISSUE; MESSENGER-RNA; GENE; METABOLISM; PROTEIN; PHOSPHORYLATION	To optimize glucose utilization, double transgenic mice were created by crossing mice overexpressing glucose transporter GLUT4 with mice overexpressing hexokinase (HKII) in muscle. Transgenic mice overexpressing GLUT4 alone have exhibited improvements in glucose tolerance and insulin action. In vitro studies of hexose uptake in solens muscle from transgenic mice suggested that GLUT4 was limiting the glucose flux except at high glucose concentration, where hexokinase became the limiting step. In vivo, glucose tolerance was similar in GLUT4 and GLUT4/HKII mice, although stimulated plasma insulin values were significantly lower in the latter group. Insulin tolerance tests performed in diabetic GLUT4 vs. diabetic GLUT4/HKII transgenic mice yielded identical results. Again, endogenous insulin in GLUT4/HKII mice during a mild hyperglycemic clamp was stimulated by only two-vs. fourfold in GLUT4 mice. Although the overexpression of HKII alone resulted in increased glucose utilization in several muscles, the overexpression of GLUT4 plus HKII did not augment basal or stimulated in vivo glucose utilization compared to GLUT4 overexpression. In conclusion, GLUT4 is rate limiting for muscle glucose utilization but HKII might be important under hyperglycemia, The addition of HKII to GLUT4 overexpression is not sufficient to further augment glucose tolerance or insulin action, In GLUT4/HKII double transgenic mice, glucose clearance is tempered by a low insulin stimulated level.	CTR RECH ENDOCRINOL MOL & DEV,CNRS,UPR 1511,F-92190 MEUDON,FRANCE; UNIV PADUA,INST MED SEMEIOT,I-35123 PADUA,ITALY; MERCK & CO INC,RAHWAY,NJ 07065	Centre National de la Recherche Scientifique (CNRS); University of Padua; Merck & Company			Leturque, Armelle/Q-9437-2017	Leturque, Armelle/0000-0001-6570-6387				BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; FERRE P, 1986, BIOCHEM J, V233, P249, DOI 10.1042/bj2330249; HENDERSON M, 1961, J BIOL CHEM, V236, P273; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1966, BIOCHEM BIOPH RES CO, V24, P531, DOI 10.1016/0006-291X(66)90352-4; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LETURQUE A, 1981, BIOCHEM J, V200, P181, DOI 10.1042/bj2000181; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; MANCHESTER J, 1994, AM J PHYSIOL, V266, pE326, DOI 10.1152/ajpendo.1994.266.3.E326; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Tsao TS, 1996, J BIOL CHEM, V271, P14959, DOI 10.1074/jbc.271.25.14959; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	25	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1137	1144		10.1096/fasebj.11.13.9367348	http://dx.doi.org/10.1096/fasebj.11.13.9367348			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367348				2022-12-25	WOS:A1997YE98300011
J	Butler, AA; Blakesley, VA; Koval, A; DeJong, R; Groffen, J; LeRoith, D				Butler, AA; Blakesley, VA; Koval, A; DeJong, R; Groffen, J; LeRoith, D			In vivo regulation of CrkII and CrkL proto-oncogenes in the uterus by insulin-like growth factor-I - Differential effects on tyrosine phosphorylation and association with paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-CRK; V-CRK; RECEPTOR SUBSTRATE-1; SIGNALING PATHWAYS; DEPENDENT MANNER; ADAPTER PROTEINS; ENDOGENOUS CRK; BINDING; PRODUCT; CELLS	Changes in CrkII and CrkL phosphorylation are associated with insulin-like growth factor receptor activation in cultured cells. We examined whether similar changes also occur following administration of recombinant human insulin-like growth factor-I to the intact animal. In female rats starved overnight, CrkL phosphorylation was significantly increased 12 min after insulin-like growth factor-I administration. Tyrosine phosphorylation of CrkII was not detectable in either control or treated animals. Paxillin, a 65-70-kDa phosphoprotein containing high affinity binding sites common for the Src homology 2 (SH2) domains of CrkII and CrkL, was observed in both CrkII and CrkL immunoprecipitates. Insulin-like growth factor-I treatment stimulated the association of CrkII with paxillin. In contrast, the same treatment resulted in the dissociation of the CrkL-paxillin complex. Similar effects of insulin-like growth factor-I treatment on the association of CrkL with tyrosine phosphorylated paxillin were observed in fibroblasts overexpressing CrkL. This study demonstrates that the activation of the insulin-like growth factor-I receptor induces changes in the tyrosine phosphorylation and protein-protein interactions of the Crk proteins in vivo. The different responses of CrkL and CrkII to insulin-like growth factor-I receptor activation suggest distinct roles for these two adapter proteins in signal transduction.	NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA; CHILDRENS HOSP, DEPT PATHOL, SECT MOL CARCINOGENESIS, LOS ANGELES, CA 90027 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Butler, Andrew/0000-0001-7196-0170				Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Richards RG, 1996, P NATL ACAD SCI USA, V93, P12002, DOI 10.1073/pnas.93.21.12002; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469	32	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27660	27664		10.1074/jbc.272.44.27660	http://dx.doi.org/10.1074/jbc.272.44.27660			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346905	hybrid			2022-12-25	WOS:A1997YD47300031
J	Grondin, B; Cote, F; Bazinet, M; Vincent, M; Aubry, M				Grondin, B; Cote, F; Bazinet, M; Vincent, M; Aubry, M			Direct interaction of the KRAB/Cys(2)-His(2) zinc finger protein ZNF74 with a hyperphosphorylated form of the RNA polymerase II largest subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; PRE-MESSENGER-RNA; DISCRETE NUCLEAR DOMAINS; SPLICING FACTORS; TRANSCRIPTIONAL REPRESSION; DNA RECOGNITION; IN-VIVO; MATRIX; PHOSPHORYLATION; BINDING	We previously identified ZNF74 as a developmentally expressed gene commonly deleted in DiGeorge syndrome. ZNF74 encodes an RNA-binding protein tightly associated with the nuclear matrix and belongs to a large subfamily of Cys(2)-His(2) zinc finger proteins containing a KRAB (Kruppel-associated box) repressor motif, We now report on the multifunctionality of the zinc finger domain of ZNF74, This nucleic acid binding domain is shown here to function as a nuclear matrix targeting sequence and to be involved in protein-protein interaction, Ey far-Western analysis and coimmunoprecipitation studies, we demonstrate that ZNF74 interacts, via its zinc finger domain, with the hyperphosphorylated largest subunit of RNA polymerase II (pol IIo) but not with the hypophosphorylated form. The importance of the phosphorylation in this interaction is supported by the observation that phosphatase treatment inhibits ZNF74 binding. Double immunofluorescence experiments indicate that ZNF74 colocalizes with the pol IIo and the SC35 splicing factor in irregularly shaped subnuclear domains, Thus, ZNF74 sublocalization in nuclear domains enriched in pre-mRNA maturating factors, its RNA binding activity, and its direct phosphodependent interaction with the pol IIo, a form of the RNA polymerase functionally associated with pre-mRNA processing, suggest a role for this member of the KRAB multifinger protein family in RNA processing.	INST RECH CLIN MONTREAL, MONTREAL, PQ H2W 1R7, CANADA; UNIV MONTREAL, DEPT MED, MONTREAL, PQ H2W 1R7, CANADA; UNIV LAVAL, Ste Foy, PQ G1K 7P4, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Laval University								AUBRY M, 1993, HUM MOL GENET, V2, P1583, DOI 10.1093/hmg/2.10.1583; AUBRY M, 1992, GENOMICS, V13, P641, DOI 10.1016/0888-7543(92)90135-F; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BISOTTO S, 1995, J CELL SCI, V108, P1873; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CHABOT B, 1995, NUCLEIC ACIDS RES, V23, P3206, DOI 10.1093/nar/23.16.3206; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CICCHETTI P, 1995, METHOD ENZYMOL, V256, P140; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLBEREGARAPIN F, 1983, DEV BIOLOGICALS, V55, P267; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GLOVER TW, 1995, NAT GENET, V10, P257, DOI 10.1038/ng0795-257; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; Huang S, 1996, J CELL BIOL, V133, P719, DOI 10.1083/jcb.133.4.719; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KIM WY, 1986, J BIOL CHEM, V261, P14219; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARINEAU C, 1992, NUCLEIC ACIDS RES, V20, P1430, DOI 10.1093/nar/20.6.1430; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; SUZUKI M, 1994, NUCLEIC ACIDS RES, V22, P3397, DOI 10.1093/nar/22.16.3397; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401; ZHANG GH, 1994, NATURE, V372, P809	65	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27877	27885		10.1074/jbc.272.44.27877	http://dx.doi.org/10.1074/jbc.272.44.27877			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346935	hybrid			2022-12-25	WOS:A1997YD47300061
J	JosephLiauzun, E; Farges, R; Delmas, P; Ferrara, P; Loison, G				JosephLiauzun, E; Farges, R; Delmas, P; Ferrara, P; Loison, G			The M-r 18,000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP TRANSLOCATOR; LEYDIG TUMOR-CELLS; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; MOLECULAR-CLONING; HIGH-LEVEL; YEAST; EXPRESSION; DIETHYLPYROCARBONATE; LOCALIZATION	The peripheral type benzodiazepine receptor (PBR) binds benzodiazepines such as R05-4864 and isoquinoline carboxamide derivatives such as PK11195. This receptor includes an M-r 18,000 isoquinoline-binding subunit predominantly located in mitochondrial membranes. This protein has been found to copurify with two other mitochondrial proteins, namely the outer membrane voltage-dependent anion channel (VDAC), also known as mitochondrial porin, and the inner membrane adenine nucleotide carrier. In vitro reconstitution experiments suggested that the PBR was a multimeric complex in which the isoquinoline binding site was on the M-r 18,000 subunit, denoted pk18, whereas the benzodiazepine binding site required the association of this subunit with VDAC to be expressed. Untransformed cells of the yeast Saccharomyces cerevisiae are devoid of specific binding sites for isoquinolines and benzodiazepines, whereas yeast cells transformed with a pk18-expressing vector exhibit R05-4864 and PK11195 binding sites that are pharmacologically identical to those of the PBR. To clarify the role of VDAC and of the adenine nucleotide carrier, if any, in the constitution of the benzodiazepine binding site, yeast host strains were constructed in which the corresponding genes had been knocked out, Mitochondria prepared from pk18-producing cells devoid of either VDAC or adenine nucleotide carrier exhibit both benzodiazepine and isoquinoline carboxamide binding sites with little or no change in the K-d values as compared with the wild-type background. These results rule out the contention that VDAC is indispensable for establishing the benzodiazepine binding site and are in agreement with the hypothesis that the M-r 18,000 subunit carries both the isoquinoline carboxamide and benzodiazepine binding domains.	SANOFI RECH, DEPT PROT BIOCHEM, F-31676 LABEGE, FRANCE	Sanofi-Aventis; Sanofi France	JosephLiauzun, E (corresponding author), SANOFI RECH, DEPT MICROBIOL, BP 137, F-31676 LABEGE, FRANCE.							Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; AWAD M, 1989, BIOCHEM PHARMACOL, V38, P3843, DOI 10.1016/0006-2952(89)90594-7; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BENAVIDES J, 1984, LIFE SCI, V35, P1249, DOI 10.1016/0024-3205(84)90095-X; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Boujrad N, 1996, ENDOCRINOLOGY, V137, P5727, DOI 10.1210/en.137.12.5727; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; COSTA E, 1979, ANNU REV PHARMACOL, V19, P531, DOI 10.1146/annurev.pa.19.040179.002531; DOBLE A, 1987, MOL PHARMACOL, V31, P42; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Dussossoy D, 1996, CYTOMETRY, V24, P39; FARGES R, 1993, FEBS LETT, V335, P305, DOI 10.1016/0014-5793(93)80407-L; FARGES R, 1994, MOL PHARMACOL, V46, P1160; GARNIER M, 1994, MOL PHARMACOL, V45, P201; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; JOSEPHLIAUZUN E, 1994, GENE, V155, P195; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; LEPLATOIS P, 1992, GENE, V122, P139, DOI 10.1016/0378-1119(92)90041-M; LOISON G, 1989, YEAST, V5, P497, DOI 10.1002/yea.320050609; LUEDDENS HWM, 1986, MOL PHARMACOL, V29, P540; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; RIOND J, 1989, FEBS LETT, V245, P238, DOI 10.1016/0014-5793(89)80229-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SKOWRONSKI R, 1987, EUR J PHARMACOL, V143, P305, DOI 10.1016/0014-2999(87)90454-7; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; Woods MJ, 1996, BIOCHEM PHARMACOL, V52, P1805, DOI 10.1016/S0006-2952(96)00558-8	34	57	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28102	28106		10.1074/jbc.272.44.28102	http://dx.doi.org/10.1074/jbc.272.44.28102			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346965	hybrid			2022-12-25	WOS:A1997YD47300091
J	Koch, RO; Wanner, SG; Koschak, A; Hanner, M; Schwarzer, C; Kaczorowski, GJ; Slaughter, RS; Garcia, ML; Knaus, HG				Koch, RO; Wanner, SG; Koschak, A; Hanner, M; Schwarzer, C; Kaczorowski, GJ; Slaughter, RS; Garcia, ML; Knaus, HG			Complex subunit assembly of neuronal voltage-gated K+ channels - Basis for high-affinity toxin interactions and pharmacology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; RAT-BRAIN; XENOPUS-OOCYTES; MAMMALIAN BRAIN; NERVE-TERMINALS; BOVINE BRAIN; LOCALIZATION; PROTEINS; KV1.2; CHARYBDOTOXIN	Neurons require specific patterns of K+ channel subunit expression as well as the precise coassembly of channel subunits into heterotetrameric structures for proper integration and transmission of electrical signals, In vivo subunit coassembly was investigated by studying the pharmacological profile, distribution, and subunit composition of voltage-gated Shaker family K+ (K(v)1) channels in rat cerebellum that are labeled by I-125-margatoxin (I-125-MgTX; K-d, 0.08 pm), High-resolution receptor autoradiography showed spatial receptor expression mainly in basket cell terminals (52% of all cerebellar sites) and the molecular layer (39% of sites), Sequence directed antibodies indicated overlapping expression of K(v)1.1 and K(v)1.2 in basket cell terminals, whereas the molecular layer expressed K(v)1.1, K(v)1.2, K(v)1.3, and K(v)1.6 proteins, Immunoprecipitation experiments revealed that all I-125-MgTX receptors contain at least one K(v)1.2 subunit and that 83% of these receptors are heterotetramers of K(v)1.1 and K(v)1.2 subunits, Moreover, 33% of these K(v)1.1/K(v)1.2-containing receptors possess either an additional K(v)1.3 or K(v)1.6 subunit, Only a minority of the I-125-MgTX receptors (<20%) seem to be homotetrameric K(v)1.2 channels, Heterologous coexpression of K(v)1.1 and K(v)1.2 subunits in COS-1 cells leads to the formation of a complex that combines the pharmacological profile of both parent subunits, reconstituting the native MgTX receptor phenotype, Subunit assembly provides the structural basis for toxin binding pharmacology and can lead to the association of as many as three distinct channel subunits to form functional K+ channels in vivo.	UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST PHARMACOL, A-6020 INNSBRUCK, AUSTRIA; MERCK RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA	University of Innsbruck; University of Innsbruck; Merck & Company				Schwarzer, Christoph/0000-0002-6373-3717				CALVO MG, 1993, J BIOL CHEM, V268, P18866; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; HARVEY AL, 1995, TOXICON, V33, P425, DOI 10.1016/0041-0101(94)00181-7; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KNAUS HG, 1995, BIOCHEMISTRY-US, V34, P13627, DOI 10.1021/bi00041a043; Knaus HG, 1996, J NEUROSCI, V16, P955; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; MCNAMARA NMC, 1993, NEUROSCIENCE, V57, P1039, DOI 10.1016/0306-4522(93)90047-J; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHENG M, 1994, J NEUROSCI, V14, P2408; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8	30	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27577	27581		10.1074/jbc.272.44.27577	http://dx.doi.org/10.1074/jbc.272.44.27577			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346893	hybrid			2022-12-25	WOS:A1997YD47300019
J	Tarcsa, E; Marekov, LN; Andreoli, J; Idler, WW; Candi, E; Chung, SI; Steinert, PM				Tarcsa, E; Marekov, LN; Andreoli, J; Idler, WW; Candi, E; Chung, SI; Steinert, PM			The fate of trichohyalin - Sequential, post-translational modifications by peptidyl-arginine deiminase and transglutaminases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ENVELOPE PRECURSOR; HAIR FOLLICLE; SUBSTRATE-SPECIFICITY; HUMAN EPIDERMIS; HUMAN LORICRIN; CROSS-LINKING; GUINEA-PIG; PROTEIN; EXPRESSION; CITRULLINE	Trichohyalin (THH) is a major structural protein of the inner root sheath cells and medulla layer of the hair follicle and, to a lesser extent, of other specialized epithelia, THH is a high molecular weight insoluble alpha-helix-rich protein that forms rigid structures as a result of postsynthetic modifications by two Ca2+-dependent enzymes, transglutaminases (TGases) (protein cross-linking) and peptidyl-arginine deiminase (conversion of arginines to citrullines with loss of organized structure), The modified THH is thought to serve as a keratin intermediate filament matrix protein and/or as a constituent of the cell envelope, In this paper, we have explored in vitro the order of processing of THH to fulfill these functions, using an expressed truncated, more soluble form THH-8, THH-8 is a complete substrate for three known TGases expressed in epithelia, but the kinetic efficiency with TGase 3 is by far the greatest. Following maximal conversion of its arginines to citrullines, THH-8 is cross-linked even more efficiently by TGase 3, using most glutamines partially and all lysines, In addition, we show that insoluble aggregates of THH-8 or native pig tongue THH can be solubilized following peptidyl-arginine deiminase modification. Together, these data suggest an in vivo model in which THH located in insoluble cytoplasmic droplets is first modified by peptidyl-arginine deiminase which denatures it and makes it more soluble. This renders it available for efficient cross-linking by TGase 3 to form highly crosslinked rigid structures in the cells, This temporal order of reaction is supported by the observation that THH is expressed in hair follicle cells before the TGase 3 enzyme.	NIAMS, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA; KOREA GREEN CROSS CORP, KYUNGGI GI DO 449900, SOUTH KOREA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Green Cross Corporation								AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P223, DOI 10.1083/jcb.3.2.223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; Fraser R.D.B., 1972, KERATINS THEIR COMPO; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HAMILTON EH, 1992, J INVEST DERMATOL, V98, P881, DOI 10.1111/1523-1747.ep12459412; HARDING HWJ, 1972, BIOCHEMISTRY-US, V11, P2858, DOI 10.1021/bi00765a019; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUBILUS J, 1980, BIOCHIM BIOPHYS ACTA, V615, P246, DOI 10.1016/0005-2744(80)90027-3; LEE SC, 1993, J BIOL CHEM, V268, P12164; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OGUIN WM, 1991, ANN NY ACAD SCI, V642, P51; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1983, NORMAL ABNORMAL EPID, P171; ROGERS GE, 1977, ADV EXPT MED BIOL A, V86, P282; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; SIMON M, 1988, J BIOL CHEM, V263, P18093; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; STEVEN AC, 1994, J CELL SCI, V107, P693; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAMADA Y, 1995, ACTA DERM-VENEREOL, V75, P190; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; VORNER H, 1903, DERMATOL Z BERLIN, V10, P357; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8	50	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27893	27901		10.1074/jbc.272.44.27893	http://dx.doi.org/10.1074/jbc.272.44.27893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346937	hybrid			2022-12-25	WOS:A1997YD47300063
J	Barden, JA; Cuthbertson, RM; Wu, JZ; Moseley, JM; Kemp, BE				Barden, JA; Cuthbertson, RM; Wu, JZ; Moseley, JM; Kemp, BE			Solution structure of parathyroid hormone related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 (PTHrP[Ala(15)]-(1-34))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAINS; STABILIZED NMR STRUCTURE; HUMORAL HYPERCALCEMIA; H-1-NMR SPECTROSCOPY; MAGNETIC-RESONANCE; RENAL RECEPTOR; PTH RECEPTOR; MALIGNANCY; FRAGMENT; IDENTIFICATION	The structure of human parathyroid hormone (PTH) related protein (residues 1-34) containing an Ala substituted for an Ile in position 15 was studied by two-dimensional proton nuclear magnetic resonance spectroscopy, This mutant retains quite high levels of adenylate cyclase activity based on slightly reduced PTH receptor binding capacity, Three segments of helix were revealed extending from His(5) to Lys(11), Lys(13) to Arg(19), and from Phe(22) to Thr(33)/Ala(34), with a decided kink between the first two helices around Gly(12). N- and C-terminal helices were stabilized by charged and hydrophobic side chain interactions between His(5) and Glu(30), Asp(17) and both His(9) and His(25), and between Leu(8) and Ala(29,) resulting in a globular molecule occupying a single conformation, While the structure of the entire mid-molecule region differed greatly from the structure of the native peptide, the structure of both N- and C-terminal regions remains essentially unaltered, The residues responsible for initiating signal transduction in the mutant are located in the vicinity of the residues responsible for receptor binding, The C-terminal amphipathic helix forming the receptor binding site exhibits reduced binding as a result of the closely applied N-terminal signal transduction-activating region, Although not contributing directly to receptor binding, the N-terminal region can sterically affect hormone binding through modifications to certain N-terminal side chains.	UNIV SYDNEY,DEPT ANAT & HISTOL,SYDNEY,NSW 2006,AUSTRALIA; ST VINCENTS INST MED RES,MELBOURNE,VIC 3065,AUSTRALIA	University of Sydney; St. Vincent's Institute of Medical Research	Barden, JA (corresponding author), UNIV SYDNEY,BIOMED RES INST,SYDNEY,NSW 2006,AUSTRALIA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082				ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1994, BBA-PROTEIN STRUCT M, V1208, P256, DOI 10.1016/0167-4838(94)90111-2; Barden JA, 1996, BIOCHEM BIOPH RES CO, V220, P431, DOI 10.1006/bbrc.1996.0390; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; BARDEN JA, 1995, B MAGN RESON, V17, P166; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1994, X PLOR VERSION 3 1 U; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; COHEN FE, 1991, J BIOL CHEM, V266, P1997; DRAPER MW, 1982, J BIOL CHEM, V257, P3714; Dunbar ME, 1996, AM J MED SCI, V312, P287, DOI 10.1097/00000441-199612000-00007; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; HUNT NH, 1980, CLIN SCI, V58, P463, DOI 10.1042/cs0580463; Jasonoff A., 1994, BIOCHEMISTRY-US, V33, P2129; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KEMP BE, 1987, SCIENCE, V238, P1568, DOI 10.1126/science.3685995; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; LEE SC, 1989, BIOPOLYMERS, V28, P1115, DOI 10.1002/bip.360280606; LLINAS M, 1975, J AM CHEM SOC, V97, P4731, DOI 10.1021/ja00849a040; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MCKEE RL, 1988, ENDOCRINOLOGY, V122, P3008, DOI 10.1210/endo-122-6-3008; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; RAY FR, 1993, EUR J BIOCHEM, V211, P205, DOI 10.1111/j.1432-1033.1993.tb19887.x; REDFIELD AG, 1975, J MAGN RESON, V19, P250, DOI 10.1016/0022-2364(75)90073-6; ROSENBLATT M, 1980, ENDOCRINOLOGY, V107, P545, DOI 10.1210/endo-107-2-545; ROSENBLATT M, 1977, J BIOL CHEM, V252, P5847; SAUDEK V, 1990, BIOCHEMISTRY-US, V29, P4509, DOI 10.1021/bi00471a002; SCHLUTER KD, 1989, J BIOL CHEM, V264, P11087; SCHNEIDER HG, 1991, BIOCHEM J, V280, P451, DOI 10.1042/bj2800451; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SMITH LM, 1987, ARCH BIOCHEM BIOPHYS, V253, P81, DOI 10.1016/0003-9861(87)90639-4; SOMJEN D, 1990, BIOCHEM J, V272, P781; STEWART JM, 1966, SOLID PHASE PEPTIDE, P44; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	48	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29572	29578		10.1074/jbc.272.47.29572	http://dx.doi.org/10.1074/jbc.272.47.29572			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368020	hybrid			2022-12-25	WOS:A1997YG64700030
J	Inamoto, S; Segil, N; Pan, ZQ; Kimura, M; Roeder, RG				Inamoto, S; Segil, N; Pan, ZQ; Kimura, M; Roeder, RG			The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK activity on the POU domains of octamer transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; RING FINGER PROTEIN; FACTOR TFIIH; CELL-CYCLE; IMMUNOGLOBULIN PROMOTERS; SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; BINDING PROTEIN; DNA-REPAIR; COMPLEX	Octamer binding transcription factors (Oct factors) play important roles in activation of transcription of various genes but, in some cases, require cofactors that interact with the DNA binding (POU) domain, In the present study, a yeast two-hybrid screen with the Oct-1 POU domain as a bait identified MAT1 as a POU domain-binding protein, MAT1 is known to be required for the assembly of cyclin dependent kinase (CDK)-activating kinase (CAK), which is functionally associated with the general transcription factor IIH (TFIIH), Further analyses showed that MAT1 interacts with POU domains of Oct-1, Oct-2, and Oct-3 in vitro in a DNA-independent manner, MAT1-containing TFIIH was also shown to interact with POU domains of Oct-1 and Oct-2, MAT1 is shown to enhance the ability of a recombinant CDK7-cyclin H complex (bipartite CAK) to phosphorylate isolated POU domains, intact Oct-1, and the C-terminal domain of RNA polymerase II, but not the originally defined substrate, CDK2. Phosphopeptide mapping indicates that the site (Ser(385)) Of a mitosis-specific phosphorylation that inhibits Oct-1 binding to DNA is not phosphorylated by CAR, However, one CAK-phosphorylated phosphopeptide comigrates with a Cdc2-phosphorylated phosphopeptide previously shown to be mitosis-specific, suggesting that, in vitro, CAK is able to phosphorylate at least one site that is also phosphorylated in vivo, These results suggest (i) that interactions between POU domains and MAT1 can target CAK to Oct factors and result in their phosphorylation, (ii) that MAT1 not only functions as a CAK assembly factor but also acts to alter the spectrum of CAK substrates, and (iii) that a POU-MAT1 interaction may play a role in the recruitment of TFIIH to the preinitiation complex or in subsequent initiation and elongation reactions.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOL LAB,NEW YORK,NY 10021; MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029	Rockefeller University; Rockefeller University; Icahn School of Medicine at Mount Sinai				Kimura, Makoto/0000-0003-0868-5334	NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI2732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; HARPER JW, 1993, CELL, V75, P805; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; ROBERTS SB, 1991, SCIENCE, V253, P1022, DOI 10.1126/science.1887216; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; TONG X, 1995, P NATL ACAD SCI USA, V92, P3259, DOI 10.1073/pnas.92.8.3259; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; YEE A, 1995, CANCER RES, V55, P6058; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	62	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29852	29858		10.1074/jbc.272.47.29852	http://dx.doi.org/10.1074/jbc.272.47.29852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368058	hybrid			2022-12-25	WOS:A1997YG64700068
J	Kundu, M; Guermah, M; Roeder, RG; Amini, S; Khalili, K				Kundu, M; Guermah, M; Roeder, RG; Amini, S; Khalili, K			Interaction between cell cycle regulator, E2F-1, and NF-kappa B mediates repression of HIV-1 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TATA-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; T-CELLS; MOLECULAR MECHANISMS; HUMAN-LYMPHOCYTES; HTLV-III/LAV; IN-VITRO; INFECTION; TYPE-1	The NF-kappa E/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression, Some of these extracellular stimuli arrest cells in the G(1) phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1, Earlier studies indicated that E2F-1, a transcription factor that stimulates expression of S phase-specific genes, is able to repress transcription directed by the human immunodeficiency virus (HIV-1) type-1 promoter in a variety of cells, including those of glial and lymphocytic origin, Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappa B enhancer region and to interact with the NF-kappa B subunit, p50, Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappa B elements, Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins, Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences, In vitro transcription assay demonstrates that E2F-1 represses NF-kappa B mediated transcription in a cell-free system, Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappa B binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo. The results of this study suggest that NF-kappa B activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.	ALLEGHENY UNIV HLTH SCI,CTR NEUROVIROL & NEUROONCOL,PHILADELPHIA,PA 19102; ALLEGHENY UNIV HLTH SCI,DEPT NEUROL,PHILADELPHIA,PA 19102; ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Drexel University; Drexel University; Rockefeller University								AHUJA SS, 1993, J IMMUNOL, V150, P3109; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; EMILI A, 1995, J BIOL CHEM, V270, P13674, DOI 10.1074/jbc.270.23.13674; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FOLKS T, 1986, J IMMUNOL, V136, P4049; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KITAJIMA I, 1993, SCIENCE, V259, P1523, DOI 10.1126/science.8456277; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNDU M, 1995, J VIROL, V69, P6940, DOI 10.1128/JVI.69.11.6940-6946.1995; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MARGOLICK JB, 1987, J IMMUNOL, V138, P1719; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PERKINS ND, 1994, J VIROL, V68, P6820, DOI 10.1128/JVI.68.10.6820-6823.1994; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SCHUITEMAKER H, 1994, RES IMMUNOL, V145, P588, DOI 10.1016/S0923-2494(05)80038-0; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STENSTRAND K, 1987, PHOTODERMATOLOGY, V4, P36; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VINCENZI E, 1994, CHEM-BIOL INTERACT, V91, P101; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang LQ, 1997, J VIROL, V71, P1651, DOI 10.1128/JVI.71.2.1651-1656.1997	64	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29468	29474		10.1074/jbc.272.47.29468	http://dx.doi.org/10.1074/jbc.272.47.29468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368006	hybrid			2022-12-25	WOS:A1997YG64700016
J	Lallemand, C; BayatSarmadi, M; Blanchard, B; Tovey, MG				Lallemand, C; BayatSarmadi, M; Blanchard, B; Tovey, MG			Identification of a novel transcriptional regulatory element common to the p53 and interferon regulatory factor 1 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH INHIBITION; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE PKR; FACTOR-I IRF-1; DNA-DAMAGE; CYCLE CHECKPOINT; MESSENGER-RNA; KAPPA-B; EXPRESSION; BINDING	The promoter regions of both the interferon regulatory factor (IRF1) and p53 antioncogenes contain a previously unidentified sequence denoted IRF1 p53 common sequence (IPCS), which markedly increases the transcriptional activity of a reporter gene placed under the control of an heterologous promoter in transfected U937 cells, In contrast, transfection of U937 cells with reporter vectors containing p55 and IRF1 promoters with mutated IPCS sites resulted in a 4-fold reduction in the constitutive expression of those two genes. The transcriptional activity of IPCS is strictly correlated with the binding of a novel nuclear factor, IPCS-binding factor (IPCS-BF). IPCS-BF, which is composed of a single polypeptide of 26 kDa, is present constitutively in nuclear extracts of both U937 cells and peripheral blood mononuclear cells from healthy donors, The finding that the pattern of binding of IPCS-BF to the IPCS is unlike that of any known transcription factor and that the IPCS sequence does not exhibit any significant homology with any known binding site present in the data base, strongly suggest that IPCS-BF is a novel transcription factor which, by virtue of this ability to regulate the expression of the p53 and IRF1 genes, could play a central role in the control of cell proliferation and/or apoptosis.			Lallemand, C (corresponding author), IFC 1,CNRS,UPR 9045,LAB VIRAL ONCOL,7 RUE GUY MOQUET,F-94801 VILLEJUIF,FRANCE.			lallemand, christophe/0000-0001-5965-2482; Tovey, Michael/0000-0002-3058-0494				AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Beretta L, 1996, ONCOGENE, V12, P1593; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DITMER D, 1993, NAT GENET, V5, P42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUPT Y, 1995, GENE DEV, V9, P170; Hawker KL, 1996, ONCOGENE, V13, P283; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAWASAKI T, 1994, CANCER LETT, V82, P113, DOI 10.1016/0304-3835(94)90154-6; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUN XG, 1995, MOL CELL BIOL, V15, P4489; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WU HY, 1994, J BIOL CHEM, V269, P20067; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	40	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29801	29809		10.1074/jbc.272.47.29801	http://dx.doi.org/10.1074/jbc.272.47.29801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368052	hybrid			2022-12-25	WOS:A1997YG64700062
J	Liu, JL; Blakesley, VA; Gutkind, JS; LeRoith, D				Liu, JL; Blakesley, VA; Gutkind, JS; LeRoith, D			The constitutively active mutant G(alpha 13) transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; G-PROTEINS; NEOPLASTIC TRANSFORMATION; KINASE; G-ALPHA(12); PATHWAYS; GENE; ACTIVATION; MUTATION; ANTIGEN	Insulin-like growth factor-I (IGF-I) receptor plays an important role in normal cell cycle progression and tumor growth, and it is thought to be essential for cellular transformation, To test this hypothesis, we stably transfected a GTPase-deficient mutant human G(alpha 13), which is highly oncogenic when overexpressed in vitro, into R-fibroblasts derived from IGF-I receptor-deficient mice, Northern blots of multiple clones revealed the expression of a 1.8-kilobase pair mutant G(alpha 13) transcript in transfected cells, in addition to the 6-kilobase pair endogenous mRNA, The transfection resulted in a doubling of the expression of G(alpha 13) protein in these cells as assessed by Western blot analysis, The transforming ability of the mutant G(alpha 13) was tested using the soft agar assay, Nontransfected R-cells cultured with 10% fetal bovine serum failed to form colonies after 3 weeks, Most of the mutant G(alpha 13)-expressing clones formed significant numbers of colonies (11-50 colonies/1000 cells plated), Overexpression of the IGF-I receptor enabled R-cells to form colonies (27 colonies), and co transfection of the mutant G(alpha 13) caused a further increase in colony formation (117-153 colonies) in three of five clones analyzed, Apparently G(alpha 13) works through pathways other than mitogen-activated protein kinase and c-Jun N-terminal kinase in transforming R-cells, because their activities were not significantly altered by the mutant G(alpha 13) expression, These results demonstrate that G(alpha 13) can induce cellular transformation through pathways apparently independent of the IGF-I receptor and that activation of the IGF-I receptor signaling pathways, although not essential for the transforming phenotype, enhances the effect of other pathways.	NIDDK, SECT CELLULAR & MOL PHYSIOL, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				BASERGA R, 1995, CANCER RES, V55, P249; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KATO H, 1993, J BIOL CHEM, V268, P2655; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LIU JL, 1995, ENDOCRINOLOGY, V136, P2389, DOI 10.1210/en.136.6.2389; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RESNICOFF M, 1994, CANCER RES, V54, P2218; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; TORETSKY JA, 1997, IN PRESS J BIOL CHEM, V272; VALENTINIS B, 1994, ONCOGENE, V9, P825; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; WARBURTON C, 1995, RECEPTOR, V5, P35; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Zhang YH, 1996, ONCOGENE, V12, P2377	37	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29438	29441		10.1074/jbc.272.47.29438	http://dx.doi.org/10.1074/jbc.272.47.29438			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368001	hybrid			2022-12-25	WOS:A1997YG64700011
J	Swain, SD; Helgerson, SL; Davis, AR; Nelson, LK; Quinn, MT				Swain, SD; Helgerson, SL; Davis, AR; Nelson, LK; Quinn, MT			Analysis of activation-induced conformational changes in p47(phox) using tryptophan fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PROTEIN-KINASE-C; NEUTROPHIL NADPH OXIDASE; CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; ADENINE-DINUCLEOTIDE PHOSPHATE; DEPENDENT SUPEROXIDE PRODUCTION; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; PLASMA-MEMBRANE	Activation of the neutrophil NADPH oxidase requires translocation of cytosolic proteins p47(phox), P67(phox), and Pac to the plasma membrane or phagosomal membrane, where they assemble with membrane-bound flavocytochrome b, During this process, it appears that p47(phox) undergoes conformational changes, resulting in the ex exposure of binding sites involved in assembly and activation of the oxidase, In the present study, we have directly evaluated activation-induced conformational changes in p47(phox) using tryptophan fluorescence and circular dichroism spectroscopy. Treatment of p47(phox) with amphiphilic agents known to activate the NADPH oxidase (SDS and arachidonic acid) caused a dose dependent quenching in the intrinsic tryptophan fluorescence of p47(phox), whereas treatment with a number of other amphiphilic agents that failed to activate the oxidase had no effect on p47(phox) fluorescence. In addition, the concentration range of activating agents required to induce changes in fluorescence correlated with the concentration range of these agents that induced maximal NADPH oxidase activity in a cell-free assay system. We next determined if activation by phosphorylation caused the same type of conformational changes in p47(phox). Protein kinase C phosphorylation of p47(phox) in vitro resulted in comparable quenching of fluorescence, which also correlated directly with NADPH oxidase activity, Finally, the circular dichroism (CD) spectrum of p47(phox) was significantly changed by the addition of SDS, whereas treatment with a non-activating detergent had no effect on the CD spectrum, These results support the conclusion that activation by amphiphilic agents results in changes in the secondary structure of p47(phox). Thus, our studies provide direct evidence linking conformational changes in p47(phox) to the NADPH oxidase activation/assembly process and also further support the hypothesis that amphiphile-mediated activation of the NADPH oxidase induces changes in p47(phox) that are similar to those mediated by phosphorylation in rico.	MONTANA STATE UNIV,DEPT VET MOL BIOL,BOZEMAN,MT 59717; MONTANA STATE UNIV,DEPT MICROBIOL,BOZEMAN,MT 59717; BAXTER HEALTHCARE CORP,DUARTE,CA 91010	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; Baxter International Inc				Quinn, Mark/0000-0001-8114-5073	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042426] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR42426] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOXER GJ, 1985, HOSP PRACT, V40, P69; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; CLARK RA, 1987, J BIOL CHEM, V262, P4065; COHEN MS, 1994, CLIN INFECT DIS, V18, pS170, DOI 10.1093/clinids/18.Supplement_2.S170; COREY SJ, 1991, J LAB CLIN MED, V118, P343; COX JA, 1985, J CLIN INVEST, V76, P1932, DOI 10.1172/JCI112190; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DELEO FR, 1997, L LEUKOCYTE BIOL, V60, P677; DELEO GM, 1997, FASEB J, V60, P677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ElBenna J, 1995, BLOOD CELL MOL DIS, V21, P201, DOI 10.1006/bcmd.1995.0023; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; ERICKSON RW, 1992, J CLIN INVEST, V89, P1587, DOI 10.1172/JCI115753; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GORG A, 1988, ELECTROPHORESIS, V9, P37, DOI 10.1002/elps.1150090108; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KUZNICKI J, 1995, BIOCHEMISTRY-US, V34, P15389, DOI 10.1021/bi00047a001; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARKOS CA, 1988, BIOCHIM BIOPHYS ACTA, V932, P71, DOI 10.1016/0005-2728(88)90140-5; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUINN MT, 1992, BLOOD, V79, P2438; QUINN MT, 1989, BIOCHIM BIOPHYS ACTA, V987, P83, DOI 10.1016/0005-2736(89)90458-6; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; THELEN M, 1990, BLOOD, V75, P2223; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V187, P940, DOI 10.1016/0006-291X(92)91288-2; VERHOEVEN AJ, 1993, J BIOL CHEM, V268, P18593; WALLACE BA, 1984, ANAL BIOCHEM, V142, P317, DOI 10.1016/0003-2697(84)90471-8; YAMAGUCHI M, 1995, BIOCHEM BIOPH RES CO, V216, P203, DOI 10.1006/bbrc.1995.2611	61	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29502	29510		10.1074/jbc.272.47.29502	http://dx.doi.org/10.1074/jbc.272.47.29502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368011	hybrid			2022-12-25	WOS:A1997YG64700021
J	Kaneto, H; Miyagawa, J; Kajimoto, Y; Yamamoto, K; Watada, H; Umayahara, Y; Hanafusa, T; Matsuzawa, Y; Yamasaki, Y; Higashiyama, S; Taniguchi, N				Kaneto, H; Miyagawa, J; Kajimoto, Y; Yamamoto, K; Watada, H; Umayahara, Y; Hanafusa, T; Matsuzawa, Y; Yamasaki, Y; Higashiyama, S; Taniguchi, N			Expression of heparin-binding epidermal growth factor-like growth factor during pancreas development - A potential role of PDX-1 in transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INSULIN GENE; HOMEOBOX FACTOR; FACTOR-I; PROMOTER ELEMENTS; ISLET CELLS; EGF; INDUCTION; PROTEIN; MITOGEN	The development of the pancreas appears to be regulated by various growth factors, We report here the expression of heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) in the developing pancreas, Immunostaining of fetal and neonatal rat pancreata, in which endocrine cells are visible as cell clusters often associated with primitive ducts or ductular cells, revealed that most of the cluster-forming cells and primitive ducts or ductular cells express HB-EGF protein, In contrast, the exocrine pancreas lacked HB-EGF expression, Based on findings that the expression pat tern was similar to that of the homeodomain-containing transcription factor PDX-1 (IDX-1/STF-1/IPF1) and that the regulatory region of the HB-EGF gene contained sequences similar to the PDX-1-binding A element, we examined whether PDX-1 could be a potential activator of HB-EGF gene expression, The results of reporter gene analyses suggested that the HB-EGF gene promoter is PDX-1-responsive and that the activity of the promoter in pancreatic beta cell-derived beta TC1 cells depends on the PDX-1 binding site-like sequences, Gel-mobility shift analyses using an anti-PDX-l antibody indicated that PDX-1 is a specific and dominant binding factor for an A element-like sequence in the HB-EGF gene. These observations suggest the possible involvement of HB-EGF in pancreas development, While PDX-1 is essential for pancreas development, HB-EGF may function as a mediator of PDX-1 and thus be involved in the development of the endocrine pancreas.	OSAKA UNIV,SCH MED,DEPT MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University	Kaneto, H (corresponding author), OSAKA UNIV,SCH MED,DEPT MED 1,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Watada, Hirotaka/0000-0001-5961-1816				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; CHEN XR, 1995, J BIOL CHEM, V270, P18285, DOI 10.1074/jbc.270.31.18285; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GUZ Y, 1995, DEVELOPMENT, V121, P11; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; INUI Y, 1994, GASTROENTEROLOGY, V107, P1799, DOI 10.1016/0016-5085(94)90823-0; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KANAKAGANTENBEIN C, 1995, ENDOCRINOLOGY, V136, P3154, DOI 10.1210/en.136.7.3154; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MIETTINEN PJ, 1992, DEVELOPMENT, V114, P833; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OTONKOSKI T, 1994, DIABETES, V43, P947, DOI 10.2337/diabetes.43.7.947; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SANVITO F, 1994, DEVELOPMENT, V120, P3451; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Waguri M, 1997, DIABETES, V46, P1281, DOI 10.2337/diabetes.46.8.1281; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478	36	59	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29137	29143		10.1074/jbc.272.46.29137	http://dx.doi.org/10.1074/jbc.272.46.29137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360990	hybrid			2022-12-25	WOS:A1997YF68400049
J	Pombo, CM; Tsujita, T; Kyriakis, JM; Bonventre, JV; Force, T				Pombo, CM; Tsujita, T; Kyriakis, JM; Bonventre, JV; Force, T			Activation of the Ste20-like oxidant stress response kinase-1 during the initial stages of chemical anoxia-induced necrotic cell death - Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULAR CELLS; HYDROGEN-PEROXIDE; PROTEIN-KINASE; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; MESANGIAL CELLS; RENAL INJURY; MAP KINASES; BCL-2	Signal transduction mechanisms activated during the early stages of necrotic cell death are poorly characterized, We have recently identified the Sterile 20 (Ste20)-like oxidant stress response kinase-l, SOK-1, which is a member of the Ste20 kinase family, We report that SOK-1 is markedly activated as early as 20 min after chemical anoxia induced by exposure of Madin-Darby canine kidney or LLC-PK1 renal tubular epithelial cells to 2-deoxyglucose (2-DG) and any one of three inhibitors of the electron transport chain, cyanide (CN), rotenone, or antimycin A. Since oxidant stress activates SOK-I, we postulated that reactive oxygen species (ROS), which are produced by the electron transport chain during chemical anoxia, might be responsible for SOR-I activation, The time course of CN/2-DG-induced SOK-1 activation and of production of ROS, measured in cells loaded with dichlorofluorescein, were compatible with a role for ROS in SOH-l activation, Furthermore, preincubation of LLC-PK, cells with three unrelated scavengers of ROS, pyrrolidine dithiocarbamate, pyruvate, or nordihydroguaiaretic acid, reduced both cellular oxidant stress and activation of SOK-1 by CN/2-DG. An increase in cytosolic free [Ca2+] ([Ca2+](i)) was necessary but not sufficient for CN/2-DG-induced activation of SOK-1, Preincubation of cells with BAPTA-AM prevented activation of SOK-1. Incubation of cells with thapsigargin or the calcium ionophore, A23187, had no effect on SOK-1 activity, but preincubation of cells with either of these agents markedly enhanced CN/2-DG-induced activation of SOK-1 (20-fold versus 7-fold). In summary, chemical anoxia activates SOK-1 via an oxidant stress dependent mechanism that is both critically dependent upon and markedly amplified by an increase in [Ca2+](i). This requirement for dual inputs of oxidant stress and an increase in [Ca2+](i) may prevent inappropriate activation of the kinase by milder degrees of oxidant stress, which are insufficient to generate an increase in [Ca2+](i). The activation of SOK-1 may be one of the cell's earliest responses to inducers of necrotic cell death.	MASSACHUSETTS GEN HOSP E, CARDIAC UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP E, RENAL UNIT, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP E, DIABET UNIT, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School			Pombo, Celia M/L-4479-2014	Pombo, Celia M/0000-0003-2541-9468; Force, Thomas/0000-0002-0450-8659	NIDDK NIH HHS [DK50282, DK41513] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513, R55DK050282, R29DK050282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BONVENTRE JV, 1985, AM J PHYSIOL, V249, pC149, DOI 10.1152/ajpcell.1985.249.1.C149; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARROLL JM, 1992, J NEUROCHEM, V59, P1836, DOI 10.1111/j.1471-4159.1992.tb11017.x; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FISH EM, 1994, AM J PHYSIOL-RENAL, V267, pF566, DOI 10.1152/ajprenal.1994.267.4.F566; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FORCE T, 1991, J BIOL CHEM, V266, P4295; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HAJJAR RJ, 1991, J BIOL CHEM, V266, P21589; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KVIETYS PR, 1989, AM J PHYSIOL, V257, pH1640, DOI 10.1152/ajpheart.1989.257.5.H1640; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCCOY CE, 1988, J CLIN INVEST, V82, P1326, DOI 10.1172/JCI113734; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MUSCHEL RJ, 1995, CANCER RES, V55, P995; MYERS KM, 1995, J NEUROCHEM, V65, P2432; NATH KA, 1993, AM J PHYSIOL, V264, pF306, DOI 10.1152/ajprenal.1993.264.2.F306; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SALAHUDEEN AK, 1991, J CLIN INVEST, V88, P1886, DOI 10.1172/JCI115511; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; Shimizu S, 1996, ONCOGENE, V12, P2045; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; TURRENS JF, 1990, CLIN ISCHEMIC SYNDRO, P203; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZAGER RA, 1992, J CLIN INVEST, V90, P711, DOI 10.1172/JCI115942; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	61	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29372	29379		10.1074/jbc.272.46.29372	http://dx.doi.org/10.1074/jbc.272.46.29372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361019	hybrid			2022-12-25	WOS:A1997YF68400078
J	Yu, R; Tan, TH; Kong, ANT				Yu, R; Tan, TH; Kong, ANT			Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mitogen-activated protein kinases - The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; N-TERMINAL KINASE-1; C-JUN; MAP KINASE; GROWTH-FACTOR; SYNTHETIC ANTIOXIDANTS; HORSERADISH-PEROXIDASE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; HYDROGEN-PEROXIDE	Phenolic antioxidant butylated hydroxyanisole (BRA) is a commonly used food preservative with broad biological activities, including protection against acute toxicity of chemicals, modulation of macromolecule synthesis and immune response, induction of phase II detoxifying enzymes, and especially its potential tumor-promoting activities. Understanding the molecular basis underlying these diverse biological actions of BRA is thus of great importance, Here we demonstrate that BRA is capable of activating distinct mitogen-activated protein kinases (MAPKs), extracellular signal-regulated protein kinase 2 (ERK2), and c-Jun N-terminal kinase 1 (JNK1). Activation of ERK2 by BHA was rapid and transient, whereas the JNK1 activation was relatively delayed and persistent. A major metabolite of BHA, tert-butylhydroquinone (tBHQ), also activated ERK2 but weakly stimulated JNK1 activity, Furthermore, tBHQ activation of ERK2 was late and prolonged, showing a kinetics different from that induced by BHA. ERK2 activation by both compounds required the involvement of an upstream signaling kinase MAPK/ERK, kinase (MEK), as evidenced by the inhibitory effect of a MEK inhibitor, PD98059, Pretreatment with N-acetyl-L-cysteine, glutathione, or vitamin E attenuated ERK2 but not JNK1 activation by BHA and tBHQ. Modulation of intracellular H2O2 levels by direct addition of catalase or pretreatment with a catalase inhibitor, aminotriazole, also affected BHA-and tBHQ-stimulated ERK2 activity but not JNK1, indicating the involvement of oxidative stress in the ERK2 activation by these two compounds. However, we did not observe any generation of H2O2 after exposure of cells to BHA or tBHQ using a H2O2-sensitive fluorescent probe, 2',7'-dichlorofluorescein diacetate. Instead, BRA and tBHQ substantially reduced the amount of intracellular H2O2, Furthermore, BHA and tBHQ activation of ERK2 was strongly inhibited by ascorbic acid and a peroxidase inhibitor, sodium azide, suggesting the potential role of phenoxyl radicals and/or their derivatives, Taken together, our results indicate that (i) BHA and its metabolite tBHQ differentially regulate MAPK pathways, and (ii) oxidative stress due to the generation of reactive intermediates, possibly phenoxyl radicals but not H2O2, is responsible for the ERK2 activation by BHA and tBHQ, whereas the JNK1 activation may require a distinct yet unknown mechanism.	UNIV ILLINOIS,CTR PHARMACEUT BIOTECHNOL,DEPT PHARMACEUT & PHARMACODYNAM MC 865,COLL PHARM,CHICAGO,IL 60612; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine			Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021; Kong, Ah-Ng Tony/AAX-2828-2020	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875, R29GM049172] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES06887] Funding Source: Medline; NIGMS NIH HHS [R29-GM49172, R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTILL BD, 1962, J AGR FOOD CHEM, V10, P315, DOI 10.1021/jf60122a015; BENSON AM, 1978, CANCER RES, V38, P4486; BOULIKAS T, 1995, INT J ONCOL, V6, P271; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHA YN, 1978, CANCER RES, V38, P4496; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; CLAYSON DB, 1990, ANNU REV PHARMACOL, V30, P441; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; CUMMINGS SW, 1983, J BIOL CHEM, V258, P2315; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EASTMOND DA, 1986, MOL PHARMACOL, V30, P674; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIROSE M, 1987, CARCINOGENESIS, V8, P1555, DOI 10.1093/carcin/8.10.1555; ITO N, 1983, JNCI-J NATL CANCER I, V70, P343; IVERSON F, 1985, CANCER LETT, V26, P43, DOI 10.1016/0304-3835(85)90171-5; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P33, DOI 10.1016/0003-9861(90)90514-Y; KAGAN VE, 1994, BIOCHEMISTRY-US, V33, P9651, DOI 10.1021/bi00198a034; KAHL R, 1989, TOXICOLOGY, V59, P179, DOI 10.1016/0300-483X(89)90056-5; KAHL R, 1984, TOXICOLOGY, V33, P185, DOI 10.1016/0300-483X(84)90038-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUI Y, 1996, FREE RADICAL BIO MED, V21, P771; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MNSOUR SJ, 1994, SCIENCE, V265, P966; MOLDEUS P, 1982, BIOCHEM PHARMACOL, V31, P1907, DOI 10.1016/0006-2952(82)90496-8; MONROE DH, 1987, TOXICOL APPL PHARM, V90, P401, DOI 10.1016/0041-008X(87)90132-3; NAKAGAWA Y, 1994, EUR J PHARM-ENVIRON, V270, P341, DOI 10.1016/0926-6917(94)90010-8; NERA EA, 1988, TOXICOLOGY, V53, P251, DOI 10.1016/0300-483X(88)90218-1; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; Peters MMCG, 1996, CANCER RES, V56, P1006; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RAHIMTULA A, 1983, CHEM-BIOL INTERACT, V45, P125, DOI 10.1016/0009-2797(83)90048-0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO DNR, 1989, J BIOL CHEM, V265, P844; REHWOLDT R, 1986, FOOD CHEM TOXICOL, V24, P1039, DOI 10.1016/0278-6915(86)90286-3; ROGERS CG, 1992, MUTAT RES, V280, P17, DOI 10.1016/0165-1218(92)90014-Q; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROSSING D, 1985, TOXICOLOGY, V34, P67, DOI 10.1016/0300-483X(85)90079-4; SAKAI A, 1990, CARCINOGENESIS, V11, P1985, DOI 10.1093/carcin/11.11.1985; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHILDERMAN PAEL, 1995, CARCINOGENESIS, V16, P507, DOI 10.1093/carcin/16.3.507; SCHILDERMAN PAEL, 1992, CARCINOGENESIS, V13, P585, DOI 10.1093/carcin/13.4.585; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAJIMA K, 1992, DRUG METAB DISPOS, V20, P816; THOMPSON D, 1988, BIOCHEM PHARMACOL, V37, P2201, DOI 10.1016/0006-2952(88)90582-5; THOMPSON DC, 1989, J BIOL CHEM, V264, P3957; VERHAGEN H, 1991, CHEM-BIOL INTERACT, V80, P109, DOI 10.1016/0009-2797(91)90019-4; VERHAGEN H, 1989, CARCINOGENESIS, V10, P1947, DOI 10.1093/carcin/10.10.1947; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATTENBERG LW, 1980, CANCER RES, V40, P2820; WATTENBERG LW, 1983, RADIOPROTECTORS ANTI, P461; *WHO, 1987, WHO FOOD ADDITIVE SE, V21, P25; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WURTZEN G, 1986, FOOD CHEM TOXICOL, V24, P1229, DOI 10.1016/0278-6915(86)90311-X; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5	73	101	101	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28962	28970		10.1074/jbc.272.46.28962	http://dx.doi.org/10.1074/jbc.272.46.28962			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360968	hybrid, Green Submitted			2022-12-25	WOS:A1997YF68400027
J	Destoumieux, D; Bulet, P; Loew, D; VanDorsselaer, A; Rodriguez, J; Bachere, E				Destoumieux, D; Bulet, P; Loew, D; VanDorsselaer, A; Rodriguez, J; Bachere, E			Penaeidins, a new family of antimicrobial peptides isolated from the shrimp Penaeus vannamei (decapoda)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; HORSESHOE-CRAB HEMOCYTES; HONEYBEE APIS-MELLIFERA; AMINO-ACID-SEQUENCE; INSECT DEFENSIN-A; SECONDARY STRUCTURE; INNATE IMMUNITY; CARCINUS-MAENAS; JAPONICUS BATE; SHORE CRAB	We report here the isolation of three members of a new family of antimicrobial peptides from the hemolymph of shrimps Penaeus vannamei in which immune response has not been experimentally induced. The three molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria. The complete sequences of these peptides were determined by a combination of enzymatic cleavages, Edman degradation, mass spectrometry, and cDNA cloning using a hemocyte cDNA library. The mature molecules (50 and 62 residues) are characterized by an NH2-terminal domain rich in proline residues and a COOH-terminal domain containing three intramolecular disulfide bridges. One of these molecules is post-translationally modified by a pyroglutamic acid at the first position. Comparison of the data obtained from the cDNA clones and mass spectrometry showed that two of these peptides are probably COOH-terminally amidated by elimination of a glycine residue. These molecules with no evident homology to other hitherto described antimicrobial peptides were named penaeidins.	UNIV MONTPELLIER 2, IFREMER, CNRS, F-34095 MONTPELLIER, FRANCE; INST BIOL MOL & CELLULAIRE, CNRS, UPR REPONSE IMMUNITAIRE & DEV CHEZ INSECTES 9022, F-67084 STRASBOURG, FRANCE; UNIV STRASBOURG 1, LAB SPECTROMETRIE MASSE BIOORGAN,URA 31,CNRS, FAC CHIM, F-67008 STRASBOURG, FRANCE; ESCUELA SUPER POLITECN LITORAL, CTR NACL ACUICULTURE & INVEST MARINAS, GUAYAQUIL, ECUADOR	Centre National de la Recherche Scientifique (CNRS); Ifremer; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Escuela Superior Politecnica del Litoral			Bachere, Evelyne/O-6117-2014; Destoumieux-Garzón, Delphine/O-3328-2014; BULET, Philippe/C-8557-2014	Destoumieux-Garzón, Delphine/0000-0002-8793-9138; BULET, Philippe/0000-0001-9016-265X; Rodriguez, Jenny/0000-0002-4773-0700; Damarys, Loew/0000-0002-9111-8842				BACHERE E, 1995, FISH SHELLFISH IMMUN, V5, P597, DOI 10.1016/S1050-4648(95)80044-1; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; BURNS CD, 1979, AQUACULTURE, V16, P193, DOI 10.1016/0044-8486(79)90107-8; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHISHOLM JRS, 1992, J MAR BIOL ASSOC UK, V72, P529, DOI 10.1017/S0025315400059324; COCKLE SM, 1989, J BIOL CHEM, V264, P7788; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; CRISP LM, 1989, MYCOLOGIA, V81, P709, DOI 10.2307/3759875; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; FALICK AM, 1993, J AM SOC MASS SPECTR, V4, P882, DOI 10.1016/1044-0305(93)87006-X; FANT F, 1994, P 12 EUR EXPT NMR C; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FISCHER WH, 1987, P NATL ACAD SCI USA, V84, P3628, DOI 10.1073/pnas.84.11.3628; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hetru Charles, 1994, P43; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hubert F, 1996, EUR J BIOCHEM, V240, P302, DOI 10.1111/j.1432-1033.1996.0302h.x; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; ISHIMARU K, 1995, INT J SYST BACTERIOL, V45, P134, DOI 10.1099/00207713-45-1-134; IWANAGA S, 1994, ANN NY ACAD SCI, V712, P102, DOI 10.1111/j.1749-6632.1994.tb33566.x; JAYNES JM, 1993, PLANT SCI, V89, P43, DOI 10.1016/0168-9452(93)90169-Z; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; KOPACEK P, 1993, EUR J BIOCHEM, V213, P591, DOI 10.1111/j.1432-1033.1993.tb17798.x; Landon C, 1996, EUR J BIOCHEM, V236, P395, DOI 10.1111/j.1432-1033.1996.00395.x; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; LI ZQ, 1988, FEBS LETT, V231, P299, DOI 10.1016/0014-5793(88)80837-8; Lightner D.V., 1983, CRC HDB MARICULTURE, P289; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NORELLI JL, 1994, EUPHYTICA, V77, P123, DOI 10.1007/BF02551474; RHOOBUNJONGDE W, 1991, NIPPON SUISAN GAKK, V57, P629, DOI 10.2331/suisan.57.629; RODRIGUEZ J, 1995, J CELL SCI, V108, P1043; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Schnapp D, 1996, EUR J BIOCHEM, V240, P532, DOI 10.1111/j.1432-1033.1996.0532h.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SONG YL, 1993, B I ZOOL ACAD SINICA, V32, P217; SOSERHALL K, 1996, NEW DIRECTIONS INVER, P229; VEGAVILLASANTE F, 1993, PREV VET MED, V17, P271, DOI 10.1016/0167-5877(93)90035-R; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	56	362	409	4	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28398	28406		10.1074/jbc.272.45.28398	http://dx.doi.org/10.1074/jbc.272.45.28398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353298	Green Published, hybrid			2022-12-25	WOS:A1997YF21900038
J	Weinstein, J				Weinstein, J			Cell cycle-regulated expression, phosphorylation, and degradation of p55Cdc - A mammalian homolog of CDC20/Fizzy/slp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; PROTEIN-KINASE; MITOTIC SPINDLE; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; ANAPHASE TRANSITION; PROMOTING FACTOR; GENE-EXPRESSION; TELOPHASE DISC; CDC20 GENE	p55Cdc is a mammalian protein that shows high homology to the cell cycle proteins Cdc20p of Saccharomyces cerevisiae and the product of the Drosophila fizzy (fly) gene, both of which contain WD repeats and are thought to be required for the metaphase-anaphase transition. The fzy mutants exhibit a metaphase arrest phenotype, which is accompanied by stabilization of cyclins A and B, leading to the hypothesis that fzy function is required for cell cycle-regulated ubiquitin-mediated proteolysis. p55Cdc expression was initiated at the G(1)/S transition and steady state levels of p55Cdc were highest at M and lowest in G(1). Inhibition of the 26 S proteasome prevented both mitotic exit and loss of p55Cdc at the M/G(1) transition, suggesting that p55Cdc degradation was mediated by the cell cycle-regulated proteolytic pathway. Immune complexes of p55Cdc obtained at different cell cycle stages showed a variety of proteins with dramatic differences observed in the pattern of associated proteins during the transition from G(2) to M. Immunolocalization of p55Cdc demonstrated dynamic changes in p55Cdc localization as the cells transit mitosis. p55Cdc appears to act as a regulatory protein interacting with several other proteins, perhaps via its seven WD repeats, at multiple points in the cell cycle.			Weinstein, J (corresponding author), AMGEN INC, 14-1-B, 1840 DEHAVILLAND DR, THOUSAND OAKS, CA 91320 USA.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; Hall LL, 1996, CANCER RES, V56, P3551; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Kao CT, 1996, ONCOGENE, V13, P1221; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MARGOLIS RL, 1993, BIOESSAYS, V15, P201, DOI 10.1002/bies.950150310; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGELE R, 1995, SCIENCE, V270, P1831, DOI 10.1126/science.270.5243.1831; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OToole ET, 1997, MOL BIOL CELL, V8, P1, DOI 10.1091/mbc.8.1.1; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saunders William S., 1993, Trends in Cell Biology, V3, P432, DOI 10.1016/0962-8924(93)90032-V; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Wheatley SP, 1996, J CELL BIOL, V135, P981, DOI 10.1083/jcb.135.4.981; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	74	116	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28501	28511		10.1074/jbc.272.45.28501	http://dx.doi.org/10.1074/jbc.272.45.28501			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353311	hybrid			2022-12-25	WOS:A1997YF21900051
J	Huang, CS; Ma, WY; Ding, M; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Ding, M; Bowden, GT; Dong, ZG			Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; ZETA-ISOFORM; CERAMIDE; STRESS; AP-1; ACID; PHOSPHORYLATION; TRANSFORMATION	Sphingomyelinase (SMase) and its product ceramide have recently attracted a great deal of attention because of their possible role in the signal transduction pathway. However, the role of sphingomyelinase in W-induced c-June N-terminal kinase (JNK) activation is still unclear. Thus, we investigated this issue directly using a genetic SMase-deficient (2 similar to 3% residual acid SMase activity) lymphoblast cell line, MS1418. The results showed that while UV irradiation markedly induces JNK activation in a normal human lymphoblast cell line, JY, it induces only weak JNK activation in MS1418 cells. This difference of JNK response to UV irradiation between these two cell lines was further observed in time course and dose response studies. In contrast, 12-0-tetradecanoylphorbol-13 acetate-induced JNK activation could be observed in both JY and MS1418 cells. Furthermore, significant JNK activation can be observed in MS1418 cells by exposure of the cells to SMase or C-2-ceramide, whereas phospholipase A(2) or phospholipase C did not show significant induction of JNK activity, and C-2-dihydroceramide and sphingosine induce only much weaker JNK activation in MS1418 cells than that by C-2-ceramide. These data demonstrated that SMase plays an essential role in UV-induced JNK activation.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; NIOSH,NIH,MORGANTOWN,WV 26505; UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096	NATIONAL CANCER INSTITUTE [R29CA074916] Funding Source: NIH RePORTER; NCI NIH HHS [1R29CA74916-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; GUBINS E, 1994, MOL CELL BIOL, V14, P906; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, ONCOGENE, V14, P1945, DOI 10.1038/sj.onc.1201056; Huang CS, 1996, INT J ONCOL, V8, P389; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	31	104	106	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27753	27757		10.1074/jbc.272.44.27753	http://dx.doi.org/10.1074/jbc.272.44.27753			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346918	hybrid			2022-12-25	WOS:A1997YD47300044
J	Keyer, K; Imlay, JA				Keyer, K; Imlay, JA			Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; NITRIC-OXIDE; DNA-DAMAGE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; OXIDATION; ACONITASE; PROTEIN	Phagocytes produce both nitric oxide and superoxide as components of the oxidative defense against pathogens. Neither molecule is likely at physiological concentrations to kill cells. However, two of their reaction products, hydrogen peroxide and peroxynitrite, are strong oxidants, cell-permeant, and toxic. Hydrogen peroxide generates oxidative DNA damage, while the primary mechanism of toxicity of peroxynitrite has not yet been determined. Recent in vitro studies indicated that peroxynitrite is capable of oxidizing the [4Fe-4S] clusters of a family of dehydratases (Hausladen, A., and Fridovich, I. (1994) J. Biol. Chem. 269, 29405-29408; Castro, L., Rodriguez, M., and Radi, R. (1994) J. Biol. Chem. 269, 29409-29415). We demonstrate here that peroxynitrite at 1% of its lethal dose almost fully inactivated the labile dehydratases in Escherichia coli. The rate at which peroxynitrite inactivated the clusters substantially exceeded the rate at which it oxidized thiols or spontaneously decomposed. These results suggest that these dehydratases may be primary targets of peroxynitrite in vivo. Another consequence of the cluster damage was the release of 100 mu m iron into the cytosol. During phagocytosis, this intracellular free iron could increase lethal DNA damage by hydrogen peroxide or protein modification by additional peroxynitrite. In response to peroxynitrite challenges, E. coli rapidly sequestered the intracellular free iron using an undefined scavenging system. The iron-sulfur clusters were more gradually repaired by a process that drew iron from its iron-storage proteins. These are likely to be critical events in the struggle between phagocyte and pathogen.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASTRO L, 1994, J BIOL CHEM, V269, P29409; COLMAN RF, 1968, J BIOL CHEM, V243, P2454; CORBIER C, 1992, BIOCHEMISTRY-US, V31, P12532, DOI 10.1021/bi00164a033; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; DALESSIO G, 1971, J BIOL CHEM, V246, P4326; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FLINT D H, 1990, P285; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Flint DH, 1996, J BIOL CHEM, V271, P16068; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; FUCHS JA, 1975, J BACTERIOL, V124, P140, DOI 10.1128/JB.124.1.140-148.1975; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Goldstein S, 1996, FREE RADICAL BIO MED, V21, P965, DOI 10.1016/S0891-5849(96)00280-8; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HILLMAN JD, 1975, J BACTERIOL, V122, P1175, DOI 10.1128/JB.122.3.1175-1179.1975; HUDSON AJ, 1993, EUR J BIOCHEM, V218, P985, DOI 10.1111/j.1432-1033.1993.tb18457.x; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1992, J BACTERIOL, V174, P953, DOI 10.1128/jb.174.3.953-961.1992; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KAO SM, 1985, J BIOL CHEM, V260, P478; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KUO CF, 1987, J BIOL CHEM, V262, P4724; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; LUO YZ, 1994, P NATL ACAD SCI USA, V91, P12438, DOI 10.1073/pnas.91.26.12438; LYNCH RE, 1978, J BIOL CHEM, V253, P1838; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MILLER DM, 1992, ARCH BIOCHEM BIOPHYS, V295, P240, DOI 10.1016/0003-9861(92)90513-V; Miller JH., 1972, EXPT MOL GENETICS; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; OHNISHI T, 1976, J BIOL CHEM, V251, P2105; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reed L.J., 1966, METHOD ENZYMOL, V9, P247; REEVES WJ, 1966, METHOD ENZYMOL, V9, P288; Rutter W.J., 1966, METHODS ENZYMOL, V9, P479; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; SZABO C, 1995, BIOCHEM BIOPH RES CO, V209, P739, DOI 10.1006/bbrc.1995.1561; THOMSON L, 1995, ARCH BIOCHEM BIOPHYS, V319, P491, DOI 10.1006/abbi.1995.1321; THORNELEY RNF, 1989, BIOCHEM J, V261, P181, DOI 10.1042/bj2610181; TORRIANI A, 1960, BIOCHIM BIOPHYS ACTA, V38, P460, DOI 10.1016/0006-3002(60)91281-6; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; Weitzman PDJ, 1969, METHOD ENZYMOL, V8, P22, DOI 10.1016/0076-6879(69)13009-8; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; YARIV J, 1981, BIOCHEM J, V197, P171, DOI 10.1042/bj1970171	71	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27652	27659		10.1074/jbc.272.44.27652	http://dx.doi.org/10.1074/jbc.272.44.27652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346904	hybrid			2022-12-25	WOS:A1997YD47300030
J	Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW				Barsky, SH; Sternlicht, MD; Safarians, S; Nguyen, M; Chin, K; Stewart, SD; Hiti, AL; Gray, JW			Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype	ONCOGENE			English	Article						somatic cell hybridization; spontaneous metastasis; human-human fusions	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT-MELANOMA; GROWTH-FACTOR RECEPTOR; SOMATIC-CELL HYBRIDS; HUMAN LUNG-CANCER; DNA METHYLTRANSFERASE; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; PROSTATE-CANCER; SOLID TUMORS	The highly metastatic amelanotic C8161 human melanoma line was found to exhibit complete dominance of its undifferentiated and metastatic phenotype in multiple somatic cell hybridization studies designed to bypass the presence of potential tumor suppressor genes. In a three armed approach involving somatic cell fusions of C8161 with recipient lines of greater differentiation, different lineage, and different tumorigenicity status, the metastatic and undifferentiated phenotype of C8161 was promiscuously dominant. In somatic cell hybrids produced between the C8161 and a group of non-metastatic human melanoma lines which exhibited melanocyte differentiation markers including S100, HMB-45, NKI/ C3, and melanin, the fusions were uniformly metastatic and undifferentiated. In somatic cell hybrids of C8161 and MCF-7 the fusions exhibited an estrogen independent and unresponsive, estrogen receptor (ER) negative, and highly metastatic phenotype. In fusions between C8161 and HMS-1, an immortalized 'benign' human myoepithelial line which produced an abundant extracellular matrix (ECM) and high levels of protease and angiogenic inhibitors including maspin, tissue inhibitor of metalloproteinase-1 (TIMP-1), alpha 1-antitrypsin (alpha 1-AT), protease nexin II (PN-II), thrombospondin-l and soluble basic fibroblast growth factor (bFGF) receptors, the hybrids showed complete absence of matrix, absent maspin expression, markedly decreased protease inhibitor and angiogenic inhibitor production, high levels of proteases and angiogenic factors, and a highly metastatic phenotype. In our somatic cell fusions, the human-human hybrids represented true and complete fusions and not hybrid clones selected for by loss of dominant-acting growth suppressor genes. This finding was supported by detailed comparative genomic hybridization (CGH) studies, Q-banding karyotype analysis, and autofusions of representative clones. The purposeful creation of inherently unstable human-murine fusions between C8161 and B16-F1 where loss of putative suppressor loci would be expected, resulted in fusions exhibiting decreased growth and non-metastatic behavior with progressive chromosomal loss. Neither p53, nm23, DNA methyltransferase, activated I as, fibroblast growth factor-4 (FGF-4), or epidermal growth factor receptor (EGFR) mediated the acquisition of the metastatic or undifferentiated phenotype within the C8161-human fusions. These studies are the first studies ever to successfully transfer the complete metastatic phenotype by somatic cell fusion and support the presence of a new high level regulatory pathway(s) involving dominant trans-acting factors which act pleiotropically to regulate an undifferentiated and highly metastatic phenotype.	UNIV CALIF LOS ANGELES,SCH MED,DIV SURG ONCOL,LOS ANGELES,CA 90024; UNIV CALIF SAN FRANCISCO,CTR CANC,CANC GENET PROGRAM,SAN FRANCISCO,CA 94143; CEDARS SINAI MED CTR,LAB CYTOGENET,LOS ANGELES,CA 90211; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Cedars Sinai Medical Center; University of Southern California	Barsky, SH (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA040225, R01CA056735] Funding Source: NIH RePORTER; NCI NIH HHS [CA01351, CA40225, CA56735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARSKY SH, 1983, LAB INVEST, V49, P140; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; CHAMBERS AF, 1992, BIOCHEM CELL BIOL, V70, P817, DOI 10.1139/o92-124; CHENG L, 1988, LAB INVEST, V58, P346; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ERICKSON LA, 1984, ANAL BIOCHEM, V137, P454, DOI 10.1016/0003-2697(84)90113-1; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FIDLER IJ, 1990, J NATL CANCER I, V82, P166, DOI 10.1093/jnci/82.3.166; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FUJIWARA T, 1993, CANCER RES, V53, P4129; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GOPALAKRISHNA R, 1988, P NATL ACAD SCI USA, V85, P612, DOI 10.1073/pnas.85.2.612; GOWN AM, 1984, AM J PATHOL, V114, P309; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HERRON GS, 1986, J BIOL CHEM, V261, P2814; ICHIKAWA T, 1994, CANCER RES, V54, P2299; ITO M, 1994, CANCER LETT, V78, P33, DOI 10.1016/0304-3835(94)90028-0; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KAIGHN ME, 1990, CANCER RES, V50, P1890; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZLOWSKI JM, 1984, CANCER RES, V44, P3522; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOCKSHIN A, 1985, CANCER RES, V45, P345; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUELLER BM, 1991, CANCER RES, V51, P2193; NEVINS JR, 1987, METHODS ENZYMOLOGY G, P234; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; QUINLAN DC, 1992, CANCER RES, V52, P4828; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; RODER JC, 1978, J IMMUNOL, V121, P2509; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; SOMMERS CL, 1990, CANCER RES, V50, P67; SPRUCK CH, 1993, CANCER RES, V53, P1162; STAROSELSKY AH, 1991, CANCER RES, V51, P6292; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; TSUCHIDA T, 1987, J NATL CANCER I, V78, P55, DOI 10.1093/jnci/78.1.55; VENNEGOOR C, 1985, INT J CANCER, V35, P287, DOI 10.1002/ijc.2910350302; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WELCH DR, 1994, ONCOGENE, V9, P255; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314	58	16	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2077	2091		10.1038/sj.onc.1201379	http://dx.doi.org/10.1038/sj.onc.1201379			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366525				2022-12-25	WOS:A1997YC28400009
J	Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S				Gallo, R; Provenzano, C; Carbone, R; DiFiore, PP; Castellani, L; Falcone, G; Alema, S			Regulation of the tyrosine kinase substrate Eps8 expression by growth factors, v-Src and terminal differentiation	ONCOGENE			English	Article						tyrosine kinase; Eps8; Shc; differentiation; signal transduction	QUAIL MYOTUBES; CONSTITUTIVE PHOSPHORYLATION; HIGH-EFFICIENCY; SHC PROTEINS; TRANSFORMATION; DOMAIN; CELLS; FIBROBLASTS; ONCOGENES; MUSCLE	SH3-containing proteins are involved in signal transduction by a number of growth factor receptors and in the organization of the cytoskeleton. The recently identified Eps8 protein, which contains an SH3 domain, is coupled functionally and physically to the EGFR and is tyrosine phosphorylated by this receptor and other receptors as well,Here, we examined the regulation of eps8 expression in response to mitogenic or differentiative signals, We show that Eps8 is expressed at low levels in resting fibroblasts, but its expression is strongly induced during activation by serum, phorbol esters and the v-src oncogene, Conversely, expression of Eps8, but not of other EGFR substrates such as She or Eps15, is virtually extinguished in non-proliferating, terminally differentiated murine myogenic cells, The putative role of Eps8 protein as a v-Src substrate was analysed in murine fibroblasts and in quail myogenic cells expressing a temperature-sensitive variant of the tyrosine kinase, Tyrosine phosphorylation of Eps8 was detected only at the permissive temperature, A non-myristylated, transformation-defective mutant of v-Src did not phosphorylate Eps8, whereas it phosphorylated She. Together, these findings indicate that Eps8 may be a critical substrate of v-Src, They further establish Eps8 as an example of a signal transducer whose expression senses the balance between growth and differentiation and might, therefore, be involved in the determination of the phenotype.	CNR, IST BIOL CELLULARE, I-00137 ROME, ITALY; EUROPEAN INST ONCOL, I-20141 MILAN, ITALY; UNIV BARI, IST MICROBIOL, I-70124 BARI, ITALY; UNIV ROMA TOR VERGATA, DIPARTIMENTO MED SPERIMENTALE & SCI BIOCHIM, I-00133 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro; University of Rome Tor Vergata			Falcone, Germana/A-3735-2016; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Castellani, Loriana/0000-0002-8519-3504; Alema, Stefano/0000-0002-9869-6354; Falcone, Germana/0000-0002-3508-7623	Telethon [800] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; CATLING AD, 1993, ONCOGENE, V8, P1875; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1992, ONCOGENE, V7, P1913; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARLSSON T, 1995, ONCOGENE, V10, P1475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH L, 1984, MOL CELL BIOL, V4, P1420, DOI 10.1128/MCB.4.7.1420; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDERAME MF, 1995, MOL BIOL CELL, V6, P953, DOI 10.1091/mbc.6.8.953; WONG WT, 1994, ONCOGENE, V9, P3057; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	34	31	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1929	1936		10.1038/sj.onc.1201344	http://dx.doi.org/10.1038/sj.onc.1201344			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365239				2022-12-25	WOS:A1997YA87200007
J	Jager, R; Herzer, U; Schenkel, J; Weiher, H				Jager, R; Herzer, U; Schenkel, J; Weiher, H			Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice	ONCOGENE			English	Article						bcl-2; transgenic mice; mammary gland; involution; tumorigenesis	HUMAN BREAST; CHROMOSOMAL BREAKPOINT; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; IN-VIVO; EXPRESSION; PROTEIN; DEATH; GENE; TISSUE	Expression of the apoptosis-inhibitory protein Bcl-2 has frequently been detected in human cancer including mammary carcinoma. The functional significance of its expression has been well established in experimental tumors of the lymphoid system, however, remains to be elucidated for epithelial tumors. In order to assess the role of Bcl-2 in mammary tumorigenesis me have generated WAP-bcl-2 transgenic mice. The strong overexpression of Bcl-2 in lactating mammary glands was preserved during early postlactational involution and apoptosis of alveolar epithelial cells was prevented without influencing the dedifferentiation of the milk-producing epithelium. Although Bcl-2 overexpression was not sufficient to induce spontaneous tumors it, however, led to an accelerated development of MMTVmyc transgene-induced mammary tumors. In the mammary glands of MMTVmyc transgenic mice, a high proportion of apoptotic cells was detected which was significantly reduced in the mammary glands of WAP-bcl-2/MMTVmyc double transgenic mice. Taken together, these results suggest that Bcl-2 contributes to mammary tumorigenesis by inhibiting apoptosis.	FORSCHUNGSZENTRUM KARLSRUHE,GENET INST,D-76021 KARLSRUHE,GERMANY	Helmholtz Association; Karlsruhe Institute of Technology			Jager, Richard/B-9478-2009	Jager, Richard/0000-0002-1623-1917				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; ANDRES AC, 1991, ONCOGENE, V6, P771; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; BCHINI O, 1991, ENDOCRINOLOGY, V128, P539, DOI 10.1210/endo-128-1-539; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; BURDON T, 1991, J BIOL CHEM, V266, P6909; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HAGUE A, 1994, ONCOGENE, V9, P3367; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; HOGAN B, 1986, MANIPULATING MOUSE E; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; JIANG SX, 1995, J PATHOL, V177, P135, DOI 10.1002/path.1711770206; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LI B, 1996, MOL CARCINOG, V14, P75; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pullan S, 1996, J CELL SCI, V109, P631; SANDGREN EP, 1995, CANCER RES, V55, P3915; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG TTY, 1995, CANCER RES, V55, P2487; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	56	137	140	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1787	1795		10.1038/sj.onc.1201353	http://dx.doi.org/10.1038/sj.onc.1201353			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362445				2022-12-25	WOS:A1997XZ72500005
J	Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ				Pells, S; Divjak, M; Romanowski, P; Impey, H; Hawkins, NJ; Clarke, AR; Hooper, ML; Williamson, DJ			Developmentally-regulated expression of murine K-ras isoforms	ONCOGENE			English	Article						ras; expression; splicing	STEM-CELL LINE; C-MYC; DIFFERENTIAL EXPRESSION; PROTO-ONCOGENE; N-RAS; MOUSE; GENE; TRANSFORMATION; PROTEINS; MEMBRANE	The products (p21) of the three mammalian H-, N- and K-ras genes play important roles in intracellular signal transduction, linking membrane receptor kinases to the nuclear pathway through raf and mitogen activated protein kinase. They are involved in the regulation of proliferation and differentiation, and activating mutations of these genes are commonly associated with human cancers. Two p21 proteins are encoded by the K-ras gene (p21(K-rasA) and p21(K-rasB)) due to alternative splicing of the fast exon. While the four p21(ras) proteins are highly homologous, their sequences diverge significantly at the C-termini, to which distinct biochemical and perhaps even functional differences may be ascribed. However, H-, N- and K-rasB appear to be ubiquitously expressed, with little evidence of tissue-specific or developmental regulation. In contrast, we now demonstrate that the expression of K-rasA is strikingly different, K-rasA is induced during differentiation of pluripotent embryonal stem cells in vitro. Its expression during early embryogenesis is limited temporally and spatially in a tissue-specific distribution which is largely maintained as an adult. This suggests a distinct biological role for p21(K-rasA).	UNIV EDINBURGH,DEPT PATHOL,CRC LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ST VINCENTS HOSP,CTR IMMUNOL,DARLINGHURST,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH PATHOL,KENSINGTON,NSW 2052,AUSTRALIA	University of Edinburgh; St Vincents Hospital Sydney; University of New South Wales Sydney			Clarke, Alan R/A-6256-2008; Hawkins, Nicholas J/A-8461-2008; clarke, alan r/P-2820-2014	Hawkins, Nicholas J/0000-0002-2204-3189; Clarke, Alan/0000-0002-4281-426X; Pells, Stephen/0000-0001-5866-5759				AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARBONE A, 1991, ONCOGENE, V6, P731; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANDYSIDE AH, 1989, ROUX ARCH DEV BIOL, V198, P48, DOI 10.1007/BF00376370; Hogan B. L. M, 1983, CANCER SURV, V2, P115; JACKS T, 1995, COMMUNICATION; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOCKETT TJ, 1987, EXP CELL RES, V173, P370, DOI 10.1016/0014-4827(87)90277-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARTIN GR, 1975, TERATOMAS DIFFERENTI, P169; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1983, TERATOCARCINOMA STEM, P451; MULLER R, 1982, MOL CELL BIOL, V3, P1062; NEWMAN CMH, 1993, BIOCHIM BIOPHYS ACTA, V1155, P79, DOI 10.1016/0304-419X(93)90023-6; PAL SK, 1993, MOL REPROD DEV, V35, P8, DOI 10.1002/mrd.1080350103; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YAMAUCHI N, 1994, MOL CELL BIOL, V14, P6655, DOI 10.1128/MCB.14.10.6655; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780	39	71	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1781	1786		10.1038/sj.onc.1201354	http://dx.doi.org/10.1038/sj.onc.1201354			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362444				2022-12-25	WOS:A1997XZ72500004
J	Jiang, Y; Gram, H; Zhao, M; New, LG; Gu, J; Feng, LL; DiPadova, F; Ulevitch, RJ; Han, JH				Jiang, Y; Gram, H; Zhao, M; New, LG; Gu, J; Feng, LL; DiPadova, F; Ulevitch, RJ; Han, JH			Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; MAJOR ACTIVATOR; FISSION YEAST; STRESS; CELLS; PHOSPHORYLATION; IDENTIFICATION; CASCADE; GLOMERULONEPHRITIS	We have cloned and characterized a new member of the p38 group of mitogen-activated protein kinases here termed p38 delta. Sequence comparisons revealed that p38 delta is approximately 60% identical to the other three p38 isoforms but only 40-45% to the other mitogen-activated protein kinase family members. It contains the TGY dual phosphorylation site present in all p38 group members and is activated by a group of extracellular stimuli including cytokines and environmental stresses that also activate the other three known p38 isoforms. However, unlike the other p38 isoforms, the kinase activity of p38 delta is not blocked by the pyridinyl imidazole, 4-(4-fluorophenyl)-2- 2(4-hydroxyphenyl)-5-(4-pyridyl)-imidazole (identicalto SB202190). p38 delta can be activated by MKK3 and MKK6, known activators of the other isoforms. Nonetheless, in-gel kinase assays provide evidence for additional activators. The data presented herein show that p38 delta has many properties that are similar to those of other p38 group members. Nonetheless important differences exist among the four members of the p38 group of enzymes, and thus each may have highly specific, individual contributions to biologic events involving activation of the p38 pathways.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; NOVARTIS PHARMA AG, CH-4002 BASEL, SWITZERLAND	Scripps Research Institute; Novartis			Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM37696, GM51417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Cano E, 1996, ONCOGENE, V12, P805; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FENG LL, 1993, J AM SOC NEPHROL, V3, P1753; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fujinaka H, 1997, J IMMUNOL, V158, P4978; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MARAIS R, 1993, CELL, V73, P361; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shimizu A, 1996, LAB INVEST, V74, P941; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	46	409	448	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30122	30128		10.1074/jbc.272.48.30122	http://dx.doi.org/10.1074/jbc.272.48.30122			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374491	hybrid			2022-12-25	WOS:A1997YH61300023
J	Thissen, JA; Gross, JM; Subramanian, K; Meyer, T; Casey, PJ				Thissen, JA; Gross, JM; Subramanian, K; Meyer, T; Casey, PJ			Prenylation-dependent association of Ki-Ras with microtubules - Evidence for a role in subcellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; EPITHELIAL-CELLS; BOVINE BRAIN; CYTOSKELETON; MEMBRANE; TUBULIN; IDENTIFICATION; FARNESYL; INVITRO; P21RAS	We recently identified a prenyl peptide-binding protein in microsomal membranes from bovine brain (Thissen, J. A., and Casey, P. J. (1993) J. Biol Chem. 268, 13780-13783), Through a variety of approaches, this binding protein has been identified as the cytoskeletal protein tubulin, Prenyl peptides bind to purified tubulin with a K-d of 40 nM and also bind to tubulin polymerized into microtubules, Microtubule affinity chromatography of extracts from cells in which the prenyl protein pool was metabolically labeled revealed that prenyl proteins bound to the immobilized microtubules; one, a 24-kDa protein, was tentatively identified as a GTP-binding protein. Of several prenylated GTP-binding proteins tested, including Ki-Ras4B, Ha-Ras, RhoB, RhoA, and Rap1B, only Ki-Ras was found to bind significantly to microtubules, and this was in a prenylation-dependent fashion. A potential significance of the interaction of Ki-Ras4B with microtubules was indicated from analysis of the localization of newly synthesized Ki-Ras4B and Ha-Ras, each tagged with green fluorescence protein (GFP). Treatment of NIH-3T3 cells expressing GFP-Ki-Ras with Taxol (paclitaxel) resulted in accumulation of the expressed protein in intracellular locations, whereas in control cells the protein was correctly targeted to the plasma membrane, importantly, such treatment with paclitaxel did not affect the cellular localization of expressed GFP-Ha-Ras. These results indicate that an intact microtubule network may be directly involved in Ki-Ras processing and/or targeting and provide direct evidence for a physiological distinction between Ki-Ras and Ha-Ras in cells. Additionally, the finding that paclitaxel treatment of cells disrupts Ki-Ras trafficking suggests an additional mechanism for the anti-proliferative effects of this drug.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University; Duke University	Thissen, JA (corresponding author), DUKE UNIV, MED CTR, DEPT PHARMACOL & CANC BIOL, DURHAM, NC 27710 USA.			Gross, Jeffrey/0000-0002-9422-6312; Meyer, Tobias/0000-0003-4339-3804; Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM 51457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BARNES G, 1992, MOL BIOL CELL, V3, P29, DOI 10.1091/mbc.3.1.29; Best A, 1996, J BIOL CHEM, V271, P3756; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIFULCO M, 1993, J CELL PHYSIOL, V155, P340, DOI 10.1002/jcp.1041550215; BROWN MJ, 1991, J AM CHEM SOC, V113, P3176, DOI 10.1021/ja00008a058; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; EIPPER BA, 1972, P NATL ACAD SCI USA, V69, P2283, DOI 10.1073/pnas.69.8.2283; ENDO A, 1992, J LIPID RES, V33, P1569; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; FAUST J, 1987, J BIOL CHEM, V262, P1996; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; JAMES GL, 1994, J BIOL CHEM, V269, P14182; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; NISHIO K, 1995, INT J CANCER, V63, P688, DOI 10.1002/ijc.2910630514; Olah E, 1996, ANTICANCER RES, V16, P2469; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; RAMASCHI G, 1994, BBA-GEN SUBJECTS, V1199, P20, DOI 10.1016/0304-4165(94)90091-4; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SCHMIDT RA, 1982, J CELL BIOL, V95, P144, DOI 10.1083/jcb.95.1.144; SIMON JR, 1991, MICRON MICROSC ACTA, V22, P405, DOI 10.1016/0739-6260(91)90058-8; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; THISSEN JA, 1995, METHOD ENZYMOL, V250, P158; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; VOTER WA, 1984, J BIOL CHEM, V259, P430; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	102	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30362	30370		10.1074/jbc.272.48.30362	http://dx.doi.org/10.1074/jbc.272.48.30362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374526	hybrid			2022-12-25	WOS:A1997YH61300058
J	Wysocki, R; Bobrowicz, P; Ulaszewski, S				Wysocki, R; Bobrowicz, P; Ulaszewski, S			The Saccharomyces cerevisiae ACR3 gene encodes a putative membrane protein involved in arsenite transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE OPERON; ESCHERICHIA-COLI; ARSB PROTEIN; ANION PUMP; MOLECULAR CHARACTERIZATION; LEISHMANIA-TARENTOLAE; NUCLEOTIDE-SEQUENCE; DRUG-RESISTANCE; YEAST; CELLS	The cluster of three genes, ACR1, ACR2, and ACR3, previously was shown to confer arsenical resistance in Saccharomyces cerevisiae, The overexpression of ACR3 induced high level arsenite resistance, The presence of ACR3 together with ACR2 on a multicopy plasmid was conducive to increased arsenate resistance, The function of ACR3 gene has now been investigated. Amino acid sequence analysis of Acr3p showed that this hypothetical protein has hydrophobic character with 10 putative transmembrane spans and is probably located in yeast plasma membrane, We constructed the acr3 null mutation. The resulting disruptants were 5-fold more sensitive to arsenate and arsenite than wild-type cells, The acr3 disruptants showed wild-type sensitivity to antimony, tellurite, cadmium, and phenylarsine oxide, The mechanism of arsenical resistance was assayed by transport experiments using radioactive arsenite, We did not observe any significant differences in the accumulation of (AsO33-)-As-76 wild-type cells, acr1 and acr3 disruptants, However, the high dosage of ACR3 gene resulted in loss of arsenite uptake, These results suggest that arsenite resistance in yeast is mediated by an arsenite transporter (Acr3p).	UNIV WROCLAW, INST MICROBIOL, PL-51148 WROCLAW, POLAND	University of Wroclaw				Wysocki, Robert/0000-0002-3274-2629				Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BROER S, 1993, J BACTERIOL, V175, P3480, DOI 10.1128/jb.175.11.3480-3485.1993; BunYa M, 1996, CURR GENET, V29, P344, DOI 10.1007/s002940050055; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHANG EC, 1989, J BACTERIOL, V171, P6349, DOI 10.1128/jb.171.11.6349-6352.1989; CHEN CM, 1986, J BIOL CHEM, V261, P5030; COLE SPC, 1994, CANCER RES, V54, P5902; Dey S, 1996, P NATL ACAD SCI USA, V93, P2192, DOI 10.1073/pnas.93.5.2192; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, MOL BIOCHEM PARASIT, V67, P49, DOI 10.1016/0166-6851(94)90095-7; EHRENHOFERMURRAY AE, 1994, MOL GEN GENET, V244, P287, DOI 10.1007/BF00285456; FRANCISCO MJDS, 1989, MOL MICROBIOL, V3, P15, DOI 10.1111/j.1365-2958.1989.tb00098.x; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7288, DOI 10.1021/bi00189a033; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HUANG RN, 1995, ENVIRON MOL MUTAGEN, V25, P188, DOI 10.1002/em.2850250304; Huang RN, 1996, TOXICOL APPL PHARM, V136, P243, DOI 10.1006/taap.1996.0031; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; Kaiser C., 1994, METHODS YEAST GENETI; Kochhar TS, 1996, TOXICOL LETT, V84, P37, DOI 10.1016/0378-4274(95)03536-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE TC, 1985, CARCINOGENESIS, V6, P1421, DOI 10.1093/carcin/6.10.1421; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; NOVICK RP, 1968, J BACTERIOL, V95, P1335, DOI 10.1128/JB.95.4.1335-1342.1968; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; Pierce J. S., 1970, Journal of the Institute of Brewing, V76, P442; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; SZINICZ L, 1988, ARCH TOXICOL, V61, P444, DOI 10.1007/BF00293690; TAKEMARU K, 1995, MICROBIOL-UK, V141, P323, DOI 10.1099/13500872-141-2-323; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TISA LS, 1990, J BIOL CHEM, V265, P190; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU JH, 1993, MOL MICROBIOL, V8, P615, DOI 10.1111/j.1365-2958.1993.tb01605.x; WU JH, 1992, J BIOL CHEM, V267, P12570	51	176	186	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30061	30066		10.1074/jbc.272.48.30061	http://dx.doi.org/10.1074/jbc.272.48.30061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374482	hybrid			2022-12-25	WOS:A1997YH61300014
J	Hackam, DJ; Rotstein, OD; Zhang, WJ; Demaurex, N; Woodside, M; Tsai, O; Grinstein, S				Hackam, DJ; Rotstein, OD; Zhang, WJ; Demaurex, N; Woodside, M; Tsai, O; Grinstein, S			Regulation of phagosomal acidification - Differential targeting of Na+/H+ exchangers, Na+/K+-ATPases, and vacuolar-type H+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH REGULATION; MYCOBACTERIUM-BOVIS BCG; PROTEIN-KINASE-C; LYSOSOME FUSION; MURINE MACROPHAGES; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; MOUSE STRAINS; AMILORIDE; AVIUM	Vacuolar type (V) ATPases are thought to be the main determinant of phagosomal acidification, In phagosomes containing mycobacteria, which ostensibly impair the delivery of V-ATPases to the phagosomal membrane, the pH would be expected to be near neutral, This prediction was tested by microfluorescence ratio imaging using macrophages from mice susceptible to mycobacterial infection, Although less acidic than their counterparts containing dead bacteria, phagosomes containing live Mycobacteria bovis were nearly 1 pH unit more acidic than the cytosol, suggesting the existence of alternate H+ transport mechanisms, We there fore investigated whether Na+/H+ exchange (NHE) contributes to phagosomal acidification, Immunoblotting, reverse transcriptase-polymerase chain reaction, and pharmacological studies indicated that NHE1 is the predominant isoform of the exchanger in macrophages. Fractionation revealed that NHE1 is incorporated into the phagosomal membrane, and measurements of pH indicated that it is functional in this location, Nevertheless, acidification of the lumen of phagosomes containing either latex beads or live M. bovis was insensitive to (3-methylsulfonyl-4-piperidinobenzoyl)-guanidine methanesulfonate, a potent inhibitor of NHE1, This may have been due to the absence of an appropriate lumen to cytosol Na+ gradient, because the phagosomal membrane was found to be devoid of Na+/K+ pumps, Unexpectedly, the acidification of M. bovis phagosomes was fully reversed by specific inhibitors of the vacuolar H+-ATPase, suggesting that ATPases are present only transiently or in reduced quantities in the phagosomal membrane, Alternatively, acid equivalents accumulated in endosomes by V-ATPases may be delivered to the mycobacterial phagosome by carrier vesicles devoid of ATPases.	UNIV TORONTO, DIV CELL BIOL, HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO HOSP, DEPT SURG, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto				Hackam, David/0000-0001-5195-8807; Demaurex, Nicolas/0000-0002-9933-6772				ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BOUVIER G, 1994, J LEUKOCYTE BIOL, V55, P729, DOI 10.1002/jlb.55.6.729; Brisseau GF, 1996, J BIOL CHEM, V271, P2005, DOI 10.1074/jbc.271.4.2005; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; FORGET A, 1981, INFECT IMMUN, V32, P42, DOI 10.1128/IAI.32.1.42-47.1981; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GRINSTEIN S, 1986, AM J PHYSIOL, V250, pC283, DOI 10.1152/ajpcell.1986.250.2.C283; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; Hackam DJ, 1996, ARCH SURG-CHICAGO, V131, P1296; Hackam DJ, 1996, SHOCK, V5, P17, DOI 10.1097/00024382-199601000-00005; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hackam DJ, 1996, J IMMUNOL, V156, P4377; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNE AA, 1991, FEBS LETT, V284, P219, DOI 10.1016/0014-5793(91)80689-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS GL, 1990, J BIOL CHEM, V265, P21099; LUTZ DA, 1993, ANAL BIOCHEM, V214, P205, DOI 10.1006/abio.1993.1478; NANDA A, 1992, J BIOL CHEM, V267, P22740; Oh YK, 1996, INFECT IMMUN, V64, P319, DOI 10.1128/IAI.64.1.319-325.1996; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; Russell DG, 1996, J IMMUNOL, V156, P4764; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SIPE DM, 1991, J BIOL CHEM, V266, P3469; STEINBERG TH, 1994, METHOD ENZYMOL, V236, P147; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TEIXEIRA HC, 1995, IMMUNOL LETT, V46, P15, DOI 10.1016/0165-2478(95)00009-T; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; TSE CM, 1993, J BIOL CHEM, V268, P11917; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; XU SM, 1994, J IMMUNOL, V153, P2568; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	57	122	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29810	29820		10.1074/jbc.272.47.29810	http://dx.doi.org/10.1074/jbc.272.47.29810			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368053	hybrid			2022-12-25	WOS:A1997YG64700063
J	Bendall, HH; Scherer, DC; Edson, CR; Ballard, DW; Oltz, EM				Bendall, HH; Scherer, DC; Edson, CR; Ballard, DW; Oltz, EM			Transcription factor NF-kappa B regulates inducible Oct-2 gene expression in precursor B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL DIFFERENTIATION; PROTEIN; ACTIVATION; DEFECTS; DOMAIN	The POU transcription factors Oct-1 and Oct-2 regulate the activity of octamer-dependent promoters, including those that direct transcription from rearranged immunoglobulin genes, Unlike Oct-1, which is constitutively expressed in many cell types, Oct-2 expression is restricted primarily to B lymphocytes and can be induced in precursor B cells by stimulation with bacterial Lipopolysaccharide (LPS), However, the precise factors that mediate this induction mechanism remain unknown. In the present study, we monitored Oct-2; expression in cells arrested for the activation of NF-kappa B, an LPS-responsive member of the Rel transcription factor family. Despite stimulation with LPS, disruption of the NF-kappa B signaling pathway in precursor B cells led to the loss of inducible Oct-2 DNA binding activity in vitro and the suppression of Oct-2-directed transcription in vivo. This biochemical defect correlated with a specific block to Oct-2 gene expression at the level of transcription, whereas the expression of Oct-1 was unaffected. The finding that Oct-2 is under NF-kappa B control highlights an important cross-talk mechanism involving two distinct transcription factor families that regulate B lymphocyte function.	VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University					NIAID NIH HHS [AI01412, AI36944, AI33839] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036944, R21AI036944, R01AI033839] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BAUERLE PA, 1988, SCIENCE, V242, P540; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; GSTAIGER M, 1995, NATURE, V373, P60; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KEMLER I, 1990, FASEB J, V4, P1444, DOI 10.1096/fasebj.4.5.2407588; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; OBrien DP, 1997, MOL CELL BIOL, V17, P3477, DOI 10.1128/MCB.17.7.3477; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0	22	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28826	28828		10.1074/jbc.272.46.28826	http://dx.doi.org/10.1074/jbc.272.46.28826			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360945				2022-12-25	WOS:A1997YF68400004
J	DaSilva, J; Pierrat, B; Mary, JL; Lesslauer, W				DaSilva, J; Pierrat, B; Mary, JL; Lesslauer, W			Blockade of p38 mitogen-activated protein kinase pathway inhibits inducible nitric-oxide synthase expression in mouse astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; INFLAMMATORY CYTOKINES; FACTOR RECEPTORS; MAMMALIAN-CELLS; MAPKAP KINASE-2; MESSENGER-RNA; MICE LACKING; TNF RECEPTOR; STRESS	Treatment of mouse astrocyte cultures with combined interleukin (IL)-1 alpha and tumor necrosis factor (TNF)-alpha induced expression of inducible nitric-oxide synthase (iNOS), resulting in sustained release of large amounts of nitric oxide, whereas TNF-alpha and IL-1 alpha individually were unable to induce iNOS expression in astrocytes. The role of MAPK cascades and of NF-kappa B activation in the early intracellular signal transduction involved in iNOS transcription in TNF-alpha/IL-1 alpha-stimulated astrocytes was investigated. TNF-alpha and IL-1 alpha activated all p42/44(MAPK), p38(MAPK), and p54(JNK) pathways as determined by immunoprecipitation kinase assays using specific antibodies and substrates, The p38(MAPK) pathway is specifically involved in TNF-alpha/IL-1 alpha-induced iNOS expression, since iNOS protein and nitric oxide release in the presence of a specific inhibitor of p38(MAPK), 4-(4-fluorophenyl)-2 -2-(4-hydroxyphenyl)-5-(4-pyridyl)-imidazole (FHPI), were dramatically diminished. In contrast, PD98059, a specific inhibitor of MEK1 had no effect on iNOS expression, p38(MAPK) did not couple NF-kappa B to iNOS transcription, but NF-KB had a clear role in NOS transcription regulation, Northern blot analysis showed that the p38(MAPK) pathway controlled iNOS expression at the transcriptional level, since iNOS mRNA was reduced in the presence of FHPI in TNF-alpha/IL-1 alpha-stimulated astrocytes. iNOS expression was investigated with TNF receptor (TNFR)-1- and TNFR-2-deficient mice, The TNF-alpha activity in TNF-alpha/IL-1 alpha-stimulated astrocytes was exclusively mediated through TNFR-1, most likely because TNFR-2-mediated signals in astrocytes did not connect to the p38(MAPK) pathway. These data suggest that TNF-alpha/IL-1 alpha-induced iNOS expression depends on a yet undetermined second pathway in addition to p38(MAPK).			DaSilva, J (corresponding author), F HOFFMANN LA ROCHE & CO LTD,PRPN,DEPT CENT NERVOUS SYST DIS,CH-4070 BASEL,SWITZERLAND.							Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding MZ, 1997, J BIOL CHEM, V272, P11327; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EBERHARDT W, 1994, BIOCHEM BIOPH RES CO, V200, P163, DOI 10.1006/bbrc.1994.1429; Farivar RS, 1996, J BIOL CHEM, V271, P31585, DOI 10.1074/jbc.271.49.31585; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; FISCHER G, 1985, EXP CELL RES, V159, P273, DOI 10.1016/S0014-4827(85)80001-X; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heitmeier MR, 1997, J BIOL CHEM, V272, P13697, DOI 10.1074/jbc.272.21.13697; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; KANNO K, 1994, AM J PHYSIOL-HEART C, V267, pH2318, DOI 10.1152/ajpheart.1994.267.6.H2318; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; Kopnisky KL, 1997, J NEUROCHEM, V68, P935; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEIST M, 1995, J IMMUNOL, V154, P1307; Liu J, 1996, J IMMUNOL, V157, P3569; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nishiya T, 1997, FEBS LETT, V408, P33, DOI 10.1016/S0014-5793(97)00383-9; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ridley SH, 1997, J IMMUNOL, V158, P3165; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salkowski CA, 1997, J IMMUNOL, V158, P905; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Vieira LQ, 1996, J IMMUNOL, V157, P827; WANG X, 1996, SCIENCE, V272, P1247; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; XIE QW, 1994, J BIOL CHEM, V269, P4705; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	61	258	266	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28373	28380		10.1074/jbc.272.45.28373	http://dx.doi.org/10.1074/jbc.272.45.28373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353295	hybrid			2022-12-25	WOS:A1997YF21900035
J	Deloche, O; Liberek, K; Zylicz, M; Georgopoulos, C				Deloche, O; Liberek, K; Zylicz, M; Georgopoulos, C			Purification and biochemical properties of Saccharomyces cerevisiae Mdj1p, the mitochondrial DnaJ homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ATPASE ACTIVITY; INNER MEMBRANE; NMR STRUCTURE; J-DOMAIN; GRPE; BINDING; HSP70	The DnaK/DnaJ/GrpE heat shock proteins of Escherichia coli constitute the prototype DnaK chaperone machine. Various studies have shown that these three proteins work synergistically in a diverse array of biological functions, including protein folding and disaggregation, proteolysis, and transport across biological membranes, We have overexpressed and purified the mitochondrial Saccharomyces cerevisiae DnaJ homologue, Mdj1p Delta 55, which lacks the mitochondrial presequence, and studied its biochemical properties in well defined in vitro systems, We find that Mdj1p Delta 55 interacts with DnaK as judged both by an enzyme-linked immunosorbent assay, as well as stimulation of DnaK's weak ATPase activity in the presence of GrpE, In addition, Mdj1p Delta 55 not only interacts with denatured firefly luciferase on its own, but also enables DnaK to bind to it in an ATP-dependent mode, Using co-immunoprecipitation assays we can demonstrate the presence of a stable Mdj1p Delta 55-luciferase-DnaK complex. However, in contrast to DnaJ, Mdj1p Delta 55 does not appear to interact well with certain seemingly folded proteins, such as the sigma (32) heat shock transcription factor or the lambda P DNA replication protein, Finally, Mdj1p Delta 55 can substitute perfectly well for DnaJ in the refolding of denatured firefly luciferase by the DnaK chaperone machine. These studies demonstrate that Mdj1p Delta 55 has conserved most of DnacJ's known biological properties, thus supporting an analogous functional role in yeast mitochondria.	UNIV GDANSK, DEPT CELLULAR & MOL BIOL, PL-80822 GDANSK, POLAND	Fahrenheit Universities; University of Gdansk	Deloche, O (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1 RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.		Liberek, Krzysztof/F-5812-2011	Liberek, Krzysztof/0000-0002-7532-9279				Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; Deloche O, 1997, J BACTERIOL, V179, P6066, DOI 10.1128/jb.179.19.6066-6075.1997; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Pellecchia M, 1996, J MOL BIOL, V260, P236, DOI 10.1006/jmbi.1996.0395; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; WALL D, 1994, J BIOL CHEM, V269, P5446; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; Westermann B, 1996, MOL CELL BIOL, V16, P7063; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	36	20	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28539	28544		10.1074/jbc.272.45.28539	http://dx.doi.org/10.1074/jbc.272.45.28539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353316	hybrid			2022-12-25	WOS:A1997YF21900056
J	Glover, CJ; Hartman, KD; Felsted, RL				Glover, CJ; Hartman, KD; Felsted, RL			Human N-myristoyltransferase amino-terminal domain involved in targeting the enzyme to the ribosomal subcellular fraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MYRISTOYL-COA; DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BOVINE BRAIN; GENE-PRODUCT; RNA-BINDING; SUBSTRATE-SPECIFICITY; TRANSFERASE-ACTIVITY; CANDIDA-ALBICANS	N-Myristoyltransferase (NMT) catalyzes the cotranslational acylation with myristic acid of the NH2-terminal glycines of a number of cellular and viral proteins. Most of the in vitro NMT activity (60-85%) in isoosmotic cell homogenates of human lymphoblastic leukemia (i.e. CEM and MOLT-4) and cervical carcinoma (i.e. HeLa) cells was shown to be associated with the ribosomal subcellular fractions by differential centrifugation. Also found in the ribosomal fractions was a approximate to 60-kDa protein that was specifically immunoblotted with an anti-human NMT (hNMT) peptide antibody. This approximate to 60-kDa protein was stable in the presence of proteolytic enzyme inhibitors but was gradually converted into a approximate to 46-kDa species when stored in the absence of protease inhibitors. Sucrose density gradient centrifugation of the ribosomal fraction resulted in the hNMT activity sedimenting exactly coincident with the 260 nm absorption profile and exhibiting A(260)/A(260) absorption ratios >1.8, indicating an association of NMT with putative ribosomal particle (s)/subunit(s), The subcellular targeting of hNMT was also examined by immunoblotting subcellular fractions from HeLa cells transfected with plasmids containing FLAG epitope-tagged hNMT inserts corresponding either to the originally assigned hNMT gene or to an alternative open reading frame initiated from an in-frame start site upstream from the assumed hNMT start site. Anti-FLAG immunoblotting of cells transfected with a plasmid containing the larger insert revealed FLAG-NMT primarily in the ribosomal fraction with an apparent molecular mass similar to the approximate to 60-kDa native hNMT. In contrast, immunoblotting of cells transfected with a plasmid containing the smaller insert identified a approximate to 50-kDa FLAG-NMT predominantly in the cytosolic fraction. An analysis of mixtures of CEM ribosomes and serial dilutions of purified recombinant FLAG-NMTs demonstrated that the approximate to 60-kDa FLAG-NMT binds ribosomes with higher affinity than the approximate to 50-kDa FLAG-NMT. These in vivo and-in vitro subcellular targeting and recombinant expression experiments identify a native hNMT that is 10-12 kDa larger than the enzyme predicted by the originally assigned hNMT gene and which is apparently translated from an alternative up stream start site. The data also indicate that although the unique NH2-terminal residues encoded by this larger open reading frame are not required for in vitro catalytic activity, they do provide signal(s) involved in targeting hNMT to the ribosomal subcellular fraction where cotranslational N-myristoylation occurs.			Glover, CJ (corresponding author), NCI,PHARMACOL & EXPT THERAPEUT SECT,NIH,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,FREDERICK,MD 21702, USA.							AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BHARUCHA AD, 1992, METHOD ENZYMOL, V216, P168; Borgese N, 1996, J CELL BIOL, V135, P1501, DOI 10.1083/jcb.135.6.1501; BOUTIN JA, 1991, EUR J BIOCHEM, V201, P257, DOI 10.1111/j.1432-1033.1991.tb16282.x; BOUTIN JA, 1993, EUR J BIOCHEM, V214, P853, DOI 10.1111/j.1432-1033.1993.tb17989.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FELSTED RL, 1995, J NATL CANCER I, V87, P1571, DOI 10.1093/jnci/87.21.1571; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GLOVER CJ, 1988, BIOCHEM J, V250, P485, DOI 10.1042/bj2500485; GLOVER CJ, 1995, J BIOL CHEM, V270, P23226, DOI 10.1074/jbc.270.39.23226; GLOVER CJ, 1991, BIOCHEM PHARMACOL, V41, P1067, DOI 10.1016/0006-2952(91)90215-Q; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GRAHAM JM, 1993, BIOMEMBRANE PROTOCOL, V19, P1; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KING MJ, 1992, MOL CELL BIOCHEM, V113, P77; KING MJ, 1991, FASEB J, V5, pA1157; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KNOLL LJ, 1995, METHOD ENZYMOL, V250, P405; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODGE JK, 1994, J BIOL CHEM, V269, P2996; MAGNUSON BA, 1995, J NATL CANCER I, V87, P1630, DOI 10.1093/jnci/87.21.1630; Magnuson BA, 1996, BBA-LIPID LIPID MET, V1300, P119, DOI 10.1016/0005-2760(95)00240-5; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MCILHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137, DOI 10.1111/j.1432-1033.1994.tb18851.x; MCILHINNEY RAJ, 1993, BIOCHEM J, V290, P405, DOI 10.1042/bj2900405; McIlhinney RAJ, 1996, EXP CELL RES, V223, P348, DOI 10.1006/excr.1996.0090; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NOLL H, 1967, NATURE, V215, P360, DOI 10.1038/215360a0; Ntwasa M, 1997, J CELL SCI, V110, P149; OLSON EN, 1986, J BIOL CHEM, V261, P2458; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; RAJU RVS, 1995, MOL CELL BIOCHEM, V149, P191, DOI 10.1007/BF01076577; Raju RVS, 1996, MOL CELL BIOCHEM, V155, P69, DOI 10.1007/BF00714335; RAJU RVS, 1994, J BIOL CHEM, V269, P12080; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; ROCQUE WJ, 1993, J BIOL CHEM, V268, P9964; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; STEENSGAARD J, 1970, EUR J BIOCHEM, V16, P66, DOI 10.1111/j.1432-1033.1970.tb01054.x; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VANDERZEIJST BAM, 1975, HDB BIOCH MOL BIOL, V1, P426; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Watanabe Y, 1996, BIOCHEMISTRY-US, V35, P562, DOI 10.1021/bi951703+; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; Wu SY, 1996, BIOCHEMISTRY-US, V35, P8275, DOI 10.1021/bi953028+; WU SY, 1993, J BIOL CHEM, V268, P10796; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; YU G, 1992, VIROLOGY, V187, P46, DOI 10.1016/0042-6822(92)90293-X; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792; Zwerner R K, 1979, Methods Enzymol, V58, P221	78	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28680	28689		10.1074/jbc.272.45.28680	http://dx.doi.org/10.1074/jbc.272.45.28680			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353336	hybrid			2022-12-25	WOS:A1997YF21900076
J	Mehta, DP; Etchison, JR; Wu, RR; Freeze, HH				Mehta, DP; Etchison, JR; Wu, RR; Freeze, HH			UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase from Dictyostelium discoideum recognizes serine-containing peptides and eukaryotic cysteine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; LINKED OLIGOSACCHARIDES; IDENTIFICATION; GLYCOSYLATION; SPECIFICITY; PHOSPHORYLATION; PURIFICATION; TRANSFERASE; ANALOGS; GALNAC	Phosphoglycosylation catalyzed by UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase (Ser:GlcNAc phosphotransferase) adds GlcNAc alpha-1-P to peptidyl-Ser of selected Dictyostelium discoideum proteins, Lysosomal cysteine proteinase (CP), proteinase-1(CP7), is the major phosphoglycosylated protein in bacterially grown amoebae. GlcNAc-1-P is added within a Ser-rich domain containing SSS, SGSG, or SGSQ repeated motifs that are not found in other papain-like CPs, We studied the substrate specificity. of the transferase using peptides containing these motifs and 12 other peptides with one or more Ser residues, Phosphoglycosylation is comparable for all three Dictyostelium CP motifs, but it is not restricted to them, Flanking residues in the other peptides strongly influence phosphoglyco, sylation efficiency, Dictyostelium microsomal membranes also phosphoglycosylate endogenous accepters, and some of these accepters occur as an 18 S complex with the transferase, CP-serine motif peptides inhibit endogenous acceptor phosphoglycosylation weakly (30-40%) at 800 mu M, whereas catalytically inactive proteinase-1(CP7) and other non-phosphoglycosylated eukaryotic CPs, lacking the serine domain, inhibit transferase activity at 1-4 mu M. SDS denaturation destroys the inhibitory potential of all CPs showing that transferase recognizes a conformation-dependent feature that is shared by all, Proteinase-1(CP7) expressed in Escherichia coli lacks GlcNAc-1-P, but it is a substrate for Ser:GlcNAc phosphotransferase, K-m = 5.6 mu M. Thus, Ser: GlcNAc phosphotransferase recognizes both acceptor peptide sequences and a conformational feature of eukaryotic CPs, This may be physiologically important for establishing or maintaining non-overlapping groups of GlcNAc-1-P- and Man-6-P-modified Dictyostelium proteins that reside in functionally distinct endo-lysosomal vesicles.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	PHS HHS [R01 32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1994, FASEB J, V8, P1019, DOI 10.1096/fasebj.8.13.7926366; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Capasso JM, 1996, BBA-BIOMEMBRANES, V1281, P15, DOI 10.1016/0005-2736(95)00298-7; DAWSON RMC, 1986, DATA BIOCH RES, P485; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Etchison JR, 1996, GLYCOBIOLOGY, V6, P177, DOI 10.1093/glycob/6.2.177; FREEZE HH, 1992, J BIOL CHEM, V267, P4431; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1997, NEW COMPREHENSIVE BI, V29, P91; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MAEDA K, 1971, J ANTIBIOT, V24, P402, DOI 10.7164/antibiotics.24.402; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; Ord T, 1997, ARCH BIOCHEM BIOPHYS, V339, P64, DOI 10.1006/abbi.1996.9870; RITONJA A, 1989, FEBS LETT, V247, P419, DOI 10.1016/0014-5793(89)81383-3; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Souza GM, 1997, J CELL SCI, V110, P2239; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28638	28645		10.1074/jbc.272.45.28638	http://dx.doi.org/10.1074/jbc.272.45.28638			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353330	hybrid			2022-12-25	WOS:A1997YF21900070
J	Oluwatosin, YE; Kane, PM				Oluwatosin, YE; Kane, PM			Mutations in the CYS4 gene provide evidence for regulation of the yeast vacuolar H+-ATPase by oxidation and reduction in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; CYSTATHIONINE BETA-SYNTHASE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CYSTEINE BIOSYNTHESIS; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SHUTTLE VECTORS; ENZYME COMPLEX; ACIDIFICATION	The vma41-1 mutant was identified in a genetic screen designed to identify novel genes required for vacuolar H+-ATPase activity in Saccharomyces cerevisiae. The VMA41 gene was cloned and shown to be allelic to the CYS4 gene, The CYS4 gene encodes the first enzyme: in cysteine biosynthesis, and in addition to cysteine auxotrophy, cys4 mutants have much lower levels of intracellular glutathione than wild-type cells. cys4 mutants display the pH-dependent growth phenotypes characteristic of vma mutants and are unable to accumulate quinacrine in the vacuole, indicating loss of vacuolar acidification in vivo. The vacuolar proton-translocating ATPases (V-ATPase) is synthesized at normal levels and assembled at the vacuolar membrane in cys4 mutants, but its specific activity is reduced (47% of wild type) and the activity is unstable. Addition of reduced glutathione to the growth medium complements the pH-dependent growth phenotype, partially restores vacuolar acidification, and restores wild type levels of ATPase activity. The CYS4 gene was deleted in a strain in which the catalytic site cysteine residue implicated in oxidative inhibition of the yeast V-ATPase has been mutagenized (Liu, Q., Leng, X.-H., Newman, P., Vasilyeva, E., Kane, P. M., and Forgac, M. (1997) J. Biol. Chem. 272, 11750-11756). This catalytic site point mutation suppresses the effects of the cys4 mutation. The data indicate that the acidification defect of cys4 mutants arises from inactivation of the vacuolar ATPase in the less reducing cytosol resulting from loss of Cys4p activity and provide the first evidence for the modulation of V-ATPase activity by the redox state of the environment in vivo.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIGMS NIH HHS [R01 GM050322, R01-GM50322] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Chaudhuri B, 1997, GENETICS, V145, P75; CHEREST H, 1993, J BACTERIOL, V175, P5366, DOI 10.1128/JB.175.17.5366-5374.1993; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KLAPHOLZ S, 1982, GENETICS, V100, P387; KRUGER WD, 1994, P NATL ACAD SCI USA, V91, P6614, DOI 10.1073/pnas.91.14.6614; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; ONO B, 1992, CURR GENET, V21, P285, DOI 10.1007/BF00351684; ONO BI, 1988, J BACTERIOL, V170, P5883, DOI 10.1128/jb.170.12.5883-5889.1988; PASZEWSKI A, 1992, CURR GENET, V22, P273, DOI 10.1007/BF00317920; RANDOLPH E, 1992, BIOTECHNIQUES, V13, P18; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	57	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28149	28157		10.1074/jbc.272.44.28149	http://dx.doi.org/10.1074/jbc.272.44.28149			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346971	hybrid			2022-12-25	WOS:A1997YD47300097
J	Souchelnytskyi, S; Tamaki, K; Engstrom, U; Wernstedt, C; tenDijke, P; Heldin, CH				Souchelnytskyi, S; Tamaki, K; Engstrom, U; Wernstedt, C; tenDijke, P; Heldin, CH			Phosphorylation of Ser(465) and Ser(467) in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASE RECEPTORS; MAD-RELATED PROTEIN; TGF-BETA; ACTS DOWNSTREAM; FAMILY SIGNALS; I RECEPTORS; COMPLEX; MOTHERS; ACTIVIN; DPP	Members of the Smad family of intracellular signal transducers are essential for transforming growth factor-beta (TGF-beta) to exert its multifunctional effects. After activation of TGF-beta receptors, Smad2 and Smad3 be come phosphorylated and form heteromeric complexes with Smad4. Thereafter, these activated Smad complexes translocate to the nucleus, where they may direct transcriptional responses, Here we report that TGF-beta mediates phosphorylation of Smad2 at two serine residues in the C terminus, i.e. Ser(465) and Ser(467), which are phosphorylated in an obligate order; phosphorylation of Ser(465) requires that Ser467 be phosphorylated. Transfection of Smad2 with mutation of Ser(465) and/or Ser(467) to alanine residues into Mv1Lu cells resulted in dominant-negative inhibition of TGF-beta signaling. These Smad2 mutants were found to stably interact with an activated TGF-beta receptor complex, in contrast to wild-type Smad2, which interacts only transiently, Mutation of Ser(465) and Ser(467) in Smad2 abrogated complex formation of this mutant with Smad4 and blocked the nuclear accumulation not only of Smad2, but also of Smad4. Thus, heteromeric complex formation of Smad2 with Smad4 is required for nuclear translocation of Smad4. Moreover, peptides from the C terminus of Smad2 containing phosphorylated Ser(465) and Ser467 were found to bind Smad4 in vitro, whereas the corresponding unphosphorylated peptides were less effective, Thus, phosphorylated Ser(465) and Ser(467) in Smad2 may provide a recognition site for interaction with Smad4, and phosphorylation of these sites is a key event in Smad2 activation.			Souchelnytskyi, S (corresponding author), LUDWIG INST CANC RES, BOX 595, S-75124 UPPSALA, SWEDEN.		Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/J-9446-2014; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276				Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LIN HY, 1993, TRENDS CELL BIOL, V11, P972; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	46	325	347	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28107	28115		10.1074/jbc.272.44.28107	http://dx.doi.org/10.1074/jbc.272.44.28107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346966	hybrid			2022-12-25	WOS:A1997YD47300092
J	Yamauchi, JJ; Nagao, M; Kaziro, Y; Itoh, H				Yamauchi, JJ; Nagao, M; Kaziro, Y; Itoh, H			Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors - Involvement of G beta gamma and G alpha(q/11) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; C-JUN KINASE; MAP KINASE; TRANSDUCTION PATHWAY; DEPENDENT ACTIVATION; REGULATED KINASE; ALPHA-SUBUNITS; MESSENGER-RNAS; CDNA CLONING; COS-7 CELLS	Various extracellular stimuli activate three classes of mitogen-activated protein kinases (MAPKs): extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 MAPK. In mammalian cells, p38 MAPK is activated by endotoxins, inflammatory cytokines, and environmental stresses, We show here that p38 MAPK is also activated upon stimulation of G protein-coupled receptors (G(q)/G(11)-coupled m1 and G(i)-coupled m2 muscarinic acetylcholine and G(s)-coupled beta-adrenergic receptors) in human embryonal kidney 293 cells. The activation of p38 MAPK through the m2 and beta-adrenergic receptors was completely inhibited by coexpression of G alpha(o), whereas the activation by the mi receptor was only partially inhibited. Furthermore, we show that overexpression of G beta gamma or a constitutively activated mutant of G alpha(11), but not G alpha(s) and G alpha(i), can stimulate p38 MAPK. These results suggest that the signal from the m2 and beta-adrenergic receptors to p38 MAPK is mediated by G beta gamma, whereas the signal from the m1 receptor is mediated by both G beta gamma and G alpha(q/11).	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FAURE M, 1994, J BIOL CHEM, V269, P7851; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUTHIN GR, 1984, MOL PHARMACOL, V26, P164; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PERELTA EG, 1987, EMBO J, V6, P3923; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SHREEVE SM, 1984, J BIOL CHEM, V259, P2398; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	62	126	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27771	27777		10.1074/jbc.272.44.27771	http://dx.doi.org/10.1074/jbc.272.44.27771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346921	hybrid			2022-12-25	WOS:A1997YD47300047
J	Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP				Isfort, RJ; Cody, DB; Doersen, CJ; Richards, WG; Yoder, BK; Wilkinson, JE; Kier, LD; Jirtle, RL; Isenberg, JS; Klounig, JE; Woychik, RP			The tetratricopeptide repeat containing Tg737 gene is a liver neoplasia tumor suppressor gene	ONCOGENE			English	Article						Tg737; tumor suppressor gene; liver neoplasia	POLYCYSTIC KIDNEY-DISEASE; STEM-CELLS; HUMAN HOMOLOG; SNAP HELIX; GROWTH; PROTEIN; DIFFERENTIATION; MUTATION; MOUSE; CARCINOGENESIS	The Tg737 gene was investigated for gross alterations in a series of rodent/human liver tumors and human tumorigenic cell lines. The Tg737 gene was found to be altered in approximately 40% of the rodent chemically-induced liver tumors, 40% of the human liver tumors, and in liver, kidney and pancreatic human tumor cell lines. Ectopic re-expression of the Tg737 gene in a Tg737 deleted mouse liver tumor cell line resulted in suppression of tumorigenic growth, without altering in vitro cell culture growth. Treatment of mice which are either homozygous normal or heterozygous deleted at the Tg737 locus with the carcinogen diethylnitrosamine resulted in an increase in preneoplastic foci formation in the Tg737 heterozygous deleted mice. Ectopic expression of the Tg737 gene results in multinucleated cells, loss of Tg737 gene expression results in the proliferation of liver stem cells (oval cells) without concomitant differentiation, and reexpression of the Tg737 gene reestablished responsiveness to external differentiation factors. We believe this is the first report demonstrating tumor suppression activity for a tetratricopeptide repeat gene family member and provides insights into the function of this family of genes in mammalian cells.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,SCH VET MED,KNOXVILLE,TN; MONSANTO AGR CO,ST LOUIS,MO; DUKE UNIV,MED CTR,DURHAM,NC; INDIANA UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,INDIANAPOLIS,IN 46202	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Monsanto; Duke University; Indiana University System; Indiana University-Purdue University Indianapolis	Isfort, RJ (corresponding author), PROCTER & GAMBLE CO,MIAMI VALLEY LABS,POB 398707,CINCINNATI,OH 45247, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732				ATERMAN K, 1992, J CANCER RES CLIN, V118, P87, DOI 10.1007/BF01187498; AVNER ED, 1994, LANCET, V344, P833, DOI 10.1016/S0140-6736(94)92820-7; Avner Ellis D., 1994, V5, P63; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; BRILL S, 1993, P SOC EXP BIOL MED, V204, P261; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; COLEMAN WB, 1993, AM J PATHOL, V142, P1373; FACTOR VM, 1994, AM J PATHOL, V145, P409; Fausto N, 1990, CURR OPIN CELL BIOL, V2, P1036, DOI 10.1016/0955-0674(90)90153-6; FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HENNINGS H, 1993, P SOC EXP BIOL MED, V202, P1; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; ISFORT R, 1987, ONCOGENE RES, V2, P81; ISFORT RJ, 1994, INT J CANCER, V59, P114, DOI 10.1002/ijc.2910590121; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; ISFORT RJ, 1997, IN PRESS J CELL SCI; ISFORT RJ, 1997, IN PRESS MOL CARCINO; KUMADA K, 1995, J CELL SCI, V108, P895; LEBOEUF RA, 1986, CARCINOGENESIS, V7, P1431, DOI 10.1093/carcin/7.9.1431; LILLEBERG SL, 1992, PROG CLIN BIOL RES, V376, P203; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; MARCEAU N, 1989, IN VITRO CELL DEV B, V25, P336; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; PUGH TD, 1992, CANCER RES, V52, P280; Richards WG, 1996, AM J PATHOL, V149, P1919; RICHARDS WG, 1997, IN PRESS HEPATOLOGY; RIJKSEN G, 1993, J CELL PHYSIOL, V154, P393, DOI 10.1002/jcp.1041540223; RUBIN H, 1993, DIFFERENTIATION, V53, P123, DOI 10.1111/j.1432-0436.1993.tb00652.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SELL S, 1993, INT J DEV BIOL, V37, P189; SELL S, 1994, LAB INVEST, V70, P6; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SORIANO P, 1991, CELL, V64, P692; THORGEIRSSON SS, 1993, AM J PATHOL, V142, P1331; WILLIAMS ED, 1992, AM J PATHOL, V141, P773	40	30	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1797	1803		10.1038/sj.onc.1201535	http://dx.doi.org/10.1038/sj.onc.1201535			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362446				2022-12-25	WOS:A1997XZ72500006
J	Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W				Sobczak, K; Kozlowski, P; Napierala, M; Czarny, J; Wozniak, M; Kapuscinska, M; Losko, M; Koziczak, M; Jasinska, A; Powierska, J; Braczkowski, R; Breborowicz, J; Godlewski, D; Mackiewicz, A; Krzyzosiak, W			Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from western Poland	ONCOGENE			English	Article						BRCA1; mutations and variants; SSCP-heteroduplex analysis; Polish women; positive family history	BREAST-CANCER SUSCEPTIBILITY; POLYMERASE CHAIN-REACTION; OVARIAN-CANCER; GERMLINE MUTATIONS; RAPID DETECTION; GENE; FAMILIES; P53; DNA; PCR	Three different novel BRCA1 mutations, five independent cases of the same 12 bp insertion-duplication in intron-20 and two novel rare BRCA1 sequence variants were identified among 122 Polish women with positive, in most cases moderate family history of breast and/or ovarian cancer, 80 controls and 34 unselected breast cancer tissue specimens, All mutations and variants were germline. The 4153 delA frameshift mutation, the Tyr105Cys missense mutation and two cases of the alteration in intron-20 were found in the group of healthy women with positive family history. Two other cases of the intronic insertion mere found in unselected controls. Their carriers had no family history of breast or ovarian cancer but other cancers occurred in their families. The 1782 Trp/STOP nonsense mutation and one case of the insertion in intron-20 were first found in tissue specimens of breast cancer patient and breast/ovarian cancer patient, respectively. Their carriers also had no family history of breast or ovarian cancer. The distribution of the insertion in intron-20 in analysed groups and results of RT-PCR experiments suggest a less prominent role for this variant considered earlier a splicing mutation. This study shows also, that more population-oriented research is needed, involving women with less profound or even no family history of breast and ovarian cancer, to better understand the role and significance of different BRCA1 variants and mutations.	POLISH ACAD SCI,INST BIOORGAN CHEM,CANC GENET LAB,PL-61704 POZNAN,POLAND; WIELKOPOLSKA CANC CTR,CANC EPIDEMIOL & PREVENT UNION,PL-61866 POZNAN,POLAND; SILESIAN UNIV,SCH MED,DEPT INTERNAL MED,BYTOM,POLAND; UNIV SCH MED SCI,CHAIR ONCOL,PL-61878 POZNAN,POLAND; UNIV SCH MED SCI,WIELKOPOLSKA CANC CTR,DEPT CANC IMMUNOL,PL-61866 POZNAN,POLAND	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Wielkopolskie Centrum Onkologii; Medical University Silesia; Wielkopolskie Centrum Onkologii			Kozlowski, Piotr/I-1860-2019; Woźniak, Marcin/F-2936-2013; Wozniak, Marcin/B-6319-2018	Kozlowski, Piotr/0000-0003-3770-7715; Woźniak, Marcin/0000-0003-4491-3824; Wozniak, Marcin/0000-0002-3213-229X; Sobczak, Krzysztof/0000-0001-8352-9812; Jasinska, Anna/0000-0002-1897-4570				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FRIEND S, 1995, NAT GENET, V11, P238, DOI 10.1038/ng1195-238; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; Johannsson O, 1996, AM J HUM GENET, V58, P441; Kozlowski P, 1996, NUCLEIC ACIDS RES, V24, P1177, DOI 10.1093/nar/24.6.1177; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P42; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SOBCZAK K, 1995, ACTA BIOCHIM POL, V42, P363; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THOMPSON WD, 1994, CANCER, V74, P279; Wagner TMU, 1996, LANCET, V347, P1263, DOI 10.1016/S0140-6736(96)90781-3; WOOSTER R, 1995, TRENDS GENET, V11, P3, DOI 10.1016/S0168-9525(00)88974-X; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; ZATONSKI WA, 1993, CANC POLAND	32	22	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1773	1779		10.1038/sj.onc.1201360	http://dx.doi.org/10.1038/sj.onc.1201360			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362443	Bronze			2022-12-25	WOS:A1997XZ72500003
J	Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB				Metcalfe, SM; Canman, CE; Milner, J; Morris, RE; Goldman, S; Kastan, MB			Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells	ONCOGENE			English	Article						rapamycin; p53; G1 arrest	ATAXIA-TELANGIECTASIA GENE; P34CDC2 KINASE ACTIVATION; CYCLE CHECKPOINT PATHWAY; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; PROTEIN-KINASE; MESSENGER-RNA; GROWTH ARREST; TARGET	Certain growth regulatory kinases contain domain related to the phospho-inositol 3 (PI-3) kinase catalytic site, These include the ATM gene product, DNA-PKcs, and the target of rapamycin (TOR in yeast: and FRAP in mammalian cells), Rapamycin inhibits growth factor signalling and induces G1 arrest in many cell types, Some growth regulatory PI-3 kinases appear functionally linked to p53 and we have explored potential links between cellular effects induced by rapamycin and p53. In p53 null cells rapamycin inhibited cell cycling but did not induce G1 arrest, In cells which showed selective G1 arrest in response to rapamycin, rapamycin had no effect on basal levels of p53 protein, Similarly p21(WAF1) protein,vas not induced by rapamycin, The kinetics of the cellular p53/p21(WAF1) response to ionising radiation was unaffected by rapamycin; and the ability of growth factor to protect against p53-mediated apoptosis in response to DNA damage was also unaffected by rapamycin. The ATM gene is mutated in the cancer susceptibility syndrome ataxia telangiectasia (AT) but such mutant cells showed a similar sensitivity to rapamycin compared to their normal counterparts, RKO cell lines of common genetic background, but with different levels of functional p53 protein, also responded similarly to rapamycin, Thus, although rapamycin and p53 are each able to induce G1 arrest, they appear to act through independent growth regulatory pathways.	JOHNS HOPKINS UNIV HOSP, CTR ONCOL, BALTIMORE, MD 21287 USA; UNIV YORK, YCRC P53 RES GRP, YORK YO1 5DD, N YORKSHIRE, ENGLAND; STANFORD UNIV, MED CTR,SCH MED,DEPT CARDIOTHORAC SURG, TRANSPLANTAT IMMUNOL LAB, STANFORD, CA 94305 USA	Johns Hopkins University; Johns Hopkins Medicine; University of York - UK; Stanford University	Metcalfe, SM (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT SURG, CAMBRIDGE CB2 2QQ, ENGLAND.			, Christine/0000-0001-8892-7430	NATIONAL CANCER INSTITUTE [R01CA061949, T32CA060441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005777, R37ES005777] Funding Source: NIH RePORTER; NCI NIH HHS [CA61949, T32CA60441] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BARBER NC, 1996, IN PRESS MOL BIOL CE; Beamish H, 1996, ONCOGENE, V13, P963; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CAO W, 1995, TRANSPLANTATION, V59, P390, DOI 10.1097/00007890-199502150-00014; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hollis CM, 1996, BIOCHEM SOC T, V24, pS66, DOI 10.1042/bst024066s; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; METCALFE S, 1991, TRANSPLANTATION, V51, P1318, DOI 10.1097/00007890-199106000-00039; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHI YF, 1995, CANCER RES, V55, P1982	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1635	1642		10.1038/sj.onc.1201341	http://dx.doi.org/10.1038/sj.onc.1201341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349496				2022-12-25	WOS:A1997XY63100002
J	Jia, YP; Patel, SS				Jia, YP; Patel, SS			Kinetic mechanism of GTP binding and RNA synthesis during transcription initiation by bacteriophage T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; REVERSE-TRANSCRIPTASE; NUCLEOTIDE; FLUORESCENCE; SEQUENCE; DYNAMICS; FIDELITY	We have used stopped-flow and rapid chemical quench-flow methods to investigate the kinetics of the early steps during transcription initiation by bacteriophage T7 RNA polymerase. Most promoters of T7 RNA polymerase initiate with two GTPs. The kinetics of GTP binding was investigated by monitoring the fluorescence changes resulting from GTP binding to polymerase and fluorescent 2-aminopurine-containing promoter DNA complex. Scheme 1 was determined from studies of T7 Phi 10 promoter at 25 degrees C, where (E.D)(n) represents the polymerase.DNA complex in different conformations. GTP(E) and GTP(I) represent the elongating and initiating GTP molecules incorporated at the +2 and +1 positions, respectively. Our studies show that GTP at the elongation site binds with at least 10-fold tighter affinity than the GTP at the initiation site, Two conformational changes were revealed upon GTP binding to the polymerase-2-aminopurine DNA complex. The first conformational change occurred upon GTP binding to the elongation site. This conformational change was reversible, and studies with partially melted DNA and incorrect NTPs suggested that it may represent a DNA melting and/or base pairing step. A second rate-limiting conformational change whose rate was same as the maximum rate of pppGpG synthesis occurred after two GTPs were bound. As with DNA polymerases, this rate-limiting conformational change probably occurs at each NMP incorporation event and may be involved in proper positioning of the initiation and the elongating GTPs within the polymerase active site to achieve efficient and accurate RNA synthesis.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University					NIGMS NIH HHS [GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Chamberlin M., 1982, ENZYMES, V15, P87; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FOX JJ, 1958, J AM CHEM SOC, V80, P1669, DOI 10.1021/ja01540a041; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P3271, DOI 10.1021/bi00227a015; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KATI WM, 1992, J BIOL CHEM, V267, P25988; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P322, DOI 10.1016/S0959-440X(96)80050-9; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; SEN R, 1993, BIOCHEM BIOPH RES CO, V195, P616, DOI 10.1006/bbrc.1993.2090; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; WARD DC, 1969, J BIOL CHEM, V244, P1228; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	25	46	47	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30147	30153		10.1074/jbc.272.48.30147	http://dx.doi.org/10.1074/jbc.272.48.30147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374495	hybrid			2022-12-25	WOS:A1997YH61300027
J	Lee, KJ; Suh, YA; Cho, YG; Cho, YS; Ha, GW; Chung, KH; Hwang, JH; Yun, YD; Lee, DS; Kim, CM; Sung, YC				Lee, KJ; Suh, YA; Cho, YG; Cho, YS; Ha, GW; Chung, KH; Hwang, JH; Yun, YD; Lee, DS; Kim, CM; Sung, YC			Hepatitis C virus E2 protein purified from mammalian cells is frequently recognized by E2-specific antibodies in patient sera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT CELLS; NEUTRALIZING ANTIBODIES; ENVELOPE GLYCOPROTEINS; EXPRESSED PROTEIN; NON-A; GENOME; PURIFICATION; CLEAVAGE; E1; OLIGOMERIZATION	The envelope protein of hepatitis C virus (HCV) is composed of two membrane-associated glycoproteins, E1 and E2. To obtain HCV E2 protein as a secretory form at a high level, we constructed a recombinant chinese hamster ovary (CHO) cell line expressing a C-terminal truncated E2 (E2t) fused to human growth hormone (hGH), CHO/hGHE2t. The hGHE2t fusion protein was purified from the culture supernatant using anti-hGH mAb affinity chromatography at approximately 80% purity. The purified hGHE2t protein appeared to be assembled into oligomers linked by intermolecular disulfide bond(s) when density gradient centrifugation and SDS-polyacrylamide gel electrophoresis were employed. When the purified fusion protein was used for testing its ability to bind to antibodies specific for HCV by enzyme-linked immunosorbent assay, the protein was recognized by antibodies in sera from 90% of HCV-positive patients. Treatment of hGHE2t protein by beta-mercapto-ethanol, but not by heat and SDS, significantly reduced its reactivity to the antibodies of patient sera, suggesting that intermolecular and/or intramolecular disulfide bonds are important for its ability to recognize its specific antibody and that the E2 protein contains discontinuous antigenic epitope(s).	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,CTR BIOFUNCT MOL,SCH ENVIRONM ENGN,POHANG 790784,SOUTH KOREA; KOREA GREEN CROSS CORP,YONGIN,KYUNGGI DO,SOUTH KOREA; MOGAM BIOTECHNOL RES INST,YONGIN,KYUNGGI DO,SOUTH KOREA; KOREA CANC CTR HOSP,SEOUL,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Green Cross Corporation; National Cancer Center - Korea (NCC)								ALLORE RJ, 1984, ANAL BIOCHEM, V137, P523, DOI 10.1016/0003-2697(84)90121-0; CHAKRABARTI S, 1990, VIROLOGY, V178, P134, DOI 10.1016/0042-6822(90)90386-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN DY, 1993, LANCET, V342, P933, DOI 10.1016/0140-6736(93)91983-S; CHO YG, 1993, MOL CELLS, V3, P195; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARADA S, 1995, J GEN VIROL, V76, P1223, DOI 10.1099/0022-1317-76-5-1223; HARLOW E, 1988, ANTIBODIES LAB MANUA, P561; HSU HH, 1993, HEPATOLOGY, V17, P763, DOI 10.1016/0270-9139(93)90149-H; HULST MM, 1993, J VIROL, V67, P5435, DOI 10.1128/JVI.67.9.5435-5442.1993; INOUE Y, 1992, J GEN VIROL, V73, P2151, DOI 10.1099/0022-1317-73-8-2151; JACOB AF, 1996, J GEN VIROL, V77, P1055; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANFORD RE, 1993, VIROLOGY, V197, P225, DOI 10.1006/viro.1993.1583; MATSUURA Y, 1994, VIROLOGY, V205, P141, DOI 10.1006/viro.1994.1629; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NISHIHARA T, 1993, GENE, V129, P207, DOI 10.1016/0378-1119(93)90270-D; OKAMOTO H, 1991, J GEN VIROL, V72, P2696; PACHL C, 1987, J VIROL, V61, P315, DOI 10.1128/JVI.61.2.315-325.1987; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; RHODES AD, 1994, J GEN VIROL, V75, P207, DOI 10.1099/0022-1317-75-1-207; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; RUMENAPF T, 1993, J VIROL, V67, P3288; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; SPAETE RR, 1992, VIROLOGY, V188, P819, DOI 10.1016/0042-6822(92)90537-Y; WEILAND E, 1990, J VIROL, V64, P3563, DOI 10.1128/JVI.64.8.3563-3569.1990; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989	38	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30040	30046		10.1074/jbc.272.48.30040	http://dx.doi.org/10.1074/jbc.272.48.30040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374479	hybrid			2022-12-25	WOS:A1997YH61300011
J	Lubin, IM; Healey, JF; Barrow, RT; Scandella, D; Lollar, P				Lubin, IM; Healey, JF; Barrow, RT; Scandella, D; Lollar, P			Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; HEMOPHILIA-A; ANTIBODIES; DOMAIN; PROTEINS; LOCALIZATION; FRAGMENTS; RESIDUES	Antibodies directed to the A2 domain of factor VIII (fVIII) are usually an important component of the polyclonal response in patients who have clinically significant inhibitory antibodies to fVIII. A major determinant of the A2 epitope has been located by homolog scanning mutagenesis using recombinant hybrid human/porcine fVIII molecules to a sequence bounded by Arg(484)-Ile(508) (Healey, J. F., Lubin, I. M., Nakai, H., Saenko, E. L., Hoyer, L. W., Scandella, D., and Lollar, P. (1995) J. Biol. Chem. 270, 14505-14509). Within this region, human residues Arg(484), Pro(485), Tyr(487), Ser(488), Arg(489), Pro(492), Val(495) Phe501, and Ile(508) differ from porcine fVIII. We stably expressed in mammalian cells nine active B-domainless human fVIII molecules containing single alanine substitutions at these sites. Their inhibition by a murine an ti-A2 monoclonal antibody, monoclonal antibody (mAb) 413, and by three A2-specific alloimmune and two A2-specific autoimmune human inhibitor plasmas was measured by the Bethesda assay. The inhibition of Arg(484) --> Ala, Tyr(487) --> Ala, Arg(489) --> Ala, and Arg(492) --> Ala by mAb413 was reduced by greater than 90% compared with wild-type, B-domainless human fVIII. mAb413 inhibited the most severely affected mutant, Arg(489) --> Ala, 0.01% as well as wild-type fVIII, For all five patient plasmas, the Tyr(487) --> Ala mutant displayed the greatest reduction in inhibition. The inhibition of the Tyr(487) --> Ala mutant by these antibodies ranged from 10% to 20% that of wild-type fVIII. The inhibition of the Ser(488) --> Ala, Arg(489) --> Ala, Pro(492) --> Ala, Val(495) --> Ala, Phe(501) --> Ala, and Ile(508) --> Ala mutants by most of the plasmas also was significantly reduced, In contrast, the Arg(484) --> Ala and Pro(485) --> Ala mutants were relatively unaffected. Thus, although mAb413 binds to the same region as human A2 inhibitors, it recognizes a different set of amino acid side chains. The side chains recognized by human A2 inhibitors appear to be similar, despite the differing immune settings that give rise to fVIII alloantibodies and autoantibodies.	EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; AMER RED CROSS, HOLLAND LAB, ROCKVILLE, MD 20855 USA	Emory University; American Red Cross					NHLBI NIH HHS [R01-HL46215, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046215, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; Bevington P. R., 1969, DATA REDUCTION ERROR; BRETTLER DB, 1989, ARCH INTERN MED, V149, P1381, DOI 10.1001/archinte.149.6.1381; Brettler DB, 1996, BAILLIERE CLIN HAEM, V9, P319, DOI 10.1016/S0950-3536(96)80066-7; Cohen AJ, 1996, BAILLIERE CLIN HAEM, V9, P331, DOI 10.1016/S0950-3536(96)80067-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FIKSSIGAUD M, 1993, VOX SANG, V64, P210, DOI 10.1111/j.1423-0410.1993.tb03057.x; FULCHER CA, 1985, P NATL ACAD SCI USA, V82, P7728, DOI 10.1073/pnas.82.22.7728; Hay C, 1995, ADV EXP MED BIOL, V386, P143; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; JIN L, 1994, PROTEIN SCI, V3, P2351, DOI 10.1002/pro.5560031219; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KERNOFF PBA, 1984, FACTOR 8 INHIBITORS, P207; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; MORRISON AE, 1993, BLOOD, V81, P1513; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1993, BLOOD, V82, P1767; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; Shulman N R, 1969, Trans Assoc Am Physicians, V82, P388; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; Zhong D., 1996, Blood, V88, p324A	38	45	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30191	30195		10.1074/jbc.272.48.30191	http://dx.doi.org/10.1074/jbc.272.48.30191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374501	hybrid			2022-12-25	WOS:A1997YH61300033
J	Gilberger, TW; Walter, RD; Muller, S				Gilberger, TW; Walter, RD; Muller, S			Identification and characterization of the functional amino acids at the active site of the large thioredoxin reductase from Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART LIPOAMIDE DEHYDROGENASE; 2-ELECTRON REDUCED ENZYME; ESCHERICHIA-COLI; GLUTATHIONE-REDUCTASE; DIRECTED MUTAGENESIS; PIG-HEART; DIFFERENTIAL REACTIVITY; CATALYTIC MECHANISM; DISULFIDE; SEQUENCE	The thioredoxin system, composed of the pyridine nucleotide disulfide oxidoreductase thioredoxin reductase, the small peptide thioredoxin, and NADPH as a reducing cofactor, is one of the major thiol-reducing systems of the cell, Recent studies revealed that Plasmodium falciparum and human thioredoxin reductase represent a novel class of enzymes, called large thioredoxin reductases, The large thioredoxin reductases are substantially different from the isofunctional prokaryotic Escherichia coli enzyme, The putative essential amino acids at the catalytic center of large thioredoxin reductase from P, falciparum were determined by using site-directed mutagenesis techniques, To analyze the putative active site cysteines (Cys(88) and Cys(93)) three mutant proteins were constructed substituting alanine or serine residues for cysteine residues, Further, to evaluate the function of His(509) as a putative proton donor/acceptor of large thioredoxin reductase this residue was replaced by either glutamine or alanine, All mutants were expressed in the E. coli system and characterized, Steady state kinetic analysis revealed that the replacement of Cys(88) by either alanine or serine and Cys(93) by alanine resulted in a total loss of enzymatic activity, These results clearly identify Cys(88) and Cys(93) as the active site thiols of large thioredoxin reductase. The replacement of His(509) by glutamine yielded in a 95% loss of thioredoxin reductase activity; replacement by alanine provoked a loss of 97% of enzymatic activity, These results identify His(509) as active site base, but imply that its function can be substituted, although inefficiently, by an alternative proton donor, similar to glutathione reductase, Spectral analysis of wild type P, falciparum thioredoxin reductase revealed a 550-nm absorption band upon reduction which resembles the EH2 form of glutathione reductase and lipoamide dehydrogenase. This spectral feature, recently also reported for the human placenta protein (Arscott, L, D,, Gromer, S,, Schirmer, R, H., Becker K., and Williams, C, H., Jr, (1997) PI oc. Natl, Acad. Sci, U, S, A, 94, 3621-3626), further illustrates the similarity between large thioredoxin reductases and glutathione reductases and stresses the profound differences to small E, coli thioredoxin reductase.	BERNHARD NOCHT INST TROP MED, D-20359 HAMBURG, GERMANY	Bernhard Nocht Institut fur Tropenmedizin				Gilberger, Tim-Wolf/0000-0002-7965-8272				ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; DEONARAIN MP, 1990, P ROY SOC B-BIOL SCI, V241, P179, DOI 10.1098/rspb.1990.0083; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; DISTEFANO MD, 1989, BIOCHEMISTRY-US, V28, P1168, DOI 10.1021/bi00429a035; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Muller S, 1995, MOL BIOCHEM PARASIT, V74, P11, DOI 10.1016/0166-6851(95)02476-X; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; MULROONEY SB, 1994, BIOCHEMISTRY-US, V33, P3148, DOI 10.1021/bi00177a002; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; PAI EF, 1983, J BIOL CHEM, V258, P1752; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; SAHLMAN L, 1984, J BIOL CHEM, V259, P2403; Sambrook J., 1989, MOL CLONING LAB MANU, V2; THORPE C, 1976, J BIOL CHEM, V251, P3553; THORPE C, 1981, BIOCHEMISTRY-US, V20, P1507, DOI 10.1021/bi00509a015; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Wang PF, 1996, BIOCHEMISTRY-US, V35, P4812, DOI 10.1021/bi9526793; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; ZANETTI G, 1967, J BIOL CHEM, V242, P5232	31	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29584	29589		10.1074/jbc.272.47.29584	http://dx.doi.org/10.1074/jbc.272.47.29584			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368022	hybrid			2022-12-25	WOS:A1997YG64700032
J	Kim, J; Kemper, B				Kim, J; Kemper, B			Phenobarbital alters protein binding to the CYP2B1/2 phenobarbital-responsive unit in native chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; RAT-LIVER; TRANSCRIPTIONAL REGULATION; CYTOCHROME-P450 GENES; INDUCTION; SEQUENCE; PROMOTER; COMMON; INVIVO; RNAS	Phenobarbital is a classical inducer of the drug metabolizing cytochrome P450 genes, but the molecular mechanism of induction has not been elucidated, Functional analyses have identified a phenobarbital-responsive unit in the rat CYP2B1/2 and mouse Cyp2b10 genes about -2.3 kilobase pairs from the transcriptional start site, but little or no changes in protein binding to this region were observed in vitro, To examine the role of chromatin structure, protein binding to the phenobarbital-responsive unit assessed by in vitro DNase I footprinting was compared with that assessed by DNase I in vivo footprints in native chromatin, A region centered on a putative nuclear factor-1 site was the major protected region in in vitro footprints, and there were no detectable differences in binding between extracts from control and phenobarbital-treated animals. In contrast, phenobarbital treatment dramatically altered the protection pattern in native chromatin. In control samples a core region of about 25 base pairs (bp) centered on the nuclear factor-1 site was protected, However, after phenobarbital treatment, the protection of this core region was increased, and more dramatically the region of protection was extended 20 bp to either side so that a total of about 60 bp were protected. These results provide the first evidence that phenobarbital treatment alters the composition or architecture of proteins binding to the phenobarbital-responsive unit region and indicate that chromatin structure is important in this process, Because proteins are bound to the region in the untreated animal, the mechanism of induction involves the activation of proteins bound to the region and possibly recruitment of additional regulatory proteins rather than conversion of a closed chromatin structure to an open one that can bind regulatory factors.	UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; CHEN D, 1994, J BIOL CHEM, V269, P5420; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HE JS, 1991, J BIOL CHEM, V266, P7864; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Honkakoski P, 1997, J BIOL CHEM, V272, P14943, DOI 10.1074/jbc.272.23.14943; KIM J, 1991, BIOCHEMISTRY-US, V30, P10287, DOI 10.1021/bi00106a029; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Park YK, 1996, J BIOL CHEM, V271, P23725, DOI 10.1074/jbc.271.39.23725; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; REMMER H, 1958, NATURWISSENSCHAFTEN, V45, P189, DOI 10.1007/BF00621338; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811	23	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29423	29425		10.1074/jbc.272.47.29423	http://dx.doi.org/10.1074/jbc.272.47.29423			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367997	hybrid			2022-12-25	WOS:A1997YG64700007
J	Liu, Y; Watanabe, H; Nifuji, A; Yamada, Y; Olson, EN; Noda, M				Liu, Y; Watanabe, H; Nifuji, A; Yamada, Y; Olson, EN; Noda, M			Overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression in osteoblastic osteosarcoma ROS17/2.8 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOD FAMILY; DNA-BINDING; PROTEIN; RNA; OSTEOPONTIN; MYOGENESIS; FRAGMENTS; SEQUENCE	Cell differentiation is determined by a certain set of transcription factors such as MyoD in myogenesis, However, transcription factors that play a positive role in phenotypic gene expression in skeletal cells are largely unknown, except the recently identified CBFA1. Scleraxis is a helix-loop-helix-type transcription factor whose transcripts are expressed in sclerotome and in a certain set of skeletal cells; however, nothing is known about its function with regard to the regulation of cell function, To examine possible roles of scleraxis, we overexpressed scleraxis in osteoblastic ROS17/2.8 cells, which express low levels of scleraxis, Scleraxis overexpression enhanced expression of the aggrecan gene, which is not normally expressed at high levels in these osteoblastic cells, Overexpression of scleraxis also increased mRNA levels of type II collagen and osteopontin while suppressing expression of osteoblast phenotype-related genes encoding type I collagen and alkaline phosphatase, Transient transfection experiments indicated that scleraxis enhanced the chloramphenicol acetyltransferase activity of the reporter construct AgCAT-8, which contained an 8-kilobase pair (kb) fragment of the aggrecan gene including both the promoter and its first intron, Deletion analysis identified a 1-kb region that is responsive to scleraxis within the aggrecan gene, This region contains two adjacent E-box sequences, A 29-base pair DNA fragment (AgE) containing these E-box sequences bound to proteins in the ROS17/2.8 cell nuclear extracts as well as to in vitro translated scleraxis, This binding was competed with unlabeled AgE, but not with a mutated E-box DNA sequence (mAgE), indicating the specificity of the binding activity, The AgE binding activity in the ROS17/2.8 cell nuclear extracts was enhanced in the cells overexpressing scleraxis and was supershifted by the antiserum raised against scleraxis, Furthermore, AgE, but not mAgE, conferred responsiveness to scleraxis overexpression to a heterologous promoter, Finally, replacement mutation of the AgE sequence within the 2.5-kb AgCAT-1 construct significantly reduced its responsiveness to scleraxis, These results indicate that overexpression of a single helix-loop-helix-type transcription factor, scleraxis, enhances aggrecan gene expression via binding to the E box-containing AgE sequence in ROS17/2.8 cells.	TOKYO MED & DENT UNIV,MED RES INST,DIV FUNCT DISORDER RES,DEPT MOL PHARMACOL,CHIYODA KU,TOKYO 101,JAPAN; NIDR,MOL BIOL SECT,NIH,BETHESDA,MD 20892; UNIV TEXAS,SW MED CTR,HARMON CTR BASIC RES CANC,DALLAS,TX 75235	Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIES J, 1980, AM J TROP MED HYG, V29, P1089, DOI 10.4269/ajtmh.1980.29.1089; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P144; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Liu Y, 1996, J ENDOCRINOL, V151, P491, DOI 10.1677/joe.0.1510491; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; SIDDHANTI SR, 1994, J CELL BIOCHEM, V55, P310, DOI 10.1002/jcb.240550307; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	29	61	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29880	29885		10.1074/jbc.272.47.29880	http://dx.doi.org/10.1074/jbc.272.47.29880			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368062	hybrid			2022-12-25	WOS:A1997YG64700072
J	Nielsen, LB; McCormick, SPA; Pierotti, V; Tam, C; Gunn, MD; Shizuya, H; Young, SG				Nielsen, LB; McCormick, SPA; Pierotti, V; Tam, C; Gunn, MD; Shizuya, H; Young, SG			Human apolipoprotein B transgenic mice generated with 207- and 145-kilobase pair bacterial artificial chromosomes - Evidence that a distant 5'-element confers appropriate transgene expression in the intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; BINDING-PROTEIN GENE; HORMONE FUSION GENES; AMINO-ACID SEQUENCE; CIS-ACTING ELEMENTS; BETA-GLOBIN GENE; GUT EPITHELIUM; TYROSINASE GENE; COMPLETE CDNA; HIGH-LEVEL	We reported previously that similar to 80-kilobase pair (kb) P1 bacteriophage clones spanning either the human or mouse apoB gene (clones p158 and p649, respectively) confer apoB expression in the liver of transgenic mice, but not in the intestine, We hypothesized that the absence of intestinal expression was due to the fact that these clones lacked a distant DNA element controlling intestinal expression, To test this possibility, transgenic mice were generated with 145- and 207-kb bacterial artificial chromosomes (BACs) that contained the human apoB gene and more extensive 5'- and 3'-flanking sequences, RNase protection, in situ hybridization, immunohistochemical, and genetic complementation studies revealed that the BAC transgenic mice manifested appropriate apoB gene expression in both the intestine and the liver, indicating that both BACs contained the distant intestinal element, To determine whether the regulatory element was located 5' or 3' to the apoB gene, transgenic mice were generated by co-microinjecting embryos with p158 and either the 5'- or 3'-sequences from the 145-kb BAG. Analysis of these mice indicated that the apoB gene's intestinal element is located 5' to the structural gene, Cumulatively, the transgenic mouse studies suggest that the intestinal element is located between -33 and -70 kb 5' to the apoB gene.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; CALTECH,DIV BIOL,PASADENA,CA 91125	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Institute of Technology	Nielsen, LB (corresponding author), UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 419100,SAN FRANCISCO,CA 94141, USA.			Gunn, Michael/0000-0003-4602-0667; Tam-Amersdorfer, Carmen/0000-0003-3123-6342; Young, Stephen/0000-0001-7270-3176; McCormick, Sally/0000-0001-9857-0703	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHEN SH, 1986, J BIOL CHEM, V261, P2918; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; ECCLES S, 1990, New Biologist, V2, P801; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FARESE RV, 1992, J CLIN INVEST, V90, P256, DOI 10.1172/JCI115845; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KNOTT TJ, 1986, NUCLEIC ACIDS RES, V14, P7501, DOI 10.1093/nar/14.18.7501; Langman J., 1981, MED EMBRYOLOGY; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MATHEW MK, 1988, BIOCHEMISTRY-US, V27, P9204, DOI 10.1021/bi00426a019; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; McCormick SPA, 1996, TRENDS CARDIOVAS MED, V6, P16, DOI 10.1016/1050-1738(95)00125-5; MCCORMICK SPA, 1994, GENET ANAL-BIOMOL E, V11, P158, DOI 10.1016/1050-3862(94)90036-1; Montoliu L, 1996, EMBO J, V15, P6026, DOI 10.1002/j.1460-2075.1996.tb00991.x; PAULWEBER B, 1961, J BIOL CHEM, V266, P24149; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; ROTH KA, 1991, J BIOL CHEM, V266, P5949; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIMON TC, 1993, J BIOL CHEM, V268, P18345; STAMATOYANNOPOULOS JA, 1995, EMBO J, V14, P106, DOI 10.1002/j.1460-2075.1995.tb06980.x; TAYLOR JM, 1993, CURR OPIN LIPIDOL, V4, P84, DOI 10.1097/00041433-199304000-00002; WALSH A, 1993, J LIPID RES, V34, P617; Wilcox J N, 1986, Methods Enzymol, V124, P510; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; YOUNG SG, 1986, J BIOL CHEM, V261, P2995; Young Stephen G., 1994, Current Opinion in Lipidology, V5, P94, DOI 10.1097/00041433-199404000-00005	48	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29752	29758		10.1074/jbc.272.47.29752	http://dx.doi.org/10.1074/jbc.272.47.29752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368045	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:A1997YG64700055
J	Bhat, MK; Yu, CL; Yap, N; Zhan, QM; Hayashi, Y; Seth, P; Cheng, SY				Bhat, MK; Yu, CL; Yap, N; Zhan, QM; Hayashi, Y; Seth, P; Cheng, SY			Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO-REPRESSOR; NUCLEAR; PROTEIN; CELLS; GENE; EXPRESSION; PROMOTER; BINDING	Thyroid hormone nuclear receptors (TRs) are ligand-dependent transcription factors which regulate growth, differentiation, and development, The molecular mechanisms by which TRs mediate these diverse effects are unclear, One emerging hypothesis suggests that TRs could mediate these diverse effects via cooperation with different transcription factors/receptors, Indeed, we have recently shown that the human TR subtype beta 1 (h-TR beta 1) interacts with the tumor suppressor p53, p53 is a transcription factor that plays a critical role in cell cycle regulation and tumor development, To assess the physiological relevance of the interaction of h-TR beta 1 with p53, the present study addressed the question as to whether the functions of h-TR beta 1 could be modulated by p53, We first compared the h-TR beta 1-mediated transcriptional activity in two pairs of isogenic cell lines, RKO/RKO E6 and MCF-7/MCF-7 E6, RKO and MCF-7 cells are colon and breast carcinoma cell lines, respectively, that contain p53 but lack TR beta 1, The isogenic RKO E6 and MCF-7 E6 cells are stable clones expressing high levels of papillomavirus type 16 E6 protein, In these cells, the level of p53 protein was lower than the parental cells, The impairment of p53 functions in these EG-containing cells led to an activation of TR beta 1-mediated transcriptional activity, Furthermore, in a growth hormone-producing cell line in which the expression of the growth hormone gene is positively regulated by TRs, overexpression of the wild-type p53 led to repression in the expression of the growth hormone gene, Thus, TRs could cross-talk with p53 in its signaling pathways to regulate gene regulatory functions, The present findings further strengthen the hypothesis that mediation of the pleiotropic effects of T-3 requires the cooperation of TRs with a large network of transcription factors.	NCI, MOL BIOL LAB, MED BRANCH, NIH, BETHESDA, MD 20892 USA; NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA; NAGOYA UNIV, ENVIRONM MED RES INST, DEPT ENDOCRINOL & METAB, NAGOYA, AICHI 464, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University			Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				BHAT MK, 1995, BIOCHEMISTRY-US, V34, P10591, DOI 10.1021/bi00033a034; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng Sheue-Yann, 1995, Journal of Biomedical Science, V2, P77, DOI 10.1007/BF02253060; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DESESI CR, 1986, ENDOCRINOLOGY, V116, P2026; DESESI CR, 1981, ENDOCRINOLOGY, V108, P259; DESESI CR, 1984, ENDOCRINOLOGY, V114, P293; DOBNER PR, 1981, P NATL ACAD SCI-BIOL, V78, P2230, DOI 10.1073/pnas.78.4.2230; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FAN SJ, 1995, CANCER RES, V55, P1649; GUERNSEY D L, 1990, Critical Reviews in Oncogenesis, V1, P389; Hayashi Y, 1996, MOL ENDOCRINOL, V10, P100, DOI 10.1210/me.10.1.100; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Katayose D, 1995, CLIN CANCER RES, V1, P889; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; ONATE SA, 1995, SCIENCE, V270, P1354; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Ting YT, 1997, J BIOL CHEM, V272, P4129, DOI 10.1074/jbc.272.7.4129; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhu XG, 1997, J BIOL CHEM, V272, P9048	34	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28989	28993		10.1074/jbc.272.46.28989	http://dx.doi.org/10.1074/jbc.272.46.28989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360971	hybrid			2022-12-25	WOS:A1997YF68400030
J	Newport, G; Agabian, N				Newport, G; Agabian, N			KEX2 influences Candida albicans proteinase secretion and hyphal formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SACCHAROMYCES-CEREVISIAE; ASPARTIC PROTEINASE; SHARED FUNCTIONS; SHUTTLE VECTOR; GENE ENCODES; IN-VIVO; EXPRESSION; YEAST; SEQUENCE	Candida albicans possesses at least seven differentially expressed genes that encode virulence-related secretory aspartyl proteinases (Saps), Sap DNA sequences predict post-translational processing at lysine arginine residues in the preproteins, reminiscent of the maturation of Saccharomyces cerevisiae alpha-factor, where a prepropolypeptide is converted into a biologically active pheromone by Kex2, a subtilisin-like proprotein convertase. To investigate involvement of a C. albicans KEX2 homologue in Sap activation, a genetic selection was performed based on KEX2 function, A kex2 strain of S. cerevisiae was transformed with a C. albicans genomic DNA library and screened for the production of active alpha-factor. Positive clones were assayed for killer toxin activity, another Kex2-dependent phenotype. Plasmids that rescued both defects contained a sequence encoding a protein homologous to S. cerevisiae Kex2. Both alleles of the C. albicans REX2 were inactivated by successive mutations, Null mutants continued to secrete active Sap2; however, the enzyme was abnormally processed and secreted at reduced levels, Unexpectedly, null mutants were incapable of forming hyphae, instead differentiating into aberrantly shaped cells. The ability to normally process Sap2 and form hyphae was restored upon transformation of null mutants with a KEX2-containing plasmid.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [R01 AI33317] Funding Source: Medline; NIDCR NIH HHS [P01 DE07946] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGABIAN N, 1994, J MED VET MYCOL, V32, P229; AKASHI T, 1993, J GEN MICROBIOL, V139, P2185, DOI 10.1099/00221287-139-9-2185; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANGLIKER H, 1995, J MED CHEM, V38, P4014, DOI 10.1021/jm00020a016; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; CHAMBERS RS, 1993, J GEN MICROBIOL, V139, P325, DOI 10.1099/00221287-139-2-325; CRANDALL M, 1987, J GEN MICROBIOL, V133, P2817; CUTFIELD SM, 1995, STRUCTURE, V3, P1261, DOI 10.1016/S0969-2126(01)00261-1; DAVEY J, 1994, EMBO J, V13, P5910, DOI 10.1002/j.1460-2075.1994.tb06936.x; DeBernardis F, 1996, INFECT IMMUN, V64, P466, DOI 10.1128/IAI.64.2.466-471.1996; ENDERLIN CS, 1994, YEAST, V10, P67, DOI 10.1002/yea.320100107; FONZI WA, 1993, GENETICS, V134, P717; GILLUM AM, 1984, MOL GEN GENET, V198, P179, DOI 10.1007/BF00328721; GLEE PM, 1995, INFECT IMMUN, V63, P1373, DOI 10.1128/IAI.63.4.1373-1379.1995; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Hoegl L, 1996, J MOL MED, V74, P135, DOI 10.1007/BF01575445; HUBE B, 1994, MOL MICROBIOL, V14, P87, DOI 10.1111/j.1365-2958.1994.tb01269.x; Inoue H, 1996, EUR J BIOCHEM, V237, P719, DOI 10.1111/j.1432-1033.1996.0719p.x; JONES S, 1994, J CLIN MICROBIOL, V32, P2869, DOI 10.1128/JCM.32.11.2869-2870.1994; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kohler GA, 1997, J BACTERIOL, V179, P2331; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; LARRIBA G, 1995, FEMS MICROBIOL LETT, V125, P121; LEIBOWITZ MJ, 1976, P NATL ACAD SCI USA, V73, P2061, DOI 10.1073/pnas.73.6.2061; LIN XL, 1993, J BIOL CHEM, V268, P20143; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MONOD M, 1994, MOL MICROBIOL, V13, P357, DOI 10.1111/j.1365-2958.1994.tb00429.x; MORRISON CJ, 1993, INFECT IMMUN, V61, P2030, DOI 10.1128/IAI.61.5.2030-2036.1993; Odds FC., 1988, CANDIDA CANDIDOSIS; OLLERT MW, 1995, J CLIN MICROBIOL, V33, P2543, DOI 10.1128/JCM.33.10.2543-2549.1995; OLLERT MW, 1993, INFECT IMMUN, V61, P4560, DOI 10.1128/IAI.61.11.4560-4568.1993; PFALLER MA, 1994, J CLIN MICROBIOL, V32, P59, DOI 10.1128/JCM.32.1.59-64.1994; PLA J, 1995, GENE, V165, P115, DOI 10.1016/0378-1119(95)00492-O; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Redding K, 1996, MOL CELL BIOL, V16, P6208; Reichard U, 1996, MYCOSES, V39, P99, DOI 10.1111/j.1439-0507.1996.tb00109.x; ROGERS DT, 1979, BIOCHEM BIOPH RES CO, V90, P187, DOI 10.1016/0006-291X(79)91607-3; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; RUCHEL R, 1992, J MED VET MYCOL, V30, P123; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SLUTSKY B, 1985, SCIENCE, V230, P666, DOI 10.1126/science.3901258; Staab JF, 1996, J BIOL CHEM, V271, P6298, DOI 10.1074/jbc.271.11.6298; Staib F, 1965, Sabouraudia, V4, P187; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; SWEET SP, 1995, J MED MICROBIOL, V43, P452, DOI 10.1099/00222615-43-6-452; TANGUYROUGEAU C, 1988, FEBS LETT, V234, P464, DOI 10.1016/0014-5793(88)80139-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Togni G, 1996, MICROBIOL-SGM, V142, P493, DOI 10.1099/13500872-142-3-493; West RW, 1996, GENE, V169, P119, DOI 10.1016/0378-1119(95)00774-1; WHITE TC, 1993, J BACTERIOL, V175, P6126, DOI 10.1128/JB.175.19.6126-6133.1993; WHITE TC, 1995, J BACTERIOL, V177, P5215, DOI 10.1128/jb.177.18.5215-5221.1995; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; Wosten HAB, 1996, EMBO J, V15, P4274, DOI 10.1002/j.1460-2075.1996.tb00802.x; Wu T, 1996, J MED MICROBIOL, V44, P311, DOI 10.1099/00222615-44-4-311	57	90	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28954	28961		10.1074/jbc.272.46.28954	http://dx.doi.org/10.1074/jbc.272.46.28954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360967	hybrid			2022-12-25	WOS:A1997YF68400026
J	Reddy, SAG; Huang, JH; Liao, WSL				Reddy, SAG; Huang, JH; Liao, WSL			Phosphatidylinositol 3-kinase in interleukin 1 signaling - Physical interaction with the interleukin 1 receptor and requirement in NF kappa B and AP-1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; C/EBP-LIKE; IN-VITRO; CELLS; BINDING; ASSOCIATION; WORTMANNIN	The signaling mechanisms utilized by the proinflammatory cytokine interleukin-l (IL-1) to activate the transcription factors NF kappa B and activator protein-1 (AP-1) are poorly defined. We present evidence here that IL-1 not only stimulates a dramatic increase in phosphatidylinositol 3-kinase (PI 3-kinase) activity but also induces the physical interaction of its type I receptor with the p85 regulatory subunit of PI 3-kinase. Furthermore, two PI S-kinase-specific inhibitors, wortmannin and a dominant-negative mutant of the p85 subunit, inhibited IL-induced activation of both NF kappa B and AP-1. Transient transfection experiments indicated that whereas overexpression of PI S-kinase may be sufficient to induce AP-1 and increase nuclear c-Fos protein levels, PI 3-kinase may need to cooperate with other IL-l-inducible signals to fully activate NF kappa B-dependent gene expression. In this regard, cotransfection studies suggested that PI 3-kinase may functionally interact with the recently-identified IL-l-receptor-associated kinase to activate NF kappa B. Our results thus indicate that PI 3-kinase is a novel signal transducer in IL-1 signaling and that it may differentially mediate the activation of NF kappa B and AP-1.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NIAMS NIH HHS [AR38858] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038858, R01AR038858] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN HM, 1993, MOL CELL BIOL, V13, P6766, DOI 10.1128/MCB.13.11.6766; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GARCIA P, 1993, J BIOL CHEM, V268, P25146; GUNTHER R, 1989, IMMUNOPHARM IMMUNOT, V11, P559, DOI 10.3109/08923978909005385; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HEGUY A, 1992, J BIOL CHEM, V267, P2605; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LI XX, 1991, J BIOL CHEM, V266, P15192; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rzymkiewicz DM, 1996, J BIOL CHEM, V271, P17241, DOI 10.1074/jbc.271.29.17241; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	211	220	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29167	29173		10.1074/jbc.272.46.29167	http://dx.doi.org/10.1074/jbc.272.46.29167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360994	hybrid			2022-12-25	WOS:A1997YF68400053
J	Kakinuma, A; Chazenbalk, GD; Tanaka, K; Nagayama, Y; McLachlan, SM; Rapport, B				Kakinuma, A; Chazenbalk, GD; Tanaka, K; Nagayama, Y; McLachlan, SM; Rapport, B			An N-linked glycosylation motif from the noncleaving luteinizing hormone receptor substituted for the homologous region (Gly(367) to Glu(369)) of the thyrotropin receptor prevents cleavage at its second, downstream site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; MOLECULAR-CLONING; EXTRACELLULAR DOMAIN; MAMMALIAN-CELLS; EXPRESSION; BINDING; GENE; ACID; MEMBRANES; SEQUENCE	The thyrotropin receptor (TSHR) exists in two forms (single polypeptide and two subunits), whereas the lutropin/chorionic gonadotropin receptor (LH/CGR) is a single chain, Recent data suggest that the TSHR cleaves at two sites, We mutagenized selected chimeric TSH-LH/CGR to localize the cleavage sites in the TSHR, All 23 receptors mutated in the estimated vicinity of the upstream site cleaved into two subunits as determined by I-125-TSH cross-linking to intact cells, In contrast, in a series of mutations homologous to the noncleaving LH/GGR, the downstream TSHR cleavage site localized to three amino acids (GQE(367-369)). Remarkably, group substitution of these residues, but not substitution of individual residues, abolished cleavage, Moreover, the mutation that prevented cleavage (GQE(367-369)NET) transposed a motif (NET291-293) that is glycosylated in the LH/CGR, TSHR cleavage or noncleavage after substitution of GQE(367-369) with Other triplets (AAA, NQE, and NQT) was consistent with a role for N-linked glycosylation at this site. In summary, our data (i) support the concept that the TSHR cleaves at two sites, (ii) relate TSHR residues GQE(367-369) to cleavage at the second, downstream site, and (iii) suggest that cleavage or noncleavage at site two is related to N-linked glycosylation. These findings provide new insight into the evolutionary divergence of two closely related receptors.	VET ADM MED CTR,THYROID MOL BIOL UNIT 111T,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019289] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19289] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAN T, 1992, ENDOCRINOLOGY, V131, P815, DOI 10.1210/en.131.2.815; BUCKLAND PR, 1982, FEBS LETT, V145, P245, DOI 10.1016/0014-5793(82)80176-2; CHAZENBALK GD, 1994, J BIOL CHEM, V269, P32209; Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; Chazenbalk GD, 1996, BIOCHEM BIOPH RES CO, V225, P479, DOI 10.1006/bbrc.1996.1198; Couet J, 1996, J BIOL CHEM, V271, P4545; Davis DP, 1997, MOL ENDOCRINOL, V11, P550, DOI 10.1210/me.11.5.550; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; Graves PN, 1996, ENDOCRINOLOGY, V137, P3915, DOI 10.1210/en.137.9.3915; GROSS B, 1991, BIOCHEM BIOPH RES CO, V177, P679, DOI 10.1016/0006-291X(91)91842-Z; Kakinuma A, 1996, ENDOCRINOLOGY, V137, P2664, DOI 10.1210/en.137.7.2664; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; POTTER E, 1994, BIOCHEM BIOPH RES CO, V205, P361, DOI 10.1006/bbrc.1994.2673; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	30	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28296	28300		10.1074/jbc.272.45.28296	http://dx.doi.org/10.1074/jbc.272.45.28296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353284	hybrid			2022-12-25	WOS:A1997YF21900024
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			Characterization of two homologous yeast genes that encode mitochondrial iron transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ALCALIGENES-EUTROPHUS; EFFLUX SYSTEM; ZINC; OXIDASE; PROTEIN; IDENTIFICATION; EXPRESSION; RESISTANCE; COBALT	Two different yeast genes were identified that when overexpressed suppressed the low iron growth defect of a mutation in the endoplasmic reticulum iron binding enzyme methyl sterol oxidase. These genes were determined to be novel and highly related, The deduced amino acid sequences indicated that both were membrane proteins having two identical histidine-rich motifs. The predicted proteins, while not ABC transporters, are homologous to a widely distributed family of transition metal transporters present in all kingdoms. Subcellular fractionation and fluorescence microscopy localized these gene products to mitochondria. Based on this result we term these genes Mitochondrial Fe Transporters (MFT). Cells with disruptions in both genes show a growth defect on low iron medium, suggesting that these genes have redundant function and can affect cytosolic iron levels. Measurement of mitochondrial iron in cells grown in iron-rich medium overexpressing MFT1 or MFT2 show a 25-fold increase in iron compared with mitochondria from control cells, These results suggest that the mitochondria may act as a reservoir for iron that can be mobilized and used for cytosolic purposes.	UNIV UTAH,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah								AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; EIDE D, 1992, J BIOL CHEM, V267, P20774; GEITZ RD, 1988, GENE, V74, P527; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; NIES DH, 1989, P NATL ACAD SCI USA, V86, P7351, DOI 10.1073/pnas.86.19.7351; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F, 1979, METHODS YEAST GENETI; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203	23	67	72	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28485	28493		10.1074/jbc.272.45.28485	http://dx.doi.org/10.1074/jbc.272.45.28485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353309	hybrid			2022-12-25	WOS:A1997YF21900049
J	Schinkmann, K; Blenis, J				Schinkmann, K; Blenis, J			Cloning and characterization of a human STE20-like protein kinase with unusual cofactor requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; SIGNAL-TRANSDUCTION; C-JUN; SACCHAROMYCES-CEREVISIAE; CASCADE; PATHWAY; STRESS; YEAST; ACTIVATION; GROWTH	We cloned and characterized a novel human member of the STE20 serine/threonine protein kinase family named mst-3. Based on its domain structure, mst-3 belongs to the SPS1 subgroup of STE20-like proteins, which includes germinal center (GC) kinase, hematopoietic progenitor kinase (HPK), kinase homologous to STE20/SPS-1 (KHS), kinases responsive to stress (KRS1/2), the mammalian STE20-like kinases (mst1/2), and the recently published STE20/oxidant stress response kinase SOK-1. mst-3 is most closely related to SOK-1, with 88% amino acid similarity in the kinase domain. The similarity of the mst-3 kinase domain to STE20 is 42%. The mst-3 transcript is ubiquitously expressed, and the protein was found in all human, mouse, and monkey cell lines tested. An in vitro kinase assay showed that mst-3 can phosphorylate! basic exogenous substrates as well as itself. Interestingly, mst-3 prefers Mn2+ to Mg2+ as a divalent cation and can use both GTP and ATP as phosphate donors. Like SOK-1, mst-3 is activated by autophosphorylation. However, a physiological stimulus of mst-3 activity was not identified. mst-3 activity does not change upon exposure to several mitogenic and stress stimuli. Overexpression of mst b wild-type or kinase dead protein affects neither the extracellular signal-regulated kinases (ERK1/2 or ERK6, c-Jun N-terminal kinase (JNK), p38, nor pp70S6 kinase, suggesting that mst-3 is part of a novel signaling pathway.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMMERER G, 1994, CURR OPIN CELL BIOL, V5, P254; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATZ P, 1994, J BIOL CHEM, V269, P16802; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NG TI, 1992, VIROLOGY, V191, P9, DOI 10.1016/0042-6822(92)90161-H; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WHITE MF, 1984, J BIOL CHEM, V259, P255; WHITE MF, 1986, ENZYMES, V17, P248	48	95	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28695	28703		10.1074/jbc.272.45.28695	http://dx.doi.org/10.1074/jbc.272.45.28695			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353338	hybrid			2022-12-25	WOS:A1997YF21900078
J	Yang, WM; Yao, YL; Sun, JM; Davie, JR; Seto, E				Yang, WM; Yao, YL; Sun, JM; Davie, JR; Seto, E			Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSCRIPTIONAL REPRESSION; NUCLEAR MATRIX; YEAST; ACETYLTRANSFERASE; REGULATOR; RPD3; ACETYLATION; EXPRESSION; PROTEINS	Several human cDNAs encoding a histone deacetylase protein, HDAC3, have been isolated. Analysis of the predicted amino acid sequence of HDAC3 revealed an open reading frame of 428 amino acids with a predicted molecular mass of 49 kDa. The HDAC3 protein is 50% identical in DNA sequence and 53% identical in protein sequence compared with the previously cloned human HDAC1, Comparison of the HDAC3 sequence with human HDAC2 also yielded similar results, with 51% identity in DNA sequence and 52% identity in protein sequence. The expressed HDAC3 protein is functionally active because it possesses histone deacetylase activity, represses transcription when tethered to a promoter, and binds transcription factor YY1. Similar to HDAC1 and HDAC2, HDAC3 is ubiquitously expressed in many different cell types.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,DEPT MED MICROBIOL & IMMUNOL,MOL ONCOL PROGRAM,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DEPT BIOCHEM & MOL BIOL,TAMPA,FL 33612; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Manitoba				Davie, James/0000-0002-0420-6888; Yang, Wen-Ming/0000-0002-5871-5979				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Davie JR, 1996, J CELL BIOCHEM, V62, P149, DOI 10.1002/(SICI)1097-4644(199608)62:2<149::AID-JCB2>3.0.CO;2-S; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1983, ANTIBODIES LAB MANUA; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; RON D, 1992, BIOTECHNIQUES, V13, P866; RUBERTIS FD, 1996, NATURE, V384, P589; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2002, MOL CLONING LAB MANU; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	35	392	431	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28001	28007		10.1074/jbc.272.44.28001	http://dx.doi.org/10.1074/jbc.272.44.28001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346952	hybrid			2022-12-25	WOS:A1997YD47300078
J	Floettmann, JE; Rowe, M				Floettmann, JE; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappa B activation	ONCOGENE			English	Article						EBV; LMP1; NF-KB; TNF-receptor; TRAF; signaling	CELL-DEATH; TRANSFORMING PROTEIN; LYMPHOCYTE-TRANSFORMATION; MONOCLONAL-ANTIBODIES; TRANSIENT EXPRESSION; CYTOPLASMIC DOMAIN; SEQUENCE VARIATION; NUCLEAR PROTEIN-2; TNF RECEPTOR; PHENOTYPE	The Epstein-Barr virus Latent Membrane Protein-1 (LMP1) has structural features and functions consistent with it being a constitutively active cell surface receptor. The known association of LMP1 with members of the TRAF family of proteins suggests that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor (TNFR) family of cell surface receptors that signal by forming dimers or trimers in response to binding of extracellular ligands. However, interactions between LMP1 and the TRAFs have so far only been described for the C-terminal activation region 1 (CTAR1) of LMP1 and no direct interactions of the TRAFs with the second NF-kappa B activation domain (CTAR2) have been reported. We have now mapped the NF-kappa B activation domain of CTAR2 to a highly conserved stretch of 6 amino acids at the far C-terminus (codons 379 to 384 in B95.8 LMP1). In addition, we constructed chimeric receptor molecules which contain the ligand-binding extracellular domain and the transmembrane domain of rat CD2 fused to the C-terminus of LMP1 encoding the CTAR1 and/or the CTAR2 domain. Interestingly, the function of a chimera encoding CTAR2 alone, as well as the function of a chimera encoding both CTAR1 and CTAR2 was found to be inducible upon antibody-mediated crosslinking. These inducible chimeric proteins also allowed us to demonstrate that LMP1 mediated NF-kappa B activation is an immediate event following activation of LMP1.	UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XX,S GLAM,WALES	Cardiff University			Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326				Ansieau S, 1996, P NATL ACAD SCI USA, V93, P14053, DOI 10.1073/pnas.93.24.14053; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1996, MOL CELL BIOL, V16, P7098; ELIOPOULOS A, 1997, IN PRESS ONCOGENE, V14; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUEN DS, 1995, ONCOGENE, V10, P549; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; ROBERTSON ES, 1995, EBV REPORT, V2, P73; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549	46	106	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1851	1858		10.1038/sj.onc.1201359	http://dx.doi.org/10.1038/sj.onc.1201359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362452				2022-12-25	WOS:A1997XZ72500012
J	Wrenger, S; Hoffmann, T; Faust, J; MrestaniKlaus, C; Brandt, W; Neubert, K; Kraft, M; Olek, S; Frank, R; Ansorge, S; Reinhold, D				Wrenger, S; Hoffmann, T; Faust, J; MrestaniKlaus, C; Brandt, W; Neubert, K; Kraft, M; Olek, S; Frank, R; Ansorge, S; Reinhold, D			The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL-PEPTIDASE-IV; HUMAN LYMPHOCYTE-T; VIRUS TYPE-III; CORRELATION SPECTROSCOPY; COHERENCE TRANSFER; ROTATING FRAME; PROLIFERATION; PROTEIN; INHIBITION; CD26	Evidence exists that the human immunodeficiency virus-1 (HIV-1) transactivator Tat occurs extracellularly and is involved in the immunosuppression of non-HIV-1-infected T cells of acquired immunodeficiency syndrome (AIDS) patients, The mechanism of this immunosuppressive activity of Tat has been controversially discussed, Interestingly, Tat binds to the T cell activation marker CD26, which has been shown to play a key role in the regulation of growth of lymphocytes and to inhibit its dipeptidyl peptidase IV (DpIV) activity, Here we show that the N-terminal nonapeptide MDPVDPNIE of Tat is a competitive inhibitor of DP TV and suppresses DNA synthesis of tetanus toxoid-stimulated peripheral blood mononuclear cells, Amino acid exchanges at positions 5 and 6 strongly weaken these effects. H-1 nuclear magnetic resonance and molecular dynamics simulations of Tat(1-9), I-5-Tat(1-9), and L-6-Tat(1-9) suggest a similar backbone conformation for Tat(1-9) and L-6-Tat(1-9). The solution conformation of I-5-Tat(1-9) considerably differs from the other two. However, Tat(1-9) fits into our previously proposed active site model of DP TV in contrast to I-5-Tat(1-9) and L-6-Tat(1-9), Conformational alterations with regard to the parent peptide and spatial hindrances between these both compounds and DP TV can explain the loss of inhibitory activity. Our data suggest that the N-terminal residues of HIV-1 Tat do interact directly with the active site of DPIV and that DP TV does mediate Tat's immunosuppressive effects.	UNIV MAGDEBURG,INST EXPT INTERNAL MED,CTR INTERNAL MED,D-39120 MAGDEBURG,GERMANY; UNIV HALLE WITTENBERG,INST BIOCHEM,DEPT BIOCHEM & BIOTECHNOL,D-06120 HALLE,GERMANY; UNIV HEIDELBERG,CTR MOL BIOL,D-69120 HEIDELBERG,GERMANY	Otto von Guericke University; Martin Luther University Halle Wittenberg; Ruprecht Karls University Heidelberg				Wrenger, Sabine/0000-0002-9733-6162				AUE WP, 1976, J CHEM PHYS, V64, P229; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BRANDT W, 1995, INT J PEPT PROT RES, V46, P494; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUHLING F, 1995, IMMUNOL LETT, V45, P47, DOI 10.1016/0165-2478(94)00230-O; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; GASTEIGER J, 1985, ANGEW CHEM, V97, P699; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; KRAFT M, 1994, PEPTIDES 1994, P349; LANE C, 1985, NEW ENGL J MED, V131, P79; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MEYAARD L, 1992, EUR J IMMUNOL, V22, P2729, DOI 10.1002/eji.1830221038; MULLER L, 1979, MOL PHYS, V38, P963, DOI 10.1080/00268977900102161; REINHOLD D, 1993, IMMUNOBIOLOGY, V188, P403, DOI 10.1016/S0171-2985(11)80223-8; Reinhold D, 1996, IMMUNOBIOLOGY, V195, P119, DOI 10.1016/S0171-2985(96)80010-6; REINHOLD D, 1994, IMMUNOBIOLOGY, V192, P121, DOI 10.1016/S0171-2985(11)80412-2; Schmitz T, 1996, J CLIN INVEST, V97, P1545, DOI 10.1172/JCI118577; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SCHON E, 1989, SCAND J IMMUNOL, V29, P127, DOI 10.1111/j.1365-3083.1989.tb01108.x; SCHON E, 1991, BIOL CHEM H-S, V372, P305, DOI 10.1515/bchm3.1991.372.1.305; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wrenger S, 1996, FEBS LETT, V383, P145, DOI 10.1016/0014-5793(96)00221-9	35	60	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30283	30288		10.1074/jbc.272.48.30283	http://dx.doi.org/10.1074/jbc.272.48.30283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374514	hybrid			2022-12-25	WOS:A1997YH61300046
J	Ezura, Y; Tournay, O; Nifuji, A; Noda, M				Ezura, Y; Tournay, O; Nifuji, A; Noda, M			Identification of a novel suppressive vitamin D response sequence in the 5'-flanking region of the murine Id1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORAMPHENICOL-ACETYL-TRANSFERASE; RETINOID-X-RECEPTOR; LOOP-HELIX PROTEIN; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSCRIPTIONAL REPRESSION; HORMONE-RECEPTOR; 24-HYDROXYLASE GENE; NEGATIVE REGULATION; DNA-SEQUENCES; KINASE-C	Vitamin D promotes differentiation of cells either by simply enhancing phenotypic gene expression and/or by suppressing expression of inhibitors of differentiation. previously, we reported that expression of a gene encoding Idl, a negative type helix-loop-helix transcription factor, was transcriptionally suppressed by 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) (1). To identify the sequence required for the negative regulation by 1,25(OH)(2)D-3, a 1,5-kilobase 5'-flanking region of murine Idl gene was examined by transiently transfecting luciferase reporter constructs into ROS17/2.8 osteoblastic cells. The transcriptional activity of this construct was repressed by 10(-8) hz 1,25(OH)(3)D-3. Deletion analysis revealed that a 57-base pair (bp) upstream response sequence (URS) (-1146/-1090) was required for the suppression by 1,25(OH)(2)D-3. This sequence conferred negative responsiveness to 1,25(OH)(2)D-3 to a heterologous SV40 promoter. The 57-bp URS contained not only Egr-1 consensus sequence (2) but also four direct repeats of a heptamer sequence (C/A)CAGCCC. Electrophoresis mobility shift assay revealed that the 57-bp URS formed specific nuclear protein-DNA complexes, which were neither competed by previously known positive and negative vitamin D response elements nor supershifted by anti-vitamin D receptor antibody, suggesting the absence of vitamin D receptor in these complexes. These results indicate the involvement of the novel 57-bp sequence in the vitamin D suppression of Idl gene transcription.	TOKYO MED & DENT UNIV, MED RES INST, DEPT MOL PHARMACOL, TOKYO 101, JAPAN; MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA	Tokyo Medical & Dental University (TMDU); Memorial Sloan Kettering Cancer Center			Ezura, Yoichi/L-9485-2016; Nifuji, Akira/AAX-7907-2021	Nifuji, Akira/0000-0002-8182-4380				ALROY I, 1995, MOL CELL BIOL, V15, P5789; Ausubel F.M., 1987, CURRENT PROTOCOLS MO, P241; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BERTHOLD A, 1990, BIOMED BIOCHIM ACTA, V49, P1243; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARR FE, 1994, J BIOL CHEM, V269, P4175; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HAUSSLER MR, 1995, BONE, V17, pS33, DOI 10.1016/8756-3282(95)00205-R; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P1533, DOI 10.1210/me.9.11.1533; Sakoda K, 1996, BIOCHEM BIOPH RES CO, V219, P31, DOI 10.1006/bbrc.1996.0176; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Wang DS, 1996, J BONE MINER RES, V11, P472; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900	51	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29865	29872		10.1074/jbc.272.47.29865	http://dx.doi.org/10.1074/jbc.272.47.29865			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368060	hybrid			2022-12-25	WOS:A1997YG64700070
J	Newberry, EP; Boudreaux, JM; Towler, DA				Newberry, EP; Boudreaux, JM; Towler, DA			Stimulus-selective inhibition of rat osteocalcin promoter induction and protein-DNA interactions by the homeodomain repressor Msx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENT MICE; GENE; GROWTH; BONE; TRANSCRIPTION; ELEMENT; CALCIFICATION; EXPRESSION; RECEPTORS; MUTATION	Osteocalcin (OC) is a matrix calcium-binding protein expressed in osteoblasts and odontoblasts undergoing mineralization. OC expression is up-regulated in part by signals initiated by basic fibroblast growth factor (FGF2), cyclic AMP or forskolin (FSK), and calcitriol via defined elements and DNA-protein interactions in the OC promoter, We identified the OC gene as a target for transcriptional suppression by Msx2, a homeodomain transcription factor that controls ossification in the developing skull, in this study, we examine the effects of Msx2 expression on OC promoter activation (luciferase reporter) by FGF2/FSK and calcitriol in MC3T3-E1 osteoblasts, Expression of Msx2 decreases basal activity of the 1-kilobase (-1050 to +32) rat OC promoter by 80%; however, the promoter is still inducible 3-fold by calcitriol, By contrast, OC promoter induction by FGF2/FSK is completely abrogated by Msx2, Because intrinsic Msx2 DNA binding activity is not required for the Msx2 suppressor function, we assessed whether Msx2 represses OC activation by regulating DNA-protein interactions at the FGF2 response element (OCFRE) and compared these interactions with those occurring at the calcitriol response element (VDRE), Treatment of MC3T3-E1 cells with FGF2/FSK or calcitriol up-regulates specific DNA-protein interactions at the OCFRE or VDRE, respectively, as detected by gel shift assay, Preincubation of crude nuclear extracts with recombinant glutathione S-transferase (GST)-Msx2 dose-dependently inhibits OCFRE DNA binding activity, whereas GST has no effect, Msx2 itself does not bind the OCFRE. Residues 132-148 required for Msx2 core suppressor function in transfection assays are also required to inhibit OCFRE DNA binding activity, By contrast, GST-Msx2 has no effect on calcitriol-regulated DNA-protein interactions at the VDRE, Using gel shift as an assay, the OCFRE DNA-binding protein OCFREB was purified to about 50% homogeneity from MG63 osteosarcoma cells, Recombinant Msx2 inhibits purified OCFREB DNA binding activity, whereas the Msx2 variant lacking residues 132-148 is inactive, Thus, Msx2 abrogates up-regulation of the OC promoter by FGF2/FSK in part by inhibiting OCFREB binding to the OCFRE.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV METAB & BONE & MINERAL DIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Newberry, EP (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,DIV ENDOCRINOL,BOX 8103,660 S EUCLID,ST LOUIS,MO 63110, USA.		Boudreaux, Jeanne/AAU-8580-2020	Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731, T32AR007033] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07033, AR43731] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149; DEMAY MB, 1992, MOL ENDOCRINOL, V6, P557, DOI 10.1210/me.6.4.557; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODIG M, 1996, J BONE MINER RES S1, V11, pS260; DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy Patricia, 1996, P183; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hoffmann HM, 1996, J CELL BIOCHEM, V61, P310, DOI 10.1002/(SICI)1097-4644(19960501)61:2<310::AID-JCB14>3.0.CO;2-P; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LIU YH, 1995, P NATL ACAD SCI USA, V92, P6137, DOI 10.1073/pnas.92.13.6137; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Marks Sandy C. Jr., 1996, P3; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Stein Gary S., 1996, P69; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Towler Dwight A., 1996, P1173; Winograd J, 1997, HUM MOL GENET, V6, P369, DOI 10.1093/hmg/6.3.369; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	36	42	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29607	29613		10.1074/jbc.272.47.29607	http://dx.doi.org/10.1074/jbc.272.47.29607			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368026	hybrid			2022-12-25	WOS:A1997YG64700036
J	Paz, K; Hemi, R; LeRoith, D; Karasik, A; Elhanany, E; Kanety, H; Zick, Y				Paz, K; Hemi, R; LeRoith, D; Karasik, A; Elhanany, E; Kanety, H; Zick, Y			Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; P55 TNF-RECEPTOR; CELL-DEATH; KINASE-ACTIVITY; AMINO-ACIDS; SUBSTRATE-1; PROTEIN; SPHINGOMYELINASE; RESISTANCE	Tumor necrosis factor alpha (TNF alpha) or chronic hyperinsulinemia that induce insulin resistance trigger increased Ser/Thr phosphorylation of the insulin receptor (Hi) and of its major insulin receptor substrates, IRS-1 and IRS-2. To unravel the molecular basis for this uncoupling in insulin signaling, we undertook to study the interaction of Ser/Thr-phosphorylated IRS-1 and IRS-2 with the insulin receptor. We could demonstrate that, similar to IRS-1, IRS-2 also interacts with the juxtamembrane (JM) domain (amino acids 943-984) but not with the carboxyl-terminal region (amino acids 1245-1331) of IR expressed in bacteria as His(6) fusion peptides, Moreover, incubation of rat hepatoma Fao cells with TNF alpha, bacterial sphingomyelinase, or other Ser(P)/Thr(P)-elevating agents reduced insulin-induced Tyr phosphorylation of IRS-I and IRS-2, markedly elevated their Ser(P)/Thr(P) levels, and significantly reduced their ability to interact with the JM region of IR. Withdrawal of TNF alpha for periods as short as 30 min reversed its inhibitory effects on IR-IRS interactions, Similar inhibitory effects were obtained when Fao cells were subjected to prolonged (20-60 min) pretreatment with insulin, Incubation of the cell extracts with alkaline phosphatase reversed the inhibitory effects of insulin. These findings suggest that insulin resistance is associated with enhanced Ser/Thr phosphorylation of IRS-1 and IRS-S, which impairs their interaction with the JIVE region of IR. Such impaired interactions abolish the ability of IRS-1 and IRS-2 to undergo insulin-induced Tyr phosphorylation and further propagate the insulin receptor signal. Moreover, the reversibility of the TNF alpha effects and the ability to mimic its action by exogenously added sphingomyelinase argue against the involvement of a proteolytic cascade in mediating the acute inhibitory effects of TNF alpha on insulin action.	WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL; CHAIM SHEBA MED CTR, INST ENDOCRINOL, IL-52621 TEL HASHOMER, ISRAEL; NIH, DIABET BRANCH, BETHESDA, MD 20982 USA; ISRAEL INST BIOL RES, DEPT BIOCHEM, IL-70400 NESS ZIONA, ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012					AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COHEN SA, 1986, NATURE, V320, P769, DOI 10.1038/320769a0; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kanety H, 1996, J BIOL CHEM, V271, P9895, DOI 10.1074/jbc.271.17.9895; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTH RA, 1994, HORM RES, V41, P51, DOI 10.1159/000183961; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Skolnik Edward Y., 1996, Cytokine and Growth Factor Reviews, V7, P161, DOI 10.1016/1359-6101(96)00021-4; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZICK Y, 1983, J BIOL CHEM, V258, P75; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	44	420	440	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29911	29918		10.1074/jbc.272.47.29911	http://dx.doi.org/10.1074/jbc.272.47.29911			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368067	hybrid			2022-12-25	WOS:A1997YG64700077
J	Guy, HI; Bouvier, A; Evans, DR				Guy, HI; Bouvier, A; Evans, DR			The smallest carbamoyl-phosphate synthetase - A single catalytic subdomain catalyzes all three partial reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; INITIATES PYRIMIDINE BIOSYNTHESIS; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; LARGE SUBUNIT; AMIDOTRANSFERASE DOMAIN; REVERSIBLE DISSOCIATION; CONTROLLED PROTEOLYSIS; NUCLEOTIDE-SEQUENCE; LIMITED PROTEOLYSIS	Escherichia coli carbamoyl-phosphate synthetase (CPSase) is comprised of a 40-kDa glutaminase (GLN) and a 120-kDa synthetase (CPS) subunit, The CPS subunit consists of two homologous domains, CPS.A and CPS.B, which catalyze the two different ATP-dependent partial reactions involved in carbamoyl phosphate synthesis, Sequence similarities and controlled proteolysis experiments suggest that the CPS subdomains consist, in turn, of three subdomains, designated Al, A2, A3 and B1, B2, B3 for CPS.A and CPS.B, respectively, Previous studies of individually cloned CPS.A and CPS.B from E. coli and mammalian CPSase have shown that homologous dimers of either of these ''half-molecules'' could catalyze all three reactions involved in ammonia-dependent carbamoyl phosphate synthesis, Four smaller recombinant proteins were made for this study as follows: 1) A1-A2 in which the A3 subdomain was deleted from CPS.A, 2) B1-B2 lacking subdomain B3 of CPS.B, 3) the A2 subdomain of CPS.A, and 4) the B2 subdomain of CPS.B. When associated with the GLN subunit, A1-A2 and B1-B2 had both glutamine-and ammonia-dependent CPSase activities comparable to the wild-type protein, In contrast, the 27-kDa A2 and B2 recombinant proteins, which represent only 17% of the mass of the parent protein, were unable to use glutamine as a nitrogen donor, but the ammonia-dependent activity was enhanced 14-16-fold. The hyperactivity suggests that A2 and B2 are the catalytic subdomains and that Al and B1 are attenuation domains which suppress the intrinsically high activity and are required for the physical association with the GLN subunit.	WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47399] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELAL AT, 1982, J BACTERIOL, V151, P1411, DOI 10.1128/JB.151.3.1411-1419.1982; ALONSO E, 1992, J BIOL CHEM, V267, P4524; ALONSO E, 1995, EUR J BIOCHEM, V229, P377, DOI 10.1111/j.1432-1033.1995.tb20478.x; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; BAUR H, 1989, EUR J BIOCHEM, V179, P53, DOI 10.1111/j.1432-1033.1989.tb14520.x; BEIN K, 1991, J BIOL CHEM, V266, P3791; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPARIAN MG, 1991, J BIOL CHEM, V266, P3387; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; GHIM SY, 1994, MICROBIOL-UK, V140, P479, DOI 10.1099/00221287-140-3-479; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUADALAJARA A, 1987, EUR J BIOCHEM, V165, P163, DOI 10.1111/j.1432-1033.1987.tb11207.x; GUILLOU F, 1992, BIOCHEMISTRY-US, V31, P1656, DOI 10.1021/bi00121a012; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; Guy HI, 1997, J BIOL CHEM, V272, P19913, DOI 10.1074/jbc.272.32.19913; Guy HI, 1996, J BIOL CHEM, V271, P13762, DOI 10.1074/jbc.271.23.13762; GUY HI, 1994, J BIOL CHEM, V269, P7702; Hanahan D, 1985, DNA CLONING PRACTICA; HELBING CC, 1994, J BIOL CHEM, V269, P11743; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HONG J, 1995, J BIOL CHEM, V270, P14130, DOI 10.1074/jbc.270.23.14130; HUTTER R, 1986, ANNU REV MICROBIOL, V40, P55, DOI 10.1146/annurev.mi.40.100186.000415; JavidMajd F, 1996, BIOCHEMISTRY-US, V35, P14362, DOI 10.1021/bi961184q; KIM H, 1991, BIOCHEMISTRY-US, V30, P10322, DOI 10.1021/bi00106a033; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LIM F, 1988, J BIOL CHEM, V263, P11493; LUSTY CJ, 1992, FEBS LETT, V314, P135, DOI 10.1016/0014-5793(92)80959-K; LUSTY CJ, 1993, BIOCHEMISTRY-US, V32, P1278, DOI 10.1021/bi00056a012; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; Maniatis T., 1982, MOL CLONING; MAREYA SM, 1995, BIOORGAN MED CHEM, V3, P525, DOI 10.1016/0968-0896(95)00042-F; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MILES BW, 1993, BIOCHEMISTRY-US, V32, P232, DOI 10.1021/bi00052a030; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, P NATL ACAD SCI USA, V82, P2244, DOI 10.1073/pnas.82.8.2244; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RUBINO SD, 1987, J BIOL CHEM, V262, P4382; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; Rubio V, 1995, BIOCHEM SOC T, V23, P879, DOI 10.1042/bst0230879; RUMSBY PC, 1984, BIOCHEM J, V217, P435, DOI 10.1042/bj2170435; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SOUCIET JL, 1989, GENE, V79, P59, DOI 10.1016/0378-1119(89)90092-9; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; TAKAI T, 1988, J BIOL CHEM, V263, P2651; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; TROTTA PP, 1974, J BIOL CHEM, V249, P492; ZIMMERMANN BH, 1993, BIOCHEMISTRY-US, V32, P1519, DOI 10.1021/bi00057a016	64	15	15	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29255	29262		10.1074/jbc.272.46.29255	http://dx.doi.org/10.1074/jbc.272.46.29255			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361005	hybrid			2022-12-25	WOS:A1997YF68400064
J	Wang, J; Giacomini, KM				Wang, J; Giacomini, KM			Molecular determinants of substrate selectivity in Na+-dependent nucleoside transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; COTRANSPORTERS; PROTEINS; ANALOGS; BIOLOGY; RABBIT; CELLS	In mammalian cells, the salvage of purine and pyrimidine nucleosides is mediated by both facilitated and Na+-dependent nucleoside transporters. These transporters also play important roles in the transmembrane flux of therapeutic nucleoside analogs, which are widely used in the treatment of cancer and viral infections, The N1, N2, and N3 Na+-dependent nucleoside transporters differ in terms of their transport selectivity for purine and pyrimidine nucleosides. N1 is purine-selective, N2 is pyrimidine-selective, and N3 is broadly selective, To identify structural domains involved in substrate binding and molecular determinants responsible for distinct transport selectivity, chimeric transporters were made from the cloned rat N1 and N2 transporters, Of the 14 transmembrane domains (TM) of N1 and N2, transplanting TM8-9 of N1 into N2 converted N2 from a pyrimidine- to a purine-selective transporter. Transplanting only TM8 generated a chimera with characteristics similar to the N3 transporter that has yet to be cloned. These data suggest that TRZ8-9 confer substrate selectivity and may form at least part of a substrate-binding site in Na+-dependent nucleoside transporters.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Giacomini, Kathleen/AEF-2452-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042230] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42230] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Borgland SL, 1997, J PHARMACOL EXP THER, V281, P347; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CARON MG, 1993, NATURE, V366, P409, DOI 10.1038/366409a0; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; KAPLAN JH, 1993, CELL, V72, P13, DOI 10.1016/0092-8674(93)90045-R; LERMAN BB, 1991, CIRCULATION, V83, P1499, DOI 10.1161/01.CIR.83.5.1499; Mani Sridhar, 1996, Current Opinion in Oncology, V8, P525; MORSE GD, 1993, CLIN PHARMACOKINET, V24, P101, DOI 10.2165/00003088-199324020-00002; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; Redlak MJ, 1996, BIOCHEM BIOPH RES CO, V225, P106, DOI 10.1006/bbrc.1996.1137; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Roovers KI, 1996, J CELL PHYSIOL, V166, P593, DOI 10.1002/(SICI)1097-4652(199603)166:3<593::AID-JCP14>3.0.CO;2-8; Sadee W, 1995, PHARM RES-DORDR, V12, P1823, DOI 10.1023/A:1016211015926; Schaner ME, 1997, PHARMACEUT RES, V14, P1316, DOI 10.1023/A:1012148016794; WANG J, 1997, IN PRESS AM J PHYSL; Wiley JS, 1997, NAT MED, V3, P25, DOI 10.1038/nm0197-25; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; WU XC, 1992, J BIOL CHEM, V267, P8813; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	27	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28845	28848		10.1074/jbc.272.46.28845	http://dx.doi.org/10.1074/jbc.272.46.28845			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360950	hybrid			2022-12-25	WOS:A1997YF68400009
J	Adler, HT; Nallaseth, FS; Walter, G; Tkachuk, DC				Adler, HT; Nallaseth, FS; Walter, G; Tkachuk, DC			HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD SHOCK DOMAINS; 11Q23 TRANSLOCATIONS; DNA-BINDING; ALL-1 GENE; MYELOID LEUKEMOGENESIS; DROSOPHILA-TRITHORAX; PUTATIVE ONCOGENE; POTENT INHIBITOR; CRUCIFORM DNA; OKADAIC ACID	One of the most common chromosomal abnormalities in acute leukemia is a reciprocal translocation involving the HRX gene at chromosome locus 11q23, resulting in HRX fusion proteins. Using the yeast two-hybrid system, in vitro binding studies, and human cell culture coimmunoprecipitation experiments, we show here that a region of the HRX protein that is consistently retained in HRX leukemic fusion proteins interacts directly with SET, another protein implicated in leukemia. We have identified the binding sites on HRX for SET and show that these sequences are clustered near the A.T hooks that have been shown to bind DNA. We also show that carboxyl-terminal SET sequences, possibly the acidic tail of SET, bind to HRX. We have also found serine/threonine-specific protein phosphatase activity in anti-HRX coimmunoprecipitates. Using the phosphatase inhibitor okadaic acid and Western blotting, the phosphatase was identified as protein phosphatase 2A (PP2A). Mutation of a single amino acid in one of the SET binding sites of HRX resulted in lower amounts of both coimmunoprecipitated SET protein and coimmunoprecipitated PP2A. These results suggest that the leukemogenic effects of HRX fusion proteins may be related to interactions with SET and PP2A.	UNIV CALIF SAN DIEGO, DEPT PATHOL, LA JOLLA, CA 92093 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	University of California System; University of California San Diego; University of Washington; University of Washington Seattle	Adler, HT (corresponding author), VA PUGET SOUND HLTH CARE SYST, SEATTLE DIV, 1660 S COLUMBIAN WAY, RES MAIL STOP 151, SEATTLE, WA 98108 USA.							ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ASHAR HR, 1995, CELL, V82, P57; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREEN TR, 1993, DEVELOPMENT, V117, P119; Broeker PL, 1996, CURR TOP MICROBIOL, V211, P259; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fidanza V, 1996, CANCER RES, V56, P1179; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORNEROD M, 1995, ONCOGENE, V10, P1739; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HUNGER SP, 1993, BLOOD, V81, P3197; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; Ito T, 1996, MOL CELL BIOL, V16, P3112; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; Joh T, 1996, ONCOGENE, V13, P1945; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KOBAYASHI H, 1993, BLOOD, V81, P3027; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Leshkowitz D, 1996, ONCOGENE, V13, P2027; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Lochner K, 1996, CANCER RES, V56, P2171; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Rasio D, 1996, CANCER RES, V56, P1766; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; Rogaia D, 1997, CANCER RES, V57, P799; RUBNITZ JE, 1994, BLOOD, V84, P1747; Rubnitz JE, 1996, LEUKEMIA, V10, P74; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TAMKUN JW, 1995, CURR OPIN GENET DEV, V5, P473, DOI 10.1016/0959-437X(95)90051-H; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tkachenko A, 1997, CANCER RES, V57, P2276; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Williams AJ, 1997, AM J PATHOL, V150, P911; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Wu DY, 1996, J VIROL, V70, P6020, DOI 10.1128/JVI.70.9.6020-6028.1996; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Young BD, 1996, CANCER SURV, V28, P225; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	68	87	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28407	28414		10.1074/jbc.272.45.28407	http://dx.doi.org/10.1074/jbc.272.45.28407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353299	hybrid			2022-12-25	WOS:A1997YF21900039
J	Hamilton, BJN; Burns, CM; Nichols, RC; Rigby, WFC				Hamilton, BJN; Burns, CM; Nichols, RC; Rigby, WFC			Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes - The roles of cytoplasmic location, transcription, and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; HNRNP PROTEINS; TERMINAL DOMAIN; OKADAIC ACID; CALF THYMUS; IN-VIVO; GM-CSF; SEQUENCE; DEGRADATION	The heterogeneous nuclear ribonucleoprotein Al (hnRNP A1) shuttles between the cytoplasm and nucleus and plays important roles in RNA metabolism, Whereas nuclear hnRNP Al has been shown to bind intronic sequences and modulate splicing, cytoplasmic hnRNP Al is associated with poly(A)(+) RNA, indicating different RNA ligand specificity. Previous studies indicated that cytoplasmic hnRNP Al is capable of high-affinity binding of reiterated AUUUA sequences (ARE) that have been shown to modulate mRNA turnover and translation. Through a combination of two-dimensional gel and proteolysis studies, we establish hnRNP Al (or structurally related proteins that are post-translationally regulated in an identical manner) as the dominant cytoplasmic protein in human T lymphocytes capable of interacting with the ARE contained within the context of full-length granulocyte-macrophage colony-stimulating factor mRNA. We additionally demonstrate that cytoplasmic hnRNP Al preferentially binds ARE relative to pre-mRNAs in both cross-linking and mobility shift experiments. RNA polymerase II inhibition increased the binding of ARE (AUBP activity) and poly(U)-Sepharose by cytoplasmic hnRNP Al, while nuclear hnRNP Al binding was unaffected. Nuclear and cytoplasmic hnRNP Al could be distinguished by the differential sensitivity of their RNA binding to diamide and N-ethyhmaleimide. The increase in AUBP activity of cytoplasmic hnRNP Al following RNA polymerase II inhibition correlated with serine-threonine dephosphorylation, as determined by inhibitor and metabolic labeling studies, Thus, cytoplasmic and nuclear hnRNP Al exhibit different RNA binding profiles, perhaps transduced through serine-threonine phosphorylation. These findings are relevant to the specific ability of hnRNP Al to serve distinct roles in post-transcriptional regulation of gene expression in both the nucleus and cytoplasm.	DARTMOUTH HITCHCOCK MED CTR,DEPT MED,SECT CONNECT TISSUE DIS,DARTMOUTH MED SCH,LEBANON,NH 03756; DARTMOUTH HITCHCOCK MED CTR,DEPT MICROBIOL,SECT CONNECT TISSUE DIS,DARTMOUTH MED SCH,LEBANON,NH 03756; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007576] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI34928] Funding Source: Medline; NIAMS NIH HHS [T32 AR07576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMERO SA, 1993, MOL CELL BIOL, V13, P5323, DOI 10.1128/MCB.13.9.5323; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; BUVOLI M, 1990, NUCLEIC ACIDS RES, V18, P6595, DOI 10.1093/nar/18.22.6595; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CASASFINET JR, 1991, J MOL BIOL, V221, P693, DOI 10.1016/0022-2836(91)80081-5; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COBIANCHI F, 1993, NUCLEIC ACIDS RES, V21, P949, DOI 10.1093/nar/21.4.949; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HENICS T, 1994, J BIOL CHEM, V269, P5377; HERRICK G, 1976, J BIOL CHEM, V251, P2124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, J BIOL CHEM, V265, P17094; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; NAGY E, 1994, CELL IMMUNOL, V159, P140, DOI 10.1006/cimm.1994.1303; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROSENBERGER U, 1995, BIOCHEM J, V305, P269, DOI 10.1042/bj3050269; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tsukamoto H, 1996, J CLIN INVEST, V97, P2823, DOI 10.1172/JCI118738; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WEIGHARDT F, 1997, IN PRESS J CELL SCI; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZANDOMENI R, 1983, J MOL BIOL, V167, P561, DOI 10.1016/S0022-2836(83)80098-9; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	68	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28732	28741		10.1074/jbc.272.45.28732	http://dx.doi.org/10.1074/jbc.272.45.28732			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353343	hybrid			2022-12-25	WOS:A1997YF21900083
J	Hassel, B; Rathjen, FG; Volkmer, H				Hassel, B; Rathjen, FG; Volkmer, H			Organization of the neurofascin gene and analysis of developmentally regulated alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; N-CAM GENE; IMMUNOGLOBULIN SUPERFAMILY; VASE EXON; SURFACE RECOGNITION; NEURITE OUTGROWTH; GENOMIC STRUCTURE; AXONAL SURFACE; SPINAL-CORD; L1 FAMILY	Neurofascin is an axonal member of the L1 subgroup of the immunoglobulin superfamily implicated in neurite extension in the course of embryonic development. Here we have isolated and characterized the gene encoding chicken neurofascin. Comparison of genomic sequences with cDNA sequences provides the structure and localization of intron/exon boundaries and indicates that neurofascin isoforms are generated by alternative splicing of its pre-mRNA. The neurofascin gene is composed of 33 exons distributed over 72 kilobases. Each of the six immunoglobulin- and five fibronectin-type III-like domains is encoded by two exons. While introns between domains are of phase 1, others are of phase 0, 1, or 2. Alternative splicing of neurofascin is developmentally regulated as shown by polymerase chain reaction analysis. Furthermore, plasmid libraries from long range polymerase chain reaction-amplified cDNA of neurofascin were used to examine and quantify the distribution of alternatively spliced exons in individual neurofascin molecules; We found 50. different neurofascin isoforms at different developmental stages and revealed the existence of one major ''early'' in comparison with multiple ''late'' neurofascin isoforms.	MAX DELBRUCK CTR MOL MED, D-13122 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Volkmer, Hansjuergen/AAU-9641-2021	Volkmer, Hansjuergen/0000-0002-3867-0603				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bateman A, 1996, EMBO J, V15, P6050, DOI 10.1002/j.1460-2075.1996.tb00993.x; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; Burmeister M, 1996, MAMM GENOME, V7, P558, DOI 10.1007/s003359900168; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; COLWELL G, 1992, GENOMICS, V14, P875, DOI 10.1016/S0888-7543(05)80108-9; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; GIGER RJ, 1995, EUR J BIOCHEM, V227, P617, DOI 10.1111/j.1432-1033.1995.tb20181.x; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; JOUET M, 1995, MOL BRAIN RES, V30, P378, DOI 10.1016/0169-328X(95)00027-P; KAYYEM JF, 1992, J CELL BIOL, V118, P1259, DOI 10.1083/jcb.118.5.1259; Kenwrick S, 1996, J MED GENET, V33, P59, DOI 10.1136/jmg.33.1.59; KOHL A, 1992, J NEUROSCI RES, V32, P167, DOI 10.1002/jnr.490320206; KOZLOV SV, 1995, GENOMICS, V30, P141, DOI 10.1006/geno.1995.9892; KROGER S, 1990, J NEUROSCI, V10, P3118; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIU L, 1993, J NEUROSCI RES, V35, P327, DOI 10.1002/jnr.490350313; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MOSCOSO LM, 1995, J COMP NEUROL, V352, P321, DOI 10.1002/cne.903520302; NAKANO R, 1991, BIOCHEM BIOPH RES CO, V178, P282, DOI 10.1016/0006-291X(91)91811-P; OGRADY P, 1994, J BIOL CHEM, V269, P25193; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Plagge A, 1997, GENE, V192, P215, DOI 10.1016/S0378-1119(97)00066-8; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; REID RA, 1992, J MOL NEUROSCI, V3, P127, DOI 10.1007/BF02919404; REYES AA, 1991, MOL CELL BIOL, V11, P1654, DOI 10.1128/MCB.11.3.1654; ROSENTHAL A, 1993, CYTOGENET CELL GENET, V64, P185; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SCHREWE H, 1990, MOL CELL BIOL, V10, P2738, DOI 10.1128/MCB.10.6.2738; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHIGA T, 1991, J COMP NEUROL, V310, P234, DOI 10.1002/cne.903100208; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; SMALL SJ, 1988, NEURON, V1, P1007, DOI 10.1016/0896-6273(88)90158-4; VOLKMER H, 1992, J CELL BIOL, V118, P149, DOI 10.1083/jcb.118.1.149; Volkmer H, 1996, J CELL BIOL, V135, P1059, DOI 10.1083/jcb.135.4.1059; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; Walsh F. S., 1991, SEMIN NEUROSCI, V3, P271; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	61	50	52	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28742	28749		10.1074/jbc.272.45.28742	http://dx.doi.org/10.1074/jbc.272.45.28742			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353344	hybrid			2022-12-25	WOS:A1997YF21900084
J	Nusse, O; Serrander, L; FoyouziYoussefi, R; Monod, A; Lew, DP; Krause, KH				Nusse, O; Serrander, L; FoyouziYoussefi, R; Monod, A; Lew, DP; Krause, KH			Store-operated Ca2+ influx and stimulation of exocytosis in HL-60 granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED HUMAN-NEUTROPHILS; PROTEIN-KINASE-C; PHOSPHOLIPASE-D; INTRACELLULAR CALCIUM; SIGNAL-TRANSDUCTION; ENZYME-SECRETION; CHROMAFFIN CELLS; ACTIVATION; RECEPTOR; RELEASE	This study addresses the role of store-operated Ca2+ influx in the regulation of exocytosis in inflammatory cells. In HL-60 granulocytes, which do not possess voltage-operated Ca2+ channels, the chemotactic peptide fMet-Leu-Phe (fMLP) was able to stimulate store-operated Ca2+ influx and to trigger exocytosis of primary granules. An efficient triggering of exocytosis by fMLP required the presence of extracellular Ca2+ and was inhibited by blockers of store-operated Ca2+ influx. However, receptor-independent activation of store-operated Ca2+ influx through thapsigargin did not trigger exocytosis. fMLP was unable to stimulate exocytosis in the absence of cytosolic free Ca2+ concentration [Ca2+](c) elevations. However, a second signal generated by fMLP synergized with store-operated Ca2+ influx to trigger exocytosis and led to a left shift of the exocytosis/[Ca2+], relationship in ionomycin-stimulated cells. The synergistic fMLP-generated signaling cascade was long-lasting, involved a pertussis toxin-sensitive G protein and a phosphatidylinositol 3-kinase. In summary, store-operated Ca2+ influx is crucial for the efficient triggering of exocytosis in HL-60 granulocytes, but, as opposed to Ca2+ influx through voltage-operated Ca2+ channels in neurons, it is not a sufficient stimulus by itself and requires synergistic receptor-generated signals.			Nusse, O (corresponding author), UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND.		Krause, Karl-Heinz/E-8030-2011; Nüsse, Oliver/J-8645-2013; Serrander, Lena/W-4117-2017	Krause, Karl-Heinz/0000-0002-9033-6768; Nüsse, Oliver/0000-0003-0068-8346; Serrander, Lena/0000-0002-9058-3582				ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; Brandolini L, 1996, J LEUKOCYTE BIOL, V59, P427, DOI 10.1002/jlb.59.3.427; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; COCKCROFT S, 1981, BIOCHEM J, V200, P501, DOI 10.1042/bj2000501; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1991, BIOCHEM J, V275, P127, DOI 10.1042/bj2750127; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DEWALD B, 1988, J BIOL CHEM, V263, P16179; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; FoyouziYoussefi R, 1997, BIOCHEM J, V322, P709, DOI 10.1042/bj3220709; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KRAUSE KH, 1992, EUR J PHARM-MOLEC PH, V227, P221, DOI 10.1016/0922-4106(92)90131-E; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEW PD, 1981, J CLIN INVEST, V67, P1, DOI 10.1172/JCI110000; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; Merritt JE, 1997, CELL SIGNAL, V9, P53, DOI 10.1016/S0898-6568(96)00097-6; NACCACHE PH, 1985, J CELL PHYSIOL, V122, P273, DOI 10.1002/jcp.1041220217; NOVICK SF, 1994, NATURE, V370, P191; NUSSE O, 1988, J CELL BIOL, V107, P2117, DOI 10.1083/jcb.107.6.2117; PAI JK, 1988, J BIOL CHEM, V263, P12472; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V161, P276, DOI 10.1016/0006-291X(89)91592-1; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SMOLEN JE, 1987, J LEUKOCYTE BIOL, V41, P8, DOI 10.1002/jlb.41.1.8; SMOLEN JE, 1990, BIOCHIM BIOPHYS ACTA, V1052, P133, DOI 10.1016/0167-4889(90)90068-O; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3	49	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28360	28367		10.1074/jbc.272.45.28360	http://dx.doi.org/10.1074/jbc.272.45.28360			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353293	hybrid			2022-12-25	WOS:A1997YF21900033
J	Stam, JC; Sander, EE; Michiels, F; vanLeeuwen, FN; Kain, HET; vanderKammen, RA; Collard, JG				Stam, JC; Sander, EE; Michiels, F; vanLeeuwen, FN; Kain, HET; vanderKammen, RA; Collard, JG			Targeting of Tiam1 to the plasma membrane requires the cooperative function of the N-terminal pleckstrin homology domain and an adjacent protein interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BRUTON TYROSINE KINASE; RHO-LIKE PROTEINS; PH DOMAIN; RAS TRANSFORMATION; CDC42 GTPASES; BINDING; ACTIVATION; ASSOCIATION; RAC1	The Rho-like GTPases Cdc42, Rac, and Rho play key roles in the regulation of the actin cytoskeleton and are implicated in transcriptional activation and cell transformation. We have previously identified the invasion-inducing Tiam1 gene, which encodes an activator of Pac, In fibroblasts, Tiam1 induces Rac-mediated membrane ruffling, which requires the N-terminal pleckstrin homology (PHn) domain. Here we show that this PHn domain is part of a protein interaction domain, which mediates membrane localization of Tiam1. After subcellular fractionation, up to 50% of Tiam1 is recovered in the Triton X-100-insoluble high speed pellet that contains small protein complexes. The regions in Tiam1 that are responsible for these protein interactions comprise the PHn domain, an adjacent putative coiled coil region (CC), and an additional flanking region (Ex). Deletions in each of these regions abolish membrane localization of Tiam1 and membrane ruffling, suggesting that they function cooperatively. Indeed, only polypeptides encompassing the PHn-CC-Ex region, and not the PHn-CC or the Ex region, localize at the membrane. These results indicate that the N-terminal PH domain is part of a larger functional Tiam1 domain that mediates protein complex formation and membrane localization of Tiam1.	NETHERLANDS CANC INST,DIV CELL BIOL H1,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Collard JG, 1996, INT J ONCOL, V8, P131; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FOX JE, 1992, METHODS ENZYMOL, V42; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HILL CS, 1995, CELL, V70, P419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANBERGEN H, 1992, EXP CELL RES, V199, P90; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Yan SR, 1996, FEBS LETT, V380, P198; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHANG J, 1992, J BIOL CHEM, V267, P4686; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	47	128	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28447	28454		10.1074/jbc.272.45.28447	http://dx.doi.org/10.1074/jbc.272.45.28447			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353304	hybrid			2022-12-25	WOS:A1997YF21900044
J	Wells, MJ; Hatton, MWC; Hewlett, B; Podor, TJ; Sheffield, WP; Blajchman, MA				Wells, MJ; Hatton, MWC; Hewlett, B; Podor, TJ; Sheffield, WP; Blajchman, MA			Cytokeratin 18 is expressed on the hepatocyte plasma membrane surface and interacts with thrombin-antithrombin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED-PROTEIN; TISSUE-PLASMINOGEN ACTIVATOR; AMYLOID-BETA PEPTIDE; HEPARIN-COFACTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; INTERMEDIATE FILAMENTS; UROKINASE RECEPTOR; KERATIN FILAMENTS; EPITHELIAL-CELLS; CARCINOMA CELLS	During experiments to identify putative hepatic receptors for thrombin-antithrombin (TAT) complexes, a 45-kDa protein was identified by ligand blotting. Following gel purification, amino acid sequencing revealed the 45-kDa TAT-binding polypeptide to be cytokeratin 18 (CK18). The presence of CK18 on the surface of intact rat hepatoma cells was demonstrated by binding of I-125-anti-CK18 antibodies. Anti-CR18 antibodies reduced the binding and internalization of I-125-TAT by rat hepatoma cells. Immunocytochemical analysis, to determine the location of CK18 in vivo, revealed a periportal gradient of CK18 staining; with hepatocytes around the portal triads demonstrating striking pericellular staining. In addition, anti-CK18 IgG associated with perfused livers to a significantly greater extent than preimmune IgG. Taken together, these data provide evidence that CK18 is found on the extracellular surface of hepatocytes and could play a role in TAT removal. Finally, these data, in conjunction with recent reports of CK8 (Hembrough, T. A., Li, L., and Gonias, S. L. (1996) J. Biol. Chem. 271, 25684-25691) and CK1 cell membrane surface expression (Schmaier, A. H. (1997) Thromb. Hemostasis 78, 101-107), indicate a novel role for these proteins as putative cellular receptors or cofactors to cellular receptors.	MCMASTER UNIV,MED CTR,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University				Sheffield, William Peter/0000-0002-5870-8189				ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHEN M, 1993, NEUROLOGY, V43, P1223, DOI 10.1212/WNL.43.6.1223; CHOU CF, 1994, BIOCHEM J, V298, P457, DOI 10.1042/bj2980457; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; DONALD PJ, 1991, OTOLARYNG HEAD NECK, V105, P781, DOI 10.1177/019459989110500603; DUBERNARD V, 1995, FEBS LETT, V364, P109, DOI 10.1016/0014-5793(95)00362-D; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; FAIR DS, 1986, THROMB RES, V41, P67, DOI 10.1016/0049-3848(86)90280-X; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRANKE WW, 1981, EXP CELL RES, V131, P299, DOI 10.1016/0014-4827(81)90234-2; FRENCH SW, 1989, ELECTRON MICROSC REV, V2, P17, DOI 10.1016/0892-0354(89)90009-9; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FURMANIAKKAZMIERCZAK E, 1995, BIOCHEM CELL BIOL, V73, P105, DOI 10.1139/o95-012; GEORGE JN, 1978, J LAB CLIN MED, V92, P430; GETTINS PGW, 1996, SERPINS STRUCTURE FU, P161; GODFROID E, 1991, J CELL SCI, V99, P595; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HATTON MWC, 1994, METABOLISM, V43, P1430, DOI 10.1016/0026-0495(94)90040-X; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBBARD AL, 1983, J CELL BIOL, V96, P230, DOI 10.1083/jcb.96.1.230; HUNT LT, 1982, BIOCHEM BIOPH RES CO, V95, P866; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Lundblad R L, 1976, Methods Enzymol, V45, P156; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOROIANU J, 1993, P NATL ACAD SCI USA, V90, P3815, DOI 10.1073/pnas.90.9.3815; OKANOUE T, 1985, HEPATOLOGY, V5, P1, DOI 10.1002/hep.1840050102; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIZZO SV, 1990, AM J MED, V87, pS10; POLLER W, 1995, J BIOL CHEM, V270, P2841, DOI 10.1074/jbc.270.6.2841; POLSON A, 1990, IMMUNOL INVEST, V19, P253; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; SEMENKOVICH CF, 1990, BIOCHEMISTRY-US, V29, P9708, DOI 10.1021/bi00493a028; Sheffield WP, 1995, MOL BASIS THROMBOSIS, P355; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1993, J INVEST DERMATOL, V100, P729, DOI 10.1111/1523-1747.ep12475665; TAKEYA H, 1994, BIOCHEM BIOPH RES CO, V200, P1334, DOI 10.1006/bbrc.1994.1597; VOORSCHUUR AH, 1994, BIOCHEM J, V303, P809, DOI 10.1042/bj3030809; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	57	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28574	28581		10.1074/jbc.272.45.28574	http://dx.doi.org/10.1074/jbc.272.45.28574			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353322	hybrid			2022-12-25	WOS:A1997YF21900062
J	Okamoto, H; Fujita, H; Matsuyama, S; Tsuyama, S				Okamoto, H; Fujita, H; Matsuyama, S; Tsuyama, S			Purification, characterization, and localization of an ADP-ribosylactin hydrolase that uses ADP-ribosylated actin from rat brains as a substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-SPECIFIC MONO(ADP-RIBOSYL)ATION; ADENYLATE-CYCLASE SYSTEM; RIBOSYLARGININE HYDROLASE; TURKEY ERYTHROCYTES; BOTULINUM-C2 TOXIN; PROTEIN-KINASE; BOVINE BRAIN; 2 PROTEINS; RIBOSYLTRANSFERASE; BINDING	Mammalian ADP-ribosylation is poorly understood, An ADP-ribosylprotein hydrolase that acted on ADP-ribosylated actin was purified from rat brain. The molecular weight of this enzyme was 62,000 as determined by SDS-polyacrylamide gel electrophoresis and gel filtration, Enzyme activity with ADP-ribosylated actin as a substrate was inhibited by NAD, ATP, ADP, and ADP-ribose, but not by AMP, Mg2+ increased V-max, Purified ADP-ribosylactin hydrolase catalyzed the hydrolysis of ADP-ribosylated subunits G(s) alpha, G(i) alpha, and G(o) alpha and elongation factor-2, After de-ADP-ribosylation by the purified ADP-ribosylactin hydrolase, the proteins were re-ADP-ribosylated by brain mono-ADP-ribosyltransferases and bacterial toxins, The actin that was de-modified by ADP-ribosylactin hydrolase could form actin filaments, Two kinds of monoclonal antibodies against ADP-ribosylactin hydrolase were prepared and characterized, In an immunohistochemical study, the plasma membranes and cytoplasmic regions of the nerve cells in the rat brain were immunoreactive. In subcellular fractionation of the brains, most of the ADP-ribosylactin hydrolase activity was found in the cytosol and synaptosome fractions. When the synaptosomes were treated with a hypotonic solution, ADP-ribosylactin hydrolase activity was found in the supernatant, Our findings suggest that brain ADP-ribosylactin hydrolase has the important function of polymerizing actin for signal transduction in the cytosol of nerve cells and synaptosomes.	UNIV OSAKA PREFECTURE,DEPT VET SCI,MOL BIOL LAB,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University								AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; EARL DCN, 1965, BIOCHEM J, V94, P721, DOI 10.1042/bj0940721; FUJITA H, 1995, INT J BIOCHEM CELL B, V27, P1065, DOI 10.1016/1357-2725(95)00070-6; GEIPEL U, 1989, EUR J BIOCHEM, V179, P229, DOI 10.1111/j.1432-1033.1989.tb14545.x; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HONJO T, 1968, J BIOL CHEM, V243, P3553; HUANG KP, 1976, ANAL BIOCHEM, V72, P593, DOI 10.1016/0003-2697(76)90571-6; JUST I, 1994, EUR J BIOCHEM, V221, P1047, DOI 10.1111/j.1432-1033.1994.tb18823.x; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1984, P NATL ACAD SCI-BIOL, V81, P2703, DOI 10.1073/pnas.81.9.2703; LELKES PI, 1986, FEBS LETT, V208, P357, DOI 10.1016/0014-5793(86)81049-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1991, J NEUROCHEM, V57, P1380, DOI 10.1111/j.1471-4159.1991.tb08304.x; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1986, BIOCHEMISTRY-US, V25, P5408, DOI 10.1021/bi00367a010; MOSS J, 1992, J BIOL CHEM, V267, P10481; MOSS J, 1985, P NATL ACAD SCI USA, V82, P5603, DOI 10.1073/pnas.82.17.5603; OBARA S, 1989, BIOCHEM BIOPH RES CO, V163, P452, DOI 10.1016/0006-291X(89)92157-8; OHISHI I, 1986, BIOCHEM BIOPH RES CO, V136, P802, DOI 10.1016/0006-291X(86)90511-5; PATERSON JE, 1990, J BIOL CHEM, V265, P17062; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; SAYHAN O, 1986, BIOCHEM BIOPH RES CO, V139, P1210, DOI 10.1016/S0006-291X(86)80306-0; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKADA T, 1993, J BIOL CHEM, V268, P17837; TANIGAWA Y, 1984, J BIOL CHEM, V259, P2022; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TITANJI VPK, 1977, BIOCHIM BIOPHYS ACTA, V481, P140, DOI 10.1016/0005-2744(77)90145-0; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; WEGNER A, 1988, J BIOL CHEM, V263, P13739; WEIR JP, 1982, METHOD ENZYMOL, V85, P371; WOOD T, 1964, BIOCHEM J, V91, P453, DOI 10.1042/bj0910453; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	46	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28116	28125		10.1074/jbc.272.44.28116	http://dx.doi.org/10.1074/jbc.272.44.28116			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346967	hybrid			2022-12-25	WOS:A1997YD47300093
J	vandePut, FHMM; Elliott, AC				vandePut, FHMM; Elliott, AC			The endoplasmic reticulum can act as a functional Ca2+ in all subcellular regions of the pancreatic acinar cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-TRISPHOSPHATE; CALRETICULIN INCREASES; EXOCRINE PANCREAS; GUINEA-PIG; RELEASE; STORES; OSCILLATIONS; CA-2+; OVEREXPRESSION; SECRETION	Stimulation of pancreatic acinar cells raises [Ca2+](i) via Ca2+ release from inositol-1,4,5-trisphosphate (InsP(3))-sensitive intracellular Ca2+ stores, generally considered to reside within the endoplasmic reticulum (ER), However, with physiological doses of cholinergic agonists, the [Ca2+](i) increase is localized to the apical (secretory) pole of the cell, leading to suggestions that zymogen (secretory) granules themselves may constitute an InsP(3)-sensitive Ca2+ store responsible for localized Ca2+ release, We have therefore re-investigated whether the ER in pancreatic acinar cells is capable of acting as a functional Ca2+ store in all, or only some, cellular regions. In streptolysin 0-permeabilized cells, the ER accumulated up to 25 mmol of Ca-45(2+) per liter ER volume by an ATP-dependent, thapsigargin-sensitive, process, This tracer Ca2+ uptake was dependent on ambient (loading) [Ca2+], as was the intra-ER free [Ca2+], assessed by imaging the fluorescence of Magfura-8 within the Ca2+ stores, Comparison of free and total intra-ER [Ca2+] indicated that 200-300 Ca2+ ions are bound within the ER lumen for every Ca2+ ion remaining free. Subcellular analysis showed that EB stores in all regions of the permeabilized cell took up Ca2+ at loading [Ca2+] between 60 nM and 1 mu M. Thapsigargin released Ca2+ from stores in all cellular regions, as did InsP(3). Immunofluorescence with antibodies against sarco(endo)plasmic reticulum-2b type Ca2+,Mg2+-ATP-ase or calreticulin confirmed that ER Ca2+ stores were present throughout the cytoplasm. In summary, these results clearly show that the endoplasmic reticulum can act as a functional Ca2+ store in all regions of the acinar cell, including the apical pole.	UNIV MANCHESTER,SCH BIOL SCI,CELL PHYSIOL GRP,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester				Elliott, Austin/0000-0003-3569-9002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CASE RM, 1973, J PHYSIOL-LONDON, V235, P75, DOI 10.1113/jphysiol.1973.sp010379; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DELAAGE M, 1967, BIOCHEM BIOPH RES CO, V28, P390, DOI 10.1016/0006-291X(67)90323-3; DORMER RL, 1981, AM J PHYSIOL, V240, pG38, DOI 10.1152/ajpgi.1981.240.1.G38; DORMER RL, 1993, BIOCHIM BIOPHYS ACTA, V1152, P225, DOI 10.1016/0005-2736(93)90253-V; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; ELLIOTT AC, 1992, EUR J PHYSL, V422, P245; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KHANNA NC, 1986, BIOCHEMISTRY-US, V25, P1078, DOI 10.1021/bi00353a020; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; Roderick HL, 1997, FEBS LETT, V405, P181, DOI 10.1016/S0014-5793(97)00183-X; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHREURS VVAM, 1976, BIOCHIM BIOPHYS ACTA, V436, P664, DOI 10.1016/0005-2736(76)90448-X; SCHREURS VVAM, 1975, BIOCHIM BIOPHYS ACTA, V404, P257, DOI 10.1016/0304-4165(75)90332-3; SCHREURS VVAM, 1976, BIOCHIM BIOPHYS ACTA, V419, P320, DOI 10.1016/0005-2736(76)90358-8; STEIN EA, 1964, BIOCHEMISTRY-US, V3, P56, DOI 10.1021/bi00889a010; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; VANDEPUT FHMM, 1993, J MEMBRANE BIOL, V135, P153, DOI 10.1007/BF00231441; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WILLEMS PHGM, 1994, PFLUG ARCH EUR J PHY, V427, P233, DOI 10.1007/BF00374529; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; Yule DI, 1997, J BIOL CHEM, V272, P9093	38	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27764	27770		10.1074/jbc.272.44.27764	http://dx.doi.org/10.1074/jbc.272.44.27764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346920	hybrid			2022-12-25	WOS:A1997YD47300046
J	Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD				Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD			Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation	ONCOGENE			English	Article						apoptosis; CD40; cell cycle; Burkitt lymphoma; gamma-irradiation; Bcl-2	RADIATION-INDUCED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; CYCLE PROGRESSION; GENE-EXPRESSION; DNA-DAMAGE; DEATH; GROWTH; LINES; PROTECTS	Bcl-2 can inhibit apoptosis induced by a variety of stimuli, including radiation and its presence in tumour cells would be expected to indicate poor prognosis. Bcl-2-expressing tumours, however, are often low-grade and highly responsive to therapy. To investigate this apparent paradox, we analysed in vitro the responses of Burkitt lymphoma (BL) cells to gamma-irradiation in the presence and absence of Bcl-2. High-level expression of Bcl-2 was shown to promote BL cell survival following irradiation. However, a significant proportion of Bcl-2-rescued cells subsequently underwent apoptosis after an extended period in culture. In addition, in different BL lines, Bcl-2 was found either to promote or to inhibit long-term proliferative activity following gamma-irradiation. This differential regulation of proliferation correlated both with differential effects of Bcl-2 on the cell cycle and with differences in p53 status. Thus, by one week after irradiation, BL cells expressing only wild-type p53 (wt/wt) had arrested in G1, whereas those with a mutant allele (wt/mu) were arrested in all phases of the cell cycle. The proportion of Bcl-2-rescued cells subsequently underwent apoptosis was reduced Ligation of CD40 at the time of irradiation in wt/wt BL cells, but not in wt/mu cells, CD40-ligation reduced both G1-arrest and apoptosis in parallel. These results indicate that, whilst Bcl-2 can delay apoptosis in BL cells following gamma-irradiation, the protein can also cause growth-arrest and thereby promote apoptosis, Long-term survival following Bcl-2-mediated rescue of gamma-irradiated cells may depend on p53 status and require additional death-repressing or growth-promoting signals.	UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; LOYOLA UNIV,CARDINAL BERNADINE CANC CTR,CHICAGO,IL 60611	University of Birmingham; University of Birmingham; Loyola University Chicago			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	NATIONAL CANCER INSTITUTE [R01CA055840, R55CA055840] Funding Source: NIH RePORTER; NCI NIH HHS [CA55840] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRACEY TS, 1995, ONCOGENE, V10, P2391; CAMPOS L, 1993, BLOOD, V81, P3091; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Gilbert MS, 1996, CELL DEATH DIFFER, V3, P215; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herod JJO, 1996, CANCER RES, V56, P2178; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRUMAN II, 1991, J CELL PHYSIOL, V148, P267, DOI 10.1002/jcp.1041480212; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LEPELLEY P, 1995, LEUKEMIA, V9, P726; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lock RB, 1996, CANCER RES, V56, P4006; MARVEL J, 1994, ONCOGENE, V9, P1117; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MILNER AE, 1993, ONCOGENE, V8, P3385; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PIRIS MA, 1994, BRIT J CANCER, V69, P337, DOI 10.1038/bjc.1994.61; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SEKI H, 1995, CELL IMMUNOL, V163, P30, DOI 10.1006/cimm.1995.1095; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Soldatenkov VA, 1996, INT J ONCOL, V9, P547; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Tjalma W, 1997, J CLIN PATHOL, V50, P33, DOI 10.1136/jcp.50.1.33; Walker A, 1997, CANCER RES, V57, P1939; Wang H, 1996, ONCOGENE, V13, P373; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1815	1822		10.1038/sj.onc.1201355	http://dx.doi.org/10.1038/sj.onc.1201355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362448				2022-12-25	WOS:A1997XZ72500008
J	Babnigg, G; Bowersox, SR; Villereal, ML				Babnigg, G; Bowersox, SR; Villereal, ML			The role of pp60(c-src) in the regulation of calcium entry via store-operated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	6th International Cell Biology Meeting	DEC 07-11, 1996	SAN FRANCISCO, CA				NIH 3T3 CELLS; C-SRC; TYROSINE PHOSPHORYLATION; DEPENDENT SUPPRESSION; KINASE; PROTEIN; TRANSFORMATION; FIBROBLASTS; RECEPTOR; INFLUX	In many cell types, G protein-coupled receptors stimulate a transient Ca2+ release from internal stores followed by a sustained, capacitative Ca2+ entry, which is mediated by store-operated channels (SOCs), Although it is clear that SOCs are activated by depletion of internal Ca2+ stores, the mechanism for this process is not well understood, Previously, we have reported that inhibitors of tyrosine kinase activity block the bradykinin-and thapsigarin-stimulated Ca2+ entry in fibroblasts, suggesting that a tyrosine kinase activity may be involved in relaying the message from the empty internal Ca2+ stores to the plasma membrane Ca2+ channel (Lee, K.-M., Toscas, K,, and Villereal, RI, L, (1993) J, Biol, Chem, 268, 9945-9948), We also have demonstrated that bradykinin activates the nonreceptor tyrosine kinase c-src (Lee, K.-M., and Villereal, hi. L, (1996) Am. J, Physiol. 270, C1430-C1437). We investigated whether c-src plays a role in the regulation of SOCs by monitoring capacitative Ca2+ entry in 3T3-like embryonic fibroblast lines derived from either wild type or src(-)/src(-) (Src(-)) transgenic mice, We report that Ca2+ entry, following store depletion by either bradykinin or thapsigargin, is dramatically lower in Src-fibroblasts than in wild type fibroblasts. The level of capacitative Ca2+ entry in Src(-) cells is restored to nearly normal levels by transfecting Src-cells with chicken c-src, These data suggest that c-src may play a major role in the regulation of SOCs.	UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago					NIGMS NIH HHS [GM54500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONACCORSI L, 1995, FEBS LETT, V364, P83, DOI 10.1016/0014-5793(95)00369-K; BYRON KL, 1992, J BIOL CHEM, V267, P108; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Lee KM, 1996, AM J PHYSIOL-CELL PH, V270, pC1430, DOI 10.1152/ajpcell.1996.270.5.C1430; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LIN PH, 1995, ONCOGENE, V10, P401; MEUCCI O, 1995, BIOCHEM BIOPH RES CO, V209, P630, DOI 10.1006/bbrc.1995.1546; MILLER BA, 1994, CELL CALCIUM, V16, P481, DOI 10.1016/0143-4160(94)90078-7; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	23	54	57	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29434	29437		10.1074/jbc.272.47.29434	http://dx.doi.org/10.1074/jbc.272.47.29434			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	YG647	9368000	hybrid			2022-12-25	WOS:A1997YG64700010
J	Degroote, S; LoGuidice, JM; Strecker, G; Ducourouble, MP; Roussel, P; Lamblin, G				Degroote, S; LoGuidice, JM; Strecker, G; Ducourouble, MP; Roussel, P; Lamblin, G			Characterization of an N-acetylglucosamine-6-O-sulfotransferase from human respiratory mucosa active on mucin carbohydrate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE RESIDUES; CYSTIC-FIBROSIS GENE; L-SELECTIN; LINKED OLIGOSACCHARIDES; ENZYMATIC SULFATION; LEWIS-X; SULFOTRANSFERASE; BIOSYNTHESIS; LIGAND; CELLS	A microsomal GlcNAc-6-O-sulfotransferase activity from human bronchial mucosa, able to transfer a sulfate group from adenosine 3'-phosphate 5'-phosphosulfate onto methyl-N-acetylglucosaminides or terminal N-acetylglucosamine residues of carbohydrate chains from human respiratory mucins, has been characterized. The reaction products containing a terminal HO3S-6GlcNAc were identified by high performance anion-exchange chromatography. Using methyl-beta-N-acetylglucosaminide as a substrate, the optimal activity was obtained with 0.1% Triton X-100, 30 mM NaF, 20 mM Mn2+, 5 mM AMP in a 30 mM MOPS (3-(N-morpholino) propanesulfonic acid) buffer at pH 6.7, The apparent K-m values for adenosine 3'-phosphate 5'-phosphosulfate and methyl-beta-N-acetylglucosaminide were observed at 9.1 x 10(-6) M and 0.54 x 10(-3) M, respectively. The enzyme had more affinity for carbohydrate chains with a terminal GlcNAc residue than for methyl-beta-N-acetylglucosaminide; it was unable to catalyze the transfer of sulfate to position 6 of the GlcNAc residue contained in a terminal Gal beta 1-4GlcNAc sequence. However, oligosaccharides with a nonreducing terminal HO3S-6GlcNAc were substrates for a beta 1-4 galactosyltransferase from human bronchial mucosa. These data point out that GlcNAc-6-O-sulfotransferase must act before beta 1-4 galactosylation in mucin-type oligosaccharide biosynthesis.	INSERM, U377, F-59045 LILLE, FRANCE; UNIV SCI & TECHNOL LILLE, CNRS, UMR 111, F-59650 VILLENEUVE DASCQ, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille			GUIDICE, Jean-Marc LO/O-3177-2017	GUIDICE, Jean-Marc LO/0000-0003-3486-6809; Groux-Degroote, Sophie/0000-0002-9964-6519				BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Boat T F, 1976, Mod Probl Paediatr, V19, P141; CACAN R, 1995, METHODS GLYCONJUGATE, P201; CARNOY C, 1993, AM J RESP CELL MOL, V9, P323, DOI 10.1165/ajrcmb/9.3.323; CARTER SR, 1988, J BIOL CHEM, V263, P11977; CHANDRASEKARAN EV, 1995, BIOCHEMISTRY-US, V34, P2925, DOI 10.1021/bi00009a024; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; DELUCA S, 1968, J BIOL CHEM, V243, P2725; DOSANJH A, 1994, AM J PHYSIOL, V266, pC360, DOI 10.1152/ajpcell.1994.266.2.C360; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GOSO Y, 1993, GLYCOCONJUGATE J, V10, P226, DOI 10.1007/BF01209822; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HOIBY N, 1988, CHEST, V94, pS97, DOI 10.1378/chest.94.2_Supplement.97S; JAIN RK, 1995, CARBOHYD RES, V268, P279, DOI 10.1016/0008-6215(94)00323-8; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; Lamblin G, 1976, Mod Probl Paediatr, V19, P153; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LAMBLIN G, 1991, AM REV RESPIR DIS, V144, pS19, DOI 10.1164/ajrccm/144.3_pt_2.S19; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAZATIN JO, 1994, GLYCOSYLATION DIS, V1, P263; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MILLER RR, 1979, ARCH BIOCHEM BIOPHYS, V198, P31, DOI 10.1016/0003-9861(79)90392-8; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; Porchet N, 1995, BIOCHEM SOC T, V23, P800, DOI 10.1042/bst0230800; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Roussel P, 1996, GLYCOPROTEINS DIS, P351; ROUSSEL P, 1996, ENV IMPACT AIRWAYS I, V93, P437; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; SLOMIANY A, 1988, ARCH ORAL BIOL, V33, P669, DOI 10.1016/0003-9969(88)90122-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; STRECKER G, 1992, BIOCHIMIE, V74, P39, DOI 10.1016/0300-9084(92)90182-E; SUZUKI S, 1960, J BIOL CHEM, V235, P257; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANKUIK JA, 1987, FEBS LETT, V221, P150, DOI 10.1016/0014-5793(87)80370-8; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WHITTEMORE RM, 1986, ARCH BIOCHEM BIOPHYS, V249, P464, DOI 10.1016/0003-9861(86)90023-8; Zhang YL, 1995, J CLIN INVEST, V96, P2997, DOI 10.1172/JCI118372	49	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29493	29501		10.1074/jbc.272.47.29493	http://dx.doi.org/10.1074/jbc.272.47.29493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368010	hybrid			2022-12-25	WOS:A1997YG64700020
J	Salerno, JC; Harris, DE; Irizarry, K; Patel, B; Morales, AJ; Smith, SME; Martasek, P; Roman, LJ; Masters, BSS; Jones, CL; Weissman, BA; Lane, P; Liu, Q; Gross, SS				Salerno, JC; Harris, DE; Irizarry, K; Patel, B; Morales, AJ; Smith, SME; Martasek, P; Roman, LJ; Masters, BSS; Jones, CL; Weissman, BA; Lane, P; Liu, Q; Gross, SS			An autoinhibitory control element defines calcium-regulated isoforms of nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; ELECTRON-TRANSFER; L-ARGININE; PROTEIN; IDENTIFICATION; BIOSYNTHESIS; FLAVOPROTEIN; SEQUENCES; EVOLUTION; REDUCTASE	Nitric oxide synthases (NOSs) are classified functionally, based an whether calmodulin binding is Ca2+-dependent (cNOS) or Ca2+-independent (iNOS). This key dichotomy has not been defined at the molecular level, Here we show that cNOS isoforms contain a unique polypeptide insert in their FMN binding domains which is not shared with iNOS or other related flavoproteins. Previously identified autoinhibitory domains in calmodulin-regulated enzymes raise the possibility that the polypeptide insert is the autoinhibitory domain of cNOSs. Consistent with this possibility, three-dimensional molecular modeling suggested that the insert originates from a site immediately adjacent to the calmodulin binding sequence, Synthetic peptides derived from the 45-amino acid insert of endothelial NOS were found to potently inhibit binding of calmodulin and activation of cNOS isoforms, This inhibition was associated with peptide binding to NOS, rather than free calmodulin, and inhibition could be reversed by increasing calmodulin concentration, In contrast, insert-derived peptides did not interfere with the arginine site of cNOS, as assessed from [H-3]N-G-nitro-L-arginine binding, nor did they potently effect iNOS activity, Limited proteolysis studies showed that calmodulin's ability to gate electron flow through cNOSs is associated with displacement of the insert polypeptide; this is the first specific calmodulin-induced change in NOS conformation to be identified, Together, our findings strongly suggest that the insert is an autoinhibitory control element, docking with a site on cNOSs which impedes calmodulin binding and enzymatic activation, The autoinhibitory control element molecularly defines cNOSs and offers a unique target for developing novel NOS activators and inhibitors.	CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021; RENSSELAER POLYTECH INST,DEPT BIOL,TROY,NY 12180; AENEAS BIOTECHNOL,TROY,NY 12180; UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM BIOCHEM & STRUCT BIOL,NEW YORK,NY 10021	Cornell University; Rensselaer Polytechnic Institute; University of Texas System; University of Texas Health San Antonio; Cornell University			salerno, john c/A-2595-2014; Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444; Lane, Paul/0000-0003-1595-3237	NHLBI NIH HHS [HL 30050, HL 44603, HL 50656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030050, R01HL050656, R01HL030050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; Gross SS, 1996, METHOD ENZYMOL, V268, P159; GROSS SS, 1992, J BIOL CHEM, V267, P25722; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IMPARL JM, 1995, ARCH BIOCHEM BIOPHYS, V318, P3780; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KIM JJ, 1996, FLAVINS FLAVOPROTEIN, P455; Liu Q, 1996, METHOD ENZYMOL, V268, P311; Lowe PN, 1996, BIOCHEM J, V314, P55, DOI 10.1042/bj3140055; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Ruan J, 1996, J BIOL CHEM, V271, P22679, DOI 10.1074/jbc.271.37.22679; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WATENPAUGH KD, 1973, P NATL ACAD SCI USA, V70, P3857, DOI 10.1073/pnas.70.12.3857	33	211	217	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29769	29777		10.1074/jbc.272.47.29769	http://dx.doi.org/10.1074/jbc.272.47.29769			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368047	Green Accepted, hybrid			2022-12-25	WOS:A1997YG64700057
J	Knauer, MF; Kridel, SJ; Hawley, SB; Knauer, DJ				Knauer, MF; Kridel, SJ; Hawley, SB; Knauer, DJ			The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; HUMAN ANTITHROMBIN-III; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; BINDING-SITE; INTERNALIZATION; DEGRADATION; PROTEOGLYCANS; PURIFICATION	Protease nexin 1 (PN1) is a serine protease inhibitor (SERPIN) that acts as a suicide substrate for thrombin (Th) and urokinase-type plasminogen activator (uPA), PN1 forms 1:1 stoichiometric complexes with these proteases, which are then rapidly bound, internalized, and degraded, The low density lipoprotein receptor-related protein (LRP) is the receptor responsible for the internalization of protease-PN1 complexes, However, we found that the LRP is not significantly involved in the initial cell surface binding of thrombin-PN1, leading us to investigate what cellular component was responsible for this initial interaction, Since Th-PN1 complexes retain a high-affinity for heparin after complex formation, unlike several of the other SERPINs, we tested the possibility that cell surface heparins were involved in initial complex binding, Soluble heparin was found to be a potent inhibitor of the binding of Th-PN1 to the cell surface and greatly facilitated the dissociation of Th-PN1 complexes pre-bound in the absence of soluble heparin, To ascertain the role of cell surface heparins, further studies were done using complexes of thrombin and PN1(K7E), a variant of PN1 in which the heparin binding site was rendered non-functional, When added at equal initial concentrations of complexes, Th-PN1(K7E) was catabolized B-to 10-fold less efficiently than Th-PN1, a direct result of the greatly diminished initial binding of the Th-PN1(K7E) complexes, These data demonstrate the sizable contribution of cell surface heparins to Thrombin-PN1 complex binding and support a model in which these heparins act to concentrate the complexes at the cell surface facilitating their subsequent LRP-dependent endocytosis.	UNIV CALIF IRVINE, SCH BIOL SCI, DEPT DEV & CELL BIOL, IRVINE, CA 92697 USA; Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	University of California System; University of California Irvine; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM34001-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONESE M, 1994, J BIOL CHEM, V269, P17886; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; EVANS DL, 1991, J BIOL CHEM, V266, P22307; GILLESPIE LS, 1991, J BIOL CHEM, V266, P3995; Hardy MM, 1997, J BIOL CHEM, V272, P6812, DOI 10.1074/jbc.272.10.6812; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HOWARD EW, 1987, J CELL PHYSIOL, V131, P276, DOI 10.1002/jcp.1041310219; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; Veiga SS, 1997, J BIOL CHEM, V272, P12529, DOI 10.1074/jbc.272.19.12529; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLNOW TE, 1994, J CELL SCI, V107, P719	30	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29039	29045		10.1074/jbc.272.46.29039	http://dx.doi.org/10.1074/jbc.272.46.29039			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360977	hybrid			2022-12-25	WOS:A1997YF68400036
J	Hunter, T; Bannister, WH; Hunter, GJ				Hunter, T; Bannister, WH; Hunter, GJ			Cloning, expression, and characterization of two manganese superoxide dismutases from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; METHYL VIOLOGEN; LIFE-SPAN; C-ELEGANS; DOSAGE COMPENSATION; SEX DETERMINATION; OXIDATIVE DAMAGE; SENSITIVE MUTANT; GENE; NEMATODE	Two genes encoding manganese superoxide dismutase (sod-2 and sod-3) have been identified in the nematode Caenorhabditis elegans. Each gene is composed of five exons, and intron positions are identical; however, intron sizes and sequences are not the same, The predicted protein sequences are 86.3% homologous (91.8% conservative), and the cDNAs are only 75.2% homologous, Both deduced protein sequences contain the expected N-terminal mitochondrial transit peptides. Reverse transcriptase polymerase chain reaction analysis shows that both genes are expressed under normal growth conditions and that their RNA transcripts are trans-spliced to the SL-1 leader sequence. The latter result together with Northern blot analysis indicate that both genes have mono-cistronic transcripts, The sod-3 gene was mapped to chromosome X, and the location of sod-2 was confirmed to be chromosome I, Polymerase chain reaction was used to amplify the cDNA regions encoding the predicted mature manganese superoxide dismutase proteins and each was cloned and expressed to high levels in Escherichia coli cells deficient in cytosolic superoxide dismutases. Both proteins were shown to be active in E. coli, providing similar protection against methyl viologen-induced oxidative stress. The expressed enzymes, which were not inhibited by hydrogen peroxide or cyanide, are dimeric, show quite different electrophoretic mobilities and isoelectric points, but exhibit comparable specific activities.	UNIV MALTA, DEPT PHYSIOL & BIOCHEM, MSIDA MSD06, MALTA	University of Malta				Hunter, Therese/0000-0002-3447-5800; Hunter, Gary/0000-0002-0336-6556				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BEYER WF, 1991, J BIOL CHEM, V266, P303; BLUM J, 1983, ARCH BIOCHEM BIOPHYS, V222, P35, DOI 10.1016/0003-9861(83)90499-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1974, GENETICS, V77, P71; COMPAN I, 1993, J BACTERIOL, V175, P1687, DOI 10.1128/JB.175.6.1687-1696.1993; DARR D, 1995, FREE RADICAL BIO MED, V18, P195, DOI 10.1016/0891-5849(94)00118-4; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; FRIEDMAN DB, 1988, GENETICS, V118, P75; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GIGLIO AM, 1994, BIOCHEM MOL BIOL INT, V33, P41; GIGLIO MP, 1994, BIOCHEM MOL BIOL INT, V33, P37; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HARTMAN P, 1995, J GERONTOL A-BIOL, V50, pB322, DOI 10.1093/gerona/50A.6.B322; HASSAN HM, 1978, J BIOL CHEM, V253, P8143; HASSAN HM, 1977, J BIOL CHEM, V252, P7667; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; HONDA S, 1993, J GERONTOL, V48, pB57, DOI 10.1093/geronj/48.2.B57; HOPKIN KA, 1992, J BIOL CHEM, V267, P24253; HUANG XY, 1989, J MOL BIOL, V206, P411, DOI 10.1016/0022-2836(89)90490-7; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; ISHII N, 1990, MUTAT RES, V237, P165, DOI 10.1016/0921-8734(90)90022-J; ISHII N, 1993, MECH AGEING DEV, V68, P1, DOI 10.1016/0047-6374(93)90135-E; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lithgow GJ, 1996, BIOESSAYS, V18, P809, DOI 10.1002/bies.950181007; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MEYER BJ, 1988, TRENDS GENET, V4, P337, DOI 10.1016/0168-9525(88)90053-4; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MUIRAS ML, 1993, MUTAT RES, V295, P47, DOI 10.1016/0921-8734(93)90010-Z; NUSBAUM C, 1989, GENETICS, V122, P579; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; PRIVALLE CT, 1992, J BIOL CHEM, V267, P9140; REED DJ, 1986, FUND APPL TOXICOL, V6, P591, DOI 10.1016/0272-0590(86)90171-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Suzuki N, 1996, DNA Res, V3, P171, DOI 10.1093/dnares/3.3.171; TOUATI D, 1988, J BACTERIOL, V170, P2511, DOI 10.1128/jb.170.6.2511-2520.1988; VANFLETEREN JR, 1992, COMP BIOCHEM PHYS B, V102, P219, DOI 10.1016/0305-0491(92)90114-7; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER UG, 1993, PROTEIN SCI, V2, P814, DOI 10.1002/pro.5560020511; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; YSEBAERTVANNESTE M, 1980, ANAL BIOCHEM, V107, P86, DOI 10.1016/0003-2697(80)90496-0; ZHU DH, 1993, P NATL ACAD SCI USA, V90, P9310, DOI 10.1073/pnas.90.20.9310; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	69	112	125	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28652	28659		10.1074/jbc.272.45.28652	http://dx.doi.org/10.1074/jbc.272.45.28652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353332	hybrid			2022-12-25	WOS:A1997YF21900072
J	Kamitani, T; Kito, K; Nguyen, HP; Yeh, ETH				Kamitani, T; Kito, K; Nguyen, HP; Yeh, ETH			Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; DEGRADATION; IDENTIFICATION; CONJUGATION; COMPLEX; HOMOLOG	NEDD8 is a novel 81 amino acid polypeptide which is 60% identical and 80% homologous to ubiquitin, Northern blot analysis showed that the NEDD8 message was developmentally down-regulated, In adult tissues, NEDD8 expression was mostly restricted to the heart and skeletal muscle. Antiserum specific for NEDD8 detected a 6-kDa monomer in SK-N-SH, BJAB, and HL60 cell lysates, A 14-kDa band was also detected in BJAB, HL60, and SK-MEL28 but not in SK-N-SH and K562 cell lysates, An approximately 90-kDa band was detected in all cell lines tested, Thus, NEDD8 is likely to be conjugated to other proteins in a manner analogous to ubiquitination. However, the conjugation pattern of NEDD8 is entirely different from that of ubiquitin in all cell lines tested, To study NEDD8 conjugation in more detail, hemagglutinin-epitope-tagged NEDD8 was expressed in COS cells. Western blot analysis revealed an NEDD8 monomer and a series of higher molecular weight NEDD8-conjugated proteins or NEDD8 multimers, Immunocytochemical analysis showed that NEDD8 expression was highly enriched in the nucleus and was much weaker in the cytosol, In contrast, ubiquitin expression was detectable equally well in the nucleus and cytosol, Mutational analysis showed that the C terminus of NEDD8 was efficiently cleaved and that Gly-76 was required for conjugation of NEDD8 to other proteins, Taken together, NEDD8 provides another substrate for covalent protein modification and may play a unique role during development.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV MOL MED,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,INST MOL MED PREVENT HUMAN DIS,RES CTR CARDIOVASC DIS,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NHLBI NIH HHS [HL-45851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boddy MN, 1996, ONCOGENE, V13, P971; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOPKIN K, 1997, J NIH RES, V9, P36; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAMITANI T, 1991, CLIN IMMUNOL IMMUNOP, V58, P217, DOI 10.1016/0090-1229(91)90138-Z; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113	26	347	356	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28557	28562		10.1074/jbc.272.45.28557	http://dx.doi.org/10.1074/jbc.272.45.28557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353319	hybrid			2022-12-25	WOS:A1997YF21900059
J	Mitchell, AG; Martin, CE				Mitchell, AG; Martin, CE			Fah1p, a Saccharomyces cerevisiae cytochrome b(5) fusion protein, and its Arabidopsis thaliana homolog that lacks the cytochrome b(5) domain both function in the alpha-hydroxylation of sphingolipid-associated very long chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; RICINUS-COMMUNIS L; XYLENE MONOOXYGENASE; ALKANE HYDROXYLASE; GENE; EXPRESSION; B5; SEQUENCE; SEGMENT; STRAINS	A search of the Saccharomyces cerevisiae genome data base for cytochrome b(5)-like sequences identified a 1.152-kilobase pair open reading frame, located on chromosome XIII at locus YMR272C (FAH1). That gene encodes a putative 384-amino acid protein with an amino-terminal cytochrome b(5) domain, The b(5) core domain shows a 52% identity and 70% similarity to that of the yeast microsomal cytochrome b(5) and a 35% identity and 54% similarity to the b(5) core domain of OLE1, the S. cerevisiae Delta-9 fatty acid desaturase, Expression of the S. cerevisiae FAH1 cytochrome b(5) domain in Escherichia coli produces a soluble protein that exhibits the typical oxidized versus reduced differential absorbance spectra of cytochrome b(5). Sequence analysis of Fah1p reveals other similarities to Ole1p, Both proteins are predicted to have two hydrophobic domains, each capable of spanning the membrane twice, and both have the HX(2-3)(XH)H motifs that are characteristic of membrane-bound fatty acid desaturases, These similarities to Ole1p suggested that Fah1p played a role in the biosynthesis or modification of fatty acids. Disruption of the FAH1 gene in S. cerevisiae did not give any visible phenotype, and there was no observable difference in content or distribution of the most abundant long chain saturated and unsaturated 14-18-carbon fatty acid species, Northern blot analysis, however, showed that this gene is expressed at much lower levels (similar to 150-fold) than the OLE1 gene, suggesting that it might act on a smaller subset of fatty acids, Analysis of sphingolipid-derived very long chain fatty acids revealed an approximately 40 fold reduction of alpha-HO 26:0 and a complementary increase in 26:0 in the gene-disrupted fah1 Delta strain, GAL1 expression of the S. cerevisiae FAH1 genes in the fah1 Delta strain restores alpha-HO 26:0 fatty acids to wild type levels, Also identified are a number of homologs to this gene in other Species, Expression of an Arabidopsis thaliana FAH1 gene, which does not contain the cytochrome b(5) domain, in the fah1 Delta strain produced an approximately 25-fold increase in alpha-HO 26:0 and reduced the levels of its 26-carbon precursor, suggesting that it functions in very long chain fatty acid hydroxylation using an alternate electron transfer mechanism.	RUTGERS STATE UNIV,DEPT BIOL SCI,NELSON LABS,PISCATAWAY,NJ 08855; RUTGERS STATE UNIV,BUR BIOL RES,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick								Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DAILEY HA, 1978, J BIOL CHEM, V253, P8203; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GARGANO S, 1995, LIPIDS, V30, P899, DOI 10.1007/BF02537480; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUIARD B, 1979, J MOL BIOL, V135, P639, DOI 10.1016/0022-2836(79)90169-4; KAYA K, 1984, J BIOL CHEM, V259, P3548; KOK M, 1989, J BIOL CHEM, V264, P5435; LEDERER F, 1994, BIOCHIMIE, V76, P674, DOI 10.1016/0300-9084(94)90144-9; LESTER RL, 1993, J BIOL CHEM, V268, P845; LIANGTAO L, 1996, J BIOL CHEM, V271, P16927; MANIATIS T, 1998, MOL CLONING; MATHEWS FS, 1972, J MOL BIOL, V64, P449, DOI 10.1016/0022-2836(72)90510-4; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; NISHIMOTO M, 1989, BIOCHEMISTRY-US, V32, P8863; NURMINEN T, 1971, BIOCHEM J, V125, P963, DOI 10.1042/bj1250963; OZOLS J, 1974, BIOCHEMISTRY-US, V13, P426, DOI 10.1021/bi00700a005; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1982, METHODS YEAST GENETI; SHIGEMATSU H, 1987, INT J BIOCHEM, V19, P41, DOI 10.1016/0020-711X(87)90121-2; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SMITH MA, 1994, BIOCHEM J, V303, P73, DOI 10.1042/bj3030073; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; STORCH EM, 1995, BIOCHEMISTRY-US, V34, P9682, DOI 10.1021/bi00030a005; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; TRUAN G, 1994, GENE, V149, P123; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; VERGERES G, 1992, J BIOL CHEM, V267, P12583	39	82	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28281	28288		10.1074/jbc.272.45.28281	http://dx.doi.org/10.1074/jbc.272.45.28281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353282	hybrid			2022-12-25	WOS:A1997YF21900022
J	Stephens, KM; McMacken, R				Stephens, KM; McMacken, R			Functional properties of replication fork assemblies established by the bacteriophage lambda O and P replication proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; SINGLE-STRANDED-DNA; HEAT-SHOCK PROTEINS; SPECIALIZED NUCLEOPROTEIN STRUCTURES; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; PHAGE-LAMBDA; PLASMID DNA; INITIATION	We have used a set of bacteriophage lambda and Escherichia coli replication proteins to establish rolling circle DNA replication in vitro to permit characterization of the functional properties of lambda replication forks. We demonstrate that the lambda replication fork assembly synthesizes leading strand DNA chains at a physiological rate of 650-750 nucleotides/s at 30 degrees C. This rate is identical to the fork movement rate we obtained using a minimal protein system, composed solely off. coli DnaB helicase and DNA polymerase III holoenzyme. Our data are consistent with the conclusion that these two key bacterial replication proteins constitute the basic functional unit of a lambda replication fork, A comparison of rolling circle DNA replication in the minimal and lambda replication systems indicated that DNA synthesis proceeded for more extensive periods in the lambda system and produced longer DNA chains, which averaged nearly 200 kilobases in length. The higher potency of the lambda replication system is believed to result from its capacity to mediate efficient reloading of DnaB helicase onto rolling circle replication products, thereby permitting reinitiation of DNA chain elongation following spontaneous termination events. E. coli single-stranded DNA-binding protein and primase individually stimulated rolling circle DNA replication, but they apparently act indirectly by blocking accumulation of inhibitory free single-stranded DNA product. Finally, in the course of this work, we discovered that E. coli DNA polymerase III holoenzyme is itself capable of carrying out significant strand displacement DNA synthesis at about 50 nucleotides/s when it is supplemented with E. coli single-stranded DNA-binding protein.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIEHS NIH HHS [ES-03819] Funding Source: Medline; NIGMS NIH HHS [GM32253] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032253] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1968, COLD SPRING HARB SYM, V33, P289, DOI 10.1101/SQB.1968.033.01.033; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BASTIA D, 1975, J MOL BIOL, V98, P305, DOI 10.1016/S0022-2836(75)80120-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARTER BJ, 1969, BIOCHIM BIOPHYS ACTA, V195, P494, DOI 10.1016/0005-2787(69)90656-X; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; ERDILE L, 1984, VIROLOGY, V139, P97, DOI 10.1016/0042-6822(84)90333-7; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KLINKERT J, 1978, J VIROL, V25, P730, DOI 10.1128/JVI.25.3.730-737.1978; Kornberg A., 1992, DNA REPLICATION; KUHN B, 1979, J BIOL CHEM, V254, P1343; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAMED R, 1973, BIOCHIM BIOPHYS ACTA, V305, P163, DOI 10.1016/0005-2728(73)90241-7; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LEBOWITZ JH, 1984, ADV EXP MED BIOL, V179, P77; LEBOWITZ JH, 1984, NUCLEIC ACIDS RES, V12, P3069, DOI 10.1093/nar/12.7.3069; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P7545, DOI 10.1093/nar/16.15.7545; MAKI H, 1988, J BIOL CHEM, V263, P6570; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARIANS KJ, 1996, ESCHERICHIA COLI SAL, P749; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCMACKEN R, 1977, P NATL ACAD SCI USA, V74, P4190, DOI 10.1073/pnas.74.10.4190; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROWEN L, 1978, J BIOL CHEM, V253, P758; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SKALKA A, 1972, J MOL BIOL, V64, P541, DOI 10.1016/0022-2836(72)90081-2; TAKAHASHI S, 1975, MOL GEN GENET, V142, P137, DOI 10.1007/BF00266095; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSURIMOTO T, 1981, NUCLEIC ACIDS RES, V9, P1789, DOI 10.1093/nar/9.8.1789; UEDA K, 1978, J BIOL CHEM, V253, P261; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WU CA, 1992, J BIOL CHEM, V267, P4030; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	67	15	15	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28800	28813		10.1074/jbc.272.45.28800	http://dx.doi.org/10.1074/jbc.272.45.28800			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353352	hybrid			2022-12-25	WOS:A1997YF21900092
J	Sung, P				Sung, P			Communication - Function of yeast Rad52 protein as a mediator between replication protein A and the Rad51 recombinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; REPAIR; RECA; FILAMENT; ENCODES; GENE	The RAD51 and RAD52 genes of Saccharomyces cerevisiae are key members of the RAD52 epistasis group required for genetic recombination and the repair of DNA double-stranded breaks. The RAD51 encoded product mediates the DNA strand exchange reaction. Efficient strand exchange is contingent upon the addition of the heterotrimeric single-stranded DNA binding factor replication protein A (RPA) after Rad51 has nucleated onto the single-stranded DNA However, if the single-stranded DNA is incubated with Rad51 and RPA simultaneously to mimic what may be expected to occur in vivo, the efficiency of strand exchange decreases dramatically, revealing an inhibitory effect of RPA that is distinct from its stimulatory function. Interestingly, the inclusion of Rad52 protein, which has been purified in this study from yeast cells, restores the efficiency of strand exchange. Thus, Rad52 functions as a co-factor for the Rad51 recombinase, acting specifically to overcome the apparent competition by RPA for binding to single-stranded DNA.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,SAN ANTONIO,TX 78245; SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77555	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sung, P (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MOL MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES07061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		COX MM, 1987, ANN REV BIOCH, V56, P29; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JIANG H, 1993, J BIOL CHEM, V268, P7904; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MORRICAL SW, 1990, J BIOL CHEM, V265, P15096; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875	18	434	441	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28194	28197		10.1074/jbc.272.45.28194	http://dx.doi.org/10.1074/jbc.272.45.28194			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353267	hybrid			2022-12-25	WOS:A1997YF21900007
J	DeMaria, CT; Sun, Y; Long, L; Wagner, BJ; Brewer, G				DeMaria, CT; Sun, Y; Long, L; Wagner, BJ; Brewer, G			Structural determinants in AUF1 required for high affinity binding to A+U-rich elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PROTEIN-PROTEIN-INTERACTION; RNA-BINDING; POLY(A)-BINDING PROTEIN; DOMAIN; MOTIFS; TETRAMERS; CLONING; KINASE; SITE	AUF1 is an RNA binding protein that contains two nonidentical RNA recognition motifs (RRMs), AUF1 binds to A + U-rich elements (AREs) with high affinity. The binding of AUF1 to AREs is believed to serve as a signal to an mRNA-processing pathway that degrades mRNAs encoding many cytokines, oncoproteins, and G protein-coupled receptors, Because the ARE binding activity of AUF1 appears central to the regulation of many important genes, we analyzed the domains of the protein that are important for this activity. Examination of the RNA binding affinity of various AUF1 mutants suggests that both RRMs may be required for binding to the human c-fos ARE. However, the two RRMs together are not sufficient, Highest affinity binding of AUF1 to an ARE requires an alanine-rich region of the N terminus and a short glutamine-rich region in the C terminus. In addition, the N terminus is required for dimerization of AUF1, However, AUF1 binds an ARE as a hexameric protein. Thus, protein-protein interactions are important for high affinity ARE binding activity of AUF1.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MICROBIOL & IMMUNOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PLAST & RECONSTRUCT SURG, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NCI NIH HHS [CA12197, CA52443] Funding Source: Medline; NIAID NIH HHS [T32-AI07401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERS GK, 1964, BIOCHEMISTRY-US, V3, P723, DOI 10.1021/bi00893a021; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BARNETT SF, 1991, MOL CELL BIOL, V11, P864, DOI 10.1128/MCB.11.2.864; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; FREIFELDER D, 1982, PHYSICAL BIOCH APPLI, P460; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Kim MK, 1996, MOL CELL BIOL, V16, P4366; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Pace C N, 1986, Methods Enzymol, V131, P266; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Parks JS, 1997, J LIPID RES, V38, P266; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SERING, 1997, J BIOL CHEM, V272, P13109; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; Zeng QY, 1997, RNA, V3, P303; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	41	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27635	27643		10.1074/jbc.272.44.27635	http://dx.doi.org/10.1074/jbc.272.44.27635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346902	hybrid			2022-12-25	WOS:A1997YD47300028
J	Huang, XF; Compans, RW; Chen, SY; Lamb, RA; Arvan, P				Huang, XF; Compans, RW; Chen, SY; Lamb, RA; Arvan, P			Polarized apical targeting directed by the signal/anchor region of simian virus 5 hemagglutinin-neuraminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CANINE KIDNEY-CELLS; EPITHELIAL-CELLS; MDCK CELLS; SURFACE EXPRESSION; SORTING SIGNAL; INFLUENZA HEMAGGLUTININ; ENDOPLASMIC-RETICULUM; CYTOPLASMIC DOMAINS; VIRAL GLYCOPROTEINS	To examine the possibility of independent cytoplasmic/transmembrane domain-based apical sorting, we have investigated paramyxovirus SV5 hemagglutinin-neuraminidase (HN), a type II membrane protein with a small N-terminal signal/anchor region. In SV5-infected Madin-Darby canine kidney (MDCK) cells, >90% of HN is found on the apical surface. We have expressed chimeric proteins in which the N terminus of HN, including its signal/anchor region, is attached to a (normally cytosolic) reporter pyruvate kinase (Ph). PK itself expressed immediately downstream from a cleavable signal peptide was converted to a 58-kDa N-linked glycosylated form, which was secreted predominantly (80%) to the basolateral surface of MDCK cells. By contrast, Stably expressed PK chimeras, now anchored as type II membrane proteins with either the first 48 or 72 amino acids of HN, received similar N-linked glycosylation, yet exhibited polarized transport with a preferentially (75%) apical distribution. These results suggest that the N-terminal signal/anchor region of HN contains independent sorting information for apical specific targeting in MDCK cells.	UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35209 USA; EMORY UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, ATLANTA, GA 30322 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR COMPREHENS CANC, DEPT CANC BIOL, WINSTON SALEM, NC 27157 USA; NORTHWESTERN UNIV, HOWARD HUGHES MED INST, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV ENDOCRINOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOL BIOL, BRONX, NY 10461 USA	University of Alabama System; University of Alabama Birmingham; Emory University; Wake Forest University; Wake Forest Baptist Medical Center; Howard Hughes Medical Institute; Northwestern University; Northwestern University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine			Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NIAID NIH HHS [AI-12680] Funding Source: Medline; NIDDK NIH HHS [DK-40344] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012680, R01AI012680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040344, R29DK040344] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN SY, 1991, J VIROL, V65, P5902, DOI 10.1128/JVI.65.11.5902-5909.1991; COMPLANS RW, 1991, CURR TOP MICROBIOL I, V170, P142; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HIEBERT SW, 1988, J CELL BIOL, V107, P865, DOI 10.1083/jcb.107.3.865; HIEBERT SW, 1985, J VIROL, V54, P1; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JONES LV, 1985, MOL CELL BIOL, V5, P2181, DOI 10.1128/MCB.5.9.2181; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; Leser GP, 1996, MOL BIOL CELL, V7, P155, DOI 10.1091/mbc.7.1.155; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LONBERG N, 1983, P NATL ACAD SCI-BIOL, V80, P3661, DOI 10.1073/pnas.80.12.3661; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCQUEEN N, 1986, P NATL ACAD SCI USA, V83, P9318, DOI 10.1073/pnas.83.24.9318; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MELLMAN I, 1993, J CELL SCI, P1; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; PATERSON RG, 1985, P NATL ACAD SCI USA, V82, P7520, DOI 10.1073/pnas.82.22.7520; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RACCHI M, 1993, J BIOL CHEM, V268, P5735; RANDALL RE, 1987, J GEN VIROL, V68, P2769, DOI 10.1099/0022-1317-68-11-2769; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; ROTH MG, 1983, CELL, V33, P435, DOI 10.1016/0092-8674(83)90425-7; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; ROTH MG, 1979, P NATL ACAD SCI USA, V76, P6430, DOI 10.1073/pnas.76.12.6430; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; STEPHENS EB, 1986, CELL, V47, P1053, DOI 10.1016/0092-8674(86)90820-2; STEPHENS EB, 1986, EMBO J, V5, P237, DOI 10.1002/j.1460-2075.1986.tb04204.x; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	56	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27598	27604		10.1074/jbc.272.44.27598	http://dx.doi.org/10.1074/jbc.272.44.27598			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346896	hybrid			2022-12-25	WOS:A1997YD47300022
J	Schaller, F; Weiler, EW				Schaller, F; Weiler, EW			Molecular cloning and characterization of 12-oxophytodienoate reductase, an enzyme of the octadecanoid signaling pathway from Arabidopsis thaliana - Structural and functional relationship to yeast old yellow enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID HYDROPEROXIDES; ALLENE OXIDE SYNTHASE; JASMONIC ACID; TENDRIL COILING; LIFE-CYCLE; PROTEINS; BIOSYNTHESIS; INHIBITORS; METABOLISM; MECHANISM	Using partial amino acid sequence information for 12-oxophytodienoate-10,11-reductase obtained from Corydalis sempervirens we have cloned the homologous enzyme from Arabidopsis thaliana. The open reading frame of the cDNA encodes a polypeptide of 372 amino acids (M-r = 41,165) with significant similarity to the sequence of Old Yellow Enzyme from Saccharomyces carlsbergensis (Saito, K., Thiele, D. J., Davio, M., Lockridge, O., and Massey, V. (1991) J. Biol. Chem. 266, 20720-20724), a flavin (FMN)-protein catalyzing the NADPH-dependent reduction of the olefinic bond of alpha,beta-unsaturated carbonyls. Specifically, all residues required for binding of FMN in Old Yellow Enzyme are conserved in the A. thaliana sequence, as are all residues associated with catalytic activity. The enzyme was functionally expressed from its cDNA in Escherichia coli and thus proven to encode OPDA reductase. Further similarities of OPDA reductase and yeast Old Yellow Enzyme include their binding to and elution by reductant from N-(4-hydroxybenzoyl)aminohexyl-Sepharose the immunoreactivity of yeast Old Yellow Enzyme with an antiserum raised against plant OPDA reductase and the demonstration that Old Yellow Enzyme is an active OPDA reductase. It is thus conceivable that the physiological role of Old Yellow Enzymes now known from bacteria, yeasts, and higher plants, is in oxylipin metabolism.	RUHR UNIV BOCHUM,LEHRSTUHL PFLANZENPHYSIOL,D-44780 BOCHUM,GERMANY	Ruhr University Bochum								ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Blee E, 1996, PLANT PHYSIOL, V110, P445, DOI 10.1104/pp.110.2.445; BOLAND W, 1995, ANGEW CHEM, V107, P1715; BOTHA A, 1994, S AFR J SCI, V90, P604; BRUIN J, 1992, EXPERIENTIA, V48, P525, DOI 10.1007/BF01928181; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; COETZEE DJ, 1992, SYST APPL MICROBIOL, V15, P311, DOI 10.1016/S0723-2020(11)80105-0; FALKENSTEIN E, 1991, PLANTA, V185, P316, DOI 10.1007/BF00201050; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; GUNDLACH H, 1992, P NATL ACAD SCI USA, V89, P2389, DOI 10.1073/pnas.89.6.2389; HAMBERG M, 1988, LIPIDS, V23, P469, DOI 10.1007/BF02535522; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; Howe GA, 1996, PLANT CELL, V8, P2067, DOI 10.1105/tpc.8.11.2067; Karplus PA, 1995, FASEB J, V9, P1518, DOI 10.1096/fasebj.9.15.8529830; KEY G, 1988, PLANTA, V176, P472, DOI 10.1007/BF00397653; KINOSITA K, 1977, BIOCHIM BIOPHYS ACTA, V471, P227, DOI 10.1016/0005-2736(77)90252-8; KOCK JLF, 1991, S AFR J SCI, V87, P73; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krumm T, 1995, FEBS LETT, V377, P523, DOI 10.1016/0014-5793(95)01398-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laudert D, 1997, ANAL BIOCHEM, V246, P211, DOI 10.1006/abio.1997.2012; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MIRANDA M, 1995, YEAST, V11, P459, DOI 10.1002/yea.320110509; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Peters W, 1996, J PLANT PHYSIOL, V149, P233, DOI 10.1016/S0176-1617(96)80202-1; SAITO K, 1991, J BIOL CHEM, V266, P20720; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schaller F, 1997, EUR J BIOCHEM, V245, P294, DOI 10.1111/j.1432-1033.1997.t01-1-00294.x; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; Smith B J, 1988, Methods Mol Biol, V3, P71, DOI 10.1385/0-89603-126-8:71; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; STOTT K, 1993, J BIOL CHEM, V268, P6097; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA J, 1980, PLANT PHYSIOL, V66, P246, DOI 10.1104/pp.66.2.246; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; Warburg O, 1933, BIOCHEM Z, V266, P377; WEILER EW, 1994, FEBS LETT, V345, P9, DOI 10.1016/0014-5793(94)00411-0; WEILER EW, 1993, PHYTOCHEMISTRY, V32, P591, DOI 10.1016/S0031-9422(00)95142-2	46	117	127	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28066	28072		10.1074/jbc.272.44.28066	http://dx.doi.org/10.1074/jbc.272.44.28066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346960	hybrid			2022-12-25	WOS:A1997YD47300086
J	Song, XL; vonKampen, J; Slaughter, CA; DeMartino, GN				Song, XL; vonKampen, J; Slaughter, CA; DeMartino, GN			Relative functions of the alpha and beta subunits of the proteasome activator, PA28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; 20-S PROTEASOME; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; MOLECULAR-CLONING; 26-S PROTEASE; 26S PROTEASE; PURIFICATION; COMPLEX	PA28 is a 180,000-dalton protein that activates hydrolysis of small nonubiquitinated peptides by the 20 S proteasome. PA28 is composed of two homologous subunits, alpha and beta arranged in alternating positions in a ring-shaped oligomer with a likely stoichiometry of (alpha beta)(3). Our previous work demonstrated that the carboxyl terminus of the alpha subunit was necessary for PA28 to bind to and activate the proteasome. The goals of this work were to define the exact structural basis for this effect and to determine the relative roles of the alpha and beta subunits in proteasome activation. Each subunit and various mutants of the alpha subunit were expressed in Escherichia coli and purified. PA28 alpha stimulated the proteasome, but had a much greater K-act than native heteromeric PA28. In contrast, PA28 beta was unable to stimulate the proteasome. Mutants of the alpha subunit in which the carboxyl-terminal tyrosine residue was deleted or substituted with charged amino acids could neither bind to nor activate the proteasome. However, substitution of the carboxyl-terminal tyrosine with other amino acids resulted in proteins which could stimulate the proteasome to various extents. Tryptophan mutants stimulated the proteasome as well as did native PA28, whereas serine or phenylalanine mutants stimulated the proteasome much poorer than did wild type PA28 alpha. Deletion of the ''KEKE'' motif, a 28-amino acid domain near the amino terminus of PA28 alpha, had no effect on proteasome stimulatory activity. Hetero-oligomeric PA28 proteins were reconstituted from isolated wild type and mutant subunits. PA28 reconstituted from wild type subunits had structural and functional properties that were indistinguishable from those of the native hetero-oligomeric protein. PA28 molecules reconstituted from inactive a subunits and wild type beta subunits remained inactive. However, PA28 molecules reconstituted from suboptimally active alpha mutants and wild type beta subunits had the same activity as native heteromeric PA28. These results indicate that the beta subunit modulates PA28 activity, perhaps by influencing the affinity of PA28 for the proteasome.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046181, R01DK046181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1993, ENZYME PROTEIN, V47, P314, DOI 10.1159/000468689; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; Kuehn L, 1996, FEBS LETT, V394, P183, DOI 10.1016/0014-5793(96)00946-5; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; MOTT JD, 1994, J BIOL CHEM, V269, P31466; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	41	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27994	28000		10.1074/jbc.272.44.27994	http://dx.doi.org/10.1074/jbc.272.44.27994			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346951	hybrid			2022-12-25	WOS:A1997YD47300077
J	Sudbeck, P; Scherer, G				Sudbeck, P; Scherer, G			Two independent nuclear localization signals are present in the DNA-binding high-mobility group domains of SRY and SOX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL SEX REVERSAL; DETERMINING GENE SRY; CAMPOMELIC DYSPLASIA; TRANSCRIPTION FACTOR; MOLECULAR-BASIS; EXPRESSION; SEQUENCE; MUTATIONS; FAMILY; CONSENSUS	SRY and SOX9, members of the family of high-mobility group (HMG) domain transcription factors, are both essential for testis formation during human embryonic development. The HMG domain is a DNA-binding and DNA-bending motif comprising about 80 amino acid residues. It has been shown that SRY and SOX9 are nuclear proteins. Using normal or mutant SRY-beta-galactosidase and SOX9-beta-galactosidase fusion proteins in transfection studies involving COS-7 cells, we have identified two nuclear localization signals (NLSs) within the HMG domains of both proteins that can independently direct the fusion proteins into the nucleus. Only mutational inactivation of both NLS motifs resulted in complete exclusion of the fusion proteins from the nucleus. The NLS sequences are located at the N and C termini of the HMG domain and are a bipartite NLS motif and a basic cluster NLS motif, respectively. Both NLS motifs are conserved in the HMG domains of other transcription factors. The implications of the present results are discussed regarding (a) the apparent dual function of certain basic amino acid residues in the HMG domain of SRY in both DNA binding and in nuclear localization and (b) the possible control of SOX9 in early gonadal differentiation at the level of nuclear translocation.	UNIV FREIBURG, INST HUMAN GENET, D-79106 FREIBURG, GERMANY	University of Freiburg								AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUNN TL, 1995, GENE, V161, P223, DOI 10.1016/0378-1119(95)00280-J; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; Meyer J, 1996, CYTOGENET CELL GENET, V72, P246, DOI 10.1159/000134200; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Sudbeck P, 1996, NAT GENET, V13, P230, DOI 10.1038/ng0696-230; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WOLF U, 1995, J MOL MED-JMM, V73, P325; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744	34	147	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27848	27852		10.1074/jbc.272.44.27848	http://dx.doi.org/10.1074/jbc.272.44.27848			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346931	hybrid			2022-12-25	WOS:A1997YD47300057
J	Wang, ZY; Melmed, S				Wang, ZY; Melmed, S			Identification of an upstream enhancer within a functional promoter of the human leukemia inhibitory factor receptor gene and its alternative promoter usage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; ALPHA-SUBUNIT GENE; NF-KAPPA-B; BINDING PROTEINS; LIF RECEPTOR; CYTOKINE RECEPTORS; CNTF RECEPTOR; MESSENGER-RNA; ONCOSTATIN-M; EXPRESSION	Knockout of the leukemia inhibitory factor receptor (LIFR) gene results in disrupted placental architecture, imbalanced bone development, and losses of functional neurons. We here report the identification df an enhancer in a functional human LIFR gene promoter and alternative promoter usage by this gene. A single transcription start site was identified in placental JEG-3 cells and a genomic clone containing 4876-nucleotide upstream sequences was found to have promoter activity in JEG-3 cells. However, in osteogenic sarcoma U-2 OS cell, Northern blot using a probe of the first exon detected in JEG-3 cells failed to detect LIFR transcripts. 5'-Rapid amplification of cDNA ends (RACE) revealed an alternative first exon and a 0.6-kilobase pair (kb) 5'-flanking region possessed promoter activity in U-2 OS cells. For the 4.8-kb promoter active in placental cells, a minimal promoter was localized within -162 nucleotides. Three regions increased and one inhibited promoter activity. Subcloning of an activation region (-4876 to -3453 nucleotides) into SV40 promoter either upstream or downstream in either orientation to the luciferase reporter resulted in 10-35-fold luciferase induction, demonstrating the characteristics of an enhancer. Transfections into nine cell lines of different tissue origin indicated that the cloned promoter and enhancer in the 4.8-kb fragment was placental tissue-specific. A 226-base pair fragment (-4625 to -4400 nucleotides) was further localized as the minimal enhancer region, in which deletion of either element A (-4625 to -4581 nucleotides) or element B (-4418 to -4400 nucleotides) resulted in the loss of enhancer activity. Electrophoretic mobility shift assay confirmed that these two elements bind to specific nuclear proteins individually. In the middle region between element A and B, disruption of enhancer integrity also led to a loss of enhancer activity, although two SP1 and three NF-kappa B/c-Rel binding sites did not contribute to enhancer function. These results demonstrate a complex regulation of the human LIFR gene, including alternative promoter usage and tissue-specific elements at the transcription level.	UNIV CALIF LOS ANGELES,SCH MED,CEDARS SINAI MED CTR,DIV ENDOCRINOL,B131,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIDDK NIH HHS [DK50238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bousquet C, 1997, J BIOL CHEM, V272, P10551; CHAMBERLIN ME, 1994, J BIOL CHEM, V269, P17152; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; JACQUEMIN P, 1994, MOL CELL BIOL, V14, P93, DOI 10.1128/MCB.14.1.93; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOJIMA K, 1995, HUM REPROD, V10, P1907, DOI 10.1093/oxfordjournals.humrep.a136205; KOJIMA K, 1995, MOL HUM REPROD, V1, P1907; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIU ZY, 1995, MOL ENDOCRINOL, V9, P1477, DOI 10.1210/me.9.11.1477; MANDL CW, 1991, BIOTECHNIQUES, V10, P485; MARUSIC A, 1993, J BONE MINER RES, V8, P617; MARUYAMA K, 1994, GENE, V138, P171; Michaelson JS, 1996, J IMMUNOL, V156, P2828; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PITTMAN RH, 1994, J BIOL CHEM, V269, P19360; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 2002, MOL CLONING LAB MANU; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Stefana B, 1996, P NATL ACAD SCI USA, V93, P12502, DOI 10.1073/pnas.93.22.12502; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TOMIDA M, 1993, FEBS LETT, V334, P193, DOI 10.1016/0014-5793(93)81710-H; Wang ZY, 1996, ENDOCRINOLOGY, V137, P2947, DOI 10.1210/en.137.7.2947; WARE CB, 1995, DEVELOPMENT, V121, P1283	46	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27957	27965		10.1074/jbc.272.44.27957	http://dx.doi.org/10.1074/jbc.272.44.27957			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346946	hybrid			2022-12-25	WOS:A1997YD47300072
J	Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH				Baskaran, K; Erfurth, F; Taborn, G; Copeland, NG; Gilbert, DJ; Jenkins, NA; Iannaccone, PM; Domer, PH			Cloning and developmental expression of the murine homolog of the acute leukemia proto-oncogene AF4	ONCOGENE			English	Article						AF4; MLL; acute leukemia; transcription factor	BONE MORPHOGENETIC PROTEIN-4; DIFFERENTIAL EXPRESSION; PROMYELOCYTIC LEUKEMIA; DROSOPHILA-TRITHORAX; TRANSCRIPTION FACTOR; BINDING DOMAINS; GENE-EXPRESSION; MICE LACKING; DNA-BINDING; ALL-1 GENE	AF4 is the 4q21 gene involved in the acute lymphoblastic leukemia associated t(4;11)(q21;q23) where it forms a fusion gene with MLL, In order to gain insight into AF4's role in leukemogenesis we have studied its functional domains and expression pattern during murine development, We have cloned the murine homolog, Af4. We have demonstrated that 5' half of Af4 encodes a region with transcriptional transactivation activity which is disrupted by the t(4;11) in human leukemias, We have also localized the murine AF4 protein to the nucleus supporting a role for AF4 in transcription, The developmental expression pattern of Af4 was determined in situ hybridization and suggests Af4 plays an important role in the development of the hematopoietic, cardiovascular, skeletal and central nervous systems, A repeating pattern of Af4 expression in development is downregulation with differentiation of a tissue, Among the cell types where this pattern of down-regulation is noted are B-lymphocytes. These findings raise the possibility that the disruption of normal AF4 function by the translocation may contribute to leukemogenesis.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHILDRENS MEM INST EDUC & RES,CHICAGO,IL 60614; FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Chicago; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [R29 CA 65911-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA065911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chakrabarti L, 1996, HUM MOL GENET, V5, P275, DOI 10.1093/hmg/5.2.275; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN CS, 1993, BLOOD, V82, P1080; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COLLINS SJ, 1987, BLOOD, V70, P1233; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fidanza V, 1996, CANCER RES, V56, P1179; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Green EL, 1981, GENETICS PROBABILITY, P77; GRIOGORIADIS AE, 1995, TRENDS GENET, V11, P436; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAUANG S, 1992, NATURE, V360, P745; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KAPPIANPUR AR, 1994, BLOOD, V83, P1200; KEHRL JH, 1995, STEM CELLS, V13, P223, DOI 10.1002/stem.5530130304; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OKUDA T, 1996, CELL, V78, P45; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PUI CH, 1991, BLOOD, V77, P440; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1993, DEVELOPMENT, V118, P47; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitzmann J, 1995, ONCOGENE, V11, P2273; SPENCE RP, 1988, CANCER RES, V48, P324; STEA B, 1988, INT J RADIAT ONCOL, V15, P1233, DOI 10.1016/0360-3016(88)90209-X; Theiler K, 1989, HOUSE MOUSE ATLAS EM, P78; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YOUNG PE, 1995, BLOOD, V85, P96, DOI 10.1182/blood.V85.1.96.bloodjournal85196; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735; ZION L, 1995, BLOOD, V86, P2876	57	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1967	1978		10.1038/sj.onc.1201365	http://dx.doi.org/10.1038/sj.onc.1201365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365243				2022-12-25	WOS:A1997YA87200011
J	Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N				Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N			p53 expression overcomes p21(WAF1/CIP1)-mediated G(1) arrest and induces apoptosis in human cancer cells	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); apoptosis; G(1) arrest; adenoviral vector	WILD-TYPE P53; ADENOVIRUS-MEDIATED TRANSFER; CYCLIN-DEPENDENT KINASES; LUNG-CANCER; IN-VIVO; TUMOR SUPPRESSION; GENE-TRANSFER; P21; INHIBITOR; GROWTH	The p21(WAF1/CIP1) gene, which encodes a cyclin-dependent kinase inhibitor, may be critical for tumor suppressor gene p53-induced cell cycle arrest The p53 gene is known to regulate G(1) checkpoint, which can either induce G(1) arrest or initiate apoptosis, To directly examine the role of p21(WAF1/CIP1) in the control of p53 function, we have introduced human p21(WAF1/CIP1) gene into a p53-deficient human non-small cell lung cancer cell line H1299 using a p21(WAF1/CIP1)-expressing adenoviral vector (AdCMVp21). Infection with AdCMVp21 resulted in high levels of p21(WAF1/CIP1) expression and significantly suppressed the growth of H1299 cells through the G, arrest of the cell cycle, In contrast, transient expression of the wild-type p53 gene by a recombinant adenoviral vector (AdCMVp53) in H1299 cells induced apoptotic cell death and resulted in a rapid loss of cell viability, We then examined the effects of combined infection with AdCMVp21 and AdCMVp53 on H1299 cells to explore the dominant function of these molecules, Interestingly, introduction of exogenous p53 overcame p21(WAF1/CIP1)-mediated cell cycle arrest at G(1) and induced apoptosis, although viral-transduced p21(WAF1/CIP1) expression level was unaffected, These observations suggest that p53 expression converts a p21(WAF1/CIP1)-mediated growth arrest into apoptosis, The result was repeated with two additional human colon adenocarcinoma cell lines with the different p53 status, mutant p53-expressing DLD-1 and wild-type p53-expressing LoVo, suggesting that this phemonenon is a general event among human cancer cells, Thus, p53-mediated apoptotic pathway is dominant over the growth arrest pathway, indicating that p53 may be an essential upstream mediator of p21(WAF1/CIP1) in the regulation of a cell process leading either to growth arrest or to apoptotic suicide.	OKAYAMA UNIV,SCH MED,DEPT SURG 1,OKAYAMA 700,JAPAN; OKAYAMA UNIV,SCH MED,DEPT CELL CHEM,OKAYAMA 700,JAPAN; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,HOUSTON,TX 77030	Okayama University; Okayama University; University of Texas System; UTMD Anderson Cancer Center			Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN YQ, 1995, CANCER RES, V55, P4536; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; GomezManzano C, 1996, CANCER RES, V56, P694; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG WW, 1994, CANCER GENE THER, V1, P5	23	81	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1903	1909		10.1038/sj.onc.1201362	http://dx.doi.org/10.1038/sj.onc.1201362			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365236				2022-12-25	WOS:A1997YA87200004
J	Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H				Yamaguchi, R; Mazaki, Y; Hirota, K; Hashimoto, S; Sabe, H			Mitosis specific serine phosphorylation and downregulation of one of the focal adhesion protein, paxillin	ONCOGENE			English	Article						focal adhesion proteins; mitosis; paxillin; phosphorylation; protein-degradation	I-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CELL-ADHESION; BINDING-SITE; C-SRC	Mitotic cells typically lack well-formed focal adhesions, As an approach to explore the dynamic process regulating the focal adhesion assembly, we examined states of focal adhesion proteins during mitosis of the cell cycle. We found that the amount of paxillin was significantly reduced during mitosis of the cell cycle, whereas other focal adhesion proteins including talin, vinculin and Focal Adhesion Kinase did not. Proteolytic degradation appeared to be involved in the mitotic reduction, but transcriptional and/or translational controls of the mRNA were not essential for this downregulation. Moreover, concurrent with the decreased protein level, phosphorylation status of paxillin altered during mitosis; mitotic paxillin was phosphorylated primarily on serine and dephosphorylated on tyrosine while interphase one was phosphorylated both on serine and tyrosine. We found that mitotic phosphorylation created an electrophoretically slow-migrating population of paxillin which was barely detected in interphase cells. This mitotic specific modification occurred with both alpha and beta isoforms of paxillin. We also examined the fate of paxillin protein by changing its protein amount. We found that majority of paxillin overexpressed was subjected to the specific modification but not to the downregulation in the mitotic arrested cells. On the other hand, paxillin exogenously expressed at a moderate level was subjected to both the mitotic modification and downregulation. Collectively, we concluded that paxillin's specific serine phosphorylation together with the proteolytic downregulation of a limited fraction of paxillin is taken place during the mitosis of the cell cycle.	JAPAN SCI & TECHNOL CORP, PRECURSORY RES EMBRYON SCI & TECHNOL, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, KYOTO 606, JAPAN	Japan Science & Technology Agency (JST); Kyoto University			Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827; Yamaguchi, Ryuji/0000-0002-1706-7063; Mazaki, Yuichi/0000-0003-4192-0834				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moir RD, 1995, INT REV CYTOL, V162B, P141; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFALLER R, 1995, J BIOL CHEM, V270, P19066, DOI 10.1074/jbc.270.32.19066; POMIES P, 1992, BIOCHEM BIOPH RES CO, V189, P1429, DOI 10.1016/0006-291X(92)90234-C; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrooke J., 1989, MOL CLONING LAB MANU; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tanaka T, 1996, FEBS LETT, V399, P53, DOI 10.1016/S0014-5793(96)01280-X; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	43	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	1997	15	15					1753	1761		10.1038/sj.onc.1201345	http://dx.doi.org/10.1038/sj.onc.1201345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362441				2022-12-25	WOS:A1997XZ72500001
J	Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A				Masutani, H; MagnaghiJaulin, L; Ali, SAS; Groisman, R; Robin, P; HarelBellan, A			Activation of the c-fos SRE through SAP-1a	ONCOGENE			English	Article						c-fos; SAP-1; serum response element (SRE); serum response factor (SRF); ternary complex factor (TCF)	SERUM RESPONSE FACTOR; FACTOR-DEPENDENT TRANSCRIPTION; DNA-BINDING SPECIFICITIES; TERNARY COMPLEX-FORMATION; FACTORS ELK-1; MAP KINASE; PROTEIN ELK-1; FACTOR P62TCF; GROWTH-FACTOR; ETS FAMILY	TCFs, which are members of the Ets family of transcription factors, are recruited to the Serum Response Element (SRE) in the c-fos promoter by SRF. These Ets proteins, which are substrates for the MAP kinases, are direct targets of the Ras/MAP kinase signal transduction pathway, In this paper, we demonstrate that one of the TCFs, SAP-la, displays a significant level of autonomous binding to the SRE Ets box, in contrast to previous observations, deletion of the SRF binding domain did not modulate the autonomous binding of SAP-la. Also, the autonomous binding was not modulated by the phosphorylation of SAP-la by MAP kinases, The autonomous binding was also detected in live cells: transfected SAP-la was able to restore the response of a CArG-less SRE in PC12 cells. The response occurred in the absence of SRF recruitment since a mutant of SAP-la in which the B-box, a domain required for interaction with SRF, had been deleted was still able to transactivate the CArG-less SRE. The transactivation was repressed by a Ras transdominant negative mutant, indicating the involvement of the Ras/MAP kinase pathway. Taken together, these data demonstrate that SAP-la is capable of binding to the c-fos SRE in the absence of SRF.	INST GUSTAVE ROUSSY,LAB BIOL TUMEURS HUMAINES,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Harel-Bellan, Annick/M-9795-2015; Masutani, Hiroshi/B-5114-2014	Groisman, Sonia/0000-0003-1153-3841; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Masutani, Hiroshi/0000-0001-7633-2827				BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, NUCLEIC ACIDS RES, V24, P1052, DOI 10.1093/nar/24.6.1052; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TROUCHE D, 1991, BLOOD, V77, P55; TROUCHE D, 1993, BIOCHEM BIOPH RES CO, V196, P611, DOI 10.1006/bbrc.1993.2293; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	34	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1661	1669		10.1038/sj.onc.1201328	http://dx.doi.org/10.1038/sj.onc.1201328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349499				2022-12-25	WOS:A1997XY63100005
J	Hirose, Y; Manley, JL				Hirose, Y; Manley, JL			Creatine phosphate, not ATP, is required for 3' end cleavage of mammalian pre-mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA POLYADENYLATION; LATE TRANSCRIPTION UNIT; POLY(A) ADDITION SITE; SPECIFICITY FACTOR; POLY(A)-BINDING PROTEIN; PROCESSING FACTORS; AAUAAA SEQUENCE; 160-KD SUBUNIT; POLYMERASE-II; GLOBIN GENE	The poly(A) tail of a mammalian mRNA is generated by endonucleolytic cleavage and poly(A) addition, Previous studies conducted with nuclear extracts suggested an ATP requirement for the cleavage step, We have reexamined the cofactor requirement, initially with the SV40 late pre-mRNA, which requires for cleavage four protein factors, cleavage and polyadenylation specificity factor, cleavage stimulation factor, cleavage factor I, and cleavage factor II. Using highly purified preparations of these factors, which lacked detectable creatine phosphokinase and ATPase activities, creatine phosphate (CP) was, surprisingly, found to be sufficient to promote efficient cleavage, Although other phosphate compounds substituted poorly or not at all for CP, another phosphoguanidine, arginine phosphate, was fully functional. Notably, ATP was neither necessary nor sufficient, and could in fact inhibit the reaction. Treatment of the purified factors with hexokinase plus glucose (to deplete any contaminating ATP) was without effect, as was addition of EDTA, Using P-32-labeled CP, we found that neither hydrolysis of CP nor phosphate transfer from CP occurred during the cleavage reaction. CP also allowed cleavage of the adenovirus 2 L3 pre-mRNA, However, in this case, ATP both enhanced the reaction and influenced the precise site of cleavage, perhaps reflecting the requirement of poly(A) polymerase for cleavage of this RNA, These results indicate that ATP is not essential for 3' pre-mRNA cleavage and that CP or a related compound can function as a necessary cofactor.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIS I, 1975, BIOCHEM J, V152, P23, DOI 10.1042/bj1520023; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; CANDE WZ, 1983, NATURE, V304, P557, DOI 10.1038/304557a0; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; ENNOR AH, 1958, PHYSIOL REV, V38, P631, DOI 10.1152/physrev.1958.38.4.631; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; Gilmartin GM, 1996, J VIROL, V70, P1775, DOI 10.1128/JVI.70.3.1775-1783.1996; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KOONS SJ, 1982, EXP CELL RES, V140, P401, DOI 10.1016/0014-4827(82)90130-6; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; LYZLOVA SN, 1991, PHOSPHAGEN KINASES, P1; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MANOS P, 1993, DEV NEUROSCI-BASEL, V15, P271, DOI 10.1159/000111344; MANOS P, 1992, J COMP NEUROL, V326, P273, DOI 10.1002/cne.903260209; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MOORE CL, 1988, MOL CELL BIOL, V8, P226, DOI 10.1128/MCB.8.1.226; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; PRESCOTT JC, 1992, J BIOL CHEM, V267, P8175; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; RMEGSEGGER U, 1996, J BIOL CHEM, V271, P6107; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; SHEETS MD, 1989, GENE DEV, V3, P1401, DOI 10.1101/gad.3.9.1401; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SPERRY AO, 1986, MOL CELL BIOL, V6, P4734, DOI 10.1128/MCB.6.12.4734; STEFANO JE, 1988, MOL CELL BIOL, V8, P2052, DOI 10.1128/MCB.8.5.2052; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; WILUSZ J, 1990, MOL CELL BIOL, V10, P1244, DOI 10.1128/MCB.10.3.1244; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; ZARKOWER D, 1986, MOL CELL BIOL, V6, P2317, DOI 10.1128/MCB.6.7.2317; ZHANG F, 1987, MOL CELL BIOL, V7, P3277, DOI 10.1128/MCB.7.9.3277; Zhao J, 1997, J BIOL CHEM, V272, P10831	67	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29636	29642		10.1074/jbc.272.47.29636	http://dx.doi.org/10.1074/jbc.272.47.29636			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368030	hybrid			2022-12-25	WOS:A1997YG64700040
J	Jaitner, BK; Becker, J; Linnemann, T; Herrmann, C; Wittinghofer, A; Block, C				Jaitner, BK; Becker, J; Linnemann, T; Herrmann, C; Wittinghofer, A; Block, C			Discrimination of amino acids mediating Ras binding from noninteracting residues affecting Raf activation by double mutant analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HA-RAS; PROTEIN-KINASE; IN-VITRO; PLASMA-MEMBRANE; DOMAIN; IDENTIFICATION; TRANSFORMATION; P21(RAS); COMPLEX; INTERFACE	The contribution of residues outside the Has binding domain of Raf (RafRBD) to Ras-Raf interaction and Ras-dependent Raf activation has remained unresolved. Here, we utilize a double mutant approach to identify complementary interacting amino acids that are involved in Ras-Raf interaction and activation. Biochemical analysis demonstrates that Raf-Arg(59) and Raf-Arg(67) from RafRBD are interacting residues complementary to Ras-Glu(37) located in the Ras effector region. Raf-Arg(59) and Raf-Arg(67) also mediate interaction with Ras-Glu(37) in Has-dependent Raf activation, The characteristics observed here can be used as criteria for a role of residues from other regions of Raf in Ras-Raf interaction and activation. We developed a quantitative two-hybrid system as a tool to investigate the effect of point mutations on protein-protein interactions that elude biochemical analysis of bacterially expressed proteins. This assay shows that Raf-Ser(257) in the RafCR2 domain does not contribute to Ras-Raf interaction and that the Raf-S257L mutation does not restore Raf binding to Ras-E37G, Yet, Raf-S257L displays high constitutive kinase activity and further activation by Ras-G12V/E37G is still impaired as compared with activation by Ras-G12V, This strongly suggests that the RafCR2 domain is an independent domain involved in the control of Raf activity and a common mechanism for constitutively activating mutants may be the interference with the inactive ground state of the kinase.	MAX PLANCK INST MOL PHYSIOL, ABT STRUKTURELLE BIOL, D-44026 DORTMUND, GERMANY	Max Planck Society								BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SCHEFFLER JE, 1994, BIOCHEMISTRY-US, V35, P22340; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29927	29933		10.1074/jbc.272.47.29927	http://dx.doi.org/10.1074/jbc.272.47.29927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368069	hybrid			2022-12-25	WOS:A1997YG64700079
J	Allan, CM; Taylor, S; Taylor, JM				Allan, CM; Taylor, S; Taylor, JM			Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; E MESSENGER-RNA; TRANSGENIC MICE; C-I; CONTROL REGION; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; ELEMENTS CONTROL; A-I; LOCUS	We show that the liver-specific expression of all four genes in the human apolipoprotein (ape) E/C-I/C-IV/C-II gene cluster in transgenic mice is determined by the coordinate action of two distinct hepatic control regions (HCR). These enhancers are positioned 15 kilobases (kb) (HCR.1) and 26 kb (HCR.2) downstream of the apoE gene. To investigate the action of each HCR, transgenic mice were generated with a 70-kb human genomic fragment that contained the complete apoE gene cluster or with this fragment modified by the specific deletion of HCR.1, HCR.2, or both HCR domains. Hepatic expression of all four apolipoprotein genes was observed in transgenic mice in which either HCR,I or HCR.2 was deleted, but no transgene expression was found in the liver in the absence of both HCR domains. The overall patterns of transgene expression suggested that HCR.2 was the dominant element for apoC-IV and apoC-II expression and that HCR.1 was dominant for the apoE/C-I expression, No liver-specific transcriptional activity was identified for the proximal promoter of any gene in the cluster; all liver-specific activity was associated with HCR.1 and HCR.2. Thus, the HCRs of the apoE gene cluster constitute unique regulatory domains for determining the requirements for apolipoprotein gene expression in the liver.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL-37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; Allan CM, 1996, J LIPID RES, V37, P1510; ANDERSSON Y, 1991, J LIPID RES, V32, P1805; BASU SK, 1982, J BIOL CHEM, V257, P9788; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; Dang Q, 1996, J BIOL CHEM, V271, P28667, DOI 10.1074/jbc.271.45.28667; DAWSON PA, 1989, J LIPID RES, V30, P403; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GILMAN M, 1993, CURRENT PROTOCOLS MO, V1; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; JI ZS, 1994, J BIOL CHEM, V269, P2764; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LI WH, 1988, J LIPID RES, V29, P245; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LUO CC, 1989, J LIPID RES, V30, P1735; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MYKLEBOST O, 1984, J BIOL CHEM, V259, P4401; MYKLEBOST O, 1988, HUM GENET, V78, P244, DOI 10.1007/BF00291670; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; NOSSEL HL, 1976, J CLIN INVEST, V58, P1136, DOI 10.1172/JCI108566; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETERSON KR, 1995, P NATL ACAD SCI USA, V92, P5655, DOI 10.1073/pnas.92.12.5655; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLANCO JI, 1995, LIFE SCI, V56, P1865, DOI 10.1016/0024-3205(95)00161-X; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; RAISONNIER A, 1991, J MOL EVOL, V32, P211; REARDON CA, 1986, J BIOL CHEM, V261, P9858; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHONFELD G, 1980, J CELL BIOL, V86, P562, DOI 10.1083/jcb.86.2.562; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SHEN PY, 1992, ARCH BIOCHEM BIOPHYS, V297, P345, DOI 10.1016/0003-9861(92)90683-N; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; TAYLOR JM, 1991, CURR OPIN LIPIDOL, V2, P73; VANECK MM, 1994, GENOMICS, V21, P110, DOI 10.1006/geno.1994.1231; VORGIA P, 1996, CIRCULATION, V94, P397; WEI CF, 1985, J BIOL CHEM, V260, P5211; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WU AL, 1979, J BIOL CHEM, V254, P7316; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Zhang LH, 1996, J BIOL CHEM, V271, P1776, DOI 10.1074/jbc.271.3.1776	55	91	96	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29113	29119		10.1074/jbc.272.46.29113	http://dx.doi.org/10.1074/jbc.272.46.29113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360987	hybrid			2022-12-25	WOS:A1997YF68400046
J	Park, SK; Provost, JJ; Bae, CD; Ho, WT; Exton, JH				Park, SK; Provost, JJ; Bae, CD; Ho, WT; Exton, JH			Cloning and characterization of phospholipase D from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; GTP-BINDING PROTEIN; KINASE-C; REGULATORY PROTEIN; HL-60 CELLS; D ACTIVATION; RHOB P20; MEMBRANE; ARF; PURIFICATION	The regulation of phospholipase D cloned from rat brain (rPLD) was examined in vivo and in vitro. The enzyme was a shorter splice variant of human phospholipase D 1 (Hammond, S. M., Altshuller, Y. M., Sung, T.-C., Rudge, S. M., Rose, K., Engebrecht, J. A., Morris, A. J., and Frohman, M. A. (1995) J. Biol. Chem. 270, 29640-29643). Its expression in COS-7 cells led to increased phospholipase D (PLD) activity that was further stimulated by constitutively active V14RhoA. V14RhoA had no effect on the endogenous PLD of the COS-7 cells, but constitutively active L71ARF3 increased its activity. In contrast, L71ARF3 did not activate rPLD expressed in the cells. Addition of phorbol ester markedly increased the endogenous PLD activity of COS-7 cells, and there was a further increase in the cells expressing rPLD. In membranes from COS-7 cells expressing rPLD, addition of myristoylated ADP-ribosylation factor (ARF) and RhoA in vitro stimulated PLD activity. The effect of ARF was greater than that of RhoA, although the concentrations for half-maximal stimulation (0.08-0.2 mu M) were similar. Membranes isolated from cells expressing rPLD plus L71ARF3 and/or V14RhoA also showed higher PLD activity but no synergism between the two G proteins. Addition of phorbol ester and protein kinase C alpha (PKC alpha) also stimulated PLD activity in membranes from COS-7 cells expressing rPLD, but it had no effect on the activity in control (vector) membranes and did not enhance the effects of constitutively active ARF or Rho. The stimulation by PKC alpha did not require ATP and was not increased by addition of this nucleotide. No synergism between ARF and Rho and between these and PKC alpha on PLD activity was observed when these were added to membranes from cells expressing rPLD. Oleate inhibited the PLD activity of membranes from both control and rPLD-expressing cells. In summary, these results indicate that in vitro, rPLD is stimulated by ARF, RhoA, and PKC alpha and inhibited by oleate. However, in intact COS-7 cells, ARF activates endogenous PLD but not rPLD, whereas the reverse is true for RhoA, In addition, the effects of phorbol ester are much greater in the intact cells. It is concluded that the regulation of rPLD in intact COS-7 cells differs significantly from that seen in vitro; possible reasons for this are discussed.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47448] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; ISOMURA M, 1991, ONCOGENE, V6, P119; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; Kim JH, 1996, J BIOL CHEM, V271, P25213, DOI 10.1074/jbc.271.41.25213; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUSNER DJ, 1994, BIOCHEM J, V304, P485, DOI 10.1042/bj3040485; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Shimooku K, 1996, FEBS LETT, V387, P141, DOI 10.1016/0014-5793(96)00483-8; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; UEDA T, 1990, J BIOL CHEM, V265, P9373; Vinggaard AM, 1997, CELL SIGNAL, V9, P189, DOI 10.1016/S0898-6568(96)00140-4	40	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29263	29271		10.1074/jbc.272.46.29263	http://dx.doi.org/10.1074/jbc.272.46.29263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361006	hybrid			2022-12-25	WOS:A1997YF68400065
J	Wang, SX; Nakamura, N; Mure, M; Klinman, JP; SandersLoehr, J				Wang, SX; Nakamura, N; Mure, M; Klinman, JP; SandersLoehr, J			Characterization of the native lysine tyrosylquinone cofactor in lysyl oxidase by Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPA QUINONE COFACTOR; AMINE OXIDASE; PURIFICATION; ENZYME	Lysine tyrosylquinone (LTQ) recently has been identified as the active site cofactor in lysyl oxidase by isolation and characterization of a derivatized active site peptide, Reported in this study is the first characterization of the underivatized cofactor in native lysyl oxidase by resonance Raman (RR) spectrometry. The spectrum is characterized by a unique set of vibrational modes in the 1200 to 1700 cm(-1) region. We show that the RR spectrum of lysyl oxidase closely matches that of a synthetic LTQ model compound, 4-n-butylamino-5-ethyl-1,2-benzoquinone, in aqueous solutions but differs significantly from those of other topa quinone-containing amine oxidases under similar conditions, Furthermore, we have observed the same O-18 shift of the C=O stretch in both the lysyl oxidase enzyme and the LTQ cofactor model compound, The RR spectra of different model compounds and their D shifts give additional evidence for the protonation state of LTQ cofactor in the enzyme, The overall similarity of these spectra and their shifts shows that the lysyl oxidase cofactor and the model LTQ compound have the same structure and properties. These data provide strong and independent support for the new cofactor structure, unambiguously ruling out the possibility that the structure originally reported had been derived from a spurious side reaction during the derivatization of the protein and isolation of the active site peptide.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CELL & MOL BIOL,BERKELEY,CA 94720; OREGON GRAD INST SCI & TECHNOL,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97291	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972	NIGMS NIH HHS [GM-39296, GM-34468] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468, R01GM039296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; LORD RC, 1970, J MOL BIOL, V50, P509, DOI 10.1016/0022-2836(70)90208-1; MOENNELOCCOZ P, 1995, BIOCHEMISTRY-US, V34, P7020, DOI 10.1021/bi00021a013; Nakamura N, 1996, J BIOL CHEM, V271, P4718; Nakamura N, 1997, BIOCHEMISTRY-US, V36, P11479, DOI 10.1021/bi9708139; Patai S, 1988, CHEM QUINONOID COMPO, V2; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9	13	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28841	28844		10.1074/jbc.272.46.28841	http://dx.doi.org/10.1074/jbc.272.46.28841			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360949	hybrid, Green Accepted			2022-12-25	WOS:A1997YF68400008
J	Engel, E; Richter, K; Obermeyer, G; Briza, P; Kungl, AJ; Simon, B; Auer, M; Ebner, C; Rheinberger, HJ; Breitenbach, M; Ferreira, F				Engel, E; Richter, K; Obermeyer, G; Briza, P; Kungl, AJ; Simon, B; Auer, M; Ebner, C; Rheinberger, HJ; Breitenbach, M; Ferreira, F			Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IGE CROSS-REACTIVITIES; REGULATORY LIGHT-CHAIN; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; LILIUM-LONGIFLORUM; ACTIN-BINDING; PROTEIN; CALMODULIN; IDENTIFICATION	We have isolated a cDNA clone coding for a birch pollen allergen, Bet v 4. The deduced amino acid sequence of Bet v 4 contained two typical EF-hand calcium-binding domains, Sequence similarities of Bet v 4 to calmodulin are primarily confined to the calcium-binding domains, However, significant sequence similarities extending outside the Ca2+-binding sites were found with a recently described group of pollen-specific allergens of Brassica and Bermuda grass, Both EF-hand domains of Bet v 4 are able to bind Ca2+, as demonstrated by Ca-45(2+) blot overlay of wild type and calcium-binding deficient mutants of Bet v 4, Among pollen-allergic patients, protein-bound Ca2+ was not an absolute requirement for IgE recognition of Bet v 4, However, disruption of the carboxyl-terminal Ca2+-binding domain indicated that most IgE antibodies from allergic patients are directed against this site. IgE inhibition experiments suggested that Bet v 4 represents a high;ly cross-reactive pollen allergen. Pre-absorption of allergic sera with Bet v 4 drastically reduced IgE binding to proteins of similar molecular weight in pollen extracts from distantly related plant species (e.g. timothy grass, mugwort, lily) but not in extracts from plant-derived foodstuff, To test for a possible biological role in pollen germination and tube growth, we introduced recombinant Bet v 4 protein into growing lily pollen tubes by iontophoresis. As a result, cytoplasmic streaming stopped in the vicinity of the electrode tip, and a slight depolarization of the membrane voltage was measured. These effects were not observed with Ca2+-binding deficient mutants of Bet v 4, Thus, Bet v 4 and homologous proteins represent a new class of pollen-specific Ca2+-binding allergens that may have a physiological role as inhibitors of cytoplasmic streaming in outgrowing pollen tubes.	SALZBURG UNIV,INST GENET & ALLGEMEINE BIOL,A-5020 SALZBURG,AUSTRIA; SALZBURG UNIV,INST PFLANZENPHYSIOL,A-5020 SALZBURG,AUSTRIA; NOVARTIS FORSCHUNGSINST,A-1235 VIENNA,AUSTRIA; INST ALLGEMEINE & EXPT PATHOL,A-1090 VIENNA,AUSTRIA	Salzburg University; Salzburg University; Novartis			Ferreira, Fatima/AAB-4321-2019; Obermeyer, Gerhard/G-4061-2013; Ferreira, Fatima/E-4889-2011; Briza, Peter/D-7309-2012; ENGEL, Erwan/HHC-1529-2022; Obermeyer, Gerhard/M-5942-2019	Ferreira, Fatima/0000-0003-0989-2335; Obermeyer, Gerhard/0000-0001-8102-6322; Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Obermeyer, Gerhard/0000-0001-8102-6322; Kungl, Andreas/0000-0003-3362-797X; Auer, Manfred/0000-0001-8920-3522				BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1992, J ALLERGY CLIN IMMUN, V90, P909, DOI 10.1016/0091-6749(92)90463-C; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BREWBAKE JL, 1963, AM J BOT, V50, P859, DOI 10.2307/2439772; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASILVA ACR, 1995, J BIOL CHEM, V270, P6773, DOI 10.1074/jbc.270.12.6773; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DIRKSEN A, 1978, ALLERGY, V33, P299; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Kungl AJ, 1996, BIOCHEM BIOPH RES CO, V223, P187, DOI 10.1006/bbrc.1996.0867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LING V, 1993, PLANT MOL BIOL, V22, P207, DOI 10.1007/BF00014929; LOEWENSTEIN H, 1983, ALLERGY CPH, V38, P162; MARINI F, 1993, NUCLEIC ACIDS RES, V21, P2277, DOI 10.1093/nar/21.9.2277; NOBILING R, 1987, PROTOPLASMA, V139, P20, DOI 10.1007/BF01417531; OBERMEYER G, 1995, J EXP BOT, V46, P803, DOI 10.1093/jxb/46.7.803; OBERMEYER G, 1991, EUR J CELL BIOL, V56, P319; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; RATHORE KS, 1991, DEV BIOL, V148, P612, DOI 10.1016/0012-1606(91)90278-B; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SISTRUNK ML, 1994, PLANT CELL, V6, P1553, DOI 10.1105/tpc.6.11.1553; SORENSON MM, 1995, J BIOL CHEM, V270, P9770, DOI 10.1074/jbc.270.17.9770; Spieksma F., 1991, ALLERGENIC POLLEN PO, P203; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; STEER MW, 1989, NEW PHYTOL, V111, P323, DOI 10.1111/j.1469-8137.1989.tb00697.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1992, J EXP MED, V175, P365; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VIANDER M, 1979, ALLERGY, V34, P289; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	59	113	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28630	28637		10.1074/jbc.272.45.28630	http://dx.doi.org/10.1074/jbc.272.45.28630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353329	hybrid			2022-12-25	WOS:A1997YF21900069
J	Razik, MA; Lee, K; Price, RR; Williams, MR; Ongjoco, RR; Dole, MK; Rudner, SL; Kwatra, MM; Schwinn, DA				Razik, MA; Lee, K; Price, RR; Williams, MR; Ongjoco, RR; Dole, MK; Rudner, SL; Kwatra, MM; Schwinn, DA			Transcriptional regulation of the human alpha(1a)-adrenergic receptor gene - Characterization of the 5'-regulatory and promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(1B) ADRENERGIC-RECEPTOR; GROWTH-FACTOR-I; ALPHA(1)-ADRENERGIC RECEPTOR; MESSENGER-RNA; MOLECULAR-CLONING; HUMAN PROSTATE; ALPHA-1-ADRENERGIC RECEPTOR; DIHYDROFOLATE-REDUCTASE; EXPRESSION; IDENTIFICATION	We recently cloned cDNAs encoding three subtypes of human alpha(1)-adrenergic receptors (alpha(1)ARs), alpha(1a), alpha(1b), and alpha(1d) (Schwinn, D. A., Johnston, G. L., Page, S. O., Mosley, M. J., Wilson, K. H., Worman, N. P., Campbell, S., Fidock, M. D., Furness, L. M., Parry-Smith, D. J., Peter, B., and Bailey, D. S. (1995) J. Pharmacol. Exp. Ther. 272, 134-142) and demonstrated predominance of alpha(1a)ARs in many human tissues (Price, D. T., Lefkowitz, R. J., Caron, M. G., Berkowitz, D., and Schwinn, D. A. (1994) Mol. Pharmacol. 45, 171-175). Several lines of evidence indicate that alpha(1a)ARs are important in clinical diseases such as myocardial hypertrophy and benign prostatic hyperplasia. Therefore, we initiated studies to understand mechanisms underlying regulation of alpha(1a)AR gene transcription, A genomic clone containing 6.2 kb of 5'-untranslated region of the human alpha(1a)AR gene was recently isolated. Ribonuclease protection and primer extension assays indicate that alpha(1a)AR gene transcription occurs at multiple initiation sites with the major site located 696 base pairs upstream of the ATG, where a classic initiator sequence is located. Transfection of luciferase reporter constructs containing varying amounts of 5'-untranslated region into human SK-N-MC neuroblastoma cells indicate that a region extending 125 base pairs upstream from the main transcription initiation site contains full alpha(1a)AR promoter activity. Furthermore, distinct activator and suppressor elements lie 2-3 and 3-5 kilobase pairs upstream, respectively. Although the alpha(1a)AR promoter contains neither TATA or CAAT elements, gel shift mobility assays targeting three GC boxes immediately upstream of the main transcription initiation site confirm binding of Spl. Activity of the alpha(1a)AR promoter is cell-specific, demonstrating highest activity in cells endogenously expressing alpha(1a)ARs. The human alpha(1a)AR gene also contains several cis regulatory elements, including several insulin and cAMP response elements. Consistent with these observations, we provide the first evidence that treatment of SK-N-MC cells with insulin and cAMP elevating agents leads to an increase in alpha(1a)AR expression. In conclusion, these data represent the first characterization of the alpha(1a)AR gene; our findings should facilitate further studies designed to understand mechanisms regulating alpha(1)AR subtype-specific expression in healthy and diseased human tissue.	DUKE UNIV, MED CTR, DEPT ANESTHESIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University; Duke University			Kwatra, Madan/ABD-2008-2020	Schwinn, Debra/0000-0002-9696-5231	NIA NIH HHS [AG13853, AG00745] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013853] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen LQ, 1995, J BIOL CHEM, V270, P30980, DOI 10.1074/jbc.270.52.30980; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DENG CL, 1994, J RECEPTOR RES, V14, P119, DOI 10.3109/10799899409067000; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORRAY C, 1994, MOL PHARMACOL, V45, P703; GAO B, 1995, J BIOL CHEM, V270, P5614, DOI 10.1074/jbc.270.10.5614; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; GAO B, 1994, J BIOL CHEM, V269, P15762; Graham RM, 1996, CIRC RES, V78, P737, DOI 10.1161/01.RES.78.5.737; Granneman JG, 1997, MOL PHARMACOL, V51, P644, DOI 10.1124/mol.51.4.644; HAENDLER B, 1990, EUR J BIOCHEM, V190, P477, DOI 10.1111/j.1432-1033.1990.tb15598.x; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; HOD Y, 1988, J BIOL CHEM, V263, P7747; Hu ZW, 1996, J CLIN INVEST, V98, P1826, DOI 10.1172/JCI118983; KANASAKI M, 1994, J CLIN INVEST, V94, P2245, DOI 10.1172/JCI117587; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE K, 1997, IN PRESS DNA SEQ; Lee SH, 1996, J BIOL CHEM, V271, P25292, DOI 10.1074/jbc.271.41.25292; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; MARSHALL I, 1995, BRIT J PHARMACOL, V115, P781, DOI 10.1111/j.1476-5381.1995.tb15001.x; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; PARK K, 1993, J BIOL CHEM, V268, P17811; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PRICE DT, 1994, MOL PHARMACOL, V45, P171; PRICE DT, 1994, MOL PHARMACOL, V46, P221; PRICE DT, 1993, J UROLOGY, V150, P546, DOI 10.1016/S0022-5347(17)35544-1; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Richardson CD, 1997, PROSTATE, V33, P55; Rokosh DG, 1996, J BIOL CHEM, V271, P5839, DOI 10.1074/jbc.271.10.5839; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SEARLES RP, 1995, J BIOL CHEM, V270, P157, DOI 10.1074/jbc.270.1.157; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TERZIC A, 1993, PHARMACOL REV, V45, P147; TITUS DE, 1991, PROTOCOLS APPLICATIO, P58; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WEINBERG DH, 1994, BIOCHEM BIOPH RES CO, V201, P1296, DOI 10.1006/bbrc.1994.1845; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOOD KV, 1991, BIOLUMINESCENCE CHEM; Yamazaki T, 1997, CIRCULATION, V95, P1260; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	58	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28237	28246		10.1074/jbc.272.45.28237	http://dx.doi.org/10.1074/jbc.272.45.28237			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353275	hybrid			2022-12-25	WOS:A1997YF21900015
J	Ma, JJ; Zhao, JY; Drumm, ML; Xie, JX; Davis, PB				Ma, JJ; Zhao, JY; Drumm, ML; Xie, JX; Davis, PB			Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CL CHANNEL; ATP HYDROLYSIS; MOLECULAR MECHANISMS; CFTR; PHOSPHORYLATION; PROTEIN; PYROPHOSPHATE; INACTIVATION; STATES	For a cystic fibrosis transmembrane conductance regulator (CFTR) channel to enter its open state, serine residues in the R domain must be phosphorylated by cAMP-dependent protein kinase, and intracellular ATP must bind to the nucleotide-binding folds and subsequently be hydrolyzed, CFTR with its It domain partially removed, Delta R(708-835)-CFTR, forms a chloride channel that opens independently of protein kinase A phosphorylation, with open probability approximately one-third that of the wild type CFTR channel, Deletion of this portion of the R domain from CFTR alters the response of the channel to 5'-adenylylimidodiphosphate, pyrophosphate, and vanadate, compounds that prolong burst duration of the wild type CFTR channel but fail to do so in the Delta R-CFTR. In addition, the addition of exogenous unphosphorylated R domain protein, which blocks the wild type CFTR channel, has no effect on the Delta R-CFTR channel, However, when the exogenous R domain is phosphorylated, significant stimulation of the Delta R-CFTR channel results; P-o increases from 0.10 to 0.22. These data are consistent with a model for CFTR function in which the R domain in the unphosphorylated state interacts with the first nucleotide binding fold to inhibit either binding or hydrolysis of ATP or transduction of the effect to open the pore, but when the R domain is phosphorylated, it undergoes conformational change and interacts at a separate site in the first nucleotide binding fold to stimulate either binding or hydrolysis of ATP or transduction of the effect to open the pore.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, R01DK045965] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/DK49003] Funding Source: Medline; NIDDK NIH HHS [DK27651, DK45965] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CIACCIA AV, 1994, PEDIATR PULM, V10, P180; DULHANTY AM, 1994, FEBS LETT, V343, P109, DOI 10.1016/0014-5793(94)80300-5; FRIZZELL RA, 1995, AM J RESP CRIT CARE, V151, pS54, DOI 10.1164/ajrccm/151.3_Pt_2.S54; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; MA J, 1995, J BIOL CHEM, V271, P7351; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINTER MC, 1996, PEDIATR PULM, V13, P212; XIE JX, 1995, J BIOL CHEM, V270, P28084; Xie JX, 1996, BIOPHYS J, V71, P3148, DOI 10.1016/S0006-3495(96)79508-5; Zhao Jiying, 1997, Biophysical Journal, V72, pA33	36	65	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28133	28141		10.1074/jbc.272.44.28133	http://dx.doi.org/10.1074/jbc.272.44.28133			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346969	hybrid			2022-12-25	WOS:A1997YD47300095
J	Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG				Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG			Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours	ONCOGENE			English	Article						benign; chromosome 6, 7, 9, 11 and 17; loss of heterozygosity; ovarian tumours; tumour suppressor genes, PCR, microsatellite	LOW-GRADE; CARCINOMA; MUTATION; TUMORS; P53; OVEREXPRESSION; REGION; CDKN2; GENE; RARE	It is presently unclear if ovarian cancers arise through malignant transformation of pre-existing benign tumours, The apparent rarity of loss of heterozygosity (LOH) reported for benign tumours has led to speculation that they lack malignant potential and represent a biological entity distinct from ovarian carcinoma, We reasoned that the absence of detectable LOH may be due to the masking of such losses by contamination with normal tissue present in excess in the majority of benign tumour biopsies, Therefore we utilized a microdissection technique to examine for LOH using 14 microsatellite markers on chromosome arms 6q, 7p, 7q, 9p, 11q and 17p in 31 solitary benign epithelial ovarian tumours, LOH was detected on all chromosome arms with the most frequent LOH occurring on 7p (27%) and 9p (26%), In addition, a point mutation in codon 157 of TP53 was detected in one tumour which is the first report of a TP53 mutation in a solitary benign ovarian tumour, In total 48% of tumours harboured genetic alterations which supports the idea that all benign ovarian tumours may carry a genetic predisposition to malignancy and are therefore not inherently different from their malignant counterparts.	UNIV SOUTHAMPTON,PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND	University of Southampton			campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; DODSON MK, 1993, CANCER RES, V53, P4456; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gabra H, 1996, CANCER RES, V56, P950; Kerr J, 1996, ONCOGENE, V13, P1815; KIM JW, 1995, GYNECOL ONCOL, V57, P199, DOI 10.1006/gyno.1995.1125; MILNER BJ, 1993, CANCER RES, V53, P2128; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SCHULTZ DC, 1995, CANCER RES, V55, P2150; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	21	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2031	2035		10.1038/sj.onc.1201372	http://dx.doi.org/10.1038/sj.onc.1201372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366520				2022-12-25	WOS:A1997YC28400004
J	Sweet, DH; Wolff, NA; Pritchard, JB				Sweet, DH; Wolff, NA; Pritchard, JB			Expression closing and characterization of ROAT1 - The basolateral organic anion transporter in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PARA-AMINOHIPPURATE TRANSPORT; RENAL PROXIMAL TUBULE; MEMBRANE-VESICLES; FUNCTIONAL EXPRESSION; TRANSMEMBRANE PROTEINS; P-AMINOHIPPURATE; CLONING; NA+; URATE	Expression cloning in Xenopus laevis oocytes was used to isolate an organic anion transport protein from rat kidney, A cDNA library was constructed from size-fractionated poly(A)(+) RNA and screened for probenecid-sensitive transport of p-aminohippurate (PAH), A 2,227-base pair cDNA clone containing a 1,656-base pair open reading frame coding for a peptide 551 amino acids long was isolated and named ROAT1, ROAT1-mediated transport of 50 mu M [H-3]PAH was independent of imposed changes in membrane potential, Transport was significantly inhibited at 4 degrees C, or upon incubation with other organic anions, but nea, by the organic cation tetraethyl-ammonium, by the multidrug resistance ATPase inhibitor cyclosporin A, or by urate, External glutarate and alpha-ketoglutarate (1 mM), both counterions for basolateral PAH exchange, also inhibited transport, suggesting that ROAT1 is functionally similar to the basolateral PAH carrier. Consistent with this conclusion, PAH uptake was trans-stimulated in oocytes preloaded with glutarate, whereas the dicarboxylate methylsuccinate, which is not accepted by the basolateral exchanger, did not trans-stimulate. Finally, ROAT1-mediated PAH transport was saturable, with an estimated K-m of 70 mu M. Each of these properties is identical to those previously described for the basolateral alpha-ketoglutarate/PAH exchanger in isolated membrane vesicles or intact renal tubules.	NIEHS,LAB PHARMACOL & CHEM,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Sweet, Douglas H/H-7914-2013	Sweet, Douglas H/0000-0002-8911-9184				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; Benson DA, 1997, NUCLEIC ACIDS RES, V25, P1, DOI 10.1093/nar/25.1.1; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; CHATSUDTHIPONG V, 1992, AM J PHYSIOL, V263, pF384, DOI 10.1152/ajprenal.1992.263.3.F384; COADY MJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P130, DOI 10.1016/0003-9861(90)90622-6; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; CSERZO M, 1994, J MOL BIOL, V243, P388, DOI 10.1006/jmbi.1994.1666; FRITZSCH G, 1984, PFLUG ARCH EUR J PHY, V400, P250, DOI 10.1007/BF00581555; FRITZSCH G, 1989, BIOCHIM BIOPHYS ACTA, V978, P249, DOI 10.1016/0005-2736(89)90122-3; GASSER R, 1988, MOL PHARMACOL, V33, P22; *GEN COMP GROUP, 1996, GCG WISC PACK VERS 9; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HAGENBUCH B, 1990, J BIOL CHEM, V265, P5357; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLOHAN PD, 1975, J PHARMACOL EXP THER, V195, P22; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; MARTINEZ F, 1990, AM J PHYSIOL, V258, pF1145, DOI 10.1152/ajprenal.1990.258.5.F1145; MILLER DS, 1993, AM J PHYSIOL, V264, pR882, DOI 10.1152/ajpregu.1993.264.5.R882; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PRITCHARD JB, 1990, J PHARMACOL EXP THER, V255, P969; PRITCHARD JB, 1995, J PHARMACOL EXP THER, V274, P1278; PRITCHARD JB, 1988, AM J PHYSIOL, V255, pF597, DOI 10.1152/ajprenal.1988.255.4.F597; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; SIMONSON GD, 1994, J CELL SCI, V107, P1065; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SWEET DH, 1996, FASEB J*, V10, pA127; ULLRICH KJ, 1987, PFLUG ARCH EUR J PHY, V409, P229, DOI 10.1007/BF00583470; WERNER D, 1991, AM J PHYSIOL, V261, pF265, DOI 10.1152/ajprenal.1991.261.2.F265; WERNER D, 1990, J PHARMACOL EXP THER, V252, P792; WOLFF NA, 1992, MOL CELL BIOCHEM, V114, P35	40	368	378	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30088	30095		10.1074/jbc.272.48.30088	http://dx.doi.org/10.1074/jbc.272.48.30088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374486	hybrid			2022-12-25	WOS:A1997YH61300018
J	Fu, J; Ren, MD; Kreibich, G				Fu, J; Ren, MD; Kreibich, G			Interactions among subunits of the oligosaccharyltransferase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; PROTEIN COMPLEX; RIBOPHORIN-I; MOLECULAR-CLONING; RIBOSOME BINDING; YEAST; MEMBRANE; POLYPEPTIDES; IDENTIFICATION	The mammalian oIigosaccharyltransferase (OST) is an oligomeric complex composed of three membrane proteins of the endoplasmic reticulum: ribophorin I (RI), ribophorin II (RII), and OST48. In addition, sequence homology between the Ost2 subunit of the yeast OST complex and Dad1 (defender against apoptotic death) suggests that Dad1 may represent a fourth subunit of the mammalian OST complex. In attempts to elucidate the structural organization of this complex, we have studied the interactions among its subunits. Using the yeast two-hybrid system, we have shown that the luminal domains of RI and RII (Ra and RIIL, respectively) interacted with the luminal domain of OST48 (OST48L), but no direct interaction was observed between RIL and RIIL. These results were confirmed by biochemical assays. Deletion analyses using the yeast two-hybrid system showed that subdomain of RIL or RIIL adjacent to the respective transmembrane domains interacted with OST48L. Of the three equal length subdomains of OST48L, the one at the N terminus and the one next to the transmembrane domain interacted with RIL. None of these three subdomains of OST48L interacted with RIIL. The yeast two-hybrid assay also revealed affinity between the cytoplasmically located N-terminal region of Dad1 and the short cytoplasmic tail of OST48, thus placing Dad1 firmly into the OST complex. Tn addition, we found a homotypic interaction between the cytoplasmic domains of RI, which may play a role in the formation of the oligomeric array formed by components of the translocation machinery.	NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; AUSUBEL FM, 1992, SHORT PROTOCOLS MOLB; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; CRIMAUDO C, 1987, EMBO J, V6, P75, DOI 10.1002/j.1460-2075.1987.tb04721.x; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Garabedian Michael J., 1993, Methods (Orlando), V5, P138, DOI 10.1006/meth.1993.1018; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HARNIKORT V, 1987, J CELL BIOL, V104, P855, DOI 10.1083/jcb.104.4.855; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KARAOGLU D, 1995, PROTEIN KINESIS DYNA, P83; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KREIBICH G, 1978, J CELL BIOL, V77, P488, DOI 10.1083/jcb.77.2.488; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KUMAR V, 1994, J BIOL CHEM, V269, P13451; LIU F, 1995, MOL CELL BIOL, V15, P3479; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; PIROZZI G, 1991, BIOCHEM BIOPH RES CO, V176, P1482, DOI 10.1016/0006-291X(91)90454-F; SABATINI DD, 1995, METABOLIC BASIS INHE, V1, P459; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; SILBERSTEIN S, 1992, J BIOL CHEM, V267, P23658; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; YU Y, 1990, J CELL BIOL, V111, P1335, DOI 10.1083/jcb.111.4.1335; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29687	29692		10.1074/jbc.272.47.29687	http://dx.doi.org/10.1074/jbc.272.47.29687			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368036	hybrid			2022-12-25	WOS:A1997YG64700046
J	Perou, CM; Leslie, JD; Green, W; Li, LT; Ward, DM; Kaplan, J				Perou, CM; Leslie, JD; Green, W; Li, LT; Ward, DM; Kaplan, J			The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ARTIFICIAL CHROMOSOMES; COMPLEMENTATION; IDENTIFICATION; COMPARTMENTS; MACROPHAGES; ENDOCYTOSIS; MUTATION; DEFECT	The human autosomal recessive disorder Chediak-Higashi syndrome and its murine homologue beige are associated with the formation of giant lysosomes that cluster near the perinuclear region of cells, We prepared a polyclonal antiserum against a glutathione S-transferase-Beige fusion protein and demonstrated by Western analysis that the beige gene encodes a protein of 400 kDa that is expressed in cultured murine fibroblasts as well as most mouse tissues, The protein was not detected in either cultured fibroblasts or mouse tissues from two different beige mutants, Cultured fibroblasts transformed with multiple copies of yeast artificial chromosomes that contain the full-length beige gene showed much higher levels of Beige protein than either wild type fibroblasts or mouse tissues. Subcellular fractionation experiments demonstrated that the Beige protein was cytosolic and, under the conditions of isolation, had no measurable membrane association, Cultured mouse fibroblasts in which the Beige protein was overexpressed had smaller than normal lysosomes that were more peripherally distributed than in control cells, These findings, coupled with earlier published results, suggest that the Beige protein regulates lysosomal fission.	UNIV UTAH, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah			Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	NCI NIH HHS [5 P30 CA 42014] Funding Source: Medline; NHLBI NIH HHS [HL26922] Funding Source: Medline; NIDDK NIH HHS [T32DK07115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026922, R37HL026922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK Y, 1987, AM J PEDIAT HEMATOL, V9, P42; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; BURKHARDT JK, 1993, EXP MED, V178, P1945; EDELSON PJ, 1978, J EXP MED, V147, P77, DOI 10.1084/jem.147.1.77; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; Kelley E. M, 1957, MOUSE NEWS LETT, V16, P36; MCVEYWARD D, 1997, IN PRESS CELL BIOL; MURPHY RF, 1985, P NATL ACAD SCI USA, V82, P8523, DOI 10.1073/pnas.82.24.8523; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OLIVER C, 1975, LAB INVEST, V32, P17; Perou CM, 1997, GENOMICS, V42, P366, DOI 10.1006/geno.1997.4740; Perou CM, 1996, P NATL ACAD SCI USA, V93, P5905, DOI 10.1073/pnas.93.12.5905; PEROU CM, 1993, SOMAT CELL MOLEC GEN, V19, P459, DOI 10.1007/BF01233251; PEROU CM, 1993, J CELL SCI, V106, P99; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Perou CM, 1997, GENOMICS, V39, P136, DOI 10.1006/geno.1996.4478; SPICER SS, 1981, FED PROC, V40, P1451; SRIVASTAVA AK, 1991, GENE, V103, P53, DOI 10.1016/0378-1119(91)90390-W; WARD DM, 1995, J CELL BIOL, V129, P1229, DOI 10.1083/jcb.129.5.1229; WILSON RB, 1989, METHOD CELL BIOL, V31, P293	21	95	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29790	29794		10.1074/jbc.272.47.29790	http://dx.doi.org/10.1074/jbc.272.47.29790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368050	hybrid			2022-12-25	WOS:A1997YG64700060
J	Aichinger, G; Karlsson, L; Jackson, MR; Vestberg, M; Vaughan, JH; Teyton, L; Lechler, RI; Peterson, PA				Aichinger, G; Karlsson, L; Jackson, MR; Vestberg, M; Vaughan, JH; Teyton, L; Lechler, RI; Peterson, PA			Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; DROSOPHILA-MELANOGASTER CELLS; HLA-DR MOLECULES; INVARIANT-CHAIN; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; SURFACE EXPRESSION; PEPTIDE BINDING; MHC MOLECULES	We have analyzed the ability of major histocompatibility (MHC) class II molecules to capture proteins in the biosynthetic pathway and whether this may be associated with MHC class II dependent antigen processing, When coexpressed with HLA-DR 4 molecules in HeLa cells, influenza hemagglutinin was inhibited from folding and trimerization in the biosynthetic pathway, targeted to endosomal compartments, and rapidly degraded. Due to the interaction with MHC class II molecules, therefore, unfolded forms of hemagglutinin were bypassing the quality control mechanism of the secretory pathway, More important, however, the transport, endocytosis, and rapid degradation of unfolded hemagglutinin in the presence of MHC class II molecules suggest that proteins captured in the endoplasmic reticulum by class II molecules may become substrates for antigen processing and presentation to CD4-positive T cells. In insect cells we show that this phenomenon is not restricted to a few proteins such as hemagglutinin. A highly heterogeneous mixture of proteins from the endoplasmic reticulum including coexpressed hemagglutinin can form stable complexes with soluble HLA DR alpha and beta chains that were transported into the supernatant. This mechanism may gain biological significance in abnormal situations associated with accumulation of unfolded or malfolded proteins in the endoplasmic reticulum, for example during viral infections.	RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, LA JOLLA, CA 92039 USA; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT IMMUNOL, LONDON W12 0NN, ENGLAND	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute; University of California System; University of California San Diego; Imperial College London								ANDERSON MS, 1993, J EXP MED, V178, P1959, DOI 10.1084/jem.178.6.1959; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1995, IMMUNITY, V2, P301, DOI 10.1016/1074-7613(95)90054-3; BODMER H, 1994, SCIENCE, V263, P1258; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; BUSCH R, 1995, EUR J IMMUNOL, V25, P48, DOI 10.1002/eji.1830250110; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CLAESSONWELSH L, 1985, J IMMUNOL, V135, P3551; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DENG H, 1993, J EXP MED, V187, P1675; DODI AI, 1994, EUR J IMMUNOL, V24, P1632, DOI 10.1002/eji.1830240727; DOMS RW, 1985, J BIOL CHEM, V260, P2973; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GORGA JC, 1986, CELL IMMUNOL, V103, P160, DOI 10.1016/0008-8749(86)90077-8; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HELENIUS A, 1987, CHEM SCRIPTA, V27B, P229; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JENSEN PE, 1993, J IMMUNOL, V150, P3347; KITTLESEN DJ, 1993, J EXP MED, V177, P1021, DOI 10.1084/jem.177.4.1021; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEE P, 1988, J IMMUNOL, V140, P1063; Lightstone L, 1997, P NATL ACAD SCI USA, V94, P5772, DOI 10.1073/pnas.94.11.5772; Lindner R, 1996, EMBO J, V15, P6910, DOI 10.1002/j.1460-2075.1996.tb01083.x; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOWELL J, 1985, J EXP MED, V162, P1371, DOI 10.1084/jem.162.4.1371; PATERA AC, 1995, EUR J IMMUNOL, V25, P1803, DOI 10.1002/eji.1830250702; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; Quaratino S, 1996, J EXP MED, V183, P349, DOI 10.1084/jem.183.2.349; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SETTE A, 1993, J IMMUNOL, V151, P3163; SETTE A, 1989, J IMMUNOL, V143, P1265; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEISS S, 1991, CELL, V64, P767, DOI 10.1016/0092-8674(91)90506-T; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	74	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29127	29136		10.1074/jbc.272.46.29127	http://dx.doi.org/10.1074/jbc.272.46.29127			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360989	hybrid			2022-12-25	WOS:A1997YF68400048
J	Bin, OY; Pan, HQ; Lu, L; Li, J; Stambrook, P; Li, B; Dai, W				Bin, OY; Pan, HQ; Lu, L; Li, J; Stambrook, P; Li, B; Dai, W			Human prk is a conserved protein serine/threonine kinase involved in regulating M phase functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS CDC25 PHOSPHATASE; DROSOPHILA POLO; CELL-DIVISION; CYCLE; GENE; HOMOLOG; YEAST; PHOSPHORYLATION; LOCALIZATION; INHIBITORS	Human prk encodes a novel protein serine/threonine kinase capable of strongly phosphorylating casein but not histone HL in vitro. prk expression is tightly regulated at various levels during different stages of the cell cycle in lung fibroblasts. The Prk kinase activity is relatively low during mitosis, G(1), and G(1)/S, and peaks during late S and G(2) stages of the cell cycle. Recombinant human Prk expressed through the baculoviral vector system is capable of phosphorylating Cdc25C, a positive regulator for the G(2)/M transition. Human prk shares significant sequence homology with Saccharomyces cerevisiae CDC5 and Drosophila melanogaster polo, both of which are essential for mitosis and meiosis. Full-length prk, transcripts greatly potentiate progesterone-induced meiotic maturation of Xenopus laevis oocytes. Oh the other hand, antisense prk transcripts significantly delay and reduce the rate of oocyte maturation. When expressed in ii CDC5 mutant strain of S. cerevisiae, human Prk, but not a deletional mutant protein, fully rescues the temperature-sensitive phenotype of the budding yeast. Taken together, prk may represent a new protein kinase, playing an important role in regulating the onset and/or progression of mitosis' in mammalian cells.	UNIV CINCINNATI,COLL MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT CELL BIOL,CINCINNATI,OH 45267; WRIGHT STATE UNIV,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Wright State University Dayton					NCI NIH HHS [CA59985] Funding Source: Medline; NIAID NIH HHS [AI32483] Funding Source: Medline; NIGMS NIH HHS [GM48634] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032483] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DONAHUE PJ, 1995, J BIOL CHEM, V270, P10351; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HARTWELL LH, 1973, GENETICS, V74, P267; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LU L, 1990, J BIOL CHEM, V265, P16190; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SCHWARTS RM, 1979, ATLAS PROTEIN SEQUEN; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281	31	112	117	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28646	28651		10.1074/jbc.272.45.28646	http://dx.doi.org/10.1074/jbc.272.45.28646			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353331	hybrid			2022-12-25	WOS:A1997YF21900071
J	Dairaghi, DJ; Oldham, ER; Bacon, KB; Schall, TJ				Dairaghi, DJ; Oldham, ER; Bacon, KB; Schall, TJ			Communication - Chemokine receptor CCR3 function is highly dependent on local pH and ionic strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; CHEMOATTRACTANT; EOSINOPHILS; EOTAXIN	The CC chemokine receptor 3 (CCR3) plays an important role in the regulation of the migration of eosinophils, a leukocyte population involved in many inflammatory pathologies including asthma. CCR3 binds to the CC chemokine eotaxin, a promigratory cytokine originally isolated as the key component in a model of eosinophil-induced airway inflammation. We show here that eotaxin/CCR3 binding interactions exhibit a marked sensitivity to relatively small changes in the extracellular environment. In particular, modest variations in the pH and the level of sodium chloride over a range of physiologic and near physiologic conditions had dramatic effects on eotaxin binding and CCR3-mediated cytoplasmic Ca2+ mobilization. These biochemical indices were reflected at the functional level as well; small changes in pH and salt also resulted in striking changes in the migration of primary human eosinophils in vitro. These results reveal that relatively small perturbations in extracellular buffer conditions can yield widely disparate interpretations of CCR3 ligand binding and affinities and suggest that modulation of the tissue microenvironment might be utilized to control the affinity and efficacy of chemokine-mediated cell migration.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOBIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								BACON KB, 1988, BRIT J PHARMACOL, V95, P966, DOI 10.1111/j.1476-5381.1988.tb11727.x; BANGIA N, 1994, MOL IMMUNOL, V31, P1303, DOI 10.1016/0161-5890(94)90048-5; BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUTTERFIELD JH, 1994, SAMTERS IMMUNOLOGIC, P501; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GLEICH GJ, 1994, SAMTERS IMMUNOLOGICA, P205; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; KAY AB, 1992, BRIT MED BULL, V48, P51, DOI 10.1093/oxfordjournals.bmb.a072541; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498; Williams AJ, 1997, MOL PHARMACOL, V51, P1060, DOI 10.1124/mol.51.6.1060	17	48	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28206	28209		10.1074/jbc.272.45.28206	http://dx.doi.org/10.1074/jbc.272.45.28206			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353270	hybrid			2022-12-25	WOS:A1997YF21900010
J	Elser, B; Kriz, W; Bonventre, JV; Englert, C; Witzgall, R				Elser, B; Kriz, W; Bonventre, JV; Englert, C; Witzgall, R			The Kruppel-associated box (KRAB) zinc finger protein Kid-1 and the Wilms' tumor protein WT1, two transcriptional repressor proteins, bind to heteroduplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; DOMAIN; SUBFAMILY; SEQUENCE; SITES	Zinc finger proteins of the Cys(2)His(2) class represent a large group of DNA-binding proteins. A major subfamily of those proteins, the Kruppel-associated box (KRAB) domain-containing Cys(2)His(2)-zinc finger proteins, have been described as potent transcriptional repressors. So far, however, no DNA-binding sites for KRAB domain-containing zinc finger proteins have been isolated. Using a polymerase chain reaction-based selection strategy with double-and single-stranded DNA, we failed to reveal a binding site for Kid-1, one member of KRAB-zinc finger proteins. Binding of Kid-1 both to single-and homoduplex double-stranded DNA was negligible. We now present evidence that Kid-1 binds to heteroduplex DNA. Similar to Kid-1, the non-KRAB-zinc finger protein WT1 also bound avidly to heteroduplex DNA (both the -KTS and +KTS splice variant of WT1), whereas the POU domain protein Oct-6, the ets domain protein Ets-1 and the RING finger of BRCA-1 did not bind to heteroduplex DNA. Binding of WT1 to heteroduplex DNA was markedly reduced in naturally occurring mutants. The recognition of certain DNA structures by transcriptional repressor proteins may therefore represent a more common phenomenon than previously thought.	UNIV HEIDELBERG,INST ANAT & CELL BIOL 1,D-69120 HEIDELBERG,GERMANY; HARVARD UNIV,SCH MED,DEPT MED,CHARLESTOWN,MA 02129; MASSACHUSETTS GEN HOSP,RENAL UNIT,CHARLESTOWN,MA 02129; FORSCHUNGSZENTRUM KARLSRUHE,INST GENET,D-76021 KARLSRUHE,GERMANY	Ruprecht Karls University Heidelberg; Harvard University; Harvard University; Massachusetts General Hospital; Helmholtz Association; Karlsruhe Institute of Technology				Englert, Christoph/0000-0002-5931-3189; Witzgall, Ralph/0000-0002-5283-4846				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PIERROU S, 1995, ANAL BIOCHEM, V229, P99, DOI 10.1006/abio.1995.1384; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27908	27912		10.1074/jbc.272.44.27908	http://dx.doi.org/10.1074/jbc.272.44.27908			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346939	hybrid			2022-12-25	WOS:A1997YD47300065
J	Raso, V; Brown, M; McGrath, J; Liu, S; Stafford, WF				Raso, V; Brown, M; McGrath, J; Liu, S; Stafford, WF			Antibodies capable of releasing diphtheria toxin in response to the low pH found in endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; BOUNDARY ANALYSIS; ENTRY; CELLS	Diphtheria toxin (DT) undergoes a rapid conformational change in response to the acidity encountered within endosomes. That transition is integral to the passage of its catalytic domain into the cytosol and thus its lethal action. The importance of this translocation mechanism led us to develop several monoclonal antibodies that bind DT at neutral pH but spontaneously release the toxin when critical epitopes denature or unfold upon lowering the pH to 4.5-5.5. Hybridomas were selected using a microtiter plate assay that measured the pH-dependent detachment of antibody from immobilized toxin. The acid-sensitive epitopes involved were on the catalytic, transmembrane, and receptor binding domains of DT. This pH-induced disruption of the binding of toxin to these monoclonal antibodies was analyzed by sedimentation velocity ultracentrifugation. Antibody combining sites were fully occupied at pH 5.5, partially bound at pH 5.0, and totally empty at pH 4.5. It was estimated that the K-alpha for antibody-toxin binding was similar to 1000-fold lower at pH 5.0 than at neutral pH. This novel acid-triggered release mechanism provides a basis for delivery of antibody-bound toxin into cells accompanied by its immediate dissociation as the complex enters acidic vesicles.			Raso, V (corresponding author), BOSTON BIOMED RES INST, 20 STANIFORD ST, BOSTON, MA 02114 USA.		Stafford, Walter/ABC-6553-2020		NATIONAL CANCER INSTITUTE [R01CA049856, R01CA049254] Funding Source: NIH RePORTER; NCI NIH HHS [CA49254, CA49856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; Cann J. R., 1970, INTERACTING MACROMOL; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GEISOW MJ, 1984, EXP CELL RES, V150, P29, DOI 10.1016/0014-4827(84)90698-0; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; HAYAKAWA S, 1983, J BIOL CHEM, V258, P4311; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Raso V, 1990, Semin Cancer Biol, V1, P227; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Yphantis D, 1994, MODERN ANAL ULTRACEN, P209; ZUCKER DR, 1984, MOL IMMUNOL, V21, P785, DOI 10.1016/0161-5890(84)90165-2	21	2	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27618	27622		10.1074/jbc.272.44.27618	http://dx.doi.org/10.1074/jbc.272.44.27618			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346899	hybrid			2022-12-25	WOS:A1997YD47300025
J	Takeshita, A; Cardona, GR; Koibuchi, N; Suen, CS; Chin, WW				Takeshita, A; Cardona, GR; Koibuchi, N; Suen, CS; Chin, WW			TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; IDENTIFICATION	Nuclear hormone receptors (NRs) are ligand-dependent transcription factors that regulate target gene transcription, We report the molecular cloning and characterization of a novel human cDNA encoding TRAM-1, a thyroid hormone receptor activator molecule, a similar to 160-kDa protein homologous with SRC-1/TIF2, by far-Western-based expression screening. TRAM-1 binds to thyroid hormone receptor (TR) and other NRs in a ligand-dependent manner and enhances ligand-induced transcriptional activity of TR. The AF-2 region in NRs has been thought to play a critical role in mediating ligand-dependent transactivation by the interaction with coactivators. Surprisingly, TRAM-1 retains strong ligand-dependent interaction with an AF-2 mutant of TR (E457A), while SRC-1 fails to interact with this mutant. Furthermore, we identified a critical TRAM-1 binding site in rat TR beta 1 outside of AF-2, as TRAM-1 shows weak ligand-dependent interaction with a helix 3 ligand binding domain TR mutant (K288A), compared with SRC-1. These results suggest that TRAM-1 is a coactivator that may exhibit its activity by interacting with subdomains of NRs other than the AF-2 region, in contrast to SRC-1/TIF2.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; WYETH AYERST RES,WOMENS HLTH RES INST,RADNOR,PA 19087	Harvard University; Harvard Medical School; Pfizer	Takeshita, A (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,ROOM 905,20 SHATTUCK ST,BOSTON,MA 02115, USA.			Koibuchi, Noriyuki/0000-0002-2247-9740				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DOUARIN BL, 1995, EMBO J, V14, P2020; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RON D, 1992, BIOTECHNIQUES, V13, P866; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TONE Y, 1994, J BIOL CHEM, V269, P31157; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910	22	311	316	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27629	27634		10.1074/jbc.272.44.27629	http://dx.doi.org/10.1074/jbc.272.44.27629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346901	hybrid			2022-12-25	WOS:A1997YD47300027
J	Li, L; Karlsson, OP; Wieslander, A				Li, L; Karlsson, OP; Wieslander, A			Activating amphiphiles cause a conformational change of the 1,2-diacylglycerol 3-glucosyltransferase from Acholeplasma laidlawii membranes according to proteolytic digestion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; ANIONIC PHOSPHOLIPIDS; PHASE-EQUILIBRIA; LIPID REGULATION; ENZYME	1,2-Diacylglycerol 3-glucosyltransferase synthesizes the major nonbilayer-prone lipid monoglucosyldiacylglycerol (MGlcDAG) in the membrane of Acholeplasma laidlawii, which is important for the spontaneous curvature, and is a regulatory site for the lipid surface charge density, A potential connection between activity and a conformational change of this enzyme, governed by essential lipid activators, was studied with purified MGlcDAG synthase in different lipid aggregates, Critical fractions of anionic phospholipids 1,2-dioleoyl-phosphatidylglycerol (DOPG) and 1,2-dioleoyl-phosphatidylserine (DOPG) were essential for the restoration of enzyme activity, while the zwitterionic 1,2-dioleoyl-phosphatidylcholine (DOPC) and the uncharged di glucosyldiacylglycerol (DGlcDAG) were not, Proteolytic resistance had a very good correlation with the enzyme activity in various lipid CHAPS mixed micelles. Anionic lipids DOPG and DOPS could protect the exposed MGlcDAG:synthase from digestion, whereas DOPC and DGlcDAG could not, Similar features were observed in liposome bilayers, Likewise, the detergent dodecylphosphoglycerol (PGD), with a phosphatidylglycerol-Like headgroup, could also stimulate the MGlcDAG synthase activity efficiently with a concomitant protection toward proteolytic digestion, Neither proteolytic resistance nor restored enzyme activity was observed using soluble glycerol 3-phosphate, It is concluded that in addition to critical amounts, both the negatively charged headgroup and hydrophobic chains of the activator amphiphiles, but not a certain aggregate curvature, seem necessary for a proper conformation and the resulting active state of the MGlcDAG synthase.	UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN	Umea University								Andersson AS, 1996, BIOCHEMISTRY-US, V35, P11119, DOI 10.1021/bi960561w; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Arnold U, 1996, EUR J BIOCHEM, V237, P862, DOI 10.1111/j.1432-1033.1996.0862p.x; BandorowiczPikula J, 1996, MOL MEMBR BIOL, V13, P241; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; CHRISTIANSSON A, 1985, J BIOL CHEM, V260, P3984; Chupin V, 1996, BIOCHEMISTRY-US, V35, P3141, DOI 10.1021/bi952482a; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; DAHLQVIST A, 1995, BIOCHEMISTRY-US, V34, P13381, DOI 10.1021/bi00041a015; DEJONGH HHJ, 1995, FEBS LETT, V360, P255, DOI 10.1016/0014-5793(95)00115-P; IMAI T, 1995, BBA-PROTEIN STRUCT M, V1246, P189, DOI 10.1016/0167-4838(94)00195-M; Jones PC, 1996, MOL MEMBR BIOL, V13, P53, DOI 10.3109/09687689609160575; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NYSTROM S, 1992, EUR J BIOCHEM, V204, P231, DOI 10.1111/j.1432-1033.1992.tb16629.x; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; SMITH PF, 1969, J BACTERIOL, V99, P480, DOI 10.1128/JB.99.2.480-486.1969; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; Webb T, 1997, BIOCHEM J, V321, P83, DOI 10.1042/bj3210083; WIESLANDER A, 1977, BIOCHIM BIOPHYS ACTA, V466, P336, DOI 10.1016/0005-2736(77)90229-2	27	7	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29602	29606		10.1074/jbc.272.47.29602	http://dx.doi.org/10.1074/jbc.272.47.29602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368025	hybrid			2022-12-25	WOS:A1997YG64700035
J	Lotfi, CFP; Todorovic, Z; Armelin, HA; Schimmer, BP				Lotfi, CFP; Todorovic, Z; Armelin, HA; Schimmer, BP			Unmasking a growth-promoting effect of the adrenocorticotropic hormone in Y1 mouse adrenocortical tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-DEPENDENT ACTIVATION; SIGNALING PATHWAYS; PHORBOL ESTER; ADRENAL-CELLS; ANTISENSE RNA; CYCLIC-AMP; FOS; ACTH; MONOPHOSPHATE	The adrenocorticotropic hormone (ACTH) inhibits the growth of Y1 mouse adrenocortical tumor cells as well as normal adrenocortical cells in culture but stimulates adrenocortical cell growth in vivo. In this study, we investigated this paradoxical effect of ACTH on cell proliferation in Y1 adrenal cells and have unmasked a growth promoting effect of the hormone. Y1 cells were arrested in the G(1) phase of the cell cycle by serum starvation and monitored for progression through S phase by measuring [H-3]thymidine incorporation into DNA and by measuring the number of nuclei labeled with bromodeoxyuridine. Y1 cells were stimulated to progress through S phase and to divide after a brief pulse of ACTH (up to 2 h), This effect of ACTH appeared to be cAMP independent, since ACTH also induced cell cycle progression in Kin-8, a Y1 mutant with defective cAMP-dependent protein kinase activity, The growth-promoting effect of ACTH in Y1 was preceded by the rapid activation of p44 and p42 mitogen-activated protein kinases and by the accumulation of c-FOS protein, In contrast, continuous treatment with ACTH (14 h) inhibited cell cycle progression in Y1 cells by a cAMP-dependent pathway. The inhibitory effect of ACTH mapped to the midpoint of G,, Together, the results demonstrate a dual effect of ACTH on cell cycle progress, a cAMP-independent growth-promoting effect early in G(1) possibly mediated by mitogen-activated protein kinase and c-FOS, and a cAMP-dependent inhibitory effect at mid-G(1). It is suggested that the growth-inhibitory effect of ACTH at mid-G(1) represents an ACTH-regulated check point that limits cell cycle progression.	UNIV TORONTO, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto	Lotfi, CFP (corresponding author), UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05599970 SAO PAULO, BRAZIL.		Armelin, Hugo/P-4390-2015; Lotfi, Claudimara/B-7354-2011	Armelin, Hugo/0000-0001-9557-0804; Lotfi, Claudimara/0000-0002-9881-7099				Armelin HA, 1996, ENDOCR RES, V22, P373, DOI 10.1080/07435809609043721; ARMELIN MCS, 1977, J CELL PHYSIOL, V93, P1, DOI 10.1002/jcp.1040930102; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; GILL GN, 1977, J CELL PHYSIOL, V92, P65, DOI 10.1002/jcp.1040920109; GOSPODAROWICZ D, 1975, ENDOCRINOLOGY, V97, P102, DOI 10.1210/endo-97-1-102; HARPER JF, 1984, COMPUT BIOL MED, V14, P437, DOI 10.1016/0010-4825(84)90044-1; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Holzwarth MA, 1996, ENDOCR RES, V22, P401, DOI 10.1080/07435809609043724; HORNSBY PJ, 1985, ENDOCR RES, V10, P259; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KIMURA E, 1983, REV BRAS GENET, V6, P211; KIMURA E, 1990, J BIOL CHEM, V265, P3518; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUDLOW JE, 1980, P NATL ACAD SCI-BIOL, V77, P2767, DOI 10.1073/pnas.77.5.2767; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MASUI H, 1971, P NATL ACAD SCI USA, V68, P3206, DOI 10.1073/pnas.68.12.3206; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Mitani F, 1996, ENDOCR RES, V22, P421, DOI 10.1080/07435809609043728; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SCHIMMER BP, 1985, ENDOCR RES, V11, P199, DOI 10.1080/07435808509032978; SCHIMMER BP, 1976, MOL CELL ENDOCRINOL, V4, P263, DOI 10.1016/0303-7207(76)90060-5; SCHIMMER BP, 1985, METHOD ENZYMOL, V109, P350; SCHIMMER BP, 1989, DRUG RESISTANCE MAMM, V1, P185; SCHIMMER BP, 1981, FUNCTIONALLY DIFFERE, P61; Trejo J, 1996, J BIOL CHEM, V271, P21536, DOI 10.1074/jbc.271.35.21536; VIARD I, 1994, J STEROID BIOCHEM, V50, P219, DOI 10.1016/0960-0760(94)90125-2; WEIDMAN ER, 1977, J CELL PHYSIOL, V90, P91, DOI 10.1002/jcp.1040900112; WIDMAIER EP, 1985, MOL CELL ENDOCRINOL, V43, P181, DOI 10.1016/0303-7207(85)90082-6; YASUMURA Y, 1966, CANCER RES, V26, P529	41	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29886	29891		10.1074/jbc.272.47.29886	http://dx.doi.org/10.1074/jbc.272.47.29886			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368063	hybrid			2022-12-25	WOS:A1997YG64700073
J	Sirrenberg, C; Endres, M; Becker, K; Bauer, MF; Walther, E; Neupert, W; Brunner, M				Sirrenberg, C; Endres, M; Becker, K; Bauer, MF; Walther, E; Neupert, W; Brunner, M			Functional cooperation and stoichiometry of protein translocases of the outer and inner membranes of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; PRECURSOR PROTEINS; PROCESSING PEPTIDASE; INTERMEMBRANE SPACE; NEUROSPORA-CRASSA; RECEPTOR-SITES; CONTACT SITES; IMPORT; TRANSPORT; MACHINERY	The qualitative relationship between preprotein translocases in the mitochondrial outer and inner membranes was determined by both a functional analysis and a determination of characteristic components of the translocases. Translocation contact sites of isolated mitochondria were saturated with intermediates of a matrix-targeted precursor of the beta-subunit of the F-1-ATPase (pF(1) beta), and import of preproteins into the different mitochondrial subcompartments was monitored, A strong inhibition (75-95%) was observed for preproteins with an N-terminal matrix targeting signal, indicating that a significant portion of the contact sites was blocked by accumulated F-1 beta. Insertion of preproteins into the outer membrane and import into the intermembrane space of preproteins without matrix targeting signals was inhibited by about 45%, indicating that functional outer membrane translocases were available despite saturation of contact sites, Similarly, import of members of the mitochondrial carrier family into the inner membrane was only partly inhibited (40-50%), demonstrating that functional Tim22 translocases were available to cooperate with the Tom machinery in the import of carrier proteins, The stoichiometry of Tom40, Tim23, and Tim22 in mitochondria was determined to be 5:1:0.22, We conclude that translocases of the outer membrane are present in excess over translocases of the inner membrane.			Sirrenberg, C (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Brunner, Michael/0000-0001-9798-3047				ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BAUER MF, 1996, HDB BIOL PHYSICS, V2, P791; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; Dekker PJT, 1996, BIOL CHEM, V377, P535; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MEYER A, 1993, J CELL BIOL, V121, P1233; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1987, EMBO J, V6, P3449, DOI 10.1002/j.1460-2075.1987.tb02668.x; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RASSOW J, 1990, NUCLEIC ACIDS RES, V18, P4922, DOI 10.1093/nar/18.16.4922; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; VANDERKLEI IJ, 1994, MICROSC RES TECHNIQ, V27, P284, DOI 10.1002/jemt.1070270404	27	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29963	29966		10.1074/jbc.272.47.29963	http://dx.doi.org/10.1074/jbc.272.47.29963			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368075	hybrid			2022-12-25	WOS:A1997YG64700085
J	Sparrow, LG; McKern, NM; Gorman, JJ; Strike, PM; Robinson, CP; Bentley, JD; Ward, CW				Sparrow, LG; McKern, NM; Gorman, JJ; Strike, PM; Robinson, CP; Bentley, JD; Ward, CW			The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FIBRONECTIN TYPE-III; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; MESSENGER-RNA; ALPHA-SUBUNIT; BETA-SUBUNIT; PROTEINS; KINASE	The human insulin receptor is a homodimer consisting of two monomers linked by disulfide bonds, Each monomer comprises an alpha-chain that is entirely extracellular and a beta-chain that spans the cell membrane, The alpha-chain has a total of 37 cysteine residues, most of which form intrachain disulfide bonds, whereas the beta-chain contains 10 cysteine residues, four of which are in the extracellular region, There are two classes of disulfide bonds in the insulin receptor, those that can be reduced under mild reducing conditions to give alpha-beta monomers (class I) and those that require stronger reducing conditions (class II), The number of class I disulfides is small and includes the alpha-alpha dimer bond Cys(524), In this report we describe the use of cyanogen bromide and protease digestion of the exon 11 plus form of the receptor ectodomain to identify disulfide linkages between the beta-chain residues Cys(798) and Cys(807) and between the alpha-chain Cys(647) and the beta-chain Cys(872), The latter bond is the sole alpha-beta link in the molecule and implies a side-by-side alignment of the two fibronectin III domains of the receptor, Also presented is evidence for additional alpha-alpha dimer bond(s) involving at least one of the cysteine residues of the triplet at positions 682, 683, and 685, Evidence is also presented to show that Cys(884) exists as a buried thiol in the soluble ectodomain.	CSIRO,DIV MOL SCI,PARKVILLE,VIC 3052,AUSTRALIA; CSIRO,BIOMOL RES INST,PARKVILLE,VIC 3052,AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO)								BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BILAN PJ, 1994, BIOCHEM BIOPH RES CO, V205, P1891, DOI 10.1006/bbrc.1994.2891; CAMPBELL ID, 1994, STRUCTURE, V2, P333, DOI 10.1016/S0969-2126(00)00034-4; CHEATHAM B, 1992, J BIOL CHEM, V267, P7108; CHIACCHIA KB, 1991, BIOCHEM BIOPH RES CO, V176, P1178, DOI 10.1016/0006-291X(91)90409-Z; Cosgrove L, 1995, PROTEIN EXPRES PURIF, V6, P789, DOI 10.1006/prep.1995.0010; CZECH MP, 1981, TRENDS BIOCHEM SCI, V6, P222, DOI 10.1016/0968-0004(81)90081-5; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DURONIO V, 1988, J BIOL CHEM, V263, P5436; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FINN FM, 1990, P NATL ACAD SCI USA, V87, P419, DOI 10.1073/pnas.87.1.419; GOLDSTEIN BJ, 1990, MOL ENDOCRINOL, V4, P235, DOI 10.1210/mend-4-2-235; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; Kabat EA, 1991, SEQUENCES PROTEINS I; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; MACAULAY SL, 1994, BIOCHEM J, V303, P575, DOI 10.1042/bj3030575; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RIDGE KD, 1988, P NATL ACAD SCI USA, V85, P9489, DOI 10.1073/pnas.85.24.9489; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIA MA, 1983, J BIOL CHEM, V258, P4450; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Sparrow LG, 1997, PROTEIN PEPTIDE LETT, V4, P271; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WIELAND T, 1972, PEPTIDES 72, P38; WILDEN PA, 1987, BIOCHEM J, V245, P325, DOI 10.1042/bj2450325; XU QY, 1990, J BIOL CHEM, V265, P18673	40	86	89	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29460	29467		10.1074/jbc.272.47.29460	http://dx.doi.org/10.1074/jbc.272.47.29460			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368005	hybrid			2022-12-25	WOS:A1997YG64700015
J	Zhou, LX; Chen, H; Lin, CH; Cong, LN; McGibbon, MA; Sciacchitano, S; Lesniak, MA; Quon, MJ; Taylor, SI				Zhou, LX; Chen, H; Lin, CH; Cong, LN; McGibbon, MA; Sciacchitano, S; Lesniak, MA; Quon, MJ; Taylor, SI			Insulin receptor substrate-2 (IRS-2) can mediate the action of insulin to stimulate translocation of GLUT4 to the cell surface in rat adipose cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; ACTIVATION; MICE; PROTEIN; DOMAIN; KINASE; BINDS	Insulin receptor substrates-1 and -2 (IRS-1 and -2) are important substrates of the insulin receptor tyrosine kinase, Previous studies have focused upon the role of IRS-1 in mediating the actions of insulin, In the present study, we demonstrate that IRS-2 can mediate translocation of the insulin responsive glucose transporter GLUT4 in a physiologically relevant target cell for insulin action, Co-immunoprecipitation experiments performed on cell lysates derived from freshly isolated rat adipose cells incubated in the presence or absence of insulin indicated that twice as much phosphatidylinositol 3-kinase was associated with endogenous IRS-1 as with IRS-2 after insulin stimulation, When rat adipose cells in primary culture were transfected with expression vectors for IRS-1 or IRS-2, we observed 40-fold over-expression of human IRS-1 or murine IRS-2. In addition, anti-phosphotyrosine immunoblotting experiments confirmed that the recombinant substrates were phosphorylated in response to insulin stimulation, To examine the role of IRS-2 in insulin-stimulated translocation of GLUT4, we studied the effects of overexpression of IRS-1 and -2 on translocation of a co-transfected epitope-tagged GLUT4 (GLUT4-HA). Overexpression of IRS-1 or IRS-2 in adipose cells resulted in a significant increase in the basal level of cell surface GLUT4 (in the absence of insulin). Interestingly, at maximally effective concentrations of insulin (60 nM), the level of cell surface GLUT4 in cells overexpressing IRS-1 or -2 significantly exceeded the maximal recruitment observed in the control cells (160 and 135% of control, respectively; p < 0.003), Our data directly demonstrate that IRS-2, like IRS-1, is capable of participating in insulin signal transduction pathways leading to the recruitment of GLUT4, Thus, IRS-2 may provide an alternative pathway for critical metabolic actions of insulin.	NHLBI,HYPERTENS ENDOCRINE BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Zhou, LX (corresponding author), NIDDK,DIABET BRANCH,NIH,BETHESDA,MD 20892, USA.		Quon, Michael/B-1970-2008; Sciacchitano, Salvatore/AAM-5895-2020	Sciacchitano, Salvatore/0000-0003-1492-5365; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707				ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	38	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29829	29833		10.1074/jbc.272.47.29829	http://dx.doi.org/10.1074/jbc.272.47.29829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368055	hybrid			2022-12-25	WOS:A1997YG64700065
J	Dubois, T; Rommel, C; Howell, S; Steinhussen, U; Soneji, Y; Morrice, N; Moelling, R; Aitken, A				Dubois, T; Rommel, C; Howell, S; Steinhussen, U; Soneji, Y; Morrice, N; Moelling, R; Aitken, A			14-3-3 is phosphorylated by casein kinase I on residue 233 - Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; T-CELLS; 14-3-3-PROTEINS ASSOCIATE; TRYPTOPHAN-HYDROXYLASE; SIGNALING PROTEINS; MOLECULAR-CLONING; FAMILY; IDENTIFICATION; EXPRESSION; ISOFORM	14-3-3 proteins mediate interactions between proteins involved in signal transduction and cell cycle regulation, Phosphorylation of target proteins as well as 14-3-3 are important for protein-protein interactions, Here, we describe the purification of a protein kinase from porcine brain that phosphorylates 14-3-3 zeta on Thr-233, This protein kinase has been identified as casein kinase I alpha (CKI alpha) by peptide mapping analysis and sequencing, Among mammalian 14-3-3, only 14-3-3 tau possesses a phosphorylatable residue at the same position (Ser-233), and we show that this residue is also phosphorylated by CKI. In addition, we show that 14-3-3 zeta is exclusively phosphorylated on Thr-233 in human embryonic kidney 293 cells. The residue 233 is located within a region shown to be important for the association of 14-3-3 to target proteins, me showed previously that, in 293 cells, only the unphosphorylated form of 14-3-3 zeta associates with the regulatory domain of c-Raf, me have now shown that in vivo phosphorylation of 14-3-3 zeta at the CKI alpha site (Thr-233) negatively regulates its binding to c-Raf, and may be important in Raf-mediated signal transduction.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND; MRC, PROT PHOSPHORYLAT UNIT, DUNDEE DD1 4HN, SCOTLAND	University of Zurich	Dubois, T (corresponding author), NATL INST MED RES, DIV PROT STRUCT, MILL HILL, LONDON NW7 1AA, ENGLAND.		; Dubois, Thierry/D-2852-2017	Soneji, Yasmina/0000-0001-9189-6348; Dubois, Thierry/0000-0003-4739-6164				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CELIS A, 1988, FEBS LETT, V227, P14, DOI 10.1016/0014-5793(88)81404-2; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; DESDOUITS F, 1995, J BIOL CHEM, V270, P8772, DOI 10.1074/jbc.270.15.8772; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Dubois T, 1997, J PROTEIN CHEM, V16, P513, DOI 10.1023/A:1026321813463; Estrada E, 1996, J BIOL CHEM, V271, P32064, DOI 10.1074/jbc.271.50.32064; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GROSS SD, 1995, J CELL BIOL, V130, P711, DOI 10.1083/jcb.130.3.711; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOEKSTRA MF, 1995, J CELL BIOCH SA, V21; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Meller N, 1996, MOL CELL BIOL, V16, P5782; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MILNE DM, 1992, ONCOGENE, V7, P1361; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Pietromonaco SF, 1996, BLOOD CELL MOL DIS, V22, P225, DOI 10.1006/bcmd.1996.0103; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rommel C, 1996, ONCOGENE, V12, P609; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P123; VARELA I, 1988, FEBS LETT, V231, P361, DOI 10.1016/0014-5793(88)80850-0; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JR, 1996, BIOCHEMISTRY-US, V35, P16319, DOI 10.1021/bi9614444	65	121	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28882	28888		10.1074/jbc.272.46.28882	http://dx.doi.org/10.1074/jbc.272.46.28882			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360956	hybrid			2022-12-25	WOS:A1997YF68400015
J	Emsley, J; King, SL; Bergelson, JM; Liddington, RC				Emsley, J; King, SL; Bergelson, JM; Liddington, RC			Crystal structure of the I domain from integrin alpha 2 beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADHESION; LIGAND-BINDING; A-DOMAIN; LAMININ RECEPTOR; VLA-2; IDENTIFICATION; COLLAGEN; SITE; CD11B/CD18; PLATELETS	We have determined the high resolution crystal structure of the I domain from the alpha-subunit of the integrin alpha 2 beta 1, a cell surface adhesion receptor for collagen and the human pathogen echovirus-1. The domain, as expected, adopts the dinucleotide-binding fold, and contains a metal ion-dependent adhesion site motif with bound Mg2+ at the top of the beta-sheet. Comparison with the crystal structures of the leukocyte integrin I domains reveals a new helix (the C-helix) protruding from the metal ion-dependent adhesion site face of the domain which creates a groove centered on the magnesium ion. Modeling of a collagen triple helix into the groove suggests that a glutamic acid side chain from collagen can coordinate the metal ion, and that the C-helix insert is a major determinant of binding specificity. The binding site for echovirus-1 maps to a distinct surface of the alpha 2-I domain (one edge of the beta-sheet), consistent with data showing that virus and collagen binding occur by different mechanisms. Comparison with the homologous von Willebrand factor A3 domain, which also binds collagen, suggests that the two domains bind collagen in different ways.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; DANA FARBER CANC INST,DIV INFECT DIS,BOSTON,MA 02115	University of Leicester; Harvard University; Dana-Farber Cancer Institute			emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030				BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KERN A, 1994, J BIOL CHEM, V269, P22811; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Nicholls A., 1992, GRASP GRAPHICAL REPR; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell D, 1996, SEMIN CELL DEV BIOL, V7, P649, DOI 10.1006/scdb.1996.0079	27	247	259	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28512	28517		10.1074/jbc.272.45.28512	http://dx.doi.org/10.1074/jbc.272.45.28512			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353312	hybrid			2022-12-25	WOS:A1997YF21900052
J	Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO				Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO			Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CYTOPLASMIC ACCUMULATION; DEPENDENT KINASES; PROTEIN-KINASE; HELA-CELLS; ACTIVATION; PHOSPHORYLATION; PHOSPHATASE; MITOSIS; P34(CDC2)	Cdc25 regulates entry into mitosis by regulating the activation of cyclin B/cdc2. In humans, at least two cdc25 isoforms have roles in controlling the G(2)/M transition. Here we show, using bacterially expressed recombinant proteins, that two cdc25B splice variants, cdc25B2 and cdc25B3, are capable of activating cyclin A/cdk2 and cyclin B/cdc2, but that mitotic hyperphosphorylation of these proteins increases their activity toward only cyclin B1/cdc2, Cdc25C has only very low activity in its unphosphorylated form, add following hyperphosphorylation it will efficiently catalyze the activation of only cyclin B/cdc2, This was reflected by the in vivo activity of the immunoprecipitated cdc25B and cdc25C from interphase and mitotic HeLa cells. The increased activity of the hyperphosphorylated cdc25s toward cyclin B1/cdc2 was in large part due to increased binding of this substrate. The substrate specificity, activities; and timing of the hyperphosphorylation of cdc25B and cdc25C during G(2) and M suggest that these two mitotic cdc25 isoforms are activated by different kinases and perform different functions during progression through G(2) into mitosis.	UNIV QUEENSLAND,ROYAL BRISBANE HOSP,JOINT ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	Royal Brisbane & Women's Hospital; University of Queensland	Gabrielli, BG (corresponding author), UNIV QUEENSLAND,ROYAL BRISBANE HOSP,HYDRO QUEBEC RES INST,QUEENSLAND CANC FUND,RES LABS,HERSTON,QLD 4029,AUSTRALIA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651				ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BAILLY E, 1992, J CELL SCI, V101, P529; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; OGG S, 1994, J BIOL CHEM, V269, P30461; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; VILLAMORUZZI E, 1993, BIOCHEM BIOPH RES CO, V196, P1248, DOI 10.1006/bbrc.1993.2386; Xu X, 1996, J BIOL CHEM, V271, P5118; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	26	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28607	28614		10.1074/jbc.272.45.28607	http://dx.doi.org/10.1074/jbc.272.45.28607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353326	hybrid			2022-12-25	WOS:A1997YF21900066
J	He, CZ; Burch, JBE				He, CZ; Burch, JBE			The chicken GATA-6 locus contains multiple control regions that confer distinct patterns of heart region-specific expression in transgenic mouse embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SKELETAL-MUSCLE; GENE-EXPRESSION; HOMEOBOX GENES; MESODERM; IDENTIFICATION; EMBRYOGENESIS; MORPHOGENESIS; GATA-4/5/6; CHROMATIN	The GATA-6 transcription factor is expressed in cardiogenic cells and during subsequent stages of heart development in diverse vertebrate species. To gain insights into the molecular events that govern this heart-restricted expression, we isolated the chicken GATA-6 gene and used several approaches to screen for associated control regions. Our analysis of two chicken GATA-6/lacZ constructs in transgenic mouse embryos was particularly revealing. One GATA-6/lacZ construct, which has 1.5 kilobase pairs of upstream sequences along with the promoter and first intron, was expressed exclusively in the atrioventricular canal region of the heart. This expression pattern is novel and appears to mark specialized myocardial cells that induce underlying endocardial cells to initiate valve formation. The other GATA-6/ lacZ construct, which has an additional 7.7 kilobase pairs of upstream sequences, was expressed in the ventricle and outflow tract in addition to the atrioventricular canal. The failure of these GATA-6 control regions to function as enhancers in transfected cardiac myocyte cultures underscores the importance of using transgenic approaches to elucidate transcriptional controls that function in the developing heart. Although the endogenous GATA-6 gene is expressed throughout the heart, our results indicate that this is effected in a heart region-specific manner.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927] Funding Source: Medline; NHLBI NIH HHS [HL55373] Funding Source: Medline; NIGMS NIH HHS [GM35535] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHANTHOMAS PS, 1993, DEV DYNAM, V197, P203, DOI 10.1002/aja.1001970305; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; Davis DL, 1996, ANTISENSE NUCLEIC A, V6, P259, DOI 10.1089/oli.1.1996.6.259; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRIESHAMMER U, 1995, DEVELOPMENT, V121, P2245; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HOGAN B, 1994, MANIPULATING MOUSE E, P373; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG JX, 1995, ANN NY ACAD SCI, V752, P317, DOI 10.1111/j.1749-6632.1995.tb17441.x; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KELLEY C, 1993, DEVELOPMENT, V118, P817; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KILEDJIAN M, 1990, NUCLEIC ACIDS RES, V18, P957, DOI 10.1093/nar/18.4.957; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Ross RS, 1996, DEVELOPMENT, V122, P1799; Sambrook J., 2002, MOL CLONING LAB MANU; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STERN CD, 1993, ESSENTIAL DEV BIOL P, P195; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; Wei Y, 1996, DEVELOPMENT, V122, P2779; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Zhang HB, 1996, DEVELOPMENT, V122, P2977; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	51	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28550	28556		10.1074/jbc.272.45.28550	http://dx.doi.org/10.1074/jbc.272.45.28550			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353318	hybrid			2022-12-25	WOS:A1997YF21900058
J	Murphy, MEP; Turley, S; Adman, ET				Murphy, MEP; Turley, S; Adman, ET			Structure of nitrite bound to copper-containing nitrite reductase from Alcaligenes faecalis - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; X-RAY STRUCTURE; ACHROMOBACTER-CYCLOCLASTES; DISSIMILATORY NITRITE; CRYSTAL-STRUCTURES; PROTEIN STRUCTURES; SUBSTRATE ADDUCT; STRAIN S-6; SITE; CENTERS	The structures of oxidized, reduced, nitrite-soaked oxidized and nitrite-soaked reduced nitrite reductase from Alcaligenes faecalis have been determined at 1.8-2.0 Angstrom resolution using data collected at -160 degrees C. The active site at cryogenic temperature, as at room temperature, contains a tetrahedral type II copper site liganded by three histidines and a water molecule. The solvent site is empty when crystals are reduced with ascorbate. A fully occupied oxygen-coordinate nitrite occupies the solvent site in crystals soaked in nitrite. Ascorbate-reduced crystals soaked in a glycerol-methanol solution and nitrite at -40 degrees C remain colorless at -160 degrees C but turn amber-brown when warmed, suggesting that NO is released. Nitrite is found at one-half occupancy. Five new solvent sites in the oxidized nitrite bound form exhibit defined but different occupancies in the other three forms. These results support a previously proposed mechanism by which nitrite is bound primarily by a single oxygen atom that is protonable, and after reduction and cleavage of that N-O bond, NO is released leaving the oxygen atom bound to the Cu site as hydroxide or water.	UNIV WASHINGTON,SCH MED,DEPT BIOL STRUCT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Murphy, Michael/R-6805-2017	Murphy, Michael/0000-0003-2589-0014	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031770] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31770] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM ZHL, 1993, BIOCHEM J, V295, P587, DOI 10.1042/bj2950587; ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; ARGOS P, 1978, J MOL BIOL, V126, P141, DOI 10.1016/0022-2836(78)90356-X; ARNEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649, DOI 10.1107/S0021889894001858; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR VERSION 3 1; COYNE MS, 1989, APPL ENVIRON MICROB, V55, P2924, DOI 10.1128/AEM.55.11.2924-2931.1989; Dodd FE, 1997, ACTA CRYSTALLOGR D, V53, P406, DOI 10.1107/S0907444997002667; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GOMISRUTH FX, 1994, J BIOL CHEM, V269, P17111; Halfen JA, 1996, J AM CHEM SOC, V118, P763, DOI 10.1021/ja952691i; HALFEN JA, 1994, J AM CHEM SOC, V116, P5475, DOI 10.1021/ja00091a064; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; HOWES BD, 1994, BIOCHEMISTRY-US, V33, P3171, DOI 10.1021/bi00177a005; HULSE CL, 1989, J AM CHEM SOC, V111, P2322, DOI 10.1021/ja00188a067; JACKSON MA, 1991, FEBS LETT, V291, P41, DOI 10.1016/0014-5793(91)81099-T; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAKUTANI T, 1981, J BIOCHEM-TOKYO, V89, P463, DOI 10.1093/oxfordjournals.jbchem.a133221; KAKUTANI T, 1981, J BIOCHEM, V89, P453, DOI 10.1093/oxfordjournals.jbchem.a133220; KIM CH, 1984, J BIOL CHEM, V259, P2092; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LIBBY E, 1992, BIOCHEM BIOPH RES CO, V187, P1529, DOI 10.1016/0006-291X(92)90476-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURPHY MEP, 1995, BIOCHEMISTRY-US, V34, P12107, DOI 10.1021/bi00038a003; Murphy MEP, 1997, PROTEIN SCI, V6, P761; NISHIYAMA M, 1993, J GEN MICROBIOL, V139, P725, DOI 10.1099/00221287-139-4-725; OTWINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P87; PETERSLIBEU CA, 1997, IN PRESS BIOCHEMISTR; Stibrany RT, 1996, INORG CHIM ACTA, V243, P33, DOI 10.1016/0020-1693(95)04889-8; STRANGE RW, 1995, NAT STRUCT BIOL, V2, P287, DOI 10.1038/nsb0495-287; SUZUKI S, 1994, J AM CHEM SOC, V116, P11145, DOI 10.1021/ja00103a035; TOLMAN WB, 1991, INORG CHEM, V30, P4877, DOI 10.1021/ic00026a005; Tolman WB, 1993, BIOINORGANIC CHEM CO, P406; TURLEY S, 1988, J MOL BIOL, V200, P417, DOI 10.1016/0022-2836(88)90251-3; 1994, ACTA CRYSTALLOGR, V50, P760	40	182	184	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28455	28460		10.1074/jbc.272.45.28455	http://dx.doi.org/10.1074/jbc.272.45.28455			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353305	hybrid			2022-12-25	WOS:A1997YF21900045
J	Venema, VJ; Ju, H; Zou, R; Venema, RC				Venema, VJ; Ju, H; Zou, R; Venema, RC			Communication - Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle - Identification of a novel caveolin scaffolding/inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTEIN; CELLS; ENZYME; LOCALIZATION; DYSTROPHIN; SARCOLEMMA; INHIBITION; ISOFORMS	Neuronal nitric-oxide synthase (nNOS) has been shown previously to interact with alpha(1)-syntrophin in the dystrophin complex of skeletal muscle. In the present study, we have examined whether nNOS also interacts with caveolin-3 in skeletal muscle. nNOS and caveolin-3 are coimmunoprecipitated from rat skeletal muscle homogenates by antibodies directed against either of the two proteins. Synthetic peptides corresponding to the membrane-proximal caveolin-3 residues 65-84 and 109-130 and homologous caveolin-1 residues 82-101 and 135-156 potently inhibit the catalytic activity of purified, recombinant nNOS. Purified nNOS also binds to a glutathione S-transferase-caveolin-1 fusion protein in in vitro binding assays. In vitro binding is completely abolished by preincubation of nNOS with either of the two caveolin-3 inhibitory peptides. Interactions between nNOS and caveolin-3, therefore, appear to be direct and to involve two distinct caveolin scaffolding/inhibitory domains. Other caveolin-interacting enzymes, including endothelial nitric-oxide synthase and the c-Src tyrosine kinase, are also potently inhibited by each of the four caveolin peptides. Inhibitory interactions mediated by two different caveolin domains may thus be a general feature of enzyme docking to caveolin proteins in plasmalemmal caveolae.	MED COLL GEORGIA, VASC BIOL CTR, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PEDIAT, AUGUSTA, GA 30912 USA; MED COLL GEORGIA, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bredt DS, 1996, P SOC EXP BIOL MED, V211, P41; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; Venema VJ, 1996, BIOCHEM BIOPH RES CO, V226, P703, DOI 10.1006/bbrc.1996.1417	27	213	215	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28187	28190		10.1074/jbc.272.45.28187	http://dx.doi.org/10.1074/jbc.272.45.28187			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353265	hybrid			2022-12-25	WOS:A1997YF21900005
J	Vito, P; Ghayur, T; DAdamio, L				Vito, P; Ghayur, T; DAdamio, L			Generation of anti-apoptotic presenilin-2 polypeptides by alternative transcription, proteolysis, and caspase-3 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; T-CELL HYBRIDOMAS; MISSENSE MUTATIONS; ICE/CED-3 PROTEASE; DEATH; ACTIVATION; GENE; APOPAIN/CPP32; REQUIREMENT; ALG-3	PS2, the chromosome 1 familial Alzheimer's disease gene, has been shown to be involved in programmed cell death by three complementary experimental approaches, Reduction of PS2 protein levels by antisense RNA protects from apoptosis, whereas overexpression of an Alzheimer's PS2 mutant increases cell death induced by several stimuli, In addition, ALG-3, a truncated PS2 cDNA, encodes an artificial COOH-terminal PS2 segment that dominantly inhibits apoptosis, Here we describe a physiological COOH-terminal PS2 polypeptide (PS2s, Met(298)-Ile(448)) generated by both an alternative PS2 transcript and proteolytic cleavage, We find that PS2s protects transfected cells from Fas-and tumor necrosis factor alpha (TNF alpha)-induced apoptosis, Furthermore, a similar anti-apoptotic COOH-terminal PS2 polypeptide (PS2Ccas) is generated by caspase-3 cleavage at Asp(329). These results suggest that caspase-3 not only activates pro-apoptotic substrates but also generates a negative feedback signal in which PS2Ccas antagonizes the progression of cell death. Thus, whereas PS2 is required for apoptosis, PS2s and PS2Ccas oppose this process, and the balance between PS2 and these COOH-terminal fragments may dictate the cell fate.	NIAID, T CELL MOL BIOL UNIT, CELLULAR & MOL IMMUNOL LAB, NIH, BETHESDA, MD 20892 USA; 3 BASF RES CORP, WORCESTER, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); BASF			vito, pasquale/ABF-5505-2020	vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lacana E, 1997, J IMMUNOL, V158, P5129; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHI YF, 1990, J IMMUNOL, V144, P3326; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710	33	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28315	28320		10.1074/jbc.272.45.28315	http://dx.doi.org/10.1074/jbc.272.45.28315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353287	hybrid			2022-12-25	WOS:A1997YF21900027
J	Yu, R; Hinkle, PM				Yu, R; Hinkle, PM			Desensitization of thyrotropin-releasing hormone receptor-mediated responses involves multiple steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE FORMATION; PITUITARY-TUMOR CELLS; PROTEIN-KINASE-C; PHOSPHOINOSITIDE HYDROLYSIS; GENE-TRANSFER; GH4C1 CELLS; CALCIUM; MECHANISM; TRH; PHOSPHODIESTERASE	Desensitization and recovery of the inositol 1,4,5-trisphosphate (IP3) and intracellular free calcium concentration ([Ca2+](i)) responses to thyrotropin-releasing hormone (TRH) were measured in HEK298 cells stably expressing the G protein coupled TRH receptor, TRH caused a large, rapid, and transient increase in IP3 and a biphasic increase in [Ca2+](i). Desensitization of the TRH response was measured by exposing cells to TRH, washing, and then incubating the cells in hormone-free medium before reintroducing TRH and measuring IP3, [Ca2+](i), and intracellular Ca2+ pool size, When cells were incubated with 1 mu M TRH for 10 s or 10 min and reexposed to TRH, there was almost no IP3, or [Ca2+](i) increase, The IP3, response recovered first, followed by the [Ca2+](i) response, The ionomycin-releasable intracellular Ca2+ pool was almost completely depleted by TRH, and pool refilling was slow, Thrombin, endothelin, and carbachol, when combined, stimulated large increases in IP3 and [Ca2+](i), but did not block the IP3 or [Ca2+](i) responses to TRH measured 10 min later. In contrast, cells exposed to TRH first responded to combined agonists with a nearly normal increase in IP3, but no rise in [Ca2+](i), Thus, the IP3 response to TRH displays homologous desensitization, whereas the [Ca2+](i) response displays heterologous desensitization because depletion of intracellular Ca2+ pools prevents responses to other hormones.	UNIV ROCHESTER, SCH MED & DENT, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ANDERSON L, 1995, BIOCHEM J, V311, P385, DOI 10.1042/bj3110385; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Bohm SK, 1997, BIOCHEM J, V322, P1; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUMMOND AH, 1984, MOL PHARMACOL, V25, P201; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1994, J BIOL CHEM, V269, P6779; HINKLE PM, 1982, J BIOL CHEM, V257, P5462; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; IMAI A, 1985, J BIOL CHEM, V260, P536; KOSHIYAMA H, 1991, BIOCHEM BIOPH RES CO, V177, P551, DOI 10.1016/0006-291X(91)92019-G; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MARTIN TFJ, 1986, J BIOL CHEM, V261, P2918; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; NELSON EJ, 1994, J BIOL CHEM, V269, P30854; PARKER I, 1995, CIBA F SYMP, V188, P50; PERLMAN JH, 1991, ENDOCRINOLOGY, V129, P2679, DOI 10.1210/endo-129-5-2679; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; Shupnik MA, 1996, MOL ENDOCRINOL, V10, P90, DOI 10.1210/me.10.1.90; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; TORJESEN PA, 1988, MOL CELL ENDOCRINOL, V56, P107, DOI 10.1016/0303-7207(88)90014-7; VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28301	28307		10.1074/jbc.272.45.28301	http://dx.doi.org/10.1074/jbc.272.45.28301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353285	hybrid			2022-12-25	WOS:A1997YF21900025
J	Lin, MCM; Li, JJ; Wang, EJ; Princler, GL; Kauffman, FC; Kung, HF				Lin, MCM; Li, JJ; Wang, EJ; Princler, GL; Kauffman, FC; Kung, HF			Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene	FASEB JOURNAL			English	Article						MTP; gene expression; HepG2; rats	MODERATE ALCOHOL-CONSUMPTION; B-CONTAINING LIPOPROTEINS; CORONARY HEART-DISEASE; APOLIPOPROTEIN-B; HEPG2 CELLS; SECRETION; ABETALIPOPROTEINEMIA; EXPRESSION; RISK; MEN	Microsomal triglyceride transfer protein (MTP) plays a central role in the assembly and secretion of apoB-containing lipoproteins. In this study, we investigated the effect of ethanol on the expression of the large subunit of MTP in a human liver hepatoma cell line, the HepG2 cells, Exposure of HepG2 cells to low concentrations of ethanol reduced MTP mRNA levels in a concentration-and time-dependent manner, The level of MTP mRNA decreased significantly (P < 0.05, -26% relative to pretreatment control) when the concentration of ethanol in the culture medium was 50 ppm (0.005%, v/v), Maximal suppression (-50%) was observed at 100 ppm ethanol; the MTP mRNA levels remained at 50% of control when the ethanol concentration was raised to 10,000 ppm, Furthermore, a 10-day ethanol treatment caused a significant 50% decrease in the MTP activity and apoB secretion rate in HepG2 cells. To investigate the molecular mechanisms underlying this phenomenon, we examined the effect of ethanol on the promoter activity of the MTP gene. Transient transfection analysis of human MTP promoter-driven luciferase gene expression showed that ethanol down-regulates MTP promoter activity in a manner parallel to that observed for mRNA levels, Deletion analysis suggested that the MTP promoter sequence contains a negative ethanol response element -612 to -142 bp upstream of the transcription start site, To evaluate the in vivo relevance of the effect of ethanol on MTP mRNA levels, rats were given a single oral dose of ethanol, with hepatic and intestinal MTP mRNA measured 3 h after dosing, Rats receiving 1 or 3 g/kg of ethanol exhibited substantially lower hepatic and intestinal MTP mRNA levels, Taken together, these results strongly suggest that ethanol can modulate the secretion of apoB-containing lipoproteins by down-regulating the expression of MTP large subunit, primarily through inhibiting the transcription of the MTP gene.	NCI,FREDERICK CANC RES & DEV CTR,LAB BIOCHEM PHYSIOL,NIH,FREDERICK,MD 21702; RUTGERS STATE UNIV,DEPT PHARMACOL & TOXICOL,PISCATAWAY,NJ 08855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Rutgers State University New Brunswick	Lin, MCM (corresponding author), UNIV MED & DENT NEW JERSEY,SCH OSTEOPATH MED,DEPT CELL BIOL,STRATFORD,NJ 08084, USA.			Li, Jian Jian/0000-0003-3694-9675				BARAONA E, 1979, J LIPID RES, V20, P289; Bartek W, 1996, FASEB J, V10, P4617; BENNETT AJ, 1995, BIOCHEM BIOPH RES CO, V212, P473, DOI 10.1006/bbrc.1995.1994; BRETT DJ, 1995, BIOCHEM J, V310, P11, DOI 10.1042/bj3100011; CASTELLI WP, 1977, LANCET, V2, P153; CONTALDO F, 1989, METABOLISM, V38, P166, DOI 10.1016/0026-0495(89)90257-6; CRIQUI MH, 1987, EUR HEART J, V8, P19, DOI 10.1093/eurheartj/8.suppl_B.19; Dashti N, 1996, J LIPID RES, V37, P810; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HOJNACKI JL, 1994, NUTR RES, V14, P1241, DOI 10.1016/S0271-5317(05)80250-7; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kuske T, 1996, FASEB J, V10, P4615; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIEBER CS, 1984, ALCOHOL CLIN EXP RES, V8, P409, DOI 10.1111/j.1530-0277.1984.tb05689.x; Liesen T, 1996, MOL MICROBIOL, V21, P621, DOI 10.1111/j.1365-2958.1996.tb02570.x; LIN MCM, 1994, J BIOL CHEM, V269, P29138; LIN MCM, 1995, J LIPID RES, V36, P1073; NEUMAN MG, 1993, BIOCHEM BIOPH RES CO, V197, P932, DOI 10.1006/bbrc.1993.2569; PATEL SB, 1994, CIRCULATION, V90, P1186; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; VALIMAKI M, 1988, EUR J CLIN INVEST, V18, P472, DOI 10.1111/j.1365-2362.1988.tb01042.x; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3	35	32	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1145	1152		10.1096/fasebj.11.13.9367349	http://dx.doi.org/10.1096/fasebj.11.13.9367349			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367349				2022-12-25	WOS:A1997YE98300012
J	Masui, R; Mikawa, T; Kuramitsu, S				Masui, R; Mikawa, T; Kuramitsu, S			Local folding of the N-terminal domain of Escherichia coli RecA controls protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; AMINO-ACID-RESIDUES; BINDING; COMPLEXES; RECOMBINATION; ASSOCIATION; GENE; L2	To obtain structural information about the self-association of the protein RecA, we studied urea denaturation of RecA by circular dichroism spectroscopy and gelfiltration. Gel filtration analysis showed that urea at low concentrations, 1.0-1.2 M, dissociated the RecA oligomer to almost a monomeric state prior to the unfolding of each molecule, Upon treatment with 1.0 M urea, the circular dichroism spectrum showed a decrease in the a-helical content of RecA, A similar decrease was observed in the absence of urea for RecA at an extremely low protein concentration; the RecA oligomer dissociated to an almost completely monomeric state, The properties of RecA at low urea concentrations were similar to those of a truncated RecA lacking the first 33 N-terminal residues (Delta 33RecA). Addition of a synthetic peptide corresponding to the 33 N-terminal residues to Delta 33RecA increased the alpha-helical content, These results suggest that local folding of the N-terminal domain is coupled to protein-protein interactions of monomeric RecA, which are involved in the regulation of filament formation, The dissociation constant for interaction between RecA monomers was determined from the ellipticity data to be 0.1 mu M.	OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Osaka University			Mikawa, Tsutomu/E-6510-2013	Mikawa, Tsutomu/0000-0003-2325-5084				BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; KURAMITSU S, 1984, BIOCHEMISTRY-US, V23, P2363, DOI 10.1021/bi00306a006; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; Maraboeuf F, 1995, J BIOL CHEM, V270, P30927, DOI 10.1074/jbc.270.52.30927; MIKAWA T, 1995, J MOL BIOL, V250, P471, DOI 10.1006/jmbi.1995.0391; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SANCAR A, 1980, P NATL ACAD SCI-BIOL, V77, P2611, DOI 10.1073/pnas.77.5.2611; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WATANABE R, 1994, J BIOCHEM-TOKYO, V116, P960, DOI 10.1093/oxfordjournals.jbchem.a124653; WILLIAMS RC, 1986, J MOL BIOL, V187, P109, DOI 10.1016/0022-2836(86)90410-9; Yu X, 1995, BIOPHYS J, V69, P2728, DOI 10.1016/S0006-3495(95)80144-X; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101; ZLOTNICK A, 1988, J MOL BIOL, V209, P447	23	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27707	27715		10.1074/jbc.272.44.27707	http://dx.doi.org/10.1074/jbc.272.44.27707			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346912	hybrid			2022-12-25	WOS:A1997YD47300038
J	Welch, H; Maridonneau-Parini I				Welch, H; Maridonneau-Parini I			Lyn and Fgr are activated in distinct membrane fractions of human granulocytic cells	ONCOGENE			English	Article						Fgr; Lyn; Src; Hck; neutrophil; NB4 cells	PROTEIN-TYROSINE KINASE; ADHERENT HUMAN NEUTROPHILS; FC-GAMMA-RII; FUNCTIONAL ASSOCIATION; PLASMA-MEMBRANE; SRC; FAMILY; P58(C-FGR); RECEPTOR; HCK	We have previously shown that the src-family protein-tyrosine kinase Hck is localized on the azurophil granules of human granulocytes, translocates towards the phagosomes during phagocytosis of opsonized zymosan and is activated during this process. Hck is also activated upon cell stimulation with the calcium ionophore A23187, but not with PMA or the chemotactic peptide fMLP. Here, we investigated whether the src-family kinases Lyn and Fgr are activated under the same conditions. Upon stimulation of human neutrophils or retinoic acid-differentiated NB4 cells with fMLP, only Lyn is activated. Cell stimulation with opsonized zymosan or A23187 leads to simultaneous activation of Lyn and Fgr. In cell fractionation experiments with differentiated NB4 cells, kinases show a similar the subcellular localization: Both co-fractionate quantitatively with plasma-membrane marker in two fractions that sediment at 11000g and 200000g. Lyn is selectively activated in the 200 000 g fraction, whereas Fgr is activated in the 11 000 g fraction and distinct sets of tyrosine phosphorylated proteins are found in these fractions. The results suggest that these kinases exert their functional roles in distinct cellular compartments in human granulocytic cells.	CNRS, INST PHARMACOL & BIOL STRUCT,UPR 9062, F-31077 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011	Welch, Heidi/0000-0001-7865-7000; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; Hardie G, 1995, PROTEIN KINASE FACTS, V2; Katagiri K, 1996, J BIOL CHEM, V271, P11557, DOI 10.1074/jbc.271.19.11557; KHANNAGUPTA A, 1994, BLOOD, V84, P294; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KRYPTA RM, 1988, EMBO J, V7, P3837; LANOTTE M, 1991, BLOOD, V77, P1080; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOHN H, 1995, BIOCHEM J, V309, P657; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TESTA U, 1994, CANCER RES, V54, P4508; VARMUS HE, 1994, BLOOD, V83, P5; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch H, 1997, J BIOL CHEM, V272, P102; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1995, J INFLAMM, V45, P297; Yan SR, 1996, J BIOL CHEM, V271, P23464, DOI 10.1074/jbc.271.38.23464; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	33	26	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2021	2029		10.1038/sj.onc.1201356	http://dx.doi.org/10.1038/sj.onc.1201356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366519				2022-12-25	WOS:A1997YC28400003
J	Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB				Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB			cAMP-induced NF-kappa B (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation	ONCOGENE			English	Article						c-myb; NF-kappa B; cAMP; erythroid differentiation; murine erythroleukemia cells	DEPENDENT PROTEIN-KINASE; INDUCED ERYTHROID-DIFFERENTIATION; JUN FAMILY MEMBERS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION FACTORS; MESSENGER-RNA; B/REL FAMILY; ACTIVATION; LINE	During hexamethylene bisactamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells erythroid genes are transcriptionally activated while c-myb and several other nuclear proto-oncogenes are down-regulated. Differentiation is inhibited by cAMP analogues and the adenyl cyclase-stimulating agent forskolin. We found that these drugs prevented the late down-regulation of c-myb which is known to be critical for MEL cell differentiation. Since the increase in c-myb mRNA levels was due to increased mRNA transcription, we examined the transcription factors NF-kappa B and AP-1 which have been implicated in the regulation of c-myb expression. Binding of MEL cell nuclear proteins to a NF-kappa B recognition sequence in c-myb intron 1 was strongly induced by 8-Br-cAMP or forskolin; induction was delayed and correlated with the up-regulation of c-myb. The cAMP-induced NF-kappa B complex contained p50 and RelB; in co-transfection assays, p50 and RelB transactivated a reporter construct containing the c-myb intronic NF-kappa B site upstream of a minimal promoter. 8-Br-cAMP and forskolin also increased the DNA binding activity of AP-1 complexes containing JunB, JunD and c-Fos in MEL cells Which could cooperate with NF-kappa B. We conclude that inhibition of MEL cell differentiation by pharmacological doses of cAMP can be explained by the up-regulation of c-myb which is mediated, at least in part, by NF-kappa B p50/RelB heterodimers.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92093; TEMPLE UNIV,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Hazen, Stanley L/ABD-5845-2021; Reddy, E. Premkumar/F-6233-2011					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEEBE SJ, 1986, ENZYMES, V17, P43; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELDRIDGE MG, 1992, BIOTECHNIQUES, V12, P848; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHERSA P, 1994, GENE, V151, P331, DOI 10.1016/0378-1119(94)90681-5; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; Gudi T, 1996, J BIOL CHEM, V271, P4597; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MELLONI E, 1989, J BIOL CHEM, V264, P18414; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUDRY R, 1990, EXP CELL RES, V191, P278, DOI 10.1016/0014-4827(90)90015-3; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; PILZ RB, 1993, J BIOL CHEM, V268, P20252; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSSON D, 1995, MOL CELL BIOL, V15, P772; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; SHERMAN ML, 1988, J CELL PHYSIOL, V134, P429, DOI 10.1002/jcp.1041340314; SHERMAN ML, 1986, BIOCHEM BIOPH RES CO, V134, P845, DOI 10.1016/S0006-291X(86)80497-1; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; ZONG H, 1997, CELL, V89, P413	67	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1859	1870		10.1038/sj.onc.1201530	http://dx.doi.org/10.1038/sj.onc.1201530			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362453				2022-12-25	WOS:A1997XZ72500013
J	Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R				Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R			Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors	ONCOGENE			English	Article						colon cancer; replication error; microsatellites; mononucleotide repeats	II RECEPTOR GENE; INSTABILITY; CANCER; MUTATIONS; SEQUENCES; COLON; CELLS	We have recently shown that analysis of BAT-26, was sufficient to establish the Replication Error status of colorectal tumors and cell lines without the need for matching normal DNA, BAT-26, a poly(A) tract in the 5th intron of the hMSH2 gene, does not present significant size variation either between the allleles of one individual or between alleles of different individuals, In colorectal tumors without defects in the replication error system (RER- phenotype), BAT-26 is also quasi-monomorphic, On the contrary, in RER+ colorectal tumors, BAT-26 shows unstable shortened alleles, In order to see whether this behaviour was specific for BAT-26, or was a more general phenomenon for mononucleotide repeat microsatellites, we analysed eight other mononucleotide repeats, In control individuals (72 samples) and in RER- colorectal tumors and cell lines (55 samples), these microsatellites were polymorphic, dimorphic, quasi-monomorphic or monomorphic, indicating that the quasi-monomorphic nature of BAT-26 was not a general rule, All of them showed a tendency to be shorter in RER+ colorectal tumors and cell lines (19 samples), but only quasi-monomorphic and monomorphic mononucleotide repeats could be used to determine the RER status of tumors without matching normal DNA, although with a lower efficiency than BAT-26 due to either a smaller range of shortening in RER+ tumors or to a larger number of false negative cases.	INST CURIE,INSERM,U434,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; CHEN JS, 1995, CANCER RES, V55, P174; Cottu PH, 1996, ONCOGENE, V13, P2727; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOLODNER RD, 1995, CANCER RES, V55, P242; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MALHOSYAN S, 1996, NATURE, V382, P499; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	20	116	130	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1713	1718		10.1038/sj.onc.1201337	http://dx.doi.org/10.1038/sj.onc.1201337			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349505				2022-12-25	WOS:A1997XY63100011
J	Fichard, A; Tillet, E; Delacoux, F; Ruggiero, F				Fichard, A; Tillet, E; Delacoux, F; Ruggiero, F			Human recombinant alpha 1(V) collagen chain - Homotrimeric assembly and subsequent processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS SYNDROME; V COLLAGEN; CORNEAL FIBRILLOGENESIS; STRUCTURAL-ANALYSIS; TRIPLE-HELIX; B-CHAINS; EXPRESSION; CELLS; MUTATION; INVITRO	Human embryonic kidney cells (293-EBNA) have been transfected with the full length human alpha 1 chain of collagen V using an episomal vector, High yields (15 mu g/ml) of recombinant collagen were secreted in the culture medium, In presence of ascorbate, the alpha 1(V) collagen is correctly folded into a stable triple helix as shown by electron microscopy and pepsin resistance, Circular dichroism data confirm the triple helix conformation and indicate a melting temperature of 37.5 degrees C for the recombinant homotrimer, The major secreted form is a 250-kDa polypeptide (alpha 1FL), N-terminal sequencing and collagenase digestion indicate that alpha 1FL retains the complete N-propeptide but lacks the C-propeptide. However, alpha 1FL might undergo a further N-terminal trimming into a form (alpha 1TH) corresponding to the main triple-helix domain plus the major part of the NC2 domain, This processing is different from the one of the heterotrimeric (alpha 1(V))(2) alpha 2(V) and could have some physiological relevance, Analysis of cell homogenates indicates the presence of a 280-kDa polypeptide that is disulfide-linked through its C-terminal globular domain, This C-propeptide is rapidly cleaved after secretion in the medium, giving the first evidence of a C-terminal processing of recombinant fibrillar collagens, Rotary shadowing observations not only confirm the presence of a globular domain at the N-terminal end of the molecule but reveal the presence of a kink within the triple helix in a region poor in iminoacids. This region could represent a target for proteases, Together with the thermal stability data, these results might explain the low amount of (alpha 1(V))(3) recovered from tissues.	UNIV LYON 1,INST BIOL & CHIM PROT,CNRS,UPR 412,F-69367 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1				Tillet, Emmanuelle/0000-0002-0076-8007; RUGGIERO, Florence/0000-0003-2915-5359				ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BENTZ H, 1978, EUR J BIOCHEM, V92, P563, DOI 10.1111/j.1432-1033.1978.tb12778.x; BIRK DE, 1990, J CELL SCI, V95, P649; BROEK DL, 1985, J BIOL CHEM, V260, P555; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FICHARD A, 1994, MATRIX BIOL, V14, P515; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GEDDIS AE, 1993, MATRIX, V13, P339; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HARALSON MA, 1984, ARCH BIOCHEM BIOPHYS, V229, P509, DOI 10.1016/0003-9861(84)90182-6; Kielty Cay M., 1993, P103; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUMAMOTO CA, 1981, J BIOL CHEM, V256, P7053; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LI Y, 1995, CELL, V80, P1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORIKAWA T, 1980, BIOCHEMISTRY-US, V19, P2646, DOI 10.1021/bi00553a017; Nicholls AC, 1996, J MED GENET, V33, P940, DOI 10.1136/jmg.33.11.940; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; PIEZ KA, 1970, BIOCHEMISTRY-US, V9, P4129, DOI 10.1021/bi00823a015; Ruggiero F, 1996, INVEST OPHTH VIS SCI, V37, P1749; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Tomita M, 1995, BIOCHEM J, V312, P847, DOI 10.1042/bj3120847; Toriello HV, 1996, NAT GENET, V13, P361, DOI 10.1038/ng0796-361; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Wenstrup RJ, 1996, HUM MOL GENET, V5, P1733, DOI 10.1093/hmg/5.11.1733	40	67	70	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30083	30087		10.1074/jbc.272.48.30083	http://dx.doi.org/10.1074/jbc.272.48.30083			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374485	hybrid			2022-12-25	WOS:A1997YH61300017
J	vandenWijngaard, PWJ; Vredenberg, WJ				vandenWijngaard, PWJ; Vredenberg, WJ			A 50-picosiemens anion channel of the chloroplast envelope is involved in chloroplast protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; ION CHANNELS; MEMBRANE; TRANSLOCATION	Single channel recordings were used to investigate the changes on the pea chloroplast envelope during protein import, In the inside-out patch configuration a 50-picosiemens (pS) anion channel of the chloroplast envelope membrane was identified, The open time probability of the channel was decreased by the addition of the wild type precursor protein of ferredoxin (wt-prefd) to the pipette-filling solution in the presence of 0.5 mM ATP. In the absence of ATP or in the presence of 50 mu M ATP, wt-prefd did not affect the open time probability of the channel, A deletion mutant of prefd, Delta 6-14-prefd, which is inactive in in vitro import, was also unable to affect the open time probability of the 50-pS anion channel, In the presence of 100 mu M ATP, wt-prefd decreased the open time probability of the channel to a lesser extent, as did the transit peptide alone, It is concluded that the 50 pS anion channel could be part of the protein import machinery of the inner membrane. In addition the precursor protein under im port conditions induced burst-like increases of the envelope conductivity. The implication of both responses for the chloroplast protein import process are discussed.			vandenWijngaard, PWJ (corresponding author), AGR UNIV WAGENINGEN,DEPT PLANT PHYSIOL,ARBORETUMLAAN 4,NL-6703 BD WAGENINGEN,NETHERLANDS.							BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FLUGGE UI, 1984, FEBS LETT, V169, P85, DOI 10.1016/0014-5793(84)80294-X; FUKS B, 1995, J BIOL CHEM, V270, P9947, DOI 10.1074/jbc.270.17.9947; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heiber T, 1995, BIOCHEMISTRY-US, V34, P15906, DOI 10.1021/bi00049a005; Heinemann Stefan H., 1995, P53; KESSLER F, 1994, SCIENCE, V266, P1033; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; Lu Y, 1997, J BIOL CHEM, V272, P13555, DOI 10.1074/jbc.272.21.13555; MI F, 1994, PLANT PHYSIOL, V105, P955, DOI 10.1104/pp.105.3.955; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; POTTOSIN II, 1992, FEBS LETT, V308, P87, DOI 10.1016/0014-5793(92)81057-S; POTTOSIN II, 1993, FEBS LETT, V330, P211, DOI 10.1016/0014-5793(93)80275-Y; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; THEG SM, 1989, J BIOL CHEM, V264, P6730; VREDENBERG W, 1995, BBA-BIOENERGETICS, V1230, P77, DOI 10.1016/0005-2728(95)00036-I	21	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29430	29433		10.1074/jbc.272.47.29430	http://dx.doi.org/10.1074/jbc.272.47.29430			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367999	hybrid			2022-12-25	WOS:A1997YG64700009
J	Furie, BC; Ratcliffe, JV; Tward, J; Jorgensen, MJ; Blaszkowsky, LS; DiMichele, D; Furie, B				Furie, BC; Ratcliffe, JV; Tward, J; Jorgensen, MJ; Blaszkowsky, LS; DiMichele, D; Furie, B			The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on all adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROTEIN-C; INVITRO ANTICOAGULANT ACTIVITY; CARBOXYGLUTAMIC ACID RESIDUES; PHOSPHOLIPID-BINDING SITE; HAMSTER OVARY CELLS; MATRIX GLA PROTEIN; HUMAN FACTOR-IX; BLOOD-COAGULATION; NUCLEOTIDE-SEQUENCE; HUMAN-PROTHROMBIN	The propeptides of the vitamin K-dependent proteins contain gamma-carboxylation recognition site that is required for gamma-glutamyl carboxylation. To determine whether the propeptide is sufficient to direct carboxylation, two mutant prothrombin species were expressed and characterized with regard to posttranslational gamma-carboxylation. A double point mutant, in which serine substituted for cysteines 17 and 22 disrupted a conserved loop formed by a disulfide bond, was fully carboxylated when expressed in Chinese hamster ovary cells. A propeptide/thrombin chimeric protein, constructed by deleting the Cia, aromatic amino acid stack, and kringle domains of prothrombin, has the signal peptide and propeptide juxtaposed to a glutamate-rich COOH-terminal region Of prothrombin, residues 249-530. Of the 8 glutamic acid residues contained within the first 40 residues of the NH2 terminus adjacent to the propeptide, at least seven were fully carboxylated as demonstrated by direct gamma-carboxyglutamic acid analysis of the alkaline hydrolysate and by NH2-terminal sequence analysis. These results indicate that the gamma-carboxylation recognition site within the prothrombin propeptide in a prothrombin propeptide-thrombin chimeric protein is sufficient to direct gamma-carboxylase-catalyzed carboxylation of adjacent glutamic acid residues in a glutamate-rich region of thrombin that is not normally gamma-carboxylated. Furthermore, the disulfide loop in the Gla domain of prothrombin is not required for complete carboxylation.	TUFTS UNIV NEW ENGLAND MED CTR,DIV HEMATOL ONCOL,CTR HEMOSTASIS & THROMBOSIS RES,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts University				Tward, Jonathan/0000-0001-7765-4473	NHLBI NIH HHS [HL42443, HL18834, HL38216] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038216, P01HL042443, R01HL018834, R37HL038216, R37HL018834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLANCHARD RA, 1983, J LAB CLIN MED, V101, P242; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; Bristol JA, 1996, BLOOD, V88, P2585, DOI 10.1182/blood.V88.7.2585.bloodjournal8872585; BROWN MA, 1997, THROMB HAEMOSTASIS S, V78, pA639; CAIRNS JR, 1991, ANAL BIOCHEM, V199, P93, DOI 10.1016/0003-2697(91)90274-W; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; CHASIN LA, 1980, P NATL ACAD SCI USA, V77, P4216; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHOO KH, 1982, NATURE, V299, P178, DOI 10.1038/299178a0; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FRIEZNERDEGEN SJ, 1987, BIOCHEMISTRY-US, V26, P6165; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBBARD BR, 1989, P NATL ACAD SCI USA, V86, P6893, DOI 10.1073/pnas.86.18.6893; HUBER P, 1990, J BIOL CHEM, V265, P12467; IRWIN DM, 1985, BIOCHEMISTRY-US, V24, P6854, DOI 10.1021/bi00345a018; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KAUFMAN RJ, 1986, J BIOL CHEM, V261, P9622; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; KOTKOW KJ, 1993, METHOD ENZYMOL, V222, P435; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; KUWADA M, 1983, ANAL BIOCHEM, V131, P173, DOI 10.1016/0003-2697(83)90150-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Lingenfelter SE, 1996, BIOCHEMISTRY-US, V35, P8234, DOI 10.1021/bi9523318; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; OOSTRA BA, 1983, NATURE, V304, P456, DOI 10.1038/304456a0; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; SANFORD DG, 1991, BIOCHEMISTRY-US, V30, P9835, DOI 10.1021/bi00105a004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; WU SM, 1990, J BIOL CHEM, V265, P13124; Wu SM, 1997, J BIOL CHEM, V272, P11718, DOI 10.1074/jbc.272.18.11718; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHANG L, 1992, BLOOD, V80, P942; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009	62	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28258	28262		10.1074/jbc.272.45.28258	http://dx.doi.org/10.1074/jbc.272.45.28258			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353278	hybrid			2022-12-25	WOS:A1997YF21900018
J	Harris, CM; Massey, V				Harris, CM; Massey, V			The oxidative half-reaction of xanthine dehydrogenase with NAD; Reaction kinetics and steady-state mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-2-DEPENDENT TYPES; RAPID REACTION; OXIDASE; REDOX; PURIFICATION; INACTIVATION; FLAVIN; SITE; FAD	The reaction between reduced xanthine dehydrogenase (XDH) from bovine milk and NAD has been studied in detail. An understanding of this reaction is necessary for a complete description of XDH turnover with its presumed natural electron acceptor and to address the preference of WH for NAD over oxygen as a substrate. The reaction between pre-reduced XDH and NAD was studied by stopped-flow spectrophotometry. The reaction was found to involve two rounds of oxidation with 2 eq of NAD. The first round goes to completion, and the second round reaches a slightly disfavored equilibrium. Rapid binding of NAD with an apparent K-d of 25 +/- 2 mu M is followed by NAD reduction at a rate constant of 130 +/- 13 s(-1). NADH dissociation at a rate constant of 42 +/- 12 s(-1) completes a round of oxidation. These steps have been successfully tested and modeled to repeat themselves in the second round of oxidation. The association rate constant for NAD binding was estimated to be much greater than any rate constant measured in the oxidation by molecular oxygen, thus explaining how NAD competes with oxygen for reducing equivalents. Rate constants for NAD reduction and NADH dissociation are respectively 21- and 7-fold greater than k(cat), indicating that the reductive half-reaction of the enzyme by xanthine is mostly rate-limiting in xanthine/NAD turnover. A steady-state mechanism for XDH is discussed.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIGMS NIH HHS [GM08270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BRAY RC, 1964, J BIOL CHEM, V239, P2667; DARDENNE SC, 1990, BIOCHEMISTRY-US, V29, P9046, DOI 10.1021/bi00490a023; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; Harris CM, 1997, J BIOL CHEM, V272, P22514, DOI 10.1074/jbc.272.36.22514; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HUNT J, 1992, J BIOL CHEM, V267, P21479; HUNT J, 1994, J BIOL CHEM, V269, P18904; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KOMAI H, 1969, J BIOL CHEM, V244, P1692; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1970, J BIOL CHEM, V245, P2837; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; MAYHEW SG, 1969, J BIOL CHEM, V244, P803; NISHINO T, 1989, J BIOL CHEM, V264, P5468; NISHINO T, 1991, ADV EXP MED BIOL, V309, P327; NISHINO T, 1989, J BIOL CHEM, V264, P6075; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; SCHOPFER LM, 1988, J BIOL CHEM, V263, P13528; Segel I. H., 1976, BIOCH CALCULATIONS, P414; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048	29	41	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28335	28341		10.1074/jbc.272.45.28335	http://dx.doi.org/10.1074/jbc.272.45.28335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353290	hybrid			2022-12-25	WOS:A1997YF21900030
J	Paudel, HK				Paudel, HK			Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of tau protein in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; GLUTATHIONE METABOLISM; ANTIPARALLEL DIMERS; SELF-ASSOCIATION; BOVINE BRAIN; ISOFORMS; PURIFICATION	In Alzheimer's disease, the microtubule-associated protein tau forms paired helical filaments (PHFs) that are the major structural component of neurofibrillary tangles. Although tau isolated from PHFs (PHF-tau) is abnormally phosphorylated, the role of this abnormal phosphorylation in PHF assembly is not known. Previously, neuronal cdc2-like protein kinase (NCLK) was shown to phosphorylate tau on sites that are abnormally phosphorylated in PHF-tau (Paudel, H. g., Lew, J., All, Z., and Wang, J. H. (1993) J. Biol. Chem. 268, 23512-23518). In this study, phosphorylation by NCLK was found to promote dimerization of recombinant human tau (R-tau) and brain tau (B-tau) purified from brain extract. Chemical cross-linking by disuccinimidyl suberate (DSS), a homobifunctional chemical cross-linker that specifically cross-linked R-tau dimers, and a Superose 12 gel filtration chromatography revealed that R-tau preparations contain mixtures of monomeric and dimeric R-tau species. When the structure of NCLK-phosphorylated R-tau was studied by a similar approach, DSS preferentially cross-linked the phosphorylated R-tau over the nonphosphorylated R-tau, and the phosphorylated R-tau eluted as a dimeric species from the gel filtration column. Phosphorylated R-tau became resistant to DSS upon dephosphorylation and was recovered as a monomeric species from the gel filtration column. In the presence of a low concentration of dithiothreitol (1.65 mu M), R-tau formed disulfide crosslinked R-tau dimers. When compared, phosphorylated R-tau formed more disulfide cross-linked dimers than the nonphosphorylated R-tau. B-tau also was specifically cross-linked to dimers by DSS. When B-tau and NCLK-phosphorylated B-tau were treated with DSS, phosphorylated B-tau was preferentially cross-linked over nonphosphorylated counterpart. Taken together, these results suggest that phosphorylation by NCLK promotes dimerization and formation of disulfide crosslinked tau dimers, which is suggested to be the key step leading to PHF assembly (Schweers, O., Mandelkow, E.M., Biernat, J., and Mandelkow, E. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 8463-8467).	SIR MORTIMER B DAVIS JEWISH HOSP, LADY DAVIS INST MED RES, BLOOMFIELD CTR RES AGING, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL, PQ H3T 1E2, CANADA	Lady Davis Institute; McGill University; McGill University								ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; DEANCOS JG, 1993, J BIOL CHEM, V268, P7976; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GUTTMANN RP, 1995, J NEUROCHEM, V64, P1209; HOSOI T, 1995, J BIOCHEM-TOKYO, V117, P711; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P6207; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WILLE H, 1992, J BIOL CHEM, V267, P10737	34	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28328	28334		10.1074/jbc.272.45.28328	http://dx.doi.org/10.1074/jbc.272.45.28328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353289	hybrid			2022-12-25	WOS:A1997YF21900029
J	Tang, SQ; Morgan, KG; Parker, C; Ware, JA				Tang, SQ; Morgan, KG; Parker, C; Ware, JA			Requirement for protein kinase C theta for cell cycle progression and formation of actin stress fibers and filopodia in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; CDC42 GTPASES; ANGIOGENESIS; GROWTH; RHO; EXPRESSION; BINDING; FAMILY; ACTIVATION	Activation of the protein kinase C (PKC) family with phorbol esters induces endothelial proliferation and angiogenesis, but which of the events that constitute angiogenesis are affected by individual members of the PMC family is unknown. In rat capillary endothelial (BCE) cells, serum stimulation increased expression of a single PKC isoenzyme, PKC theta, and its translocation to the periphery. Conditional overexpression of a dominant-negative mutant of PKC theta markedly inhibited RCE proliferation, as well as closure of a ''wound'' by RCE migration and formation of capillary rings and tubules in vitro. PKC theta inhibition delayed the endothelial cell cycle at the G(2)/M phase and prevented formation of actin stress fibers and filopodia but not lamellipodia. The defect in cell morphology and wound closure in PKC theta-kn cells was reversed by overexpressing kinase-active PKC theta, indicating that these RCE functions depend upon PKC theta substrates. Thus, PKC theta is required for multiple processes essential for angiogenesis and wound repair, including endothelial mitosis, maintenance of a normal actin cytoskeleton, and formation of an enclosed tube.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV CARDIOL,DEPT MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,VASC BIOL UNIT,BRONX,NY 10461; HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115; BOSTON BIOMED RES INST,BOSTON,MA 02114	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Harvard Medical School; Boston Biomedical Research Institute				Morgan, Kathleen/0000-0003-3300-3630	NHLBI NIH HHS [HL51043, HL47032] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051043, R01HL047032] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAIER G, 1993, J BIOL CHEM, V268, P4997; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; CHANG JD, 1993, J BIOL CHEM, V268, P14208; COOMBER BL, 1991, EXP CELL RES, V194, P42, DOI 10.1016/0014-4827(91)90127-G; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; DAVIET I, 1989, BIOCHEM BIOPH RES CO, V158, P584, DOI 10.1016/S0006-291X(89)80089-0; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FUJISE A, 1994, J BIOL CHEM, V269, P31642; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOOCK TC, 1991, J CELL BIOL, V112, P654; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Kosaka C, 1996, AM J PHYSIOL-CELL PH, V270, pC170, DOI 10.1152/ajpcell.1996.270.1.C170; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHNO S, 1990, J BIOL CHEM, V265, P6296; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PRESTA M, 1991, CELL REGUL, V199, P719; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; TANG DG, 1993, PROSTAG OTH LIPID M, V45, P249, DOI 10.1016/0090-6980(93)90051-8; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9158; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE GE, 1983, J CELL BIOL, V97, P416, DOI 10.1083/jcb.97.2.416; WONG AJ, 1983, SCIENCE, V219, P867, DOI 10.1126/science.6681677; WONG MKK, 1990, ARTERIOSCLEROSIS, V10, P76, DOI 10.1161/01.ATV.10.1.76; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHOU W, 1993, J BIOL CHEM, V268, P23041; ZIGIMOND SH, 1996, CURR OPIN CELL BIOL, V8, P66	47	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28704	28711		10.1074/jbc.272.45.28704	http://dx.doi.org/10.1074/jbc.272.45.28704			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353339	hybrid			2022-12-25	WOS:A1997YF21900079
J	Burks, DJ; Pons, S; Towery, H; SmithHall, J; Myers, MG; Yenush, L; White, MF				Burks, DJ; Pons, S; Towery, H; SmithHall, J; Myers, MG; Yenush, L; White, MF			Heterologous pleckstrin homology domains do not couple IRS-1 to the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; PH DOMAINS; SUBSTRATE-1; DYNAMIN; BINDING; PROTEIN; ACTIVATION; SUBUNITS; REGION	Pleckstrin homology (PH) domains occur in many signaling proteins, including substrates for the insulin receptor tyrosine kinase (IRS proteins). Based on the hypothesis that PH domains may have a common function such as membrane targeting we tested the ability of PH domains from other signaling molecules to link IRS-1 to the insulin receptor. Chimeric IRS-1 proteins containing a homologous PH domain derived from other HRS proteins (IRS-2 or Gab-1) were tyrosine phosphorylated normally in response to insulin. In contrast, heterologous PH domains from the beta-adrenergic receptor kinase, phospholipase C gamma, or spectrin failed to mediate tyrosine phosphorylation of chimeric IRS-1 proteins, even in cells expressing high levels of insulin receptor. Moreover, IRS-1 proteins containing heterologous PH domains did not bind phosphorylated NPEY motifs derived from the insulin receptor, suggesting that the presence of these structures interfered with the function of the adjacent PTB binding domain. Thus, tyrosine phosphorylation of IRS-1 by the insulin receptor specifically requires a PH domain derived from IRS proteins.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Yenush, Lynne/J-8815-2014; Pons, Sebastian/K-7794-2014	Yenush, Lynne/0000-0001-8589-7002; Pons, Sebastian/0000-0003-1027-0621	NIDDK NIH HHS [T32 DK 07260, DK43808, P30 DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808, T32DK007260, P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HEIDENREICH KA, 1985, J NEUROCHEM, V45, P1642, DOI 10.1111/j.1471-4159.1985.tb07237.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JENNY TF, 1994, PROTEINS, V20, P1, DOI 10.1002/prot.340200102; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OWERBACH D, 1982, DIABETES, V31, P275, DOI 10.2337/diabetes.31.3.275; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PONS S, 1995, MOL CELL BIOL, V15, P4453; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	34	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27716	27721		10.1074/jbc.272.44.27716	http://dx.doi.org/10.1074/jbc.272.44.27716			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346913	hybrid			2022-12-25	WOS:A1997YD47300039
J	Ding, YM; Davisson, RL; Hardy, DO; Zhu, LJ; Merrill, DC; Catterall, JF; Sigmund, CD				Ding, YM; Davisson, RL; Hardy, DO; Zhu, LJ; Merrill, DC; Catterall, JF; Sigmund, CD			The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BLOOD-PRESSURE; MOUSE KIDNEY; HUMAN RENIN; CONVERTING ENZYME; KAP GENE; RAT; SYSTEM; HYPERTENSION; LOCALIZATION	Transgenic mice were generated containing a 1542-base pair fragment of the kidney androgen-regulated protein (KBP) promoter fused to the human angiotensinogen (HAGT) gene with the goal of specifically targeting inducible expression of renin-angiotensin system components to the kidney. High level expression of both KAP-HAGT and endogenous KAP mRNA was evident in the kidney of male mice from two independent transgenic lines. Renal expression of the transgene in female mice was undetectable under basal conditions but could be strongly induced by administration of testosterone. Testosterone treatment did not cause a transcriptional induction id any ether tissues examined. However, an analysis of Six androgen target tissues in males revealed that the transgene was expressed in epididymis. No other extra-renal expression of the transgene was detected. In situ hybridization demonstrated that expression of HAGT (and KAP) mRNA in males and testosterone-treated females was restricted to proximal tubule epithelial cells in the renal cortex. Although there was no detectable human angiotensinogen protein in plasma, it was evident in the urine, consistent with a pathway of synthesis in proximal tubule cells and release into the tubular lumen. These results demonstrate that 1542 base pairs of the KAP promoter is sufficient to drive expression of a heterologous reporter gene in a tissue-specific, cell-specific, and androgen-regulated fashion in transgenic mice.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, TRANSGEN ANIM FACIL, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, GENET PROGRAM, IOWA CITY, IA 52242 USA; ROCKEFELLER UNIV, POPULAT COUNCIL, NEW YORK, NY 10021 USA	University of Iowa; University of Iowa; University of Iowa; Population Council; Rockefeller University			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL55006, HL48058] Funding Source: Medline; NICHD NIH HHS [HD13541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055006, R01HL048058, R37HL048058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BUNNEMANN B, 1992, J CARDIOVASC PHARM, V19, pS51, DOI 10.1097/00005344-199219006-00010; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; CATTERALL JF, 1986, RECENT PROG HORM RES, V42, P71; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DZAU VJ, 1986, HYPERTENSION, V8, P553, DOI 10.1161/01.HYP.8.7.553; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF582, DOI 10.1152/ajprenal.1988.254.4.F582; HALL J E, 1991, Comprehensive Therapy, V17, P8; HALL JE, 1977, AM J PHYSIOL, V232, pF538, DOI 10.1152/ajprenal.1977.232.6.F538; HALL JE, 1990, ACTA PHYSIOL SCAND, V139, P48; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; HOGAN E, 1986, MANIPULATING MOUSE E; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JOHNSTON CI, 1993, KIDNEY INT, V44, pS59; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KAKINUMA Y, 1993, KIDNEY INT, V43, P1229, DOI 10.1038/ki.1993.174; KASIK JW, 1993, MOL CELL ENDOCRINOL, V90, P239, DOI 10.1016/0303-7207(93)90157-F; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LEVENS NR, 1981, CIRC RES, V48, P157, DOI 10.1161/01.RES.48.2.157; LINDPAINTNER K, 1991, CARDIOLOGY, V79, P32, DOI 10.1159/000174905; LINDPAINTNER K, 1991, ACTA CARDIOL, V46, P385; LINDZEY J, 1994, VITAM HORM, V49, P383; MATTSON DL, 1991, AM J PHYSIOL, V260, pR1200, DOI 10.1152/ajpregu.1991.260.6.R1200; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; MESEGUER A, 1987, MOL ENDOCRINOL, V1, P535, DOI 10.1210/mend-1-8-535; MESEGUER A, 1990, MOL ENDOCRINOL, V4, P1240, DOI 10.1210/mend-4-8-1240; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; NIU EM, 1991, DNA CELL BIOL, V10, P41, DOI 10.1089/dna.1991.10.41; PAGE MJ, 1982, MOL CELL ENDOCRINOL, V27, P343, DOI 10.1016/0303-7207(82)90099-5; PENG Y, 1995, AM J PHYSIOL-RENAL, V269, pF40, DOI 10.1152/ajprenal.1995.269.1.F40; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; SIGMUND CD, 1993, HYPERTENSION, V22, P599, DOI 10.1161/01.HYP.22.4.599; TAN JA, 1992, J BIOL CHEM, V267, P4456; TAUGNER R, 1982, KLIN WOCHENSCHR, V60, P1218, DOI 10.1007/BF01716726; TOOLE JJ, 1979, CELL, V17, P441, DOI 10.1016/0092-8674(79)90170-3; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; YANG GY, 1994, J BIOL CHEM, V269, P32497	42	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28142	28148		10.1074/jbc.272.44.28142	http://dx.doi.org/10.1074/jbc.272.44.28142			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346970	hybrid			2022-12-25	WOS:A1997YD47300096
J	Okada, S; Kao, AW; Ceresa, BP; Blaikie, P; Margolis, B; Pessin, JE				Okada, S; Kao, AW; Ceresa, BP; Blaikie, P; Margolis, B; Pessin, JE			The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; PHOSPHOTYROSINE INTERACTION DOMAIN; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; PHOSPHORYLATED PROTEINS; SH2-CONTAINING PROTEINS; INSULIN-RECEPTOR; SEVENLESS GENE; PTB DOMAIN	In addition to tyrosine phosphorylation of the 66-, 52-, and 46-kDa Shc isoforms, epidermal growth factor (EGF) treatment of Chinese hamster ovary cells expressing the human EGF receptor also resulted in the serine/ threonine phosphorylation of approximately 50% of the 66-kDa Shc proteins. The serine/threonine phosphorylation occurred subsequent to tyrosine phosphorylation and was prevented by pretreatment of the cells with the MEK-specific inhibitor PD98059. Surprisingly, only the gel-shifted 66-kDa Shc isoform (serine/threonine phosphorylated) was tyrosine phosphorylated and associated with Grb2. In contrast, only the non-serine/threonine-phosphorylated fraction of 66-kDa Shc was associated with the EGF receptor. To assess the relationship between the three Shc isoforms in EGF-stimulated signaling, the cDNA encoding the 66-kDa Shc species was cloned from a 16-day-old mouse embryo library. Sequence alignment confirmed that the 66-kDa Shc cDNA resulted from alternative splicing of the primary Shc transcript generating a 110-amino acid extension at the amino terminus. Co-immunoprecipitation of Shc and Grb2 from cells overexpressing the 52/46-kDa Shc isoforms versus the 66-kDa Shc species directly demonstrated a competition of binding for a limited pool of Grb2 proteins. Furthermore, expression of the 66-kDa Shc isoform markedly accelerated the inactivation of ERK following EGF stimulation. Together, these data indicate that the serine/threonine phosphorylation of 66-kDa Shc impairs its ability to associate with the tyrosine-phosphorylated EGF receptor and can function in a dominant-interfering manner by inhibiting EGF receptor downstream signaling pathways.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV MICHIGAN,HOWARD HUGHES MED INST,DEPT INTERNAL MED & BIOL CHEM,ANN ARBOR,MI 48109	University of Iowa; Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NIDDK NIH HHS [DK33823, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER LN, 1993, NATURE, V363, P85; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GiorgettiPeraldi S, 1997, MOL CELL BIOL, V17, P1180, DOI 10.1128/MCB.17.3.1180; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Holt KH, 1996, MOL CELL BIOL, V16, P577; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMIT L, 1994, J BIOL CHEM, V269, P20209; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	50	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28042	28049		10.1074/jbc.272.44.28042	http://dx.doi.org/10.1074/jbc.272.44.28042			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346957	hybrid			2022-12-25	WOS:A1997YD47300083
J	Yan, ZF; Deng, XB; Chen, MX; Xu, Y; Ahram, M; Sloane, BF; Friedman, E				Yan, ZF; Deng, XB; Chen, MX; Xu, Y; Ahram, M; Sloane, BF; Friedman, E			Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; INTERCELLULAR-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; ANTISENSE OLIGONUCLEOTIDES; COLORECTAL CARCINOMAS; TUMOR PROGRESSION; CATHEPSIN-B; DIFFERENTIATION; MUTATIONS; ASSOCIATION	Colon carcinomas commonly contain mutations in Ki-ras4B, but very rarely in Ha-ras, suggesting that different Ras isoforms may have distinct functions in colon epithelial cell biology, In an earlier study we had demonstrated that oncogenic Ki-ras4B(Val-12), but not oncogenic Ha-ras(Val-12), blocks the apicobasal polarization of colon epithelial cells by preventing normal glycosylation of the integrin beta 1 chain of the collagen receptor, As a result, only the Ki-ras mutated cells exhibited altered cell to substratum attachment, whereas mutation of either Res isoform activated mitogen-activated protein kinases. We have now asked whether intercellular adhesion proteins implicated in establishing basolateral polarity in colon epithelial cells are modulated by oncogenic Ki-Ras4B(Val-12) proteins but not oncogenic Ha-Ras(Val-12) proteins, The embryonic adhesion protein carcinoembryonic antigen (CEA) was up-regulated on the mRNA and protein levels in each of three stable Ki-ras(Val-12) transfectant lines but in none of three stable Ha-ras(Val-12) transfectant lines. The elevated protein levels of CEA in Ki-ras4B(Val-12) transfectant cells were decreased by blocking expression of Ki-ras4B(Val-12) with antisense oligonucleotides. N-cadherin levels were decreased in only the Ki-ras transfectants, whereas E-cadherin levels were unchanged. Immunohistochemical analysis demonstrated that Ki-ras4B(Val-12) transfectant cells did not polarize into cells with discrete apical and basal regions and so could not restrict expression of CEA to the apical region, These unpolarized cells displayed elevated levels of CEA all along their surface membrane where CEA mediated random, multilayered associations of tumor cells, This aggregation was both calcium-independent and blocked by Fab' fragments of anti-CEA monoclonal antibody col-1. Trafficking of the lysosomal cysteine protease cathepsin B may also be altered when cell polarity cannot be established. Ki-ras4B(Val-12) transfectant cells expressed 2-fold elevated protein levels of the lysosomal cysteine protease cathepsin B but did not up-regulate cathepsin B mRNA expression. One function of oncogenic c-Ki-Ras proteins in colon cancer progression may be to up-regulate CEA and thus to prevent the lateral adhesion of adjacent colon epithelial cells that normally form a monolayer in vivo.	SUNY HLTH SCI CTR,DEPT PATHOL,SYRACUSE,NY 13210; WAYNE STATE UNIV,DEPT PHARMACOL,DETROIT,MI 48201; WAYNE STATE UNIV,CANC BIOL PROGRAM,DETROIT,MI 48201	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Wayne State University; Wayne State University			Ahram, Mamoun/D-8497-2015; Sloane, Bonnie F/A-1050-2009	Ahram, Mamoun/0000-0003-4457-3604; 	NATIONAL CANCER INSTITUTE [R01CA067405, R01CA045783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA67405, R01 CA45783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPO E, 1994, AM J PATHOL, V145, P301; Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GRIMM T, 1995, CANCER RES, V55, P3254; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; HUANG F, 1994, ONCOGENE, V9, P3701; JESSUP JM, 1993, BRIT J CANCER, V67, P464, DOI 10.1038/bjc.1993.88; KUROKI M, 1989, INT J CANCER, V44, P208, DOI 10.1002/ijc.2910440204; MAHER J, 1995, ONCOGENE, V11, P1639; MONIA BP, 1992, J BIOL CHEM, V267, P19954; OJAKIAN GK, 1994, J CELL SCI, V107, P561; SHIBATA D, 1993, J NATL CANCER I, V85, P1058, DOI 10.1093/jnci/85.13.1058; SLOANE BF, 1994, J CELL SCI, V107, P373; SUCHY B, 1992, INT J CANCER, V52, P30, DOI 10.1002/ijc.2910520107; TIBBETTS LM, 1993, CANCER, V71, P315, DOI 10.1002/1097-0142(19930115)71:2<315::AID-CNCR2820710208>3.0.CO;2-B; WANG AZ, 1990, J CELL SCI, V95, P153; YAN Z, 1993, CELL GROWTH DIFFER, V4, P1; YAN ZF, 1994, J BIOL CHEM, V269, P13231	25	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27902	27907		10.1074/jbc.272.44.27902	http://dx.doi.org/10.1074/jbc.272.44.27902			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346938	hybrid			2022-12-25	WOS:A1997YD47300064
J	Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M				Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M			Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells	ONCOGENE			English	Article						CREB; dominant negative; malignant melanoma; metastasis; collagenase	HUMAN MELANOCYTES; MEDIATED INDUCTION; CYCLIC-AMP; BINDING; GENE; EXPRESSION; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION; TYROSINASE	The ATF/CREB family of eukaryotic transcription factors contain the bZIP structural motif and mediate their transcriptional activities via heterodimerization with ATF and AP-1 family members, Quenching of CREB-associated proteins by a dominant-negative CREB that is mutated within its DNA-binding domain decreases radiation resistance of human melanoma cells, The purpose of this study was to determine the role of CREB in tumor growth and metastasis of human melanoma using KCREB. Highly metastatic MeWo were transfected with the and subsequently analysed for changes in their tumorigenic and metastatic potential, Expression of KCREB in MeWo human cells decreased their tumorigenic and metastatic potential in nude mice compared with parental and control transfected cells, The KCREB-transfected cells displayed downregulation of 72kDa collagenase type IV (MMP-2) mRNA expression and activity and decreased invasiveness through Matrigel-coated filters, Moreover, transcriptional activities mediated by the CAT gene driven by the MMP-2 promoter were decreased by 14-45-fold in KCREB-transfected cells, In addition, the cell-surface adhesion molecule MCAM/MUC18 that is involved in metastasis of human melanoma was downregulated in the KCREB-transfected cells, These data indicate that, through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of the metastatic phenotype of human melanoma cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10029	University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai			Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R21CA064137, R29CA051995, R01CA051995, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 64137, CA 51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIDLER IJ, 1990, CANCER RES, V50, P6130; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang SY, 1996, ONCOGENE, V13, P2339; Huang SY, 1996, CLIN CANCER RES, V2, P1969; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LESTER BR, 1992, CURR OPIN ONCOL, V6, P106; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1995, ONCOGENE, V11, P1399; MOHLER JL, 1991, CANCER RES, V50, P6580; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PATRIN AW, 1991, P NATL ACAD SCI USA, V86, P1254; RADINSKY R, 1994, ONCOGENE, V9, P1977; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SINGH RK, 1995, CANCER RES, V55, P3669; VANLEEUWEN RL, 1994, INT J CANCER, V57, P894, DOI 10.1002/ijc.2910570620; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Xie SH, 1997, CANCER RES, V57, P2295; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang YM, 1996, ONCOGENE, V12, P2223	46	109	113	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2069	2075		10.1038/sj.onc.1201358	http://dx.doi.org/10.1038/sj.onc.1201358			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366524				2022-12-25	WOS:A1997YC28400008
J	Karasaki, H; Obata, M; Ogawa, K; Lee, GH				Karasaki, H; Obata, M; Ogawa, K; Lee, GH			Roles of the Pas1 and Par2 genes in determination of the unique, intermediate susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis: Differential effects on tumor multiplicity, size and Kras2 mutations	ONCOGENE			English	Article						lung tumor; susceptibility gene; interactions; urethane; mouse	HEPATOCARCINOGEN SENSITIVITY LOCI; ADENOMA RESISTANCE LOCUS; HA-RAS GENE; PULMONARY ADENOMA; LIVER-TUMORS; SINGLE-GENE; A/J MICE; MOUSE; ACTIVATION; PROTOONCOGENE	The C3H/HeJ (C3H), A/J and BALB/cByJ (BALB) mouse strains are respectively resistant, sensitive and intermediate regarding the induction of lung tumors by urethane. The phenotypic difference between C3H and A/J is largely determined by the Pas1 (Pulmonary adenoma susceptibility 1) gene an chromosome 6, the A/J allele of which dominantly increases the tumor burden. We recently found Chat BALB mice possess a unique lung tumor resistance gene on chromosome 18, designated Par2 (Pulmonary adenoma resistance 2), which partially, but dominantly suppresses the sensitive phenotype of A/J mice (Oncogene 13: 1599-1604, 1996). It has, however, remained unclear why BALB mice carrying the Par2 gene are significantly more sensitive to urethane-induced lung carcinogenesis than C3H mice that have no dominant lung tumor resistance genes. In the present study, using (C3H x BALB)F-1 x C3H backcross mice treated with urethane, we demonstrated that BALB mice possess the disease allele of the Pas1 gene despite their 15-fold more resistance relative to A/J mice (LOD = 22.6). The BALB Par2 allele only significantly reduced the mean lung tumor multiplicity (LOD=4.4) in the backcross population carrying the BALB allele of Pas1, indicating that the intermediate BALB phenotype may at least in part be the result of interactions between these two dominant genes. While the BALB Pas1 allele increased both the mean multiplicity and size of lung tumors, the BALB Par2 allele affected only the mean tumor multiplicity, implying that they are involved in different stages of multi-step lung carcinogenesis. In addition, we found that 68% of lung tumors from the BALB Pas1-positive backcross mice contained activating point mutations of the KRas2 oncogene, tightly linked to the Pas1 locus, whereas these genetic alterations were absent in tumors from BALB Pas1-negative mice. The Pal2 genotype exhibited no effect on this parameter. Since the activating point mutations mere observed exclusively in the BALB allele as already reported with lung tumors in (C57BL/6J x BALB/cJ)F-1 mice, BALB Pas1 or possibly Kras2 itself may confer selective growth advantage on the affected urethane-initiated lung lesions.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								BELINSKY SA, 1989, CANCER RES, V49, P5305; BITTNER J. J., 1938, Public Health Reports, V53, P2197, DOI 10.2307/4582733; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; CHEN B, 1993, CARCINOGENESIS, V14, P1603, DOI 10.1093/carcin/14.8.1603; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DEVEREUX TR, 1991, CARCINOGENESIS, V12, P299, DOI 10.1093/carcin/12.2.299; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; DRAGANI TA, 1991, CANCER RES, V51, P6299; Dragani TA, 1996, FASEB J, V10, P865, DOI 10.1096/fasebj.10.8.8666163; DRAGANI TA, 1991, ONCOGENE, V6, P333; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, MOL CARCINOGEN, V14, P190, DOI 10.1002/mc.2940140308; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; MALKINSON AM, 1994, MOL CARCINOGEN, V10, P61, DOI 10.1002/mc.2940100202; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; MASSEY TE, 1995, CARCINOGENESIS, V16, P1065, DOI 10.1093/carcin/16.5.1065; MATZINGER SA, 1994, MOL CARCINOGEN, V11, P42, DOI 10.1002/mc.2940110108; Obata M, 1996, ONCOGENE, V13, P1599; OHMORI H, 1992, CARCINOGENESIS, V13, P851, DOI 10.1093/carcin/13.5.851; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; Snedecor G.W., 1989, AMES IOWA STATE U PR; Strong LC, 1936, J HERED, V27, P21, DOI 10.1093/oxfordjournals.jhered.a104133; SUZUKI Y, 1990, ONCOGENE, V5, P1037; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	38	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1833	1840		10.1038/sj.onc.1201357	http://dx.doi.org/10.1038/sj.onc.1201357			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362450				2022-12-25	WOS:A1997XZ72500010
J	Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Krett, N; Halgren, R; Rosen, S; Kufe, D; Kharbanda, S; Anderson, K				Chauhan, D; Pandey, P; Ogata, A; Teoh, G; Krett, N; Halgren, R; Rosen, S; Kufe, D; Kharbanda, S; Anderson, K			Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DEATH; CED-3; ICE; ACTIVATION; INHIBITION; PROTEASES; CLEAVAGE; KINASE; P35	Cytochrome c is a mitochondrial protein that induces apoptosis when accumulated in the cytosol in response to diverse stress inducers. This protein has also been shown to cause apoptosis when added to cell free extracts. In this report, we studied the role of cytochrome c (cyto-c) in dexamethasone (Dex), anti-Fas monoclonal antibody (mAb), and ionizing radiation-induced apoptosis in multiple myeloma cells, The results demonstrate that ionizing radiation-induced apoptosis is associated with an increase in cytosolic cyto-c levels, whereas apoptosis induced by Dex or anti Fas mAb has no detectable effect on cyto-e release. By contrast, caspase-3 was activated in response to all of these agents. Thus, our findings suggest that Dex or anti-Fas mAb-induced apoptosis is not accompanied by cyto-c release and that there are at least two different pathways leading to activation of caspases and induction of apoptosis in multiple myeloma cells that can be distinguished by accumulation of cytosolic cyto-c.	NORTHWESTERN UNIV,SCH MED,ROBERT H LURIE CANC CTR,CHICAGO,IL 60611	Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Chauhan, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT ADULT ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.			Ogata, Atsushi/0000-0003-3944-3442	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GOLDMANLEIKIN RE, 1989, J LAB CLIN INVEST, V113, P345; HARDIN J, 1994, BLOOD, V84, P3063; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MOALLI PA, 1992, BLOOD, V79, P213; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; WILLIE AH, 1980, INT REV CYTOL, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	24	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					29995	29997		10.1074/jbc.272.48.29995	http://dx.doi.org/10.1074/jbc.272.48.29995			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374472	hybrid			2022-12-25	WOS:A1997YH61300004
J	Bakker, H; Friedmann, I; Oka, S; Kawasaki, T; Nifantev, N; Schachner, M; Mantei, N				Bakker, H; Friedmann, I; Oka, S; Kawasaki, T; Nifantev, N; Schachner, M; Mantei, N			Expression cloning of a cDNA encoding a sulfotransferase involved in the biosynthesis of the HNK-1 carbohydrate epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONYL GLYCOLIPIDS; CELL-ADHESION MOLECULES; NERVOUS-SYSTEM; DEVELOPMENTAL EXPRESSION; L2/HNK-1 CARBOHYDRATE; SULFOGLUCURONYL GLYCOLIPIDS; HNK-1-REACTIVE ANTIGENS; GENE FAMILY	The HNK-1 carbohydrate epitope is expressed on several neural adhesion glycoproteins and as a glycolipid, and is involved in cell. interactions, The structural element of the epitope common to glycoproteins and glycolipids has been determined to be sulfate-3-GlcA beta 1-->3Gal beta 1-->4GlcNAc. The glucuronyltransferase and sulfotransferase are considered to be the key enzymes in the biosynthesis of this epitope because the rest of the structure occurs often in glycoconjugates. Here we describe the isolation of the rat sulfotransferase cDNA via an expression cloning strategy, The clone finally isolated predicts a protein of 356 amino acids, uith characteristics of a type II transmembrane protein and with no sequence similarity to other known sulfotransferases, Both the enzyme expressed as a soluble fusion protein and homogenates of cells transfected with the full-length cDNA could transfer sulfate from a sulfate donor to acceptor substrates containing terminal glucuronic acid.	ETH HONGGERBERG,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 60601,JAPAN; RUSSIAN ACAD SCI,ND ZELINSKII ORGAN CHEM INST,MOSCOW 117913,RUSSIA; UNIV HAMBURG,ZENTRUM MOL NEUROBIOL,D-20246 HAMBURG,GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; Kyoto University; Russian Academy of Sciences; Zelinsky Institute of Organic Chemistry; University of Hamburg; University Medical Center Hamburg-Eppendorf			Bakker, Hans/AAA-1623-2020; Nifantiev, Nikolay E/O-6579-2015; Bakker, Hans/A-1787-2017	Bakker, Hans/0000-0002-1364-9154; Nifantiev, Nikolay E/0000-0002-0727-4050; Bakker, Hans/0000-0002-1364-9154				ABO T, 1981, J IMMUNOL, V127, P1024; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CUMMINGS L, 1993, BIOCHEM BIOPH RES CO, V195, P814, DOI 10.1006/bbrc.1993.2118; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fukuda M, 1996, GLYCOBIOLOGY, V6, P683, DOI 10.1093/glycob/6.7.683; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HOLLEY JA, 1987, DEV NEUROSCI-BASEL, V9, P105, DOI 10.1159/000111613; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; ILYAS AA, 1984, BIOCHEM BIOPH RES CO, V122, P1206, DOI 10.1016/0006-291X(84)91220-8; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LOW K, 1994, EUR J NEUROSCI, V6, P1773, DOI 10.1111/j.1460-9568.1994.tb00570.x; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MARTINI R, 1994, J NEUROSCI, V14, P7180; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; MOLLICONE R, 1995, TRANSFUS CLIN BIOL, V2, P235, DOI 10.1016/S1246-7820(05)80089-8; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OKA S, 1992, J BIOL CHEM, V267, P22711; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WERNECKE H, 1985, J NEUROIMMUNOL, V9, P115, DOI 10.1016/S0165-5728(85)80012-6; Yuen CT, 1997, J BIOL CHEM, V272, P8924	39	98	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29942	29946		10.1074/jbc.272.47.29942	http://dx.doi.org/10.1074/jbc.272.47.29942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368071	hybrid			2022-12-25	WOS:A1997YG64700081
J	Heydemann, A; Boehmler, JH; Simon, MC				Heydemann, A; Boehmler, JH; Simon, MC			Expression of two myeloid cell-specific genes requires the novel transcription factor, c-fes expression factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR PROMOTER; PROTEIN-TYROSINE KINASE; SCAVENGER RECEPTOR GENE; LEUCINE ZIPPER PROTEIN; CHICKEN LYSOZYME GENE; HL-60 LEUKEMIA-CELLS; TRANSGENIC MICE; FACTOR PU.1; T-CELLS; GRANULOCYTIC DIFFERENTIATION	The protein product of the c-fes proto-oncogene has been implicated in the normal development of myeloid cells (macrophages and granulocytes). We have previously shown that 151 base pairs of c-fes 5'-flanking sequences are sufficient for myeloid cell-specific expression and include functional binding sites for Spl, PU.1, and a novel nuclear factor (Heydemann, A., Juang, G., Hennessy, K., Parmacek, M. S., and Simon, M. C. (1996) Mol, Cell Biol, 16, 1676-1686), This novel hematopoietic transcription factor, termed FEF (c-fes expression factor), binds to a cis-acting element that is located at nucleotides -9 to -4 of the c-fes promoter between two Ets binding sites (at -19 to -15 and -4 to +1) which bind PU.1. We now show that a FEF binding site exists in the myeloid cell-specific regulatory region of a second gene, the -2.7-kilobase pair enhancer of chicken lysozyme. The lysozyme FEF site is immediately 5' to a PU.1 site, analogous to their arrangement in the c-fes promoter, and allows the formation of a preliminary FEF consensus site, 5'-GAAT(C/G)A-3'. This consensus site does not match any sites for known transcription factors. Importantly, although PU.1 binds immediately 3' of the FEF site in both the c-fes promoter and the chicken lysozyme enhancer (CLE), we show that they bind independently, The FEF sites are required for high levels of transcription by both the CLE and the c-fes promoter in transient transfection experiments, Importantly, elimination of the CLE FEF site abolishes all transcriptional activity of this enhancer element, Mutation of the adjacent PU.1 site in either the c-fes promoter or the CLE, reduces activity by approximately 50%. Therefore, transcription of both lysozyme and fee in myeloid cells requires FEF and PU.1. UV cross-linking experiments show that the FEF binding activity consists of a single 70-kDa protein in both human and murine cell lines, FEF binding activity is not affected by antibodies that specifically recognize a number of cloned transcription factors, Collectively, these data indicate that we have identified a novel transcription factor that is functionally important for the expression of at least two myeloid cell-specific genes.	UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago			Simon, Celeste/AAG-3941-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ALCALAY M, 1990, ONCOGENE, V5, P267; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; CARE A, 1994, ONCOGENE, V9, P739; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EICHBAUM Q, 1994, GENOMICS, V22, P656, DOI 10.1006/geno.1994.1445; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREZ M, 1981, CELL, V25, P743, DOI 10.1016/0092-8674(81)90182-3; He YF, 1996, BBA-GENE STRUCT EXPR, V1306, P179, DOI 10.1016/0167-4781(96)00005-X; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; KONIMATO Y, 1995, MOL CELL BIOL, V15, P59; LANFRANCONE L, 1989, INT J CANCER, P35; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAYGALLET D, 1995, ONCOGENE, V11, P303; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sippel A E, 1987, Results Probl Cell Differ, V14, P255; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YATES KE, 1995, ONCOGENE, V10, P1239; YU G, 1988, MOL PHARMACOL, V33, P384; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	52	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29527	29537		10.1074/jbc.272.47.29527	http://dx.doi.org/10.1074/jbc.272.47.29527			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368014	hybrid			2022-12-25	WOS:A1997YG64700024
J	Hsu, MH; Chiang, SC; Ye, RD; Prossnitz, ER				Hsu, MH; Chiang, SC; Ye, RD; Prossnitz, ER			Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PERTUSSIS TOXIN; CHEMOATTRACTANT RECEPTORS; NEUTRAL ENDOPEPTIDASE; HUMAN-NEUTROPHILS; EXPRESSION; INHIBITION; MEMBRANE; CALCIUM; PROTEIN	The human N-formyl peptide receptor (FPR) is a member of the family of leukocyte, G protein-coupled, chemoattractant receptors, To determine the role(s) of receptor phosphorylation in FPR processing and formylmethionylleucylphenylalanine (fMLF) mediated chemotaxis, we utilized U937 cells expressing the recombinant wild type receptor and a mutant form of the FPR, This mutant, which lacks all of the serine and threonine residues in the C terminus of the receptor, Delta ST, has recently been shown to produce a receptor capable of fMLF binding and G protein activation but was demonstrated not to undergo fMLF-dependent phosphorylation or desensitization of the calcium mobilization response upon repeated exposure to agonist (Prossnitz, E. R. (1997) J. Biol. Chem. 272, 15213-15219). In this report, we examined the role of receptor phosphorylation in FPR internalization and leukocyte chemotaxis. Whereas the wild type receptor was rapidly internalized upon stimulation, the phosphorylation-deficient mutant was not, remaining entirely on the cell surface, In addition, contrary to the hypothesis that receptor processing and recycling are required for chemotaxis, we found no defect in the ability of the mutant FPR to migrate up a concentration gradient of fMLF. These results indicate that phosphorylation of the FPR is a necessary step in receptor internalization but that receptor phosphorylation, desensitization, and internalization are not required for chemotaxis,	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI33503, AI36357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R01AI033503, R56AI033503, R29AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BECKER EL, 1972, J IMMUNOL, V108, P396; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; HUU TP, 1979, BIOMEDICINE, V30, P121; KEW RR, 1997, L LEUKOCYTE BIOL, V61, P329; LAD PM, 1986, FEBS LETT, V200, P91, DOI 10.1016/0014-5793(86)80517-8; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; PAINTER RG, 1988, J BIOL CHEM, V263, P9456; PAINTER RG, 1995, J LEUKOCYTE BIOL, V58, P468, DOI 10.1002/jlb.58.4.468; PEREZ HD, 1982, J IMMUNOL, V129, P2718; PEREZ HD, 1986, J IMMUNOL, V136, P1803; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; SCHIFFMANN E, 1975, J IMMUNOL, V114, P1831; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WILDE MW, 1989, J BIOL CHEM, V264, P190; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9; ZIGMOND SH, 1989, AM J RESP CELL MOL, V1, P451, DOI 10.1165/ajrcmb/1.6.451; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	28	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29426	29429		10.1074/jbc.272.47.29426	http://dx.doi.org/10.1074/jbc.272.47.29426			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367998	hybrid			2022-12-25	WOS:A1997YG64700008
J	Bassilana, F; Champigny, G; Waldmann, R; deWeille, JR; Heurteaux, C; Lazdunski, M				Bassilana, F; Champigny, G; Waldmann, R; deWeille, JR; Heurteaux, C; Lazdunski, M			The acid-sensitive ionic channel subunit ASIC and the mammalian degenerin MDEG form a heteromultimeric H+-gated Na+ channel with novel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SODIUM CURRENT; ROOT GANGLION NEURONS; CAENORHABDITIS-ELEGANS; HOMOLOGOUS SUBUNITS; SENSORY NEURONS; NEURODEGENERATION; EXPRESSION; RECEPTOR; PROTONS; CLONING	Proton-gated cation channels are acid sensors that are present in both sensory neurons and in neurons of the central nervous system. One of these acid sensing ion channels (ASIC) has been recently cloned. This paper shows that ASIC and the mammalian degenerin MDEG, which are colocalized in the same brain regions, can directly associate with each other. Immunoprecipitation of MDEG causes coprecipitation of ASIC. Moreover, coexpression of ASIC and MDEG subunits in Xenopus oocytes generates an amiloride-sensitive H+-gated Na+ channel with novel properties (different kinetics, ionic selectivity, and pH sensitivity). In addition, coexpression of MDEG with mutants of the ASIC subunit can create constitutively active channels that become completely nonselective for Na+ versus K+ and H+-gated channels that have a drastically altered pH sensitivity compared with MDEG. These data clearly show that ASIC and MDEG can form heteromultimeric assemblies with novel properties. Heteromultimeric assembly is probably used for creating a diversity of H+-gated cation channels acting as neuronal acid sensors in different pH ranges.	CNRS,INST PHARMACOL MOL & CELLULAIRE,UPR 411,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; de Weille, Jan R/F-8103-2014; HEURTEAUX, Catherine/M-4947-2016	Waldmann, Rainer/0000-0002-4599-2926; de Weille, Jan R/0000-0002-0505-3166; HEURTEAUX, Catherine/0000-0002-9741-9777; Bassilana, Frederic/0000-0003-2063-8450				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; HERMAN RK, 1996, BIOESSAYS, V48, P199; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1987, BRAIN RES, V436, P352, DOI 10.1016/0006-8993(87)91678-7; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	26	179	194	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28819	28822		10.1074/jbc.272.46.28819	http://dx.doi.org/10.1074/jbc.272.46.28819			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360943	hybrid			2022-12-25	WOS:A1997YF68400002
J	Brooks, EE; Gray, NS; Joly, A; Kerwar, SS; Lum, R; Mackman, RL; Norman, TC; Rosete, J; Rowe, M; Schow, SR; Schultz, PG; Wang, XB; Wick, MM; Shiffman, D				Brooks, EE; Gray, NS; Joly, A; Kerwar, SS; Lum, R; Mackman, RL; Norman, TC; Rosete, J; Rowe, M; Schow, SR; Schultz, PG; Wang, XB; Wick, MM; Shiffman, D			CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; OLIGONUCLEOTIDES	The activity of cyclin-dependent kinase 2 (CDK2) is essential for progression of cells from G(1) to the S phase of the mammalian cell cycle. CVT-313 is a potent CDK2 inhibitor, which was identified from a purine analog library with an IC50 of 0.5 mu M in vitro. Inhibition was competitive with respect to ATP (K-i = 95 nM), and selective CVT-313 had no effect on other, nonrelated ATP-dependent serine/threonine kinases, When added to CDK1 or CDK4, a 8.5- and 430-fold higher concentration of CVT-313 was required for half-maximal inhibition of the enzyme activity. In cells exposed to CVT-313, hyperphosphorylation of the retinoblastoma gene product was inhibited, and progression through the cell cycle was arrested at the G(1)/S boundary, The growth of mouse, rat, and human cells in culture was also inhibited by CVT-313 with the IC50 for growth arrest ranging from 1.25 to 20 mu M. To evaluate the effects of CVT-313 in vivo, we tested this agent in a rat carotid artery model of restenosis, A brief intraluminal exposure of CVT-313 to a denuded rat carotid artery resulted in more than 80% inhibition of neointima formation. These observations suggest that CVT-313 is a promising candidate for evaluation in other disease models related to aberrant cell proliferation.	CV THERAPEUT, PALO ALTO, CA 94304 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley								ABE J, 1994, BIOCHEM BIOPH RES CO, V198, P16, DOI 10.1006/bbrc.1994.1003; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; Norman TC, 1996, J AM CHEM SOC, V118, P7430, DOI 10.1021/ja9614934; Nugiel DA, 1997, J ORG CHEM, V62, P201, DOI 10.1021/jo961909w; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	16	130	149	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29207	29211		10.1074/jbc.272.46.29207	http://dx.doi.org/10.1074/jbc.272.46.29207			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360999	hybrid			2022-12-25	WOS:A1997YF68400058
J	Galione, A; Jones, KT; Lai, FA; Swann, K				Galione, A; Jones, KT; Lai, FA; Swann, K			A cytosolic sperm protein factor mobilizes Ca2+ from intracellular stores by activating multiple Ca2+ release mechanisms independently of low molecular weight messengers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CALCIUM OSCILLATIONS; MAMMALIAN EGGS; FERTILIZATION; WAVES; THAPSIGARGIN; RECEPTORS; RYANODINE	Ca2+ oscillations can be induced in mammalian eggs and somatic cells by microinjection of a cytosolic sperm protein factor. The nature of the sperm factor-induced Ca2+ signaling was investigated by adding sperm protein extracts to homogenates of sea urchin eggs, which contain multiple classes of Ca2+ release mechanisms. We show that the sperm factor mobilizes Ca2+ from nonmitochondrial Ca2+ stores in egg homogenates after a distinct latency. This latency is abolished by preincubation of sperm extracts with egg cytosol. The preincubation step is highly temperature-dependent and generates a high molecular weight, protein-based Ca2+-releasing agent that can also mobilize Ca2+ from purified egg microsomes. This Ca2+ release appears to be mediated via both inositol 1,4,5-trisphosphate and ryanodine receptors, since homologous desensitization of these two release mechanisms by their respective agonists inhibits further release by the sperm factor. However, sperm factor-induced Ca2+ release by these channels is independent of inositol 1,4,5-trisphosphate or cADPR since antagonists of either of these two messengers did not block the Ca2+ release effected by the sperm factor. The sperm protein factor may cause Ca2+ release via an enzymatic step that generates a protein-based Ca2+-releasing agent.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	University of Oxford; MRC National Institute for Medical Research	Galione, A (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Jones, Keith/AAA-3479-2021; Jones, Keith/C-9821-2013; Galione, Antony/E-5884-2011	Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851; Swann, Karl/0000-0002-4355-1449; Galione, Antony/0000-0002-4132-7646; Lai, Tony/0000-0003-2852-8547	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; ALLEN RD, 1958, EXP CELL RES, V15, P163, DOI 10.1016/0014-4827(58)90072-7; BERRIE CP, 1996, BIOCHEM J, V311, P369; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DALE B, 1978, NATURE, V275, P217, DOI 10.1038/275217a0; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Genazzani AA, 1996, BIOCHEM J, V315, P721, DOI 10.1042/bj3150721; GUTFREUND H, 1996, KINETICS LIFE SCI; HOMA ST, 1994, HUM REPROD, V9, P2356, DOI 10.1093/oxfordjournals.humrep.a138452; JONES KT, 1995, J BIOL CHEM, V270, P6671, DOI 10.1074/jbc.270.12.6671; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; Lawrence Y, 1997, DEVELOPMENT, V124, P233; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; MCCULLOH DH, 1992, J GEN PHYSIOL, V99, P137, DOI 10.1085/jgp.99.2.137; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Palermo GD, 1997, MOL HUM REPROD, V3, P367, DOI 10.1093/molehr/3.4.367; Parrington J, 1996, NATURE, V379, P364, DOI 10.1038/379364a0; Sette C, 1997, DEVELOPMENT, V124, P2267; Stricker SA, 1997, DEV BIOL, V186, P185, DOI 10.1006/dbio.1997.8594; Stricker SA, 1996, DEV BIOL, V176, P243, DOI 10.1006/dbio.1996.0131; SWANN K, 1990, DEVELOPMENT, V110, P1295; Swann K, 1997, BIOESSAYS, V19, P371, DOI 10.1002/bies.950190504; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; SWANN K, 1994, INT REV CYTOL, V152, P183, DOI 10.1016/S0074-7696(08)62557-7; TESARIK J, 1994, HUM REPROD, V9, P511, DOI 10.1093/oxfordjournals.humrep.a138537; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Wu H, 1997, MOL REPROD DEV, V46, P176, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;176::AID-MRD8&gt;3.0.CO;2-N	31	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28901	28905		10.1074/jbc.272.46.28901	http://dx.doi.org/10.1074/jbc.272.46.28901			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360959	hybrid, Green Published			2022-12-25	WOS:A1997YF68400018
J	PazElizur, T; Barak, P; Livneh, Z				PazElizur, T; Barak, P; Livneh, Z			Anti-mutagenic activity of DNA damage-binding proteins mediated by direct inhibition of translesion replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APURINIC APYRIMIDINIC SITES; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; EXCISION-REPAIR; UV MUTAGENESIS; DEOXYRIBONUCLEIC-ACID; INVITRO REPLICATION; BETA SUBUNIT; RECA PROTEIN; ABASIC SITES	DNA lesions that block replication can be bypassed in Escherichia coli by a special DNA synthesis process termed translesion replication, This process is mutagenic due to the miscoding nature of the DNA lesions, We report that the repair enzyme formamido-pyrimidine DNA glycosylase and the general DNA damage recognition protein UvrA each inhibit specifically translesion replication through an abasic site analog by purified DNA polymerases I and II, and DNA polymerase III (alpha subunit) from E. coli. In vice experiments suggest that a similar inhibitory mechanism prevents at least 70% of the mutations caused by ultraviolet light DNA lesions in E. coli. These results suggest that DNA damage-binding proteins regulate mutagenesis by a novel mechanism that involves direct inhibition of translesion replication. This mechanism provides anti-mutagenic defense against DNA lesions that have escaped DNA repair.	WEIZMANN INST SCI,FAC BIOCHEM,DEPT BIOL CHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BONNER CA, 1988, J BIOL CHEM, V263, P18946; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHAMBERS RW, 1985, P NATL ACAD SCI USA, V82, P7173, DOI 10.1073/pnas.82.21.7173; COX MM, 1981, J BIOL CHEM, V256, P4676; FRIEDBERG EC, 1995, DNA REPAIR; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2378, DOI 10.1021/bi00279a012; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MAKI H, 1985, J BIOL CHEM, V260, P2987; Miller J.H., 1972, EXPT MOL GENETICS; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; RUIZRUBIO M, 1988, J BACTERIOL, V170, P5371, DOI 10.1128/jb.170.11.5371-5374.1988; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SANCAR GB, 1987, J BIOL CHEM, V262, P478; SCHAAPER RM, 1982, MUTAT RES, V106, P1, DOI 10.1016/0027-5107(82)90186-5; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SHWARTZ H, 1987, J BIOL CHEM, V262, P10518; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SNOWDEN A, 1990, BIOCHEMISTRY-US, V29, P7251, DOI 10.1021/bi00483a013; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; Tomer G, 1996, P NATL ACAD SCI USA, V93, P1376, DOI 10.1073/pnas.93.4.1376; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	40	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28906	28911		10.1074/jbc.272.46.28906	http://dx.doi.org/10.1074/jbc.272.46.28906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360960	hybrid			2022-12-25	WOS:A1997YF68400019
J	Pinner, E; Gruenheid, S; Raymond, M; Gros, P				Pinner, E; Gruenheid, S; Raymond, M; Gros, P			Functional complementation of the yeast divalent cation transporter family SMF by NRAMP2, a member of the mammalian natural resistance-associated macrophage protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-BOVIS BCG; INTRACELLULAR PARASITES; GENETIC-CONTROL; H+-ATPASE; EXPRESSION; INFECTION; MICE; SUSCEPTIBILITY; SEQUENCE; MUTATION	The mammalian NRAMP gene family has two members, NRAMP1 and NRAMP2 that encode integral membrane proteins, Nramp1 is expressed exclusively in macrophages where it is found in the phagosomal membrane, and NRAMP1 mutations cause susceptibility to infection by abrogating the capacity of macrophages to control intracellular microbial replication. Nramp2 is highly similar to Nramp1, but is expressed in several tissues and cell types, The Nramp protein family is remarkably conserved throughout evolution, and recent data suggest that the mammalian Nramp2 and the yeast homologues Smf1 and Smf2 transport divalent cations, We tested whether structural similarity between the mammalian Nramp and the yeast Smf proteins results in functional complementation in yeast, Wild-type and mutant variants of the Nramp1 and Nramp2 proteins were expressed in a yeast mutant bearing null alleles at the SMF1 and SMF2 loci, and complementation of the phenotypes of this yeast mutant was investigated, Nramp2, but not Nramp1, was found to complement hypersensitivity to EGTA of the smf1/smf2 mutant under oxidative stress conditions (methyl viologen), We also observed that the smf1/smf2 double mutant is hypersensitive to growth at alkaline pH (pH 7.9) and that Nramp2 could complement this phenotype as well, Complementation by Nramp2 was specific and required a functional protein as independent mutations in residues highly conserved in all members of the Nramp family abrogated Nramp2 complementation. Since Mn2+ was the only divalent cation capable of completely suppressing both the EGTA and pH phenotypes, our results suggest that Nramp2 can transport Mn2+ in yeast.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA	McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal				Gruenheid, Samantha/0000-0002-0908-6715	NIAID NIH HHS [AI35237-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI035237, R01AI035237] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; Belouchi A, 1997, PLANT MOL BIOL, V33, P1085, DOI 10.1023/A:1005723304911; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; Cellier M, 1996, TRENDS GENET, V12, P201, DOI 10.1016/0168-9525(96)30042-5; Cellier M, 1997, J LEUKOCYTE BIOL, V61, P96, DOI 10.1002/jlb.61.1.96; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DESCOTEAUX S, 1994, INFECT IMMUN, V62, P3572, DOI 10.1128/IAI.62.8.3572-3575.1994; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GROS P, 1983, J IMMUNOL, V131, P1966; GROS P, 1981, J IMMUNOL, V127, P2417; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; LISSNER CR, 1983, J IMMUNOL, V131, P3006; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SHERMAN F, 1982, METHODS YEAST GENETI, P163; STACH JL, 1984, J IMMUNOL, V132, P888; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; Vidal SM, 1996, J IMMUNOL, V157, P3559; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WEST AH, 1992, J BIOL CHEM, V267, P24625; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	36	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28933	28938		10.1074/jbc.272.46.28933	http://dx.doi.org/10.1074/jbc.272.46.28933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360964	hybrid			2022-12-25	WOS:A1997YF68400023
J	Diviani, D; Lattion, AL; Cotecchia, S				Diviani, D; Lattion, AL; Cotecchia, S			Characterization of the phosphorylation sites involved in G protein-coupled receptor kinase- and protein kinase C-mediated desensitization of the alpha(1B)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; RHODOPSIN KINASE; MULTIPLE PHOSPHORYLATION; CARBOXYL-TERMINUS; 48-KDA PROTEIN; IN-VIVO; IDENTIFICATION; SPECIFICITY; ACTIVATION; TRUNCATION	Catecholamines as well as phorbol esters can induce the phosphorylation and desensitization of the alpha(1B)-adrenergic receptor (alpha(1B)AR). In this study, phosphoamino acid analysis of the phosphorylated alpha(1B)AR revealed that both epinephrine-and phorbol ester-induced phosphorylation predominantly occurs at serine residues of the receptor, The findings obtained with receptor mutants in which portions of the C-tail were truncated or deleted indicated that a region of 21 amino acids (393-413) of the carboxyl terminus including seven serines contains the main phosphorylation sites involved in agonist-as well as phorbol ester-induced phosphorylation and desensitization of the alpha(1B)AR. To identify the serines invoved in agonist-versus phorbol ester-dependent regulation of the receptor, two different strategies were adopted, the seven serines were either substituted with alanine or reintroduced into a mutant lacking all of them, Our findings indicate that Ser(394) and Ser(400) were phosphorylated following phorbol ester-induced activation of protein kinase C, whereas Ser(404), Ser(408), and Ser(410) were phosphorylated upon stimulation of the alpha(1B)AR with epinephrine, The observation that overexpression of G protein-coupled kinase 2 (GRK2) could increase agonist-induced phosphorylation of Ser(404), Ser(408), and Ser(410), strongly suggests that these serines are the phosphorylation sites of the alpha(1B)AR for kinases of the GRK family, Phorbol ester-induced phosphorylation of the Ser(394) and Ser(400) as well as GRK2-mediated phosphorylation of the Ser(404), Ser(408), and Ser(410), resulted in the desensitization of cu,BAR-mediated inositol phosphate response, This study provides generalities about the biochemical mechanisms underlying homologous and heterologous desensitization of G protein-coupled receptors linked to the activation of phospholipase C.	INST PHARMACOL & TOXICOL, FAC MED, CH-1005 LAUSANNE, SWITZERLAND	University of Geneva				Diviani, Dario/0000-0003-4375-3718				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Diviani D, 1996, J BIOL CHEM, V271, P5049; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; Greene NM, 1997, J BIOL CHEM, V272, P10341; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Lembo PMC, 1995, MOL PHARMACOL, V48, P1024; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Widmann C, 1996, J BIOL CHEM, V271, P19957, DOI 10.1074/jbc.271.33.19957; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YUAN NY, 1994, J BIOL CHEM, V269, P23032	35	113	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28712	28719		10.1074/jbc.272.45.28712	http://dx.doi.org/10.1074/jbc.272.45.28712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353340	hybrid			2022-12-25	WOS:A1997YF21900080
J	Tiger, CF; Champliaud, MF; PedrosaDomellof, F; Thornell, LE; Ekblom, P; Gullberg, D				Tiger, CF; Champliaud, MF; PedrosaDomellof, F; Thornell, LE; Ekblom, P; Gullberg, D			Presence of laminin alpha 5 chain and lack of laminin alpha 1 chain during human muscle development and in muscular dystrophies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; EXTRACELLULAR-MATRIX; DIFFERENTIAL EXPRESSION; MONOCLONAL-ANTIBODIES; SKELETAL-MUSCLE; MOLECULAR-CLONING; MYOGENIC CELLS; MEROSIN; KIDNEY; MYOBLASTS	There is currently a great interest in identifying laminin isoforms expressed in developing and regenerating skeletal muscle. Laminin alpha 1 has been reported to localize to human fetal muscle and to be induced in muscular dystrophies based on immunohistochemistry with the monoclonal antibody 4C7, suggested to recognize the human laminin alpha 1 chain. Nevertheless, there seems to be no expression of laminin alpha 1 protein or mRNA in developing or dystrophic mouse skeletal muscle fibers. To address the discrepancy between the results obtained in developing and dystrophic human and mouse muscle we expressed the E3 domain of human laminin alpha 1 chain as a recombinant protein and made antibodies specific for human laminin alpha 1 chain (anti-hLN-alpha 1G4/G5). We also made antibodies to the human laminin alpha 5 chain purified from placenta. In the present report we show that hLN-alpha 1G4/G5 antibodies react with a 400-kDa laminin alpha 1 chain and that 4C7 reacts with a 380-kDa laminin alpha 5 chain. Immunohistochemistry with the hLN-alpha 1G4/G5 antibody and 4C7 revealed that the two antibodies stained human kidney, developing and dystrophic muscle in distinct patterns. Our data indicate that the previously reported expression patterns in developing, adult, and dystrophic human muscle tissues with 4C7 should be re-interpreted as an expression of laminin alpha 5 chain. Our data are also consistent with earlier work in mouse, indicating that laminin alpha 1 is largely an epithelial laminin chain not present in developing or dystrophic muscle fibers.	UPPSALA UNIV,DEPT ANIM PHYSIOL,BMC,S-75124 UPPSALA,SWEDEN; HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,SCH MED,CHARLESTOWN,MA 02142; UMEA UNIV,DEPT ANAT,S-90187 UMEA,SWEDEN	Uppsala University; Harvard University; Massachusetts General Hospital; Umea University			Thornell, Lars-Eric/L-8358-2019; Gullberg, Donald/H-2495-2016	Gullberg, Donald/0000-0002-7245-4437; Pedrosa Domellof, Fatima/0000-0002-0648-4996				Allamand V, 1997, HUM MOL GENET, V6, P747, DOI 10.1093/hmg/6.5.747; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BISCHOFF R, 1990, DEVELOPMENT, V109, P943; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; Durbeej M, 1996, MATRIX BIOL, V15, P397, DOI 10.1016/S0945-053X(96)90159-6; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; Ekblom P, 1996, CURR OPIN CELL BIOL, V8, P700, DOI 10.1016/S0955-0674(96)80112-8; EKBLOM P, 1980, DEV BIOL, V74, P263, DOI 10.1016/0012-1606(80)90429-7; Eng H, 1997, DIFFERENTIATION, V61, P169, DOI 10.1046/j.1432-0436.1997.6130169.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; EVELLING T, 1996, DEV DYNAM, V207, P355; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; Gullberg D, 1995, INT J DEV BIOL, V39, P845; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; Jaspars LH, 1996, CELL ADHES COMMUN, V4, P269, DOI 10.3109/15419069609010771; JIN P, 1993, DIFFERENTIATION, V54, P47; KLEIN G, 1990, DEVELOPMENT, V110, P823; Korhonen M, 1997, J HISTOCHEM CYTOCHEM, V45, P569, DOI 10.1177/002215549704500409; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; MUNDEGAR RR, 1995, MUSCLE NERVE, V18, P992, DOI 10.1002/mus.880180911; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; ROSE O, 1994, DEV DYNAM, V201, P245, DOI 10.1002/aja.1002010308; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHULER F, 1995, J CELL SCI, V108, P3795; SEWRY CA, 1995, HISTOCHEM J, V27, P497; SEWRY CA, 1995, NEUROMUSCULAR DISORD, V5, P307, DOI 10.1016/0960-8966(94)00072-H; SOROKIN LM, 1992, EXP CELL RES, V201, P137, DOI 10.1016/0014-4827(92)90357-E; SOROKIN LM, 1997, IN PRESS DEV BIOL; SUNADA Y, 1995, NEUROLOGY, V45, P2084, DOI 10.1212/WNL.45.11.2084; TALTS JF, 1993, INT J CANCER, V54, P868, DOI 10.1002/ijc.2910540524; TIGER CF, 1997, IN PRESS MUSCLE NERV; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VACHON PH, 1995, AM J PHYSIOL-GASTR L, V268, pG857, DOI 10.1152/ajpgi.1995.268.5.G857; VIRTANEN I, 1995, J HISTOCHEM CYTOCHEM, V43, P621, DOI 10.1177/43.6.7769233; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	52	188	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28590	28595		10.1074/jbc.272.45.28590	http://dx.doi.org/10.1074/jbc.272.45.28590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353324	hybrid			2022-12-25	WOS:A1997YF21900064
J	Elble, RC; Widom, J; Gruber, AD; AbdelGhany, M; Levine, R; Goodwin, A; Cheng, HC; Pauli, BU				Elble, RC; Widom, J; Gruber, AD; AbdelGhany, M; Levine, R; Goodwin, A; Cheng, HC; Pauli, BU			Cloning and characterization of lung endothelial cell adhesion molecule-1 suggest it is an endothelial chloride channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE TRACHEA; METASTASIS; GLYCOPROTEIN; RECOGNITION; EXPRESSION; LU-ECAM-1; SEQUENCE; PROTEINS	Lung-endothelial cell adhesion molecule-1 (Lu-ECAM-1) is an endothelial cell surface molecule that mediates adhesion of metastatic melanoma cells to lung endothelium, Here we analyze the organization of the Lu-ECAM-1 protein complex, report the sequence of Lu-ECAM-1 cDNAs, and reveal a novel function of the protein, Lu-ECAM-1 immunopurified from bovine aortic endothelial cells (BAEC) consists of tightly associated glycoproteins of 90, 38, and 32 kDa, with minor components of 130 and 120 kDa, We present evidence that all of these protein species are encoded by a single open reading frame whose initial translation product is proteolytically processed to yield the other products, Correct processing in. vitro was demonstrated by transfection of the longest cDNA into human embryonic kidney 293 cells; immunoblot analysis showed that the similar to 120-kDa precursor gave rise to 90- and 38-kDa products, RNA blots of BAEC mRNA detected messages in agreement with the sizes of the cDNA clones in addition to several of high molecular weight, DNA blot analysis showed that Lu-ECAM-1 is conserved throughout its length in all mammals tested, usually as a single or low copy gene, In the bovine, Lu-ECAM-1 protein is 88% identical to a calcium-dependent chloride channel described recently in tracheal epithelium, Ca-CC, Probes for Lu-ECAM-1 mRNA and protein confirmed the presence of a homolog in this tissue, We show that messages for both proteins are present in lung while only Ca-CC is present in trachea and only Lu-ECAM-1 is present in BAEC, These results suggest that endothelial cells express a chloride channel that is related to, but distinct from, that expressed in tracheal epithelium, They further suggest that an adhesion molecule can also be a chloride channel.	CORNELL UNIV,COLL VET MED,DEPT PATHOL,CANC BIOL LABS,ITHACA,NY 14853	Cornell University			Gruber, Achim D./ABA-4514-2021		NATIONAL CANCER INSTITUTE [T32CA009682, R01CA047668] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09682, CA 47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1991, AM J RESP CELL MOL B, V4, P193; AUGUSTINVOSS HG, 1991, EXP CELL RES, V192, P346, DOI 10.1016/0014-4827(91)90051-U; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Elble RC, 1996, CURR TOP MICROBIOL, V213, P107; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P330; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PAULI BU, 1988, LAB INVEST, V58, P379; PAULI BU, 1997, ENCY CANC, V1, P464; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; QIAN LA, 1993, MOL CELL BIOL, V13, P1686, DOI 10.1128/MCB.13.3.1686; RAN S, 1992, J BIOL CHEM, V267, P3618; Sambrook J., 2002, MOL CLONING LAB MANU; TAKADA A, 1993, CANCER RES, V53, P354; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	31	82	90	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27853	27861		10.1074/jbc.272.44.27853	http://dx.doi.org/10.1074/jbc.272.44.27853			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346932	hybrid			2022-12-25	WOS:A1997YD47300058
J	Nikaido, K; Liu, PQ; Ames, GFL				Nikaido, K; Liu, PQ; Ames, GFL			Purification and characterization of HisP, the ATP-binding subunit of a traffic ATPase (ABC transporter), the histidine permease of Salmonella typhimurium - Solubility, dimerization, and ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MALTOSE TRANSPORT; CYSTIC-FIBROSIS; PERIPLASMIC TRANSPORT; CONFORMATIONAL CHANGE; MULTIDRUG-RESISTANCE; PROTEIN CONFORMATION; MEMBRANE-COMPONENTS; CIRCULAR-DICHROISM	The nucleotide-binding subunit, HisP, of the histidine permease, a traffic ATPase (ABC transporter), has been purified as a soluble protein and characterized. Addition of a 6-histidine extension (HisP((His6))) allows a rapid and effective metal affinity purification, giving a 30-fold purification with a yield of 50%. HisP((his6)) is indistinguishable from underivatized HisP when incorporated into the permease membrane-bound complex, HisQMP(2). Purified HisP((his6)) has a strong tendency to precipitate; 5 mM ATP and 20% glycerol maintain it in solution at a high protein concentration. HisP((his6)) is active as a dimer, binds ATP with a K-d value of 205 mu M, and hydrolyzes it at a rate comparable to that of HisQMP(2); in contrast to the latter, it does not display cooperativity for ATP. HisP((his6)) has been characterized with respect to substrate and inhibitor specificity and Various physico-chemical characteristics. Its pH optimum is 7 and it requires a cation for activity, with Co(2+)and Mn2+ being more effective than Mg2+ at lower concentrations but inhibitory in the higher concentration range. In contrast to the intact complex, HisP((his6)) is not inhibited by vanadate but is inhibited by N-ethylmaleimide. Neither the soluble receptor, HisJ, nor the transport substrate, histidine, has any effect on the activity.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1968, J BACTERIOL, V96, P1742, DOI 10.1128/JB.96.5.1742-1749.1968; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1968, J BACTERIOL, V95, P833, DOI 10.1128/JB.95.3.833-843.1968; AMES GF, 1964, ARCH BIOCHEM BIOPHYS, V104, P1, DOI 10.1016/S0003-9861(64)80028-X; AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; AMES GFL, 1978, P NATL ACAD SCI USA, V75, P5447, DOI 10.1073/pnas.75.11.5447; AMES GFL, 1981, EUR J BIOCHEM, V115, P525; AMES GFL, 1990, BACTERIAL ENERGETICS, P225; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu CE, 1997, J BIOL CHEM, V272, P859, DOI 10.1074/jbc.272.2.859; MIMURA CS, 1990, J BIOL CHEM, V265, P19535; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MORBACH S, 1993, J BIOL CHEM, V268, P18617; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; PARCZEL A, 1992, ANAL BICHEM, V203, P83; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WALTER C, 1992, J BIOL CHEM, V267, P8863; WEICHELMAN K, 1988, ANAL BIOCHEM, V175, P231; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	104	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27745	27752		10.1074/jbc.272.44.27745	http://dx.doi.org/10.1074/jbc.272.44.27745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346917	hybrid			2022-12-25	WOS:A1997YD47300043
J	Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS				Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS			Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro	ONCOGENE			English	Article						p16; glioma; invasion; MMP-2; tumor-suppressor	IN-VITRO; CELL-CYCLE; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; GLIOBLASTOMA CELLS; TUMOR PROGRESSION; MALIGNANT GLIOMAS; RAT BRAIN; EXPRESSION	Malignant gliomas extensively infiltrate the surrounding normal brain, and their diffuse invasion is one of the most important barriers to successful therapy, Recent studies indicate that the progression of gliomas from low-grade to high-grade may depend on the acquisition of a new phenotype and the subsequent addition of genetic defects, One of the most frequent abnormalities in the progression of gliomas is the inactivation of tumor-suppressor gene p16, suggesting that loss of p16 is associated with acquisition of malignant characteristics. Consistent with this hypothesis, our previous studies showed that restoring wild-type p16 activity into p16-null malignant glioma cells modified their phenotype, In order to understand whether the biological consequences of p16 inactivation in high-grade gliomas included facilitating invasiveness, we used a recombinant replication-deficient adenovirus carrying the cDNA of the p16/CDKN2 gene to infect and express high levels of p16 protein in p16-null SNB19 glioma cells, Invasion of SNB19 glioma cells was tested into two models: invasion of glioma cells through Matrigel-coated transwell inserts and invasion of tumor-cell spheroids into fetal rat-brain aggregates in a co-culture system, Matrigel invasion assays showed that the SNB19 cells expressing exogenous p16 exhibited significantly reduced invasion, Similarly, invasion of p16-treated SNB19 cells into fetal rat-brain aggregates was reduced during a 72 h time period compared to invasion of the adenovirus-control and mock-infected cells, Expression of matrix metalloproteinase-2 (MMP-2), an enzyme involved in tumor-cell invasion, in SNB19 cells expressing p16 was significantly reduced compared to that of parental SNB19 and vector-infected cells, Our results show that restoring wild-type p16 activity into p16-null SNB19 glioma cells significantly inhibits tumor-cell invasion, thus suggesting a novel function of the p16 gene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV BERGEN,DEPT ANAT & CELL BIOL,BERGEN,NORWAY	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bergen				Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [R01CA056792] Funding Source: NIH RePORTER; NCI NIH HHS [CA56792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALBELDA SM, 1993, LAB INVEST, V68, P4; ARAP W, 1995, CANCER RES, V55, P1351; BJERKVIG R, 1986, CANCER RES, V46, P4071; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; CHINTALA SK, 1996, CANC LETT, V103, P102; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; EASTHAM JA, 1995, CANCER RES, V55, P5151; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; GIANI C, 1994, CANCER RES, V54, P6338; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; GOMEZMANZANO C, 1996, CANCER RES, V54, P6353; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; Hsu SC, 1996, CANCER RES, V56, P5684; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; Li J, 1996, ONCOGENE, V13, P2379; LI Y, 1994, CANCER RES, V54, P6078; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MASUYAMA JI, 1992, J IMMUNOL, V148, P1367; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakagawa T, 1996, J NEURO-ONCOL, V28, P13, DOI 10.1007/BF00300442; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RATNER S, 1988, J IMMUNOL, V140, P583; REED JA, 1995, CANCER RES, V55, P2713; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WELCH DR, 1994, ONCOGENE, V9, P255; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	50	83	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2049	2057		10.1038/sj.onc.1201382	http://dx.doi.org/10.1038/sj.onc.1201382			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366522				2022-12-25	WOS:A1997YC28400006
J	Simonian, PL; Grillot, DAM; Nunez, G				Simonian, PL; Grillot, DAM; Nunez, G			Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2	ONCOGENE			English	Article						Bak; Bcl-X-L; Ecl-2; apoptosis; chemotherapy; cell death	HOMOLOG BAK; APOPTOSIS; EXPRESSION; CISPLATIN; SURVIVAL; BCL-X(L); DOMAIN; BH1	Bak has been shown to both promote apoptosis and to inhibit cell death while two other members of the Bcl-2 family of proteins, Bcl-X-L and Bcl-2 delay apoptosis induced by various stimuli including chemotherapeutic agents. We generated clones with stable expression of Bak wild-type (wt) and Bak with its BH3 (Delta 78-86) domain deleted (Delta BH3) in FL5.12 cells or FL5.12 cells expressing either Bcl-X-L or Bcl-2 to determine if Bak could accelerate apoptosis and antagonize the death repressor activity of Bcl-X-L and Bcl-2 during chemotherapy-induced apoptosis. We found that Bah accelerated cell death in FL5.12 cells treated with etoposide, fluorouracil or taxol. In FL5.12 cells expressing Bcl-X-L and Bak wt or Bak Delta BH3, both Bak wt or Bak Delta BH3 were able to antagonize the protective effect of Bcl-X-L when treated with etoposide or fluorouracil. Bak wt or Bak Delta BH3 were also able to abrogate the protective effect of Bcl-2 in cells expressing Bcl-2 and Bak wt or Bak Delta BH3 when challenged by etoposide or fluorouracil. Immunoprecipitation studies revealed that deletion of BH3 disrupted heterodimerization between Bak and Bcl-X-L and that both Bak wt and Bak Delta BH3 failed to interact with Bcl-2. These results demonstrate that Bak does not require its BH3 domain to promote apoptosis in stably transfected cells. Furthermore, Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-X-L and Bcl-2.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [CA-64556, CA-64421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Krajewska M, 1996, CANCER RES, V56, P2422; Middleton G, 1996, DEVELOPMENT, V122, P695; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	18	46	46	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1871	1875		10.1038/sj.onc.1201350	http://dx.doi.org/10.1038/sj.onc.1201350			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362454				2022-12-25	WOS:A1997XZ72500014
J	Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG				Chung, YJ; Park, SW; Song, JM; Lee, KY; Seo, EJ; Choi, SW; Rhyu, MG			Evidence of genetic progression in human gastric carcinomas with microsatellite instability	ONCOGENE			English	Article						gastric carcinoma; mutator phenotype; transforming growth factor beta receptor type II; BAX; insulin-like growth factor II receptor	NONPOLYPOSIS COLON-CANCER; CELL LUNG-CANCER; II RECEPTOR GENE; COLORECTAL-CANCER; MISMATCH REPAIR; MUTATOR PHENOTYPE; BETA RECEPTOR; MUTATIONS; HOMOLOG; CARCINOGENESIS	Mutator phenotype tumors provide unique opportunities to unravel malignant progression because of various gene alterations acquired during clonal tumor evolution, Gastric carcinomas, which have been known to show frequent genetic instability, would be composed of initial gene alterations shared by most tumor areas and subsequent alterations restricted to particular tumor sites, To analyse the timing of genetic events, we examined separate sites of tumor tissue obtained from a given gastric carcinoma patient with microsatellite instability (MSI), Our study included 95 normal/tumor area pairs from 25 patients, Six of the 25 patients (24%) demonstrated various levels of MSI ranging from 7% (two of 30) to 97% (28 of 29) of markers tested in multiple tumor sites. Of the six patients, five manifested frameshift mutations in a tract of ten deoxyadenosines within transforming growth factor beta receptor type II and four demonstrated frameshift mutations in a tract of eight deoxyguanosines within BAX. These mutations were common to all tumor sites regardless of the various level of MSI phenotype, indicating initial events, Two of the six patients exhibited frameshift mutations in mononucleotide repeats of mismatch repair genes, hMSH3 and hMSH6, and the insulin-like growth factor II receptor in restricted tumor areas, indicating additional alterations. Insulin-like growth factor II receptor mutations appear to be caused by hMSH3 and hMSH6 mutations because the former mutations were confined to tumor portions with the latter two mismatch repair lesions, These results provide genetic progression evidence for gastric carcinomas of the mutator pathway, In this pathway, mismatch repair insufficiency initially targets mononucleotide tracts of transforming growth factor beta receptor type II and BAX. During tumorigenesis, primary mismatch repair failure may give rise to the secondary mismatch repair lesions, frameshift mutations of hMSH3 and hMSH6, which result in another tumorigenic mutation in the insulin-like growth factor II receptor.	CATHOLIC UNIV,COLL MED,DEPT MICROBIOL,SOCHO GU,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT CLIN PATHOL,SEOUL 137701,SOUTH KOREA; CATHOLIC UNIV,COLL MED,DEPT INTERNAL MED,SEOUL 137701,SOUTH KOREA	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1996, JPN J CANCER RES, V87, P595, DOI 10.1111/j.1349-7006.1996.tb00265.x; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHONG JM, 1994, CANCER RES, V54, P4595; Chung YJ, 1996, CANCER RES, V56, P4662; CORREA P, 1994, CANCER RES, V54, pS1941; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EYFJORD JE, 1995, CANCER RES, V55, P646; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Larson AA, 1996, CANCER RES, V56, P1426; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKA Y, 1985, J BIOL CHEM, V260, P9435; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OOTA K, 1977, INT HIST CLASSIFICAT, V18; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RHYU MG, 1994, ONCOGENE, V9, P29; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhu JG, 1996, ONCOGENE, V12, P1417	39	70	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1719	1726		10.1038/sj.onc.1201343	http://dx.doi.org/10.1038/sj.onc.1201343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349506				2022-12-25	WOS:A1997XY63100012
J	Petrenko, O; Ischenko, I; Enrietto, PJ				Petrenko, O; Ischenko, I; Enrietto, PJ			Characterization of changes in gene expression associated with malignant transformation by the NF-kappa B family member, v-Rel	ONCOGENE			English	Article						v-Rel; NF-kappa B; oncogene; transformation	RECEPTOR FUSION PROTEIN; BONE-MARROW CELLS; C-REL; TRANSCRIPTIONAL REGULATION; HEMATOPOIETIC-CELLS; TARGETED DISRUPTION; HOMOLOGY DOMAIN; LYMPHOID-CELLS; GROWTH-FACTOR; MICE LACKING	In this study, alterations in gene expression patterns have been examined in v-Rel-transformed avian bone marrow cells, Using a conditional v-Rel estrogen receptor chimera (v-RelER) which transforms cells in an estrogen-dependent manner, we constructed subtraction cDNA libraries from v-RelER-transformed bone marrow cells, Several different sequences were identified whose expression was altered upon hormone activation of v-RelER. These include two genes related to the MIP-I chemokine family (mip-1 beta and a tca3 homologue), a cell surface antigen sca-2 and the transcription factor nfkb1. The expression of each gene was assayed in a number of wild-type and mutant v-Rel-expressing fibroblast and hematopoietic cells, All v-Rel-transformed hematopoietic cells tested express high levels of nfkb1 and sca-2. In fibroblasts, wild-type v-Rel induced expression of mip-1 beta and nfkb1, while nontransforming mutants of v-Rel failed to do so, suggesting a role for these two genes in v-Rel mediated transformation, Finally, these genes are expressed at high levels in cells overexpressing wild-type and truncated forms of c-Rel, implying that v-Rel transforms, in part, by induction of c-Rel target genes.			Petrenko, O (corresponding author), SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.				NCI NIH HHS [CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURD PR, 1987, J IMMUNOL, V139, P3126; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERNST H, 1987, J BIOL CHEM, V262, P1206; FRANKEL S, 1994, J MOL BIOL, V235, P1351, DOI 10.1006/jmbi.1994.1090; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Gilmore TD, 1996, ONCOGENE, V13, P1367; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HODGSON J, 1995, J VIROL, V69, P1971, DOI 10.1128/JVI.69.3.1971-1979.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LARSEN J, 1993, ONCOGENE, V8, P3221; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; Lloyd AR, 1996, J IMMUNOL, V156, P932; LU D, 1991, ONCOGENE, V6, P1235; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Noda S, 1996, J EXP MED, V183, P2355, DOI 10.1084/jem.183.5.2355; OHNO H, 1993, LEUKEMIA, V7, P2057; SAITOH SI, 1995, J IMMUNOL, V155, P5574; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SPRANGRUDE GJ, 1989, J IMMUNOL, V142, P425; TAUB DD, 1995, J IMMUNOL, V155, P3877; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walker AK, 1996, ONCOGENE, V12, P2515; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; White DW, 1996, MOL CELL BIOL, V16, P1169; WIDMER F, 1990, J CELL BIOL, V111, P3035, DOI 10.1083/jcb.111.6.3035; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	65	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1671	1680		10.1038/sj.onc.1201334	http://dx.doi.org/10.1038/sj.onc.1201334			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349500				2022-12-25	WOS:A1997XY63100006
J	Biffo, S; Sanvito, F; Costa, S; Preve, L; Pignatelli, R; Spinardi, L; Marchisio, PC				Biffo, S; Sanvito, F; Costa, S; Preve, L; Pignatelli, R; Spinardi, L; Marchisio, PC			Isolation of a novel beta(4) integrin-binding protein (p27(BBP)) expressed in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; ALPHA(6)BETA(4) INTEGRIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; HEMIDESMOSOME FORMATION; PYLORIC ATRESIA; BETA-4 SUBUNIT; NUCLEAR MATRIX; ADHESION; ALPHA-6-BETA-4	The integrin beta(4) has a long cytodomain necessary for hemidesmosome formation. A yeast two-hybrid screen using beta(4) cytodomain uncovered a protein called p27(BBP) that represents a beta(4) interactor. Both in yeast and in vitro, p27(BBP) binds the two NH2-terminal fibronectin type III modules of beta(4), a region required for signaling and hemidesmosome formation, Sequence analysis of p27(BBP) revealed that p27(BBP) was not previously known and has no homology with any isolated mammalian protein, bat 85% identical to a yeast gene product of unknown function, Expression studies by Northern analysis and in situ hybridization showed that, in vivo, p27(BBP) mRNA is highly expressed in epithelia and proliferating embryonic epithelial cells, An antibody raised against p27(BBP) COOH-terminal domain showed that all beta(4)-containing epithelial cell lines expressed p27(BBP). The p27(BBP) protein is insoluble and present in the intermediate filament pool, Furthermore, subcellular fractionation indicated the presence of p27(BBP) both in the cytoplasm and in the nucleus, Confocal analysis of cultured cells showed that part of p27(BBP) immunoreactivity was both nuclear and in the membrane closely apposed to beta(4). These results suggest that the p27(BBP) is an in vivo interactor of beta(4), possibly linking beta(4) to the intermediate filament cytoskeleton.	UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; SAN RAFFAELE SCI INST,DEPT PATHOL,I-20132 MILAN,ITALY	University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Biffo, S (corresponding author), SAN RAFFAELE SCI INST,DEPT BIOL & TECHNOL RES,DIBIT,VIA OLGETTINA 58,I-20132 MILAN,ITALY.		Spinardi, Laura/I-6925-2015	Spinardi, Laura/0000-0002-4619-853X; biffo, stefano/0000-0002-3780-1050	Telethon [762, 826] Funding Source: Medline	Telethon(Fondazione Telethon)		BROCCOLI D, 1991, GENOMICS, V10, P68, DOI 10.1016/0888-7543(91)90485-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; DECHANT G, 1993, DEVELOPMENT, V119, P545; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Giancotti FG, 1996, J CELL SCI, V109, P1165; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KOZAK M, 1982, J MOL BIOL, V156, P807, DOI 10.1016/0022-2836(82)90143-7; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; NATALI PG, 1992, J CELL SCI, V103, P1243; NICKERSON JA, 1990, P NATL ACAD SCI USA, V87, P2259, DOI 10.1073/pnas.87.6.2259; Niessen CM, 1996, J CELL SCI, V109, P1695; Niessen CM, 1997, MOL BIOL CELL, V8, P555, DOI 10.1091/mbc.8.4.555; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Penman J, 1997, P NATL ACAD SCI USA, V94, P3732, DOI 10.1073/pnas.94.8.3732; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; Sambrook J., 1989, MOL CLONING LAB MANU, V2, P32; SONNENBERG A, 1990, J CELL SCI, V96, P207; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SWAFFIELD J, 1995, CURRENT PROTOCOLS MO; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	41	83	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30314	30321		10.1074/jbc.272.48.30314	http://dx.doi.org/10.1074/jbc.272.48.30314			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374518	hybrid			2022-12-25	WOS:A1997YH61300050
J	Khurana, S; Arpin, M; Patterson, R; Donowitz, M				Khurana, S; Arpin, M; Patterson, R; Donowitz, M			Ileal microvillar protein villin is tyrosine-phosphorylated and associates with PLC-gamma(1) - Role of cytoskeletal rearrangement in the carbachol-induced inhibition of ileal NaCl absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-ABSORBING CELLS; BRUSH-BORDER; F-ACTIN; DEPENDENT MANNER; EPITHELIAL-CELLS; FILAMENTS; GELSOLIN; TRANSLOCATION; MEMBRANE; BINDING	In ileal absorptive cells, carbachol inhibits NaCl absorption and its component brush border Na+/H+ exchanger, acting via basolateral membrane receptors, This carbachol effect involves (i) activation of brush border phosphatidylinositol 4,5-bisphosphate-specific phospholipase C (PLC) activity and brush border but not basolateral membrane translocation of PLC-gamma(1) (Khurana, S., Kreydiyyeh, S., Aronzon, A., Hoogerwerf, W. A., Rhee, S. G., Donowitz, M., and Cohen, M. E. (1996) Biochem, J. 313, 509-518); and (ii) brush border tyrosine kinase(s) because mucosal but not serosal addition of the tyrosine kinase inhibitor genistein prevents the carbachol-induced inhibition of NaCl absorption and brush border Na+/H+ exchange, In the present work we identify a pool of villin (a brush border actin-binding protein) in the microvillus membrane fraction of rabbit ileum; this pool of villin is tyrosine-phosphorylated and associates with brush border membrane PLC-gamma(1), Villin is present both in the Triton X-100-soluble and -insoluble fractions of the brush border, The Triton X-100-soluble pool is approximately 4-fold smaller than the brush border pool of villin that is present in the Triton X-100- insoluble fraction, Only the villin present in the Triton X-100-soluble fraction of ileal villus brush border associates with PLC-gamma(1), and is tyrosine phosphorylated. Carbachol increases the tyrosine phosphorylation of villin rapidly (as early as 30 s) and transiently, Carbachol also increases the amount of tyrosine-phosphorylated villin that associates with PLC-gamma(1), These studies demonstrate that carbachol effects on NaCl absorption are accompanied by an increase in brush border PLC-gamma(1), association with villin and an increase in tyrosine phosphorylation of villin, To study the role of cytoskeletal rearrangement in carbachol-induced inhibition of NaCl absorption, we used the F-actin stabilizing drug jasplakinolide. Jasplakinolide prevents the carbachol inhibition of ileal Nacl absorption, This suggests that F-actin severing is necessary for carbachol to inhibit ileal villus NaCl absorption, Since villin is known to sever actin, these studies suggest a role for villin in the signaling cascade that begins at the basolateral membrane with carbachol binding to its receptor and ends at the apical membrane in inhibition of NaCl absorption.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; INST CURIE,F-75231 PARIS,FRANCE	Johns Hopkins University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Khurana, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,ROSS 925,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.			Khurana, Seema/0000-0002-6884-810X	NATIONAL CANCER INSTITUTE [R01CA047135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523, P01DK044484] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47135] Funding Source: Medline; NIDDK NIH HHS [P01 DK 44484, R01 DK 26523] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BOOTH AG, 1976, J CELL SCI, V21, P449; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GOLIGORSKY MS, 1986, J MEMBRANE BIOL, V92, P151, DOI 10.1007/BF01870704; HIRST BH, 1985, BIOCHEM J, V231, P641, DOI 10.1042/bj2310641; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; HOWE CL, 1980, J CELL BIOL, V85, P916, DOI 10.1083/jcb.85.3.916; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; Itoh T, 1996, J BIOL CHEM, V271, P27931, DOI 10.1074/jbc.271.44.27931; JAISER F, 1996, 29 ANN M AM SOC NEPH, P1310; Janecki A, 1997, FASEB J, V11, P2971; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; KLUMPERMAN J, 1991, EUR J CELL BIOL, V54, P76; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P648, DOI 10.1083/jcb.92.3.648; Matthews JB, 1997, AM J PHYSIOL-CELL PH, V272, pC254, DOI 10.1152/ajpcell.1997.272.1.C254; MOOSEKER MS, 1980, J CELL BIOL, V87, P809, DOI 10.1083/jcb.87.3.809; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Tanford C., 1973, HYDROPHOBIC EFFECT; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	30	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30115	30121		10.1074/jbc.272.48.30115	http://dx.doi.org/10.1074/jbc.272.48.30115			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374490	hybrid			2022-12-25	WOS:A1997YH61300022
J	Antoine, M; Reimers, K; Dickson, C; Kiefer, P				Antoine, M; Reimers, K; Dickson, C; Kiefer, P			Fibroblast growth factor 3, a protein with dual subcellular localization, is targeted to the nucleus and nucleolus by the concerted action of two nuclear localization signals and a nucleolar retention signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT; FACTOR FAMILY; TRANSLOCATION SEQUENCE; MITOGENIC ACTIVITY; ONCOGENE INT-2; MULTIPLE ROLES; XENOPUS-LAEVIS; MESSENGER-RNA; EXPRESSION; RECEPTOR	The major isoform of fibroblast growth factor 3 (FGF3) is initiated from a CUG codon, and the resultant product is distributed to the nucleus/nucleolus and secretory pathway. This dual subcellular localization is achieved in part by the competing effects of two classical intracellular targeting signals located near the amino terminus, At the extreme amino terminus is a short stretch of 29 amino acids before a signal peptide necessary for translocation into the endoplasmic reticulum, which is next to an adjacent bipartite nuclear localization signal. The carboxyl-terminal region of FGF3 is also implicated in nuclear/nucleolar localization. We describe here the characterization of carboxyl-terminal signals by showing they are capable of directing a heterologous protein, beta-galactosidase, to the nucleus. Furthermore, appending both the amino-and carboxyl terminal domains onto beta-galactosidase, reproduces the dual subcellular localization properties of FGF3. Nuclear uptake of FGF3 appears to be signal-mediated since it binds to karyopherin alpha, the nuclear localization signal binding subunit of a heterodimeric receptor of the nuclear import machinery. The import of FGF3 into the nucleus is energy-dependent, and the inhibition of this process has demonstrated the importance of the nucleolar retention signal in nucleoplasmic and nucleolar accumulation.	RUHR UNIV BOCHUM,FAK MED,INST HYG & MIKROBIOL,ABT MED MIKROBIOL VIROL,D-44780 BOCHUM,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Ruhr University Bochum; Cancer Research UK								ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FALKNER FG, 1988, VIROLOGY, V164, P450, DOI 10.1016/0042-6822(88)90559-4; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kiefer P, 1996, GENE, V168, P211, DOI 10.1016/0378-1119(95)00736-9; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; ORNITZ DM, 1992, JNCI-J NATL CANCER I, V84, P887, DOI 10.1093/jnci/84.11.887; PETERS G, 1991, SEMIN VIROL, V2, P319; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	52	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29475	29481		10.1074/jbc.272.47.29475	http://dx.doi.org/10.1074/jbc.272.47.29475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368007	hybrid			2022-12-25	WOS:A1997YG64700017
J	Kim, JS; Pabo, CO				Kim, JS; Pabo, CO			Transcriptional repression by zinc finger peptides - Exploring the potential for applications in gene therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; CRYSTAL-STRUCTURE; SELECTION; SEQUENCE; PROTEIN; COMPLEX; RECOGNITION; UPSTREAM; ELEMENT; DOMAINS	A series of studies were performed to determine whether zinc finger peptides could efficiently repress transcription from RNA polymerase Il promoters in vivo and to determine how such repression might depend on the position of the zinc finger binding site with respect to those of the TATA box or the initiator element. Promoter constructs were prepared with Zif268 binding sites inserted at various positions, and the activity of a reporter gene was measured in transfection studies. We found that the peptide containing the three zinc fingers of Zif268 could efficiently repress activated transcription when bound to a site near the TATA box (19-fold repression) or when bound to a site near the initiator element (18-fold repression). Repression was even more effective when the zinc finger peptide was bound to both of these sites (63-fold repression). Novel zinc finger peptides that had been selected via phage display also served as repressors of activated transcription, but repression with these proteins was somewhat less efficient than with the Zif268 peptide.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			KIM, Jin-Soo/M-6918-2013	KIM, Jin-Soo/0000-0003-4847-1306				Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kim JS, 1997, P NATL ACAD SCI USA, V94, P3616, DOI 10.1073/pnas.94.8.3616; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MCBRYANT SJ, 1995, J MOL BIOL, V250, P315, DOI 10.1006/jmbi.1995.0379; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344	28	48	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29795	29800		10.1074/jbc.272.47.29795	http://dx.doi.org/10.1074/jbc.272.47.29795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368051	hybrid			2022-12-25	WOS:A1997YG64700061
J	Craddock, BL; Welham, MJ				Craddock, BL; Welham, MJ			Interleukin-3 induces association of the protein-tyrosine phosphatase SHP2 and phosphatidylinositol 3-kinase with a 100-kDa tyrosine-phosphorylated protein in hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; INSULIN-RECEPTOR SUBSTRATE-1; SRC HOMOLOGY-2 DOMAINS; STEEL FACTOR; P85 SUBUNIT; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; FAMILY MEMBERS	We have observed previously the co-immunoprecipitation of the p85 subunit of phosphatidylinositol-3 kinase (PI3K) and SHP2 in murine lymphohemopoietic cells after stimulation with interleukin-3. We have investigated this interaction in more detail and now report the identification of a potentially novel 100-kDa protein (termed p100), which is inducibly phosphorylated on tyrosine after interleukin-3 treatment and which co-immunoprecipitates with both p85 PI3K and SHP2. The Src homology region 2 domains of both p85 and SHP2 appear to mediate their interactions with p100. Sequential precipitation analyses suggest that these interactions are direct and do not involve Grb2, and that the same p100 protein, or a portion of it, interacts with both p85 and SHP2, implying that p100 may serve to link these two proteins. Far Western blotting with both full-length p85 and isolated p85 Src homology region 2 domains supports this view, Interestingly, p100 also appears to be a substrate for the SHP2 phosphatase activity. In addition, p100 is precipitated by Grb2-glutathione S-transferase fusion proteins, an interaction largely mediated by the Grb2 SH3 domains, p100 appears to be distinct from JAK2, Vav, STATE, and c-Cbl, Although largely cytosolic, p100 can be detected associated with SHP2 and PI3K in crude membrane fractions after interleukin-3 stimulation. We propose that p100 plays a role as an adaptor molecule, linking PI3K and SHP2 in IL-3 signaling.	UNIV BATH, DEPT PHARM & PHARMACOL, PHARMACOL GRP, BATH BA2 7AY, AVON, ENGLAND	University of Bath								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; DURONIO V, 1992, EXP HEMATOL, V20, P505; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liu L, 1997, J BIOL CHEM, V272, P10998; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; OKUDA K, 1992, BLOOD, V79, P2880; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TOKER A, 1994, J BIOL CHEM, V269, P32358; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	76	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29281	29289		10.1074/jbc.272.46.29281	http://dx.doi.org/10.1074/jbc.272.46.29281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361008	hybrid			2022-12-25	WOS:A1997YF68400067
J	Lu, DS; Boyd, B; Lingwood, CA				Lu, DS; Boyd, B; Lingwood, CA			Identification of the key protein for zinc uptake in Hemophilus influenzae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PARASANGUIS; HAEMOPHILUS-INFLUENZAE; GENE ENCODES; TRANSPORT; BACTERIA; PURIFICATION; VIRULENCE; SYSTEMS; ADHESIN; YEAST	Very little is known about specific mechanisms for zinc accumulation and transport in bacteria, In this study a putative adhesin B in Hemophilus influenzae, the product of gene HI0119, has been identified as a periplasmic zinc-binding protein (PZP1), A pzp1-deficient mutant has been constructed which is defective for growth under aerobic conditions and grows poorly under anaerobic conditions, The growth defect is specifically rescued by supplementing the growth medium with high concentrations of zinc. Subcellular fractionation was used to localize PZP1 to the periplasmic region in a nontypeable H, influenzae strain and in a transfected recombinant Escherichia coli strain (TApzp1). Recombinant PZP1, purified from a periplasmic extract off. coli strain TApzp1, contained similar to two zinc atoms/protein molecule as determined by neutron activation analysis and atomic absorption spectroscopy, The zinc atoms could be removed by incubation with EDTA, and, by further addition of zinc, a total of five zinc atoms/PZP1 could be bound. Direct binding of Zn-65 to the recombinant protein by Western blot was demonstrated, Taken together, these results provide direct evidence that PZP1 plays a key role in zinc uptake by H, influenzae.	UNIV TORONTO, HOSP SICK CHILDREN, DIV MICROBIOL, RES INST, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MED GENET & MICROBIOL BIOCHEM, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT LAB MED & PATHOBIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Lu, desheng/E-4822-2013	Lu, desheng/0000-0002-3616-6657; Lu, Desheng/0000-0002-0314-5649				AMES GFL, 1994, METHOD ENZYMOL, V235, P234; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Berry AM, 1996, INFECT IMMUN, V64, P5255, DOI 10.1128/IAI.64.12.5255-5262.1996; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCHEDER F, 1974, EUR J BIOCHEM, V45, P555, DOI 10.1111/j.1432-1033.1974.tb03581.x; BURNETTECURLEY D, 1995, INFECT IMMUN, V63, P4669, DOI 10.1128/IAI.63.12.4669-4674.1995; CHIPLEY JR, 1972, CAN J MICROBIOL, V84, P297; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; FAILLA ML, 1977, ZINC FUNCTIONS TRANS, P151; FENNO JC, 1995, MOL MICROBIOL, V15, P849, DOI 10.1111/j.1365-2958.1995.tb02355.x; FENNO JC, 1989, INFECT IMMUN, V57, P3527, DOI 10.1128/IAI.57.11.3527-3533.1989; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HUGHES MN, 1989, METALS MICROORGANISM, P120; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KY, 1971, MICROBIOS, V3, P215; MOXON ER, 1989, HAEMOPHILUS INFLUENZ, P1722; OLIGINO L, 1993, INFECT IMMUN, V61, P1016, DOI 10.1128/IAI.61.3.1016-1022.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4191; SCHMIEDESKAMP M, 1994, CURR OPIN STRUC BIOL, V4, P28, DOI 10.1016/S0959-440X(94)90056-6; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SWANCUTT MA, 1989, INFECT IMMUN, V57, P3314, DOI 10.1128/IAI.57.11.3314-3323.1989; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURK DC, 1985, J MED MICROBIOL, V18, P1; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WEBB M, 1970, BIOCHIM BIOPHYS ACTA, V222, P428, DOI 10.1016/0304-4165(70)90133-9; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454; [No title captured]	31	49	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29033	29038		10.1074/jbc.272.46.29033	http://dx.doi.org/10.1074/jbc.272.46.29033			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360976	hybrid			2022-12-25	WOS:A1997YF68400035
J	Tilton, B; Andjelkovic, M; Didichenko, SA; Hemmings, BA; Thelen, M				Tilton, B; Andjelkovic, M; Didichenko, SA; Hemmings, BA; Thelen, M			G-protein-coupled receptors and Fc gamma-receptors mediate activation of Akt protein kinase B in human phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL LEUKOCYTES; MYELOID-DERIVED CELLS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; RESPIRATORY BURST; GRO-ALPHA; INTERLEUKIN-8 RECEPTORS; BETA-GAMMA; CHEMOTACTIC CYTOKINES	Activation of the serine/threonine kinase Akt, also called protein kinase B (PRE), was investigated in human neutrophils. Stimulation of the cells with the chemoattractant fMet-Leu-Phe or the chemokines IL-8 and GRO alpha leads to the rapid and transient activation of PKB. Maximum PKB activation correlates with the well documented kinetics of respiratory burst and exocytosis. Wortmannin, a selective inhibitor of phosphoinositide 3-kinases (PI 3-kinases) in neutrophils; abrogates PKB activation. Similarly homo and heterotypic crosslinking of Fc gamma IIA and Fc gamma IIIB causes a transient activation of PKB that is sensitive to wortmannin treatment. Kinase activity measurements in immunoprecipitates from lysates of the myelocytic GM-1 cells or GM-1/CXCR1 cells, which are transfected with the IL-8 receptor 1, confirmed the transient activation of PKB observed in neutrophils. Stimulation of human monocytes with the CC chemokine RANTES (regulated on activation normal T cell expressed and secreted) also results in the activation of PKB. Preincubation of monocytes and neutrophils with Bordetella pertussis toxin inhibits fMet-Leu-Phe and RANTES-stimulated PKB activation, demonstrating that coupling of the receptors to heterotrimeric Gi-protein is required. The data show, that activation of PKB by G(i)-protein-coupled receptors is mediated by PI 3-kinase and suggest that PRE is a constituent of neutrophil activating pathways.	UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN 9,SWITZERLAND; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Bern; Friedrich Miescher Institute for Biomedical Research								Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini Marco, 1992, News in Physiological Sciences, V7, P215; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHAUDHRY A, 1994, CELL SIGNAL, V6, P457, DOI 10.1016/0898-6568(94)90093-0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Dewald B, 1986, Methods Enzymol, V132, P267; DEWALD B, 1988, J BIOL CHEM, V263, P16179; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; EDBERG JC, 1992, IMMUNOL RES, V11, P239, DOI 10.1007/BF02919130; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; GAROTTA G, 1991, J LEUKOCYTE BIOL, V49, P294, DOI 10.1002/jlb.49.3.294; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LIN CT, 1994, J CLIN IMMUNOL, V14, P1, DOI 10.1007/BF01541170; LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; Moser B, 1997, TRENDS MICROBIOL, V5, P88, DOI 10.1016/S0966-842X(97)01019-6; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; Popik W, 1996, MOL CELL BIOL, V16, P6532; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SALMON JE, 1991, J IMMUNOL, V146, P997; Santana C, 1996, J LEUKOCYTE BIOL, V60, P433, DOI 10.1002/jlb.60.4.433; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Trotta R, 1996, J EXP MED, V184, P1027, DOI 10.1084/jem.184.3.1027; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; WYMANN MP, 1987, J BIOL CHEM, V262, P12048; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553	70	131	132	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28096	28101		10.1074/jbc.272.44.28096	http://dx.doi.org/10.1074/jbc.272.44.28096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346964	hybrid			2022-12-25	WOS:A1997YD47300090
J	Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C				Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C			Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours	ONCOGENE			English	Article						TSG101; FHIT; splicing; tumour	BREAKPOINT; CANCER; 3P14.2; CELLS	Intragenic deletions of TSG101, the human homolog of a mouse gene (tsg101) that acts to suppress malignant cell growth, were reported in human breast tumours, We screened TSG101 for somatic mutations in DNA and RNA samples isolated from a variety of common human malignancies, EBV-immortalised B-cells, and normal lung parenchyma, Intragenic TSG101 deletions in RNA transcripts were frequently found in all types of samples, Analysis of DNA failed to show genomic rearrangements corresponding to transcripts containing deletions in the same samples, The breakpoints of most transcript deletions coincide with genuine or cryptic splice site sequences, suggesting that they result from alternative or aberrant splicing, A similar spectrum of transcript deletions has previously been described in the putative tumour suppressor gene FHIT. We analysed FHIT in the same series of RNA samples and detected truncated FHIT transcripts frequently in both tumour and normal tissues, In addition, transcripts from TSG101, FHIT and seven other genes were analysed in RNA isolated from normal peripheral blood lymphocytes, Large TSC101 and FHIT intragenic transcript deletions were detected and these appeared to be the predominant transcript in 'aged' lymphocytes. Similar alterations were not detected in transcripts of the other genes which were analysed, Our findings demonstrate that truncated TSG101 and FHIT transcripts are commonly detected in both normal and malignant tissues and that a significant fraction of these are likely to be the result of aberrant splicing, While we cannot exclude that alterations in TSG101 and FHIT occur during cancer development, our data indicate that in this context the commonly observed transcript abnormalities are misleading.	ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,ACAD DEPT ONCOL,CRC,CAMBRIDGE CB2 2QQ,ENGLAND; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Stanford University; Stanford University			Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; BARSKI, PIOTR/0000-0002-2002-6748				Druck T, 1997, CANCER RES, V57, P504; Flaman JM, 1996, ONCOGENE, V12, P813; Fong KM, 1997, CANCER RES, V57, P2256; Foster KA, 1996, CANCER RES, V56, P3622; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Hayashi S, 1997, CANCER RES, V57, P1981; Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lochner K, 1996, CANCER RES, V56, P2171; Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164; Nam DK, 1996, GENE, V178, P169, DOI 10.1016/0378-1119(96)00364-2; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770	17	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2119	2126		10.1038/sj.onc.1201591	http://dx.doi.org/10.1038/sj.onc.1201591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366528				2022-12-25	WOS:A1997YC28400012
J	Hande, MP; Balajee, AS; Natarajan, AT				Hande, MP; Balajee, AS; Natarajan, AT			Induction of telomerase activity by UV-irradiation in Chinese hamster cells	ONCOGENE			English	Article						telomeres; telomerase; UV radiation; hamster cells	HUMAN-CHROMOSOMES; CANCER; ACQUISITION; ASSOCIATION; ACTIVATION; SEQUENCES; (TTAGGG)N; TISSUES; REPEATS; ENZYME	Telomerase is a ribonucleoprotein whose activity has been detected in germline cells and in neoplastic and immortal cells. Telomerase compensates the telomere loss arising by the end replication problem by synthesizing telomeric repeats at the 3' end of the eukaryotic chromosomes, Telomerase is reactivated during cancer progression in human and mice. In order to determine whether the telomerase activity can be upregulated in vitro in response to DNA damaging agents, we examined the telomerase activity in five Chinese hamster cell lines following exposure to 5 J/m(2) or 40 J/m(2) UV-C radiation, All the cell lines tested showed an increase in telomerase activity in the PCR-based telomeric repeat amplification protocol (TRAP) in a dose dependent manner, This increase in telomerase activity correlated well with the number of cells being in the S and G(2)/M phase after UV exposure, However, in unirradiated control cells, similar levels of telomerase activity were observed in different phases of the cell cycle, Furthermore, telomeric signals were clustered in one or more parts of the disintegrating nuclear particles of the apoptotic cell as detected by fluorescence in situ hybridization (FISH), This is the first study to demonstrate the induction of telomerase activity following exposure to DNA-damaging agents like UV radiation in Chinese hamster cells in vitro.	LEIDEN STATE UNIV,DEPT RADIAT GENET & CHEM MUTAGENESIS,MGC,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Hande, M. Prakash/B-1645-2008	Hande, M. Prakash/0000-0002-4511-6256				ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, SEMIN CELL DEV BIOL, V7, P31, DOI 10.1006/scdb.1996.0006; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARNETT MA, 1993, NUCLEIC ACIDS RES, V21, P27, DOI 10.1093/nar/21.1.27; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHADENEAU C, 1995, ONCOGENE, V11, P893; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; Duchaud E, 1996, CANCER RES, V56, P1400; FLINT J, 1994, AM J HUM GENET, V55, P505; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IJDO JW, 1991, NUCLEIC ACIDS RES, V19, P4780, DOI 10.1093/nar/19.17.4780; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, NAT GENET, V9, P104, DOI 10.1038/ng0295-104; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MURNANE JP, 1993, MOL CELL BIOL, V13, P977, DOI 10.1128/MCB.13.2.977; OH HJ, 1997, UNPUB BR J CANC; Pandita TK, 1996, ONCOGENE, V13, P1423; SABATIER L, 1995, RADIAT ENVIRON BIOPH, V34, P229, DOI 10.1007/BF01209747; Slijepcevic P, 1996, CHROMOSOMA, V104, P596, DOI 10.1007/s004120050152; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Ueda M, 1997, CANCER RES, V57, P370; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wright WE, 1996, DEV GENET, V18, P173; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	34	41	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1747	1752		10.1038/sj.onc.1201327	http://dx.doi.org/10.1038/sj.onc.1201327			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349510				2022-12-25	WOS:A1997XY63100016
J	Gremlich, S; Bonny, C; Waeber, G; Thorens, B				Gremlich, S; Bonny, C; Waeber, G; Thorens, B			Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE ACTIVITY; DEPENDENT DIABETES-MELLITUS; LONG-TERM EXPOSURE; HOMEOBOX FACTOR; FACTOR STF-1; BETA-CELLS; GENE; HOMEODOMAIN; TRANSCRIPTION; ACTIVATION	IDX-1 (islet/duodenum homeobox-1) is a transcription factor expressed in the duodenum and pancreatic beta and delta cells, It is required for embryonic development of the pancreas and transactivates the Glut2, glucokinase, insulin, and somatostatin genes, Here we show that exposure of isolated rat pancreatic islets to palmitic acid induced a similar to 70% decrease in IDX-1 mRNA and protein expression as well as 40 and 65% decreases in the binding activity of IDX-1 for its cognate cis-regulatory elements of the Glut2 and insulin promoters, respectively, The inhibitory effect of palmitic acid required its mitochondrial oxidation since it was prevented by the carnitine palmitoyltransferase I inhibitor bromopalmitic acid, The palmitic acid effect on IDX-1 was correlated with decreases in GLUT2 and glucokinase expression of 40 and 25%, respectively, at both the mRNA and protein levels, Insulin and somatostatin mRNA expression was also decreased by 40 and 60%, whereas glucagon mRNA expression was not modified, After 48 h of exposure to fatty acids, total islet insulin, somatostatin, and glucagon contents were decreased by 85, 55, and 65%, respectively, At the same time, total hormone release was strongly stimulated (13-fold) for glucagon, whereas its was only marginally increased for insulin and somatostatin (1.5- and 1.7-fold, respectively), These results indicate that elevated fatty acid levels 1) negatively regulate Idx-1 expression; 2) decrease the expression of genes transactivated by IDX-1 such as those for GLUT2, glucokinase, insulin, and somatostatin; and 3) lead to an important increase in glucagon synthesis and secretion, Fatty acids thus have pleiotropic effects on pancreatic islet gene expression, and the negative control of Idx-1 expression may be an initial event in the development of these multiple defects.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; UNIV LAUSANNE HOSP,DEPT INTERNAL MED B,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)				Waeber, Gerard/0000-0003-4193-788X				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Larsson O, 1996, J BIOL CHEM, V271, P10623, DOI 10.1074/jbc.271.18.10623; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Lu M, 1996, ENDOCRINOLOGY, V137, P2959, DOI 10.1210/en.137.7.2959; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; ORRIELD MF, 1996, DEVELOPMENT CAMB, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; SAMOLS E, 1991, ENDOCRINE PANCREAS, P93; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	43	202	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30261	30269		10.1074/jbc.272.48.30261	http://dx.doi.org/10.1074/jbc.272.48.30261			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374511	hybrid			2022-12-25	WOS:A1997YH61300043
J	Morales, A; GarciaRuiz, C; Miranda, M; Mari, M; Colell, A; Ardite, E; FernandezCheca, JC				Morales, A; GarciaRuiz, C; Miranda, M; Mari, M; Colell, A; Ardite, E; FernandezCheca, JC			Tumor necrosis factor increases hepatocellular glutathione by transcriptional regulation of the heavy subunit chain of gamma-glutamylcysteine synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MANGANOUS SUPEROXIDE-DISMUTASE; ACTIVATOR INHIBITOR TYPE-2; ALPHA-INDUCED APOPTOSIS; REDUCED GLUTATHIONE; FACTOR CYTOTOXICITY; OXIDATIVE STRESS; CELL-DEATH; TNF; INDUCTION	Tumor necrosis factor (TNF) is an inflammatory cytokine that causes cell injury by generation of oxidative stress, Since glutathione (GSH) is a key cellular antioxidant that detoxifies reactive oxygen species, the purpose of our work was to examine the regulation of cellular GSH, the expression of heavy subunit chain of gamma-glutamylcysteine synthetase (gamma-GCS-HS), and control of intracellular generation of reactive oxygen species in cultured rat hepatocytes treated with TNF. Exposure of cells to TNF (10,000 units/ml) resulted in depletion of cellular GSH levels (50-70%) and overproduction of hydrogen peroxide (2-3-fold) and lipid peroxidation, However, cells treated with lower doses of TNF (250-500 units/ml) exhibited increased levels of GSH (60-80% over control). TNF treatment increased (70-100%) the levels of gamma-GCS-HS mRNA, the catalytic subunit of the regulating enzyme in GSH biosynthesis. Furthermore, intact nuclei isolated from hepatocytes treated with TNF transcribed the gamma-GCS-HS gene to a greater extent than control cells, indicating that TNF regulates gamma-GCS-HS at the transcriptional level. The capacity to synthesize GSH de novo determined in cell-free extracts incubated with GSH precursors was greater (50-70%) in hepatocytes that were treated with TNF; however, the activity of GSH synthetase remained unaltered by TNF treatment indicating that TNF selectively increased the activity of gamma-GCS. Despite activation of nuclear factor-kappa B (NF-kappa B) by TNF, this transcription factor was not required for TNF-induced transcription of gamma-GCS-HS as revealed by deletion constructs of the gamma-GCS-HS promoter subcloned in a chloramphenicol acetyltransferase reporter vector and transfected into HepG2 cells, In contrast, a construct containing AP-1 like/metal response regulatory elements increased chloramphenicol acetyltransferase activity upon exposure to TNF. Thus, TNF increases hepatocellular GSH levels by transcriptional regulation of gamma-GCS-HS gene, probably through AP-1/metal response element-like binding site(s) in its promoter, which may constitute a protective mechanism in the control of oxidative stress induced by inflammatory cytokines.	UNIV BARCELONA,HOSP CLIN & PROV,CSIC,LIVER UNIT,INST INVEST BIOMED,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN & PROV,DEPT MED,SERV BIOQUIM,E-08036 BARCELONA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona			Mari, Montserrat/A-7376-2013; miranda, merce/H-7467-2017; MARI, MONTSERRAT/M-2871-2019; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013; Colell, Anna/N-8710-2014	Mari, Montserrat/0000-0002-6116-3247; miranda, merce/0000-0001-6214-1042; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269; Colell, Anna/0000-0001-5236-1834	NIAAA NIH HHS [AA09526] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009526] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRACH MA, 1993, MOL CELL BIOL, V13, P4824; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG787; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FEINGOLD KR, 1988, BIOCHEM BIOPH RES CO, V153, P576, DOI 10.1016/S0006-291X(88)81134-3; FernandezCheca JC, 1996, SEMIN LIVER DIS, V16, P147, DOI 10.1055/s-2007-1007228; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Hack V, 1996, FASEB J, V10, P1219, DOI 10.1096/fasebj.10.10.8751725; HILL DB, 1995, HEPATOLOGY, V21, P1114, DOI 10.1002/hep.1840210434; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KUMAR S, 1991, J BIOL CHEM, V266, P20960; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MING SM, 1994, J BIOL CHEM, V269, P26512; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Rahman I, 1996, FEBS LETT, V396, P21, DOI 10.1016/0014-5793(96)01027-7; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; STRUMEYER D, 1962, BIOCHEM PREP, V9, P52; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WALLACH D, 1984, J IMMUNOL, V132, P2464; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAN N, 1990, J BIOL CHEM, V265, P1588; YAO KS, 1995, BIOCHEM PHARMACOL, V49, P275, DOI 10.1016/0006-2952(94)00544-V; YAO KS, 1995, CANCER RES, V55, P4367; ZIMMERMAN RJ, 1989, J IMMUNOL, V142, P1405	53	126	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30371	30379		10.1074/jbc.272.48.30371	http://dx.doi.org/10.1074/jbc.272.48.30371			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374527	hybrid			2022-12-25	WOS:A1997YH61300059
J	Barkett, M; Xue, D; Horvitz, HR; Gilmore, TD				Barkett, M; Xue, D; Horvitz, HR; Gilmore, TD			Phosphorylation of I kappa B-alpha inhibits its cleavage by caspase CPP32 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN SPLEEN-CELLS; V-REL ONCOGENE; INDUCED APOPTOSIS; PROTEOLYSIS; ACTIVATION; DEATH; TRANSFORMATION	I kappa B proteins function as direct regulators of Rel/NF-kappa B transcription complexes. We show that the cell-death protease CPP32 (caspase-3) in vitro specifically cleaved chicken and human I kappa B-alpha at a conserved Asp-Ser sequence. This cleavage site appears to be identical to the site at which chicken I kappa B-alpha is cleaved in vivo in temperature-sensitive v-Rel-transfarmed chicken spleen cells undergoing apoptosis. Other caspases, namely interleukin-1 beta-converting enzyme (caspase-1) and Ich-1 (caspase-2), did not cleave I kappa B-alpha. CPP32 also cleaved mammalian I kappa B-beta in vitro at the analogous Asp-Ser sequence. Cleavage of I kappa B-alpha by CPP32 was blocked by serine phosphorylation of I kappa B-alpha. Cleavage of I kappa B-alpha by a CPP32-like protease could generate a constitutive inhibitor of Rel transcription complexes. This report provides evidence for a direct biochemical interaction between the NF-kappa B signaling pathway and a cell-death protease signaling pathway.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215; MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Boston University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				XUE, DING/0000-0002-8429-8136	NCI NIH HHS [CA47763] Funding Source: Medline; NCRR NIH HHS [RR11397] Funding Source: Medline; NIGMS NIH HHS [GM08291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Rodriguez MS, 1996, ONCOGENE, V12, P2425; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073	23	145	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29419	29422		10.1074/jbc.272.47.29419	http://dx.doi.org/10.1074/jbc.272.47.29419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9367996	hybrid			2022-12-25	WOS:A1997YG64700006
J	Fire, E; Brown, CM; Roth, MG; Henis, YI; Petersen, NO				Fire, E; Brown, CM; Roth, MG; Henis, YI; Petersen, NO			Partitioning of proteins into plasma membrane microdomains - Clustering of mutant influenza virus hemagglutinins into coated pits depends on the strength of the internalization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; FLUORESCENCE CORRELATION SPECTROSCOPY; LYSOSOMAL ACID-PHOSPHATASE; TYROSINE KINASE-ACTIVITY; LOW-DENSITY-LIPOPROTEIN; DI-LEUCINE MOTIF; CYTOPLASMIC DOMAIN; MDCK CELLS; IN-VITRO	Internalization of membrane proteins involves their recruitment into plasma membrane clathrin-coated pits, with which they are thought to interact by binding to AP-2 adaptor protein complexes, To investigate the interactions of membrane proteins with coated pits at the cell surface, we applied image correlation spectroscopy to measure directly and quantitatively the clustering of influenza hemagglutinin (HA) protein mutants carrying specific cytoplasmic internalization signals. The HA system enables direct comparison between isolated internalization signals, because HA itself is excluded from coated pits, The studies presented here provide, for the first time, a direct quantitative measure for the degree of clustering of membrane proteins in coated pits at the cell surface, The degree of clustering depended on the strength of the internalization signal and on the integrity of the clathrin lattices and correlated with the internalization rates of the mutants, The clustering of the HA mutants fully correlated with their ability to co-precipitate alpha-adaptin from whole cells, the first such demonstration for a membrane protein that is not a member of the epidermal growth factor receptor family. Furthermore, both the clustering in coated pits and the co-precipitation with alpha-adaptin were dramatically reduced in the cold, suggesting that low temperature can interfere with the sorting of proteins into coated pits. In addition to the specific results reported here, the general applicability of the image correlation spectroscopy approach to study any process involving the clustering or oligomerization of membrane receptors at the cell surface is discussed.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT NEUROBIOCHEM, IL-69978 TEL AVIV, ISRAEL; UNIV WESTERN ONTARIO, DEPT CHEM, LONDON, ON N6A 5B7, CANADA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Tel Aviv University; Western University (University of Western Ontario); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Brown, Claire/B-1498-2008	Brown, Claire/0000-0003-1622-663X; Roth, Michael/0000-0002-9056-332X; Henis, Yoav/0000-0002-1408-3877	NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1977, NATURE, V270, P695, DOI 10.1038/270695a0; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CROW EL, 1960, STATISTICS MANUAL, P60; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EHRENBERG M, 1976, Q REV BIOPHYS, V9, P69, DOI 10.1017/S003358350000216X; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; ELSON EL, 1974, BIOPOLYMERS, V13, P1, DOI 10.1002/bip.1974.360130102; FIRE E, 1995, J BIOL CHEM, V270, P21075, DOI 10.1074/jbc.270.36.21075; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HENIS YI, 1985, EXP CELL RES, V160, P514, DOI 10.1016/0014-4827(85)90198-3; HENIS YI, 1993, BIOMEMBRANES PHYSICA, V1, P279; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; JACOBSON K, 1987, ANNU REV PHYSIOL, V49, P163, DOI 10.1146/annurev.ph.49.030187.001115; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PETERSEN NO, 1986, BIOPHYS J, V49, P809, DOI 10.1016/S0006-3495(86)83709-2; PETERSEN NO, 1993, BIOPHYS J, V65, P1135, DOI 10.1016/S0006-3495(93)81173-1; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Schmid SL, 1993, CURR OPIN CELL BIOL, V5, P621, DOI 10.1016/0955-0674(93)90131-9; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SOSA MA, 1993, J BIOL CHEM, V268, P12537; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; Wiseman P., 1995, THESIS U W ONTARIO L; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	73	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29538	29545		10.1074/jbc.272.47.29538	http://dx.doi.org/10.1074/jbc.272.47.29538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368015	hybrid			2022-12-25	WOS:A1997YG64700025
J	Guthrie, CR; Skalhegg, BS; McKnight, GS				Guthrie, CR; Skalhegg, BS; McKnight, GS			Two novel brain-specific splice variants of the murine C beta gene of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; EXPRESSION; MYRISTYLATION; ISOFORMS; CELLS; MUTATIONS; CLONING; FORM	We have previously characterized two murine cAMP-dependent protein kinase catalytic subunit genes, C alpha and C beta 1. Targeted disruption of the C beta 1 promoter revealed two splice variants of the C beta catalytic subunit gene (designated C beta 2 and C beta 3) that continue to be expressed. These variants arise from unique promoters and are brain specific. C beta 2 is expressed in several discrete areas in the limbic system, These include the lateral septum, the bed nucleus of the stria terminalis, the ventral medial hypothalamus, and the amygdala, In the neocortex, expression is highest in cortical areas such as the prefrontal and insular cortex that are associated limbic structures, By contrast, C beta 1 is most highly expressed in the cortex and hippocampus and is also present in all non-neuronal tissues examined, C beta 3 is expressed at very low levels with wide distribution throughout the brain, Both the C beta 2 and C beta 3 variants are enzymatically active and induce gene expression in transient transfections with a cAMP response element-reporter construct, This activity is inhibited by protein kinase A regulatory subunits, the protein kinase inhibitor, and the chemical inhibitor H-89. We also demonstrate that C beta 1 is myristoylated at the amino terminus like the C alpha isoform, but neither C beta 2 nor C beta 3 is myristoylated, The discrete expression of C beta variants in the brain suggests specific functional roles in neuronal signaling.	UNIV WASHINGTON,DEPT PHARMACOL,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07312] Funding Source: Medline; NIGMS NIH HHS [GM32875] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; ANJARD C, 1993, BIOCHEMISTRY-US, V32, P9532, DOI 10.1021/bi00088a003; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BEUSHAUSEN S, 1992, P NATL ACAD SCI USA, V89, P1641, DOI 10.1073/pnas.89.5.1641; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHELEY S, 1991, BIOCHEMISTRY-US, V30, P10246, DOI 10.1021/bi00106a024; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CLEGG CH, 1989, J BIOL CHEM, V264, P20140; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; CUMMINGS DE, 1994, MAMM GENOME, V5, P701, DOI 10.1007/BF00426076; FRANKLIN KBJ, 1997, MOUSE BAIN STEREOTAX; GABELLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GORDON JI, 1991, J BIOL CHEM, V266, P8647; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; LIU FC, 1995, J NEUROSCI, V15, P2367, DOI 10.1523/JNEUROSCI.15-03-02367.1995; MELENDEZ A, 1995, GENETICS, V141, P1507; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; THOMAS J, 1991, J BIOL CHEM, V266, P10906; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WIEMANN S, 1991, J BIOL CHEM, V266, P5140; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	31	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29560	29565		10.1074/jbc.272.47.29560	http://dx.doi.org/10.1074/jbc.272.47.29560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368018	hybrid			2022-12-25	WOS:A1997YG64700028
J	Madsen, CS; Regan, CP; Owens, GK				Madsen, CS; Regan, CP; Owens, GK			Interaction of CArG elements and a GC-rich repressor element in transcriptional regulation of the smooth muscle myosin heavy chain gene in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; LIGATION-MEDIATED PCR; C-FOS; PROMOTER ELEMENTS; ALTERED EXPRESSION; ISOFORM DIVERSITY; PROTEIN-BINDING; DNA; IDENTIFICATION; ATHEROSCLEROSIS	We have previously shown that maximal expression of the rat smooth muscle myosin heavy chain (SM-MHC) gene in cultured rat aortic smooth muscle cells (SMCs) required the presence of a highly conserved domain (nucleotides -1321 and -1095) that contained two positive acting serum response factor (SRF) binding elements (CArG boxes 1 and 2) and a negative-acting GC-rich element that was recognized by Spl (Madsen, C. S., Hershey, J. C., Hautmann, M. B., White, S. L., and Owens, G. K. (1997) J. Biol. Chem, 272, 6332-6340). In this study, to better understand the functional role of these three cis elements, we created a series of SM-MHC reporter-gene constructs in which each element was mutated either alone or in combination with each other and tested them for activity in transient transfection assays using primary cultured rat aortic SMCs. Results demonstrated that the most proximal SRF binding element (CArG-boxl) was active in the absence of CArG-box2, but only upon removal of the GC-rich repressor, In contrast, regardless of sequence context, CArG-box2 was active only when CArG-boxl was present, We further demonstrated using electrophoretic mobility shift assays that Sp1 binding to the GC-rich repressor element did not prevent SRF binding to the adjacent CArG-box2. Thus, unlike other proteins reported to inhibit SRF activity, the repressor activity associated with the GC-rich element does not appear to function through direct inhibition of SRF binding, As a first step toward understanding the importance of these elements in vivo, we performed in vivo footprinting on the intact rat aorta, We demonstrated that both CArG boxes and the GC-rich element were bound by protein within the animal, Additionally, using the rat carotid injury model we showed that Sp1 protein was significantly increased in SMCs located within the myointimal lesion, suggesting that increased expression of this putative repressor factor may contribute to the decreased SM MHC expression within SMCs found in myointimal lesions.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MOL PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908	University of Virginia				Regan, Chris/0000-0002-3201-5878	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL038854, T32HL007284] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL07284, P01-HL19242, R01-HL38854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CORJAY MH, 1990, J CELL PHYSIOL, V145, P391, DOI 10.1002/jcp.1041450302; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FRID MG, 1993, J VASC RES, V30, P279, DOI 10.1159/000159007; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GHIVIZZANI SC, 1993, J BIOL CHEM, V268, P8675; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERRING BP, 1997, AM J PHYSIOL, V41, pC1394; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; Holifield B, 1996, J CLIN INVEST, V97, P814, DOI 10.1172/JCI118481; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; KARAGIANNI N, 1994, ONCOGENE, V9, P2327; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KELLEY CA, 1994, CAN J PHYSL PHARM, V72, P12351; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kim SW, 1996, MOL CELL BIOL, V16, P4465; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; KUROO M, 1989, J BIOL CHEM, V264, P18272; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MIANO JM, 1993, AM J PATHOL, V142, P715; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; OWENS GK, 1995, PHYSIOL REV, V75, P487; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SHARROCKS AD, 1995, NUCLEIC ACIDS RES, V23, P2442, DOI 10.1093/nar/23.13.2442; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SUZUKI J, 1995, TRANSPLANT P, V27, P578; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANTANABE M, 1996, CIRC RES, V78, P978; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297	59	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29842	29851		10.1074/jbc.272.47.29842	http://dx.doi.org/10.1074/jbc.272.47.29842			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368057	hybrid			2022-12-25	WOS:A1997YG64700067
J	Balsinde, J; Balboa, MA; Dennis, EA				Balsinde, J; Balboa, MA; Dennis, EA			Antisense inhibition of group VI Ca2+-independent phospholipase A(2) blocks phospholipid fatty acid remodeling in murine P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; BROMOENOL LACTONE; CELLS; TRIACYLGLYCEROL; BIOSYNTHESIS; MOBILIZATION; GENERATION; ENZYMES	A major issue in lipid signaling relates to the role of particular phospholipase A(2) isoforms in mediating receptor-triggered responses, This has been difficult to study because of the lack of isoform specific inhibitors, Based on the use of the Group VI Ca2+-independent phospholipase A(2) (iPLA(2)) inhibitor bromoenol lactone (EEL), we previously suggested a role for the iPLA(2) in mediating phospholipid fatty acid turnover (Balsinde, J,, Bianco, I, D,, Ackermann, E, J,, Conde-Frieboes, K., and Dennis, E, A. (1995) Proc, Natl, Acad, Sci, U, S, A, 92: 8527-8531), We have now further evaluated the role of the iPLA(2) in phospholipid remodeling by using antisense RNA technology, We show herein that inhibition of iPLA(2) expression by a specific antisense oligonucleotide decreases both the steady-state levels of lysophosphatidylcholine and the capacity of the cell to incorporate arachidonic acid into membrane phospholipids. These effects correlate with a decrease in both iPLA(2) activity and protein in the antisense-treated cells. Collectively these data provide further evidence that the iPLA(2) plays a major role in regulating phospholipid fatty acyl turnover in P388D(1) macrophages. In stark contrast, experiments with activated cells confirmed that the iPLA(2) does not play a significant role in receptor-coupled arachidonate mobilization in these cells, as manifested by the lack of an effect of the iPLA(2) antisense oligonucleotide on PAF-stimulated arachidonate release.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019; Balboa, María A./V-9493-2018	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140; Balboa, María A./0000-0002-2130-5298	NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ASMIS R, 1994, ANN NY ACAD SCI, V744, P1, DOI 10.1111/j.1749-6632.1994.tb52718.x; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLANK ML, 1995, BIOCHEM BIOPH RES CO, V210, P1052, DOI 10.1006/bbrc.1995.1763; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CHILTON FH, 1987, BIOCHEM BIOPH RES CO, V145, P1126, DOI 10.1016/0006-291X(87)91554-3; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dillon DA, 1997, J BIOL CHEM, V272, P10361; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; KUWAE T, 1990, J BIOL CHEM, V265, P5002; Kuwae T, 1997, BBA-LIPID LIPID MET, V1344, P74, DOI 10.1016/S0005-2760(96)00135-X; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SUGIURA T, 1995, BBA-LIPID LIPID MET, V1255, P167, DOI 10.1016/0005-2760(94)00237-S; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567	25	186	191	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29317	29321		10.1074/jbc.272.46.29317	http://dx.doi.org/10.1074/jbc.272.46.29317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361012	Green Published, hybrid			2022-12-25	WOS:A1997YF68400071
J	Bergwitz, C; Jusseaume, SA; Luck, MD; Juppner, H; Gardella, TJ				Bergwitz, C; Jusseaume, SA; Luck, MD; Juppner, H; Gardella, TJ			Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(PTH)/PTH-RELATED PEPTIDE; CHIMERIC RECEPTORS; ADENYLATE-CYCLASE; BINDING-AFFINITY; COMMON RECEPTOR; INDIAN HEDGEHOG; PROTEIN; EXPRESSION; ACTIVATION; SECRETIN	The parathyroid hormone (PTH)-2 receptor displays strong ligand selectivity in that it responds fully to PTH but not at all to PTH-related peptide (PTHrP), In contrast, the PTH-1 receptor (PTH/PTHrP receptor) responds fully to both ligands, Previously it was shown that two divergent residues in PTH and PTHrP account for PTH-2 receptor selectivity; position 23 (Trp in PTH and Phe in PTHrP) determines binding selectivity and position 5 (Ile in PTH and His in PTHrP) determines signaling selectivity, To identify sites in the PTH-2 receptor involved in discriminating between His(5) and Ile(5), we constructed PTH-S receptor/PTH-1 receptor chimeras, expressed them in COS-7 cells, and tested for cAMP responsiveness to [Trp(23)] PTHrP-(1-36), and to the nondiscriminating peptide [Ile(5),Trp(23)]PTHrP-(1-36) (the Phe(23) --> Trp modification enabled high affinity binding of each ligand to the PTH-2 receptor), The chimeras revealed that the membrane-spanning/loop region of the receptor determined His(5)/Ile(5) signaling selectivity, Subsequent analysis of smaller cassette substitutions and then individual point mutations led to the identification of two single residues that function as major determinants of residue 5 signaling selectivity, These residues, Ile(244) at the extracellular end of transmembrane helix 3, and Tyr(318) at the COOH-terminal portion of extracellular loop 2, are replaced by Leu and Ile in the PTH-1 receptor, respectively, The results thus indicate a functional interaction between two residues in the core region of the PTH-2 receptor and residue 5 of the ligand.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-11794] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell A, 1996, J BIOL CHEM, V271, P4518; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2215, DOI 10.1210/endo-125-4-2215; Behar V, 1996, ENDOCRINOLOGY, V137, P4217, DOI 10.1210/en.137.10.4217; Bergwitz C, 1996, J BIOL CHEM, V271, P26469, DOI 10.1074/jbc.271.43.26469; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; CAULFIELD MP, 1990, ENDOCRINOLOGY, V127, P83, DOI 10.1210/endo-127-1-83; Gardella TJ, 1996, J BIOL CHEM, V271, P19888, DOI 10.1074/jbc.271.33.19888; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; ROST B, 1995, PROTEIN SCI, V4, P521; SCHERTLER G, 1995, NATURE, V362, P770; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P325; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SHIGENO C, 1988, J BIOL CHEM, V263, P3872; STROOP S, 1994, BIOCHEMISTRY-US, V34, P1050; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; Usdin TB, 1997, ENDOCRINOLOGY, V138, P831, DOI 10.1210/en.138.2.831; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; Usdin TB, 1996, ENDOCRINOLOGY, V137, P4285, DOI 10.1210/en.137.10.4285; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Zhou AT, 1997, P NATL ACAD SCI USA, V94, P3644, DOI 10.1073/pnas.94.8.3644	32	68	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28861	28868		10.1074/jbc.272.46.28861	http://dx.doi.org/10.1074/jbc.272.46.28861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360953	hybrid			2022-12-25	WOS:A1997YF68400012
J	Hayes, F; Hallet, B; Cao, YH				Hayes, F; Hallet, B; Cao, YH			Insertion mutagenesis as a tool in the modification of protein function - Extended substrate specificity conferred by pentapeptide insertions in the Omega-LOOP of TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-ENZYME INTERMEDIATE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RESOLUTION; SPECTRUM; MUTANTS; CEPHALOSPORINS; RESISTANCE; HYDROLYSIS; EVOLUTION	The TEM-1 beta-lactamase enzyme efficiently hydrolyzes beta-lactam antibiotics such as ampicillin but cleaves third generation cephalosporin antibiotics poorly. Variant beta-lactamases that conferred elevated levels of resistance to the cephalosporin ceftazidime were identified in a set of beta-lactamase derivatives previously generated by pentapeptide scanning mutagenesis in which a variable 5-amino acid cassette was introduced randomly in the target protein, This mutagenesis procedure was also modified to allow the direct selection of variant beta-lactamases with pentapeptide insertions that conferred extended substrate specificities, All insertions associated with enhanced resistance to ceftazidime were targetted to the 19-amino acid Omega-loop region, which forms part of the catalytic pocket of the beta-lactamase enzyme. However, pentapeptide insertions in the C-and N-terminal halves of this region had different effects on the ability of the enzyme to hydrolyze ampicillin in vivo. Larger insertions that increased the length of the Omega-loop by up to 2-fold also retained catalytic activity toward ampicillin and/or ceftazidime in vivo. In accord with previous substitution mutation studies, these results emphasize the extreme flexibility of the Omega-loop with regards the primary structure requirements for ceftazidime hydrolysis by beta-lactamase. The potential of pentapeptide scanning mutagenesis in mimicking evolution events that result from the insertion and excision of transposons in nature is discussed.			Hayes, F (corresponding author), UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,S PARKS RD,OXFORD OX1 3QU,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Berg DE, 1989, MOBILE DNA; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Cao YH, 1997, J MOL BIOL, V274, P39, DOI 10.1006/jmbi.1997.1380; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; Guillaume G, 1997, J BIOL CHEM, V272, P5438, DOI 10.1074/jbc.272.9.5438; Hallet B, 1997, NUCLEIC ACIDS RES, V25, P1866, DOI 10.1093/nar/25.9.1866; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; MAHILLON J, 1988, EMBO J, V7, P1515, DOI 10.1002/j.1460-2075.1988.tb02971.x; Maveyraud L, 1996, J BIOL CHEM, V271, P10482, DOI 10.1074/jbc.271.18.10482; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO JA, 1993, CURR OPIN GENET DEV, V3, P845, DOI 10.1016/0959-437X(93)90003-8; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUMMERS DK, 1988, EMBO J, V7, P851, DOI 10.1002/j.1460-2075.1988.tb02884.x; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469	31	34	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28833	28836		10.1074/jbc.272.46.28833	http://dx.doi.org/10.1074/jbc.272.46.28833			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360947	hybrid			2022-12-25	WOS:A1997YF68400006
J	Bhagwat, M; Meara, D; Nossal, NG				Bhagwat, M; Meara, D; Nossal, NG			Identification of residues of T4 RNase H required for catalysis and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POLYMERASE-I; ENDONUCLEASE; REPLICATION; EXONUCLEASE; MUTAGENESIS; SUBSTRATE; PROTEINS; CLEAVAGE; INVITRO	Bacteriophage T4 RNase H, which removes the RNA primers that initiate lagging strand fragments, has a 5'-to 3'-exonuclease activity on DNA DNA and RNA DNA duplexes and an endonuclease activity on flap or forked DNA structures (Bhagwat, M., Hobbs, L. J., and Nossal, N. J. (1997) J. Biol. Chem. 272, 28523-28530). It is a member of the RAD2 family of prokaryotic and eukaryotic replication and repair nucleases, The crystal structure of T4 RNase H, in the absence of DNA, shows two Mg2+ ions coordinated to the amino acids highly conserved in this family, It also shows a disordered region proposed to be involved in DNA binding (Mueser, T. C., Nossal, N. G., and Hyde, C. C. Cell (1996) 85, 1101-1112). To identify the amino acids essential for catalysis and DNA binding, we have constructed and characterized three kinds of T4 RNase H mutant proteins based on the possible roles of the amino acid residues: mutants of acidic residues coordinated to each of the two Mg2+ ions (Mg2+ - 1: D19N, D71N, D132N, and D155N; and Mg2+ - 2: D157N and D200N); mutants of conserved basic residues in or near the disordered region (K87A and R90A); and mutants of residues with hydroxyl side chains involved in the hydrogen bonding network (Y86F and S153A), Our studies show that Mg2+- 1 and the residues surrounding it are important for catalysis and that Lys(87) is necessary for DNA binding.	NIDDK,MOL & CELLULAR BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; COZZARELLI NR, 1969, J MOL BIOL, V45, P513, DOI 10.1016/0022-2836(69)90309-X; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; Gerlt J. A., 1993, NUCLEASES, P1; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; ODA Y, 1993, J BIOL CHEM, V268, P88; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; XU SY, 1991, J BACTERIOL, V173, P5030, DOI 10.1128/jb.173.16.5030-5035.1991; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	29	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28531	28538		10.1074/jbc.272.45.28531	http://dx.doi.org/10.1074/jbc.272.45.28531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353315	hybrid			2022-12-25	WOS:A1997YF21900055
J	Eggert, M; Michel, J; Schneider, S; Bornfleth, H; Baniahmad, A; Fackelmayer, FO; Schmidt, S; Renkawitz, R				Eggert, M; Michel, J; Schneider, S; Bornfleth, H; Baniahmad, A; Fackelmayer, FO; Schmidt, S; Renkawitz, R			The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES TRANSCRIPTIONAL ACTIVATION; THYROID-HORMONE RECEPTOR; CHICKEN LYSOZYME GENE; IN-VITRO; MONOCLONAL-ANTIBODY; DNA-REPLICATION; CO-REPRESSOR; DOMAIN; CELLS; ACID	The glucocorticoid receptor (GR) is a ligand-dependent transcription factor that is able to modulate gene activity by binding to its response element, interacting with other transcription factors, and contacting several accessory proteins such as coactivators. Here we show that GRIP120, one of the factors we have identified to interact with the glucocorticoid receptor, is identical to the heterogeneous nuclear ribonucleoprotein U (hnRNP U), a nuclear matrix protein binding to RNA as well as to scaffold attachment regions, GR hnRNP U complexes were identified by blotting and coimmunoprecipitation. The subnuclear distribution of GR and hnRNP U was characterized by indirect immunofluorescent labeling and confocal laser microscopy demonstrating a colocalization of both proteins, Using a nuclear transport-deficient deletion of hnRNP U, nuclear translocation was seen to be dependent on GR and dexamethasone. Transient transfections were used to identify possible interaction domains, Overexpressed hnRNP U interfered with glucocorticoid induction, and the COOH-terminal domains of both proteins were sufficient in mediating the transcriptional interference, A possible functional role for this GR binding-protein in addition to its binding to the nuclear matrix, to RNA, and to scaffold attachment regions is discussed.	UNIV GIESSEN, GENET INST, D-35392 GIESSEN, GERMANY; UNIV HEIDELBERG, INST ANGEW PHYS, D-69120 HEIDELBERG, GERMANY; UNIV CONSTANCE, FAK BIOL, D-78646 CONSTANCE, GERMANY	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; University of Konstanz								BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1997, STEROID THYROID RETI; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BARRACK ER, 1980, J BIOL CHEM, V255, P7265; BARRACK ER, 1982, RECENT PROG HORM RES, V38, P133; BASKIN Y, 1995, SCIENCE, V268, P1564, DOI 10.1126/science.7777854; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berezney R, 1976, Adv Enzyme Regul, V14, P63, DOI 10.1016/0065-2571(76)90008-X; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BORNFLETH H, 1996, MODELLGESTUTZTE SEGM, P408; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; EISEN LP, 1985, J BIOL CHEM, V260, P1805; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; FACKELMAYER FO, 1994, BIOCHEMISTRY-US, V33, P10416, DOI 10.1021/bi00200a024; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Hughes TA, 1995, J CELL SCI, P59; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1996, MOL CELL BIOL, V16, P4366; KIRSCH TM, 1986, BIOCHEM BIOPH RES CO, V137, P640, DOI 10.1016/0006-291X(86)91126-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauber AH, 1995, INT REV CYTOL, V162B, P337; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; MUNKEL C, 1995, BIOIMAGING, V3, P108; NELKIN BD, 1980, NUCLEIC ACIDS RES, V8, P5623, DOI 10.1093/nar/8.23.5623; Nickel J, 1995, NUCLEIC ACIDS RES, V23, P4785, DOI 10.1093/nar/23.23.4785; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; ONATE SA, 1995, SCIENCE, V270, P1354; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHMITT J, 1993, NUCLEIC ACIDS RES, V21, P2673, DOI 10.1093/nar/21.11.2673; SCHUCHARD M, 1991, BIOCHEMISTRY-US, V30, P4535, DOI 10.1021/bi00232a024; SCHUTZ G, 1977, COLD SPRING HARB SYM, V42, P617, DOI 10.1101/SQB.1978.042.01.064; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STUURMAN N, 1992, J CELL SCI, V101, P773; SWANECK GE, 1979, P NATL ACAD SCI USA, V76, P1049, DOI 10.1073/pnas.76.3.1049; Tang YT, 1996, MOL CELL BIOL, V16, P1989; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; VANSTEENSEL B, 1995, J CELL BIOCHEM, V57, P465, DOI 10.1002/jcb.240570312; VANSTEENSEL B, 1991, FEBS LETT, V292, P229, DOI 10.1016/0014-5793(91)80873-2; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; VONKRIES JP, 1994, NUCLEIC ACIDS RES, V22, P1215, DOI 10.1093/nar/22.7.1215; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	63	72	76	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28471	28478		10.1074/jbc.272.45.28471	http://dx.doi.org/10.1074/jbc.272.45.28471			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353307	hybrid			2022-12-25	WOS:A1997YF21900047
J	Li, F; Hui, DY				Li, F; Hui, DY			Modified low density lipoprotein enhances the secretion of bile salt-stimulated cholesterol esterase by human monocyte-macrophages - Species-specific difference in macrophage cholesteryl ester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; DEPENDENT PROTEIN-KINASE; UNESTERIFIED CHOLESTEROL; RAT-LIVER; MOLECULAR-CLONING; PORCINE PANCREAS; MESSENGER-RNA; FOAM CELLS; EXPRESSION; GENE	Reverse transcriptase-polymerase chain reaction was used to study the biosynthesis of two different cholesteryl ester hydrolases by human and mouse macrophages. Oligonucleotide primers for bile salt-stimulated cholesterol esterase yielded positive reactions with RNA isolated from human peripheral blood monocytes, monocyte-derived macrophages, the human monocytic THP-1 cells, and phorbol ester-induced THP-1 macrophages. In contrast, oligonucleotide primers for hormone-sensitive lipase yielded positive reactions only with RNA isolated from non-differentiated human THP-1 monocytic cells and peripheral blood monocytes, but not those obtained from differentiated THP-1 macrophages or monocyte-derived macrophages, Thus, while human monocytes were capable of synthesizing both enzymes, human macrophages synthesized only bile salt-stimulated cholesterol esterase and not the hormone-sensitive lipase. The synthesis of bile salt-stimulated cholesterol esterase by human macrophages was confirmed by detection of bile salt-stimulated cholesteryl ester hydrolytic activity in conditioned media of differentiated THP-1 cells and human peripheral blood monocyte-derived macrophages, Moreover, incubating human macrophages with oxidized low density lipoprotein (LDL) or acetylated LDL increased bile salt-stimulated cholesterol esterase activity in the conditioned media of these cells. These results with human macrophages were contrasted with results of studies with mouse macrophages, which showed the presence of hormone-sensitive lipase mRNA but not the bile salt-stimulated cholesterol esterase mRNA, Taken together, these results demonstrated species-specific differences in expression of cholesteryl ester hydrolytic enzymes in macrophages. The expression of bile salt-stimulated cholesterol esterase by human macrophages, in a proc ess inducible by modified LDL, suggests a role of this protein in atherogenesis.	UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, CINCINNATI, OH 45267 USA	University of Cincinnati					NIDDK NIH HHS [DK46405, DK40917] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046405, R01DK040917] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRODTEPPLEY J, 1995, BBA-MOL BASIS DIS, V1272, P69, DOI 10.1016/0925-4439(95)00083-G; BRODTEPPLEY J, 1994, J LIPID RES, V35, P27; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS JA, 1994, ARTERIOSCLER THROMB, V14, P443, DOI 10.1161/01.ATV.14.3.443; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; GHOSH S, 1992, BIOCHEM CELL BIOL, V70, P800, DOI 10.1139/o92-121; GHOSH S, 1991, LIPIDS, V26, P793, DOI 10.1007/BF02536160; GHOSH S, 1989, LIPIDS, V24, P733, DOI 10.1007/BF02535213; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; HAKAMATA H, 1994, ARTERIOSCLER THROMB, V14, P1860, DOI 10.1161/01.ATV.14.11.1860; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERNELL O, 1994, J PEDIATR-US, V125, pS56, DOI 10.1016/S0022-3476(06)80737-7; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; HYUN J, 1969, J BIOL CHEM, V244, P1937; Innerarity T L, 1986, Methods Enzymol, V129, P542; ISHII I, 1992, ARTERIOSCLER THROMB, V12, P1139, DOI 10.1161/01.ATV.12.10.1139; KHOO JC, 1993, J LIPID RES, V34, P1969; KHOO JC, 1981, J BIOL CHEM, V256, P2659; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KRUTH HS, 1985, ATHEROSCLEROSIS, V57, P337, DOI 10.1016/0021-9150(85)90045-0; KUMAR BV, 1992, BIOCHEMISTRY-US, V31, P6077, DOI 10.1021/bi00141a017; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Li F, 1996, BIOCHEMISTRY-US, V35, P6657, DOI 10.1021/bi952313q; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; LIDMER AS, 1995, GENOMICS, V29, P115, DOI 10.1006/geno.1995.1221; LOMBARDO D, 1978, BIOCHIM BIOPHYS ACTA, V527, P142, DOI 10.1016/0005-2744(78)90263-2; MOMSEN WE, 1977, BIOCHIM BIOPHYS ACTA, V486, P103, DOI 10.1016/0005-2760(77)90074-1; MORA R, 1987, ATHEROSCLEROSIS, V67, P143, DOI 10.1016/0021-9150(87)90274-7; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; REMAURY A, 1995, BIOCHEM BIOPH RES CO, V207, P175, DOI 10.1006/bbrc.1995.1169; REUE K, 1991, J LIPID RES, V32, P267; ROUDANI S, 1994, EUR J CELL BIOL, V65, P132; Rudd E.A., 1984, P185; RUDD EA, 1987, BIOCHIM BIOPHYS ACTA, V918, P106, DOI 10.1016/0005-2760(87)90184-6; Shamir R, 1996, J CLIN INVEST, V97, P1696, DOI 10.1172/JCI118596; SMALL CA, 1989, FEBS LETT, V247, P205, DOI 10.1016/0014-5793(89)81335-3; Smith E B, 1974, Adv Lipid Res, V12, P1; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; ZOLFAGHARI R, 1992, ARTERIOSCLER THROMB, V12, P295, DOI 10.1161/01.ATV.12.3.295; ZOLFAGHARI R, 1993, J BIOL CHEM, V268, P13532	50	85	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28666	28671		10.1074/jbc.272.45.28666	http://dx.doi.org/10.1074/jbc.272.45.28666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353334	hybrid			2022-12-25	WOS:A1997YF21900074
J	Scott, DA; Docampo, R; Dvorak, JA; Shi, SL; Leapman, RD				Scott, DA; Docampo, R; Dvorak, JA; Shi, SL; Leapman, RD			In situ compositional analysis of acidocalcisomes in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PROBE MICROANALYSIS; ELEMENTAL COMPOSITION; CYSTEINE PROTEINASE; LYSOSOMAL COMPARTMENT; CRITHIDIA-FASCICULATA; AFRICAN TRYPANOSOMES; GRANULES INSITU; CA-2+ TRANSPORT; CALCIUM STORES; CA2+ RELEASE	We measured the elemental content of different compartments in Trypanosoma cruzi epimastigotes using quick freezing, ultracryomicrotomy, and electron probe microanalysis. Vacuoles identified by high electron density contained (in units of mmol/kg dry weight +/- S.E.) large amounts of phosphorus (1390 +/- 13), magnesium (646 +/- 19), calcium (171 +/- 5), sodium (161 +/- 18), and zinc (148 +/- 6). No other compartment had appreciable calcium or zinc content. Iron (128 +/- 16 mmol/kg) was detected only in vacuoles distinct from the electron-dense vacuoles and other organelles. Incubation of cells for 70 min in culture medium in the presence of ionomycin plus nigericin led to a very significant 3- or 2-fold increase in potassium in the electron-dense vacuoles and the iron-rich vacuoles, respectively, with no significant change in the other elements investigated, This indicated the acidic nature of the vacuoles and demonstrated that the electron-dense vacuoles correspond to what were described previously as acidocalcisomes, i.e. acidic compartments rich in Ca2+. The acidocalcisomes were investigated by separation of epimastigote fractions on Percoll gradients in combination with Triton WR-1339 treatment. This detergent caused a rapid vacuolation; these vacuoles were shown by electron microscopy to be largely transparent, with a diffuse matrix. Percoll gradient fractionation demonstrated decreases in the density of various organelle markers in detergent-treated cells compared with controls. Large decreases in the density of the acidocalcisome and the mitochondrion were seen, as well as smaller decreases in the density of the other markers. Conventional electron microscopy of epimastigotes loaded with gold-labeled transferrin indicated that the endosomal system was separate from vacuoles that probably corresponded to the calcium-containing organelles detected by electron probe microanalysis. The combined results provide evidence that acidocalcisomes are organelles different from lysosomes or other organelles previously described in these parasites.	UNIV ILLINOIS, COLL VET MED, DEPT VET PATHOBIOL, MOL PARASITOL LAB, URBANA, IL 61802 USA; NIAID, PARASIT DIS LAB, BETHESDA, MD 20892 USA; NIH, NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, BETHESDA, MD 20892 USA	University of Illinois System; University of Illinois Urbana-Champaign; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA				Scott, David/0000-0002-8668-2449; Leapman, Richard/0000-0002-8575-4084	NIAID NIH HHS [AI-23259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 1996, BIOL PHARM BULL, V19, P1291; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616; ATKINSON AW, 1974, PROTOPLASMA, V81, P77, DOI 10.1007/BF02055775; Avila Jose Luis, 1992, V18, P189; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; Bode HP, 1996, PFLUG ARCH EUR J PHY, V432, P97, DOI 10.1007/s004240050110; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; BONTEMPI E, 1989, MOL BIOCHEM PARASIT, V33, P43, DOI 10.1016/0166-6851(89)90040-6; BOVERIS A, 1986, MOL BIOCHEM PARASIT, V19, P163, DOI 10.1016/0166-6851(86)90121-0; CANNATA JJB, 1982, MOL BIOCHEM PARASIT, V6, P151, DOI 10.1016/0166-6851(82)90074-3; CARVALHO TUD, 1977, J PARASITOL, V63, P1116, DOI 10.2307/3279861; CAZZULO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186, DOI 10.1016/0167-4838(90)90166-D; DESOUZA W, 1979, ACTA TROP, V36, P253; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; DVORAK JA, 1988, MOL BIOCHEM PARASIT, V31, P19, DOI 10.1016/0166-6851(88)90141-7; Egerton R.F., 1996, ELECT ENERGY LOSS SP, P245; FIORI CD, 1992, NIST NIH DESKTOP SPE; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HALL TA, 1983, Q REV BIOPHYS, V16, P279, DOI 10.1017/S0033583500005114; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; HEALY N, 1992, PARASITOLOGY, V104, P315, DOI 10.1017/S003118200006176X; Hensgens CMH, 1996, EUR J BIOCHEM, V242, P327, DOI 10.1111/j.1432-1033.1996.0327r.x; HORISBERGER M, 1985, HISTOCHEMISTRY, V82, P219, DOI 10.1007/BF00501398; KRIVANEK OL, 1987, ULTRAMICROSCOPY, V22, P103, DOI 10.1016/0304-3991(87)90054-4; KUNDMANN M, 1990, EL P SOFTWARE MACINT; LEAPMAN RD, 1988, ULTRAMICROSCOPY, V24, P251, DOI 10.1016/0304-3991(88)90314-2; LEAPMAN RD, 1991, J MICROSC-OXFORD, V161, P3, DOI 10.1111/j.1365-2818.1991.tb03070.x; LEFURGEY A, 1990, MOL BIOCHEM PARASIT, V40, P77, DOI 10.1016/0166-6851(90)90081-V; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; LIMA MF, 1990, MOL BIOCHEM PARASIT, V38, P245, DOI 10.1016/0166-6851(90)90027-J; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; Moreno SNJ, 1996, BIOCHEM J, V313, P655, DOI 10.1042/bj3130655; OPPERDOES FR, 1982, MOL BIOCHEM PARASIT, V6, P181, DOI 10.1016/0166-6851(82)90077-9; ORNBERG RL, 1988, J BIOL CHEM, V263, P1488; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; SCHLATTERER C, 1994, CELL CALCIUM, V16, P101, DOI 10.1016/0143-4160(94)90005-1; SCOTT DA, 1995, BIOCHEM J, V310, P789, DOI 10.1042/bj3100789; SCOTT DA, 1995, INT J PARASITOL, V25, P657, DOI 10.1016/0020-7519(95)99370-X; Shi SL, 1996, MICROSC RES TECHNIQ, V33, P241; SHUMAN H, 1976, ULTRAMICROSCOPY, V1, P317, DOI 10.1016/0304-3991(76)90049-8; Silva LHP, 1953, FOLIA CLIN BIOL, V20, P191; Silveira FT, 1979, HILEIA MED BELEM, V1, P61; SOARES MJ, 1991, PARASITOL RES, V77, P461, DOI 10.1007/BF00928410; SOARES MJ, 1992, J CELL SCI, V102, P157; SOMLYO AV, 1988, P NATL ACAD SCI USA, V85, P6222, DOI 10.1073/pnas.85.16.6222; SOMLYO AV, 1977, J CELL BIOL, V74, P828, DOI 10.1083/jcb.74.3.828; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; STEINERT M, 1965, EXP CELL RES, V39, P69, DOI 10.1016/0014-4827(65)90008-X; TONER JJ, 1972, BIOCHEM BIOPH RES CO, V46, P652, DOI 10.1016/S0006-291X(72)80190-6; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VICKERMAN K, 1977, ANN SOC BELG MED TR, V57, P441; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; WADA Y, 1994, J BIOENERG BIOMEMBR, V26, P631, DOI 10.1007/BF00831538; WEBSTER P, 1989, EUR J CELL BIOL, V49, P303; WILLIAMSON J, 1981, J PROTOZOOL, V28, P460, DOI 10.1111/j.1550-7408.1981.tb05320.x; Xu CW, 1996, MOL CELL BIOL, V16, P564; ZIEROLD K, 1988, METHOD MICROBIOL, V20, P91, DOI 10.1016/S0580-9517(08)70049-7	71	92	94	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28020	28029		10.1074/jbc.272.44.28020	http://dx.doi.org/10.1074/jbc.272.44.28020			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346954	hybrid			2022-12-25	WOS:A1997YD47300080
J	Lai, MT; DiCera, E; Shafer, JA				Lai, MT; DiCera, E; Shafer, JA			Kinetic pathway for the slow to fast transition of thrombin - Evidence of linked ligand binding at structurally distinct domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; PROCOAGULANT; FIBRINOGEN; INHIBITION; ENZYME	The kinetic pathway for the Na+ -induced slow --> fast transition of thrombin was characterized, The slow form was shown to consist of two conformers in a 3:1 ratio (E-s2:E-s1) at 5 degrees C, pH 7.4, Gamma/2 0.3.E-s2 binds Na+ 3 orders of magnitude faster than does E-s1. The small molecule active site-directed inhibitor L-371,912, and the exosite I binding ligand hirugen, like Na+, bind selectively to E-s2 and induce the slow --> fast conversion of thrombin. The slow --> fast transition is limited by the rate of conversion of E-s1 to E-s2 (k similar to 28 s(-1) at 5 degrees C), Replacement of Arg-221a or Lys-224 at the Na+ binding site with Ala appears to selectively alter the slow form and reduce the apparent affinity of the mutants for Na+ and L-371,912, This replacement, however, has little effect on the affinity for the inhibitor in the presence of saturating concentrations of Na+, The kinetically linked ligand binding at the Na+ binding site, exosite I, and the active site of thrombin characterized in the present study indicates the basis for the plasticity of this important enzyme, and suggests the possibility that the substrate specificity and, therefore, the procoagulant and anticoagulant activities of thrombin may be subject to allosteric regulation by as yet unidentified physiologically important effecters.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)	Lai, MT (corresponding author), MERCK RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FERSHT A, 1984, ENZYME STRUCTURE MEC, P121; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; LEWIS SD, 1993, THROMB RES, V70, P173, DOI 10.1016/0049-3848(93)90158-K; LEWIS SD, 1995, THROMB HAEMOSTASIS, V74, P1107; LUNDBLAD RL, 1985, THROMB RES, V37, P53, DOI 10.1016/0049-3848(85)90032-5; Lyle TA, 1997, BIOORG MED CHEM LETT, V7, P67, DOI 10.1016/S0960-894X(96)00583-5; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; Nayal M, 1996, J MOL BIOL, V256, P228, DOI 10.1006/jmbi.1996.0081; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SUZUKI K, 1983, J BIOCHEM-TOKYO, V96, P455; VILLANUEVA GB, 1983, THROMB RES, V29, P489, DOI 10.1016/0049-3848(83)90344-4; WALKER FJ, 1984, SEMIN THROMB HEMOST, V10, P131, DOI 10.1055/s-2007-1004415; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; ZHANG E, 1997, BIOPHYS CHEM, V63, P18	24	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30275	30282		10.1074/jbc.272.48.30275	http://dx.doi.org/10.1074/jbc.272.48.30275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374513	hybrid			2022-12-25	WOS:A1997YH61300045
J	Bourgeois, L; BrillardBourdet, M; Deperthes, D; Juliano, MA; Juliano, L; Tremblay, RR; Dube, JY; Gauthier, F				Bourgeois, L; BrillardBourdet, M; Deperthes, D; Juliano, MA; Juliano, L; Tremblay, RR; Dube, JY; Gauthier, F			Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-SPECIFIC ANTIGEN; HUMAN GLANDULAR KALLIKREIN; PROTEIN-C INHIBITOR; RAT-SUBMAXILLARY-GLAND; SUICIDE SUBSTRATE; SEMINAL PLASMA; HUMAN SEMEN; PURIFICATION; EXPRESSION; SITE	The third human tissue kallikrein to be identified, hK2, could be an alternate or complementary marker to kallikrein hK3 (prostate-specific antigen) for prostate diseases, Most of the hK2 in seminal plasma forms an inactive complex with protein C inhibitor (PCI), a serpin secreted by seminal vesicles, As serpin inhibitors behave as suicide substrates that are cleaved early in the interaction with their target enzyme, and kallikreins have different sensitivities to serpin inhibitors, we prepared a series of substrates with intramolecularly quenched fluorescence based on the sequences of the serpin reactive loops, They were used to compare the substrate specificities of hK1 and hK2, which both have trypsin-like specificity, and thus differ from chymotrypsin-like hK3, The serpin-derived peptides behaved as kallikrein substrates whose sensitivities reflected the specificity of the parent inhibitory proteins, Substrates derived from PCI were the most sensitive for both hK1 and hK2 with specificity constants of about 10(7) M-1.s(-1). Those derived from antithrombin III and alpha(2)-antiplasmin were more specific for hK2 while a kallistatin-derived substrate was specifically cleaved by hK1, hK1 and hK2 substrates of greater specificity were obtained using chimeric peptides based on the sequence of serpin reactive loops, The main difference between specificities of hK1 and hK2 arise because hK2 can accommodate positively charged as well as small residues at P-2 and requires an arginyl residue at P-1, Thus, unlike hK1, hK2 does not cleave kininogen derived substrates overlapping the region of N-terminal insertion of bradykinin in human kininogens.	UNIV TOURS, ENZYMOL & PROT CHEM LAB, CNRS, EP 117, F-37032 TOURS, FRANCE; CHUL, RES CTR, HORMONAL BIOREGULAT LAB, Ste Foy, PQ, CANADA; UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT BIOPHYS, SAO PAULO, BRAZIL	Centre National de la Recherche Scientifique (CNRS); Universite de Tours; Laval University; Universidade Federal de Sao Paulo (UNIFESP)			Juliano, Luiz/D-7204-2012	Juliano, Luiz/0000-0002-5589-2822				Alves LC, 1996, PEPTIDE RES, V9, P92; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BRIDON DP, 1995, UROLOGY, V45, P801, DOI 10.1016/S0090-4295(99)80087-9; BRILLARDBOURDET M, 1995, BBA-PROTEIN STRUCT M, V1246, P47, DOI 10.1016/0167-4838(94)00179-K; Catalona WJ, 1996, PROSTATE, P64; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CHAPDELAINE P, 1988, FEBS LETT, V236, P205, DOI 10.1016/0014-5793(88)80315-6; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; CHRISTENSSON A, 1994, EUR J BIOCHEM, V220, P45, DOI 10.1111/j.1432-1033.1994.tb18597.x; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; Deperthes D, 1996, J ANDROL, V17, P659; Deperthes D, 1995, BBA-GEN SUBJECTS, V1245, P311, DOI 10.1016/0304-4165(95)00118-2; ELMOUJAHED A, 1990, FEBS LETT, V265, P137, DOI 10.1016/0014-5793(90)80903-V; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; ESPANA F, 1995, EUR J BIOCHEM, V234, P641, DOI 10.1111/j.1432-1033.1995.641_b.x; FIEDLER F, 1987, EUR J BIOCHEM, V163, P303, DOI 10.1111/j.1432-1033.1987.tb10801.x; Frenette G, 1997, BBA-GEN SUBJECTS, V1334, P109, DOI 10.1016/S0304-4165(96)00080-3; GEIGER R, 1981, METHOD ENZYMOL, V80, P466; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; IRIE A, 1986, BIOCHEM INT, V13, P375; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Komiyama T, 1996, PROTEIN SCI, V5, P874; Kumar A, 1996, CANCER RES, V56, P5397; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LILJA H, 1992, CANCER, V70, P230, DOI 10.1002/1097-0142(19920701)70:1+<230::AID-CNCR2820701310>3.0.CO;2-Y; LILJA H, 1985, J CLIN INVEST, V76, P1899, DOI 10.1172/JCI112185; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MOREAU T, 1992, J BIOL CHEM, V267, P10045; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PIMENTA DC, 1997, IN PRESS BIOCH J; RIEGMAN PHJ, 1992, GENOMICS, V14, P6, DOI 10.1016/S0888-7543(05)80275-7; SAEDI MS, 1995, MOL CELL ENDOCRINOL, V109, P237, DOI 10.1016/0303-7207(95)03508-5; SHORI DK, 1992, BIOCHEM PHARMACOL, V43, P1209, DOI 10.1016/0006-2952(92)90494-4; Tremblay RR, 1997, AM J PATHOL, V150, P455; VIHINEN M, 1994, BIOCHEM BIOPH RES CO, V204, P1251, DOI 10.1006/bbrc.1994.2597; WANG MC, 1979, INVEST UROL, V17, P159; Young CYF, 1996, PROSTATE, P17; YU JX, 1994, J BIOL CHEM, V269, P18843; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	44	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29590	29595		10.1074/jbc.272.47.29590	http://dx.doi.org/10.1074/jbc.272.47.29590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368023	hybrid			2022-12-25	WOS:A1997YG64700033
J	Braun, P; Persson, B; Kaback, HR; vonHeijne, G				Braun, P; Persson, B; Kaback, HR; vonHeijne, G			Alanine insertion scanning mutagenesis of lactose permease transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LAC CARRIER PROTEIN; POLYTOPIC MEMBRANE-PROTEIN; METAL-BINDING SITES; AMINO-ACID-RESIDUES; ESCHERICHIA-COLI; CARBOXYL TERMINUS; SEQUENCE; EXPRESSION; PROXIMITY	A priori, single residue insertions into transmembrane helices are expected to be highly disruptive to protein structure and function. We have carried out a systematic analysis of the phenotypes associated with Ala insertions into transmembrane helices in lactose permease, a multispanning Escherichia coli inner membrane protein, Insertion of alanine into the center of 7 transmembrane helices was found to abolish stable integration of lactose permease into the membrane or uphill lactose transport. A more detailed Ala insertion scan was made of transmembrane helix III. The results pinpoint a central region of similar to 2 helical turns that is crucial for lactose permease stability and/or activity. A Trp scan in this region identified 2 residues essential for lactose permease stability. From these results, it appears that transmembrane helices have differential sensitivities to single residue insertions and that such mutations may be useful for identifying structurally and/or functionally important helix segments.	VAXJO UNIV,DEPT ENGN & NAT SCI,S-35195 VAXJO,SWEDEN; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MOL GENET & MICROBIOL,LOS ANGELES,CA 90095	Linnaeus University; Vaxjo University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Braun, P (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.		von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; FOSTER DL, 1983, J BIOL CHEM, V258, P31; Goswitz VC, 1996, J BIOL CHEM, V271, P21927, DOI 10.1074/jbc.271.36.21927; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; HEINZ DW, 1994, J MOL BIOL, V236, P869, DOI 10.1006/jmbi.1994.1195; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; JUNG K, 1995, BIOCHEMISTRY-US, V34, P6272, DOI 10.1021/bi00019a003; KABACK HR, 1994, J EXP BIOL, V196, P183; KABACK HR, 1996, HDB BIOL PHYS, V2, P203; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; MCKENNA E, 1992, P NATL ACAD SCI USA, V89, P11954, DOI 10.1073/pnas.89.24.11954; MCKENNA E, 1991, P NATL ACAD SCI USA, V88, P2969, DOI 10.1073/pnas.88.8.2969; Mingarro I, 1996, PROTEIN SCI, V5, P1339, DOI 10.1002/pro.5560050712; ROEPE PD, 1989, P NATL ACAD SCI USA, V86, P3992, DOI 10.1073/pnas.86.11.3992; SAHINTOTH M, 1994, PROTEIN SCI, V3, P2302, DOI 10.1002/pro.5560031215; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; SHARP LL, 1995, BIOCHEMISTRY-US, V34, P9166, DOI 10.1021/bi00028a028; SHARP LL, 1995, P NATL ACAD SCI USA, V92, P7946, DOI 10.1073/pnas.92.17.7946; STOCHAJ U, 1988, J BACTERIOL, V170, P2639, DOI 10.1128/jb.170.6.2639-2645.1988; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VANIWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595, DOI 10.1021/bi00104a005; VIITANEN PV, 1985, BIOCHEMISTRY-US, V24, P7628, DOI 10.1021/bi00347a020; Wallin E, 1997, PROTEIN SCI, V6, P808; Wen JA, 1996, NAT STRUCT BIOL, V3, P141, DOI 10.1038/nsb0296-141; WU JH, 1995, BIOCHEMISTRY-US, V34, P8257, DOI 10.1021/bi00026a007; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; Wu JH, 1996, P NATL ACAD SCI USA, V93, P10123, DOI 10.1073/pnas.93.19.10123	38	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29566	29571		10.1074/jbc.272.47.29566	http://dx.doi.org/10.1074/jbc.272.47.29566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368019	hybrid			2022-12-25	WOS:A1997YG64700029
J	Caccuri, AM; Antonini, G; Nicotra, M; Battistoni, A; LoBello, M; Board, PG; Parker, MW; Ricci, G				Caccuri, AM; Antonini, G; Nicotra, M; Battistoni, A; LoBello, M; Board, PG; Parker, MW; Ricci, G			Catalytic mechanism and role of hydroxyl residues in the active site of theta class glutathione S-transferases - Investigation of Ser-9 and Tyr-113 in a glutathione S-transferase from the Australian sheep blowfly, Lucilia cuprina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BI-BI MECHANISM; KINETICS; FLEXIBILITY; MUTAGENESIS; ISOMERASE; MUTATION; BINDING; P1-1; RAT; PI	Spectroscopic and kinetic studies have been performed on the Australian sheep blowfly Lucilia cuprina glutathione S-transferase (Lucilia GST; EC 2.5.1.18) to clarify its catalytic mechanism, Steady state kinetics of Lucilia GST are non-Michaelian, but the quite hyperbolic isothermic binding of GSH suggests that a steady state random sequential Bi Ri mechanism is consistent with the anomalous kinetics observed. The rate-limiting step of the reaction is a viscosity-dependent physical event, and stopped-flow experiments indicate that product release is rate-limiting, Spectroscopic and kinetic data demonstrate that Lucilia GST is able to lower the pK(a) of the bound GSH from 9.0 to about 6.5. Based on crystallographic suggestions, the role of two hydroxyl residues, Ser-9 and Tyr-113, has been investigated. Removal of the hydroxyl group of Ser-9 by site-directed mutagenesis raises the pK(a) of bound GSH to about 7.6, and a very low turnover number (about 0.5% of that of wild type) is observed. This inactivation may be explained by a strong contribution of the Ser-9 hydroxyl group to the productive binding of GSH and by an involvement in the stabilization of the ionized GSH. This serine residue is highly conserved in the Theta class GSTs, so the present findings may be applicable to all of the family members, Tyr-113 appears not to be essential for the GSH activation. Stopped-flow data indicate that removal of the hydroxyl group of Tyr-113 does not change the rate-limiting step of reaction but causes an increase of the rate constants of both the formation and release of the GSH conjugate, Tyr-113 resides on alpha-helix 4, and its hydroxyl group hydrogen bonds directly to the hydroxyl of Tyr-105, This would reduce the flexibility of a protein region that contributes to the electrophilic substrate binding site; segmental motion of alpha-helix 4 possibly modulates different aspects of the catalytic mechanism of the Lucilia GST.	UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY; CHILDRENS HOSP,IRCCS BAMBIN GESU,I-00165 ROME,ITALY; UNIV AQUILA,DEPT BASIC & APPL BIOL,I-67010 LAQUILA,ITALY; UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI,I-00185 ROME,ITALY; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOL GENET GRP,CANBERRA,ACT 2601,AUSTRALIA; ST VINCENTS INST MED RES,IAN POTTER FDN PROT CRYTALLOG LAB,FITZROY,VIC 3065,AUSTRALIA	University of Rome Tor Vergata; IRCCS Bambino Gesu; University of L'Aquila; Sapienza University Rome; Australian National University; John Curtin School of Medical Research; St. Vincent's Institute of Medical Research			Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022; Battistoni, Andrea/A-4778-2016	Parker, Michael W/0000-0002-3101-1138; Battistoni, Andrea/0000-0003-4085-7917; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961				Armstrong R N, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P1; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOARD P, 1994, BIOCHEM J, V299, P425, DOI 10.1042/bj2990425; BOARD PG, 1995, BIOCHEM J, V311, P247, DOI 10.1042/bj3110247; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1991, ITAL J BIOCHEM, V40, P304; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; Habig W H, 1981, Methods Enzymol, V77, P398; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; LIU SX, 1992, J BIOL CHEM, V267, P4296; LoBello M, 1997, BIOCHEMISTRY-US, V36, P6207, DOI 10.1021/bi962813z; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MILLER J, 1968, REACTION MECH ORGANI, V8, P137; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Segel IH, 1975, ENZYME KINETICS, P460; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Zheng YJ, 1997, J AM CHEM SOC, V119, P1523, DOI 10.1021/ja961667h	38	63	66	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29681	29686		10.1074/jbc.272.47.29681	http://dx.doi.org/10.1074/jbc.272.47.29681			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368035	hybrid			2022-12-25	WOS:A1997YG64700045
J	Ito, H; Okamoto, K; Nakayama, H; Isobe, T; Kato, K				Ito, H; Okamoto, K; Nakayama, H; Isobe, T; Kato, K			Phosphorylation of alpha B-crystallin in response to various types of stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TUMOR-NECROSIS-FACTOR; NON-LENTICULAR TISSUES; KINASE CASCADE; RAPID PHOSPHORYLATION; IMMUNOREACTIVE ALPHA; CHAPERONE ACTIVITY; MAPKAP KINASE-2; PHORBOL ESTER; OKADAIC ACID	Phosphorylation of alpha B-crystallin, a member of the hsp27 family, in human glioma (U373 MG) cells was stimulated by exposure of the cells to various stimuli, which included heat, arsenite, phorbol 12-myristate 13-acetate (PMA), okadaic acid, H2O2, anisomycin, and high concentrations of NaCl or sorbitol, but not in response to agents that elevated intracellular levels of cyclic AMP. Cells exposed to PMA together with okadaic acid yielded three bands of P-32-labeled alpha B-crystallin when immunoprecipitated samples were subjected to electrophoresis on an isoelectric focusing gel. All of the phosphorylated residues were identified as serine, an indication that three different serine residues can act as sites of phosphorylation in alpha B-crystallin. Structural analysis by mass spectrometry revealed that phosphorylation of alpha B-crystallin occurred at serines 19, 45, and 59. Dithiothreitol and staurosporine selectively inhibited the phosphorylation induced by arsenite and the phorbol ester, respectively, SB202190, an inhibitor of p38 mitogen-activated protein (MAP) kinase, suppressed the phosphorylation induced by arsenite, anisomycin, H2O2, sorbitol, NaCl, and heat shock, but not that induced by PMA and okadaic acid, The PMA-induced phosphorylation was selectively suppressed by an inhibitor of p44 MAP kinase kinase, PD98059, Although PMA and arsenite preferentially stimulated the phosphorylation of Ser-45 and Ser-59, respectively, as determined with antibodies that recognized the respective phosphorylated forms of alpha B-crystallin, all three sites were phosphorylated in response to each stimulus, These results suggest that p38 MAP kinase or p44 MAP kinase might be involved in the signal transduction cascade that leads to the phosphorylation of alpha B-crystallin, The phosphorylation of alpha B-crystallin was also enhanced in the heart and diaphragm when rats were exposed to heat stress (42 degrees C for 20 min).	AICHI HUMAN SERV CTR,INST DEV RES,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,HACHIOJI,TOKYO 19203,JAPAN	Tokyo Metropolitan University			Isobe, Toshiaki/Q-9279-2017	Ito, Hidenori/0000-0002-6527-477X				ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNARDINI F, 1995, BIOCHEM BIOPH RES CO, V208, P742, DOI 10.1006/bbrc.1995.1400; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; DUBIN RA, 1990, GENOMICS, V7, P594, DOI 10.1016/0888-7543(90)90204-8; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUY GR, 1992, J BIOL CHEM, V267, P1846; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KASAHARA K, 1993, EUR J BIOCHEM, V213, P1101, DOI 10.1111/j.1432-1033.1993.tb17859.x; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; Nakayama H, 1996, J CHROMATOGR A, V730, P279, DOI 10.1016/0021-9673(95)00974-4; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SMITH JB, 1992, PROTEIN SCI, V1, P601, DOI 10.1002/pro.5560010506; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; VANDEROU.FJ, 1974, EUR J BIOCHEM, V49, P157; VOORTER CEM, 1989, FEBS LETT, V259, P50; WANG KY, 1995, EXP EYE RES, V61, P115; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YOSHITAKE S, 1979, EUR J BIOCHEM, V101, P395, DOI 10.1111/j.1432-1033.1979.tb19731.x	48	180	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29934	29941		10.1074/jbc.272.47.29934	http://dx.doi.org/10.1074/jbc.272.47.29934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368070	hybrid			2022-12-25	WOS:A1997YG64700080
J	Kersten, S; Reczek, PR; Noy, N				Kersten, S; Reczek, PR; Noy, N			The tetramerization region of the retinoid X receptor is important for transcriptional activation by the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAINS; NUCLEAR HORMONE RECEPTORS; ACID RECEPTOR; THYROID-HORMONE; RESPONSE ELEMENTS; LIGAND-BINDING; DIRECT REPEATS; CO-REPRESSOR; ALL-TRANS; DEPENDENT TRANSACTIVATION	The retinoid X receptor (RXR), a member of the superfamily of hormone nuclear receptors, is a ligand-inducible transcription factor that is activated by the vitamin A derivative 9-cis-retinoic acid. We previously showed that RXR self-associates into tetramers with a high affinity and that ligand binding induces rapid dissociation of receptor tetramers to smaller species. Here, the RXR region that is responsible for mediating tetramer formation is identified. It is shown that this interface, which we term the ''tetramerization domain,'' critically contains two consecutive phenylalanine residues located at the C-terminal region of the receptor. Mutation of these residues is sufficient to disrupt RXR tetramers without affecting the overall fold of the protein or interfering with ligand binding, dimer formation, or DNA binding by the receptor. Nevertheless, the tetramer-impaired mutant was found to be transcriptionally defective. The newly characterized tetramerization domain and the previously identified main dimerization interface of RXR act autonomously to affect separate intersubunit interactions that, overall, lead to formation of tetramers, Protein-protein interactions mediated by the tetramerization domain, but not those that involve the dimerization interface, are disrupted following ligand binding by RXR Overall, these data attest to the specificity of the interaction and implicate the tetramerization interface in playing a direct role in regulating transcriptional activation by RXR.	CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA; BRISTOL MYERS SQUIBB CO, BUFFALO, NY 14213 USA	Cornell University; Bristol-Myers Squibb			Kersten, Sander/A-1116-2011	Kersten, Sander/0000-0003-4488-7734	NCI NIH HHS [CA68150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1994, J BIOL CHEM, V269, P16689; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; BORTELL R, 1993, P NATL ACAD SCI USA, V90, P2300, DOI 10.1073/pnas.90.6.2300; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P13717, DOI 10.1021/bi00042a001; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; Kersten S, 1997, J BIOL CHEM, V272, P12771, DOI 10.1074/jbc.272.19.12771; Kizaki M, 1996, BLOOD, V87, P1977; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Law Simon W., 1994, Gene Expression, V4, P77; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Lin BC, 1997, J BIOL CHEM, V272, P9860; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; Nagy L, 1996, J BIOL CHEM, V271, P4355; ONATE SA, 1995, SCIENCE, V270, P1354; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; REDFERN CPF, 1995, EUR J CANCER, V31A, P486, DOI 10.1016/0959-8049(95)00066-R; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; SPANJAARD RA, 1995, J BIOL CHEM, V270, P17429, DOI 10.1074/jbc.270.29.17429; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VuDac N, 1996, MOL CELL BIOL, V16, P3350; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	77	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29759	29768		10.1074/jbc.272.47.29759	http://dx.doi.org/10.1074/jbc.272.47.29759			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368046	hybrid			2022-12-25	WOS:A1997YG64700056
J	Olson, MW; Gervasi, DC; Mobashery, S; Fridman, R				Olson, MW; Gervasi, DC; Mobashery, S; Fridman, R			Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; GELATINASE-A; PROTEOLYTIC ACTIVITY; PROGELATINASE-A; ACTIVATION; MECHANISM; CONSTANTS	The dissociation constants (K-d) of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2, for the active and latent forms of matrix metalloproteinase (MMP)-2 and MMP-9 were evaluated using surface plasmon resonance (SPR) and enzyme inhibition studies, SPR analysis shows biphasic kinetics with high (nM) and low (mu M) affinity binding sites of TIMP-2 and TIMP-1 for MMP-2 (72- and 62-kDa species) and MMP-9 (92- and 82-kDa species), respectively, In contrast, binding data of TIMP-8 to an MMP-2 45-kDa active form lacking the C-terminal domain and to an MMP-2 C-terminal domain (CTD) fragment displays monophasic kinetics with K-d values of 315 and 60 nM, respectively, This suggests that the CTD contains the high affinity binding site, whereas the catalytic domain contains the low affinity site. Also, binding of TIMP-2 to pro-MMP-2 is stronger at both the high and low affinity sites than the corresponding binding of TIMP-2 to the MMP-2 62-kDa form demonstrating the importance of the N-terminal prodomain. In addition, the K-d value of TIMP-1 for the MMP-2 62-kDa species is 28.6 nn at the high affinity site, yet neither the MMP-2 45-kDa species nor the CTD interacts with TIMP-1. Enzyme inhibition studies demonstrate that TIMPs are slow binding inhibitors with monophasic inhibition kinetics, This suggests that a single binding event results in enzyme inhibition, The kinetic parameters for the onset of inhibition are fast (k(on) -10(5) M-1 s(-1)) with slow off rates (k(off) similar to 10(-3) s(-1)). The inhibition constants (K-i) are in the 10(-7)-10(-9) hr range and correlate with the values determined by SPR.	WAYNE STATE UNIV,DEPT PATHOL,DETROIT,MI 48201; WAYNE STATE UNIV,KARMANOS CANC INST,DETROIT,MI 48201; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48201	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University					NCI NIH HHS [CA-61986] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BROWN PD, 1990, CANCER RES, V50, P6184; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIDMAN R, 1995, CANCER RES, V55, P2548; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICK BR, 1978, CAN J BIOCHEM CELL B, V56, P1055, DOI 10.1139/o78-166; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISBON AM, 1995, NAT STRUCT BIOL, V11, P938; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Taylor KB, 1996, J BIOL CHEM, V271, P23938, DOI 10.1074/jbc.271.39.23938; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	28	241	250	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29975	29983		10.1074/jbc.272.47.29975	http://dx.doi.org/10.1074/jbc.272.47.29975			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368077	hybrid			2022-12-25	WOS:A1997YG64700087
J	Panzenboeck, U; Raitmayer, S; Reicher, H; Lindner, H; Glatter, O; Malle, E; Sattler, W				Panzenboeck, U; Raitmayer, S; Reicher, H; Lindner, H; Glatter, O; Malle, E; Sattler, W			Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; HYDROGEN-PEROXIDE-CHLORIDE; SELECTIVE UPTAKE; ESTER HYDROPEROXIDES; CELLULAR CHOLESTEROL; GAS-CHROMATOGRAPHY; REACTION-PRODUCTS; FATTY-ACIDS; HUMAN SERUM	Myeloperoxidase (MPO), a protein secreted by activated phagocytes, may be a potential candidate for the generation of modified/oxidized lipoproteins in vivo via intermediate formation of HOCl, a powerful oxidant. During the present study, the effects of reagent NaOCl and OCl- generated by the MPO/H2O2/Cl- system on physicochemical and metabolic properties of high density lipoprotein (HDL) subclass 3 (HDL3) were investigated, Up to a molar oxidant:lipoprotein ratio of approximately 30:1, apolipoprotein A-I (apoA-I), the major HDL3 apolipoprotein component, represented the preferential target for OCl- attach (consuming 35-76% of the oxidant), thereby protecting HDL3 fatty acids (consuming between 17 and 30% of the oxidant) against OCl--mediated modification. At molar oxidant:HDL3 ratios greater than or equal to 60:1, we have observed pronounced consumption of HDL3 unsaturated fatty acids with concomitant formation of fatty acid chlorohydrins. Modification of HDL3 in the presence of the MPO/H2O2/Cl- system resulted in amino acid oxidation in a manner comparable with that found with reagent NaOCl only, Treatment of HDL3 with reagent NaOCl as well as modification by the MPO/H2O2/Cl- system resulted in significantly enhanced turnover rates of HDL3 by mouse peritoneal macrophages, an effect that was not a result of HDL3 aggregation as judged by dynamic and static light-scattering experiments, In comparison with native HDL3, the degradation by macrophages was enhanced by 4- and 15-fold when HDL3 was modified with reagent NaOCl or the MPO/H2O2/Cl- system, Finally, the ability of HDL3 to promote cellular cholesterol efflux from macrophages was significantly diminished after modification with reagent NaOCl. Collectively, these results demonstrate that the modification of HDL3 by hypochlorite (added as reagent or generated by the MPO/H2O2/Cl- system) transformed an antiatherogenic lipoprotein particle into a modified lipoprotein with characteristics similar to lipoproteins commonly thought to initiate foam cell formation in vivo.	GRAZ UNIV,DEPT BIOCHEM MED,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,DEPT PHYS CHEM,A-8010 GRAZ,AUSTRIA	University of Graz; University of Graz			Malle, Ernst/D-3071-2013	Panzenbock, Ute/0000-0002-0545-6758				BANKA CL, 1994, J BIOL CHEM, V269, P10288; Banka CL, 1996, CURR OPIN LIPIDOL, V7, P139, DOI 10.1097/00041433-199606000-00005; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; Christison J, 1996, BIOCHEM J, V314, P739, DOI 10.1042/bj3140739; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622; Cogny A, 1996, BIOCHEM J, V314, P285, DOI 10.1042/bj3140285; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; FOOTE CS, 1981, NATURE, V301, P715; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; GUERTIN F, 1995, BIOCHEM BIOPH RES CO, V212, P1, DOI 10.1006/bbrc.1995.1927; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; HAZEN SL, 1996, J CLIN INVEST, V98, P1; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P167, DOI 10.1016/0005-2760(92)90287-6; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KAESBERG B, 1993, ARTERIOSCLER THROMB, V13, P133, DOI 10.1161/01.ATV.13.1.133; KATRANTZIS M, 1991, FREE RADICAL BIO MED, V10, P101, DOI 10.1016/0891-5849(91)90003-L; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; LAMPERT MB, 1983, BLOOD, V62, P645; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; Malle E, 1997, AM J PATHOL, V150, P603; MALLE E, 1995, ARTERIOSCL THROM VAS, V15, P982, DOI 10.1161/01.ATV.15.7.982; Malle E, 1996, EUR J CLIN INVEST, V26, P427, DOI 10.1046/j.1365-2362.1996.159291.x; MCCALL M, 1995, ARTERIOSCL THROM VAS, V15, P1599, DOI 10.1161/01.ATV.15.10.1599; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MURAKAMI M, 1986, BIOCHEM BIOPH RES CO, V137, P29, DOI 10.1016/0006-291X(86)91171-X; NAGANO Y, 1991, P NATL ACAD SCI USA, V88, P6457, DOI 10.1073/pnas.88.15.6457; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; PANASENKO OM, 1994, FREE RADICAL BIO MED, V16, P143, DOI 10.1016/0891-5849(94)90137-6; Panzenboeck U, 1997, J LIPID RES, V38, P239; PARKS JS, 1979, J BIOL CHEM, V254, P6716; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Rifici VA, 1996, BBA-LIPID LIPID MET, V1299, P87, DOI 10.1016/0005-2760(95)00198-0; RINNINGER F, 1993, BIOCHIM BIOPHYS ACTA, V1166, P275, DOI 10.1016/0005-2760(93)90108-L; SALMON S, 1992, BIOCHIM BIOPHYS ACTA, V1125, P230, DOI 10.1016/0005-2760(92)90050-6; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SATTLER W, 1991, ANAL BIOCHEM, V198, P184, DOI 10.1016/0003-2697(91)90526-Y; SATTLER W, 1996, LIPIDS, V12, P1303; SEGREST JP, 1992, J LIPID RES, V33, P141; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; VANDENBERG J, 1994, METHOD ENZYMOL, V233, P639; VANDENBERG JJM, 1993, J LIPID RES, V34, P2005; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	61	89	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29711	29720		10.1074/jbc.272.47.29711	http://dx.doi.org/10.1074/jbc.272.47.29711			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368040	hybrid			2022-12-25	WOS:A1997YG64700050
J	Brandsma, M; Janssen, GMC; Moller, W				Brandsma, M; Janssen, GMC; Moller, W			Termination of quiescence in crustacea - The role of transfer RNA aminoacylation in the brine shrimp Artemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MESSENGER-RNA; SALINA EMBRYOS; SYNTHETASE; PURIFICATION; TRANSLATION	In quiescent embryos of the brine shrimp Artemia, the level of aminoacylation of transfer RNAs is low, During resumption of development the charging level of transfer RNAs increases, concomitant with the activation of protein synthesis. The total level of charging rises dramatically from an average of 4% to 50% within a period of 24 h of development. The restriction of in vitro translation of the quiescent embryo extract can be partially released by the addition of charged aminoacyl-tRNA, which apparently starts the flow of ribosomes into polyribosome structures, Complete reactivation of translation by aminoacyl-tRNA occurs when mRNA from preformed mRNA-ribosome complexes, like the polyribosomes extracted from developing embryos or poly(U)-programmed ribosomes, are offered to quiescent embryo extracts, With respect to the mechanism of in vivo recharging of tRNAs, are observed that the level of several aminoacyl-tRNA synthetases increase during development. Methionyl-tRNA synthetase rises more than 10-fold. In the case of valyl-tRNA synthetase, the activation is lower and shown to be due to the de novo synthesis of its mRNA and the corresponding protein product as well, We conclude that protein synthesis and thereby the gradual animation of cryptobiotic Artemia embryos is determined to a large extent by the rate by which aminoacyl-tRNAs are replenished during development at both the initiation and elongation level.	LEIDEN UNIV,DEPT MED BIOCHEM,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAGSHAW JC, 1970, DEV BIOL, V23, P23, DOI 10.1016/S0012-1606(70)80005-7; BRANDSMA M, 1995, EUR J BIOCHEM, V233, P277, DOI 10.1111/j.1432-1033.1995.277_1.x; CHANG PK, 1990, J BIOL CHEM, V265, P20898; Clegg JS, 1996, PHYSIOL ZOOL, V69, P49, DOI 10.1086/physzool.69.1.30164200; CLEGG JS, 1980, BRINE SHRIMP ARTEMIA, V2, P11; CLEMENS MJ, 1990, TRENDS BIOCHEM SCI, V15, P172, DOI 10.1016/0968-0004(90)90153-3; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CROWE JH, 1987, ARTEMIA RES ITS APPL, V2, P19; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; FINNAMORE, 1969, CELL CYCLE, P249; GOLUB A, 1968, DEV BIOL, V17, P644, DOI 10.1016/0012-1606(68)90011-0; GROSFELD H, 1976, EUR J BIOCHEM, V70, P589, DOI 10.1111/j.1432-1033.1976.tb11050.x; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HULTIN T, 1968, DEV BIOL, V17, P143, DOI 10.1016/0012-1606(68)90058-4; IWASAKI K, 1981, RNA PROTEIN SYNTHESI, P435; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; JANSSEN GMC, 1990, RIBOSOMES PROTEIN SY, P51; JANSSEN GMC, 1994, THESIS LEIDEN U NETH; KELLERMANN O, 1978, EUR J BIOCHEM, V88, P197, DOI 10.1111/j.1432-1033.1978.tb12438.x; KENMOCHI N, 1989, J BIOCHEM-TOKYO, V106, P289, DOI 10.1093/oxfordjournals.jbchem.a122846; KNECHT R, 1986, ADV METHODS PROTEIN, P56; LANKER S, 1992, CELL, V70, P647, DOI 10.1016/0092-8674(92)90433-D; Lavens P., 1987, P27; LEEHUANG S, 1977, ARCH BIOCHEM BIOPHYS, V180, P276, DOI 10.1016/0003-9861(77)90039-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACRAE TH, 1979, EUR J BIOCHEM, V100, P67, DOI 10.1111/j.1432-1033.1979.tb02034.x; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MOLLER W, 1987, ARTEMIA RES ITS APPL, V2, P451; MORENO A, 1991, BIOCHEM J, V276, P809, DOI 10.1042/bj2760809; OGILVIE A, 1979, BIOCHIM BIOPHYS ACTA, V565, P293, DOI 10.1016/0005-2787(79)90206-5; PUTZER H, 1995, MOL MICROBIOL, V16, P709, DOI 10.1111/j.1365-2958.1995.tb02432.x; REDDINGTON MA, 1978, DEV BIOL, V63, P402, DOI 10.1016/0012-1606(78)90144-6; ROJIANI MV, 1990, P NATL ACAD SCI USA, V87, P1511, DOI 10.1073/pnas.87.4.1511; Sambrook J., 2002, MOL CLONING LAB MANU; SETLOW P, 1974, J BACTERIOL, V118, P1067, DOI 10.1128/JB.118.3.1067-1074.1974; SIERRA JM, 1974, P NATL ACAD SCI USA, V71, P2693, DOI 10.1073/pnas.71.7.2693; THOMAS G, 1979, CELL BIOL INT REP, V3, P307, DOI 10.1016/S0309-1651(79)80001-6; TOCKMAN J, 1977, J BACTERIOL, V130, P1091, DOI 10.1128/JB.130.3.1091-1097.1977; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	12	12	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28912	28917		10.1074/jbc.272.46.28912	http://dx.doi.org/10.1074/jbc.272.46.28912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360961	Green Published, hybrid			2022-12-25	WOS:A1997YF68400020
J	Cantu, C; Huang, WZ; Palzkill, T				Cantu, C; Huang, WZ; Palzkill, T			Cephalosporin substrate specificity determinants of TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-STRUCTURE; EXTENDED-SPECTRUM; MUTAGENESIS; SELECTION; ENZYME; HYDROLYSIS; RESOLUTION; MUTATIONS; REVEALS; PROTEIN	beta-lactamase is a bacterial enzyme that catalyzes the hydrolysis of beta-lactam antibiotics such as penicillins and cephalosporins. TEM-1 beta-lactamase is a prevalent beta-lactamase found in Gram-negative bacteria and is capable of hydrolyzing both penicillins and cephalosporins, except for the extended-spectrum cephalosporins, To identify the sequence determinants in the active site for a given antibiotic substrate, random libraries were constructed that each contain all possible amino acid combinations for the designated region of TEM-1 beta-lactamase, To establish the determinants of substrate specificity for cephalosporins versus those for penicillins, these active site Libraries have been screened for mu tants with high levels of activity for the second generation cephalosporin cephaloridine, Based on the sequence results, substitutions of W165S, A237T, and E240C were identified as cephalosporin-specific. Kinetic analysis of these mutants was done to determine whether each is capable of distinguishing between the two classes of antibiotics. Both the A237T and E240C substitutions, alone or in combination, exhibited increased cephalosporinase activity and decreased penicillinase activity relative to the wild-type enzyme. A sequence comparison between functional mutants selected for cephaloridine hydrolytic activity and functional mutants previously selected for ampicillin hydrolytic activity suggests that TEM-1 beta-lactamase has greater restrictions in maintaining cephalosporinase activity versus maintaining penicillinase activity.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOL BIOPHYS PROGRAM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI032956, R01AI032956, R56AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bevington PR, 1969, DATA REDUCTION ERROR; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Fersht A., 1985, ENZYME STRUCTURE MEC, P99; HALL A, 1976, NATURE, V264, P803, DOI 10.1038/264803a0; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; IMTIAZ U, 1993, ANTIMICROB AGENTS CH, V37, P2438, DOI 10.1128/AAC.37.11.2438; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; JUTEAU JM, 1992, PROTEIN ENG, V5, P693, DOI 10.1093/protein/5.7.693; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; MINAMI S, 1980, ANTIMICROB AGENTS CH, V18, P382, DOI 10.1128/AAC.18.3.382; NEU HC, 1965, J BIOL CHEM, V240, P3685; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Vanhove M, 1996, PROTEINS, V25, P104, DOI 10.1002/(SICI)1097-0134(199605)25:1<104::AID-PROT8>3.3.CO;2-H; WIEDEMANN B, 1989, J ANTIMICROB CHEMOTH, V24, P1	30	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29144	29150		10.1074/jbc.272.46.29144	http://dx.doi.org/10.1074/jbc.272.46.29144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360991	hybrid			2022-12-25	WOS:A1997YF68400050
J	Tachibana, I; Bodorova, J; Berditchevski, F; Zutter, MM; Hemler, ME				Tachibana, I; Bodorova, J; Berditchevski, F; Zutter, MM; Hemler, ME			NAG-2, a novel transmembrane-4 superfamily (TM4SF) protein that complexes with integrins and other TM4SF proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; MHC CLASS-II; MONOCLONAL-ANTIBODIES; T-CELLS; TYROSINE PHOSPHORYLATION; MEMBRANE GLYCOPROTEIN; SYNCYTIUM FORMATION; SEQUENCE-ANALYSIS; B-LYMPHOCYTES; C33 ANTIGEN	Transmembrane-4 superfamily (TM4SF) proteins form complexes with integrins and other cell-surface proteins. To further characterize the major proteins present in a typical TM4SF protein complex, we raised monoclonal antibodies against proteins co-immunoprecipitated with CD81 from MDA-MB-435 breast cancer cells. Only two types of cell-surface proteins were recognized by our 35 selected antibodies. These included an integrin (alpha(6) beta(1)) and three different TM4SF proteins (CD9, CD63, and NAG-2). The protein NAG-P (novel anti gen-a) is a previously unknown 30-kDa cell-surface protein. Using an expression cloning protocol, cDNA encoding NAG-2 was isolated. When aligned with other TM4SF proteins, the deduced amino acid sequence of NAG-2 showed most identity (34%) to CD53. Flow cytometry, Northern blotting, and immunohistochemistry showed that NAG-2 is widely present in multiple tissues and cell types but is absent from brain, lymphoid cells, and platelets, Within various tissues, strongest staining was seen on fibroblasts, endothelial cells, follicular dendritic cells, and mesothelial cells. In nonstringent detergent, NAG-2 protein was co-immunoprecipitated with other TM4SF members (CD9 and CD81) and integrins (alpha(3) beta(1) and alpha(6) beta(1)). Also, two-color immunofluorescence showed that NAG-S was co-localized with CD81 on the surface of spread HT1080 cells. These results confirm the presence of NAG-S in specific TM4SF.TM4SF and TM4SF-integrin complexes.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Washington University (WUSTL)					NATIONAL CANCER INSTITUTE [R01CA070275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NCI NIH HHS [CA70275] Funding Source: Medline; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GIL ML, 1992, J IMMUNOL, V148, P2826; Gwynn B, 1996, GENOMICS, V35, P389, DOI 10.1006/geno.1996.0375; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; IMAI T, 1993, J IMMUNOL, V151, P6470; Jones PH, 1996, CELL ADHES COMMUN, V4, P297, DOI 10.3109/15419069609010773; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; Mannion BA, 1996, J IMMUNOL, V157, P2039; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; PASQUALINI R, 1993, J CELL SCI, V105, P101; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHICK MR, 1993, J IMMUNOL, V151, P1918; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; Skubitz KM, 1996, J IMMUNOL, V157, P3617; SLUPSKY JR, 1989, J BIOL CHEM, V264, P12289; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Szollosi J, 1996, J IMMUNOL, V157, P2939; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; Tomlinson MG, 1996, J MOL EVOL, V43, P312; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; WRIGHT MD, 1990, J IMMUNOL, V144, P3195; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171; ZUTTER MM, 1991, BLOOD, V77, P2231	51	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29181	29189		10.1074/jbc.272.46.29181	http://dx.doi.org/10.1074/jbc.272.46.29181			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360996	hybrid			2022-12-25	WOS:A1997YF68400055
J	King, SL; Kamata, T; Cunningham, JA; Emsley, J; Liddington, RC; Takada, Y; Bergelson, JM				King, SL; Kamata, T; Cunningham, JA; Emsley, J; Liddington, RC; Takada, Y; Bergelson, JM			Echovirus 1 interaction with the human very late antigen-2 (integrin alpha 2 beta 1) I domain - Identification of two independent virus contact sites distinct from the metal, ion-dependent adhesion site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; LIGAND-BINDING SITES; A-DOMAIN; INTERCELLULAR-ADHESION; EXTRACELLULAR-MATRIX; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; VLA-2; PROTEINS; COLLAGEN	The human integrin very late antigen (VLA)-2 (CD49b/CD29) mediates interactions with collagen and is the receptor for echovirus 1. Binding sites for both collagen and echovirus 1 have been mapped to the I domain within the alpha 2 subunit of the VLA-2 alpha 2 beta 1 heterodimer. Although murine VLA-2 interacts with collagen, it does not bind virus. We have used isolated human-murine chimeric I domains expressed as glutathione S-transferase fusion proteins in Escherichia coli to identify two groups of amino acids, 199-201 and 212-216, independently involved in virus attachment. These residues are distinct from the metal ion-dependent adhesion site previously demonstrated to be essential for VLA-2 interactions with collagen. Mutations in three metal ion-dependent adhesion site residues that abolish adhesion to collagen had no effect on virus binding. These results confirm that different sites within the I domain are responsible for VLA-2 interaction with extracellular matrix proteins and with viral ligands.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV INFECT DIS, BOSTON, MA 02115 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Scripps Research Institute; University of Leicester			emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030; takada, yoshikazu/0000-0001-5481-9589	NIAID NIH HHS [AI35667] Funding Source: Medline; NIGMS NIH HHS [GM47157, GM49899] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035667] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGELSON JM, 1993, J VIROL, V67, P6847, DOI 10.1128/JVI.67.11.6847-6852.1993; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BERGELSON JM, 1993, J CLIN INVEST, V92, P232, DOI 10.1172/JCI116555; COLOMBATTI A, 1991, BLOOD, V77, P2305; EDELMAN JM, 1994, CELL ADHES COMMUN, V2, P131, DOI 10.3109/15419069409004432; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kamata T, 1996, J BIOL CHEM, V271, P19008, DOI 10.1074/jbc.271.31.19008; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PISCHEL KD, 1987, J IMMUNOL, V138, P226; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; SANTOSO S, 1991, THROMB HAEMOSTASIS, V65, P678; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TUCKWELL D, 1995, J CELL SCI, V108, P1629; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZYLSTRA S, 1986, CANCER RES, V46, P6446	32	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28518	28522		10.1074/jbc.272.45.28518	http://dx.doi.org/10.1074/jbc.272.45.28518			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353313	hybrid			2022-12-25	WOS:A1997YF21900053
J	Lachowicz, A; VanGoor, P; Katzur, AC; Bonhomme, G; Stojilkovic, SS				Lachowicz, A; VanGoor, P; Katzur, AC; Bonhomme, G; Stojilkovic, SS			Uncoupling of calcium mobilization and entry pathways in endothelin-stimulated pituitary lactotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; FREE CA-2+ CONCENTRATIONS; RAT ANTERIOR-PITUITARY; PROLACTIN SECRETION; INOSITOL PHOSPHATE; NONEXCITABLE CELLS; INDUCED SPIKE; AR42J CELLS; CA2+ ENTRY; OSCILLATIONS	In cells expressing Ca2+-mobilizing receptors, InsP(3)- induced Ca2+ release from intracellular stores is commonly associated with extracellular Ca2+ influx. Operation of these two Ca2+ signaling pathways mediates thyrotropin-releasing hormone (TRH) and angiotensin II (AII)-induced prolactin secretion from rat pituitary lactotrophs. After an initial hyperpolarization induced by Ca2+ mobilization from the endoplasmic reticulum (ER), these agonists generated an increase in the steady-state firing of action potentials, further facilitating extracellular Ca2+ influx and prolactin release. Like TRH and AII, endothelin-l (ET-1) also induced a rapid release of Ca2+ from the ER and a concomitant spike prolactin secretion during the first 3-5 min of stimulation, However, unlike TRH and AII actions, Ca2+ mobilization was not coupled to Ca2+ influx during sustained ET-1 stimulation, as ET-1 induced a long-lasting abolition of action potential firing, This lead to a depletion of the ER Ca2+ pool, a prolonged decrease in [Ca2+](i), and sustained inhibition of prolactin release. ET-l-induced inhibition and TRH/AII-induced stimulation of Ca2+ influx and hormone secretion were reduced in the presence of the L-type Ca2+ channel blocker, nifedipine, Basal [Ca2+](i) and prolactin release were also reduced in the presence of nifedipine. Furthermore, TRH-induced Ca2+ influx and secretion were abolished by ET-1, as TRH was unable to reactivate Ca2+ influx and prolactin release in ET-l-stimulated cells. Depolarization of the cells during sustained inhibitory action of ET-1, however, increased [Ca2+](i) and prolactin release, These results indicate that L-type Ca2+ channel represents a common Ca2+ influx pathway that controls basal [Ca2+](i) and secretion and is regulated by TRH/AII and ET-1 in an opposite manner, Thus, the receptor-mediated uncoupling of Ca2+ entry from Ca2+ mobilization provides an effective control mechanism in terminating the stimulatory action of ET-1. Moreover, it makes electrically active lactotrophs quiescent and unresponsive to other calcium-mobilizing agonists.	NICHHD,ERBB,UCS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD SJ, 1991, NATURE, V352, P162; CESNJAJ M, 1995, MOL BIOL CELL, V9, P1037; CHAO HS, 1993, ENDOCRINOLOGY, V133, P505, DOI 10.1210/en.133.2.505; DUBINSKY JM, 1984, J GEN PHYSIOL, V83, P309, DOI 10.1085/jgp.83.3.309; DYMSHITZ J, 1992, NEUROENDOCRINOLOGY, V55, P724, DOI 10.1159/000126192; Gershengorn MC, 1996, PHYSIOL REV, V76, P175, DOI 10.1152/physrev.1996.76.1.175; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V183, P1090, DOI 10.1016/S0006-291X(05)80302-X; KANYICSKA B, 1991, BIOCHEM BIOPH RES CO, V174, P338, DOI 10.1016/0006-291X(91)90525-C; Kanyicska B, 1997, ENDOCRINOLOGY, V138, P3141, DOI 10.1210/en.138.8.3141; KANYICSKA B, 1993, AM J PHYSIOL, V265, pE601, DOI 10.1152/ajpendo.1993.265.4.E601; KANYICSKA B, 1995, ENDOCRINOLOGY, V136, P990, DOI 10.1210/en.136.3.990; KUKULJAN M, 1992, FEBS LETT, V301, P19, DOI 10.1016/0014-5793(92)80201-Q; LEWIS DL, 1988, ENDOCRINOLOGY, V123, P611, DOI 10.1210/endo-123-1-611; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; NELSON EJ, 1994, ENDOCRINOLOGY, V135, P1084, DOI 10.1210/en.135.3.1084; OZAWA S, 1986, PHYSIOL REV, V66, P887, DOI 10.1152/physrev.1986.66.4.887; OZAWA S, 1979, P NATL ACAD SCI USA, V76, P6017, DOI 10.1073/pnas.76.11.6017; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; RUTHERFORD RAD, 1993, BRIT J PHARMACOL, V109, P544, DOI 10.1111/j.1476-5381.1993.tb13605.x; SAMSON WK, 1990, BIOCHEM BIOPH RES CO, V169, P737, DOI 10.1016/0006-291X(90)90393-2; SAMSON WK, 1992, BIOCHEM BIOPH RES CO, V187, P590, DOI 10.1016/0006-291X(92)91235-I; SAMSON WK, 1992, ENDOCRINOLOGY, V130, P2964, DOI 10.1210/en.130.5.2964; Samson WK, 1995, ADV EXP MED BIOL, V395, P355; Sankaranarayanan S, 1996, AM J PHYSIOL-CELL PH, V271, pC1927, DOI 10.1152/ajpcell.1996.271.6.C1927; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; STOJILKOVIC SS, 1992, TRENDS PHARMACOL SCI, V13, P385, DOI 10.1016/0165-6147(92)90118-P; STOJILKOVIC SS, 1992, P NATL ACAD SCI USA, V89, P4081, DOI 10.1073/pnas.89.9.4081; STOJILKOVIC SS, 1991, J BIOL CHEM, V266, P10377; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; STOJILKOVIC SS, 1992, ENDOCR REV, V13, P256, DOI 10.1210/er.13.2.256; STOJILKOVIC SS, 1991, MOL PHARMACOL, V39, P762; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TOMIC M, 1994, ENDOCRINOLOGY, V135, P1762, DOI 10.1210/en.135.5.1762; VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WINIGER BP, 1988, BIOCHEM J, V255, P161, DOI 10.1042/bj2550161; ZHAO H, 1990, J BIOL CHEM, V265, P20856	47	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28308	28314		10.1074/jbc.272.45.28308	http://dx.doi.org/10.1074/jbc.272.45.28308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353286	hybrid			2022-12-25	WOS:A1997YF21900026
J	Leon, DA; Herberg, FW; Banky, P; Taylor, SS				Leon, DA; Herberg, FW; Banky, P; Taylor, SS			A stable alpha-helical domain at the N terminus of the RI alpha subunits of cAMP-dependent protein kinase is a novel dimerization/docking motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II REGULATORY SUBUNIT; A-KINASE; ANCHORING PROTEINS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; BINDING DOMAINS; LEUCINE-ZIPPER; CYCLIC-GMP; LOCALIZATION; SITE	The RI alpha subunit of cAMP-dependent protein kinase is maintained as an asymmetric dimer by a dimerization motif at the N terminus, Based on resistance to proteolysis and expression as a discrete domain in Escherichia coli, this motif is defined as residues 12-61. This motif is chemically, kinetically, and thermally stable, The two endogenous interchain disulfide bonds between Cys(16) and Cys(37) in RI alpha are extremely resistant to reduction even in 8 M urea, indicating that they are well shielded from the reducing environment of the cell. The disulfide bonds were present in recombinant RI alpha as well as when the dimerization domain alone was expressed in E. coli, emphasizing the unusual stability of this motif and the disulfide bonds. Although 100 mM, dithiothreitol was sufficient to reduce the disulfide bonds, it did not abolish dimerization. In addition, a stable dimer also still formed when Cys(37) was replaced with His, confirming unambiguously the original antiparallel alignment of the disulfide bonds, Thus, both in vitro and in vivo, disulfide bonds are not required for dimerization. Circular dichroism of the dimerization domain indicated a high content of a thermostable alpha-helix. Based on the CD data, trypsin resistance of the fragment, location of the disulfide bonds, and amphipathic helix predictions, potential models are discussed, A new alignment of the dimerization domains of RI, RII, and cGMP-dependent protein kinase elucidates fundamental similarities as well as significant differences among these three domains.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; RUHR UNIV BOCHUM, INST BIOCHEM SUPRAMOL SYST, D-44780 BOCHUM, GERMANY	Howard Hughes Medical Institute; University of California System; University of California San Diego; Ruhr University Bochum			Herberg, Friedrich W/B-5572-2015	Herberg, Friedrich W/0000-0001-7117-7653	NIGMS NIH HHS [GM34921] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034921] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; BUBIS J, 1987, J BIOL CHEM, V262, P14961; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HERBERG FW, 1994, BIOCHEMISTRY-US, V33, P7485, DOI 10.1021/bi00189a057; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDGRAF W, 1990, BIOCHEMISTRY-US, V29, P9921, DOI 10.1021/bi00494a024; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEON DA, 1991, BIOCHEMISTRY-US, V30, P3035, DOI 10.1021/bi00226a008; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MONKEN CE, 1985, ARCH BIOCHEM BIOPHYS, V240, P888, DOI 10.1016/0003-9861(85)90099-2; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASWAT LD, 1988, METHOD ENZYMOL, V159, P325; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TITANI K, 1981, PROTEIN PHOSPHORYLAT, P19; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WELDON SL, 1983, J BIOL CHEM, V258, P1129; ZICK SK, 1982, J BIOL CHEM, V257, P2287; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	48	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28431	28437		10.1074/jbc.272.45.28431	http://dx.doi.org/10.1074/jbc.272.45.28431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353302	hybrid			2022-12-25	WOS:A1997YF21900042
J	Martin, G; Schoonjans, K; Lefebvre, AM; Staels, B; Auwerx, J				Martin, G; Schoonjans, K; Lefebvre, AM; Staels, B; Auwerx, J			Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR alpha and PPAR gamma activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES ADIPOCYTE DIFFERENTIATION; HORMONE RECEPTOR SUPERFAMILY; INSULIN-SENSITIZING AGENT; PEROXISOME PROLIFERATOR; LIPID-METABOLISM; CDNA CLONING; PIOGLITAZONE; GLUCOSE; CELLS; BINDING	Intracellular fatty acid (FA) concentrations are in part determined by a regulated import/export system that is cent-rolled by two key proteins, i.e. fatty acid transport protein (FATP) and acyl-CoA synthetase (ACS), which respectively facilitate the transport of FAs across the cell membrane and their esterification to prevent their efflux, The aim of this investigation was to analyze the expression pattern of FATP and ACS and to determine whether their expression was altered by agents that affect FA metabolism through the activation of peroxisome proliferator-activated receptors (PPAR) such as the fibrates and thiazolidinediones, FATP mRNA was ubiquitously expressed, with highest levels being detected in adipose tissue, heart, brain, and testis. Fibrate treatment, which is known to preferentially activate PPAR gamma, induced FATP mRNA levels in rat liver and intestine and induced ACS mRNA levels in liver and kidney, The antidiabetic thiazolidinedione BRL 49653, which is a high-affinity ligand for the adipocyte-specific PPAR gamma form, caused a small induction of muscle but a robust induction of adipose tissue FATP mRNA levels. BRL 49653 did not affect liver FATP and had a tendency to decrease heart FATP mRNA levels, ACS mRNA levels in general showed a similar pattern after BRL 49653 as FATP except for the muscle where ACS mRNA was induced, This regulation of FATP and ACS expression by PPAR activators was shown to be at the transcriptional level and could also be reproduced in vitro in cell culture systems, In the hepatocyte cell lines AML-12 or Fa 32, fenofibric acid, but not BRL 49653, induced FATP and ACS mRNA levels, whereas in the 3T3-L1 preadipocyte cell line, the PPAR gamma ligand induced FATP and ACS mRNA levels quicker than fenofibric acid, Inducibility of ACS and FATP mRNA by PPAR alpha or gamma activators correlated with the tissue-specific distribution of the respective PPARs and was furthermore associated with a concomitant increase in FA uptake, Most interestingly, thiazolidinedione antidiabetic agents seem to favor adipocyte-specific FA uptake relative to muscle, perhaps underlying in part the beneficial effects of these agents on insulin-mediated glucose disposal.	INST PASTEUR, U325 INSERM, DEPT ATHEROSCLEROSE, F-59019 LILLE, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265; Lefebvre, Anne-Marie/0000-0001-5644-0441				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; AMRI EZ, 1991, J LIPID RES, V32, P1449; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; APERLO C, 1995, GENE, V162, P297, DOI 10.1016/0378-1119(95)00196-D; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; Bjorntorp P, 1996, INT J OBESITY, V20, P291; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BUCHANAN TA, 1995, J CLIN INVEST, V96, P354, DOI 10.1172/JCI118041; CASTLE CK, 1993, ARTERIOSCLER THROMB, V13, P302, DOI 10.1161/01.ATV.13.2.302; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIRAGUN A, 1988, J CELL PHYSIOL, V134, P124, DOI 10.1002/jcp.1041340115; HIRSHMAN MF, 1995, BIOCHEM BIOPH RES CO, V208, P835, DOI 10.1006/bbrc.1995.1412; IKEDA H, 1990, ARZNEIMITTEL-FORSCH, V40-1, P156; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEFEBVRE AM, 1997, IN PRESS ARTERIOSCLE; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; Marin P, 1996, J CLIN ENDOCR METAB, V81, P1018, DOI 10.1210/jc.81.3.1018; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; Poirier H, 1996, EUR J BIOCHEM, V238, P368, DOI 10.1111/j.1432-1033.1996.0368z.x; RANDLE PJ, 1963, LANCET, V1, P785; Ren J, 1996, DIABETES, V45, P1822, DOI 10.2337/diabetes.45.12.1822; SANDOUK T, 1993, AM J PHYSIOL, V264, pC1600, DOI 10.1152/ajpcell.1993.264.6.C1600; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1996, J LIPID RES, V37, P907; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Shimomura I, 1996, AM J PHYSIOL-ENDOC M, V270, pE995, DOI 10.1152/ajpendo.1996.270.6.E995; SPARKS RL, 1991, J CELL PHYSIOL, V146, P101, DOI 10.1002/jcp.1041460114; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; TEBOUL L, 1995, J BIOL CHEM, V270, P28183, DOI 10.1074/jbc.270.47.28183; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	57	438	460	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28210	28217		10.1074/jbc.272.45.28210	http://dx.doi.org/10.1074/jbc.272.45.28210			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353271	hybrid			2022-12-25	WOS:A1997YF21900011
J	Fabbrini, MS; Carpani, D; BelloRivero, I; Soria, MR				Fabbrini, MS; Carpani, D; BelloRivero, I; Soria, MR			The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated	FASEB JOURNAL			English	Article						ribosome-inactivating proteins; urokinase receptor; LDL-related receptor protein, alpha 2 macroglobulin receptor; cancer therapy	PLASMINOGEN-ACTIVATOR-INHIBITOR; RECEPTOR-RELATED-PROTEIN; RIBOSOME-INACTIVATING PROTEIN; ALPHA(2)-MACROGLOBULIN RECEPTOR; INTRACELLULAR-TRANSPORT; ENDOCYTOSIS; LIPOPROTEIN; COMPLEXES; SAPORIN; EXPRESSION	In contrast to two-chain urokinase (uPA), a chemical conjugate between uPA and native saporin (a cytotoxic plant seed ribosome-inactivating protein) did not require plasminogen activator inhibitors to be internalized, To dissect this pathway, we constructed a chimera consisting of the amino-terminal fragment (ATF) of human urokinase fused to a saporin isoform (SAP-3). The chimeric ATF-SAP toxin was expressed in Escherichia coli, purified, and characterized for its ribosome-inactivating activity. Besides being a potent inhibitor of protein synthesis in cell-free assays, ATF-SAP was specifically cytotoxic toward cells expressing human uPAR. Competition experiments indicated that both the human uPAR and the LDL-related receptor protein are involved in mediating the cell killing ability of ATF-SAP, We conclude that neither plasminogen activator inhibitors nor the catalytic moiety of urokinase are necessary to initiate these internalization pathways, Thus, saporin may play a role similar to plasminogen activator inhibitors in its ability to trigger internalization of uPAR-bound Ligands through endocytic receptors.			Fabbrini, MS (corresponding author), SAN RAFFAELE SCI INST,DIBIT DEPT BIOL & TECHNOL RES,VIA OLGETTINA 58,I-20132 MILAN,ITALY.							ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BARTHELEMY I, 1993, J BIOL CHEM, V268, P6541; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; Christensen L, 1996, INT J CANCER, V66, P441; CONESE M, 1995, FEBS LETT, V358, P73, DOI 10.1016/0014-5793(94)01399-L; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DEVRIES TJ, 1995, J PATHOL, V175, P59, DOI 10.1002/path.1711750110; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; IPPOLITI R, 1995, FASEB J, V9, P1220, DOI 10.1096/fasebj.9.12.7672515; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; MOESTRUP SK, 1993, J BIOL CHEM, V268, P16564; NYKJAER A, 1997, IN PRESS EMBO J; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	28	44	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1169	1176		10.1096/fasebj.11.13.9367352	http://dx.doi.org/10.1096/fasebj.11.13.9367352			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367352				2022-12-25	WOS:A1997YE98300015
J	Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW				Huang, YY; Yuan, ZM; Ishiko, T; Nakada, S; Utsugisawa, T; Kato, T; Kharbanda, S; Kufe, DW			Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine	ONCOGENE			English	Article						ara-C; c-Abl kinase; apoptosis; p53	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INDEPENDENT MECHANISMS; DNA-DAMAGE; P53; STRESS; CYCLE; GROWTH; DEATH; LOCALIZATION	Treatment of cells with the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) and other genotoxic agents is associated with activation of the c-Abl protein tyrosine kinase. The functional role of c-Abl in the response to DNA damage, however, remains unclear. The present studies demonstrate that cells expressing a dominant negative, kinase-inactive c-Abl (K-R) are resistant to killing by ara-C. The expression of c-Abl (K-R) blocked ara-C-induced apoptosis by a mechanism that is at least in part independent of the p53 tumor suppressor. Cells null for c-Abl also exhibited resistance to induction of apoptosis. These findings provide support for a pro-apoptotic function of c-Abl in the response to certain genotoxic drugs.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Utsugisawa, Taiju/ABD-7059-2021	Kato, Tomohisa/0000-0002-3047-9847	NCI NIH HHS [CA66996, CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; GOGA A, 1995, ONCOGENE, V11, P791; GUNJI H, 1991, CANCER RES, V51, P741; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATTIONI T, 1995, ONCOGENE, V10, P1325; OHNO Y, 1988, CANCER RES, V48, P1494; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	34	42	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	1997	15	16					1947	1952		10.1038/sj.onc.1201376	http://dx.doi.org/10.1038/sj.onc.1201376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365241				2022-12-25	WOS:A1997YA87200009
J	Koyama, Y; Yamamoto, T; Kondo, D; Funaki, H; Yaoita, E; Kawasaki, K; Sato, N; Hatakeyama, K; Kihara, I				Koyama, Y; Yamamoto, T; Kondo, D; Funaki, H; Yaoita, E; Kawasaki, K; Sato, N; Hatakeyama, K; Kihara, I			Molecular cloning of a new aquaporin from rat pancreas and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHIP28 WATER CHANNEL; KIDNEY COLLECTING DUCT; INTRINSIC PROTEIN; TRANSPORT WATER; MIP FAMILY; MEMBRANE; CDNA; EXPRESSION; LOCALIZATION; PERMEABILITY	A new water channel (aquaporin-8, gene symbol AQP8) was isolated from rat pancreas and liver by homology cloning, Ribonuclease protection assay showed intense expression of the gene in pancreas and liver, less intense in colon and salivary gland, and negligible in other organs, The full-length cDNA was obtained by ligation of similar to 1.4-kilobase (kb) cDNA isolated from the rat liver cDNA library to similar to 0.5 kb of the 5' end fragment obtained by the rapid amplification of cDNA ends method, A major transcript of similar to 1.45 kb was demonstrated in liver and colon by Northern blot analysis. Expression of the cRNA in Xenopus oocytes markedly enhanced osmotic water permeability in a mercury-sensitive manner, indicating a water channel function of this molecule, The open reading frame encoded a 263-amino acid protein with a predicted molecular size of 28 kDa. Hydropathy analysis represented six membrane-spanning domains and five connecting loops containing two sites of NPA motif as preserved in other aquaporins, Unlike other mammalian aquaporins, AQP8 has an unusual structure with a long N terminus and a short C terminus, which are found in plant aquaporin, gamma-tonoplast intrinsic protein, By in situ hybridization, AQP8 mRNA expression was assumed in hepatocytes, acinal cells of pancreas and salivary gland, and absorptive colonic epithelial cells, The physiological role(s) of AQP8 remain to be elucidated.	NIIGATA UNIV, SCH MED, INST NEPHROL, DEPT PATHOL, NIIGATA 951, JAPAN; NIIGATA UNIV, SCH MED, DEPT SURG 1, NIIGATA 951, JAPAN	Niigata University; Niigata University								AGRE P, 1993, AM J PHYSIOL, V265, pF463; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; DENKER BM, 1988, J BIOL CHEM, V263, P15634; DOUBILET H, 1961, AM J GASTROENTEROL, V35, P499; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HOFTE H, 1992, PLANT PHYSIOL, V99, P561, DOI 10.1104/pp.99.2.561; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; Preston G M, 1993, Methods Mol Biol, V15, P317, DOI 10.1385/0-89603-244-2:317; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Yamamoto T, 1997, AM J PHYSIOL-RENAL, V272, pF198, DOI 10.1152/ajprenal.1997.272.2.F198; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	29	143	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30329	30333		10.1074/jbc.272.48.30329	http://dx.doi.org/10.1074/jbc.272.48.30329			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374520	hybrid			2022-12-25	WOS:A1997YH61300052
J	Tschanz, CL; Noy, N				Tschanz, CL; Noy, N			Binding of retinol in both retinoid-binding sites of interphotoreceptor retinoid-binding protein (IRBP) is stabilized mainly by hydrophobic interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT-EPITHELIUM; FATTY-ACIDS; PHOTORECEPTORS; RHODOPSIN; MECHANISM; RELEASE	Interphotoreceptor retinoid-binding protein (IRBP) is an ocular protein which is believed to participate in the visual cycle by mediating transport of retinoids between pigment epithelium and photoreceptor cells, The molecular mechanism underlying the ability of IRBP to target particular retinoids to the specific cells that are their sites of action and metabolism is not completely clear, and little information is available regarding the structure of the protein's multiple ligand-binding sites, IRBP possesses two retinoid-binding sites, and it was reported that binding of the visual chromophore, Il cis-retinal, in one of these sites, but not in the other, is tightly regulated by another IRBP ligand, docosahexaenoic acid (Chen, Y., Houghton, L. A., Brenna, J. T., and Noy, N. (1996) J. Biol. Chem. 271, 20507), The two sites are thus functionally distinct, Here, the thermodynamic parameters governing the interactions of retinol with the IRBP retinoid-binding sites were measured, The data demonstrate that the interactions of retinol with both sites are stabilized mainly by hydrophobic interactions, and that the hydroxyl head group of retinol is not involved in formation of protein-ligand complexes, Nevertheless, the data indicate that the two sites are structurally distinct, and that binding of retinol in them occurs by remarkably different modes of interactions.	CORNELL UNIV,DIV NUTR SCI,ITHACA,NY 14853	Cornell University					NATIONAL EYE INSTITUTE [R01EY009296] Funding Source: NIH RePORTER; NEI NIH HHS [EY09296] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, J BIOL CHEM, V260, P4850; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BORST DE, 1989, J BIOL CHEM, V264, P1115; CARLSON A, 1992, BIOCHEMISTRY-US, V31, P9056, DOI 10.1021/bi00152a049; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P11311, DOI 10.1021/bi00093a007; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CROUCH RK, 1992, PHOTOCHEM PHOTOBIOL, V56, P251, DOI 10.1111/j.1751-1097.1992.tb02154.x; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FONG SL, 1988, J BIOL CHEM, V263, P15330; FONG SL, 1984, J BIOL CHEM, V259, P6534; HO MTP, 1989, J BIOL CHEM, V264, P928; JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; PUTILINA T, 1993, BIOCHEMISTRY-US, V32, P3797, DOI 10.1021/bi00065a036; ROSS PD, 1981, BIOCHEMISTRY-US, V90, P2096; SAARI JC, 1985, J BIOL CHEM, V260, P195; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; Saari John C., 1994, P351	29	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30201	30207		10.1074/jbc.272.48.30201	http://dx.doi.org/10.1074/jbc.272.48.30201			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374503	hybrid			2022-12-25	WOS:A1997YH61300035
J	Ying, SX; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Swiergiel, J; Roth, MR; Conrad, GW; Kao, WWY				Ying, SX; Shiraishi, A; Kao, CWC; Converse, RL; Funderburgh, JL; Swiergiel, J; Roth, MR; Conrad, GW; Kao, WWY			Characterization and expression of the mouse lumican gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; MACULAR CORNEAL-DYSTROPHY; COMPLETE CDNA CLONING; V COLLAGEN; STRUCTURAL IMPLICATIONS; GENOMIC ORGANIZATION; GLYCOSAMINOGLYCANS; FIBRILLOGENESIS; SEQUENCE; CELLS	Lumican is one of the major keratan sulfate proteoglycans (KSPG) in vertebrate corneas. We previously cloned the murine lumican cDNA. This study determines the structure of murine lumican gene (Lum) and its expression during mouse embryonic developments. The mouse lumican gene was isolated from a bacterial artificial chromosome mouse genomic DNA library and characterized by polymerase chain reaction and Southern hybridization. The lumican gene spans 6.9 kilobase pairs of mouse genome. The gene consists of three exons and two introns. Exon 1 constitutes 88 bases (b) of untranslated sequence. Exon 2 is 883 b and contains most of the coding sequence of lumican mRNA, and exon 3 has 152 b of coding sequence and 659 b of 3' noncoding sequence. The mouse lumican gene has a TATCA element, a presumptive TATA box, which locates 27 b 5'-upstream from the transcription initiation site, Northern hybridization and in situ hybridization indicate that ill early stages of embryonic development, day 7 post coitus the embryo expresses little or no lumican, Thereafter, different levels of lumican mRNA can be detected in various organ systems, such as cornea stroma, dermis, cartilage, heart, lung, and kidney. The cornea and heart are the two tissues that have the highest expression in adult. Immunoblotting studies found that KSPG core proteins became abundant in the cornea and sclera by postnatal day 10 but that sulfated KSPG could not be detected until after the eyes open. These results indicate that. lumican is widely distributed in most interstitial connective tissues, The modification of lumican with keratan sulfates in cornea is concurrent with eye opening and may contribute to corneal transparency.	UNIV CINCINNATI, DEPT OPHTHALMOL, CINCINNATI, OH 45267 USA; KANSAS STATE UNIV, DIV BIOL, MANHATTAN, KS 66502 USA	University System of Ohio; University of Cincinnati; Kansas State University					NEI NIH HHS [EY 10556, EY00952, EY 09368] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000952, R01EY010556, R01EY009368] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; Cai CX, 1996, EXP EYE RES, V63, P193, DOI 10.1006/exer.1996.0108; CHAKRAVARTI S, 1995, GENOMICS, V27, P481, DOI 10.1006/geno.1995.1080; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; EDWARD DP, 1988, ARCH OPHTHALMOL-CHIC, V106, P1579, DOI 10.1001/archopht.1988.01060140747049; FARRELL RA, 1973, J PHYSIOL-LONDON, V233, P589, DOI 10.1113/jphysiol.1973.sp010325; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1995, INVEST OPHTH VIS SCI, V36, P2296; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Funderburgh JL, 1996, INVEST OPHTH VIS SCI, V37, P2989; FUNDERBURGH JL, 1989, KERATAN SULPHATE CHE, P39; GHYSELINCK NB, 1993, MOL ENDOCRINOL, V7, P258, DOI 10.1210/me.7.2.258; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; HAHN RA, 1992, DEVELOPMENT, V115, P383; HART GW, 1976, J BIOL CHEM, V251, P6513; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KAO WWY, 1979, J BIOL CHEM, V254, P2234; KAO WWY, 1983, J BIOL CHEM, V258, P7779; Kresse H, 1994, EXS, V70, P73; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LINSENMAYER TF, 1990, ANN NY ACAD SCI, V580, P143, DOI 10.1111/j.1749-6632.1990.tb17926.x; LIU CY, 1994, J BIOL CHEM, V269, P24627; Marchant JK, 1996, J CELL BIOL, V135, P1415, DOI 10.1083/jcb.135.5.1415; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; MEIER S, 1973, DEV BIOL, V35, P318, DOI 10.1016/0012-1606(73)90027-4; MEIER S, 1974, P NATL ACAD SCI USA, V71, P2310, DOI 10.1073/pnas.71.6.2310; MELLES GRJ, 1995, CURR EYE RES, V14, P809, DOI 10.3109/02713689508995803; Moyer PD, 1996, DIFFERENTIATION, V60, P31, DOI 10.1046/j.1432-0436.1996.6010031.x; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; Quantock AJ, 1996, BIOPHYS J, V70, P1966, DOI 10.1016/S0006-3495(96)79761-8; RAWE IM, 1992, HISTOCHEM J, V24, P311, DOI 10.1007/BF01046162; Ruggiero F, 1996, INVEST OPHTH VIS SCI, V37, P1749; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; VIGNERON M, 1984, EMBO J, V3, P2373, DOI 10.1002/j.1460-2075.1984.tb02142.x; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002	48	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30306	30313		10.1074/jbc.272.48.30306	http://dx.doi.org/10.1074/jbc.272.48.30306			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374517	hybrid			2022-12-25	WOS:A1997YH61300049
J	Arlotta, P; Rustighi, A; Mantovani, F; Manfioletti, G; Giancotti, V; Tell, G; Damante, G				Arlotta, P; Rustighi, A; Mantovani, F; Manfioletti, G; Giancotti, V; Tell, G; Damante, G			High mobility group I proteins interfere with the homeodomains binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; HMGI-C; TRANSCRIPTION FACTORS; CIRCULAR-DICHROISM; NUCLEAR PROTEINS; THYROID-CELLS; CDC2 KINASE; E-SELECTIN; EXPRESSION; SEQUENCE	Homeodomains (HDs) constitute the DNA binding domain of several transcription factors that control cell differentiation and development in a wide variety of organisms, Most HDs recognize sequences that contain a 5'-TAAT-3' core motif, However, the DNA binding specificity of HD containing proteins does not solely determine their biological effects, and other molecular mechanisms should be responsible for their ultimate functional activity, Interference by other factors in the HD/DNA interaction could be one of the processes by which HD-containing proteins achieve the functional complexity required for their effects on the expression of target genes, Using gel-retardation assay, we demonstrate that two members of the high mobility group I (HMGI) family of nuclear proteins (HMGI-C and HMGY) can bind to a subset of HD target sequences and inhibit HDs from binding to the same sequences, The inhibition of the HD/DNA interaction occurs while incubating HPGI-C with DNA either before or after the addition of the HD, The reduced half-life of the HD DNA complex in the presence of HMGI-C, and the shift observed in the CD spectra recorded upon HMGI-C binding to DNA, strongly suggest that structural modifications of the DNA are responsible for the inhibition of the HD DNA complex formation, Moreover, by co-transfection experiments we provide evidence that this inhibition can occur also in vivo, The data reported here would suggest that HMGI proteins may be potential regulators of the function of HD-containing proteins and that they are able to interfere with the access of the HD to their target genes.	UNIV UDINE,DIPARTIMENTO SCI & TECNOL BIOMED,I-33100 UDINE,ITALY; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34100 TRIESTE,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Trieste			Damante, Giuseppe/AAC-5200-2022	Damante, Giuseppe/0000-0003-2312-4009; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Tell, Gianluca/0000-0001-8845-6448				ABDULKADIR SA, 1995, J EXP MED, V182, P487, DOI 10.1084/jem.182.2.487; ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BROWN DG, 1990, EMBO J, V9, P1329, DOI 10.1002/j.1460-2075.1990.tb08242.x; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; Damante G, 1996, EMBO J, V15, P4992, DOI 10.1002/j.1460-2075.1996.tb00879.x; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DELSAL G, 1994, BIOTECHNIQUES, V16, P134; DORMAN BP, 1973, P NATL ACAD SCI USA, V70, P255, DOI 10.1073/pnas.70.1.255; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P5347, DOI 10.1021/bi00183a043; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY DM, 1978, BIOPOLYMERS, V17, P145, DOI 10.1002/bip.1978.360170111; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; IVANOV VI, 1974, J MOL BIOL, V87, P817, DOI 10.1016/0022-2836(74)90086-2; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kaufman T C, 1990, Adv Genet, V27, P309; KIM J, 1995, EUR J IMMUNOL, V25, P798, DOI 10.1002/eji.1830250326; KleinHessling S, 1996, P NATL ACAD SCI USA, V93, P15311, DOI 10.1073/pnas.93.26.15311; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANDEL R, 1976, NUCLEIC ACIDS RES, V3, P1839, DOI 10.1093/nar/3.8.1839; Manfioletti G, 1995, GENE, V167, P249, DOI 10.1016/0378-1119(95)00666-4; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Sreenath TL, 1996, P NATL ACAD SCI USA, V93, P9636, DOI 10.1073/pnas.93.18.9636; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	60	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29904	29910		10.1074/jbc.272.47.29904	http://dx.doi.org/10.1074/jbc.272.47.29904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368066	hybrid			2022-12-25	WOS:A1997YG64700076
J	Lim, YP; Low, BC; Ong, SH; Guy, GR				Lim, YP; Low, BC; Ong, SH; Guy, GR			Growth factors stimulate tyrosine dephosphorylation of p75 and its dissociation from the SH2 domain of Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SWISS 3T3 CELLS; ADAPTER PROTEIN; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; DNA-SYNTHESIS; KAPPA-B; RECEPTOR; RAS; KINASE	The growth factor receptor binding protein (Grb2) has a key role in initiating the mitogen-activated protein kinase signaling cascade in major cell regulatory pathways. The binding of proteins to the SH2 domain of Grb2 has been reported to occur mainly after they are tyrosine-phosphorylated following receptor activation. Using an in vitro binding assay, immunoprecipitation, and Far Western techniques, we report that in quiescent cells a 75-kDa protein binds directly to the SH2 domain of Grb2. All of the tyrosine-phosphorylated p75 protein co-localizes with Grb2.Sos complex in the cytosolic fraction of the cell in vivo and undergoes tyrosine dephosphorylation when cells are treated with mitogenic ligands such as epidermal, platelet derived, and fibroblast growth factors, endothelin-1, and bombesin but not tumor necrosis factor-alpha, interferon-alpha and -gamma, interleukein-6, and leukemic inhibitory factor, which are either cell growth inhibitory or not significantly mitogenic. The dephosphorylation of p75 and the ensuing dissociation from Grb2 is rapid, occurring within 30 s following mitogenic stimulation by ligands such as epidermal growth factor, suggesting p75 to be an early component in the signal transduction pathways involving Grb2.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 119076, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Low, Boon Chuan/H-8049-2012; Low, Boon Chuan/AAU-7685-2021	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAmbrosio C, 1996, ONCOGENE, V12, P371; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SU J, 1994, J BIOL CHEM, V269, P18731; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VIRDEE K, 1994, BBA-MOL CELL RES, V1224, P489, DOI 10.1016/0167-4889(94)90286-0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29892	29898		10.1074/jbc.272.47.29892	http://dx.doi.org/10.1074/jbc.272.47.29892			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368064	hybrid			2022-12-25	WOS:A1997YG64700074
J	Hug, H; Strand, S; Grambihler, A; Galle, J; Hack, V; Stremmel, W; Krammer, PH; Galle, PR				Hug, H; Strand, S; Grambihler, A; Galle, J; Hack, V; Stremmel, W; Krammer, PH; Galle, PR			Communication - Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; T-CELL; SUPEROXIDE-DISMUTASE; INDUCED APOPTOSIS; FAS LIGAND; DEATH; INHIBITOR; RECEPTOR; DAMAGE	Oxidative stress has been associated with the induction of programmed cell death, The CD95 ligand/receptor system is a specific mediator of apoptosis. We have used the model of drug-induced apoptosis to assess whether the CD95 ligand mRNA is induced by reactive oxygen intermediates. Treatment of HepG2 hepatoma cells with bleomycin induced the production of reactive oxygen intermediates and, as an additional parameter of oxidative stress, resulted in glutathione (GSH) depletion, In parallel, CD95 ligand mRNA expression was induced, In a similar fashion CD95 ligand mRNA expression increased after treatment with H2O2. Additional treatment with the antioxidant and GSH precursor N-acetylcysteine resulted in partial restoration of intracellular GSH levels and in reduced induction of CD95 ligand mRNA, Induction of CD95 ligand mRNA by bleomycin was further reduced by combined treatment with N-acetylcysteine and deferoxamine. These data suggest a direct role of oxygen radicals in the induction of the CD95 ligand.	UNIV HEIDELBERG HOSP,DEPT GASTROENTEROL,D-69115 HEIDELBERG,GERMANY; ZMBH,CTR BIOL MOL,D-69120 HEIDELBERG,GERMANY; UNIV WURZBURG,DEPT MED,DIV NEPHROL,D-97080 WURZBURG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,TUMOR IMMUNOL PROGRAMME,PHK,DIV IMMUNOCHEM,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)			Galle, Peter R/T-5292-2018	Galle, Peter R/0000-0001-8294-0992; Stremmel, Wolfgang/0000-0002-8545-1753				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AN J, 1992, MUTAT RES, V270, P167, DOI 10.1016/0027-5107(92)90127-N; AN J, 1993, MUTAT RES, V289, P215, DOI 10.1016/0027-5107(93)90072-N; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kilinc Cumhur, 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P249; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lau HT, 1996, SCIENCE, V273, P109, DOI 10.1126/science.273.5271.109; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; SATO N, 1995, J IMMUNOL, V154, P3194; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; SUDA T, 1995, J IMMUNOL, V154, P3806; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; Williams MS, 1996, J IMMUNOL, V157, P2395; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	29	159	165	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28191	28193		10.1074/jbc.272.45.28191	http://dx.doi.org/10.1074/jbc.272.45.28191			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353266	hybrid			2022-12-25	WOS:A1997YF21900006
J	Raso, V; Brown, M; McGrath, J				Raso, V; Brown, M; McGrath, J			Intracellular targeting with low pH-triggered bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN-MALIGNANT MESOTHELIOMA; DIPHTHERIA-TOXIN; CELL-LINE; ENTRY; RICIN; DELIVERY; BEARING; ANTIGEN; IMMUNOTOXINS	Bispecific antibodies were designed to deliver a reversibly bound ligand into target cells and then spontaneously release it upon passage into acidified vesicles, These reagents were assembled by coupling monoclonal antibodies that recognize acid-sensitive epitopes on diphtheria toxin to cell type-specific monoclonal antibodies, The dual binding capacity of the bispecific antibodies was confirmed by delivery of I-125-diphtheria toxin to target molecules present on intact cells, Bispecific antibodies directed against transferrin receptors on human cells were loaded with toxin and tested for cytotoxicity. The mutant diphtheria toxins CRM107 and CRM45 were used since their inability to bind cell. receptors renders them ordinarily nontoxic, Their full cytotoxic potential, however, was restored via bispecific antibody-mediated delivery and release within low pH intracellular vesicles, Cytotoxicity was shown to be spe cific by blocking receptor sites and to be acidification-dependent by protection using NH4Cl to raise endosomal pH. Kinetics for inhibition of cellular protein synthesis was identical for native diphtheria toxin and the bispecific antibody CRM107 combination. The rate of inhibition (t(1/2) = 20 min) indicated that release of CRM107 from the antibody combining site was fast, and its toxic action was unimpeded by this delivery mechanism.			Raso, V (corresponding author), BOSTON BIOMED RES INST, 20 STANIFORD ST, BOSTON, MA 02114 USA.				NATIONAL CANCER INSTITUTE [R01CA049856, R01CA049254] Funding Source: NIH RePORTER; NCI NIH HHS [CA49856, CA49254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHA P, 1983, J BIOL CHEM, V258, P1565; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BRENNAN M, 1985, SCIENCE, V229, P81, DOI 10.1126/science.3925553; CARROLL SF, 1988, METHOD ENZYMOL, V165, P68; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CIEPLAK W, 1988, BIOCHEM BIOPH RES CO, V157, P747, DOI 10.1016/S0006-291X(88)80313-9; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GEISOW MJ, 1984, EXP CELL RES, V150, P29, DOI 10.1016/0014-4827(84)90698-0; GEISOW MJ, 1984, EXP CELL RES, V150, P36, DOI 10.1016/0014-4827(84)90699-2; GIGLIOTTI F, 1984, J INFECT DIS, V149, P43, DOI 10.1093/infdis/149.1.43; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; GRIFFIN T, 1993, JNCI-J NATL CANCER I, V85, P292, DOI 10.1093/jnci/85.4.292; GRIFFIN TW, 1987, CANCER RES, V47, P4266; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LAIRD W, 1976, J VIROL, V19, P220, DOI 10.1128/JVI.19.1.220-227.1976; MILNE JC, 1994, J BIOL CHEM, V269, P20607; NISONOFF A, 1961, ARCH BIOCHEM BIOPHYS, V93, P460, DOI 10.1016/0003-9861(61)90296-X; OVERLY CC, 1995, P NATL ACAD SCI USA, V92, P3156, DOI 10.1073/pnas.92.8.3156; RAPPUOLI R, 1983, J CHROMATOGR, V268, P543, DOI 10.1016/S0021-9673(01)95457-3; RASO V, 1984, J BIOL CHEM, V259, P1143; RASO V, 1982, IMMUNOL REV, V62, P93, DOI 10.1111/j.1600-065X.1982.tb00391.x; RASO V, 1981, CANCER RES, V41, P2073; Raso V, 1997, J BIOL CHEM, V272, P27618, DOI 10.1074/jbc.272.44.27618; RASO V, 1982, CANCER RES, V42, P457; RASO VA, 1984, RECEPTOR MEDIATED TA, V82, P119; REALE FR, 1987, CANCER RES, V47, P3199; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z; Youle R J, 1991, Semin Cell Biol, V2, P39; ZUCKER DR, 1984, MOL IMMUNOL, V21, P785, DOI 10.1016/0161-5890(84)90165-2	37	4	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27623	27628		10.1074/jbc.272.44.27623	http://dx.doi.org/10.1074/jbc.272.44.27623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346900	hybrid			2022-12-25	WOS:A1997YD47300026
J	Thomas, M; Chedin, S; Carles, C; Riva, M; Famulok, M; Sentenac, A				Thomas, M; Chedin, S; Carles, C; Riva, M; Famulok, M; Sentenac, A			Selective targeting and inhibition of yeast RNA polymerase II by RNA aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; SACCHAROMYCES-CEREVISIAE; ELONGATION COMPLEX; TERNARY COMPLEXES; RECEPTOR-BINDING; LARGEST SUBUNIT; GROWTH-FACTOR; AMINO-ACIDS; L-ARGININE; DNA	To probe the complex nucleic acid binding domains of yeast RNA polymerase II (Pol II), we have isolated in the presence of heparin RNA molecules that selectively bind to yeast Pol II. A class of RNA molecules was found to bind and strongly interfere with enzyme-DNA interaction but not with RNA chain elongation, Remarkably, one selected RNA ligand was a specific inhibitor of Saccharomyces cerevisiae Pol II. S. cerevisiae Pol I and Pol III and Pol II from Schizosaccharomyces pombe or wheat germ cells were not affected. Photocross-linking experiments showed that the RNA ligand preferentially interacted with B220, the largest subunit of Pol II and, to a lesser extent, with B150, the second largest subunit, The selected RNA was expressed in yeast cells under the control of a Pol III promoter, Yeast cells that expressed the anti-Pol II aptamer grew normally, However, a cell growth defect was observed when expressing the RNA aptamer in cells having an artificially reduced level of Pol II.	CEA SACLAY, SERV BIOCHIM & GENET MOL, F-91191 GIF SUR YVETTE, FRANCE; UNIV MUNICH, GENZENTRUM, INST BIOCHEM, D-1377 MUNICH, GERMANY	CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Munich								Archambault J, 1996, GENETICS, V142, P737; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BREAKER RR, 1994, BIOCHEMISTRY-US, V33, P11980, DOI 10.1021/bi00205a037; BUHLER JM, 1974, J BIOL CHEM, V249, P5963; BUSBY S, 1981, EUR J BIOCHEM, V118, P443, DOI 10.1111/j.1432-1033.1981.tb05540.x; CAMIER S, 1995, P NATL ACAD SCI USA, V92, P9338, DOI 10.1073/pnas.92.20.9338; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, RAV S MOL C, V3, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DEZELEE S, 1972, FEBS LETT, V21, P1, DOI 10.1016/0014-5793(72)80148-0; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FOX CF, 1965, J BIOL CHEM, V240, P2101; Geiger A, 1996, NUCLEIC ACIDS RES, V24, P1029, DOI 10.1093/nar/24.6.1029; GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509; GOOD PD, 1994, GENE, V151, P209, DOI 10.1016/0378-1119(94)90658-0; HUAIFENG M, 1983, EUR J BIOCHEM, V131, P113, DOI 10.1111/j.1432-1033.1983.tb07237.x; HUET J, 1985, J BIOL CHEM, V260, P5304; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; Jiang F, 1996, NATURE, V382, P183, DOI 10.1038/382183a0; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; King RA, 1996, CELL, V87, P893, DOI 10.1016/S0092-8674(00)81996-0; KRAKOW J, 1970, TRANSCRIPTION GENETI, V35, P78; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUBIK MF, 1994, NUCLEIC ACIDS RES, V22, P2619, DOI 10.1093/nar/22.13.2619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landick R, 1996, SCIENCE, V273, P202, DOI 10.1126/science.273.5272.202; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Liu KB, 1996, EMBO J, V15, P150, DOI 10.1002/j.1460-2075.1996.tb00343.x; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; Sentenac A, 1982, MOL BIOL YEAST SACCH, P561; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Williamson JR, 1996, NATURE, V382, P112, DOI 10.1038/382112a0	44	63	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27980	27986		10.1074/jbc.272.44.27980	http://dx.doi.org/10.1074/jbc.272.44.27980			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346949	Green Published, hybrid			2022-12-25	WOS:A1997YD47300075
J	Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL				Allay, E; Reese, JS; McGuire, EA; Koc, ON; Sedransk, N; Gerson, SL			Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O-6-alkylguanine DNA-alkyltransferase	ONCOGENE			English	Article						DNA repair; LMO1; lymphomagenesis; O-6-alkylguanine; DNA-alkyltransferase; carcinogenesis	INDUCED THYMIC LYMPHOMAS; N-METHYLNITROSOUREA; ESCHERICHIA-COLI; EXPRESSION; GENE; RAS; METHYLTRANSFERASE; PROTECTS; REPAIR; LEUKEMIA	We evaluated induction of lymphomas by the methylating carcinogen, N-methylnitrosourea [MNU], in transgenic mice expressing both LMO1 and the DNA repair gene, MGMT, in the thymus, The goal was to determine whether environmental mutagens shorten the latency or increase the incidence of LMO1+lymphomas and whether mice transgenic for both LMO1 and MGMT, and thereby able to repair O-6-methylguanine DNA adducts induced by MNU, would be protected, Mice heterozygous for LMO1 or MGMT were crossed and offspring treated with MNU at 6 weeks of age, MNU induced lymphoma incidence was highest in the LMO1 mice, 91% and lowest in the hMGMT+mice, 15%, MNU induced K-ras mutations in codon 12 in non-MGMT transgenics resulted in a shorter latency of tumors and accounting for half of the early lymphomas in LMO1 mice, The effect of MNU was abrogated in the LMO1/hMGMT transgenic mice, indicating the ability of MGMT expression to block the carcinogenic effect of MNU even in cancer prone mice, Thus, methylating agents potentiate lymphomagenesis of LMO1, in part through activation of K-ras and the MAPK pathway, a process which appear to synergize with LMO1 mediated transcription activation, O-6-alkylguanine DNA-alkyltransferase mediated DNA repair effectively blocks chemical carcinogenesis in mice carrying the LMO1 oncogene.	CASE WESTERN RESERVE UNIV,SCH MED,DIV HEMATOL ONCOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CWRU IRELAND CANC CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; UNIV PITTSBURGH,DIV HEMATOL,INST CANC,PITTSBURGH,PA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA063193, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA43703, R01CA63193] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Becker K, 1996, CANCER RES, V56, P3244; BOEHM T, 1990, ONCOGENE, V5, P1103; BREUER M, 1991, CANCER RES, V51, P958; COROMINAS M, 1991, CANCER RES, V51, P5129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ELSON A, 1995, ONCOGENE, V11, P181; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Gerson Stanton L., 1993, Current Opinion in Oncology, V5, P136; HAQQI TM, 1992, P NATL ACAD SCI USA, V89, P1253, DOI 10.1073/pnas.89.4.1253; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; KANEKO Y, 1989, LEUKEMIA, V3, P886; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; LINDEMAN G, 1994, ONCOGENE, V10, P1013; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LIU LL, 1994, CANCER RES, V54, P4648; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; MANGUES R, 1994, CANCER RES, V54, P6395; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NEALE GAM, 1995, BLOOD, V86, P3060; NEWCOMB EW, 1988, CANCER RES, V48, P5514; PAULY GT, 1994, BIOCHEMISTRY-US, V33, P9169, DOI 10.1021/bi00197a020; REBECK GW, 1991, J BACTERIOL, V173, P2068, DOI 10.1128/jb.173.6.2068-2076.1991; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; XIAO W, 1995, MUTAT RES-DNA REPAIR, V336, P133, DOI 10.1016/0921-8777(94)00048-B; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	31	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2127	2132		10.1038/sj.onc.1201384	http://dx.doi.org/10.1038/sj.onc.1201384			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366529	Bronze			2022-12-25	WOS:A1997YC28400013
J	Pochart, P; Woltering, D; Hollingsworth, NM				Pochart, P; Woltering, D; Hollingsworth, NM			Conserved properties between functionally distinct MutS homologs in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE MSH2; DNA-BASE PAIRS; MISMATCH REPAIR; DUPLEX OLIGONUCLEOTIDES; SPECIFICALLY BINDS; ESCHERICHIA-COLI; 2-HYBRID SYSTEM; HOP1 GENE; PROTEIN; HETERODIMER	In the yeast Saccharomyces cerevisiae there are five nuclear MutS homologs that act in two distinct processes. MSH2, 3, and 6 function in mismatch repair in both vegetative and meiotic cells, whereas MSH4 and MSH5 act specifically to facilitate crossovers between homologs during meiosis. Coimmunoprecipitation as well as two-hybrid experiments indicate that the Msh4 and Msh5 proteins form a hetero-oligomeric structure similar to what is observed for the Msh proteins involved in mismatch repair. Mutation of conserved amino acids in the NTP binding and putative helix-turn-helix domains of Msh5p abolish function but are still capable of interaction with Msh4p, suggesting that NTP binding plays a role downstream of hetero-oligomer formation. No hetero-oligomers are observed between the mismatch repair MutS proteins (Msh2p and Msh6p) and either Msh4p or Msh5p. These results indicate that one level of functional specificity between the mismatch repair and meiotic crossover MutS homologs in yeast is provided by the ability to form distinct hetero-oligomers.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,INST CELL & DEV BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50717, R01 GM050717] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1995, GENE DEV, V9, P234, DOI 10.1101/gad.9.2.234; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Alani E, 1997, J MOL BIOL, V265, P289, DOI 10.1006/jmbi.1996.0743; Bartel PL, 1993, USING 2 HYBRID SYSTE, P153; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; CHI NW, 1994, J BIOL CHEM, V269, P29984; CROUSE GF, 1997, MISMATCH REPAIR SYST; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HAWLEY RS, 1987, EXCHANGE CHROMOSOMAL, P497; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOLLINGSWORTH NM, 1993, GENETICS, V133, P785; Hollingsworth NM, 1997, GENETICS, V147, P33; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PROLLA TA, 1994, NATURE, V265, P1091; REENAN RAG, 1992, GENETICS, V132, P975; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	37	100	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30345	30349		10.1074/jbc.272.48.30345	http://dx.doi.org/10.1074/jbc.272.48.30345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374523	hybrid			2022-12-25	WOS:A1997YH61300055
J	Boulay, G; Zhu, X; Peyton, M; Jiang, MS; Hurst, R; Stefani, E; Birnbaumer, L				Boulay, G; Zhu, X; Peyton, M; Jiang, MS; Hurst, R; Stefani, E; Birnbaumer, L			Cloning and expression of a novel Mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the G(q) class of G protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; MUSCARINIC ACETYLCHOLINE-RECEPTOR; THYROTROPIN-RELEASING-HORMONE; PANCREATIC ACINAR-CELLS; STORE DEPLETION; PERTUSSIS-TOXIN; MAST-CELLS; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; HUMAN PLATELETS	Hormonal stimulation of G(q)-protein coupled receptors triggers Ca2+ mobilization from internal stores, This is followed by a Ca2+ entry through the plasma membrane, Drosophila Trp and Trpl proteins have been implicated in Ca2+ entry and three mammalian homologues of Drosophila Trp/Trpl, hTrp1, hTrp3 and bTrp4 (also bCCE) have been cloned and expressed, Using mouse brain RNA as template, we report here the polymerase chain reaction-based cloning and functional expression of a novel Trp, mTrp6, The cDNA encodes a protein of 930 amino acids, the sequence of which is 36.8, 36.3, 43.1, 38.6, and 74.1% identical to Drosophila Trp and Trpl, bovine Trp4, and human Trp1 and Trp3, respectively, Transient expression of mTrp6 in COS.M6 cells by transfection of the full-length mTrp6 cDNA increases Ca2+ entry induced by stimulation of co-transfected M5 muscarinic acetylcholine receptor with carbachol (CCh), as seen by dual wavelength fura 2 fluorescence ratio measurements, The mTrp6-mediated increase in Ca2+ entry activity was blocked by SKF-96365 and La3+. Ca2+ entry activity induced by thapsigargin was similar in COS cells transfected with or without the mTrp6 cDNA, The thapsigargin-stimulated Ca2+ entry could not be further stimulated by CCh in control cells but was markedly increased in mTrp6-transfected cells, Records of whole cell transmembrane currents developed in response to voltage ramps from -80 to +40 mV in control HEK cells and HEK cells stably expressing mTrp6 revealed the presence of a muscarinic receptor responsive non-selective cation conductance in Trp6 cells that was absent in control cells, Our data support the hypothesis that mTrp6 encodes an ion channel subunit that mediates Ca2+ entry stimulated by a G-protein coupled receptor, but not Ca2+ entry stimulated by intracellular Ca2+ store depletion.	UNIV CALIF LOS ANGELES,SCH MED,DEPT ANESTHESIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST BRAIN RES,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Boulay, Guylain/D-9773-2010; Peyton, Michael/A-8728-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45198] Funding Source: Medline; NIGMS NIH HHS [GM54235] Funding Source: Medline; FDA HHS [BM16733] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FDA HHS		ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAREW MA, 1995, J PHYSIOL-LONDON, V486, P349, DOI 10.1113/jphysiol.1995.sp020817; CHINO M, 1995, J BIOL CHEM, V270, P1149; CHOW SC, 1993, BIOCHEM J, V293, P395, DOI 10.1042/bj2930395; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; Dasgupta S., 1996, Society for Neuroscience Abstracts, V22, P1028; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harlow E., 1988, ANTIBODIES LAB MANUA; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU Y, 1994, BIOCHEM BIOPH RES CO, V132, P346; Innamorati G, 1996, MOL PHARMACOL, V50, P467; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; SAGE SO, 1994, TRENDS PHARMACOL SCI, V15, P282, DOI 10.1016/0165-6147(94)90007-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; STBRID G, 1993, J BIOL CHEM, V268, P21486; SUSS E, 1989, J GEN PHYSIOL, V94, P465, DOI 10.1085/jgp.94.3.465; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU XZS, 1997, CELL, V89, P1154; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	73	275	291	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29672	29680		10.1074/jbc.272.47.29672	http://dx.doi.org/10.1074/jbc.272.47.29672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368034	hybrid			2022-12-25	WOS:A1997YG64700044
J	Lingueglia, E; deWeille, JR; Bassilana, F; Heurteaux, C; Sakai, H; Waldmann, R; Lazdunski, M				Lingueglia, E; deWeille, JR; Bassilana, F; Heurteaux, C; Sakai, H; Waldmann, R; Lazdunski, M			A modulatory subunit of acid sensing ion channels in brain and dorsal root ganglion cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; EPITHELIAL SODIUM-CHANNEL; CAENORHABDITIS-ELEGANS; HOMOLOGOUS SUBUNITS; MEMBRANE TOPOLOGY; RAT; EXPRESSION; RECEPTOR; CLONING; PROTONS	MDEG1 is a cation channel expressed in brain that belongs to the degenerin/epithelial Na+ channel superfamily, It is activated by the same mutations which cause neurodegeneration in Caenorhabditis elegans if present in the degenerins DEG-1, MEC-4, and MEC-10. MDEG1 shares 67% sequence identity with the recently cloned proton gated cation channel ASIC (acid sensing ion channel), a new member of the family which is present in brain and in sensory neurons, We have now identified MDEG1 as a proton-gated channel with properties different from those of ASIC, MDEG1 requires more acidic pH values for activation and has slower inactivation kinetics, In addition, we have cloned from mouse and rat brain a splice variant form of the MDEG1 channel which differs in the first 236 amino acids, including the first transmembrane region, This new membrane protein, which has been called MDEG2, is expressed in both brain and sensory neurons, MDEG2 is activated neither by mutations that bring neurodegeneration once introduced in C. elegans degenerins nor by low pH, However, it can associate both with MDEG1 and another recently cloned H+-activated channel DRASIC to form heteropolymers which display different kinetics, pH dependences, and ion selectivities, Of particular interest is the subunit combination specific for sensory neurons, MDEG2/DRASIC. In response to a drop in pH, it gives rise to a biphasic current with a sustained current which discriminates poorly between Na+ and K+, like the native H+-gated current recorded in dorsal root ganglion cells, This sustained current is thought to be required for the tonic sensation of pain caused by acids.	INST PHARMACOL MOL & CELLULAIRE, CNRS, UPR 411, F-06560 VALBONNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Waldmann, Rainer/Q-2108-2016; HEURTEAUX, Catherine/M-4947-2016; de Weille, Jan R/F-8103-2014; LINGUEGLIA, Eric/F-5509-2013	Waldmann, Rainer/0000-0002-4599-2926; HEURTEAUX, Catherine/0000-0002-9741-9777; de Weille, Jan R/0000-0002-0505-3166; LINGUEGLIA, Eric/0000-0003-3902-3405				Barbry P, 1997, AM J PHYSIOL-GASTR L, V273, pG571, DOI 10.1152/ajpgi.1997.273.3.G571; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARDIAANOVEROS J, 1997, P ANTL ACAD SCI US, V94, P1459; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; Hall DH, 1997, J NEUROSCI, V17, P1033; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831, DOI 10.1152/jn.1983.49.3.831; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; RENARD S, 1994, J BIOL CHEM, V269, P12981; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; STEEN KH, 1995, J NEUROSCI, V15, P3982; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0	31	412	432	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29778	29783		10.1074/jbc.272.47.29778	http://dx.doi.org/10.1074/jbc.272.47.29778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368048	hybrid			2022-12-25	WOS:A1997YG64700058
J	Kruttgen, A; Heymach, JV; Kahle, PJ; Shooter, EM				Kruttgen, A; Heymach, JV; Kahle, PJ; Shooter, EM			The role of the nerve growth factor carboxyl terminus in receptor binding and conformational stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIN RECEPTOR; BIOLOGICAL-ACTIVITY; TYROSINE KINASE; SIGNAL-TRANSDUCTION; NEURONAL SURVIVAL; AFFINITY RECEPTOR; TRK; NGF; CELLS; DIFFERENTIATION	The role of the nerve growth factor (NGF) carboxyl terminus in the function of NGF is not well understood, Previous work showed that deletion of residues 112-120 abolished NGF bioactivity. Several mutagenesis studies, however, have localized the binding sites of the two NGF receptors, p75 and TrkA to other regions of the NGF molecule, To investigate the role of the NGF COOH terminus, Foe performed a detailed structure-function analysis of this region by deleting stepwise each of the nine COOH-terminal residues as well as constructing six point mutants, We found that point mutations within the 111-115 region, but not deletion of residues 116-120, significantly decreased NGF bioactivity, as determined by TrkA tyrosine phosphorylation and neurite outgrowth from PC12 cells. Mutation of the absolutely conserved Leu(112) led to severely disrupted p75 binding on A875 cells but had only a modest effect on TrkA binding to MG87-TrkA fibroblasts, This suggests that the p75 binding surface is more extended than previously believed and includes not only charged residues within loops 1 and 5 but also spatially discontinuous, uncharged residues in a region where the NH2 and COOH termini are in close proximity, Unexpectedly, deletion of COOH-terminal residues beyond Ala(116) led to significantly decreased stability, These results demonstrate that residues 111-115, but not residues 116-120, are important for both the structural stability and biological activity of NGF.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Heymach, John/AAG-2361-2019; Kruttgen, Alexander P/E-9232-2010	Heymach, John/0000-0001-9068-8942; 	NICHD NIH HHS [HD07249] Funding Source: Medline; NINDS NIH HHS [NS07158, NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSSON M, 1994, J BIOL CHEM, V269, P926; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BRADSHAW RA, 1994, PROTEIN SCI, V3, P1901, DOI 10.1002/pro.5560031102; BURTON LE, 1992, J NEUROCHEM, V59, P1937, DOI 10.1111/j.1471-4159.1992.tb11030.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHAPMAN BS, 1995, PROTEIN SCI, V4, P1696, DOI 10.1002/pro.5560040905; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1995, TRENDS BIOTECHNOL, V13, P217, DOI 10.1016/S0167-7799(00)88949-0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LUO Y, 1992, J BIOL CHEM, V267, P12275; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; Shamovsky IL, 1996, J AM CHEM SOC, V118, P9743, DOI 10.1021/ja9611194; SHIH A, 1994, J BIOL CHEM, V269, P27679; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; SUTER U, 1992, J NEUROSCI, V12, P306; TIMM DE, 1994, PROTEIN SCI, V3, P451; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; ZIMMERMANN A, 1981, P NATL ACAD SCI-BIOL, V78, P4611, DOI 10.1073/pnas.78.7.4611	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29222	29228		10.1074/jbc.272.46.29222	http://dx.doi.org/10.1074/jbc.272.46.29222			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361001	hybrid			2022-12-25	WOS:A1997YF68400060
J	LopezRodriguez, C; Botella, L; Corbi, AL				LopezRodriguez, C; Botella, L; Corbi, AL			CCAAT-enhancer-binding proteins (C/EBP) regulate the tissue specific activity of the CD11c integrin gene promoter through functional interactions with Sp1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOID CELL-DIFFERENTIATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR; P150,95 CD11C/CD18; MONOCLONAL-ANTIBODIES; TEMPORAL EXPRESSION; HUMAN-MONOCYTES; FAMILY MEMBERS; T-CELLS	The CD11c/CD18 integrin binds Lipopolysaccharide, fibrinogen, and heparin, and mediates leukocyte adhesion, spreading, and migration, CD11c/CD18 is primarily found on myeloid cells and its expression is regulated during myeloid differentiation by transcriptional mechanisms acting on the CD11c gene promoter, We now describe that CCAAT/enhancer-binding proteins (C/EBP) contribute to the basal. tissue-specific and developmentally regulated activity of the CD11c promoter, A C/EBP-binding site within the CD11c promoter (CEBP-80) is bound by CEBP alpha in undifferentiated U937 cells and by C/EBP alpha- and C/EBP beta-containing dimers in phorbol 12-myristate 13-acetate-differentiating cells, and its disruption decreased the CD11c promoter activity in a cell type-dependent manner, C/EBP alpha transactivated the CD11c promoter through the CEBP-80 element, and C/EBP alpha transactivation was also dependent on the Sp1-70- and Sp1-120 Spl binding sites. The -90/-50 fragment from the CD11c promoter, containing the adjacent CEBP-80, Sp1-70, and AP1-60 sites, differentially enhanced the activity of the minimal prolactin promoter in hematopoietic and epithelial cells, Altogether, these results demonstrate that C/EBP factors participate in the tissue-restricted and regulated expression of the CD11c/CD18 integrin through functional interactions with Sp1, suggest that Spl-related factors modulate C/EBP alpha transcriptional activity on the CD11c promoter, and demonstrate the existence of a composite regulatory element recognized by C/EBP, Spl, and AP-1 factors and whose enhancing effects are cell-type dependent.	CONSEJO SUPER INVEST CIENT,INST PARASITOL & BIOMED LOPEZ NEYRA,GRANADA 18001,SPAIN; HOSP PRINCESA,MADRID 28006,SPAIN; CONSEJO SUPER INVEST CIENT,CTR INVEST BIOL,MADRID 28006,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Botella, Luisa M/L-1392-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Lopez-Rodriguez, C/G-4482-2014	Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Lopez-Rodriguez, C/0000-0002-2311-2406				ANDERSON DC, 1986, J IMMUNOL, V137, P15; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; Blackford J, 1996, EUR J IMMUNOL, V26, P525, DOI 10.1002/eji.1830260304; CHADBURN A, 1992, HEMATOL PATHOL, V6, P193; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Corbi AL, 1997, LEUKEMIA LYMPHOMA, V25, P415, DOI 10.3109/10428199709039028; CORBI AL, 1996, LEUKOCYTE INTEGRINS; DELAHERA A, 1988, EUR J IMMUNOL, V18, P1131; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; ERNST P, 1995, IMMUNITY, V2, P311, DOI 10.1016/1074-7613(95)90139-6; ESKRA L, 1991, VET IMMUNOL IMMUNOP, V29, P213, DOI 10.1016/0165-2427(91)90015-5; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FREITAG SO, 1992, SCIENCE, V256, P379; HANSON CA, 1990, BLOOD, V76, P2360; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HULEATT JW, 1995, J IMMUNOL, V154, P5684; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; Kramer A, 1996, J BIOL CHEM, V271, P6579; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LopezRodriguez C, 1996, J IMMUNOL, V156, P3780; LopezRodriguez C, 1995, EUR J IMMUNOL, V25, P3496, DOI 10.1002/eji.1830251243; MAVILIO F, 1987, BLOOD, V69, P160; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; Noti JD, 1996, MOL CELL BIOL, V16, P2940; NUEDA A, 1995, CELL IMMUNOL, V164, P163, DOI 10.1006/cimm.1995.1157; NUEDA A, 1993, J BIOL CHEM, V268, P19305; Osada S, 1996, J BIOL CHEM, V271, P3891; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUBIO MA, 1995, BLOOD, V86, P3715, DOI 10.1182/blood.V86.10.3715.bloodjournal86103715; SARIBAN E, 1988, BLOOD, V71, P488; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTING R, 1985, BLOOD, V65, P974; SCOTT LM, 1992, BLOOD, V80, P1725; STACKER SA, 1991, J IMMUNOL, V146, P648; TEVELDE AA, 1987, IMMUNOLOGY, V61, P261; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WATANABE H, 1990, EMBO J, V9, P841, DOI 10.1002/j.1460-2075.1990.tb08181.x; YAMADA A, 1991, J IMMUNOL, V146, P53; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	51	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29120	29126		10.1074/jbc.272.46.29120	http://dx.doi.org/10.1074/jbc.272.46.29120			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360988	hybrid, Green Published			2022-12-25	WOS:A1997YF68400047
J	Moller, JV; Ning, G; Maunsbach, AB; Fujimoto, K; Asai, K; Juul, B; Lee, YJ; deGracia, AG; Falson, P; leMaire, M				Moller, JV; Ning, G; Maunsbach, AB; Fujimoto, K; Asai, K; Juul, B; Lee, YJ; deGracia, AG; Falson, P; leMaire, M			Probing of the membrane topology of sarcoplasmic reticulum Ca2+-ATPase with sequence-specific antibodies - Evidence for plasticity of the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; AMINO-ACID-SEQUENCE; CATALYTIC SUBUNIT; CA2+ BINDING; IMMUNOELECTRON MICROSCOPY; TRANSMEMBRANE TOPOLOGY; NONIONIC DETERGENT; COMPLEMENTARY-DNA; CATION OCCLUSION; CA-2+ TRANSPORT	The topology of Ca2+-ATPase in sarcoplasmic reticulum (SR) vesicles was investigated with the aid of sequence-specific antibodies, produced against oligopeptides corresponding to sequences close to the membranous portions of the protein, The antisera in competitive enzyme-linked immunosorbent assays only reacted with intact SR vesicles to a limited extent, but most epitopic regions were exposed by low concentrations of nondenaturing detergent, octaethylene glycol dodecyl ether (C12E8) or after removal of cytosolic regions by proteinase K, In particular, these treatments exposed the loop regions in the C-terminal domain, including L7-8, the loop region located between transmembrane segments M7 and M8, with a putative intravesicular position, which had immunochemical properties very similar to those of the C terminus with a documented cytosolic exposure, In contrast to this, the reactivity of the N-terminal intravesicular loop regions L1-2 and L3-4 was only increased by C12E8 treatment but not by proteinase K proteolysis, Complexation of Ca2+-ATPase with beta,gamma-CrATP stabilized the C-terminal domain of Ca2+-ATPase against proteinase K proteolysis and reaction with most of the antisera, but immunoreactivity was maintained by the L6-7 and L7-8 loops, Immunoelectron microscopic analyses of vesicles following negative staining, thin sectioning, and the SDS-digested freeze-fracture labeling method suggested that the L7-8 epitope, in contrast to L6-7 and the C terminus, can be exposed on either the intravesicular or cytosolic side of the membrane. A preponderant intravesicular location of L7-8 in intact vesicles is suggested by the susceptibility of this region to proteolytic cleavage after disruption of the vesicular barrier with C12E8 and in symmetrically reconstituted Ca2+-ATPase proteoliposomes. In conclusion, our data suggest an adaptable membrane insertion of the C-terminal Ca2+-ATPase domain, which under some conditions permits sliding of M8 through the membrane with cytosolic exposure of L7-8, of possible functional significance in connection with Ca2+ translocation, On the technical side, our data emphasize that extreme caution is needed when using nondenaturing detergents or other treatments like EGTA at alkaline pH to open up vesicles for probing of intravesicular location with antibodies.	AARHUS UNIV, INST ANAT, DEPT CELL BIOL, DK-8000 AARHUS C, DENMARK; CTR ETUD SACLAY, CEA, DEPT BIOL CELLULAIRE & MOL, SECT BIOPHYS PROT & MEMBRANES, F-91191 GIF SUR YVETTE, FRANCE; CTR ETUD SACLAY, CNRS, URA 2096, F-91191 GIF SUR YVETTE, FRANCE; KYOTO UNIV, FAC MED, DEPT ANAT, SAKYO KU, KYOTO 60601, JAPAN	Aarhus University; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Kyoto University	Moller, JV (corresponding author), AARHUS UNIV, DEPT BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS C, DENMARK.			Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Canfield VA, 1996, BIOCHEMISTRY-US, V35, P14165, DOI 10.1021/bi961851f; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COAN C, 1994, BIOCHEMISTRY-US, V33, P3722, DOI 10.1021/bi00178a032; CORNELIUS F, 1995, HDB NONMEDICAL APPL, P219; DEFORESTA B, 1989, BIOCHEMISTRY-US, V28, P2558, DOI 10.1021/bi00432a032; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FAMBROUGH DM, 1997, IN PRESS ANN NY ACAD; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Fujimoto K, 1996, FEBS LETT, V395, P29, DOI 10.1016/0014-5793(96)01002-2; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1985, BIOCHEM J, V231, P425, DOI 10.1042/bj2310425; GREEN NM, 1994, SODIUM PUMP, P110; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; Inesi G, 1995, BIOSCIENCE REP, V15, P327, DOI 10.1007/BF01788365; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1987, BIOCHEMISTRY-US, V26, P4803, DOI 10.1021/bi00389a030; LEMAIRE M, 1993, ANAL BIOCHEM, V214, P50, DOI 10.1006/abio.1993.1455; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEVY D, 1990, J BIOL CHEM, V265, P19524; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; Lutsenko S, 1997, J BIOL CHEM, V272, P5249, DOI 10.1074/jbc.272.8.5249; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MATTHEWS I, 1989, BIOCHEM BIOPH RES CO, V161, P683, DOI 10.1016/0006-291X(89)92653-3; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P1; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLER JV, 1991, SODIUM PUMP RECENT D, P259; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; NING G, 1994, ACTA HISTOCHEM CYTOC, V27, P347, DOI 10.1267/ahc.27.347; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OVCHINNIKOV YA, 1987, TRENDS BIOCHEM SCI, V12, P434, DOI 10.1016/0968-0004(87)90210-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKRIVER E, 1994, SODIUM PUMP, P354; SMITH DL, 1993, J BIOL CHEM, V268, P22469; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027	80	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29015	29032		10.1074/jbc.272.46.29015	http://dx.doi.org/10.1074/jbc.272.46.29015			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360975	hybrid			2022-12-25	WOS:A1997YF68400034
J	Shi, Y; Sullivan, SK; Pitterle, DM; Kennington, EA; Graff, JM; Blackshear, PJ				Shi, Y; Sullivan, SK; Pitterle, DM; Kennington, EA; Graff, JM; Blackshear, PJ			Mechanisms of MARCKS gene activation during Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; MIDBLASTULA TRANSITION; LAEVIS EMBRYOGENESIS; CALMODULIN-BINDING; CELLULAR SUBSTRATE; IN-VIVO; EXPRESSION	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a high affinity cellular substrate for protein kinase C, The MARCKS gene is under multiple modes of transcriptional control, including cytokine- and transformation-dependent, cell-specific, and developmental regulation, This study evaluated the transcriptional control of MARCKS gene expression during early development of Xenopus laevis, Xenopus MARCKS was highly conserved with its mammalian and avian homologues; its mRNA and protein were abundant in the maternal pool and increased after the mid-blastula transition (MBT). The Xenopus MARCKS gene was similar to those of other species, except that a second intron interrupted the 5'-untranslated region. By transiently transfecting XTC-2 cells and microinjecting Xenopus embryos with reporter gene constructs containing serial deletions of 5'-flanking MARCKS sequences, we identified a 124-base pair minimal promoter that was critical for promoter activity, Developmental gel shift assays revealed that a CBF/NF-Y/CP-1-like factor and an Sp1-like factor bound to this region in a manner correlating with the onset of Xenopus MARCKS transcription at MBT. Mutations in the promoter that abolished binding of these two factors also completely inhibited transcriptional activation of the MARCKS gene at MBT, The binding sites for these two factors are highly conserved in the human and mouse MARCKS promoters, suggesting that these elements might also regulate MARCKS transcription in other species. These studies not only increase our knowledge of the transcriptional regulation of the MARCKS genes but also have implications for the mechanisms responsible for zygotic activation of the Xenopus genome at MBT.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,SECT DIABET & METAB, DIV ENDOCRINOL METAB & NUTR,DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR,SECT DIABET & METAB, DIV ENDOCRINOL METAB & NUTR,DEPT BIOCHEM, DURHAM, NC 27710 USA; ROCKEFELLER UNIV, LAB CARDIAC MEMBRANE PHYSIOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, CTR DEV BIOL, DALLAS, TX 75235 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Rockefeller University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blackshear PJ, 1997, EXP NEUROL, V145, P46, DOI 10.1006/exnr.1997.6475; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; Blackshear PJ, 1996, DEV BRAIN RES, V96, P62, DOI 10.1016/S0165-3806(96)00097-1; BRAKENHOFF RH, 1991, NUCLEIC ACIDS RES, V19, P1279, DOI 10.1093/nar/19.6.1279; BRENNAN SM, 1991, MOL REPROD DEV, V30, P293, DOI 10.1002/mrd.1080300403; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KRIEG PA, 1987, P NATL ACAD SCI USA, V84, P2331, DOI 10.1073/pnas.84.8.2331; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MODAK SP, 1993, ONCOGENE, V8, P645; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OVSENEK N, 1990, DEV GENET, V11, P97, DOI 10.1002/dvg.1020110111; OVSENEK N, 1991, DEV BIOL, V145, P323, DOI 10.1016/0012-1606(91)90130-U; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMBROOK JE, 1989, MOL CLONING LB MANUA; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMITH JC, 1991, METHOD CELL BIOL, V36, P635; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; VILEN BJ, 1992, J BIOL CHEM, V267, P23728; WILSON C, 1986, CELL, V47, P589, DOI 10.1016/0092-8674(86)90623-9; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416	60	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29290	29300		10.1074/jbc.272.46.29290	http://dx.doi.org/10.1074/jbc.272.46.29290			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361009	hybrid			2022-12-25	WOS:A1997YF68400068
J	Takeuchi, Y; Suzawa, M; Kikuchi, T; Nishida, E; Fujita, T; Matsumoto, T				Takeuchi, Y; Suzawa, M; Kikuchi, T; Nishida, E; Fujita, T; Matsumoto, T			Differentiation and transforming growth factor-beta receptor down-regulation by collagen-alpha 2 beta 1 integrin interaction is mediated by focal adhesion kinase and its downstream signals in murine osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; COLLAGEN MESSENGER-RNA; MC3T3-E1 CELLS; MAP KINASE; TRANSDUCTION PATHWAYS; EXTRACELLULAR-MATRIX; ALKALINE-PHOSPHATASE; INVITRO; BINDING; PHOSPHORYLATION	Interaction of type I collagen (COL(I)) with alpha 2 beta 1 integrin causes differentiation and transforming growth factor (TGF)-beta receptor down-regulation in osteoblastic cells (Takeuchi, Y,, Nakayama, K,, and Matsumoto, T, (1996) J, Biol, Chem, 271, 3938-3644), The TGF-beta receptor down-regulation enables cells to escape from the inhibition of differentiation by TGF-beta. To clarify how the cell-matrix interaction regulates these phenotypic changes, signaling pathways were examined in murine MC3T3-E1 cells, Attachment of cells to COL(I) stimulated tyrosine phosphorylation of focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK), a mitogen-activated protein kinase (MAPK), and enhanced MAPK activity, Inhibition of tyrosine kinase by herbimycin A, destruction of focal adhesion by cytochalasin D, or overexpression of antisense FAK mRNA prevented the activation of ERK/MAPK and the increase in alkaline phosphatase (ALP) activity. Transient expression of a MAPK-specific phosphatase, CL100, also sup pressed the elevation of ALP activity, In addition, introduction of a constitutively active MAPK kinase enhanced ALP activity in the absence of collagen production, TGF-beta receptor down-regulation was abrogated by treatments that inactivate FAK, whereas the expression of CL100 had no effect, These results demonstrate that COL(I)-alpha 2 beta 1 integrin interaction facilitates differentiation and down-regulates TGF-beta receptors via the activation of FAK and its diverse downstream signals, These signaling pathways may play an important role in the sequential differentiation of osteoblasts during bone formation.	KYOTO UNIV, INST VIRUS RES, KYOTO 60601, JAPAN	Kyoto University	Takeuchi, Y (corresponding author), UNIV TOKYO, SCH MED, DEPT INTERNAL MED 4, BUNKYO KU, 3-28-6 MEJIRODAI, TOKYO 112, JAPAN.							CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HEINO J, 1989, J BIOL CHEM, V264, P21806; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO T, 1991, BONE, V12, P27, DOI 10.1016/8756-3282(91)90051-J; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PARSONS JT, 1994, J CELL SCI, P109; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; TSAO H, 1990, J BIOL CHEM, V265, P15471; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	36	267	278	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29309	29316		10.1074/jbc.272.46.29309	http://dx.doi.org/10.1074/jbc.272.46.29309			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361011	hybrid			2022-12-25	WOS:A1997YF68400070
J	Blystone, SD; Williams, MP; Slater, SE; Brown, EJ				Blystone, SD; Williams, MP; Slater, SE; Brown, EJ			Requirement of integrin beta(3) tyrosine 747 for beta(3) tyrosine phosphorylation and regulation of alpha(v)beta(3) avidity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUT SIGNAL-TRANSDUCTION; GLYCOPROTEIN-IIB-IIIA; CYTOPLASMIC DOMAINS; PLATELET-AGGREGATION; NPXY MOTIF; RECEPTOR; ADHESION; SUBUNIT; EXPRESSION; ALPHA	Leukocytes and platelets require stimulation for optimal beta(3) integrin receptor function, whereas beta(3) function is constitutive in many other cells, The molecular mechanisms that enhance integrin function in stimulated hematopoietic cells are poorly understood. Phosphorylation of the beta(3) cytoplasmic tail is a recently described but prevalent phenomenon, with unknown effects on gp, function. Here, we show that mutation of the beta(3) cytoplasmic tail tyrosine 747 to phenylalanine (Y747F) prevents beta(3) tyrosine phosphorylation in two cell lines. Whereas this mutation has no effect on alpha(v) beta(3)-mediated adhesion in a cell with constitutive beta(3) function, it completely abolishes adhesion and clot retraction by a cell that requires stimulation for beta(3) function. Ligand-induced conformational change as detected by LIBS-1 antibody occurs normally in Y747F mutant alpha(v) beta(3). Thus, tyrosine 747 of beta(3) is required for stimulation of alpha(v) beta(3)-mediated adhesion, probably due to its phosphorylation, Because the motif in beta(3) required for tyrosine phosphorylation is shared by several integrin beta-chains, this maybe a conserved mechanism for regulation of integrin-dependent adhesion.			Blystone, SD (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, DIV INFECT DIS, CAMPUS BOS 8051, ST LOUIS, MO 63110 USA.							BALLARD LL, 1991, CLIN EXP IMMUNOL, V84, P336; Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; GINSBERG MH, 1990, BLOOD, V76, P2017; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; JIANG YL, 1994, AM J PHYSIOL-CELL PH, V267, pC1112, DOI 10.1152/ajpcell.1994.267.4.C1112; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	26	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28757	28761		10.1074/jbc.272.45.28757	http://dx.doi.org/10.1074/jbc.272.45.28757			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353346	hybrid			2022-12-25	WOS:A1997YF21900086
J	Burgaya, F; Toutant, M; Studler, JM; Costa, A; LeBert, M; Gelman, M; Girault, JA				Burgaya, F; Toutant, M; Studler, JM; Costa, A; LeBert, M; Gelman, M; Girault, JA			Alternatively spliced focal adhesion kinase in rat brain with increased autophosphorylation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; XENOPUS-LAEVIS; PP125(FAK); EXPRESSION; PHOSPHORYLATION; BINDING; LOCALIZATION; HIPPOCAMPUS; PP60(SRC)	pp125 focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase transducing signals initiated by integrin engagement and G protein-coupled receptors, is highly expressed in brain. FAR from brain had a higher molecular weight and an increased autophosphorylation activity, than from other tissues, In addition to a 9-base insertion in the 3'-coding region, which defines FAK(+), rat striatal FAK mRNAs contained several additional short exons, coding for peptides of 28, 6, and 7 residues, respectively (termed boxes 28, 6, and 7), surrounding the autophosphorylated Tyr-397. In transfected COS 7 cells, the presence of boxes 6 and 7 conferred an increased overall tyrosine phosphorylation, a higher phosphorylation of Tyr-397 assessed with a phosphorylation state-specific antibody, and a more active autophosphorylation in immune precipitates. The presence of box 28 did not alter further these parameters, Two-dimensional phosphopeptide maps of hippocampal FAK were identical to those of FAR+6,7. The presence of the various exons did not alter the interaction of FAK with c-Src, n-Src; or Fyn. Thus, several splice isoforms of FAK are preferentially expressed in rat brain, some of which have an increased autophosphorylation activity, suggesting that FAR may have specific properties in neurons.	COLL FRANCE, INSERM U114, CHAIRE NEUROPHARMACOL, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Girault, Jean-Antoine/F-7518-2013; Le Bert, Marc/AAR-4577-2021	Girault, Jean-Antoine/0000-0002-7900-1705; Le Bert, Marc/0000-0002-5945-3800				ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; ARREGUI CO, 1994, J NEUROSCI, V14, P6967; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HENS MD, 1995, DEV BIOL, V170, P274, DOI 10.1006/dbio.1995.1214; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Malik RK, 1996, BBA-REV CANCER, V1287, P73, DOI 10.1016/0304-419X(96)00008-X; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Schaller MD, 1996, J ENDOCRINOL, V150, P1, DOI 10.1677/joe.0.1500001; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Serpente N, 1996, MOL CELL NEUROSCI, V7, P391, DOI 10.1006/mcne.1996.0028; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; Worley TL, 1996, NEUROREPORT, V7, P1133, DOI 10.1097/00001756-199604260-00006; ZHANG XA, 1995, GENE, V160, P219, DOI 10.1016/0378-1119(95)00153-W	33	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28720	28725		10.1074/jbc.272.45.28720	http://dx.doi.org/10.1074/jbc.272.45.28720			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353341	hybrid			2022-12-25	WOS:A1997YF21900081
J	Singh, N; Zanusso, G; Chen, SG; Fujioka, H; Richardson, S; Gambetti, P; Petersen, RB				Singh, N; Zanusso, G; Chen, SG; Fujioka, H; Richardson, S; Gambetti, P; Petersen, RB			Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANCHOR ATTACHMENT; CULTURED-CELLS; LINKED OLIGOSACCHARIDES; BIOCHEMICAL-PROPERTIES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; TRUNCATED FORMS; QUALITY-CONTROL; ATP HYDROLYSIS; SCRAPIE	Prion diseases are characterized by the conversion of the normal cellular prion protein (PrPC), a glycoprotein that is anchored to the cell membrane by a glycosylphosphatidylinositol moiety, into an isoform that is protease-resistant (PrPres) and pathogenic. In inherited prion diseases, mutations in the prion protein (PrPM) engender the conversion of PrPM into PrPres. We developed a cell model of Gerstmann-Straussler-Scheinker disease, a neurodegenerative condition characterized by PrPM-containing amyloid deposits and neuronal loss, by expressing the Gerstmann-Straussler-Scheinker haplotype Q217R-129V in human neuroblastoma cells, By comparison to PrPC, this genotype results in the following alterations of PrPM: 1) expression of an aberrant form lacking the glycosylphosphatidylinositol anchor, 2) increased aggregation and protease resistance, and 3) impaired transport to the cell surface, Most of these alterations are temperature sensitive, indicating that they are due to misfolding of PrPM.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Zanusso, Gianluigi/K-2823-2018; Petersen, Robert/B-5075-2011; Chen, Shu G./AAK-7301-2021; Chen, Shu/Z-2943-2019; Chen, Shu G./O-4750-2014	Zanusso, Gianluigi/0000-0001-5199-6264; Petersen, Robert/0000-0002-3154-0072; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001				BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Fra A, 1993, Subcell Biochem, V21, P143; GOLDFARB LG, 1989, AM J HUM GENET S, V45, P189; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J BIOL CHEM, V266, P1250; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; Oda K, 1996, BIOCHEM J, V316, P623, DOI 10.1042/bj3160623; PARCHI P, 1996, SEMIN VIROL, V7, P1; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1994, P NATL ACAD SCI USA, V91, P4611, DOI 10.1073/pnas.91.11.4611; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; TAGLIAVINI F, 1994, CELL, V79, P695, DOI 10.1016/0092-8674(94)90554-1; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704	46	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28461	28470		10.1074/jbc.272.45.28461	http://dx.doi.org/10.1074/jbc.272.45.28461			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353306	hybrid			2022-12-25	WOS:A1997YF21900046
J	Thinakaran, G; Harris, CL; Ratovitski, T; Davenport, F; Slunt, HH; Price, DL; Borchelt, DR; Sisodia, SS				Thinakaran, G; Harris, CL; Ratovitski, T; Davenport, F; Slunt, HH; Price, DL; Borchelt, DR; Sisodia, SS			Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; IN-VIVO; MUTATIONS; PROTEINS; SYSTEM; GENE; APP; ACCUMULATION; EXPRESSION	Mutations in two related genes, PS1 and PS2, account for the majority of early onset cases of familial Alzheimer's disease, PS1 and PS2 are homologous polytopic membrane proteins that are processed endoproteolytically into two fragments in vivo. In the present report we examine the fate of endogenous PS1 and PS2 after overexpression of human PS1 or PS2 in mouse N2a neuroblastoma cell lines and human PS1 in transgenic mice. Remarkably, in N2a cell lines and in brains of transgenic mice expressing human PS1, accumulation of human PSI derivatives is accompanied by a compensatory, and highly selective, decrease in the steady-state levels of murine PSI and PS2 derivatives. Similarly, the levels of murine PS1 derivatives are diminished in cultured cells overexpressing human PS2, To define the minimal sequence requirements for ''replacement'' we expressed familial Alzheimer's disease-linked and experimental deletion variants of PSI, These studies revealed that compromised accumulation of murine PS1 and PS2 derivatives resulting from overexpression of human PS1 occurs in a manner independent of endoproteolytic cleavage, Our results are consistent with a model in which the abundance of PS1 and PS2 fragments is regulated coordinately by competition for limiting cellular factor(s).	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Thinakaran, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV NEUROPATHOL,558 ROSS BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.				NIA NIH HHS [1PO1 AG14248] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014248] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baumeister R, 1997, Genes Funct, V1, P149; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busfield Frances, 1995, P59, DOI 10.1016/B978-012286965-5/50006-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; THINAKARAN G, 1995, J NEUROSCI, V15, P6314; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1	38	286	291	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28415	28422		10.1074/jbc.272.45.28415	http://dx.doi.org/10.1074/jbc.272.45.28415			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353300	hybrid			2022-12-25	WOS:A1997YF21900040
J	Gao, WW; Goldman, E				Gao, WW; Goldman, E			Use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis to resolve mRNA and its protein product in one gel	FASEB JOURNAL			English	Article						codon usage in Escherichia coli; rare arginine codons; translational control	T7 RNA-POLYMERASE; ESCHERICHIA-COLI; CLONED GENES; EXPRESSION; SYSTEM	We demonstrate that it is possible to simultaneously resolve both an mRNA and its protein product by electrophoresis in a single SDS-polyacrylamide gel by using double labeling with [P-32]H3PO4 and [S-35]methionine, and an elongated 5% stacking gel atop the 10% resolving gel, The mRNA is resolved in the 5% gel; the protein, as expected, resolves in the 10% gel. Using a T7 expression system, we show that putative mRNA bands in the 5% gel are: 1) labeled only with P-32 and not with S-35; 2) inducible with isopropylthiogalactopyranoside (needed to induce a T7 RNA polymerase gene under control of a lac promoter); 3) synthesized in the presence of rifampicin (T7 RNA polymerase is not inhibited by rifampicin); 4) degraded by base or RNase treatment; and 5) are largely resistant to DNase treatment, The mRNA bands were also evident in samples not treated with rifampicin, We used this technique to confirm previously published results that inhibition of expression by consecutive low-usage AGG arginine codons inserted near the 5' end of a test message in Escherichia coli is at the level of translation.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOL GENET,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center								AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2, pCH10; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; GOLDMAN E, 1982, J MOL BIOL, V158, P619, DOI 10.1016/0022-2836(82)90252-2; GOLDMAN E, 1994, METH MOL G, V3, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSENBERG AH, 1993, J BACTERIOL, V175, P716, DOI 10.1128/JB.175.3.716-722.1993; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; SIPLEY J, 1991, MOL GEN GENET, V230, P376, DOI 10.1007/BF00280294; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	15	4	4	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1153	1156		10.1096/fasebj.11.13.9367350	http://dx.doi.org/10.1096/fasebj.11.13.9367350			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367350				2022-12-25	WOS:A1997YE98300013
J	Bourguignon, LYW; Zhu, HB; Chu, A; Iida, N; Zhang, L; Hung, MC				Bourguignon, LYW; Zhu, HB; Chu, A; Iida, N; Zhang, L; Hung, MC			Interaction between the adhesion receptor, CD44, and the oncogene product, p185(HER2), promotes human ovarian tumor cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; MEMBRANE-CYTOSKELETON INTERACTION; SIGNAL-TRANSDUCTION; HYALURONAN-BINDING; CANCER CELLS; EXPRESSION; PROTEIN; DOMAIN; GP85; METASTASIS	In this study we have examined the interaction between CD44s (the standard form) and the p185(HER2) proto-oncogene in the ovarian carcinoma cell line. Surface biotinylation followed by wheat germ agglutinin column chromatography and anti-CD44-mediated immunoprecipitation indicate that both CD44s and p185(HER2) are expressed on the cell surface and most importantly, that these two molecules are physically linked to each other via interchain disulfide bonds, We have also determined that hyaluronic acid stimulates CD44s-associated p185(HER2) tyrosine kinase activity, leading to an increase in the ovarian carcinoma cell growth, After transfection of the ovarian carcinoma cell line with the adenovirus 5 EIA gene, which is known to repress p185(HER2) expression, we observed that both surface CD44s expression and CD44s-mediated cell adhesion to hyaluronic acid are significantly reduced in the transfectant cells compared with the control cells. These data suggest that down-regulation of p185(HER2) blocks CD44s expression and subsequent adhesion function, Our findings also indicate that the CD44s-p185(HER2) interaction is both functionally coupled and biosynthetically regulated, We believe that direct ''cross-talk'' between these two surface molecules (i.e, CD44s and the p185(HER2)) may be one of the most important signaling events in human ovarian carcinoma development.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Bourguignon, LYW (corresponding author), UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,1600 NW 10TH AVE,MIAMI,FL 33101, USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA066163, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, CA66163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1995, J NEURO-ONCOL, V26, P201, DOI 10.1007/BF01052623; CANNISTRA SA, 1995, CLIN CANCER RES, V1, P333; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CARTER WG, 1988, J BIOL CHEM, V263, P4193; GUNTHERT U, 1991, CANCER RES, V51, P5292; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KNUDSON W, 1989, CIBA FDN S, V143, P150; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1995, J IMMUNOL, V155, P3938; Liu D, 1996, J EXP MED, V183, P1987, DOI 10.1084/jem.183.5.1987; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; PAULI BU, 1988, HUM PATHOL, V19, P628, DOI 10.1016/S0046-8177(88)80168-0; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PIVER MS, 1991, SEMIN ONCOL, V18, P177; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; West D. C., 1989, CIBA F SYMP, V143, P201; Xia WY, 1997, CLIN CANCER RES, V3, P3; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1993, CANCER RES, V53, P891; Zhu D, 1996, ONCOGENE, V12, P2309	38	193	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27913	27918		10.1074/jbc.272.44.27913	http://dx.doi.org/10.1074/jbc.272.44.27913			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346940	hybrid			2022-12-25	WOS:A1997YD47300066
J	Hofmeister, R; Wiegmann, K; Korherr, C; Bernardo, K; Kronke, M; Falk, W				Hofmeister, R; Wiegmann, K; Korherr, C; Bernardo, K; Kronke, M; Falk, W			Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; CELL-FREE SYSTEM; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; NEUTRAL SPHINGOMYELINASE; GROWTH SUPPRESSION; GENE-EXPRESSION; CYTO-TOXICITY; T-CELLS	The cytokine interleukin-1 (IL-1) plays an important role in inflammation and regulation of immune responses, but the mechanisms of its signal transduction and cell activation processes are incompletely understood. Ceramide generated by sphingomyelinases (SMases) is known to function as an important second messenger molecule in the signaling pathway of IL-1 and tumor necrosis factor. To investigate the activation of SMases by IL-1, we used an IL-1 receptor type I (IL-1RI)-positive EL4 thymoma cell line, which is defective in IL-1R accessory protein (IL-1RAcP) expression. In this cell line (EL4D6/76), tumor necrosis factor induced ligand/receptor internalization, NF kappa B nuclear translocation, IL-2 production, and the activation of neutral (N)-SMase and acid (A)-SMase. In contrast, stimulation with IL-1 resulted only in the activation of N-SMase whereas ligand/receptor internalization, NF kappa B translocation, IL-2 production, and activation of A-SMase were not detected. Transfection of this functionally defective EL4D6/76 with IL-1RAcP cDNA restored these functions. These data suggest that A-SMase activity is strongly linked with the internalization of IL-1RI mediated by IL-1RAcP and that A-SMase and N-SMase are activated by different pathways.	UNIV REGENSBURG,DEPT INTERNAL MED 1,D-93042 REGENSBURG,GERMANY; CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,D-24105 KIEL,GERMANY	University of Regensburg; University of Kiel								Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADLEY JR, 1993, J IMMUNOL, V150, P5544; BROOKS JW, 1994, EUR CYTOKINE NETW, V5, P547; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; FALK W, 1994, LYMPHOKINE CYTOK RES, V13, P167; FALK W, 1989, LYMPHOKINE RES, V8, P263; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Hofmeister R, 1996, J INFLAMM, V47, P151; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KULL FC, 1981, CANCER RES, V41, P4885; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MARTIN M, 1994, EUR J IMMUNOL, V24, P1566, DOI 10.1002/eji.1830240717; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIMS JE, 1994, EUR CYTOKINE NETW, V5, P539; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	52	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27730	27736		10.1074/jbc.272.44.27730	http://dx.doi.org/10.1074/jbc.272.44.27730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346915	hybrid			2022-12-25	WOS:A1997YD47300041
J	Shworak, NW; Liu, J; Fritze, LMS; Schwartz, JJ; Zhang, LJ; Logeart, D; Rosenberg, RD				Shworak, NW; Liu, J; Fritze, LMS; Schwartz, JJ; Zhang, LJ; Logeart, D; Rosenberg, RD			Molecular cloning and expression of mouse and human cDNAs encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEACETYLASE N-SULFOTRANSFERASE; ANTITHROMBIN-BINDING SEQUENCE; AORTIC ENDOTHELIAL-CELLS; HAMSTER OVARY CELLS; HEPARINLIKE MOLECULES; ENDOPLASMIC-RETICULUM; ANTI-THROMBIN; HIGH-AFFINITY; PURIFICATION; BIOSYNTHESIS	The cellular rate of anticoagulant heparan sulfate proteoglycan (HSPG(act)) generation is determined by the level of a kinetically limiting microsomal activity, HSact conversion activity, which is predominantly composed of the long sought heparan sulfate D-glucosaminyl 3-O-sulfotransferase (3-OST) (Shworak, N. W., Fritze, L. M. S., Liu, J., Butler, L. D., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27063-27071; Liu, J., Shworak, N. W., Fritze, L. M. S., Edelberg, J. M., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27072-27082). Mouse 3-OST cDNAs were isolated by proteolyzing the purified enzyme with Lys-C, sequencing the resultant peptides as well as the existing amino terminus, employing degenerate polymerase chain reaction primers corresponding to the sequences of the peptides as well as the amino terminus to amplify a fragment from LTA cDNA, and utilizing the resultant probe to obtain full-length enzyme cDNAs from a lambda Zap Express LTA cDNA library. Human 3-OST cDNAs were isolated by searching the expressed sequence tag data bank with the mouse sequence, identifying a partial-length human cDNA and utilizing the clone as a probe to isolate a full-length enzyme cDNA from a lambda TriplEx human brain cDNA library. The expression of wild-type mouse 3-OST as well as protein A-tagged mouse enzyme by transient transfection of COS-7 cells and the expression of both wildtype mouse and human 3-OST by in vitro transcription/ translation demonstrate that the two cDNAs directly encode both HSact conversion and 3-OST activities, The mouse 3-OST cDNAs exhibit three different size classes because of a 5'-untranslated region of variable length, which results from the insertion of 0-1629 base pairs (bp) between residues 216 and 217; however, all cDNAs contain the same open reading frame of 933 bp. The length of the 3'-untranslated region ranges from 301 to 430 bp. The nucleic acid sequence of mouse and human 3-OST cDNAs are similar to 85% similar, encoding novel 311- and 307-amino acid proteins of 35,876 and 35,750 daltons, respectively, that are 93% similar. The encoded enzymes are predicted to be intraluminal Golgi residents, pre-sumably interacting via their C-terminal regions with an integral membrane protein. Both 3-OST species exhibit five potential N-glycosylation sites, which account for the apparent discrepancy between the molecular masses of the encoded enzyme (similar to 34 kDa) and the previously purified enzyme (similar to 46 kDa). The two 3-OST species also exhibit similar to 50% similarity with all previously identified forms of the heparan biosynthetic enzyme N-deacetylase/N-sulfotransferase, which suggests that heparan biosynthetic enzymes share a common sulfotransferase domain.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020; Logeart-Avramoglou, Delphine/N-7390-2017	Shworak, Nicholas/0000-0001-7783-4634; Logeart-Avramoglou, Delphine/0000-0002-2052-9425	NHLBI NIH HHS [HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Favaloro J, 1980, Methods Enzymol, V65, P718; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HONG WJ, 1993, BIOESSAYS, V15, P231, DOI 10.1002/bies.950150403; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1986, AM J PHYSIOL, V250, pN879; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENBERG RD, 1978, ANNU REV MED, V29, P367, DOI 10.1146/annurev.me.29.020178.002055; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; STONE KL, 1990, METHOD ENZYMOL, V193, P389, DOI 10.1016/0076-6879(90)93429-O; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WEIS K, 1994, J BIOL CHEM, V269, P19142; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG JDE, 1987, P NATL ACAD SCI USA, V84, P9175, DOI 10.1073/pnas.84.24.9175; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	68	139	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28008	28019		10.1074/jbc.272.44.28008	http://dx.doi.org/10.1074/jbc.272.44.28008			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346953	hybrid			2022-12-25	WOS:A1997YD47300079
J	Sies, H; Sharov, VS; Klotz, LO; Briviba, K				Sies, H; Sharov, VS; Klotz, LO; Briviba, K			Glutathione peroxidase protects against peroxynitrite-mediated oxidations - A new function for selenoproteins as peroxynitrite reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE NITRATION; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE; CARBON-DIOXIDE; EBSELEN; INACTIVATION; 2-(METHYLSELENO)BENZANILIDE; SELENOMETHIONINE; HYDROPEROXIDES; MECHANISM	There is a requirement for cellular defense against excessive peroxynitrite generation to protect against DNA strand breaks and mutations and against interference with protein tyrosine-based signaling and other protein functions due to formation of 3-nitrotyrosine. Here, we demonstrate a role of selenium-containing enzymes catalyzing peroxynitrite reduction using glutathione peroxidase (GPx) as an example, GPx protected against the oxidation of dihydrorhodamine 123 by peroxynitrite more effectively than ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one), a selenoorganic compound exhibiting a high second-order rate constant for the reaction with peroxynitrite, 2 x 10(6) m(-1) s(-1). Carboxymethylation of selenocysteine in GPx by iodoacetate led to the loss of ''classical'' glutathione peroxidase activity but maintained protection against peroxynitrite-mediated oxidation. The maintenance of protection by GPx against peroxynitrite requires GSH as reductant. When peroxynitrite was infused to maintain a 0.2 mu M steady-state concentration, GPx in the presence of GSH, but neither GPx nor GSH alone, effectively inhibited the hydroxylation of benzoate by peroxynitrite, Under these steady-state conditions peroxynitrite did not cause the loss of classical GPx activity. GPx, like selenomethionine, protected against protein 3-nitrotyrosine formation in human fibroblast lysates, shown in Western blots, The formation of nitrite rather than nitrate from peroxynitrite was enhanced by GPx or by selenomethionine. The results demonstrate a novel function of GPx and potentially of other selenoproteins containing selenocysteine or selenomethionine, in the GSH-dependent maintenance of a defense line against peroxynitrite-mediated oxidations, as a peroxynitrite reductase.			Sies, H (corresponding author), UNIV DUSSELDORF,INST PHYSIOL CHEM 1,POSTFACH 101007,D-40001 DUSSELDORF,GERMANY.		Sies, Helmut/ABE-7355-2020; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/B-7266-2008	Klotz, Lars Oliver/0000-0002-1261-8911; Sies, Helmut/0000-0002-1000-3198; Briviba, Karlis/0000-0003-3338-7515				ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Back TG, 1997, J AM CHEM SOC, V119, P2079, DOI 10.1021/ja963602k; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Briviba K, 1996, BIOCHEM J, V319, P13, DOI 10.1042/bj3190013; BURK RF, 1995, HEPATOLOGY, V21, P561; CHRISTISON J, 1994, BIOCHEM J, V304, P341, DOI 10.1042/bj3040341; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; FISCHER H, 1987, B SOC CHIM BELG, V96, P757; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; GLASS RS, 1989, J ORG CHEM, V54, P1092, DOI 10.1021/jo00266a018; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; Masumoto H, 1996, CHEM RES TOXICOL, V9, P1057, DOI 10.1021/tx9600560; Masumoto H, 1996, CHEM RES TOXICOL, V9, P262, DOI 10.1021/tx950115u; MASUMOTO H, 1996, FEBS LETT, V98, P179; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; NIKAWA T, 1994, BIOCHEM PHARMACOL, V47, P1007, DOI 10.1016/0006-2952(94)90411-1; Padmaja S, 1996, FREE RADICAL BIO MED, V21, P317, DOI 10.1016/0891-5849(96)00132-3; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Roussyn I, 1996, ARCH BIOCHEM BIOPHYS, V330, P216, DOI 10.1006/abbi.1996.0245; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Sies H, 1997, Adv Pharmacol, V38, P229; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Szabo C, 1997, J BIOL CHEM, V272, P9030; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; Whiteman M, 1996, FREE RADICAL RES, V25, P275, DOI 10.3109/10715769609149052; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X; ZIEGLER DM, 1992, CHEM RES TOXICOL, V5, P163, DOI 10.1021/tx00026a004	40	390	402	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27812	27817		10.1074/jbc.272.44.27812	http://dx.doi.org/10.1074/jbc.272.44.27812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346926	hybrid			2022-12-25	WOS:A1997YD47300052
J	Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT				Dirks, PB; Patel, K; Hubbard, SL; Ackerley, C; Hamel, PA; Rutka, JT			Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells	ONCOGENE			English	Article						astrocytoma; cyclins; cyclin-dependent kinases; GFAP; retinoic acid; p16; p21	RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; MAMMALIAN-CELLS; CDK INHIBITOR; MICE LACKING; P27(KIP1); ARREST; GROWTH	We have characterized the expression and activity of the cell cycle regulatory machinery and the organization of the cytoskeleton of the p16(ink4a)-deficient astrocytoma cell line, U343 MG-a (U343), following retinoic acid (RA) treatment, RA causes cell cycle arrest at low cell density and significant morphological changes in U343 cells, reflected by reorganization of the intermediate filament, GFAP, and actin, RA-induced cell cycle arrest is also associated with induction of p27(Kip1) expression, inhibition of cdk2-associated kinase activity and alteration of the phosphorylation state of the pRB-family proteins, We next determined the effect of inducing expression of the cyclin dependent kinase inhibitors (CKI's), p16(Ink4a), p21(Cip1/Waf1) or p27(Kip1) on the proliferation and morphology of these malignant astrocytoma cells in the absence and presence of RA, Induction of p16, p21 or p27, using the tetracycline repressor system, potently inhibits proliferation of U343 cells, However, rather than resembling RA-treated cells, CKI-induced U343 cells become flat with abundant cytoplasm and perinuclear vacuolization, CKI-induced morphological alterations are accompanied by a significant reorganization of glial filaments within the cytoplasm, Interestingly, when U343 cells are arrested by p16, p21 or p27 induction and with RA, a dramatic morphological cells acquiring multiple long, tapering processes reminiscent of primary astrocytes, This rearrangement is accompanied by reorganization of GFAP, vimentin and actin, Vimentin specifically relocalizes to the tips of the long processes which form, The arrangement of intermediate filaments in these cells is, in fact, indistinguishable from their arrangement in primary human astrocytes, These data demonstrate that when a strong proliferative block, produced by CKI expression, occurs in conjunction with the morphogenic signals generated by RA, these p16-deficient malignant astrocytoma cells are induced to phenotypically resemble normal astrocytes.	HOSP SICK CHILDREN,DIV NEUROSURG,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU L, 1995, ONCOGENE, V11, P405; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGLIARO LC, 1995, CELL GROWTH DIFFER, V6, P673; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUTKA JT, 1988, INT J CANCER, V53, P3634; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6	41	53	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2037	2048		10.1038/sj.onc.1201392	http://dx.doi.org/10.1038/sj.onc.1201392			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366521				2022-12-25	WOS:A1997YC28400005
J	Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T				Sakamoto, Y; Yoshida, M; Semba, K; Hunter, T			Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain	ONCOGENE			English	Article						tumor suppressor gene; phosphorylation; transcription factor; DNA binding	FACTOR-A-CHAIN; GROWTH-FACTOR; SUPPRESSOR GENE; KIDNEY DEVELOPMENT; MOLECULAR-CLONING; UROGENITAL SYSTEM; MAMMALIAN-CELLS; EXPRESSION; SITE; RECOGNITION	The Wilms' tumor suppressor gene, WT1, encodes a transcription factor in the zinc finger family, which binds to GC-rich sequences and functions as a transcriptional activator or repressor, The WT1 protein plays a crucial role in urogenital development in mammals and its function is thought to be conserved during vertebrate evolution, Although accumulating evidence suggests that WT1 regulates a subset of genes including growth factor and growth factor receptor genes, little is known about regulators or signal cascades that could modulate the function of WT1, In this study, we show that the WT1 protein expressed exogenously in fibroblasts was phosphorylated in vivo, and that treatment with forskolin, which activates the cAMP-dependent protein kinase (PKA) in vivo, induced phosphorylation of additional sites in WT1, We identified the forskolin-induced phosphorylation sites as Ser-365 and Ser-393, which lie in the zinc finger domain in zinc fingers 2 and 3, respectively, PKA phosphorylated WT1 at Ser-365 and Ser-393 in vitro, as well as at additional sites, and this phosphorylation abolished the DNA-binding activity of WT1 in vitro. Using WT1 mutants in which Ser-365 and Ser-393 were mutated to Ala individually and in combination, we showed that phosphorylation of these sites was critical for inhibition of DNA binding in vivo, Thus, coexpression of the PKA catalytic subunit with wild type WT1 reduced the level of WT1 DNA-binding activity detected in nuclear extracts, and decreased transcriptional repression activity in vivo, In contrast to wild type WT1, all of the phosphorylation site mutants retained significant DNA-binding activity and repression activity in the presence of PKA, Analysis of the mutants showed that phosphorylation of Ser-365 and Ser-395 had additive inhibitory effects on WT1 DNA-binding in vivo and that phosphorylation at both sites was required for neutralization of repression activity, Therefore, we conclude that PKA modulates the activity of WT1 in vivo through phosphorylation of Ser-365 and Ser-393, which inhibits DNA binding, This in turn results in a decrease in WT1 transcriptional repression, Our findings provide the first evidence that the function of WT1 can be modulated by its phosphorylation in vivo.	SALK INST BIOL STUDIES, MOL BIOL & VIROL LAB, LA JOLLA, CA 92037 USA; UNIV TOKYO, INST MED SCI, DEPT CELLULAR & MOL BIOL, MINATO KU, TOKYO 108, JAPAN	Salk Institute; University of Tokyo					NCI NIH HHS [CA39760, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algar EM, 1996, ONCOGENE, V12, P1005; ALOI JA, 1995, ENDOCRINOLOGY, V136, P1227, DOI 10.1210/en.136.3.1227; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1985, DNA CLONING PRACTICA; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEWITT SM, 1995, CANCER RES, V55, P5386; HSU SY, 1995, MOL ENDOCRINOL, V9, P1356, DOI 10.1210/me.9.10.1356; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Menke AL, 1996, ONCOGENE, V12, P537; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SHARMA PM, 1992, CANCER RES, V52, P6407; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	59	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	1997	15	17					2001	2012		10.1038/sj.onc.1201391	http://dx.doi.org/10.1038/sj.onc.1201391			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366517				2022-12-25	WOS:A1997YC28400001
J	Bjorkhem, I; Lutjohann, D; Breuer, O; Sakinis, A; Wennmalm, A				Bjorkhem, I; Lutjohann, D; Breuer, O; Sakinis, A; Wennmalm, A			Importance of a novel oxidative mechanism for elimination of brain cholesterol - Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with O-18(2) techniques in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURES; BIOSYNTHESIS; LIVER; CELLS; HOMEOSTASIS; HUMANS; PLASMA	The brain is the most cholesterol-rich organ in the body, Brain cholesterol is characterized by a very Bow turnover with very little exchange with lipoproteins in the circulation, Very recently we showed that there is a continuous age-dependent flux of 24(S)-hydroxycholesterol from the human brain into the circulation (Liitjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Siden, A., Diczfalusy, U., and Bjorkhem, I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9799-9804), Here we measured the rate of synthesis of cholesterol as well as the conversion of cholesterol into 24(S)-hydroxycholesterol in rat brain in vivo with use of an O-18(2) inhalation technique and mass isotopomer distribution analysis, Cholesterol synthesis was found to correspond to 0.03 +/- 0.01% of the pool per h. Conversion of cholesterol into 24(S)-hydroxycholesterol was of a similar magnitude, about 0.02% of the pool per h. Brain microsomes converted endogenous cholestesol into 24(S)-hydroxycholesterol at a similar rate when incubated in the presence of NADPH. When incubated with whole homogenate and subcellular fractions of rat brain, there was no significant conversion of tritium-labeled 24-hydroxycholesterol into more polar products. Plasma from O-18(2)-exposed rats contained 24(S)-hydroxycholesterol with an enrichment of O-18 similar to that in 24(S)-hydroxycholesterol in the brain. The results suggest that the present 24(S)hydroxylase mediated mechanism is most important for elimination of cholesterol from the brain of rats, There is a slow conversion of brain cholesterol into 24(S)-hydroxycholesterol with a rapid turnover of the small pool of the latter oxysterol due to leakage to the circulation (half-life of brain 24(S)-hydroxycholesterol is about 0.5 days as compared with 2-4 months for brain cholesterol), It is evident that the 24(S)-hydroxylation greatly facilitates transfer of cholesterol over-the blood-brain barrier and that this hydroxylation may be critical for cholesterol homeostasis in the brain.	HUDDINGE HOSP,KAROLINSKA INST,DIV CLIN CHEM,SE-14186 HUDDINGE,SWEDEN; GOTHENBURG UNIV,SAHLGRENS UNIV HOSP,DIV CLIN PHYSIOL,GOTHENBURG,SWEDEN	Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg				Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				ANDERSSON M, 1990, FEBS LETT, V269, P15, DOI 10.1016/0014-5793(90)81107-Y; ARINGER L, 1971, STEROIDS, V18, P381, DOI 10.1016/0039-128X(71)90052-3; Benthin G, 1997, BIOCHEM J, V323, P853, DOI 10.1042/bj3230853; BJORKHEM I, 1987, J LIPID RES, V28, P889; BJORKHEM I, 1979, J BIOL CHEM, V254, P5252; BJORKHEM I, 1974, CLIN CHIM ACTA, V54, P185, DOI 10.1016/0009-8981(74)90236-8; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8591; BREUER O, 1995, J BIOL CHEM, V270, P20278, DOI 10.1074/jbc.270.35.20278; DEVRIES H, 1995, THESIS BADHOEVEDEDOR; DHAR AK, 1973, J NEUROCHEM, V21, P51, DOI 10.1111/j.1471-4159.1973.tb04224.x; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; GORDON EL, 1991, IN VITRO CELL DEV B, V27, P312; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; LANGE Y, 1995, J LIPID RES, V36, P1092; LIN YY, 1974, BIOCHIM BIOPHYS ACTA, V348, P189; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; PEDERSEN JI, 1989, BIOCHEM INT, V18, P615; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; SAUCIER SE, 1989, J BIOL CHEM, V264, P6863; SEROUGNE.C, 1973, BIOCHIM BIOPHYS ACTA, V316, P244, DOI 10.1016/0005-2760(73)90014-3; SHEFER S, 1981, J LIPID RES, V22, P532; Snipes G J, 1997, Subcell Biochem, V28, P173; STAPLEGON G, 1996, J BIOL CHEM, V270, P29739; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; ZHANG J, 1995, CR ACAD SCI III-VIE, V318, P345; ZHANG J, 1996, THESIS KAROLINSKA I	30	236	240	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30178	30184		10.1074/jbc.272.48.30178	http://dx.doi.org/10.1074/jbc.272.48.30178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374499	hybrid			2022-12-25	WOS:A1997YH61300031
J	Ware, MF; Tice, DA; Parsons, SJ; Lauffenburger, DA				Ware, MF; Tice, DA; Parsons, SJ; Lauffenburger, DA			Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; EGF RECEPTOR; SH3 DOMAINS; A431 CELLS; MITOGENIC RESPONSIVENESS; SIGNAL-TRANSDUCTION; TYROSINE KINASES; ACTIVATION; DYNAMIN; PHOSPHORYLATION	Previous studies have demonstrated a requirement for the nonreceptor tyrosine kinase, cellular Src (c-Src), in epidermal growth factor (EGF)-induced mitogenesis and a synergistic interaction between c-Src and EGF receptor (EG;FR) in tumorigenesis, Although endocytic internalization of EGFR may be thought to attenuate EGF-stimulated signaling, recent evidence suggests that signaling through Ras can be amplified by repeated encounters of endosome-localized, receptor . Shc . Grb2 . Sos complexes with the plasma membrane, where Ras resides almost exclusively. Based on these reports, we examined EGFR trafficking behavior in a set of single and double c-Src/EGFR C3H10T1/2 overexpressors to determine if c-Src affects basal receptor half-life, ligand-induced internalization, and/or recycling. Our results show that overexpression of c-Src causes no change in EGFR half-life but does produce an increase in the internalization rate constant of EGF EGFR complexes when the endocytic apparatus is not stoichiometrically saturated; this effect of c-Src on EGFR endocytosis is negligible at high receptor occupancy in cells overexpressing the receptor, In neither case are EGFR recycling rate constants affected by c-Src, These data indicate a functional role for c-Src in receptor internalization, which in turn could alter some aspects of EGFR signaling related to mitogenesis and tumorigenesis.	MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; MIT,CTR BIOMED ENGN,CAMBRIDGE,MA 02139; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,CTR CANC,CHARLOTTESVILLE,VA 22903	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Virginia; University of Virginia					NCI NIH HHS [CA69213, CA71449, CA39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449, R01CA039438, R01CA069213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHANG CP, 1993, J BIOL CHEM, V268, P19312; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HENDLER FJ, 1984, J CLIN INVEST, V74, P647, DOI 10.1172/JCI111463; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HUNTS J, 1985, JPN J CANCER RES, V76, P663; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNG HJ, 1994, BIOCH MOL ASPECTS SE, V2, P19; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SINGLETARY SE, 1987, CANCER RES, V47, P403; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	42	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30185	30190		10.1074/jbc.272.48.30185	http://dx.doi.org/10.1074/jbc.272.48.30185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374500	hybrid			2022-12-25	WOS:A1997YH61300032
J	Bova, MP; Ding, LL; Horwitz, J; Fung, BKK				Bova, MP; Ding, LL; Horwitz, J; Fung, BKK			Subunit exchange of alpha A-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CALF LENS NUCLEUS; B-CRYSTALLIN; CHAPERONE ACTIVITY; MOLECULAR CHAPERONES; QUATERNARY STRUCTURE; EXPRESSION; TISSUES; TEMPERATURE; DISEASE	alpha-Crystallin, the major protein in the mammalian lens, is a molecular chaperone that can bind denaturing proteins and prevent their aggregation, Like other structurally related small heat shock proteins, each alpha-crystallin molecule is composed of an average of 40 subunits that can undergo extensive reorganization. In this study we used fluorescence resonance energy transfer to monitor the rapid exchange of recombinant cu-crystallin subunits. We labeled alpha A-crystallin with stilbene iodoacetamide (4-acetamido-4'-((iodoacetyl)amino)stilbene-2,2'-disulfonic acid), which serves as an energy donor and with lucifer yellow iodoacetamide, which serves as an energy acceptor. Upon mixing the two populations of labeled alpha A-crystallin, we observed a reversible, time-dependent decrease in stilbene iodoacetamide emission intensity and a concomitant increase in lucifer yellow iodoacetamide fluorescence, This result is indicative of an exchange reaction that brings the fluorescent alpha A-crystallin subunits close to each other. We further showed that the exchange reaction is strongly dependent on temperature, with a rate constant of 0.075 min(-1) at 37 degrees C and an activation energy of 60 kcal/mol, The subunit exchange is independent of pH and calcium concentration but decreases at low and high ionic strength, suggesting the involvement of both ionic and hydrophobic interactions, It is also markedly reduced by the binding of large denatured proteins, The degree of inhibition is directly proportional to the molecular mass and the amount of bound polypeptide, suggesting an interaction of several alpha A-crystallin subunits with multiple binding sites of the denaturing protein. Our findings reveal a dynamic organization of alpha A-crystallin subunits, which may be a key factor in preventing protein aggregation during denaturation.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NEI NIH HHS [EY07026, EY05895, EY03897] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY003897, R01EY003897, T32EY007026, R01EY005895] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bhat SP, 1996, PROTEIN ENG, V9, P713, DOI 10.1093/protein/9.8.713; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; Bloemendal H, 1981, MOL CELLULAR BIOL EY, P1; BOVA MP, 1996, INVESTIG OPHTHALMOL, V38, P251; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAUWAERT J, 1989, CURR EYE RES, V8, P397, DOI 10.3109/02713688908996387; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fairclough R H, 1978, Methods Enzymol, V48, P347; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FEIN M, 1979, INVEST OPHTH VIS SCI, V18, P761; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JEDZINIAK JA, 1972, INVEST OPHTH VISUAL, V11, P905; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MCFALLNGAI MJ, 1985, EXP EYE RES, V41, P745, DOI 10.1016/0014-4835(85)90183-6; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NENE V, 1986, MOL BIOCHEM PARASIT, V21, P179, DOI 10.1016/0166-6851(86)90021-6; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARKER KC, 1985, BIOCHEMISTRY-US, V24, P5543, DOI 10.1021/bi00341a039; PIETROWSKI D, 1994, GENE, V144, P171, DOI 10.1016/0378-1119(94)90375-1; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1979, EXP EYE RES, V28, P551, DOI 10.1016/0014-4835(79)90043-5; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V749, P227, DOI 10.1016/0167-4838(83)90229-7; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P795; SPECTOR A, 1973, INVEST OPHTH VISUAL, V12, P225; SPECTOR A, 1974, INVEST OPHTH VISUAL, V13, P982; SPECTOR A, 1971, INVEST OPHTH VISUAL, V10, P677; SPECTOR A, 1973, EXP EYE RES, V16, P115, DOI 10.1016/0014-4835(73)90306-0; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wotton D, 1996, J BIOL CHEM, V271, P2717, DOI 10.1074/jbc.271.5.2717	59	264	266	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29511	29517		10.1074/jbc.272.47.29511	http://dx.doi.org/10.1074/jbc.272.47.29511			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368012	hybrid			2022-12-25	WOS:A1997YG64700022
J	Brady, MJ; Nairn, AC; Saltiel, AR				Brady, MJ; Nairn, AC; Saltiel, AR			The regulation of glycogen synthase by protein phosphatase 1 in 3T3-L1 adipocytes - Evidence for a potential role for DARPP-32 in insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ADIPOSE-TISSUE; AFFINITY-CHROMATOGRAPHY; STIMULATION; KINASE; SUBUNIT; EXPRESSION; PHOSPHORYLATION; PHOSPHOPROTEIN; IDENTIFICATION	The stimulation of glycogen-targeted protein phosphatase 1 (PP1), glycogen synthase, and glycogen synthesis by insulin was examined during the differentiation of 3T3-L1 fibroblasts into adipocytes. Insulin treatment barely changed the low levels of glycogen synthesis measured in fibroblasts. Following differentiation into adipocytes, insulin increased glycogen synthesis up to 40-fold. After further culturing of the adipocytes for a week, insulin stimulated glycogen accumulation 700-fold, Differentiation of 3T3-L1 cells also resulted in the increased expression of glycogen synthase and in increases in both total glycogen synthase activity and -fold stimulation by insulin, While the levels of PP1 protein were unchanged by differentiation, PP1 specific activity decreased over 60%, although sensitivity to insulin treatment was augmented. Concurrently, levels of the PP1 inhibitor protein DARPP-32 were dramatically induced upon 3T3-L1 adipogenesis. DARPP-32 in both 3T3-L1 and primary rat adipocytes was exclusively localized to the particulate fractions, including the glycogen enriched pellet. PP1 activity from 3T3-L1 adipocytes exhibited a kinetic lag in vitro, which was not present in fibroblast extracts, Insulin pretreatment of the adipocyte cells overcame the in vitro lag in PP1 activity, resulting in up to 5-fold stimulation of PP1 activity being measured at early assay time points, These results suggest that in 3T3-L1 adipocytes, DARPP-32 may maintain glycogen-targeted PP1 activity in a low basal state, priming the phosphatase for stimulation by insulin.	WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CELL BIOL,ANN ARBOR,MI 48105; ROCKEFELLER UNIV,MOL & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Pfizer; Rockefeller University			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828; Nairn, Angus/0000-0002-7075-0195				Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MATOVCIK LM, 1995, FEBS LETT, V64, P67; MEISTER B, 1988, P NATL ACAD SCI USA, V85, P8713, DOI 10.1073/pnas.85.22.8713; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; NEMENOFF RA, 1983, J BIOL CHEM, V258, P9437; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; STRALFORS P, 1989, EUR J BIOCHEM, V180, P143, DOI 10.1111/j.1432-1033.1989.tb14624.x; TANG PM, 1991, J BIOL CHEM, V266, P15782; VILLAMORUZZI E, 1989, FEBS LETT, V258, P208, DOI 10.1016/0014-5793(89)81654-0; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	31	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29698	29703		10.1074/jbc.272.47.29698	http://dx.doi.org/10.1074/jbc.272.47.29698			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368038	hybrid			2022-12-25	WOS:A1997YG64700048
J	Kuriki, T; Stewart, DC; Preiss, J				Kuriki, T; Stewart, DC; Preiss, J			Construction of chimeric enzymes out of maize endosperm branching enzymes I and II: Activity and properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-STEAROTHERMOPHILUS; CATALYTIC MECHANISM; AMYLOLYTIC ENZYMES; RICE ENDOSPERM; ALPHA-AMYLASES; ZEA-MAYS; STARCH; EXPRESSION; RESOLUTION	Branching enzyme I and II isoforms from maize endosperm (mBE I and mBE II, respectively) have quite different properties, and to elucidate the domain(s) that determines the differences, chimeric genes consisting of part mBE I and part mBE II were constructed. When expressed under the control of the T7 promoter in Escherichia coli, several of the chimeric enzymes were inactive, The only fully active chimeric enzyme was mBE II-I BspHI, in which the carboxyl-terminal part of mBE II was exchanged for that of mBE I at a BspHI restriction site and was purified to homogeneity and characterized, Another chimeric enzyme, mBE I-II HindIII, in which the amino-terminal end of mBE II was replaced with that of mBE I, had very little activity and was only partially characterized, The purified mBE II-I BspHI exhibited higher activity than wild-type mBE I and mBE II when assayed by the phosphorylase a stimulation assay. mBE II-I BspHI had substrate specificity (preference for amylose rather than amylopectin) and catalytic capacity similar to mBE I, despite the fact that only the carboxyl terminus was from mBE I, suggesting that the carboxyl terminus may be involved in determining substrate specificity and catalytic capacity, In chain transfer experiments, mBE II-I BspHI transferred more short chains (with a degree of polymerization of around 6) in a fashion similar to mBE II, In contrast, mBE I-II HindIII transferred more long chains (with a degree of polymerization of around 11-12), similar to mBE I, suggesting that the amino terminus of mBEs may play a role in the size of oligosaccharide chain transferred, This study challenges the notion that the catalytic centers for branching enzymes are exclusively located in the central portion of the enzyme; it suggests instead that the amino and carboxyl termini may also be involved in determining substrate preference, catalytic capacity, and chain length transfer.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University								BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao HP, 1996, J PROTEIN CHEM, V15, P291, DOI 10.1007/BF01887118; FISHER DK, 1993, PLANT PHYSIOL, V102, P1045, DOI 10.1104/pp.102.3.1045; GUAN HP, 1994, CELL MOL BIOL, V40, P981; GUAN HP, 1994, PLANT PHYSIOL, V104, P1449, DOI 10.1104/pp.104.4.1449; GUAN HP, 1995, P NATL ACAD SCI USA, V92, P964, DOI 10.1073/pnas.92.4.964; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; HAWKER JS, 1974, ARCH BIOCHEM BIOPHYS, V160, P530, DOI 10.1016/0003-9861(74)90430-5; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KOSSMANN J, 1991, MOL GEN GENET, V203, P237; Kubota M., 1991, DENPUN KAGAKU, V38, P141; Kuriki T, 1996, J PROTEIN CHEM, V15, P305, DOI 10.1007/BF01887119; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; KURIKI T, 1995, ENZYME CHEM MOL BIOL, P87; KURIKI T, 1992, TRENDS GLYCOSCI GLYC, V4, P567; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIZUNO K, 1993, J BIOL CHEM, V268, P19084; NAKAMURA A, 1992, FEBS LETT, V296, P37, DOI 10.1016/0014-5793(92)80398-Z; NAKAMURA Y, 1992, PHYSIOL PLANTARUM, V84, P329, DOI 10.1111/j.1399-3054.1992.tb04672.x; NAKAMURA Y, 1992, PLANT PHYSIOL, V99, P1265, DOI 10.1104/pp.99.3.1265; POULSEN P, 1993, PLANT PHYSIOL, V102, P1053, DOI 10.1104/pp.102.3.1053; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; ROMEO T, 1988, GENE, V70, P363, DOI 10.1016/0378-1119(88)90208-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAKATA H, 1994, APPL ENVIRON MICROB, V60, P3096, DOI 10.1128/AEM.60.9.3096-3104.1994; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C	43	82	87	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28999	29004		10.1074/jbc.272.46.28999	http://dx.doi.org/10.1074/jbc.272.46.28999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360973	hybrid			2022-12-25	WOS:A1997YF68400032
J	Ray, BK; Ray, A				Ray, BK; Ray, A			Induction of serum amyloid A (SAA) gene by SAA-activating sequence-binding factor (SAF) in monocyte/macrophage cells - Evidence for a functional synergy between SAF and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A GENE; MESSENGER-RNA; MOLECULAR-CLONING; FAMILY PROTEINS; EXPRESSION; C/EBP; APOLIPOPROTEIN; TRANSCRIPTION; LIVER; PARTICIPATION	Serum amyloid A (SAA) is a plasma protein that is associated with many inflammatory diseases including amyloidosis, arthritis, and atherosclerosis. SAA level is significantly increased during inflammatory condition, and such abnormal expression of this protein is linked to the pathogenesis of the above-mentioned diseases, A promoter element, designated as SAA-activating sequence (SAS), located between -280 and -226 has been implicated in the induction mechanism and a nuclear factor, SAS-binding factor (SAF), has been shown to bind to this region, In this report, using a cloned SAF gene in transient transfection assay. we provide evidence that SAF potentiates SAA gene expression through SAS element. Furthermore, we show that during lipopolysaccharide-mediated induction of SAF, het eromeric complex with transcription factor Sp1 is formed, Transfection assays using both transcription factor genes have demonstrated that SAF-Sp1 heteromer is a highly potent transactivator of SAA expression.	UNIV MISSOURI,DEPT VET PATHOBIOL,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK049205, R01DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETTS JC, 1993, J BIOL CHEM, V268, P25624; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JIANG SL, 1995, J IMMUNOL, V154, P825; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LIANG JS, 1995, J LIPID RES, V36, P37; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; Lozanski G, 1996, CYTOKINE, V8, P534, DOI 10.1006/cyto.1996.0072; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; MALLE E, 1993, ATHEROSCLEROSIS, V102, P131, DOI 10.1016/0021-9150(93)90155-N; MEEK RL, 1994, P NATL ACAD SCI USA, V91, P3186, DOI 10.1073/pnas.91.8.3186; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray Alpana, 1993, Gene Expression, V3, P151; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; RIENHOFF HY, 1988, MOL CELL BIOL, V8, P3710, DOI 10.1128/MCB.8.9.3710; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STEINMETZ A, 1989, BIOCHIM BIOPHYS ACTA, V1006, P173, DOI 10.1016/0005-2760(89)90192-6; URIELISHOVAL S, 1994, AM J PATHOL, V145, P650	33	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28948	28953		10.1074/jbc.272.46.28948	http://dx.doi.org/10.1074/jbc.272.46.28948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360966	hybrid			2022-12-25	WOS:A1997YF68400025
J	Shen, ZC; JacobsLorena, M				Shen, ZC; JacobsLorena, M			Characterization of a novel gut-specific chitinase gene from the human malaria vector Anopheles gambiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOSQUITO PERITROPHIC MEMBRANE; BACILLUS-CIRCULANS WL-12; MANDUCA-SEXTA L; PARASITE CHITINASE; MOLTING FLUID; AEDES-AEGYPTI; INTEGUMENT; MECHANISM; INHIBITOR; ALIGNMENT	Chitinases that function in the molting of the larval exoskeleton have been characterized previously, However, chitinase expression in an adult insect gut has not been described. Here we report on the initial characterization and cloning of a novel chitinase gene that is expressed specifically in the midgut of adult Anopheles gambiae females, Upon feeding, chitinase is secreted into the gut lumen as an inactive pro enzyme that is later activated by trypsin. Thus, temporal regulation of chitinase activity is tightly coupled to the temporal pattern of trypsin secretion, The enzyme may play a role in structuring the chitin-containing extracellular peritrophic matrix, whose formation is also induced by feeding, A chitinase cDNA was cloned from a library enriched for gut-specific sequences, The open reading frame encodes a 525-amino acid protein comprised of a putative catalytic domain at the N terminus, a putative chitin-binding domain at the C terminus, and a threonine/serine/proline-rich amino acid stretch in between them, Northern analysis indicates that this chitinase is expressed exclusively in the guts of adult females and not in adult carcasses or in any larval or pupal tissues, The present findings suggest the possibility of using this chitinase as an antigen for a malaria transmission-blocking vaccine.			Shen, ZC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BILLINGSLEY PF, 1992, J PARASITOL, V78, P430, DOI 10.2307/3283640; Elvin CM, 1996, J BIOL CHEM, V271, P8925, DOI 10.1074/jbc.271.15.8925; ESCOTT GM, 1995, INFECT IMMUN, V63, P4770, DOI 10.1128/IAI.63.12.4770-4773.1995; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUKAMIZO T, 1985, INSECT BIOCHEM, V15, P1, DOI 10.1016/0020-1790(85)90037-X; HENRISSAT B, 1990, Protein Sequences and Data Analysis, V3, P523; Higgins D G, 1994, Methods Mol Biol, V25, P307; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; HUMPHREYS AM, 1984, J GEN MICROBIOL, V130, P1359; Jacobs-Lorena Marcelo, 1996, P318; KOGA D, 1989, INSECT BIOCHEM, V19, P123, DOI 10.1016/0020-1790(89)90082-6; KOGA D, 1983, INSECT BIOCHEM, V13, P295, DOI 10.1016/0020-1790(83)90052-5; KOGA D, 1982, INSECT BIOCHEM, V12, P493, DOI 10.1016/0020-1790(82)90017-8; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; KRISHNAN A, 1994, J BIOL CHEM, V269, P20971; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moskalyk LA, 1996, INSECT MOL BIOL, V5, P261, DOI 10.1111/j.1365-2583.1996.tb00100.x; PETERS W, 1992, ZOOPHYSIOLOGY PERITR, V130; Regev A, 1996, APPL ENVIRON MICROB, V62, P3581, DOI 10.1128/AEM.62.10.3581-3586.1996; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Shahabuddin M, 1996, INFECT IMMUN, V64, P739, DOI 10.1128/IAI.64.3.739-743.1996; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Tellam R. L., 1996, P86; TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1994, BIOSCI BIOTECH BIOCH, V58, P2283, DOI 10.1271/bbb.58.2283; Watanabe T, 1996, MOL MAR BIOL BIOTECH, V5, P299	29	108	124	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					28895	28900		10.1074/jbc.272.46.28895	http://dx.doi.org/10.1074/jbc.272.46.28895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360958	hybrid			2022-12-25	WOS:A1997YF68400017
J	Chang, YWE; Traugh, JA				Chang, YWE; Traugh, JA			Phosphorylation of elongation factor 1 and ribosomal protein S6 by multipotential S6 kinase and insulin stimulation of translational elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; MATURATION-PROMOTING FACTOR; FACTOR-I; RABBIT RETICULOCYTES; INITIATION-FACTORS; EXCHANGE ACTIVITY; CHAIN ELONGATION; PHORBOL ESTERS; MESSENGER-RNA; PURIFICATION	Stimulation of protein synthesis in response to insulin is concomitant with increased phosphorylation of initiation factors 4B and 4G and ribosomal protein S6 (Morley, S. J., and Traugh, J. A. (1993) Biochimie 75, 985-989) and is due at least in part to multipotential S6 kinase. When elongation factor 1 (EF-1) from rabbit reticulocytes was examined as substrate for multipotential S6 kinase, up to 1 mol/mol of phosphate was incorporated into the alpha, beta, and delta subunits. Phosphorylation of EF-1 resulted in a 2-2.6-fold stimulation of EF-1 activity, as measured by poly(U)-directed polyphenylalanine synthesis. The rate of elongation was also stimulated by approximately a-fold with 80 S ribosomes phosphorylated on S6 by multipotential S6 kinase. When the rates of elongation in extracts from serum-fed 3T3-L1 cells and cells serum-deprived for 1.5 h were compared, a 40% decrease was observed upon serum deprivation. The addition of insulin to serum-deprived cells for 15 min stimulated elongation to a rate equivalent to that of serum-fed cells. Similar results were obtained with partially purified EF-1, with both EF-1 and ribosomes contributing to stimulation of elongation. These data are consistent with a ribosomal transit time of 3.2 min for serum-deprived cells and 1.6 min following the addition of insulin for 15 min. Taken together, the data suggest that insulin stimulation involves coordinate regulation of EF-1 and ribosomes through phosphorylation by multipotential S6 kinase.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside					NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEC G, 1994, J BIOL CHEM, V269, P2086; BEC G, 1989, J BIOL CHEM, V264, P21131; Bensen ES, 1996, BBA-PROTEIN STRUCT M, V1292, P249, DOI 10.1016/0167-4838(95)00209-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHARD SJ, 1983, J BIOL CHEM, V258, P4003; DEVER TE, 1989, J BIOL CHEM, V264, P20518; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLOYD GA, 1979, EUR J BIOCHEM, V96, P277, DOI 10.1111/j.1432-1033.1979.tb13038.x; HASSELL JA, 1976, BIOCHEMISTRY-US, V15, P1375, DOI 10.1021/bi00652a004; HASSELL JA, 1973, BIOCHIM BIOPHYS ACTA, V324, P545, DOI 10.1016/0005-2787(73)90213-X; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JEFFREY IW, 1993, BIOCHIMIE, V75, P791, DOI 10.1016/0300-9084(93)90129-G; KHATRA BS, 1991, ARCH BIOCHEM BIOPHYS, V284, P186, DOI 10.1016/0003-9861(91)90282-N; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN TH, 1983, J BIOL CHEM, V258, P3992; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1975, J BIOL CHEM, V250, P2620; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1993, BIOCHIMIE, V75, P985, DOI 10.1016/0300-9084(93)90149-M; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MULNERLORILLON O, 1994, J BIOL CHEM, V269, P20201; NIELSEN PJ, 1980, J CELL PHYSIOL, V104, P269, DOI 10.1002/jcp.1041040302; PALEN E, 1987, J BIOL CHEM, V262, P3518; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PALEN E, 1994, BIOCHEMISTRY-US, V33, P8515, DOI 10.1021/bi00194a016; PENDERGAST AM, 1985, J BIOL CHEM, V260, P1769; PERISIC O, 1983, J BIOL CHEM, V258, P9589; PERISIC O, 1985, FEBS LETT, V183, P215, DOI 10.1016/0014-5793(85)80779-1; PETERS HI, 1995, EUR J BIOCHEM, V234, P550, DOI 10.1111/j.1432-1033.1995.550_b.x; PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; ROSENBERRY TL, 1989, J BIOL CHEM, V264, P7096; RYAZANOV AG, 1991, FEBS LETT, V285, P170, DOI 10.1016/0014-5793(91)80798-8; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAHARA SM, 1982, EUR J BIOCHEM, V126, P395; TREVILLYAN JM, 1985, J BIOL CHEM, V260, P3041; TSURUGA M, 1993, BIOSCI BIOTECH BIOCH, V57, P1740; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; YOSHIZAWA F, 1995, BIOSCI BIOTECH BIOCH, V59, P348, DOI 10.1271/bbb.59.348	51	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28252	28257		10.1074/jbc.272.45.28252	http://dx.doi.org/10.1074/jbc.272.45.28252			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353277	hybrid			2022-12-25	WOS:A1997YF21900017
J	McKay, RT; Tripet, BP; Hodges, RS; Sykes, BD				McKay, RT; Tripet, BP; Hodges, RS; Sykes, BD			Interaction of the second binding region of troponin I with the regulatory domain of skeletal muscle troponin C as determined by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; INHIBITORY REGION; BIOLOGICAL-ACTIVITY; CALCIUM-BINDING; PEPTIDE COMPLEX; RABBIT; CONTRACTION; TROPOMYOSIN; PROTEINS; AFFINITY	Two dimensional H-1,(1)5N-heteronuclear single quantum correlation NMR was used to monitor the resonance frequency changes of the backbone amide groups belonging to the N-15-labeled regulatory domain of calcium saturated troponin C (N-TnC) upon addition of synthetic skeletal N-acetyl-troponin I 115-131-amide peptide (TnI(115-131)). Utilizing the change in amide chemical shifts, the dissociation constant for 1:1 binding of TnI(115-131) to N-TnC in low salt and 100 mM KCl samples was determined to be 28 +/- 4 and 24 +/- 4 mu M, respectively. The off rate of TnI(115-131) was determined to be 300 s(-1) from observed N-TnC backbone amide H-1,N-15-heteronuclear single quantum correlation cross-peak line widths, which is on the order of the calcium off rates (Li, M. X., Gagne, S. M., Tsuda, S., Kay, C. M., Smillie, L. B., and Sykes, B. D. (1995) Biochemistry 34, 8330-8340), and agrees with kinetic expectations for biological regulation of muscle contraction. The TnI(115-131) binding site on N-TnC was determined by mapping of chemical shift changes onto the N-TnC NMR structure and was demonstrated to be in the ''hydrophobic pocket'' (Gagne, S. M., Tsuda, S., Li, M. X., Smillie, L. B., and Sykes, B. D. (1995) Nat. Struct. Biol. 2, 784-789).	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta				McKay, Ryan/0000-0002-0255-159X				BAKER JR, 1996, ACAD AM ENCY VERSION; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kobayashi T, 1996, BBA-PROTEIN STRUCT M, V1294, P25, DOI 10.1016/0167-4838(95)00258-8; KOBAYASHI T, 1995, BIOCHEMISTRY-US, V34, P10946, DOI 10.1021/bi00034a029; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; NGAI SM, 1994, J BIOL CHEM, V269, P2165; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PEARLSTONE JR, 1995, BIOCHEMISTRY-US, V34, P6932, DOI 10.1021/bi00021a004; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P9703, DOI 10.1021/bi00155a025; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; PEARLSTONE JR, 1997, BIOPHYS J, V72, P331; PEARLSTONE JR, 1995, BIOPHYS J, V68, P166; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHAW GS, 1991, J AM CHEM SOC, V113, P5557, DOI 10.1021/ja00015a006; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; Sutherland I. O, 1971, ANNUAL REPORTS NMR S, V4, P71; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Wolfram S., 1996, MATH BOOK	51	89	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28494	28500		10.1074/jbc.272.45.28494	http://dx.doi.org/10.1074/jbc.272.45.28494			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353310	hybrid			2022-12-25	WOS:A1997YF21900050
J	Low, SY; Rennie, MJ; Taylor, PM				Low, SY; Rennie, MJ; Taylor, PM			Signaling elements involved in amino acid transport responses to altered muscle cell volume	FASEB JOURNAL			English	Article						skeletal muscle; glutamine transport; phosphatidylinositol 3-kinase	RAT SKELETAL-MUSCLE; GLYCOGEN-SYNTHESIS; GLUTAMINE TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; INTEGRIN; HEPATOCYTES; ACTIVATION; SYNTHASE; INSULIN; KINASE	Skeletal muscle glutamine uptake via the transport system N-m is subject to rapid (t(1/2) = approximate to 1 min) regulation after changes in cell volume by mechanisms that remain to be elucidated. Wortmannin (phosphatidylinositol 3-kinase inhibitor) but not rapamycin (inhibitor of p(70S6) kinase activation) prevents both hypo-osmotic swelling-induced stimulation and hyperosmotic shrinkage-induced inhibition of Na+-dependent glutamine uptake in primary culture of rat skeletal muscle, G-protein inhibitors (cholera, pertussis toxins) also abolished responses of glutamine transport to cell. volume changes whereas these responses were sustained in the presence of G-protein activators (MAS 7, lysophosphatidic acid), Swelling-induced activation of glutamine transport does not seem to involve release of autocrine factors because ''conditioned'' medium from swollen cells has no effect on previously unstimulated cells, System A amino acid transport exhibits responses to cell volume change that are opposite to those of system N-m, but these are also blocked by wortmannin. Active phosphatidylinositol 3-kinase appears to be required to enable muscle cells to exhibit rapid, volume-induced changes in amino acid transport when suitably stimulated.			Low, SY (corresponding author), UNIV DUNDEE,DEPT PHYSIOL & ANAT,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010					BAQUET A, 1991, BIOCHEM J, V273, P57, DOI 10.1042/bj2730057; BAQUET A, 1990, J BIOL CHEM, V265, P955; BODE BP, 1991, J BIOL CHEM, V266, P7376; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; Clarke MSF, 1996, FASEB J, V10, P502, DOI 10.1096/fasebj.10.4.8647349; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; Haussinger D, 1996, BIOCHEM J, V313, P697; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Low SY, 1996, J PHYSIOL-LONDON, V495, P299, DOI 10.1113/jphysiol.1996.sp021594; Low SY, 1996, J PHYSIOL-LONDON, V492, P877, DOI 10.1113/jphysiol.1996.sp021353; MCCORMICK JI, 1995, BIOCHEM J, V311, P743, DOI 10.1042/bj3110743; MCDOWELL HE, 1995, AM J PHYSIOL-CELL PH, V269, pC1287, DOI 10.1152/ajpcell.1995.269.5.C1287; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Neu J, 1996, FASEB J, V10, P829, DOI 10.1096/fasebj.10.8.8666159; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PEAK M, 1992, BIOCHEM J, V282, P797, DOI 10.1042/bj2820797; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Rennie MJ, 1996, BIOCHEM SOC T, V24, P869, DOI 10.1042/bst0240869; RENNIE MJ, 1989, METABOLISM, V38, P47, DOI 10.1016/0026-0495(89)90140-6; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; SOLER C, 1993, BIOCHEM J, V289, P653, DOI 10.1042/bj2890653; TADROS LB, 1993, AM J PHYSIOL, V265, pE135, DOI 10.1152/ajpendo.1993.265.1.E135; VARNIER M, 1995, AM J PHYSIOL-ENDOC M, V269, pE309, DOI 10.1152/ajpendo.1995.269.2.E309; WILSON E, 1995, J CLIN INVEST, V96, P2353; Wymann M. P., 1993, BIOCHEM J, V296, P297	30	58	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	NOV	1997	11	13					1111	1117		10.1096/fasebj.11.13.9367345	http://dx.doi.org/10.1096/fasebj.11.13.9367345			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367345				2022-12-25	WOS:A1997YE98300008
J	Brezillon, S; Zahn, JM; Pierrot, D; Gaillard, D; Hinnrasky, J; Millart, H; Klossek, JM; Tummler, B; Puchelle, E				Brezillon, S; Zahn, JM; Pierrot, D; Gaillard, D; Hinnrasky, J; Millart, H; Klossek, JM; Tummler, B; Puchelle, E			ATP depletion induces a loss of respiratory epithelium functional integrity and down-regulates CFTR (cystic fibrosis transmembrane conductance regulator) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL PROPERTIES; NASAL EPITHELIUM; PROTEIN-KINASES; CELLS; GENE; IDENTIFICATION; DIFFERENTIATION; CHANNEL; MEMBRANE; TISSUES	To mimic the effect of ischemia on the integrity of airway epithelium and expression of cystic fibrosis transmembrane conductance regulator (CFTR), we induced an ATP depletion of the respiratory epithelium from upper airway cells (nasal tissue) and human bronchial epithelial 16HBE14o(-) cell line. Histological analysis showed that 2 h of ATP depletion led to a loss of the epithelium integrity at the interface between basal cells and columnar cells. The expression of connexin 43 (Cx43, subunit of the gap junctions) and desmoplakins 1 and 2 (DPs 1 and 2, major components of the desmosomes) proteins was inhibited. After 90 min of ATP depletion, a significant decrease of the transepithelial resistance (25%) was observed but was reversible. Similar results were obtained with the 16HBE14o(-) human bronchial epithelial cell line. ATP depletion led to actin filaments depolymerization. The expression of the mature CFTR (170 kDa) and fodrin proteins at the apical domain of the ciliated cells was down-regulated. The steady-state levels of CFTR, Cx43, DPs 1 and 2 mRNAs, semiquantified by RT-polymerase chain reaction kinetics, remained constant throughout ATP depletion in nasal tissue as in the homogeneous cell population of 16HBE14o(-) human bronchial epithelial cell line. This suggests that the down-regulation of these proteins might be posttranscriptional. The intercellular diffusion through gap junctions of Lucifer dye was completely inhibited after 90 min of ATP depletion but was reversible. The volume-dependent and the cAMP-dependent chloride secretion were inhibited in a nonreversible way. Taken together, these results suggest that an ATP depletion in human airway epithelium, mimicking ischemia, may induce a marked alteration in the junctional complexes and cytoskeleton structure concomitantly with a loss of apical CFTR expression and chloride secretion function.	UNIV REIMS,CHR MAISON BLANCHE,INSERM,U314,IFR 53,F-51092 REIMS,FRANCE; CHU MAISON BLANCHE,LAB PHARMACOL TOXICOL,IFR 53,F-51092 REIMS,FRANCE; CHU JEAN BERNARD,SERV OTORHINOLARYNGOL & CHIRURG CERVICO FACIALE,F-86021 POITIERS,FRANCE; KLIN FORSCHERGRP,D-30623 HANNOVER,GERMANY	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Reims Champagne-Ardenne; CHU de Reims; CHU Poitiers; Universite de Poitiers				BREZILLON, stephane/0000-0001-7954-8340				BACALLAO R, 1994, J CELL SCI, V107, P3301; BERGER HA, 1993, J BIOL CHEM, V268, P2037; Brezillon S, 1997, HUM PATHOL, V28, P944, DOI 10.1016/S0046-8177(97)90010-1; BREZILLON S, 1995, LAB INVEST, V72, P191; CHEVILLARD M, 1991, CELL TISSUE RES, V264, P49, DOI 10.1007/BF00305721; DECHECCHI MC, 1993, J BIOL CHEM, V268, P11321; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DUPUIT F, 1995, J CLIN INVEST, V96, P1601, DOI 10.1172/JCI118199; EGAN TM, 1991, LUNG SCI FDN, P2205; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; GOODMAN P, 1993, COMPUT MED IMAG GRAP, V17, P133, DOI 10.1016/0895-6111(93)90055-R; GORDON RE, 1982, EXP LUNG RES, V3, P46; HANSEN M, 1993, J CELL SCI, V106, P995; HAWS C, 1992, AM J PHYSIOL, V263, pL692, DOI 10.1152/ajplung.1992.263.6.L692; Herard AL, 1996, AM J RESP CELL MOL, V15, P624, DOI 10.1165/ajrcmb.15.5.8918369; HUG T, 1995, PFLUG ARCH EUR J PHY, V429, P682, DOI 10.1007/BF00373989; HULLRYDE EA, 1983, J CHROMATOGR, V275, P411, DOI 10.1016/S0378-4347(00)84388-1; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MANDEL LJ, 1994, J CELL SCI, V107, P3315; MATTHEWS JB, 1994, SURGERY, V116, P150; Molitoris BA, 1996, KIDNEY INT, V49, P1592, DOI 10.1038/ki.1996.231; MOLITORIS BA, 1993, AM J PHYSIOL, V265, pF693, DOI 10.1152/ajprenal.1993.265.5.F693; MONTEFORT S, 1993, EUR RESPIR J, V6, P1257; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; Nurko S, 1996, AM J PHYSIOL-RENAL, V270, pF39, DOI 10.1152/ajprenal.1996.270.1.F39; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; Reddy MM, 1996, AM J PHYSIOL-CELL PH, V271, pC35, DOI 10.1152/ajpcell.1996.271.1.C35; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Wersto RP, 1996, P NATL ACAD SCI USA, V93, P1167, DOI 10.1073/pnas.93.3.1167; XIE JX, 1995, J BIOL CHEM, V270, P28084	38	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27830	27838		10.1074/jbc.272.44.27830	http://dx.doi.org/10.1074/jbc.272.44.27830			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346929	hybrid			2022-12-25	WOS:A1997YD47300055
J	Cameron, AM; Nucifora, FC; Fung, ET; Livingston, DJ; Aldape, RA; Ross, CA; Snyder, SH				Cameron, AM; Nucifora, FC; Fung, ET; Livingston, DJ; Aldape, RA; Ross, CA; Snyder, SH			FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR; CYCLOSPORINE-A; FKBP12-FK506-CALCINEURIN COMPLEX; PROTEIN; FKBP-12; IDENTIFICATION; IMMUNOPHILINS; ACTIVATION; ISOMERASE	The immunophilin FKBP12 is one of the most abundant and conserved proteins in biology. It is the primary receptor for the immunosuppressant actions of the drug FK506 in whose presence FKBP12 binds to and inhibits calcineurin, disrupting interleukin formation in lymphocytes. The physiologic functions of FKBP12 are less clear, although the protein has been demonstrated to physiologically interact with the inositol 1,4,5-trisphosphate receptor (IP3R), the ryanodine receptor, and the type 1 transforming growth factor beta receptor. We now report that FKBP12 binds the IP3R at residues 1400-1401, a leucyl-prolyl dipeptide epitope that structurally resembles FK506. We further demonstrate that binding to IP3R at this site enables FKBP12 to interact with calcineurin, presumably to anchor the phosphatase to IP3R and modulate the receptor's phosphorylation status. We propose that FK506 promotes an FKBP12-calcineurin interaction by mimicking structurally similar dipeptide epitopes present within proteins that use FKBP12 to anchor calcineurin to the appropriate physiologic substrates.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOL SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			NUCIFORA, FREDERICK/X-2364-2019					ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; FUTER O, 1995, J BIOL CHEM, V270, P18935, DOI 10.1074/jbc.270.32.18935; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; IKEDA Y, 1994, J AM CHEM SOC, V116, P4143, DOI 10.1021/ja00088a086; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6	29	187	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27582	27588		10.1074/jbc.272.44.27582	http://dx.doi.org/10.1074/jbc.272.44.27582			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346894	hybrid			2022-12-25	WOS:A1997YD47300020
J	Fygenson, DK; Goodman, MF				Fygenson, DK; Goodman, MF			Appendix - Gel kinetic analysis of polymerase fidelity in the presence of multiple enzyme DNA encounters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV SO CALIF,DEPT BIOL SCI,HEDCO MOL BIOL LABS,LOS ANGELES,CA 90089	University of Southern California			Fygenson, Deborah/U-3105-2017	Fygenson, Deborah/0000-0002-5681-3938	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554, R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21422, GM42554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; GOODMAN R, 1988, INTRO STOCHASTIC MOD, P157; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533	4	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27931	27935		10.1074/jbc.272.44.27931	http://dx.doi.org/10.1074/jbc.272.44.27931			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346942	Green Submitted, hybrid			2022-12-25	WOS:A1997YD47300068
J	Lindner, RA; Kapur, A; Carver, JA				Lindner, RA; Kapur, A; Carver, JA			The interaction of the molecular chaperone, alpha-crystallin, with molten globule states of bovine alpha-lactalbumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; PROTEINS; SPECTROSCOPY; SPECIFICITY	Small heat shock proteins function in a chaperone-like manner to prevent the precipitation of proteins under conditions of stress (e.g. heat). alpha-Crystallin, the major mammalian lens protein, is a small heat shock protein. The mechanism of chaperone action of these proteins is poorly understood. In this paper, the conformational state of a protein when it forms a high molecular weight complex with alpha-crystallin is investigated by examining, using NMR spectroscopy and size exclusion high performance liquid chromatography, the interaction of alpha-crystallin with alpha-lactalbumin and its various intermediately folded (molten globule) states. The complex is formed following reduction of alpha-lactalbumin by dithiothreitol in the presence of alpha-crystallin, and this interaction has been monitored in real time by H-1 NMR spectroscopy. It is concluded that alpha-crystallin interacts with a disordered molten globule state of alpha-lactalbumin while it is on an irreversible pathway toward aggregation and precipitation. alpha-Crystallin does not interact, however, with molten globule states of alpha-lactalbumin that are stable in solution, e.g. the reduced and carboxy-amidated species. It is proposed that alpha-crystallin distinguishes between the various molten globule states of alpha-lactalbumin on the basis of the lifetimes of these states, i.e. the protein must be in a disordered molten globule state for a significant length of time and on the pathway to aggregation and precipitation for interaction to occur.	UNIV WOLLONGONG,DEPT CHEM,WOLLONGONG,NSW 2522,AUSTRALIA	University of Wollongong			Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108				ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; Arai M, 1996, FOLD DES, V1, P275, DOI 10.1016/S1359-0278(96)00041-7; AUGUSTEYN RC, 1988, BIOCHIM BIOPHYS ACTA, V957, P192, DOI 10.1016/0167-4838(88)90272-5; BALBACH J, 1995, NAT STRUCT BIOL, V2, P865, DOI 10.1038/nsb1095-865; BOELENS WC, 1995, MOL BIOL REP, V21, P75, DOI 10.1007/BF00986495; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1994, BBA-PROTEIN STRUCT M, V1204, P195, DOI 10.1016/0167-4838(94)90009-4; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 1996, EXP EYE RES, V63, P639, DOI 10.1006/exer.1996.0158; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1993, CURR BIOL, V3, P234; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Dobson CM., 1992, CURR OPIN STRUC BIOL, V2, P6; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KILBY GW, 1995, EXP EYE RES, V60, P465, DOI 10.1016/S0014-4835(05)80061-2; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; REDFIELD C, 1994, NAT STRUCT BIOL, V1, P23, DOI 10.1038/nsb0194-23	27	103	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27722	27729		10.1074/jbc.272.44.27722	http://dx.doi.org/10.1074/jbc.272.44.27722			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346914	hybrid			2022-12-25	WOS:A1997YD47300040
J	Sinnegger, MJ; Wang, ZY; Grabner, M; Hering, S; Striessnig, J; Glossmann, H; Mitterdorfer, J				Sinnegger, MJ; Wang, ZY; Grabner, M; Hering, S; Striessnig, J; Glossmann, H; Mitterdorfer, J			Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha(1A) subunit - Role of L-type MET	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY DIHYDROPYRIDINE BINDING; VOLTAGE-DEPENDENT MODULATION; MOLECULAR DETERMINANTS; SKELETAL-MUSCLE; CA2+ CHANNELS; FUNCTIONAL EXPRESSION; ALPHA-1 SUBUNIT; IVS6 SEGMENT; ANTAGONISTS; RECEPTOR	Pharmacological modulation by 1,4-dihydropyridines is a central feature of L-type calcium channels, Recently, eight L-type amino acid residues in transmembrane segments IIIS5, IIIS6, and IVS6 of the calcium channel alpha(1) subunit were identified to substantially contribute to 1,4-dihydropyridine sensitivity, To determine whether these eight L-type residues (Thr(1066), Gln(1070), Ile(1180), Ile(1183), Tyr(1490), Met(1491), Ile(1497), and Ile(1498), alpha(1C-a) numbering) are sufficient to form a high affinity 1,4-dihydropyridine binding site in a non-L-type calcium channel, we transferred them to the 1,4-dihydropyridine-insensitive alpha(1A) subunit using site-directed mutagenesis, 1,4-Dihydropyridine agonist and antagonist modulation of barium inward currents mediated by the mutant alpha(1A) subunits, coexpressed with alpha(2) delta and beta(1a) subunits in Xenopus laevis oocytes, was investigated with the two-microelectrode voltage clamp technique, The resulting mutant alpha(1A-DHPi) displayed low sensitivity for 1,4-dihydropyridines. Analysis of the 1,4-dihydropyridine binding region of an ancestral L-type alpha(1) subunit previously cloned from Musca domestica body wall muscle led to the identification of Met(1188) (alpha(1C-a) numbering) as an additional critical constituent of the L-type 1,4-dihydropyridine binding domain, The introduction of this residue into alpha(1A-DHpi) restored full sensitivity for 1,4-dihydropyridines. It also transferred functional properties considered hallmarks of 1,4-dihydropyridine agonist and antagonist effects (i.e. stereoselectivity, voltage dependence of drug modulation, and agonist-induced shift in the voltage-dependence of activation), Our gain-of-function mutants provide an excellent model for future studies of the structure-activity relationship of 1,4-dihydropyridines to obtain critical structural information for the development of drugs for neuronal, non-L-type calcium channels.	UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck			Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266; Brauns, Martina/0000-0002-0547-2731				BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Brauns T, 1997, BIOCHEMISTRY-US, V36, P3625, DOI 10.1021/bi9613584; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Durell SR, 1996, NEUROPHARMACOLOGY, V35, P761, DOI 10.1016/0028-3908(96)00097-4; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; GRABNER M, 1994, FEBS LETT, V339, P189, DOI 10.1016/0014-5793(94)80413-3; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAMP TJ, 1989, CIRC RES, V64, P338, DOI 10.1161/01.RES.64.2.338; KASS RS, 1987, CIRC RES, V61, P1; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MITTERDORFER J, 1995, BIOCHEMISTRY-US, V34, P9350, DOI 10.1021/bi00029a010; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGUINETTI MC, 1986, J GEN PHYSIOL, V88, P369, DOI 10.1085/jgp.88.3.369; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TRIGGLE DJ, 1992, CLEV CLIN J MED, V59, P617; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27686	27693		10.1074/jbc.272.44.27686	http://dx.doi.org/10.1074/jbc.272.44.27686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346909	hybrid			2022-12-25	WOS:A1997YD47300035
J	Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y				Yasuhara, N; Sahara, S; Kamada, S; Eguchi, Y; Tsujimoto, Y			Evidence against a functional site for Bcl-2 downstream of caspase cascade in preventing apoptosis	ONCOGENE			English	Article						apoptosis; bcl-2; bcl-x; caspase; ICE; CPP32; Fas; signal transduction	FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL-MEMBRANES; CYSTEINE PROTEASE; ACTIVATION; EXPRESSION; NUCLEAR; LOCALIZATION; ONCOPROTEIN	Apoptotic cell death is driven by ICE family proteases (caspases) and negatively regulated by Bcl-2 family proteins. Although it has been shown that Bcl-2 exerts anti-apoptotic activity by blocking a step(s) leading to the activation of caspases, a role for Bcl-2 and Bcl-x(L) downstream of the caspase cascade has remained unclear. Here, we show that purified active caspase-3 (CPP32/Yama/apopain) and caspase-1 (ICE) induces apoptosis when microinjected into the cytoplasm of cells, confirming our recent observations, and that the apoptosis is not at all prevented by Bcl-2 and Bcl-x(L), which are overexpressed more than sufficiently to prevent Fas-mediated and overexpressed procaspase-1-mediated apoptosis. Thus, Bcl-2 and Bcl-x(L) do not act downstream of the caspase cascade.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN	Osaka University								AKAO Y, 1994, CANCER RES, V54, P2468; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEM RJ, 1994, APOPTOSIS, V2, P89; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Hasegawa J, 1996, CANCER RES, V56, P1713; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Marin MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, ONCOGENE, V12, P2251; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSIN SA, 1996, J EXP MED, V184, P1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	41	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1921	1928		10.1038/sj.onc.1201370	http://dx.doi.org/10.1038/sj.onc.1201370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365238				2022-12-25	WOS:A1997YA87200006
J	Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y				Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y			Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-x(L) on Bax-induced caspase activation and apoptosis	ONCOGENE			English	Article						Bax; Bcl-2; Bcl-x(L); apoptosis; caspase; CPP32	CRMA-INHIBITABLE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; DEATH; FAMILY; HETERODIMERIZATION; CPP32; GENE; CHEMOTHERAPY; MITOCHONDRIA	Bcl-2 family proteins and ICE/CED-3 family proteases (caspases) are regarded as the basic regulators of apoptotic cell death. They are evolutionarily conserved and implicated in a variety of apoptosis. However, the precise mechanism by which these two families interact to regulate cell death is not yet known. In this study, we found that the overexpression of the Bcl-2 family member Bax induced apoptotic cell death in COS-7 cells through the activation of CPP32 (caspase-3)-like proteases that cleaved the DEVD tetrapeptide. This apoptotic cell death was suppressed by the viral proteins CrmA and p35, as well as by the chemically synthesized caspase inhibitors Z-Asp-CH2-DCB and zVAD-fmk. We also found that the Bax-induced apoptosis of COS-7 cells was suppressed by Bcl-x(L) and Bcl-2, though both Bcl-x(L) and Bcl-2 similarly prevented etoposide-induced apoptosis in COS-7 cells, In addition, Bcl-x(L) inhibited the activation of caspase-3-like proteases accompanying Bax-induced COS-7 cell death but Bcl-2 did not. These results indicate that the caspase activation is essential for Bax-induced apoptosis, and that the ability of Bcl-2 and Bcl-x, to prevent the Bax-induced caspase activation and apoptosis in COS-7 cells could be differentially regulated. Our results also suggest that Bcl-2 family proteins function upstream of caspase activation and control apoptosis through the regulation of caspase activity.	NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, SCH MED, DEPT NEUROSURG, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, SCH MED, CTR BIOMED RES, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	National Cancer Center - Japan; University of Tokyo; Osaka University								Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boulakia CA, 1996, ONCOGENE, V12, P529; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; DOLE M, 1994, CANCER RES, V54, P3253; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gottschalk AR, 1996, CELL DEATH DIFFER, V3, P113; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jung YK, 1996, J BIOL CHEM, V271, P5112; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SAMBROOK J, 1989, EXPRESSION CLONED GE; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Shimizu S, 1996, ONCOGENE, V12, P2251; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	56	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1763	1772		10.1038/sj.onc.1201349	http://dx.doi.org/10.1038/sj.onc.1201349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362442				2022-12-25	WOS:A1997XZ72500002
J	Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW				Knippschild, U; Milne, DM; Campbell, LE; DeMaggio, AJ; Christenson, E; Hoekstra, MF; Meek, DW			p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs	ONCOGENE			English	Article						CK1 delta; CK1 epsilon; DNA damage; p53; phosphorylation; protein kinase	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; CELLS; CHECKPOINT; EXPRESSION; GENE; IRRADIATION; APOPTOSIS; MUTATION	The p53 tumour suppressor protein plays a key role in the integration of stress signals, Multi-site phosphorylation of p53 may play an integral part in the transmission of these signals and is catalysed by many different protein kinases including an unidentified p53-N-terminus-targeted protein kinase (p53NK) which phosphorylates a group of sites at the N-terminus of the protein. In this paper, we present evidence that the delta and epsilon isoforms of casein kinase 1 (CK1 delta and CK1 epsilon) show identical features to p53NK and can phosphorylate p53 both in vitro and in vivo. Recombinant, purified glutathione S-transferase (GST)-CK1 delta and GST-CK1 epsilon fusion proteins each phosphorylate p53 in vitro at serines 4, 6 and 9, the sites recognised by p53NK. Furthermore, p53NK (i) co-purifies with CK1 delta/epsilon, (ii) shares identical kinetic properties to CK1 delta/epsilon, and (iii) is inhibited by a CK1 delta/epsilon-specific inhibitor (IC261). In addition, CK1 delta is also present in purified preparations of p53NK as judged by immunoanalysis using a CK1 delta-specific monoclonal antibody. Treatment of murine SV3T3 cells with IC261 specifically blocked phosphorylation in vivo of the CK1 delta/epsilon phosphorylation sites in p53, indicating that p53 interacts physiologically with CK1 delta and/or CK1 epsilon. Similarly, over-expression of a green fluorescent protein (GFP)-CK1 delta fusion protein led to hyper-phosphorylation of p53 at its N-terminus. Treatment of MethAp53ts cells with the topoisomerase-directed drugs etoposide or camptothecin led to increases in both CK1 delta-mRNA and -protein levels in a manner dependent on the integrity of p53, These data suggest that p53 is phosphorylated by CK1 delta and CK1 epsilon and additionally that there may be a regulatory feedback loop involving p53 and CK1 delta.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; ICOS CORP, BOTHELL, WA 98021 USA	University of Dundee; Icos Corporation								ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; FISCELLA M, 1993, ONCOGENE, V8, P1519; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Hall PA, 1996, J PATHOL, V180, P1; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lohrum M, 1996, ONCOGENE, V13, P2527; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; OTTO A, 1993, ONCOGENE, V8, P2591; PAULES RS, 1995, CANCER RES, V55, P1763; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santos JA, 1996, J CELL SCI, V109, P1847; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	146	146	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1727	1736		10.1038/sj.onc.1201541	http://dx.doi.org/10.1038/sj.onc.1201541			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349507				2022-12-25	WOS:A1997XY63100013
J	Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD				Waber, P; Dlugosz, S; Cheng, QC; Truelson, J; Nisen, PD			Genetic alterations of chromosome band 9p21-22 in head and neck cancer are not restricted to p16(INK4a)	ONCOGENE			English	Article						p16(INK4a); cyclin-dependent kinase inhibitors; chromosome 9; loss of heterozygosity; squamous cell carcinoma of the head and neck	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; ALLELIC LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; CDKN2; MUTATIONS; FREQUENCY; LINES	Although genetic alterations of chromosome band 9p21-22 occur frequently in head and neck squamous cell carcinoma (HNSCC) cell lines, alterations of the cyclin-dependent kinase inhibitor p16(INK4a) located in this region are less common in corresponding primary tumors. To further investigate genetic alterations at 9p21-22 and p16(INK4a) in primary HNSCC, a paired set of 21 tumors and blood specimens that were shown previously to exhibit allelic loss at 3p and elsewhere, were tested for LOH at 9p21-22 using eight different highly polymorphic marker. Sixteen of the samples (81%) exhibited LOH for at least one marker. Frequent LOH was found surrounding p16(INK4a) and at three additional noncontiguous regions of 9p21-22. No homozygous deletions were identified. SSCP screening and direct sequence analysis led to the identification of mutations the p16(INK4a) gene in two tumors. p16(INK4a) was not hypermethylated in any of the samples studied. Furthermore, there was no correlation between LOH at 9p21-22 and the RB1 tumor suppressor gene. These findings indicate that in the set of tumors that we tested, LOH at 9p21-22 is common in primary HNSCC but that genetic alterations of p16(INK4a) located in this region are unusual. Additional tumor suppressor genes at 9p21-22 may therefore be involved in the pathogenesis of this tumor.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,ACAD COMP SERV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARTKOVA J, 1995, CANCER RES, V55, P949; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CAIRNS P, 1995, CANCER RES, V55, P224; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALLENDER T, 1994, CANCER-AM CANCER SOC, V74, P152, DOI 10.1002/1097-0142(19940701)74:1<152::AID-CNCR2820740124>3.0.CO;2-K; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DEVOS S, 1995, GENE CHROMOSOME CANC, V14, P164; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1385; HERMAN JG, 1995, CANCER RES, V55, P4525; HUANG DP, 1994, CANCER RES, V54, P4003; HUSSUSSIAN C, 1997, NAT GENET, V8, P15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KIRKPATRIC H, 1997, IN PRESS ONCOGENE; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Liggett WH, 1996, CANCER RES, V56, P4119; LIU Q, 1995, ONCOGENE, V10, P1061; LO E, 1995, CANCER RES, V55, P2039; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; NAWROZ H, 1994, CANCER RES, V54, P1152; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Reed AL, 1996, CANCER RES, V56, P3630; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUN Y, 1995, ONCOGENE, V10, P785; UCHIDA T, 1995, BLOOD, V86, P2724, DOI 10.1182/blood.V86.7.2724.bloodjournal8672724; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber PG, 1996, ONCOGENE, V12, P365; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZHANG SY, 1994, CANCER RES, V54, P5050	42	42	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1699	1704		10.1038/sj.onc.1201336	http://dx.doi.org/10.1038/sj.onc.1201336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349503				2022-12-25	WOS:A1997XY63100009
J	Berezutskaya, E; Bagchi, S				Berezutskaya, E; Bagchi, S			The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KERATINOCYTES; GENE-PRODUCT; ZINC-BINDING; CELL-CYCLE; KAPPA-B; TYPE-16; PROTEIN; UBIQUITIN; E6; TRANSFORMATION	Human papillomaviruses (HPV) have been etiologically linked to human cervical cancer. More than 90% of cervical cancer tissues express two HPV-encoded oncoproteins E6 and E7, Both E6 and E7 proteins possess transformation activity. and together they cooperate to transform primary human keratinocytes, fibroblasts, and epithelial cells, The transforming activity of E7 is associated with its ability to bind the retinoblastoma tumor suppressor protein (Rb), However, the carboxyl-terminal mutants of E7 are also defective for transformation, suggesting that other cellular targets for E7 might exist, We screened a human placenta cDNA library by yeast two hybrid assay using HPV 16 E7 as a bait and identified the subunit 4 (S4) ATPase of the 26 S proteasome as a novel E7-binding protein, E7 binds to S4 through the carboxyl-terminal zinc binding motif, and the binding is independent of E7 sequences involved in binding to Rb, The interaction between S4 and E7 can be easily detected by in vitro protein binding assays, Moreover, we found that E7 increases the ATPase activity of S4, A recent study has shown that, in epithelial cells, E7 degrades Rb through the 26 S proteasome pathway. We hypothesize that E7 might target Rb for degradation by 26 S proteasome through its interaction with the subunit 4 of the proteasome.	UNIV ILLINOIS,COLL DENT,CTR MOL BIOL ORAL DIS,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Boyer SN, 1996, CANCER RES, V56, P4620; CLEMENS K, 1996, VIROLOGY, V214, P289; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RANDERATH KJ, 1963, CHROMATOGRAPHY, V10, P235; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ullman CG, 1996, BIOCHEM J, V319, P229, DOI 10.1042/bj3190229; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	43	114	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30135	30140		10.1074/jbc.272.48.30135	http://dx.doi.org/10.1074/jbc.272.48.30135			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374493	hybrid			2022-12-25	WOS:A1997YH61300025
J	Chen, XH; Tsien, RW				Chen, XH; Tsien, RW			Aspartate substitutions establish the concerted action of P-region glutamates in repeats I and III in forming the protonation site of L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CURRENT FLUCTUATIONS; CALCIUM CHANNELS; ION PERMEATION; ESCHERICHIA-COLI; SELECTIVITY; CELLS; DETERMINANTS; DEPENDENCE; MECHANISMS; ALTERS	Hydrogen ions reduced ion flux through voltage-gated Ca2+ channels by binding to a single protonation site with an unusually high pK(a). Recent evidence localizes the protonation site to the same locus that supports high affinity Ca2+ binding and selectivity, a set of four conserved glutamate residues near the external mouth of the pore. Remaining controversy concerns the question of whether the protonation site arises from a single glutamate, Glu-1086 (EIII), or a combination of Glu-1086 and Glu-334 (EI) working in concert. We tested these hypotheses with individual Glu --> Asp substitutions. The Glu --> Asp replacements in repeats I and III stood out in two ways. First, in both EID and EIIID, protonation was destabilized relative to wild type, whereas it was unchanged in EIID and stabilized in EIVD. The changes in affinity were entirely due to alterations in H+ off-rate. Second, the ratio of protonated conductance to deprotonated conductance was significantly closer to unity for EID and EIIID than for wild-type channels or other Asp mutants. both results support the idea that EI and EIII act together to stabilize a single titratable H+ ion and behave nearly symmetrically in influencing pore conductance. Neutralization of EIII by alanine replacement clearly failed to abolish susceptibility to protonation, indicting that no single glutamate was absolutely required. Taken together, all the evidence supports a model in which multiple carboxylates work in concert to form a single high affinity protonation site.	STANFORD UNIV,MED CTR,BECKMAN CTR,DEPT MOL & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University								CARRASCO N, 1989, BIOCHEMISTRY-US, V28, P2533, DOI 10.1021/bi00432a028; CHAIMVIMONVAT N, 1996, NEURON, V16, P1037; Chen XH, 1996, J GEN PHYSIOL, V108, P363, DOI 10.1085/jgp.108.5.363; Colquhoun David, 1995, P397; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P10166, DOI 10.1021/bi960995r; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; Klockner U, 1996, J BIOL CHEM, V271, P22293; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P665, DOI 10.1085/jgp.103.4.665; KRAFTE DS, 1988, J GEN PHYSIOL, V91, P641, DOI 10.1085/jgp.91.5.641; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; Lancaster CRD, 1996, BIOPHYS J, V70, P2469, DOI 10.1016/S0006-3495(96)79820-X; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PIETROBON D, 1988, NATURE, V333, P373, DOI 10.1038/333373a0; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; TANG SQ, 1993, J BIOL CHEM, V268, P13026; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	25	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30002	30008		10.1074/jbc.272.48.30002	http://dx.doi.org/10.1074/jbc.272.48.30002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374474	hybrid			2022-12-25	WOS:A1997YH61300006
J	Inaba, K; Wakasugi, K; Ishimori, K; Konno, T; Kataoka, M; Morishima, I				Inaba, K; Wakasugi, K; Ishimori, K; Konno, T; Kataoka, M; Morishima, I			Structural and functional roles of modules in hemoglobin - substitution of module M4 in hemoglobin subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; SEQUENCE-SPECIFIC PROTEOLYSIS; ESCHERICHIA-COLI; MINI-MYOGLOBIN; INTRINSIC FLUORESCENCE; BINDING-PROPERTIES; MOLTEN GLOBULE; CENTRAL EXON; BETA-GLOBIN; PROTEIN	The alpha- and beta-subunits of human hemoglobin consist of the modules M1, M2 + M3, and M4, which correspond to the exons 1, 2, and 3, respectively (Go, M. (1981) Nature 291, 90-92). To gain further insight into functional and structural significance of the modules, we designed two kinds of chimeric hemoglobin subunits (chimeric alpha alpha beta- and beta beta alpha-subunits), in which the module M4 was replaced by the partner subunits. CD spectra in the far-UV region showed that the secondary structure of the chimeric alpha alpha beta-subunit drastically collapsed, while the chimeric beta beta alpha-subunit conserved the native globin structure (Wakasugi, K., Ishimori, It., Imai, IT., Wada, Y., and Morishima, I. (1994) J. Biol. Chem. 269, 18750-18756). SAXS data also suggested a partially disordered structure of the chimeric alpha alpha beta-subunit. Based on tryptophan-fluorescence spectra and computer modeling from x-ray structures of native globins, steric constraint between Trp(14) and Tyr(125) would be induced in the chimeric alpha alpha beta-subunit, which would perturb the packing of the A- and H-helices and destabilize the globule structure, On the other hand, such a steric constraint was not found for the counterpart chimeric subunit, the beta beta alpha-subunit The different stabilities of these module-substituted globins imply that nodules would not always be stable ''structural'' units, and interactions between modules are crucial to construct stable globin subunits.	KYOTO UNIV,GRAD SCH ENGN,DEPT MOL ENGN,KYOTO 606,JAPAN; NATL INST PHYSIOL SCI,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,FAC SCI,DEPT EARTH & SPACE,TOYONAKA,OSAKA 560,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Osaka University			Ishimori, Koichiro/AAQ-4434-2021; Kataoka, Mikio/H-4402-2011; Wakasugi, Keisuke/AAQ-1642-2020; Ishimori, Koichiro/S-1247-2016	Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462; Inaba, Kenji/0000-0001-8229-0467; Wakasugi, Keisuke/0000-0002-8408-5616				BEYCHOK S, 1967, J BIOL CHEM, V242, P2460; BLAKE CCF, 1979, NATURE, V277, P598, DOI 10.1038/277598a0; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CRAIK CS, 1980, P NATL ACAD SCI-BIOL, V77, P1384, DOI 10.1073/pnas.77.3.1384; CRAIK CS, 1981, NATURE, V291, P87, DOI 10.1038/291087a0; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; DESANCTIS G, 1986, J MOL BIOL, V188, P73, DOI 10.1016/0022-2836(86)90481-X; DESANCTIS G, 1991, J MOL BIOL, V222, P637, DOI 10.1016/0022-2836(91)90501-V; DIIORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025, DOI 10.1073/pnas.90.5.2025; EATON WA, 1980, NATURE, V284, P183, DOI 10.1038/284183a0; Fasman GD, 1976, HDB BIOCH MOL BIOL, P183; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Glatter O., 1982, SMALL ANGLE X RAY SC; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guinier A., 1955, SMALL ANGLE SCATTERI; HIRSCH RE, 1986, BIOCHIM BIOPHYS ACTA, V872, P147, DOI 10.1016/0167-4838(86)90158-5; HIRSCH RE, 1980, BIOCHEM BIOPH RES CO, V93, P432, DOI 10.1016/0006-291X(80)91096-7; HSU MC, 1971, J AM CHEM SOC, V93, P3515; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; JONATHAN DH, 1994, J MOL BIOL, V243, P173; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P1188, DOI 10.1021/bi00219a004; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Kataoka M, 1997, PROTEIN SCI, V6, P422; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KONNO T, 1993, BIOCHIM BIOPHYS ACTA, V1162, P93, DOI 10.1016/0167-4838(93)90133-C; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OLAH GA, 1993, J BIOL CHEM, V268, P16241; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; TAINSKY M, 1973, J MOL BIOL, V75, P735, DOI 10.1016/0022-2836(73)90304-5; TAME J, 1991, J MOL BIOL, V218, P761, DOI 10.1016/0022-2836(91)90264-7; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; VALDES R, 1977, J BIOL CHEM, V252, P74; WADA Y, 1989, BIOMED ENVIRON MASS, V18, P563, DOI 10.1002/bms.1200180809; WAKASUGI K, 1994, J BIOL CHEM, V269, P18750; WAKASUGI K, 1997, IN PRESS BIOPHYS CHE	42	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30054	30060		10.1074/jbc.272.48.30054	http://dx.doi.org/10.1074/jbc.272.48.30054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374481	hybrid			2022-12-25	WOS:A1997YH61300013
J	Sawada, K; Kuroda, N; Watanabe, H; MoritaniOtsuka, C; Kanazawa, H				Sawada, K; Kuroda, N; Watanabe, H; MoritaniOtsuka, C; Kanazawa, H			Interaction of the delta and b subunits contributes to F-1 and F-0 interaction in the Escherichia coli F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; H+-ATPASE; EPSILON-SUBUNIT; NUCLEOTIDE-SEQUENCE; ALPHA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; COUPLING FACTOR; GAMMA-SUBUNIT; BETA-SUBUNIT; UNC OPERON	Interactions of the F-1-F-0-ATPase subunits between the cytoplasmic domain of the b subunit (residues 26-156, b(cyt)) and other membrane peripheral subunits including alpha, beta, gamma, delta, epsilon, and putative cytoplasmic domains of the a subunit were analyzed with the yeast two-hybrid system and in vitro reconstitution of ATPase from the purified subunits as well, Only the combination of b(cyt) fused to the activation domain of the yeast GAL-4, and delta subunit fused to the DNA binding domain resulted in the strong expression of the beta-galactosidase reporter gene, suggesting a specific interaction of these subunits, Expression of b(cyt) fused to glutathione S-transferase (GST) together with the delta subunit in Escherichia coli resulted in the overproduction of these subunits in soluble form, whereas expression of the GST-b(cyt) fusion alone had no such effect, indicating that GST-b(cyt) was protected by the co-expressed delta subunit from proteolytic attack in the cell, These results indicated that the membrane peripheral domain of b subunit stably interacted with the delta subunit in the cell, The affinity purified GST-b(cyt) did not contain significant amounts of delta, suggesting that the interaction of these subunits was relatively weak, Binding of these subunits observed in a direct binding assay significantly supported the capability of binding of the subunits, The ATPase activity was reconstituted from the purified b(cyt) together with alpha, beta, gamma, delta, and epsilon, or with the same combination except epsilon, Specific elution of the ATPase activity from glutathione affinity column with the addition of glutathione after reconstitution demonstrated that the reconstituted ATPase formed a complex, The result indicated that interaction of b and delta was stabilized by F-1 subunits other than epsilon and also suggested that b-delta interaction was important for F-1-F-0 interaction.	OKAYAMA UNIV, FAC ENGN, DEPT BIOTECHNOL, OKAYAMA 700, JAPAN	Okayama University								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P113; DUNN SD, 1980, J BIOL CHEM, V255, P6891; DUNN SD, 1992, J BIOL CHEM, V267, P7630; EYA S, 1988, J BIOL CHEM, V263, P10056; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1980, J BIOL CHEM, V255, P2037; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GAY NJ, 1981, NUCLEIC ACIDS RES, V9, P3919, DOI 10.1093/nar/9.16.3919; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HAZARD AL, 1994, J BIOL CHEM, V269, P427; HOPPE J, 1984, BIOCHIM BIOPHYS ACTA, V768, P1, DOI 10.1016/0304-4173(84)90005-3; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; Howitt SM, 1996, J BIOL CHEM, V271, P7038, DOI 10.1074/jbc.271.12.7038; KANAZAWA H, 1982, ANN NY ACAD SCI, V402, P45, DOI 10.1111/j.1749-6632.1982.tb25731.x; KANAZAWA H, 1980, P NATL ACAD SCI-BIOL, V77, P7005, DOI 10.1073/pnas.77.12.7005; KUKI M, 1988, J BIOL CHEM, V263, P17437; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; Maniatis T., 1982, MOL CLONING; MEDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115; MIKI J, 1992, ARCH BIOCHEM BIOPHYS, V294, P373, DOI 10.1016/0003-9861(92)90698-V; MONTICELLO RA, 1994, J BACTERIOL, V176, P1383, DOI 10.1128/jb.176.5.1383-1389.1994; MORITANI C, 1996, BIOCHIM BIOPHYS ACTA, V258, P14599; NIELSEN J, 1981, MOL GEN GENET, V184, P33, DOI 10.1007/BF00271191; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1991, ADV ENZYME REGUL, V64, P173; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shin YC, 1996, BBA-BIOENERGETICS, V1273, P62, DOI 10.1016/0005-2728(95)00132-8; Shin YC, 1997, ARCH BIOCHEM BIOPHYS, V340, P36, DOI 10.1006/abbi.1997.9883; STACK AE, 1994, J BACTERIOL, V176, P540, DOI 10.1128/JB.176.2.540-542.1994; STERNWEIS PC, 1978, J BIOL CHEM, V253, P3123; VIK SB, 1988, J BIOL CHEM, V263, P6599; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WILKENS S, 1997, NAT STRUCT BIOL, V4, P196; XIONG H, 1995, J BIOL CHEM, V270, P23300, DOI 10.1074/jbc.270.40.23300; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	55	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	1997	272	48					30047	30053		10.1074/jbc.272.48.30047	http://dx.doi.org/10.1074/jbc.272.48.30047			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YH613	9374480	hybrid			2022-12-25	WOS:A1997YH61300012
J	Graber, MN; Alfonso, A; Gill, DL				Graber, MN; Alfonso, A; Gill, DL			Recovery of Ca2+ pools and growth in Ca2+ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SELECTIVE-INHIBITION; CALCIUM POOLS; 5,6-EPOXYEICOSATRIENOIC ACID; PERFUSED KIDNEY; PROTEIN-KINASE; THAPSIGARGIN; LIPOXYGENASE; MECHANISM; RAT	Depletion of Ca2+ pools using the irreversible Ca2+ pump blocker, thapsigargin, induces DDT1MF-S smooth muscle cells to enter a stable nonproliferative state, Reversal of this state can be mediated by high (20%) serum treatment, which induces new Ca2+ pump protein, return of Ca2+ pools, and reentry of cells into the cell cycle; the effect of serum can be mimicked by the essential fatty acids (EFA), arachidonic, linoleic, and alpha-linolenic acids (Graber, M.N., Alfonso, A., and Gill, D.L., (1996) J. Biol. Chem, 271, 883-888), The possible requirement for EFA metabolism in inducing recovery of Ca2+ pool depleted growth-arrested cells was investigated, Neither cyclooxygenase or lipoxygenase inhibitors had any effect on arachidonic acid induced growth recovery of thapsigargin-treated cells. In contrast, the cytochrome P-450 epoxygenase inhibitors, SKF525A and metyrapone, substantially reduced arachidonic acid-induced recovery of growth while having minimal effects on control cell growth. Both epoxygenase inhibitors completely prevented the arachidonic acid-induced recovery of bradykinin-releasable Ca2+-pumping pools, whereas cyclooxygenase and lipoxygenase inhibitors had no effect, The effectiveness of the four cytochrome P-450 metabolites of arachidonic acid on recovery of Ca2+ pools were compared; 8,9- and 11,12-epoxyeicosatrienoic acid (EET) at 1.5 mu M were completely effective in recovering agonist-sensitive Ca2+ pools, whereas the 5,6- and 14,15-EETs were without effect. SKF525A did not block the action of 8,9- or 11,12-EET indicating further P-450 metabolism was not required, Hydration of the active EET molecules prevented Ca2+ pool recovery since the dihydroxy-derivatives of both 8,9- and 11,12-EET were ineffective. The specificity of effectiveness among EET molecules for subsequent resumption of growth of thapsigargin-treated cells was the same as for Ca2+ pool recovery, Significantly, the P-450 inhibitors, SKF525A metyrapone, both prevented the action of 20% serum in inducing recovery of thapsigargin treated cells, whereas cyclooxygenase and lipoxygenase inhibitors were ineffective, indicating that EFAs are the active component within serum that is responsible for recovery of Ca2+ pool depleted cells, The specific action of EETs in mediating recovery of Ca2+ pools and growth of thapsigargin-treated cells represents not only a novel action of epoxygenase products from EFAs, but also a potentially significant new signaling pathway that may effect translational control and regulate transition from a stationary to proliferative growth state.	UNIV MARYLAND,SCH MED,DEPT BIOCHEM & MOL BIOL,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Alfonso, Amparo/GLN-2591-2022	Alfonso Rancano, Maria Amparo/0000-0003-1572-9016	NHLBI NIH HHS [HL55426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL R, 1991, DRUG METAB DISPOS, V19, P620; BALAZY M, 1991, J BIOL CHEM, V266, P23561; BERRIDGE MJ, 1993, BIOCHEM J, V312, P1; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BIAN JH, 1991, J BIOL CHEM, V266, P8801; BYCZKOWSKI JZ, 1992, INT J BIOCHEM, V24, P1691, DOI 10.1016/0020-711X(92)90114-G; CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CASHMAN JR, 1992, EICOSANOIDS, V5, P153; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CUCUROU C, 1991, BIOCHEMISTRY-US, V30, P8964, DOI 10.1021/bi00101a008; CUNNINGHAM FM, 1994, LIPID MEDIATORS; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JOSEPH P, 1993, BIOCHEM J, V293, P83, DOI 10.1042/bj2930083; KAUSER K, 1991, CIRC RES, V68, P1154, DOI 10.1161/01.RES.68.4.1154; KIMURA Y, 1987, BIOCHIM BIOPHYS ACTA, V922, P278; KOHOUT TA, 1995, J BIOL CHEM, V270, P20432, DOI 10.1074/jbc.270.35.20432; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NIEUWENHUIZEN WF, 1995, BIOCHEMISTRY-US, V34, P10538, DOI 10.1021/bi00033a028; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OYEKAN AO, 1991, CIRC RES, V68, P958, DOI 10.1161/01.RES.68.4.958; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1994, TRENDS ENDOCRIN MET, V5, P256, DOI 10.1016/1043-2760(94)P3085-L; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SARUBBI D, 1991, EUR J PHARMACOL, V197, P27, DOI 10.1016/0014-2999(91)90360-3; SHEN TY, 1977, ADV DRUG RES, V12, P89; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; STERN N, 1989, AM J PHYSIOL, V257, pH434, DOI 10.1152/ajpheart.1989.257.2.H434; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOBIAS LD, 1978, LIPIDS, V14, P181; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Waldron RT, 1997, J BIOL CHEM, V272, P6440, DOI 10.1074/jbc.272.10.6440	55	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	1997	272	47					29546	29553		10.1074/jbc.272.47.29546	http://dx.doi.org/10.1074/jbc.272.47.29546			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YG647	9368016	hybrid			2022-12-25	WOS:A1997YG64700026
J	Dong, LQ; Du, HY; Porter, SG; Kolakowski, LF; Lee, AV; Mandarino, J; Fan, JB; Yee, D; Liu, F				Dong, LQ; Du, HY; Porter, SG; Kolakowski, LF; Lee, AV; Mandarino, J; Fan, JB; Yee, D; Liu, F			Cloning, chromosome localization, expression, and characterization of an Src homology 2 and pleckstrin homology domain-containing insulin receptor binding protein hGrb10 gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; BREAST-CANCER; PH DOMAINS; GRB-IR; GROWTH; CELLS; IDENTIFICATION; EFFICIENCY; ACTIVATION	hGrb10 alpha (previously named Grb-IR) is a Src-homology 2 domain-containing protein that binds with high affinity to the tyrosine-phosphorylated insulin receptor and insulin-like growth factor-1 receptor, At least two isoforms of human Grb10, (hGrb10 alpha and hGrb10 beta), which differ in the pleckstrin homology (PEI) domain and the N-terminal sequence, have previously been identified in insulin target tissues such as human skeletal muscle and fat cells, Here we report the cloning of the third isoform of the hGrb10 family (hGrb10 gamma) from human skeletal muscle and its localization to human chromosome 7, We have also determined the human chromosome localization of Grb7 to 17q21-q22 and Grb14 to chromosome 2, hGrb10 gamma contains an intact PEI domain and an N-terminal sequence that is present in hGrb10 gamma but absent in hGrb10 beta, RNase protection assays and Western blot analysis showed that hGrb10 alpha and hGrb10 gamma are differentially expressed in insulin target cells including skeletal muscle, liver, and adipocyte cells, hGrb10 gamma is also expressed in HeLa cells and various breast cancer cell lines, The protein bound with high affinity to the insulin receptor in cells, and the interaction was dependent on the tyrosine phosphorylation of the receptor, hGrb10 gamma also underwent insulin-stimulated membrane translocation and serine phosphorylation, hGrb10 gamma phosphorylation was inhibited by PD98059, a specific inhibitor of mitogen-activated protein kinase kinase, and wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, Taken together, our data suggest that hGrb10 isoforms are potential downstream signaling components of the insulin receptor tyrosine kinase and that the PH domain may play an important role in the involvement of these isoforms in signal transduction pathways initiated by insulin and other growth factors.	UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; STANFORD UNIV,SCH MED,STANFORD HUMAN GENOME CTR,PALO ALTO,CA 94304	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Stanford University				Yee, Douglas/0000-0002-3387-4009; Lee, Adrian/0000-0001-9917-514X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELALUNA S, 1988, GENE, V62, P121; Dey BR, 1996, MOL ENDOCRINOL, V10, P631, DOI 10.1210/me.10.6.631; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EHRENBORG E, 1992, GENOMICS, V12, P497, DOI 10.1016/0888-7543(92)90440-4; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; INGLEY E, 1994, J CELL BIOCHEM, V56, P436, DOI 10.1002/jcb.240560403; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Laviola L, 1997, J CLIN INVEST, V99, P830, DOI 10.1172/JCI119246; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Morrione A, 1996, CANCER RES, V56, P3165; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; OOI J, 1995, ONCOGENE, V10, P1610; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WHITE MF, 1994, J BIOL CHEM, V269, P1; YANG H, 1995, MOL ENDOCRINOL, V9, P1380, DOI 10.1210/me.9.10.1380; YEE D, 1988, CANCER RES, V48, P6691	33	65	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29104	29112		10.1074/jbc.272.46.29104	http://dx.doi.org/10.1074/jbc.272.46.29104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9360986	hybrid			2022-12-25	WOS:A1997YF68400045
J	Soucek, T; Pusch, O; Wienecke, R; DeClue, JE; Hengstschlager, M				Soucek, T; Pusch, O; Wienecke, R; DeClue, JE; Hengstschlager, M			Role of the tuberous sclerosis gene-2 product in cell cycle control - Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANTLY INHERITED CANCER; TUBEROUS-SCLEROSIS-2 TSC2 GENE; EKER RAT MODEL; DEPENDENT KINASES; THYMIDINE KINASE; RENAL-CARCINOMA; MUTATION; HETEROZYGOSITY; TRANSFORMATION; REGION	Tuberous sclerosis is an autosomal dominant disorder characterized by the development of benign growths in many tissues and organs. Linkage analysis revealed two disease-determining genes on chromosome 9 and chromosome 16. The TSC2 gene on chromosome 16 encodes a 1784-amino acid tumor suppressor protein, tuberin, that functions as a GTPase activating protein for Rap1, a member of the superfamily of Ras-related proteins, By immunoblot analyses, we found TSC2 expression to be high in G(0) as well as in early small G(1) cells. Analyses after different cell synchronization procedures revealed that TSC2 mRNA and protein expression do not fluctuate throughout the cell cycle, Using inducible expression systems we further demonstrated that TSC2 expression is not affected by overexpression of the mitogenic transcription factor E2F-1 or c-Myc. Nevertheless, antisense inhibition of tuberin expression in logarithmically growing cells markedly decreased the percentage of cells in G(1). Furthermore, we found that cells exposed to TSC2 antisense oligonucleotides did not undergo G(0) arrest after serum withdrawal, Antisense inhibition of TSC2 expression also induced quiescent G(0)-arrested fibroblasts to reenter the cell cycle. Our data show for the first time that the absence of tuberin can both induce cells to pass through the G(1)/S transition of the eukaryotic cell cycle and prevent them from entering a quiescent state. These results have clear implications for the tumor suppressor function of TSC2, We further found that reentry into the cell cycle upon loss of TSC2 is dependent on the activity of the G(1) cyclin-dependent kinases (CDKs), Cdk2 or Cdk4. Taken together with our finding that antisense inhibition of TSC2 causes up regulation of cyclin D1 expression, these results provide the first evidence for a connection between tuberin/Rap1 and the G(1) CDK-dependent regulation of the transition from G(0)/G(1) to S phase.	UNIV VIENNA, DEPT PRENATAL DIAGNOSIS & THERAPY, A-1090 VIENNA, AUSTRIA; NCI, CELLULAR ONCOL LAB, NIH, BETHESDA, MD 20892 USA	University of Vienna; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Pusch, Oliver/0000-0001-7166-2800				BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; SAMPSON JR, 1992, J MED GENET, V29, P861, DOI 10.1136/jmg.29.12.861; SCHLINGENSIEPEN KH, 1992, GENE REGULATION BIOL; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIEDERHOLT WC, 1985, NEUROLOGY, V35, P600, DOI 10.1212/WNL.35.4.600; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	42	164	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	1997	272	46					29301	29308		10.1074/jbc.272.46.29301	http://dx.doi.org/10.1074/jbc.272.46.29301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF684	9361010	hybrid			2022-12-25	WOS:A1997YF68400069
J	Borges, E; Pendl, G; Eytner, R; Steegmaier, M; Zollner, O; Vestweber, D				Borges, E; Pendl, G; Eytner, R; Steegmaier, M; Zollner, O; Vestweber, D			The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS LYMPHOCYTE ANTIGEN; NECROSIS-FACTOR-ALPHA; LEWIS-X ANTIGEN; HUMAN NEUTROPHILS; HOMING RECEPTOR; ENDOTHELIAL SELECTINS; MONOCLONAL-ANTIBODY; TYROSINE SULFATION; ADHESION MOLECULE; AMINO-TERMINUS	The HECA452 carbohydrate epitope, also termed cutaneous lymphocyte antigen, is known to bind to E-selectin and defines a human T cell subset preferentially found in inflamed skin, Activated T cells can express a functional form of the P-selectin glycoprotein ligand-l (PSGL-1), the major ligand known for P-selectin. Here we show that PSGL-1 can exist in two forms, of which only one carries the HECA452 epitope and binds to E-selectin, while the other only binds to P-selectin, We have analyzed the glycoprotein ligands for E- and P-selectin on the mouse CD8(+) T cell clone 4G3 at 4, 8, and 12 days after antigen-specific activation, Only at day 4 did the cells bind to E-selectin, whereas cells at all three activation stages bound to P-selectin, Expression of the HECA452 epitope correlated with E-selectin binding, In affinity isolation experiments, PSGL-1 was isolated as the major ligand by E-selectin-IgG and by P-selectin-IgG; however, PSGL-1 only bound to E-selectin at day 4, whereas it bound to P-selectin at all three activation stages, Immunoprecipitated PSGL-1 from cells at day 4, but not from cells at days 8 and 12, was recognized in immunoblots by monoclonal antibody HECA452. In immunoblots of total extracts of cells at day 4, HECA452 recognized a 240/140-kDa pair of protein bands as the major antigen, These bands could be completely removed by depletion of cell extracts with anti-PSGL-1 antibodies, Our data suggest that the carbohydrate requirements for binding of PSGL-1 to P-selectin differ from those necessary for binding to E-selectin. Furthermore, we conclude that the major glycoprotein carrier for the HECA452 epitope on activated 463 cells is PSGL-1.	UNIV MUNSTER,INST CELL BIOL,ZMBE,D-48149 MUNSTER,GERMANY	University of Munster				Vestweber, Dietmar/0000-0002-3517-732X				ALON R, 1994, J CELL BIOL, V127, P1485, DOI 10.1083/jcb.127.5.1485; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BORGES E, 1994, J IMMUNOL METHODS, V173, P253, DOI 10.1016/0022-1759(94)90304-2; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; DEBOER OJ, 1994, IMMUNOLOGY, V81, P359; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; Gotsch U, 1997, J CELL SCI, V110, P583; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu L, 1996, IMMUNOLOGY, V88, P207, DOI 10.1111/j.1365-2567.1996.tb00006.x; LOWE JB, 1997, SELECTINS INITATORS, V3, P143; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OHMORI K, 1993, BLOOD, V82, P2797; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; ROSSITER H, 1994, EUR J IMMUNOL, V24, P205, DOI 10.1002/eji.1830240132; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SAWADA M, 1993, BIOCHEM BIOPH RES CO, V193, P337, DOI 10.1006/bbrc.1993.1629; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; TAMATANI T, 1995, AM J PHYSIOL-HEART C, V269, pH1282, DOI 10.1152/ajpheart.1995.269.4.H1282; Tipping PG, 1996, EUR J IMMUNOL, V26, P454, DOI 10.1002/eji.1830260228; VACHINO G, 1995, J BIOL CHEM, V270, P21966, DOI 10.1074/jbc.270.37.21966; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Vestweber D, 1996, J CELL BIOCHEM, V61, P585, DOI 10.1002/(SICI)1097-4644(19960616)61:4<585::AID-JCB12>3.0.CO;2-F; VESTWEBER D, 1997, SELECTIONS INITIATOR; WELLER A, 1992, J BIOL CHEM, V267, P15176; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	43	79	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28786	28792		10.1074/jbc.272.45.28786	http://dx.doi.org/10.1074/jbc.272.45.28786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353350	hybrid			2022-12-25	WOS:A1997YF21900090
J	Mahmud, I; Ueda, N; Yamaguchi, H; Yamashita, R; Yamamoto, S; Kanaoka, Y; Urade, Y; Hayaishi, O				Mahmud, I; Ueda, N; Yamaguchi, H; Yamashita, R; Yamamoto, S; Kanaoka, Y; Urade, Y; Hayaishi, O			Prostaglandin D synthase in human megakaryoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D SYNTHETASE; CDNA CLONING; D-ISOMERASE; BETA-TRACE; PURIFICATION; LINE; IDENTIFICATION; PROTEIN; CMK	The cytosol fraction of human platelets did not convert prostaglandin (PG) H-2 to PGD(2). However, a homogenate of human megakaryoblastic CMK cells (precursor cells of platelets) produced PGD(2) from PGH(2). The PGD synthase activity was localized in the cytosol of CMK cells, and absolutely required glutathione. The catalytic properties and Western and Northern blottings indicated that the enzyme was PGD synthase of the hematopoietic type rather than the lipocalin type, When CMK cells were differentiated to megakaryocytes with phorbol ester along with induction of cyclooxygenase-l, the PGD synthase activity increased about 2-fold for 2 days and then decreased. In another human megakaryoblastic cell line, Dami, the PGD synthase increased about 10-fold by the addition of phorbol ester. Thus, the PGD synthase, which was undetectable in platelets, appeared during differentiation of megakaryoblasts to megakaryocytes.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; OSAKA BIOSCI INST,DEPT MOL BEHAV BIOL,SUITA,OSAKA 565,JAPAN	Tokushima University; Tokushima University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; ENDO T, 1995, AM J RESP CELL MOL, V12, P358, DOI 10.1165/ajrcmb.12.3.7873203; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1991, FATTY ACIDS, V47, P1; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GREENBERG SM, 1988, BLOOD, V72, P1968; HAYAISHI O, 1991, FASEB J, V5, P2575, DOI 10.1096/fasebj.5.11.1907936; HOFFMANN A, 1993, J NEUROCHEM, V61, P451; KANAOKA Y, 1996, FATTY ACIDS S1, V55, P123; KOMATSU N, 1989, BLOOD, V74, P42; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SHEPPARD KA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P223, DOI 10.1016/0167-4889(92)90073-K; TAKAHASHI Y, 1992, BIOCHEM BIOPH RES CO, V182, P433, DOI 10.1016/0006-291X(92)91750-K; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; Ueda N, 1997, BBA-LIPID LIPID MET, V1344, P103, DOI 10.1016/S0005-2760(96)00131-2; URADE Y, 1989, J IMMUNOL, V143, P2982; URADE Y, 1987, J BIOL CHEM, V262, P3820; URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L; URADE Y, 1985, J BIOL CHEM, V260, P2410; URADE Y, 1990, J BIOL CHEM, V265, P371; WATANABE K, 1994, BIOCHEM BIOPH RES CO, V203, P1110, DOI 10.1006/bbrc.1994.2297; WATANABE T, 1982, J BIOL CHEM, V257, P4847; Yamashima T, 1997, J NEUROSCI, V17, P2376	27	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28263	28266		10.1074/jbc.272.45.28263	http://dx.doi.org/10.1074/jbc.272.45.28263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353279	hybrid			2022-12-25	WOS:A1997YF21900019
J	Moeck, GS; Coulton, JW; Postle, K				Moeck, GS; Coulton, JW; Postle, K			Cell envelope signaling in Escherichia coli - Ligand binding to the ferrichrome-iron receptor FhuA promotes interaction with the energy-transducing protein TonB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE TRANSPORT; INDUCED CONFORMATIONAL CHANGE; CONSENSUS PENTAPEPTIDE; VITAMIN-B12 TRANSPORT; ENTEROBACTIN RECEPTOR; CYTOPLASMIC MEMBRANE; BTUB451 MUTATION; GENE ENCODES; K-12; SUPPRESSION	The ferrichrome-iron receptor of Escherichia coli is FhuA, an outer membrane protein that is dependent upon the energy coupling protein TonB to enable active transport of specific hydroxamate siderophores, infection by certain phages, and cell killing by the protein antibiotics colicin M and microcin 25. In vivo cross-linking studies were performed to establish at the biochemical level the interaction between FhuA and TonB. In an E. coli strain in which both proteins were expressed from the chromosome, a high molecular mass complex was detected when the ferrichrome homologue ferricrocin was added immediately prior to addition of crosslinker, The complex included both proteins; it was absent from strains of E. coli that were devoid of either FhuA or TonB, and it was detected with anti-FhuA and anti-TonB monoclonal antibodies, These results indicate that, in vivo, the binding of ferricrocin to FhuA enhances complex formation between the receptor and TonB, An in vitro system was established with which to examine the FhuA-TonB interaction, Incubation of TonB with histidine-tagged FhuA followed by addition of Ni2+-nitrilotriacetate-agarose led to the specific recovery of both TonB and FhuA. Addition of ferricrocin or colicin M to FhuA in this system greatly increased the coupling between FhuA and TonB, Conversely, a monoclonal antibody that binds near the N terminus of FhuA reduced the retention of TonB by histidine-tagged FhuA. These studies demonstrate the significance of ligand binding at the external surface of the cell to mediate signal transduction across the outer membrane.	MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL, PQ H3A 2B4, CANADA; WASHINGTON STATE UNIV, DEPT MICROBIOL, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	McGill University; Washington State University; Washington State University				Postle, Kathleen/0000-0001-9451-777X				ANTON M, 1993, MOL GEN GENET, V239, P371, DOI 10.1007/BF00276935; BASSFORD PJ, 1976, J BACTERIOL, V128, P242, DOI 10.1128/JB.128.1.242-247.1976; BELL PE, 1990, J BACTERIOL, V172, P3826, DOI 10.1128/jb.172.7.3826-3829.1990; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BRADBEER C, 1976, J BACTERIOL, V128, P99, DOI 10.1128/JB.128.1.99-104.1976; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; CARMEL G, 1990, J BACTERIOL, V172, P1861, DOI 10.1128/jb.172.4.1861-1869.1990; CARMEL G, 1991, J BACTERIOL, V173, P4394, DOI 10.1128/JB.173.14.4394-4403.1991; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HELLER KJ, 1988, GENE, V64, P147, DOI 10.1016/0378-1119(88)90488-X; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JAROSIK GP, 1994, INFECT IMMUN, V62, P2470, DOI 10.1128/IAI.62.6.2470-2477.1994; JASKULA JC, 1994, J BACTERIOL, V176, P2326, DOI 10.1128/JB.176.8.2326-2338.1994; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; KADNER RJ, 1995, J BACTERIOL, V177, P4829, DOI 10.1128/jb.177.17.4829-4835.1995; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOEBNIK R, 1993, MOL GEN GENET, V237, P152, DOI 10.1007/BF00282796; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1996, J BACTERIOL, V178, P1363, DOI 10.1128/jb.178.5.1363-1373.1996; Letellier L, 1997, J BIOL CHEM, V272, P8836; LeVier K, 1996, J BACTERIOL, V178, P7265, DOI 10.1128/jb.178.24.7265-7275.1996; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; LIU J, 1994, BIOCHEMISTRY-US, V33, P13274, DOI 10.1021/bi00249a014; Locher KP, 1997, J BIOL CHEM, V272, P1448, DOI 10.1074/jbc.272.3.1448; Means G.E., 1971, CHEM MODIFICATION PR; MOECK GS, 1995, J BACTERIOL, V177, P6118, DOI 10.1128/jb.177.21.6118-6125.1995; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Mondigler M, 1996, VIROLOGY, V219, P19, DOI 10.1006/viro.1996.0218; MONDIGLER M, 1995, FEMS MICROBIOL LETT, V130, P293; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NIKAIDO H, 1994, METHOD ENZYMOL, V235, P225; Plancon L, 1997, J BIOL CHEM, V272, P16868, DOI 10.1074/jbc.272.27.16868; Poole K, 1996, MICROBIOL-UK, V142, P1449, DOI 10.1099/13500872-142-6-1449; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; POSTLE K, 1983, P NATL ACAD SCI-BIOL, V80, P5235, DOI 10.1073/pnas.80.17.5235; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; SALOMON RA, 1992, J BACTERIOL, V174, P7428, DOI 10.1128/jb.174.22.7428-7435.1992; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; SKARE JT, 1993, J BIOL CHEM, V268, P16302; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; TUCKMAN M, 1992, J BACTERIOL, V174, P320, DOI 10.1128/jb.174.1.320-323.1992; YELTON DE, 1981, HYBRIDOMA, V1, P5, DOI 10.1089/hyb.1.1981.1.5	56	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28391	28397		10.1074/jbc.272.45.28391	http://dx.doi.org/10.1074/jbc.272.45.28391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353297	hybrid			2022-12-25	WOS:A1997YF21900037
J	Unkles, SE; Smith, J; Kanan, GJMM; Millar, LJ; Heck, IS; Boxer, DH; Kinghorn, JR				Unkles, SE; Smith, J; Kanan, GJMM; Millar, LJ; Heck, IS; Boxer, DH; Kinghorn, JR			The Aspergillus nidulans cnxABC locus is a single gene encoding two catalytic domains required for synthesis of precursor Z, an intermediate in molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDOPTERIN BIOSYNTHESIS; NITRATE ASSIMILATION; CONVERTING FACTOR; EARLY STEPS; CONTAINS; CLONING; CHLA; NIIA	The Aspergillus nidulans complex locus, cnxABC, has been shown to be required for the synthesis of precursor Z, an intermediate in the molybdopterin cofactor pathway. The locus was isolated by chromosome walking a physical distance of 65-kilobase pairs from the brlA gene and defines a single transcript that encodes, most likely, a difunctional protein with two catalytic domains, CNXA and CNXC. Mutations (cnxA) affecting the CNXA domain, mutants (cnxC) in the CNXC domain, and frameshift (cnxB) mutants disrupting both domains have greatly reduced levels of precursor Z compared with the wild type. The CNXA domain is similar at the amino acid level to the Escherichia coli moaA gene product, while CNXC is similar to the E. coli moaC product, with both E. coli products encoded by different cistrons. In the wild type, precursor Z levels are 3-4 times higher in nitrate-grown cells than in those grown on ammonium, and there is an approximately parallel increase in the 2.4-kilobase pair transcript following growth on nitrate, suggesting nitrate induction of this early section of the pathway. Analysis of the deduced amino acid sequence of several mutants has identified residues critical for the function of the protein. In the CNXA section of the protein, insertion of three amino acid residues into a domain thought to bind an iron-sulfur cofactor leads to a null phenotype as judged by complete loss of activity of the molybdoenzyme, nitrate reductase. More specifically, a mutant has been characterized in which tyrosine replaces cysteine 345, one of several cysteine residues probably involved in binding the cofactor. This supports the proposition that these residues play an essential catalytic role. An insertion of seven amino acids between residues valine 139 and serine 140, leads to a temperature-sensitive phenotype, suggesting a conformational change affecting the catalytic activity of the CNXA region only. A single base pair deletion leading to an in frame stop codon in the CNXC region, which causes a null phenotype, effectively deletes the last 20 amino acid residues of the protein, indicating that these residues are necessary for catalytic function.	MONASH UNIV,DEPT MICROBIOL,CLAYTON,VIC 3168,AUSTRALIA; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Monash University; University of Dundee	Unkles, SE (corresponding author), UNIV ST ANDREWS,SCH ENVIRONM & EVOLUTIONARY BIOL,ST ANDREWS KY16 9TH,FIFE,SCOTLAND.							Arst HN, 1996, MOL MICROBIOL, V19, P1019; ARST HN, 1982, J GEN MICROBIOL, V128, P1083; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; COVE DJ, 1963, NATURE, V198, P262, DOI 10.1038/198262a0; COVE DJ, 1979, BIOL REV, V54, P291, DOI 10.1111/j.1469-185X.1979.tb01014.x; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; GEMS DH, 1993, CURR GENET, V24, P520, DOI 10.1007/BF00351716; Gurr SJ, 1987, GENE STRUCTURE EUKAR, P93; HARTLEY MJ, 1970, GENET RES, V16, P123, DOI 10.1017/S0016672300002330; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; JOHNSTONE IL, 1985, EMBO J, V4, P1307, DOI 10.1002/j.1460-2075.1985.tb03777.x; MACCABE AP, 1990, EMBO J, V9, P279, DOI 10.1002/j.1460-2075.1990.tb08106.x; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PUNT PJ, 1995, MOL CELL BIOL, V15, P5688; RAJAGOPALAN KV, 1997, NITROGEN ASSIMILATIO; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; SCAZZOCC.C, 1974, J LESS-COMMON MET, V36, P461, DOI 10.1016/0022-5088(74)90130-1; SCAZZOCCHIO C, 1980, MOLYBDENUM MOLYBDENU, P489; SUAREZ T, 1995, EMBO J, V14, P1453, DOI 10.1002/j.1460-2075.1995.tb07132.x; TOMSETT AB, 1989, NITROGEN PHOSPHORUS, P33; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	29	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	1997	272	45					28381	28390		10.1074/jbc.272.45.28381	http://dx.doi.org/10.1074/jbc.272.45.28381			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YF219	9353296	hybrid, Green Published			2022-12-25	WOS:A1997YF21900036
J	Durand, P; LussierCacan, S; Blache, D				Durand, P; LussierCacan, S; Blache, D			Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats	FASEB JOURNAL			English	Article						atherogenesis; thrombosis; folic acid; lipid peroxidation	ENDOTHELIAL-CELL INJURY; LOW-DENSITY-LIPOPROTEIN; VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; FOLIC-ACID; FOLATE-DEFICIENCY; METHYLENETETRAHYDROFOLATE REDUCTASE; INDUCED ARTERIOSCLEROSIS; COORDINATE REGULATION	A moderate elevation of plasma homocysteine is a risk factor for atherosclerosis and arterial and veinous thrombosis. However, the mechanisms leading to vascular disorders are poorly understood because studies that have investigated the potential atherothrombogenicity of hyperhomocysteinemia in vivo are scarce. Using a rat model, we were the first to show that dietary folic acid deficiency, a major cause of basal hyperhomocysteinemia, is associated with enhanced macrophage-derived tissue factor and platelet activities. We proposed that an homocysteine-induced oxidative stress may account for this hypercoagulable state. To determine the true thrombogenicity of moderate hyperhomocysteinemia and better understand its etiology, we have carried out an acute methionine load in control and folate-deficient animals. When rats were fed the control diet, a transient fourfold increase in plasma homocysteine levels was observed 2 h after the methionine administration. As with prolonged dietary folic acid deficiency, this methionine load potentiated the platelet aggregation in response to thrombin and ADP as well as the thrombin-induced thromboxane synthesis. It also stimulated the basal and lipopolysaccharide-induced tissue factor activity of peritoneal macrophages. These prothrombotic effects were associated with an increased lipid peroxidation characterized by an elevation of plasma conjugated dienes, lipid hydroperoxides, and thiobarbituric acid-reactive substances. When rats were fed a folic acid-deficient diet, the methionine load did not cause any further increase in plasma homocysteine concentration, platelet activation, macrophage tissue factor-dependent coagulation, or lipoperoxidation. Altogether, our data showed that the prethrombotic state due to both the altered remethylation and transsulfuration pathways resulted from the moderate elevation of circulating homocysteine. We conclude that moderate hyperhomocysteinemia plays a role in the development of a thrombogenic state that might be mediated by the occurrence of oxidative stress.	UNIV BOURGOGNE, FAC MED, LAB BIOCHIM LIPOPROT, INSERM, CJF 9310, F-21033 DIJON, FRANCE; CLIN RES INST MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDERSSON A, 1995, CLIN CHEM, V41, P361; BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BLACHE D, 1995, AM J PHYSIOL-HEART C, V268, pH679, DOI 10.1152/ajpheart.1995.268.2.H679; BLOM HJ, 1995, EUR J CLIN INVEST, V25, P149, DOI 10.1111/j.1365-2362.1995.tb01541.x; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; CIAVATTI M, 1989, ARTERIOSCLEROSIS, V9, P84, DOI 10.1161/01.ATV.9.1.84; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; CRUTCHLEY DJ, 1995, CIRCULATION, V92, P238, DOI 10.1161/01.CIR.92.2.238; DESGRES J, 1979, J CHROMATOGR, V162, P133, DOI 10.1016/S0378-4347(00)81907-6; DIMINNO G, 1993, J CLIN INVEST, V92, P1400, DOI 10.1172/JCI116715; DUDMAN NPB, 1993, ARTERIOSCLER THROMB, V13, P512, DOI 10.1161/01.ATV.13.4.512; Durand P, 1996, CLIN CHIM ACTA, V252, P83, DOI 10.1016/0009-8981(96)06325-5; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Durand P, 1996, ATHEROSCLEROSIS, V121, P205, DOI 10.1016/0021-9150(95)05720-X; DURAND P, 1997, IN PRESS THROMB VASC, V17; ELSAADANI M, 1989, J LIPID RES, V30, P627; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FRONTIERA MS, 1994, J NUTR BIOCHEM, V5, P28, DOI 10.1016/0955-2863(94)90006-X; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GUTTORMSEN AB, 1994, J NUTR, V124, P1934, DOI 10.1093/jn/124.10.1934; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Harpel PC, 1996, J NUTR, V126, pS1285, DOI 10.1093/jn/126.suppl_4.1285S; HASHIZUME T, 1991, ARCH BIOCHEM BIOPHYS, V289, P47, DOI 10.1016/0003-9861(91)90440-T; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HENNEKENS CH, 1994, AM HEART J, V128, P1333, DOI 10.1016/0002-8703(94)90256-9; Iuliano L, 1996, BRIT J PHARMACOL, V119, P1438, DOI 10.1111/j.1476-5381.1996.tb16056.x; Jacques PF, 1996, CIRCULATION, V93, P7, DOI 10.1161/01.CIR.93.1.7; JAMES SJ, 1992, CARCINOGENESIS, V13, P2471, DOI 10.1093/carcin/13.12.2471; KRITCHEVSKY D, 1993, ANN NY ACAD SCI, V676, P180; Loehrer FMT, 1996, CLIN SCI, V91, P79, DOI 10.1042/cs0910079; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCCULLY KS, 1983, ATHER REV, V11, P157; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; POLETTE A, 1992, ATHEROSCLEROSIS, V96, P171, DOI 10.1016/0021-9150(92)90063-M; PRATICO D, 1992, J LAB CLIN MED, V119, P364; RICHIE JP, 1994, FASEB J, V8, P1302, DOI 10.1096/fasebj.8.15.8001743; SALONEN JT, 1991, AM J CLIN NUTR, V53, P1222, DOI 10.1093/ajcn/53.5.1222; SCHORER AE, 1985, J LAB CLIN MED, V106, P38; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Toborek M, 1996, NUTR RES, V16, P1251, DOI 10.1016/0271-5317(96)00128-5; TOBOREK M, 1995, ATHEROSCLEROSIS, V115, P217, DOI 10.1016/0021-9150(94)05516-L; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM, 1996, J NUTR, V126, pS1281, DOI 10.1093/jn/126.suppl_4.1281S; UELAND PM, 1989, J LAB CLIN MED, V114, P473; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828	57	184	195	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1997	11	13					1157	1168		10.1096/fasebj.11.13.9367351	http://dx.doi.org/10.1096/fasebj.11.13.9367351			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YE983	9367351				2022-12-25	WOS:A1997YE98300014
J	Abdollah, S; MaciasSilva, M; Tsukazaki, T; Hayashi, H; Attisano, L; Wrana, JL				Abdollah, S; MaciasSilva, M; Tsukazaki, T; Hayashi, H; Attisano, L; Wrana, JL			T beta RI phosphorylation of Smad2 on Ser(465) and Ser(467) is required for Smad2-Smad4 complex formation and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; GLYCOGEN-SYNTHASE KINASE-3; MAD-RELATED PROTEIN; RECEPTOR COMPLEX; ACTS DOWNSTREAM; DROSOPHILA; PATHWAY; FAMILY; TRANSDUCTION; ACTIVATION	Mothers against Dpp-related or Smad proteins are essential components of serine/threonine kinase receptor signaling pathways that are regulated by phosphorylation. Recently, it was demonstrated that Smad2 interacts transiently with and is a direct substrate of the transforming growth factor-beta (TGF-beta) type I receptor, T beta RI. Phosphorylation sites on Smad2 were localized to a carboxyl-terminal fragment containing three serine residues at positions 464, 465, and 467. In this report, we show that T beta RI specifically phosphorylates Smad2 on serines 465 and 467. Serine 464 is not a site of phosphorylation, but is important for efficient phosphorylation of Smad2. Phosphorylation at both sites is required to mediate association of Smad2 with Smad4 in mammalian cells, while in yeast, Smad2 interacts directly with Smad4 and does not require phosphorylation. Mutation of either serine residue 465 or 467 prevents dissociation of Smad2 from activated T beta RI and blocks TGF-beta-dependent signaling and Smad2 transcriptional activity. These results indicate that receptor-dependent phosphorylation of Smad2 on serines 465 and 467 is required in mammalian cells to permit association with Smad4 and to propagate TGF-beta signals.	HOSP SICK CHILDREN, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DIV GASTROENTEROL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MED GENET & MICROBIOL, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT ANAT & CELL BIOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Wrana, Jeffrey/F-8857-2013	Macias-Silva, Marina/0000-0002-3972-0983				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CANCER SURV, V27, P41; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAFTERY LA, 1995, GENETICS, V139, P241; Sambrook J., MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1990, CURRENT PROTOCOLS MO; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	396	419	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					27678	27685		10.1074/jbc.272.44.27678	http://dx.doi.org/10.1074/jbc.272.44.27678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346908	hybrid			2022-12-25	WOS:A1997YD47300034
J	Fasshauer, D; Otto, H; Eliason, WK; Jahn, R; Brunger, AT				Fasshauer, D; Otto, H; Eliason, WK; Jahn, R; Brunger, AT			Structural changes are associated with soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; LIGHT-SCATTERING; IN-VITRO; T-SNARE; SYNTAXIN; SNAP-25; TRANSPORT; PALMITOYLATION; SPECIFICITY; POLYMERASE	SNAP-25, syntaxin, and synaptobrevin play a key role in the regulated exocytosis of synaptic vesicles, but their mechanism of action is not understood. In vitro, the proteins spontaneously assemble into a ternary complex that can be dissociated by the ATPase N-ethylmaleimide-sensitive fusion protein and the cofactors alpha-, beta-, and gamma-SNAP. Since the structural changes associated with these reactions probably form the basis of membrane fusion, we have embarked on biophysical studies aimed at elucidating such changes in vitro using recombinant proteins. All proteins were purified in a monomeric form. Syntaxin showed significant alpha-helicity, whereas SNAP-25 and synaptobrevin exhibited characteristics of largely unstructured proteins. Formation of the ternary complex induced dramatic increases in alpha-helicity and in thermal stability. This suggests that structure is induced in SNAP-25 and synaptobrevin upon complex formation. In addition, the stoichiometry changed from 2:1 in the syntaxin-SNAP-25 complex to 1:1:1 in the ternary complex. We propose that the transition from largely unstructured monomers to a tightly packed, energetically favored ternary complex connecting two membranes is a key step in overcoming energy barriers for membrane fusion.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT BIOCHEM & MOL BIOPHYS,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Brunger, Axel/0000-0001-5121-2036; Jahn, Reinhard/0000-0003-1542-3498	NIGMS NIH HHS [GM54160-01] Funding Source: Medline; NINDS NIH HHS [5 RO1 NS33709-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Calakos N, 1996, PHYSIOL REV, V76, P1; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	30	276	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	1997	272	44					28036	28041		10.1074/jbc.272.44.28036	http://dx.doi.org/10.1074/jbc.272.44.28036			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YD473	9346956	hybrid			2022-12-25	WOS:A1997YD47300082
